<SEC-DOCUMENT>0001493152-22-022836.txt : 20220815
<SEC-HEADER>0001493152-22-022836.hdr.sgml : 20220815
<ACCEPTANCE-DATETIME>20220815155116
ACCESSION NUMBER:		0001493152-22-022836
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220815
DATE AS OF CHANGE:		20220815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		221165413

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>form20-f.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:OKYO="http://okyopharma.com/20220331">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_IFRS%2D2021_country_srt -->
<!-- Field: Set; Name: xdx; ID: xdx_036_OKYO_okyopharma.com_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20210401_20220331 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001849296 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DDocumentRegistrationStatement_false -->
<!-- Field: Set; Name: xdx; ID: xdx_07A_XDX_form20%2Df.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_077_SO_form20%2Df.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_GBP_0_iso4217%2D%2DGBP -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCentralIndexKey">0001849296</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentRegistrationStatement">false</ix:nonNumeric>
  <ix:nonFraction name="OKYO:RelatedPartyReceivables" contextRef="AsOf2022-03-31" id="xdx2ixbrl0060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2022-03-31" id="xdx2ixbrl0075" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2021-03-31" id="xdx2ixbrl0097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ConvertibleLoanNoteReserve" contextRef="AsOf2022-03-31" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0154" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0158" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ImpairmentOfLoan" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0162" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0197" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0205" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0206" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0207" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0208" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0232" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0234" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0342" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0344" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0363" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0364" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0380" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0381" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0477" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0481" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0484" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0490" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0494" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0502" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0527" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0616" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0656" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0668" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0688" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ProcessedFromOptionsExercised" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ProcessedFromOptionsExercised" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0692" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ProcessedFromWarrantsExercised" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ProcessedFromWarrantsExercised" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:CashAdvancesAndLoansToRelatedParties" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:CashAdvancesAndLoansToRelatedParties" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ChairmansBonus" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl0801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ChairmansBonus" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:GainlossOnDisposalOfLeases" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl0814" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:GainlossOnDisposalOfLeases" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0815" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0846" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_GCerroneMember" id="xdx2ixbrl0878" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_GCerroneMember" id="xdx2ixbrl0879" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_GCerroneMember" id="xdx2ixbrl0880" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_GCerroneMember" id="xdx2ixbrl0883" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_GCerroneMember" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_GJacobMember" id="xdx2ixbrl0885" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_GJacobMember" id="xdx2ixbrl0889" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_WSimonMember" id="xdx2ixbrl0894" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_WSimonMember" id="xdx2ixbrl0895" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_WSimonMember" id="xdx2ixbrl0898" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_WSimonMember" id="xdx2ixbrl0899" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0902" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0906" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0907" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember" id="xdx2ixbrl0911" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember" id="xdx2ixbrl0912" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember" id="xdx2ixbrl0915" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_GMacraeMember" id="xdx2ixbrl0918" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_GMacraeMember" id="xdx2ixbrl0919" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_GMacraeMember" id="xdx2ixbrl0920" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_GMacraeMember" id="xdx2ixbrl0921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_GMacraeMember" id="xdx2ixbrl0923" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_GMacraeMember" id="xdx2ixbrl0924" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_GMacraeMember" id="xdx2ixbrl0925" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_BDenoyerMember" id="xdx2ixbrl0927" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_BDenoyerMember" id="xdx2ixbrl0928" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_BDenoyerMember" id="xdx2ixbrl0930" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_BDenoyerMember" id="xdx2ixbrl0931" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_BDenoyerMember" id="xdx2ixbrl0932" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_BDenoyerMember" id="xdx2ixbrl0933" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2019-04-012020-03-31_custom_WSimonMember" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2019-04-012020-03-31_custom_WSimonMember" id="xdx2ixbrl0944" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0947" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember" id="xdx2ixbrl0948" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2019-04-012020-03-31_custom_GMacraeMember" id="xdx2ixbrl0951" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2019-04-012020-03-31_custom_GMacraeMember" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2019-04-012020-03-31_custom_GMacraeMember" id="xdx2ixbrl0953" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2019-04-012020-03-31_custom_LZambelettiMember" id="xdx2ixbrl0955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2019-04-012020-03-31_custom_LZambelettiMember" id="xdx2ixbrl0956" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0959" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl0960" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_JBrancaccioMember" id="xdx2ixbrl0977" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_GJacobMember" id="xdx2ixbrl0980" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_BDenoyerMember" id="xdx2ixbrl0982" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_BDenoyerMember" id="xdx2ixbrl0983" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31_custom_DirectorsMember" id="xdx2ixbrl0989" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1011" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1017" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1018" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1019" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:TaxLossesSurrenderedForResearchAndDevelopment" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1043" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:TaxLossesSurrenderedForResearchAndDevelopment" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1044" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1047" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ResearchAndDevelopmentTaxClaim" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1056" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ResearchAndDevelopmentEnhancedExpenditure" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1059" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ResearchAndDevelopmentEnhancedExpenditure" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1060" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1071" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1085" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1090" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" id="xdx2ixbrl1107" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1108" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" id="xdx2ixbrl1137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:DisposalsPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1315" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1317" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1340" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1341" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1344" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31" id="xdx2ixbrl1345" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1351" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" id="xdx2ixbrl1578" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" id="xdx2ixbrl1579" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember" id="xdx2ixbrl1691" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2021-03-31_custom_LessThanThreeMember" id="xdx2ixbrl1702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember" id="xdx2ixbrl1703" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2021-03-31" id="xdx2ixbrl1704" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2022-03-31" id="xdx2ixbrl1768" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:LeasePayments" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1793" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:ImpactOfForeignExchangeLeaseLiabilities" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DerecognitionOfLeaseLiability" contextRef="From2020-04-012021-03-31" id="xdx2ixbrl1800" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:DisposalsLeaseLiabilities" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:AdditionsToLeaseLiabilities" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:LeaseLiabilitiesInterestExpenses" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="OKYO:LeasePayment" contextRef="From2021-04-01to2022-03-31" id="xdx2ixbrl1811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl1814" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl1817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl1822" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl1825" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2022-03-31" id="xdx2ixbrl1828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GrossLeaseLiabilities" contextRef="AsOf2021-03-31_ifrs-full_NotLaterThanOneYearMember" id="xdx2ixbrl1835" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="ifrs-full:GrossLeaseLiabilities" contextRef="AsOf2021-03-31" id="xdx2ixbrl1838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="okyo-20220331.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-04-01to2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_dei_BusinessContactMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_IssuedCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_OtherReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_WarrantReservesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TranslationReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-01_custom_NonadjustingEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-012022-12-31_custom_NonadjustingEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FurnitureAndFixtureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:FurnitureAndFixtureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_CorporateAndAdministrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_CorporateAndAdministrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_CorporateAndAdministrationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_GCerroneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GCerroneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_GCerroneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GCerroneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_GJacobMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_GJacobMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_WSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_WSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_KShailubhaiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_KShailubhaiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_JBrancaccioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_JBrancaccioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_GMacraeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_GMacraeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_BDenoyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_BDenoyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_WSimonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_KShailubhaiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_GMacraeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_LZambelettiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:LZambelettiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_GJacobMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_GJacobMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_GJacobMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_BDenoyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_BDenoyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_BDenoyerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_DirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_ITEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ITEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ITEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_ITEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_ITEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_UKMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">OKYO:UKMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_UnitedStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">OKYO:UnitedStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-05-31_ifrs-full_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_ifrs-full_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_WarrantReserveOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReserveOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_LoanNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_LoanNotesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-31_custom_WarrantReserveTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReserveTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_custom_LoanNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-28_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-05-012019-05-31_custom_PrivatePlacementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-05-01</xbrli:startDate>
        <xbrli:endDate>2019-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31_custom_PrivatePlacementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_PrivatePlacementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-03-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30_custom_PrivatePlacementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:LieuOfProfessionalFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:LieuOfBrokerFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-01</xbrli:startDate>
        <xbrli:endDate>2021-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-01</xbrli:startDate>
        <xbrli:endDate>2022-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJulyTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SixJulyTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJulyTwoThousandEighteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwentyAugustTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwentyAugustTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwentyAugustTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwelveJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwelveJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:FifteenAprilTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:FifteenAprilTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-122021-04-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-12</xbrli:startDate>
        <xbrli:endDate>2021-04-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-08-292021-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-29</xbrli:startDate>
        <xbrli:endDate>2021-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-292022-01-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-29</xbrli:startDate>
        <xbrli:endDate>2022-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-152020-08-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-15</xbrli:startDate>
        <xbrli:endDate>2020-08-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-042021-01-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-04</xbrli:startDate>
        <xbrli:endDate>2021-01-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-102021-01-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-10</xbrli:startDate>
        <xbrli:endDate>2021-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-10</xbrli:startDate>
        <xbrli:endDate>2021-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-10</xbrli:startDate>
        <xbrli:endDate>2021-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-28</xbrli:startDate>
        <xbrli:endDate>2020-05-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentyNineMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentyNineMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentySevenJulyTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentySevenJulyTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:SeventeenthAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:SeventeenthAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:ThreeSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:ThreeSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_LessThanThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:LessThanThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:ThreeToTwelveMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_LessThanThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:LessThanThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:ThreeToTwelveMonthsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:WestAfricanMineralsLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_WestAfricanMineralsLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:WestAfricanMineralsLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_ifrs-full_NotLaterThanOneYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_GBPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:GBPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_GBPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:GBPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_USDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:USDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_PhaseIHumanClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIHumanClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_PhaseIIHumanClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIIHumanClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_PhaseIIIHumanClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIIIHumanClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">OKYO:AmericanDepositorySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-022022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">OKYO:AmericanDepositorySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-02</xbrli:startDate>
        <xbrli:endDate>2022-05-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-19_custom_NonadjustingEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-15_custom_NonadjustingEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001849296</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="GBP">
      <xbrli:measure>iso4217:GBP</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>OKYO:Integer</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000805" toRefs="Footnote000824"></ix:relationship>
  <ix:relationship fromRefs="Fact000806" toRefs="Footnote000824"></ix:relationship>
  <ix:relationship fromRefs="Fact000807" toRefs="Footnote000824"></ix:relationship>
  <ix:relationship fromRefs="Fact000877" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0878" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0879" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0880" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="Fact000881" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="Fact000882" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0883" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0884" toRefs="Footnote000963"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0885" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000886" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000887" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000888" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0889" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000890" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000891" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000892" toRefs="Footnote000966"></ix:relationship>
  <ix:relationship fromRefs="Fact000909" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0911" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0912" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="Fact000913" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="Fact000914" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0915" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0916" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="Fact000917" toRefs="Footnote000967"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0918" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0919" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0920" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0921" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="Fact000922" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0923" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0924" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0925" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="Fact000950" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0951" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0952" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0953" toRefs="Footnote000968"></ix:relationship>
  <ix:relationship fromRefs="Fact000926" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0927" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0928" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="Fact000929" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0930" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0931" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0932" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0933" toRefs="Footnote000969"></ix:relationship>
  <ix:relationship fromRefs="Fact000901" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0902" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0903" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000904" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000905" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0906" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0907" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000908" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000946" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0947" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0948" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000949" toRefs="Footnote000970"></ix:relationship>
  <ix:relationship fromRefs="Fact000954" toRefs="Footnote000971"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0955" toRefs="Footnote000971"></ix:relationship>
  <ix:relationship fromRefs="xdx2ixbrl0956" toRefs="Footnote000971"></ix:relationship>
  <ix:relationship fromRefs="Fact000957" toRefs="Footnote000971"></ix:relationship>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_905_edei--DocumentType_c20210401__20220331_zbunyBCdmDUj"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentType">20-F</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION
STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_904_edei--DocumentAnnualReport_c20210401__20220331_zAOYwNtlqyf9"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the fiscal year ended <span id="xdx_907_edei--DocumentPeriodEndDate_c20210401__20220331_zUbhBfDY2M1l"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate"><span id="xdx_909_edei--CurrentFiscalYearEndDate_c20210401__20220331_zxZxIWVsb9Tl"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate">March 31</ix:nonNumeric></span>, <span id="xdx_904_edei--DocumentFiscalYearFocus_c20210401__20220331_zwG5AglAsgBf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_904_edei--DocumentTransitionReport_c20210401__20220331_zpKD1DS90mv7"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from to</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_90E_edei--DocumentShellCompanyReport_c20210401__20220331_ziFF1qVP95Ik"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:DocumentShellCompanyReport">&#9744;</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<b>SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
file number: <span id="xdx_906_edei--EntityFileNumber_c20210401__20220331_zACUu4Xy6e7i"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityFileNumber">001-41386</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20210401__20220331_zROeS81mSUb1"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityRegistrantName">OKYO
Pharma Limited</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of Registrant as specified in its charter and translation of Registrant&#8217;s name into English)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20210401__20220331_zCo02XQouEGf"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Guernsey</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Jurisdiction
of incorporation or organization)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OKYO
Pharma Limited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine1_c20210401__20220331_zIg0OD5wiJ5"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressAddressLine1">Martello
Court</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressAddressLine2_c20210401__20220331_zbgxdrSp51Wk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressAddressLine2">Admiral
Park</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressCityOrTown_c20210401__20220331_zXLt7uVGP2y2"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressCityOrTown">St.
Peter Port</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressCountry_c20210401__20220331_zNmhRviZArt1"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Guernsey</ix:nonNumeric></span>
<span id="xdx_90C_edei--EntityAddressPostalZipCode_c20210401__20220331_zTMDDmw5KAti"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityAddressPostalZipCode">GY1</ix:nonNumeric></span> 3HB</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OKYO
Pharma Limited</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--ContactPersonnelName_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zM9y3sxZAOwe"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:ContactPersonnelName">Chief
Financial Officer</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zJqVtQVaNnxb"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:EntityAddressAddressLine1">107
Cheapside</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressCityOrTown_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zxmcmQVfLghj"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:EntityAddressCityOrTown">London</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_ztfpPgiQ42vb"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:EntityAddressPostalZipCode">EC2V 6DN</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressCountry_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zFUy1fwb0Yzd"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">United
Kingdom</ix:nonNumeric></span> </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--CityAreaCode_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zK81IuBluCzh"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:CityAreaCode">+44</ix:nonNumeric></span>
<span id="xdx_90D_edei--LocalPhoneNumber_c20210401__20220331__dei--EntityAddressesAddressTypeAxis__dei--BusinessContactMember_zVC0eETM4lTl"><ix:nonNumeric contextRef="From2021-04-012022-03-31_dei_BusinessContactMember" name="dei:LocalPhoneNumber">20 7495 2379</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Copies
to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ed
Lukins</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Orrick,
Herrington &amp; Sutcliffe (UK) LLP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>107
Cheapside</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>London
EC2V 6DN</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>United
Kingdom</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">American
    Depositary Shares, each representing <br />
    65 ordinary shares, having a nominal value of &#163;0.00<br />
    each Ordinary share, nominal value of &#163;0.00 each*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(*)
Not for trading, but only in connection with the listing of the American Depositary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act: <b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act: <b>None</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of July 21, 2022: <span id="xdx_906_edei--EntityCommonStockSharesOutstanding_iI_pid_c20220721_z38tabJQ4qBc"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-07-21" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,415,468</ix:nonFraction></span> ordinary shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#9744;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Yes &#9746;  <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20210401__20220331_zboCF6kJd0k2"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15 (d) of the Securities Exchange Act of 1934.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_904_edei--EntityVoluntaryFilers_c20210401__20220331_zsse30ftqEy5"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityVoluntaryFilers">Yes</ix:nonNumeric></span> &#9744;  No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#9746;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_909_edei--EntityCurrentReportingStatus_c20210401__20220331_zKZDzSst5if4"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744;  No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant was required to submit and post such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
<span id="xdx_90F_edei--EntityInteractiveDataCurrent_c20210401__20220331_ziQl0VeYb92i"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744;  No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting
company, or an emerging growth company. See definitions of &#8220;large accelerated filer, &#8220;accelerated filer&#8221;, &#8220;smaller
reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 27%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20210401__20220331_zQm9VWjz0KUc"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20210401__20220331_zWnKp48MGyOk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by checkmark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act. <span id="xdx_906_edei--EntityExTransitionPeriod_c20210401__20220331_zTeh6jxXVTVk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;
The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards
Board to its Accounting Standards Codification after April 5, 2012.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
    GAAP &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--DocumentAccountingStandard_c20210401__20220331_zenq7eHERjh5"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:DocumentAccountingStandard">International Financial Reporting Standards</ix:nonNumeric></span> as issued by the<br />
    International Accounting Standards Board &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    </span>&#9744;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the
registrant has elected to follow:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#9744;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Item 17 &#9744;  Item 18</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&#9744;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Yes &#9746;  <span id="xdx_90E_edei--EntityShellCompany_c20210401__20220331_zthKzfHQFY7f"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Z_001">PART I</a></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_002">Identity of Directors, Senior Management and Advisers</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_003">Offer Statistics and Expected Timetable</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_004">Key Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_005">Information on the Company</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    4A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_006">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_007">Operating and Financial Review and Prospects</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_008">Directors, Senior Management and Employees</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_009">Major Shareholders and Related Party Transactions</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span>2</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_010">Financial Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_011">The Offer and Listing</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_012">Additional Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_013">Quantitative and Qualitative Disclosures About Market Risk</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_014">Description of Securities Other than Equity Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Z_015">PART II</a></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_016">Defaults, Dividend Arrearages and Delinquencies</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_017">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_018">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16A</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_019">Audit Committee Financial Expert</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16B</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_020">Code of Ethics</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16C</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_021">Principal Accountant Fees and Services</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16D</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_022">Exemptions From the Listing Standards for Audit Committees</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16E</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_023">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16F</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_024">Change in Registrant&#8217;s Certifying Accountant</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16G</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_025">Corporate Governance</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    16H</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_026">Mine Safety Disclosure</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Item
    16<span style="text-decoration: underline">L</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><a href="#Z_027">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">89</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a href="#Z_028">PART III</a></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_029">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_030">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">90</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
    19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_031">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">90</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INTRODUCTION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this Annual Report on the Form 20-F references to &#8220;OKYO,&#8221; &#8220;OKYO Pharma Ltd,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221;
&#8220;us&#8221; and &#8220;our&#8221; refer to OKYO Pharma Ltd and its wholly owned subsidiary, OKYO Pharma Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely
for convenience, the trademarks, service marks and trade names in this annual report may be referred to without the &#174; and &#8482;
symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent
under applicable law, their rights thereto. This annual report contains additional trademarks, service marks and trade names of others,
which are the property of their respective owners. We do not intend to use or display other companies&#8217; trademarks, service marks
and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report, unless otherwise stated, all references to &#8220;U.S. dollars&#8221; or &#8220;US$&#8221; or &#8220;$&#8221; or
&#8220;cents&#8221; are to the currency of the United States of America, and all references to &#8220;Pounds Sterling&#8221; or &#8220;Sterling&#8221;
or &#8220;&#163;&#8221; or &#8220;pence&#8221; are to the currency of the United Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this annual report, any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension
thereof. Words importing the singular shall include the plural and vice versa, and words importing the masculine gender shall include
the feminine or neutral gender.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Presentation
of Financial Information AND OTHER DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report includes our audited consolidated financial statements as of and for the years ended March 31, 2022 2021, and 2020, which are
prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or IASB. None of our financial statements were prepared in accordance with generally accepted accounting principles in the United
States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial information is presented in United States dollars. For the convenience of the reader, in this annual report, unless otherwise
indicated, translations from Pounds Sterling into U.S. dollars were made at the rate of &#163;1.00 to $1.2183, which was the noon buying
rate of the Federal Reserve Bank of New York on July 29, 2022. Such U.S. dollar amounts are not necessarily indicative of the amounts
of U.S. dollars that could actually have been purchased upon exchange of Pounds Sterling at the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have made rounding adjustments to some of the figures included in this annual report. Accordingly, numerical figures shown as totals
in some tables may not be an arithmetic aggregation of the figures that preceded them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>CAUTIONARY
STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report contains forward-looking statements that involve substantial risks and uncertainties. All statements contained in this
Annual Report, other than statements of historical fact, including statements regarding our strategy, future operations, future financial
position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;objective,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
&#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; and &#8220;ongoing,&#8221; or the negative of these terms, or
other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties
and other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different
from the information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained
in this annual report are based upon information available to us as of the date of this annual report and, while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to
indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking
statements include statements about:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 34.65pt; text-align: justify; text-indent: -0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    development of product candidates, including statements regarding the timing of initiation, completion and the outcome of clinical
    studies or trials and related preparatory work, the period during which the results of the trials will become available and our research
    and development programs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain regulatory approval of our product candidates in the indications for which we plan to develop them,
    and any related restrictions, limitations or warnings in the label of an approved drug or therapy;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    plans to research, develop, manufacture and commercialize our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of our regulatory filings for our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    size and growth potential of the markets for our product candidates;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to raise additional capital and our ability to continue as a going concern;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    commercialization, marketing and manufacturing capabilities and strategy;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    expectations regarding our ability to obtain and maintain intellectual property protection;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to attract and retain qualified employees and key personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    estimates regarding future revenue, expenses and needs for additional financing; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments in the United States, European Union, United Kingdom and foreign countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should refer to the section titled &#8220;Risk Factors&#8221; for a discussion of important factors that may cause our actual results
to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure
you that the forward-looking statements in this annual report will prove to be accurate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in
these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that
we will achieve our objectives and plans in any specified time frame, or at all. We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we have filed as exhibits to this Annual Report completely and with the understanding
that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these
cautionary statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="Z_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_002"></span>ITEM
1: IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_003"></span>ITEM
2: OFFER STATISTICS AND EXPECTED TIMETABLE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_004"></span>ITEM
3: KEY INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Selected Financial Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.85pt; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our consolidated financial data as of the dates and for the periods indicated. The consolidated financial
statement data for the years ended March 31, 2022, 2021 and 2020 have been derived from our consolidated financial statements, as presented
at the end of this Annual Report, which have been prepared in accordance with IFRS, as issued by the IASB, and audited in accordance
with the standards of the Public Company Accounting Oversight Board (United States).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
functional currency is the pound Sterling. However, for financial reporting purposes, our financial statements, which are prepared using
the functional currency, have been translated into U.S. dollars. Our assets and liabilities are translated at the exchange rates at the
balance sheet date, our expenses are translated at average exchange rates for the period presented and shareholders&#8217; equity is
translated based on historical exchange rates. Translation adjustments are not included in determining net income (loss) but are included
in foreign exchange translation adjustment to other comprehensive loss, a component of shareholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions in currencies different from the functional currency are translated into the functional currency using the exchange
rates prevailing at the dates of the transactions. Foreign exchange differences resulting from the settlement of such transactions and
from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recorded in
general and administrative expense in the statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, 2021, and 2020, the representative exchange rates were &#163;1.00 = $1.313896, &#163;1.00 = $1.380167 and &#163;1.00
= $1.239672, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
historical results are not necessarily indicative of the results that may be expected in the future. The following selected consolidated
financial data should be read in conjunction with our audited consolidated financial statements included at the end of this Annual Report
and the related notes and Item 5, &#8220;Operating and Financial Review and Prospects&#8221; below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statement of Operations and Comprehensive Loss Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(in thousands except share and per share data)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(1,301</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(174</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(518</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,916</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,192</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,017</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,217</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,535</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,217</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,366</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,535</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">786</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net loss attributable to ordinary shareholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,431</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,353</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,544</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign currency translation adjustment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(837</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,268</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,457</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Basic and diluted net loss per ordinary share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheet Data:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold">(in thousands except share and per share data)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,701</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">6,889</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">235</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Working capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,942</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,280</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(144</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,091</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">599</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total shareholders&#8217; equity/(deficit)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,947</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,319</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(140</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
define working capital as current assets less current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Capitalization and Indebtedness</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Reasons for the Offer and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 20.25pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 16.1pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Our
business has significant risks. You should consider carefully the risks described below, together with the other information contained
in this Annual Report, including our financial statements and the related notes. If any of the following risks occur, our business, financial
condition, results of operations and future growth prospects could be materially and adversely affected. This Annual Report also contains
forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these
forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this Annual Report and
our other SEC filings. See &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; above.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have only recently committed to our new business and our product candidates are in the early stages of development and it may be some
years until we generate revenue, if at all.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
product candidates, OK-101 and OK-201, are both very early in the development stage and even the lead product candidate, OK-101, is still
in the pre-clinical stage. Through our scientific collaborators, we have only recently completed initial pre-clinical studies with respect
to OK-101 and OK-201 and our ability to generate product revenue, which is not expected to occur for several years, if ever, will depend
heavily on the successful development of the product candidates, many stages of clinical trials, regulatory approval and eventual commercialization.
We have only recently committed to our new business operating as a life sciences and biotechnology business. We currently generate no
revenue from sales of any product and may never be able to develop or commercialize a marketable product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates have not been evaluated in clinical trials and results in the clinic may not be reproduced in human trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
early stages of our business strategy carry significant risks associated with product candidates which have not been evaluated in human
clinical trials. Not only may encouraging results seen in pre-clinical trials not be indicative of results in later clinical trials but
given that the product candidates have only been evaluated in mouse models to date, unexpected or adverse effects may be seen once the
product candidates enter the human clinical trials stage which in turn may create significant hurdles to further development or lead
to the abandonment of further development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
is a high degree of failure for product candidates as they progress through clinical trials and clinical trial data may be interpreted
in varying ways which may delay, limit or prevent future regulatory approvals.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies in the life sciences and biotechnology sector have made significant initial progress only to suffer significant setbacks in
later stage clinical trials and there is a high failure rate for product candidates as they proceed through clinical trials. Data obtained
from pre-clinical and clinical activities is subject to varying interpretations which may delay, limit or prevent applications for regulatory
approvals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
development of pharmaceutical products carries significant risk of failure in early and late stage development programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of pharmaceutical products is inherently uncertain, even in late-stage product development programs. There is a high failure
rate in the development of pharmaceutical products and there is a substantial risk of adverse, undesirable, unintended or inconclusive
results from testing or pre-clinical or clinical trials, which may substantially delay, or halt entirely, or make uneconomic, any further
development of our products and may prevent or limit the commercial use of such products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the pre-clinical development of OK-101 and initial studies in animal models have been encouraging, the scope of these studies is limited,
and significant risks exist that OK-101 may never progress to a commercially viable product. Laboratory studies in animal models carry
the risk that similar results may not be seen or reproduced in future tests and trials, and there can be no guarantee that a successful
test in a mouse or other animal model will be capable of being reproduced in a human clinical trial. Small scale trials and the results
thereof, can be misleading as to efficacy, safety and other findings, as the outcome may be influenced by laboratory or demographic factors
and not due to the chemistry or biological effect of the drug candidate being evaluated. Larger scale trials often fail to produce the
same positive results seen in small scale trials for a variety of reasons and clinical trials in humans frequently fail to reproduce
efficacy seen in animal trials in the laboratory. Failure can often result after significant sums have been expended on research and
often where initial trial results (both in animals and in humans) have shown very encouraging results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
initially intends to conduct laboratory and pre-clinical trials to establish safety and efficacy of our products. Due to the inherent
risks involved in developing pharmaceutical products, there is a risk that some or all of our products will not ultimately be successfully
developed or launched. In addition, the planned clinical trials may fail to show the desired safety and efficacy. This may be the case
even if the FDA approves an IND application as positive data in animal studies may not be reflected or reproduced in human trials. Successful
completion of one stage of development of a pharmaceutical product does not ensure that subsequent stages of development will be successful.
Our inability to market any of our products currently under development would adversely affect our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently primarily dependent for our short to medium-term success on a single early-stage product, OK-101, which is a research product
that has shown pre-clinical potential but has not yet been tested on humans and has not obtained the necessary approvals required to
conduct clinical trials in humans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
commercial development of OK-101 is highly dependent on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 71.45pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    successful conduct of human trials in the initial indications of Dry Eye Disease (DED);</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    of marketing approvals for OK-101 in the United States and other jurisdictions where separate approval is required and where we subsequently
    choose to market OK-101;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of OK-101, if and when approved;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of OK-101 by patients, the medical community and third-party payers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    competing effectively with existing therapies and in particular with established products addressing the same clinical needs;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    influencing the treatment guidelines in relevant territories; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">further
    clinical trials to provide additional data to support commercialization of OK-101 and to permit wider label claims.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these milestones are not met, our business, financial condition, prospects and results of operations could be materially adversely
affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Financial Position and Need for Capital.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to raise substantial additional capital to develop and commercialize our product candidates and our failure to obtain funding
when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, our cash and cash equivalents balance was approximately $2.7 million and our working capital was approximately $6.9
million. Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will
be required to raise additional capital to complete the development and commercialization of our current product candidates. We have
historically relied upon private and public sales of our equity, as well as debt financings to fund our operations. In order to raise
additional capital, we may seek to sell additional equity and/or debt securities or obtain a credit facility or other loan, which we
may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors,
including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required
or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our
product candidate, restrict our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional
capital at acceptable terms would result in a material and adverse impact on our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern, which
may hinder our ability to obtain future financing.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mazars
LLP, our independent registered public accounting firm for the fiscal year ended March 31, 2022, has included an explanatory paragraph
in their opinion that accompanies our audited consolidated financial statements as of and for the year ended March 31, 2022, indicating
that liquidity position post October 2022 raises substantial doubt about our ability to continue as a going concern. If we are unable
to improve our liquidity position by October 2022, we may not be able to continue as a going concern. The accompanying consolidated financial
statements do not include any adjustments that might result if we are unable to continue as a going concern and, therefore, be required
to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors to suffer
the loss of all or a substantial portion of their investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
anticipate that we will continue to incur significant losses for the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of our future net losses will depend, in part, on the rate of our future expenditures, including further research and development
activity. The amount of net losses will also depend on our success in developing and commercializing OK-101 and other products that generate
significant revenue. Any failure by us to become and remain profitable could depress the value of the ADSs and could impair our ability
to expand our business, maintain our research and development efforts, diversify our product offerings or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will need to spend extensively on further research activities and there can be no guarantee that we will have access to sufficient funds
to fully realize our research and development plan or to commercialize any products derived from research activities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur further significant expenses in connection with our ongoing research and development activities in relation to our products,
including for funding clinical studies, registration, manufacturing, marketing, sales and distribution. In order to finance fully our
strategy, we may require more capital than is available from our existing cash balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access
to adequate additional financing, whether through debt financing, an equity capital raise or a suitable partnering transaction may not
be available to us on acceptable terms, or at all. Further, while the potential economic impact brought by, and the duration of the COVID-19
pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability
to access capital, which could negatively impact our short-term and long-term liquidity. If we are unable to raise capital, we could
be forced to delay, reduce or eliminate our research and development programs or commercialization efforts. Any additional equity fundraising
may be dilutive for our shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could have a material adverse effect on our business financial condition, prospects and results of operation and may
lead us to delay, reduce or abandon research and development programs or commercialization of some of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Commercialization of Our Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we successfully develop a product which shows efficacy in human subjects there remain high barriers to commercial success</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we were to receive regulatory approval for OK-101 or any other products, we may be unable to commercialize them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of factors that may inhibit our efforts to commercialize OK-101 or any other products on our own, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to or persuade adequate numbers of potential practitioners to prescribe any future
    products;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an independent sales and marketing organization;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of marketing and promotion above those anticipated by us; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to secure a suitable level of pricing and/or reimbursement approval from the relevant regulatory authorities in the countries
    we are targeting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we may only seek to enter into arrangements with third parties to perform sales and marketing services in non-core territories, any such
arrangements could result in our product revenues (or the profitability of such product revenues) being lower than if we were to market
and sell the products itself. In addition, we may not be successful in entering into arrangements with third parties to sell and market
our products or may be unable to do so on terms that are favorable to us. Acceptable third parties may fail to devote the necessary resources
and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either
on our own or in collaboration with third parties, we will not be successful in commercializing our products, which in turn would have
a material adverse effect on our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have also invested and will continue to invest resources into the development of other products, such as OK-201. Even where these products
are successfully developed and marketing approval is secured from relevant regulatory authorities, these products might not achieve commercial
success. Factors which could limit commercial success of a product include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    market acceptance or a lack of recognition of the unmet medical need for the product amongst prescribers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    competitor products entering the market;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number and relative efficacy, safety or cost of competitive products;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to supply a sufficient amount of the product to meet market demand;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    funding being available to market the product adequately;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    inability to enforce intellectual property rights, or the existence of third-party intellectual property rights;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safety
    concerns arising pre- or post-launch resulting in negative publicity or product withdrawal or narrowing of the product label and
    the group of persons who may receive the product;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">labelling
    being restricted/narrowed in the future and in the future by regulatory agencies; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusals
    by government or other healthcare payors to fund the purchase of the products by healthcare providers at a commercially viable level
    (or at all) or otherwise to restrict the availability of approved products on other grounds.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the foregoing were to occur, it could materially and adversely affect our business, financial condition, prospects and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from pharmaceutical companies. We have competitors internationally, including major multinational pharmaceutical
companies, universities and research institutions. In respect of OK-101 as an indication for the treatment of DED, there are a number
of established companies engaged in the development and marketing of preparations addressing the DED market. In addition, there are a
wide range of products addressing the DED market currently approved and marketed by a number of large and small pharmaceutical companies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our competitors have substantially greater financial, technical and other resources, such as larger research and development teams,
proven marketing and manufacturing organizations and well-established sales forces. Our competitors may succeed in developing, acquiring
or licensing drug products that are more effective or less costly than products which we are currently developing or which it may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established
pharmaceutical companies may invest heavily to accelerate the discovery and development of products that could make our products less
competitive. In addition, any new product that competes with an approved product must demonstrate compelling advantages in efficacy,
convenience, tolerability or safety in order to overcome price competition and to be commercially successful. Accordingly, our competitors
may succeed in obtaining patent protection, receiving approval from the FDA, the European Medicines Agency, or EMA, or that of another
relevant regulatory authority or discovering, developing and commercializing pharmaceutical products before we do, which would have a
material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any of our
products, if approved for sale. We will not achieve our business plan if acceptance is inhibited by price competition or the reluctance
of physicians to switch from existing drug products to our products, or if physicians switch to other new drug products or choose to
reserve our products for use in limited circumstances. Competition from lower-cost generic pharmaceuticals may also result in significant
reductions in sales volumes or prices for our products, which could materially adversely affect our business, prospects, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on third party supply, development and manufacturing and clinical service relationships and on single manufacturing sites
for certain products. Our business strategy utilizes the expertise and resources of third parties in a number of areas, including the
conduct of clinical trials, other product development, manufacture and the protection of our intellectual property rights in various
geographical locations. This strategy creates risks for us by placing critical aspects of our business in the hands of third parties
whom we may not be able to manage or control adequately and who may not always act in our best interests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
we are dependent upon third parties for the development or manufacture of certain products, our ability to procure our development or
manufacture in a manner which complies with regulatory requirements may be constrained, and our ability to develop and deliver such material
on a timely and competitive basis may be materially adversely affected, which may impact revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
requirements for pharmaceutical products tend to make the substitution of suppliers and contractors costly and time-consuming. Alternative
suppliers may not be able to manufacture products effectively or obtain the necessary manufacturing licenses from relevant regulatory
authorities. The unavailability of adequate commercial quantities, the inability to develop alternative sources, a reduction or interruption
in supply of contracted services, or a significant increase in the price of materials and services, could have a material adverse effect
on our ability to manufacture and market our products or to fulfill orders from our distributors or licensees, which in turn would have
a material adverse impact on our cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insurance
coverage and reimbursement may be limited, unavailable or may be reduced over time in certain market segments for our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and third-party payers, such as private health insurers, decide which pharmaceutical products they will cover and the amount
of reimbursement. Reimbursement may depend upon a number of factors, including the payer&#8217;s determination that use of a product
is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under the payor&#8217;s health plan;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement approval for a product from a government or other third- party payer is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement, or to demonstrate commercial
value compared to existing established treatments. Even if we are able to furnish the requested data, there is no guarantee that a third-party
payor will cover a product. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, we may be unable to achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may, in the future, seek approval to market our products in the EU, the U.S. and in selected other jurisdictions. In the EU, the pricing
of prescription pharmaceuticals is subject to national governmental control and pricing negotiations with governmental authorities can,
in some circumstances, take several years after obtaining marketing approval for a product. In addition, market acceptance and sales
of our products will depend significantly on the availability of adequate coverage and reimbursement from third-party payers and may
be affected by existing and future healthcare reform measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
continuing efforts of governments, insurance companies, managed care organizations and other payers of healthcare services to contain
or reduce costs of healthcare and/or impose price controls may materially adversely affect our ability to set prices for our products,
generate revenues and achieve or maintain profitability. Any reduction in government reimbursement programs may result in a similar reduction
in payments from private payers, which may materially adversely affect our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
expiration of certain intellectual property rights or an inability to obtain, maintain or enforce adequate intellectual property rights
for products that are marketed or in development may result in additional competition from other third-party products. Third parties
may have blocking intellectual property rights which could prevent the sale of products by us or require that compensation be paid to
such third parties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
extent of our success will, to a significant degree, depend on our ability to establish, maintain, defend and enforce adequate intellectual
property rights and to operate without infringing the proprietary or intellectual property rights of third parties. We have been granted,
or have in-licensed rights under, a number of key patent families for OK-101 (or other proprietary rights), and patent applications are
pending in the U.S., the EU, and certain other jurisdictions. We may develop or acquire further technology or products that are not patentable
or otherwise protectable. The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can
be uncertain. Patents or other rights might not be granted under any pending or future applications filed or in-licensed by us and any
claims allowed might not be sufficiently broad to protect our technologies and products from competition. Competitors may also successfully
design around key patents held by us, thereby avoiding a claim of infringement. There is a risk that not all relevant prior art has been
identified with respect to any particular patent or patent application and the existence of such prior art may invalidate any patents
granted (or result in a patent application not proceeding to grant). Patents or other registerable rights might also be revoked for other
reasons after grant. Third parties may challenge the validity, enforceability or scope of any granted patents. Our defense of our proprietary
rights could involve substantial costs (even if successful) and could result in declarations of invalidity or significantly narrow the
scope of those rights, limiting their value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may have filed applications or been granted patents, or obtained additional patents and proprietary rights, which relate to and could
be infringed by our products. An adverse outcome with respect to third party rights such as claims of infringement of patents or third-party
proprietary rights by us could subject us to significant liabilities or require us to obtain a license for the continued use of the affected
rights, which may not be available on acceptable terms or at all, or require us to cease commercialization and development efforts, or
the sale of the relevant products, in whole or in part in the relevant jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
could be subject to claims for compensation by third parties claiming an ownership interest in the intellectual property rights relating
to a commercially successful product. This may include claims from employee inventors in territories which permit such claims even where
we own the intellectual property rights in question. Any such failure to defend our proprietary intellectual property could have a material
adverse effect on our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to obtain, maintain, defend or enforce the intellectual property rights covering our products</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have had certain patents licensed to us in jurisdictions we consider to be important to our business. However, we cannot predict:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree and range of protection any patents will afford against competitors and competing technologies, including whether third parties
    will find ways to invalidate or otherwise circumvent the patents by developing a competitive product that falls outside its scope;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if,
    or when any patents will be granted;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
    granted patents will not be contested, invalidated or found unenforceable;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not others will obtain patents claiming aspects similar to those covered by the Company&#8217;s patents and patent applications;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will need to initiate litigation or administrative proceedings, or whether such litigation or proceedings will be initiated by
    third parties against us, which may be costly and time consuming; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    third parties will claim that our technology infringes upon their rights.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we believe that we have novel composition of matter on the OK-101 peptide and novel methods of its use in treating DED, we cannot be
sure that these patent applications will issue as patents. Each patent office has different patentability requirements, but we believe
that the license patent applications contain patentable subject matter. The process for issuance of a patent involves correspondence
with each local patent office in the jurisdictions in which the patent application is filed. That process, patent prosecution, involves
a discussion of any relevant prior art and typically a discussion of the scope of the claims. The patent prosecution process can take
several years depending on the jurisdiction and is not in the control of the patent owner, but in the control of the local patent office.
We cannot be sure the outcome of the patent prosecution will be successful and result in issued patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
protection is of importance to us in maintaining our competitive position in our planned product lines and a failure to obtain or retain
adequate protection could have a material adverse effect on our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to prevent disclosure of our trade secrets, know-how or other proprietary information.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to
obtain or enforce. If we are unable to protect our trade secrets adequately the value of our technology and products could be significantly
diminished. Furthermore, our employees, consultants, contract personnel or third-party partners, either accidentally or through willful
misconduct, may cause serious damage to our programs and/or our strategy by disclosing confidential information to third parties. It
is also possible that confidential information could be obtained by third parties as a result of breaches of our physical or electronic
security systems. Any disclosure of confidential data into the public domain or to third parties could allow third parties to access
confidential information and use it in competition with us. In addition, others may independently discover the confidential information.
Any action to enforce our rights against any misappropriation or unauthorized use and/or disclosure of confidential information is likely
to be time-consuming and expensive, and may ultimately be unsuccessful, or may result in a remedy that is not commercially valuable.
Any such loss of confidential information or failure to enforce our rights in relation to such confidential information, or unsatisfactory
outcome of any related litigation could have a material adverse effect on our business, prospects, financial condition or results of
operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates could infringe patents and other intellectual property rights of third parties.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability, and the ability of any third party with which we may partner to develop, manufacture, market
and sell our products and use our patent- protected technologies without infringing the patents of third parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products may infringe or may be alleged to infringe existing patents or patents that may be granted in the future which may result in
costly litigation and could result in our having to pay substantial damages or limit our ability to commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
some patent applications in Europe, the U.S. and many foreign jurisdictions may be maintained in secrecy until the patents are issued,
patent applications in such jurisdictions are typically not published until 18 months after filing, and publications in the scientific
literature often lag behind actual discoveries. Accordingly, we cannot be certain that others have not filed patents that may cover our
technologies, our products or the use of our products. Additionally, pending patent applications which have been published can, subject
to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As a
result, we may become party to, or threatened with, future adversarial proceedings or litigation regarding patents with respect to our
products and technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims
of the relevant patent or that the patent claims are invalid, and we may not be able to do this. If we are found to infringe a third
party&#8217;s patent, we could be required to obtain a license from such third party to continue developing and marketing our products
and technology or we may elect to enter into such a license in order to settle litigation or in order to resolve disputes prior to litigation.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we are able to obtain
a license, it could be non- exclusive, thereby giving our competitors access to the same technologies that are licensed to us and could
require us to make substantial royalty payments. We could also be forced, including by court order, to cease commercializing the infringing
technology or products. A finding of infringement could prevent us from commercializing our products or force us to cease some of our
business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade
secrets of third parties could have a similarly negative impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
such claims are likely to be expensive to defend, and some of our competitors may be able to sustain the costs of complex patent litigation
more effectively than us because they have substantially greater resources. Moreover, even if we are successful in defending any infringement
proceedings, we may incur substantial costs and divert management&#8217;s time and attention in doing so, which could materially adversely
affect our business, prospects, results of operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks
relating to managing growth, employee matters and other risks relating to our business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Growth
may place significant demands on our management and resources. We expect to experience growth in the number of our employees and the
scope of our operations in connection with the continued development and, in due course, the potential commercialization of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
potential growth will place a significant strain on our management and operations, and we may have difficulty managing this future potential
growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on our current executive officers and their services are critical to the successful implementation of our product
development and regulatory strategies. While suitable contracts of employment and consultancy agreements are in place including six to
12 months&#8217; notice periods for all executive officers, they may give notice to terminate their employment or services with us at
any time. The loss of the services of any of our executive officers and our inability to find suitable replacements could harm our business,
prospects, financial condition, results of operations and ability to achieve the successful development or commercialization of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Challenges
in identifying and retaining key personnel could impair our ability to conduct and grow our operations effectively. Our ability to compete
in the highly competitive pharmaceutical industry depends upon our ability to attract and retain highly qualified management and sales
teams. We are intending to recruit our own commercial team and expand our existing central infrastructure team. Many of the other pharmaceutical
companies and academic institutions that we compete against for qualified personnel have greater financial and other resources, different
risk profiles and a longer history in the industry than we do. We might not be able to attract or retain these key persons on conditions
that are economically feasible. Our inability to attract and retain these key persons could have a material adverse effect on our business,
prospects, financial conditions and results of operation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COVID-19
has adversely affected our business, and any new pandemic, epidemic or outbreak of an infectious disease may further adversely affect
our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2019, a novel strain of coronavirus, COVID-19, spread globally, substantially impacting the global economy and our operations,
including interrupting preclinical and clinical trial activities and disrupting our supply chain. The spread of an infectious disease,
including COVID-19, may also result in the inability of our suppliers to source or deliver components or raw materials necessary for
our clinical supply on a timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone certain treatments
in response to the spread of an infectious disease. Such events may result in a period of business disruption, and in reduced operations,
or doctors and medical providers may be unwilling to participate in our clinical trials, any of which could materially affect our business,
financial condition and results of operations. The extent to which COVID-19 impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus
and the actions to contain the coronavirus or treat its impact, among others. A significant pandemic as with COVID-19, or any other infectious
disease, could result in a widespread health crisis that could adversely affect the economies and financial markets worldwide, resulting
in an economic downturn that could impact our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may become subject to product liability claims.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability and associated adverse publicity as a result of the clinical testing of our products and sales
of our products once marketing approval is received from relevant regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
or civil proceedings might be filed against us by any study subjects, patients, relevant regulatory authorities, pharmaceutical companies,
and any other third party using or marketing our products. Any such product liability claims may include allegations of defects in manufacturing
or design, negligence, strict liability, a breach of warranties and a failure to warn of dangers inherent in the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit
commercialization of our products, if approved. Even if we successfully defend ourselves against such product liability claims it could
require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result
in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our products due to negative public perception;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical study participants or difficulties in recruiting new study participants;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to defend or settle the related litigation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management&#8217;s time and our resources;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to patients, study participants or subjects;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labelling, marketing or promotional restrictions;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues from product sales; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any of our products, if approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we will maintain levels of insurance customary for our sector to cover our current and future business operations, any claim that may
be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance
or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. In such cases, we would have to pay any amounts awarded by a court or negotiated
in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our partners, licensees and subcontractors were unable to obtain and maintain appropriate insurance coverage at an acceptable cost,
or to protect ourselves in any way against actions for damages, this would seriously affect the marketing of our products and, more generally,
be detrimental to our business, prospects, results of operations or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
employees, contractors, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance
with regulatory standards.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to the risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging
in fraud or other misconduct. Misconduct could include intentional failures to comply with FDA or EMA regulations or those of other relevant
regulatory authorities, to provide accurate information to the FDA, EMA or other relevant regulatory authorities, or to comply with manufacturing
standards we have established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, sales, marketing and business arrangements in the life sciences and biotechnology sector are subject to extensive laws and
regulations intended to prevent fraud, misconduct, bribery and other abusive practices. These laws and regulations may restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory
sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental or relevant regulatory authority investigations or other actions or lawsuits stemming from a failure to be in compliance
with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting
our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions,
and our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be vulnerable to disruptions of information technology systems or breaches of data security. We are dependent on information technology
systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit confidential
information, including intellectual property, proprietary business information and personal information. It is important that we do so
in a secure manner to maintain confidentiality and integrity of such confidential information. Any failure to do so could adversely affect
our business, prospects, results of operation or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
relationship of the UK with the EU could impact our ability to operate efficiently in certain jurisdictions or in certain markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
UK formally exited the EU on January 31, 2020, which is commonly known as Brexit. Under the terms of its departure, the UK entered a
transition period during which it continued to follow all EU rules until December 31, 2020, or the Transition Period. On December 30,
2020, the UK and EU signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is considerable uncertainty resulting from a lack of precedent and the complexity of the UK and EU&#8217;s intertwined legal regimes
as to how Brexit (following the Transition Period) will impact the medical devices industry in Europe. Since a significant proportion
of the regulatory framework in the UK applicable to our business and product candidates is derived from EU directives and regulations,
Brexit could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization
of our product candidates in the UK or the EU. The impact will largely depend on the model and means by which the UK&#8217;s relationship
with the EU is governed post-Brexit and the extent to which the UK chooses to diverge from the EU regulatory framework. For example,
following the Transition Period, the UK will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorizations
and our product candidates will therefore require a separate marketing authorization for such products to be marketed in the UK. It is
also unclear as to whether the relevant authorities in the EU and the UK are adequately prepared for the additional administrative burden
caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would
prevent us from, or delay commercialization of, product candidates in the UK and/or the EEA and restrict our ability to generate revenue
and achieve and sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK for its product candidates,
which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit
will have on the process to obtain regulatory approval in the UK for product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
the UK&#8217;s withdrawal from the EU has resulted in the relocation of the EMA from the UK to the Netherlands. This relocation has caused,
and may continue to cause, disruption in the administrative and medical scientific links between the EMA and the UK Medicines and Healthcare
Products Regulatory Agency, including delays in granting clinical trial authorization or marketing authorization, disruption of importation
and export of medical devices, active substance and other components of new drug formulations, and disruption of the supply chain for
clinical trial product and final authorized formulations. The cumulative effects of the disruption to the regulatory framework may add
considerably to the development lead time to marketing authorization and commercialization of product candidates in the EU and/or the
UK. Brexit may also result in a reduction of funding to the EMA once the UK no longer makes financial contributions to EU institutions,
such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product
candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize our
product candidates and whether the approval may be for a narrower indication than we seek.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
The FDA must review and approve any new pharmaceutical product before it can be marketed and sold in the United States. The FDA regulatory
review and approval process, which includes evaluation of preclinical studies and clinical trials of a product candidate and proposed
labeling, as well as the evaluation of the manufacturing process and manufacturers&#8217; facilities, all of which is lengthy, expensive
and uncertain. To obtain approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials
that the product candidate is both safe and effective for each indication where approval is sought. Even if our product candidates meet
the FDA&#8217;s safety and effectiveness endpoints in clinical trials, the FDA may not complete their review processes in a timely manner,
or we may not be able to obtain regulatory approval. The FDA has substantial discretion in the review and approval process and may refuse
to file our application for substantive review or may determine after review of our data that our application is insufficient to allow
approval of our product candidates. The FDA may require that we conduct additional preclinical studies, clinical trials or manufacturing
validation studies and submit that data before it will reconsider our application. Additional delays may result if an FDA Advisory Committee
or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections
based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy
during the period of product development, clinical trials and the review process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, EMA or other regulatory authorities also may approve a product candidate for more limited indications than requested or may impose
significant limitations in the form of narrow indications, warnings or a risk evaluation and mitigation strategy, or REMS. These regulatory
authorities may require precautions or contraindications with respect to conditions of use or may grant approval subject to the performance
of costly post-marketing clinical trials. In addition, the FDA, EMA or other regulatory authorities may not approve the labeling claims
that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could
harm the commercial prospects for our product candidates and negatively impact our business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Delays
in obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process may delay or disrupt
our product development and commercialization efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently operate manufacturing facilities for clinical or commercial production of our product candidates. Before we can begin
to commercially manufacture our product candidates, whether in a third-party facility or in our own facility, if and when established,
we must obtain regulatory approval from the FDA for our manufacturing process and facility. A manufacturing authorization must also be
obtained from the appropriate European Union and UK regulatory authorities and from other foreign regulatory authorities, as applicable.
In order to obtain approval, we will need to ensure that all of our processes, methods and equipment are compliant with Current Good
Manufacturing Practice (&#8216;cGMP&#8217;), and perform extensive audits of vendors, contract laboratories and suppliers. If any of
our vendors, contract laboratories or suppliers are found to be non-compliant with cGMP, we may experience delays or disruptions in manufacturing
while we work with these third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements
govern quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP, we will be obligated
to expend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications
and other requirements. If we fail to comply with these requirements, we would be subject to possible regulatory action and may not be
permitted to sell any product candidate that we may develop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or our third-party manufacturers fail to comply with applicable cGMP regulations, the FDA, EMA and other regulatory authorities can
impose regulatory sanctions including, among other things, refusal to approve a pending application for a new product candidate or suspension
or revocation of a pre-existing approval. Such an occurrence may cause our business, financial condition, results of operations and prospects
to be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if the supply of our products from our third-party manufacturers to us is interrupted for any reason, including due to regulatory requirements
or actions (including recalls), adverse financial developments at or affecting the supplier, failure by the supplier to comply with cGMP
requirements, contamination, business interruptions or labor shortages or disputes, there could be a significant disruption in commercial
supply of our products. We do not currently have a backup manufacturer of our product candidate supply for clinical trials or commercial
sale. An alternative manufacturer would need to be qualified through a supplement to its regulatory filing, which could result in further
delays. The regulatory authorities also may require additional clinical trials if a new manufacturer is relied upon for commercial production.
Switching manufacturers may involve substantial costs and could result in a delay in our desired clinical and commercial timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications
as our product candidates, we may not be able to have competing products approved by applicable regulatory authorities for a significant
period of time. In addition, even if we obtain orphan drug exclusivity for any of our products, such exclusivity may not protect us from
competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities in some jurisdictions, including the United States and the European Union, may designate products for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an orphan drug if it is
intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals
in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that
the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles
a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.
In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition
affecting not more than five in 10,000 persons in the European Union. Additionally, orphan drug designation is granted for products intended
for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without
incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing
the drug or biologic product. In the European Union, orphan drug designation entitles a party to a number of incentives, such as protocol
assistance and scientific advice specifically for designated orphan medicines, and potential fee reductions depending on the status of
the sponsor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
designation as an orphan product does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve,
that product candidate, nor does it limit the ability of any regulatory agency to grant orphan drug designation to product candidates
of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such
designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another
marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period,
except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation),
we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is
seven years in the United States and 10 years in the European Union. The exclusivity period in the European Union can be reduced to six
years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market
exclusivity is no longer justified. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation
was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients
with the rare disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from
competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved,
the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or
is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European
Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    second applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already
    authorized, is safer, more effective or otherwise clinically superior;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application;
    or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal
    product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval for a product candidate, our product candidates will remain subject to regulatory oversight.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses
for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and clinical effectiveness of the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of our product candidates are classified as biologics in the United States, and therefore, can only be sold if we obtain a biologics
license application, or BLA, from the FDA. The holder of an approved BLA also must submit new or supplemental applications and obtain
FDA approval for certain changes to the approved product, product labeling or manufacturing process. In addition, the holder of a an
approved BLA must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to the prohibition on promoting
products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label
use&#8221;). Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially
applicable federal and state laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign
marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as adverse events
of unanticipated severity or frequency, or problems with the facility where the product is manufactured or if a regulatory authority
disagrees with the promotion, marketing or labeling of that product (in addition to our being obligated as holder of an approved BLA
to monitor and report adverse events and any failure of a product to meet the BLA specifications), a regulatory authority may impose
restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from
the market or suspension of manufacturing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory or enforcement authority
may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 14.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    a warning letter asserting that we are in violation of the law;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our strategic
    partners;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the product or otherwise require the withdrawal of the product from the market;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of the product; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA&#8217;s policies, and those of the EMA and other regulatory authorities, may change and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature
or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad.
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not
able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability, which would negatively impact our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain and maintain approval for our product candidates in a major pharmaceutical market such as the United States, we may never
obtain approval for our product candidates in other major markets.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements
of such countries or territories regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by
regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained
in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional
administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and
costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory
requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries.
For example, in many jurisdictions outside of the United States, a product candidate must be approved for reimbursement before it can
be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products would also be subject to
approval. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays.
In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory
approval in other countries. We currently do not have any product candidates approved for sale in any jurisdiction, whether in the United
States, the European Union or any other international markets, and we do not have experience in obtaining regulatory approval in international
markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our
target market will be reduced and our ability to realize the full market potential of our product candidates will be compromised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may seek a conditional marketing authorization in the European Union for some or all of our current product candidates, but we may not
be able to obtain or maintain such designation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of its marketing authorization process, the EMA may grant marketing authorizations for certain categories of medicinal products
on the basis of less complete data than is normally required, when doing so may meet unmet medical needs of patients and serve the interest
of public health. In such cases, it is possible for the Committee for Medicinal Products for Human Use, or CHMP, to recommend the granting
of a marketing authorization, subject to certain specific obligations to be reviewed annually, which is referred to as a conditional
marketing authorization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
may apply to medicinal products for human use that fall under the jurisdiction of the EMA, including those that aim at the treatment,
the prevention, or the medical diagnosis of seriously debilitating or life-threatening diseases and those designated as orphan medicinal
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
conditional marketing authorization may be granted when the CHMP finds that, although comprehensive clinical data referring to the safety
and therapeutic utility of the medicinal product have not been supplied, all the following requirements are met:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk-benefit balance of the medicinal product is positive;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is likely that the applicant will be in a position to provide the comprehensive clinical data;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unmet
    medical needs will be fulfilled; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent
    in the fact that additional data is still required.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
granting of a conditional marketing authorization is restricted to situations in which only the clinical part of the application is not
yet fully complete. Incomplete preclinical or quality data may only be accepted if duly justified and only in the case of a product intended
to be used in emergency situations in response to public health threats. Conditional marketing authorizations are valid for one year,
on a renewable basis. The holder will be required to complete ongoing trials or to conduct new trials with a view to confirming that
the benefit-risk balance is positive. In addition, specific obligations may be imposed in relation to the collection of pharmacovigilance
data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granting
a conditional marketing authorization allows medicines to reach patients with unmet medical needs earlier than might otherwise be the
case and will ensure that additional data on a product is generated, submitted, assessed and acted upon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
legislative reform measures may have a negative impact on our business and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and
proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or
regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers
and pays for pharmaceutical products. The MMA expanded Medicare coverage for outpatient drug purchases by adding a new Medicare Part
D program and introduced a new reimbursement methodology based on average sales prices for Medicare Part B physician-administered drugs.
In addition, the MMA authorized Medicare Part D prescription drug plans to limit the number of drugs that will be covered in any therapeutic
class in their formularies. The MMA&#8217;s cost reduction initiatives and other provisions could decrease the coverage and price that
we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow
Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement
that results from the MMA may result in a similar reduction in payments from private payors. Similar regulations or reimbursement policies
may be enacted in international markets, which could similarly impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2010, the Patient Protection and Affordable Care Act (&#8216;PPACA&#8217;) (as amended by the Health Care and Education Reconciliation
Act of 2010) was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and
significantly impacts the U.S. pharmaceutical industry. The PPACA, among other things: (i) addresses a new methodology by which rebates
owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted
or injected; (ii) increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the
rebate program to individuals enrolled in Medicaid managed care organizations; (iii) establishes annual fees and taxes on manufacturers
of certain branded prescription drugs; (iv) expands the availability of lower pricing under the 340B drug pricing program by adding new
entities to the program; and (v) establishes a new Medicare Part D coverage gap discount program, in which manufacturers must agree to
offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Additionally, in the United
States, the Biologics Price Competition and Innovation Act of 2009 created an abbreviated approval pathway for biologic products that
are demonstrated to be biosimilar or &#8220;interchangeable&#8221; with an FDA-approved biologic product. This new pathway could allow
competitors to reference data from biologic products already approved after 12 years from the time of approval. This could expose us
to potential competition by lower-cost biosimilars even if we commercialize a product candidate faster than our competitors. Moreover,
the creation of this abbreviated approval pathway does not preclude or delay a third party from pursuing approval of a competitive product
candidate via the traditional approval pathway based on their own clinical trial data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
changes that may affect our business include those changes governing enrollment in federal healthcare programs, reimbursement changes,
rules regarding prescription drug benefits under the health insurance exchanges and fraud and abuse and enforcement. Continued implementation
of the PPACA and the passage of additional laws and regulations may result in the expansion of new programs such as Medicare payment
for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting
system and feedback program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
each state that does not choose to expand its Medicaid program, there likely will be fewer insured patients overall, which could impact
the sales, business and financial condition of manufacturers of branded prescription drugs. Where patients receive insurance coverage
under any of the new options made available through the PPACA, manufacturers may be required to pay Medicaid rebates on that resulting
drug utilization. The U.S. federal government also has announced delays in the implementation of key provisions of the PPACA. The implications
of these delays for our and our potential partners&#8217; business and financial condition, if any, are not yet clear.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there have been judicial and congressional challenges to certain aspects of the PPACA, and we expect the current administration
and Congress will likely continue to seek legislative and regulatory changes, including repeal and replacement of certain provisions
of the PPACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities
under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a
fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical
devices. More recently, the U.S. House of Representatives passed legislation known as the American Health Care Act of 2017, and Senate
Republicans have released a draft bill known as the Better Care Reconciliation Act of 2017, each of which would repeal certain aspects
of the PPACA if ultimately enacted. The prospects for enactment of these legislative initiatives remain uncertain. Further, Congress
could also consider other legislation to replace elements of the PPACA. We cannot know how efforts to repeal and replace the PPACA or
any future healthcare reform legislation will impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage
criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from
Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Department of Health and Human Services Office of Inspector General in the US issued final regulations on November 30, 2020 to eliminate
safe harbor protection under the anti-kickback statute for drug price reductions that pharmaceutical manufacturers pay to Medicare and
Medicaid plan sponsors and their pharmacy benefit managers. The proposal reflects a clear intent to substantially alter many of the current
drug discount and services compensation practices among pharmaceutical manufacturers and Medicare and Medicaid managed care organizations
and their pharmacy benefit managers. The proposal also reflects a skepticism that current drug discount and compensation practices among
manufacturers and pharmacy benefit managers are sufficiently transparent to health plans to ensure that all appropriate cost reductions
and value is passed through to health plans and reflected in lower health plans costs and lower premiums for beneficiaries. The Biden
Administration has delayed the effective date of this rule until January 1, 2023, and a lawsuit initiated by the Pharmaceutical Care
Management Administration has challenged this final rule. If the regulation becomes effective it could result in lower prices for pharmaceutical
products in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Centers for Medicare and Medicaid Services issued an interim final rule on November 20, 2020 that would tie prices for certain drugs
under Medicare Part B to the lowest price for those drugs available in certain countries that are members of the Organization for Economic
Co-operation and Development. This &#8220;most favored nation&#8221; drug pricing rule is also the subject of lawsuits, and a federal
court has placed an injunction on the implementation of the rule. This rule, if finalized, could also result in lower prices for pharmaceutical
products in general.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biden Administration will have the opportunity to address these regulations as well as drug pricing, health care access, and other health
care reform issues. Any further legislative or administrative action to reduce reimbursement or health benefits to beneficiaries under
the Medicare or Medicaid program could affect the payment we could collect from the sale of any product in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts
that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product
candidates or additional pricing pressures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to stringent and changing privacy laws, regulations and standards as well as contractual obligations related to data privacy
and security. Our actual or perceived failure to comply with such obligations could harm our reputation, subject us to significant fines
and liability, or otherwise adversely affect our business</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>or
prospects.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to data privacy and protection laws, regulations, policies and contractual obligations that apply to the collection, transmission,
storage, processing and use of personal information or personal data, which among other things, impose certain requirements relating
to the privacy, security and transmission of personal information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been
an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with laws, regulations
and other obligations governing personal information could result in enforcement actions against us, including fines, imprisonment of
company officials and public censure, processing penalties, claims for damages by affected individuals, damage to our reputation and
loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulatory framework for the collection, use, retention, safeguarding, disclosure, sharing, transfer and other processing of personal
information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction
in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection,
use, disclosure, transfer or other processing of personal data regarding individuals in the European Union, including personal health
data, is subject to the European Union General Data Protection Regulation (EU) 2016/679, or the GDPR, which took effect across all member
states of the European Union, or EU, in May 2018 and similar legislation in the United Kingdom. The GDPR is wide-ranging in scope and
imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other
sensitive data, obtaining consent of the individuals to whom the personal data relates, establishing a legal basis for processing, providing
information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality
of personal data that requires the adoption of administrative, physical and technical safeguards, providing notification of data breaches
to appropriate data protection authorities or data subjects, establishing means for data subjects to exercise rights in relation to their
personal data and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical
trials conducted in the EU and UK by expanding the definition of personal data to include coded data and requiring changes to informed
consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict
rules on the transfer of personal data to countries outside the European Economic Area, or EEA, including the United States and, as a
result, increases the scrutiny for transfers of personal data from clinical trial sites located in the EU to the United States. The United
Kingdom and Switzerland have adopted similar restrictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
Brexit and ongoing developments in the United Kingdom have created uncertainty with regard to data protection regulation in the United
Kingdom.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy
and data security requirements are also either in place or underway in the United States. There are a broad variety of data protection
laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review
companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state attorneys
general can all be aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered or
have been implemented at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which
became effective on January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers
about their data collection, use and sharing practices, provides such individuals with new data privacy rights (including the ability
to opt out of certain disclosures of personal information), imposes new operational requirements for covered businesses, provides a private
right of action for data breaches and creates a statutory damages framework. Virginia became the second state to adopt a comprehensive
privacy legislation on March 2, 2021 with enactment of the Virginia Consumer Data Protection Act. Many other states are considering similar
legislation, and a broad range of legislative measures also have been introduced at the federal level. Although there are limited exemptions
for clinical trial data under the CCPA, the CCPA and other similar laws could impact our business activities depending on how it is interpreted
and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
regulations promulgated pursuant to the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended, establish
privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health
information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected
health information and ensure the confidentiality, integrity and availability of electronic protected health information. These provisions
may be applicable to our business or that of our collaborators, service providers, contractors or consultants. Determining whether protected
health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and
may be subject to changing interpretation. If we are unable to properly protect the privacy and security of protected health information,
we could be found to have violated these privacy and security laws and/or breached certain contracts with our business partners (including
as a business associate). Further, if we fail to comply with applicable privacy laws, such as, to the extent applicable, HIPAA privacy
and security standards, we could face significant civil and criminal penalties. In the United States, the Department of Health and Human
Services&#8217; and state attorney&#8217;s general enforcement activity can result in financial liability and reputational harm, and
responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized
to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents.
We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated
with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at
the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Given
the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR, CCPA and other similar law
requirements are rigorous and time-intensive and require significant resources and a review of our technologies, systems and practices,
as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data.
Changes involving the GDPR, CCPA or other laws or regulations associated with the enhanced protection of certain types of sensitive data,
such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and
put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and
increase our cost of doing business, and could expose us to government enforcement actions, regulatory investigations, private litigation
and significant fines, penalties and remediation costs and could have a material adverse effect on our business, financial condition
or results of operations. Additionally, any failure by our third-party collaborators, service providers, contractors or consultants to
comply with applicable law, regulations or contractual obligations related to data privacy or security could result in proceedings against
us by governmental entities or others, fines, reputational harm and other liabilities.</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal information
and/or other confidential information. Although we endeavor to comply with our published policies and other documentation, we may at
times fail to do so or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving
compliance if our employees or vendors fail to comply with our published policies and documentation. Such failures can subject us to
potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices.
Moreover, subjects about whom we or our partners obtain information, as well as the providers who share this information with us, may
contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights or
failed to comply with data protection laws or applicable privacy notices even if we are not found liable, could be expensive and time-consuming
to defend and could result in adverse publicity that could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that new and existing laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts
to comply with the evolving data protection rules may be unsuccessful. If so, this could result in government-imposed or court&#8211;imposed
fines, or penalties or orders requiring that we change our practices, which could adversely affect our business. We must devote significant
resources to understanding and complying with this changing landscape. Failure to comply with local and foreign laws, including US federal
and state laws regarding privacy and security of personal information could expose us to government-imposed fines and penalties under
such laws, penalties or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations
and enforcement actions, litigation and significant costs for remediation, reputational harm, diminished profits and earnings, additional
reporting requirements and/or oversight, any of which could adversely affect our business, our results of operations or prospects. We
also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined
to have violated these laws, government or court investigations into these issues typically require the expenditure of significant resources
and generate negative publicity. Any of the foregoing could have a materially adverse effect on our reputation and our business, financial
condition, results of operations or prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control
laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or the U.K. Bribery Act, the U.S. Foreign Corrupt
Practices Act of 1977, or the FCPA, the U.S. domestic bribery statute contained in 18 &#167;201, the U.S. Travel Act 1961, and other
anti-corruption laws that apply in countries where we do business. The U.K. Bribery Act 2010, the FCPA and these other laws generally
prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper
or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some
other business advantage. Under the U.K. Bribery Act 2010, we may also be liable for failing to prevent a person associated with us from
committing a bribery offense. We and our commercial partners operate in a number of jurisdictions that pose a high risk of potential
U.K. Bribery Act or FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal
activities could potentially subject us to liability under the U.K. Bribery Act, FCPA or local anti-corruption laws, even if we do not
explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future
regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered
or interpreted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to other laws and regulations governing our international operations, including regulations administered by the governments
of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations,
economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency
exchange regulations, collectively referred to as the Trade Control laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the
U.K. Bribery Act, the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the U.K. Bribery
Act, the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and
other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results
of operations and liquidity. Likewise, any investigation of any potential violations of the U.K. Bribery Act, the FCPA, other anti-corruption
laws or Trade Control laws by United Kingdom, United States or other authorities could also have an adverse impact on our reputation,
our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, physicians and third-party payors will be subject, directly or indirectly, to federal and state healthcare
fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we
are found in violation of these laws and regulations, we may be required to pay a penalty or be suspended from participation in federal
or state healthcare programs, which may adversely affect our business, financial condition and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for our product candidates and begin commercializing them in the United States, our operations will be directly,
or indirectly through our prescribers, customers and purchasers, subject to various federal and state fraud and abuse laws and regulations,
including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and Physician Payments
Sunshine Act of 2010 and regulations. These laws will impact, among other things, our proposed sales, marketing and educational programs.
In addition, we may be subject to patient privacy laws by both the U.S. federal government and the states in which we conduct our business.
The laws that will affect our operations include, but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting,
    receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly,
    in cash or in kind, in return for either the referral of an individual, or the purchase, leasing, furnishing or arranging for the
    purchase, lease or order of a good, facility, item or service reimbursable under a federal healthcare program, such as the Medicare
    and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one
    hand, and prescribers, purchasers and formulary managers on the other. The PPACA amended the intent requirement of the federal Anti-Kickback
    Statute, such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    civil and criminal false claims laws and civil monetary penalty laws which prohibit, among other things, individuals or entities
    from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other government
    payors that are false or fraudulent. The PPACA provides, and recent government cases against pharmaceutical and medical device manufacturers
    support the view that federal Anti-Kickback Statute violations and certain marketing practices, including off-label promotion, may
    implicate the False Claims Act of 1863;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit,
    among other things, a person from knowingly and willfully executing a scheme or from making false or fraudulent statements to defraud
    any healthcare benefit program, regardless of the payor (e.g., public or private);</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
    (as amended by the Health Information Technology for Economic and Clinical Health Act of 2009), and their implementing regulations,
    which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information
    without appropriate authorization by entities subject to the rule, such as health plans, health care clearinghouses and health care
    providers, and their respective business associates that perform certain functions or activities that involve the use or disclosure
    of protected health information on their behalf;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    transparency laws, including the federal Physician Payment Sunshine Act, that require certain manufacturers of drugs, devices, biologics
    and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with
    specific exceptions, to report annually to the CMS information related to: (i) payments or other &#8220;transfers of value&#8221;
    made to physicians and teaching hospitals and (ii) ownership and investment interests held by physicians and their immediate family
    members;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
    consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm
    consumers; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
    and foreign law equivalents of each of the above federal laws, state and local laws that require drug manufacturers to report information
    related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state
    and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each
    other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Efforts
to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve
substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it
is possible that some of our business activities could be subject to challenge under one or more of such laws. It is possible that governmental
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving
applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws
or any other governmental regulations that may apply to us, we may be subject to significant criminal, civil and administrative sanctions
including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded
healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required
to curtail or restructure our operations, any of which could adversely affect our ability to operate our business and our results of
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the
regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation
of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s
attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable
systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that
a healthcare company may run afoul of one or more of the requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
substantial costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
generation, handling, use, storage, treatment, manufacture, transportation and disposal of, and exposure to, hazardous materials and
wastes, as well as laws and regulations relating to occupational health and safety. We contract with third parties that conduct operations
on our behalf that involve the use of hazardous and flammable materials, including chemicals and biologic materials. Our contractors
also produce and dispose of hazardous waste products. We cannot eliminate the risk of contamination or injury from these materials. In
the event of contamination or injury resulting from our contractors&#8217; use of hazardous materials, we could be held liable for any
resulting damages and any liability could exceed our resources, and our clinical trials or regulatory approvals could be suspended. We
also could incur significant costs associated with civil or criminal fines and penalties. Our third-party contractors may not carry specific
biological or hazardous waste insurance coverage, and their property, casualty and general liability insurance policies specifically
exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we maintain workers&#8217; compensation insurance for certain costs and expenses that we may incur due to injuries to our employees resulting
from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential
liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal
of biologic, hazardous or radioactive materials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations,
which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development
or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions
or liabilities, which could adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Computer
system failures, cyber-attacks or deficiencies in our, or related parties&#8217;, cyber security could result in a material disruption
of our product development programs, compromise sensitive information related to our business or trigger contractual and legal obligations,
any of which could potentially expose us to liability or reputational harm or otherwise adversely affect our business and financial results.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have implemented our security measures designed to protect the information (including but not limited to intellectual property, proprietary
business information and personal information) in our possession, custody or control. Our internal computer systems and those of current
and future third parties (such as vendors, CROs, collaborators or others) on which we rely may fail and are vulnerable to breakdown,
breach, interruption or damage from computer viruses, computer hackers, malicious code, employee error or malfeasance, theft or misuse,
denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism,
war, telecommunication and electrical failures or other compromise. Despite our security practices, there is a risk that we may be subject
to phishing and other cyberattacks in the future. The risk of a security breach or disruption, particularly through cyber-attacks or
cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity
and sophistication of attempted attacks and intrusions from around the world have increased.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against
all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate
from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations
or hostile foreign governments or agencies. Our information technology and other internal infrastructure systems, including corporate
firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations.
If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development
programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result
in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely
on third parties for the manufacture of our product candidates or any future product candidates and to conduct clinical trials, and similar
events relating to their computer systems could also have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
use, disclosure of or access to confidential or proprietary information, we could incur liability, our competitive position could be
harmed and the further development and commercialization of our product candidates or any future product candidates could be hindered
or delayed. If we were to experience a significant cybersecurity breach of our information systems or data, the costs associated with
the investigation, remediation and potential notification of the breach to counterparties, data subjects, regulators or others could
be material. In addition, our remediation efforts may not be successful. Moreover, if the information technology systems of our vendors,
CROs, collaborators or other contractors or consultants become subject to disruptions or security breaches, we may have insufficient
recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop
and implement protections to prevent future events of this nature from occurring. If we do not allocate and effectively manage the resources
necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption,
including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage
to intellectual property or other proprietary information. Furthermore, any such event that leads to unauthorized access, use, or disclosure
of personal information, including personal information regarding clinical trial participants or employees, could harm our reputation,
compel us to comply with federal and/or state breach notification laws and foreign law equivalents, cause us to breach our contractual
obligations, subject us to mandatory corrective action, and otherwise subject us to liability under laws, regulations and contracts that
protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational
damages. As cyber threats continue to evolve, we may be required to incur significant additional expenses in order to enhance our protective
measures or to remediate any information security vulnerability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance
that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would
otherwise protect us from liabilities or damages as a result of the events referenced above.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in response to the ongoing COVID-19 pandemic, varying parts of our workforce are currently working remotely on a part or full-time
basis. This could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication
disruptions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to the Ownership of Our Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
prices of the ADSs and our ordinary shares may be volatile and fluctuate substantially, which could result in substantial losses for
holders of the ADSs and our ordinary shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market prices of the ADSs on the Nasdaq Capital Market and of our ordinary shares on LSE may be volatile and fluctuate substantially.
The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme
volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, holders
of the ADSs and our ordinary shares may not be able to sell their ADSs or ordinary shares at or above the price at which they were purchased.
The market price for the ADSs and ordinary shares may be influenced by many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    success of competitive products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials of OK-101, OK-201 and any other future product candidate that we develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of clinical trials of product candidates of our competitors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    or developments in laws or regulations applicable to OK-101, OK-201 and any other future product candidates that we
    develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    entry into, and the success of, any collaboration agreements with third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
    or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    recruitment or departure of key personnel;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of expenses related to any of our product candidates or clinical development programs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of our efforts to discover, develop, acquire or in-license additional product candidates, products or technologies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
    in our financial results or those of companies that are perceived to be similar to us;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions in the biotechnology and pharmaceutical sectors;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    economic, industry and market conditions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of ADSs on the Nasdaq Capital Market and of our ordinary shares on LSE; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    other factors described in this &#8220;Risk Factors&#8221; section</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Holders
of our ADSs have fewer rights than our shareholders and must act through the depositary to exercise their rights.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our ADSs do not have the same rights as our shareholders and may only exercise their voting rights with respect to the underlying
ordinary shares in accordance with the provisions of the deposit agreement. Holders of the ADSs will appoint the depositary or its nominee
as their representative to exercise the voting rights attaching to the ordinary shares represented by the ADSs. When a general meeting
is convened, if you hold ADSs, you may not receive sufficient notice of a shareholders&#8217; meeting to permit you to withdraw the ordinary
shares underlying your ADSs to allow you to vote with respect to any specific matter. We will make all commercially reasonable efforts
to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you will receive voting materials
in time to instruct the depositary to vote, and it is possible that you, or persons who hold their ADSs through brokers, dealers or other
third parties, will not have the opportunity to exercise a right to vote. Furthermore, the depositary will not be liable for any failure
to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, you
may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your
capacity as an ADS holder, you will not be able to call a shareholders&#8217; meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
rights of our shareholders may differ from the rights typically offered to shareholders of a U.S. corporation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. The rights of holders of ordinary shares and, therefore, certain of the rights of any potential
future holders of ADSs, are governed by the laws of Guernsey, including the provisions of the Companies Law (Guernsey) 2008, and by our
Memorandum and Articles of Incorporation, or Articles. These rights differ in certain respects from the rights of shareholders in typical
U.S. corporations. See &#8220;Description of Share Capital and Memorandum and Articles of Incorporation &#8212;-Differences in Corporate
Law&#8221; in this report for a description of the principal differences between the provisions of the Guernsey Companies Law applicable
to us and, for example, the Delaware General Corporation Law relating to stockholders&#8217; rights and protections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause
us to incur debt or assume contingent liabilities and subject us to other risks.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to continue to evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary drugs,
intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    operating expenses and cash requirements;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    assumption of additional indebtedness or contingent liabilities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assimilation
    of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership,
    merger or acquisition;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
    and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing
    drugs or drug candidates and regulatory approvals; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition
    or even to offset the associated acquisition and maintenance costs.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a Foreign Private Issuer (&#8216;FPI&#8217;), we are exempt from a number of rules under the U.S. securities laws and are permitted
to file less information with the SEC than U.S. public companies</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an FPI, as defined in the SEC rules and regulations and, consequently, we are not subject to all of the disclosure requirements applicable
to companies organized within the United States. For example, we are exempt from certain rules under the Exchange Act, that regulate
disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a
security registered under the Exchange Act. In addition, our officers and directors are exempt from the reporting and &#8220;short-swing&#8221;
profit recovery provisions of Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. public
companies. We are also not required to file financial statements prepared in U.S. GAAP, to comply with Regulation FD and the proxy
rules. Accordingly, there may be less publicly available information concerning our company than there is for U.S. public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we will file an annual report on Form 20-F within four months of the close of each fiscal year ended March 31 and reports on
Form 6-K relating to certain material events promptly after we publicly announce these events. However, because of the above exemptions
for FPIs, our ADS holders will not be afforded the same protections or information generally available to investors holding shares in
public companies organized in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>While
we are an FPI, we are not subject to certain Nasdaq corporate governance rules applicable to U.S. listed companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are entitled to rely on a provision in Nasdaq&#8217;s corporate governance rules that allows us to follow the laws of Guernsey and rules
applicable to companies admitted to listing on the standard segment of the Official List of the FCA and to trading on the Main Market
of the London Stock Exchange, including, but not limited to, the Listing Rules and the Disclosure Guidance and Transparency Rules, or
DTRs, of the FCA with regard to certain aspects of corporate governance. This allows us to follow certain corporate governance practices
that differ in significant respects from the corporate governance requirements applicable to U.S. companies listed on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we have elected to rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies admitted
to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock Exchange instead
of Nasdaq regulations that require a listed U.S. company to (i) have a majority of the board of directors consist of independent directors,
(ii) require non-management directors to meet on a regular basis without management present and (iii) promptly disclose any waivers of
the code for directors or executive officers that should address certain specified items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 40pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Nasdaq listing, our audit, risk and disclosure committee are required to comply with the provisions of Section
301 of the Sarbanes-Oxley Act and Rule 10A-3 of the Exchange Act, both of which are also applicable to Nasdaq-listed U.S. companies.
Because we have elected to rely on the exemption allowing us to follow the laws of Guernsey and rules applicable to companies
admitted to listing on the standard segment of the Official List of the FCA and to trading on the Main Market of the London Stock
Exchange, however, our audit, risk and disclosure committee is not subject to additional Nasdaq requirements applicable to listed
U.S. companies, including an affirmative determination that all members of the audit, risk and disclosure committee are
&#8220;independent,&#8221; using more stringent criteria than those applicable to us as an FPI. Furthermore, Nasdaq&#8217;s
corporate governance rules require listed U.S. companies to, among other things, seek shareholder approval for the implementation of
certain equity compensation plans and issuances of ordinary shares, however as an FPI, we may elect to follow the rules applicable to companies admitted to listing on the Main Market of the London Stock Exchange in lieu of these Nasdaq
requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may lose our FPI status, which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to
incur significant legal, accounting and other expenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an FPI, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable
to U.S. domestic issuers. We may no longer be an FPI as early as September 30, 2023 (the end of our second fiscal quarter in the fiscal
year following this Nasdaq listing), which would require us to comply with all of the periodic disclosure and current reporting requirements
of the Exchange Act applicable to U.S. domestic issuers as of March 31, 2024. In order to maintain our current status as an FPI, either
(a) a majority of our outstanding voting securities must be either directly or indirectly owned of record by non-residents of the United
States or (b)(i) a majority of our executive officers or directors cannot be U.S. citizens or residents, (ii) more than 50% of our assets
must be located outside the United States and (iii) our business must be administered principally outside the United States. If we lose
our status as an FPI, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic
issuers, which are more detailed and extensive than the requirements for FPIs. We may also be required to make changes in our corporate
governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities
laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than
the cost we would incur as an FPI. As a result, we expect that a loss of FPI status would increase our legal and financial compliance
costs and is likely to make some activities highly time consuming and costly. We also expect that if we were required to comply with
the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director
and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage.
These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an emerging growth company (EGC) within the meaning of the Securities Act of 1933, or the Securities Act, and will take advantage
of certain reduced reporting requirements.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC, as defined in the Jumpstart Our Business Startups (JOBS) Act, 2012). For as long as we continue to be an EGC, we may
take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs,
including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, or
Section 404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder
approval of any golden parachute payments not previously approved. As an EGC, we are required to report only two years of financial
results and selected financial data compared to three and five years, respectively, for comparable data reported by other public
companies. We may take advantage of these exemptions until we are no longer an EGC. We could be an EGC for up to five years,
although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ADSs held by
non-affiliates exceeds $700 million as of any September 30 (the end of our second fiscal quarter) before that time, in which case we
would no longer be an EGC as of the following March 31 (our fiscal year-end). We cannot predict if investors will find our ADSs less
attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less
active trading market for our ADSs and the price of our ADSs may be more volatile in the event that we decide to make an offering of
our ADSs following our Nasdaq listing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to establish and maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable
regulations could be impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.05in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
404(a) of the Sarbanes-Oxley Act, or Section 404(a), requires that beginning with our second annual report following our IPO, management
assess and report annually on the effectiveness of our internal control over financial reporting and identify any material weaknesses
in our internal control over financial reporting. Although Section 404(b) of the Sarbanes-Oxley Act, or Section 404(b), requires our
independent registered public accounting firm to issue an annual report that addresses the effectiveness of our internal control over
financial reporting, we have opted to rely on the exemptions provided in the JOBS Act, and consequently will not be required to comply
with SEC rules that implement Section 404(b) until such time as we are no longer an EGC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our first Section 404(a) assessment will take place for our annual report for the fiscal year ending March 31, 2023. The presence
of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports, delays
in our financial reporting, which could require us to restate our operating results or our auditors may be required to issue a qualified
audit report. We might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance
with Section 404 (a). In order to maintain and improve the effectiveness of our disclosure controls and procedures and internal control
over financial reporting, we will need to expend significant resources and provide significant management oversight.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implementing
any appropriate changes to our internal control may require specific compliance training of our directors and employees, entail substantial
costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&#8217;s
attention from other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either we are unable to conclude that we have effective internal control over financial reporting or, at the appropriate time, our independent
auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal control over financial
reporting as required by Section 404(b), then in the event we have decided to make an offering of our ADSs following our Nasdaq listing,
investors may lose confidence in our operating results, the price of our ADSs could decline and we may be subject to litigation or regulatory
enforcement actions. In addition, if we are unable to meet the requirements of Section 404, we may not be able to remain listed on Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will incur significant increased costs as a result of operating as a company that publicly listed on Nasdaq in the United States, and
our management will be required to devote substantial time to new compliance initiatives.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.S. public company, and particularly after we no longer qualify as an EGC, we will incur significant legal, accounting and other expenses
that we did not incur previously. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 1987, the
listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on non-U.S. reporting
public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance
practices. Our senior management and other personnel will need to devote a substantial amount of time to these compliance initiatives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming
and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director
and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management
personnel or members for our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance
practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404, we will be required to furnish a report by our senior management on our internal control over financial reporting. However,
while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued
by our independent registered public accounting firm. To prepare for eventual compliance with Section 404, which is required once we
no longer qualify as an EGC, we will be engaged in a process to document and evaluate our internal control over financial reporting,
which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside
consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue
steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement
a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that
we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective
as required by Section 404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets
due to a loss of confidence in the reliability of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ADS
holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less favorable
results to the plaintiff(s) in any such action.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
deposit agreement governing the ADSs representing our ordinary shares provides that holders and beneficial owners of ADSs irrevocably
waive the right to a trial by jury in any legal proceeding arising out of or relating to the deposit agreement or the ADSs, including
claims under federal securities laws, against us or the depositary to the fullest extent permitted by applicable law. If this jury trial
waiver provision is prohibited by applicable law, an action could nevertheless proceed under the terms of the deposit agreement with
a jury trial. To our knowledge, the enforceability of a jury trial waiver under the federal securities laws has not been finally adjudicated
by a federal court. However, we believe that a jury trial waiver provision is generally enforceable under the laws of the State of New
York, which govern the deposit agreement, by a court of the State of New York or a federal court, which have non-exclusive jurisdiction
over matters arising under the deposit agreement, applying such law. In determining whether to enforce a jury trial waiver provision,
New York courts and federal courts will consider whether the visibility of the jury trial waiver provision within the agreement is sufficiently
prominent such that a party has knowingly waived any right to trial by jury. We believe that this is the case with respect to the deposit
agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or
counterclaim sounding in fraud or one which is based upon a creditor&#8217;s negligence in failing to liquidate collateral upon a guarantor&#8217;s
demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the
case of the deposit agreement or the ADSs. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver
by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any provision of the federal securities laws.
If you or any other holder or beneficial owner of ADSs brings a claim against us or the depositary in connection with matters arising
under the deposit agreement or the ADSs, you or such other holder or beneficial owner may not be entitled to a jury trial with respect
to such claims, which may have the effect of limiting and discouraging lawsuits against us and / or the depositary. If a lawsuit is brought
against us and / or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court,
which would be conducted according to different civil procedures and may augur different results than a trial by jury would have had,
including results that could be less favorable to the plaintiff(s) in any such action, depending on, among other things, the nature of
the claims, the judge or justice hearing such claims, and the venue of the hearing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Claims
of U.S. civil liabilities may not be enforceable against us.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. Certain members of our board of directors and senior management are not residents of the
United States, and all or a substantial portion of our assets and the assets of such persons are located outside the United States. As
a result, it may not be possible to serve process on such persons or us in the United States or to enforce judgments obtained in U.S.
courts against them or us based on civil liability provisions of the securities laws of the United States. As a result, it may not be
possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S.
courts against them or us, including judgments predicated upon the civil liability provisions of the U.S. federal securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Description of Share Capital and Memorandum and Articles of Incorporation&#8212;Enforcement of Civil Liabilities.&#8221; Additionally,
it may be difficult to assert securities law claims in actions originally instituted outside of the United States. Foreign courts may
refuse to hear a securities law claim because foreign courts may not be the most appropriate forum in which to bring such a claim. Even
if a foreign court agrees to hear a claim, it may determine that the law of the jurisdiction in which the foreign court resides, and
not U.S. law, is applicable to the claim. Further, if U.S. law is found to be applicable, the content of applicable U.S. law must be
proved as a fact, which can be a time-consuming and costly process, and certain matters of procedure would still be governed by the law
of the jurisdiction in which the foreign court resides.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
rights afforded to shareholders are governed by Guernsey law. Not all rights available to shareholders under English law or U.S. law
will be available to shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights afforded to shareholders will be governed by Guernsey law and by our Articles, and these rights differ in certain respects from
the rights of shareholders in typical English companies and U.S. corporations. In particular, Guernsey law significantly limits the circumstances
under which shareholders of companies may bring derivative actions and, in most cases, only the corporation may be the proper claimant
or plaintiff for the purposes of maintaining proceedings in respect of any wrongful act committed against it. Neither an individual nor
any group of shareholders has any right of action in such circumstances. In addition, Guernsey law does not afford appraisal rights to
dissenting shareholders in the form typically available to shareholders of a U.S. corporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
insolvency laws of Guernsey and other jurisdictions may not be as favorable to you as the U.S. bankruptcy laws.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of Guernsey. In the event of a bankruptcy, insolvency or similar event, proceedings could be initiated
in Guernsey or another relevant jurisdiction. The bankruptcy, insolvency, administrative and other laws of our and our subsidiaries&#8217;
jurisdictions of organization or incorporation may be materially different from, or in conflict with, each other and those of the United
States, including in the areas of rights of creditors, shareholders, priority of governmental and other creditors and duration of the
proceeding. The application of these laws, or any conflict among them, could call into question whether any particular jurisdiction&#8217;s
law should apply, adversely affecting your ability to enforce your rights under the ordinary shares underlying our ADSs in those jurisdictions
or limit any amounts that you may receive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are a passive foreign investment company (&#8216;PFIC&#8217;), there could be adverse U.S. federal income tax consequences to U.S.
holders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Internal Revenue Code of 1986, or the Internal Revenue Code, we will be a PFIC for any taxable year in which (1) 75% or more of our
gross income consists of passive income or (2) 50% or more of the average quarterly value of our assets consists of assets that produce,
or are held for the production of, passive income. For purposes of these tests, passive income includes dividends, interest, gains from
the sale or exchange of investment property and certain rents and royalties. In addition, for purposes of the above calculations, a non-U.S.
corporation that directly or indirectly owns at least 25% by value of the shares of another corporation is treated as if it held its
proportionate share of the assets and received directly its proportionate share of the income of such other corporation. If we are a
PFIC for any taxable year during which a U.S. Holder (as defined below under &#8220;Certain U.S. and Guernsey Tax Considerations-Material
U.S. Federal Income Tax Considerations for U.S. Holders&#8221;) holds our shares, the U.S. Holder may be subject to adverse tax consequences
regardless of whether we continue to qualify as a PFIC, including ineligibility for any preferred tax rates on capital gains or on actual
or deemed dividends, interest charges on certain taxes treated as deferred, and additional reporting requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that we were a PFIC for our taxable year ended March 31, 2022 but cannot provide any assurances regarding our PFIC status
for any past, current or future taxable years. The determination of whether we are a PFIC is a fact-intensive determination made on an
annual basis applying principles and methodologies which in some circumstances are unclear and subject to varying interpretation. In
particular, the characterization of our assets as active or passive may depend in part on our current and intended future business plans,
which are subject to change. In addition, for our current and future taxable years, the total value of our assets for PFIC testing purposes
may be determined in part by reference to the market price of our ordinary shares or ADSs from time to time, which may fluctuate considerably.
Under the income test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into
in the future and our corporate structure. The composition of our income and assets is also affected by how, and how quickly, we spend
the cash we raise in any offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain circumstances, a U.S. Holder of shares in a PFIC may alleviate some of the adverse tax consequences described above by making,
where available, a qualified electing fund, or QEF, election to include in income its pro rata share of the corporation&#8217;s income
on a current basis or a mark-to-market election. A U.S. Holder may make a QEF election with respect to our ordinary shares or ADSs only
if we agree to furnish such U.S. Holder annually with a PFIC annual information statement as specified in the applicable U.S. Treasury
Regulations. We currently do not intend to prepare or provide the information that would enable U.S. Holders to make a QEF election if
we are treated as a PFIC for any taxable year, and prospective investors should assume that a QEF election will not be available. A U.S.
Holder may be able to make a mark-to-market election with respect to our ADSs if our ADSs are treated as &#8220;marketable stock.&#8221;
Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within
the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded during any calendar year during which such
class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Our ADSs will be marketable
stock as long as they remain listed on Nasdaq and are regularly traded. There can be no assurance that out ADSs will remain listed on
Nasdaq or be regularly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, see
the section of this report entitled &#8220;Certain U.S. and Guernsey Tax Considerations-Material U.S. Federal Income Considerations for
U.S. Holders.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
change in our tax residence could have a negative effect on our future profitability.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are incorporated under the laws of Guernsey, our affairs are, and are intended to continue to be, managed and controlled in the United
Kingdom for tax purposes and therefore we are resident in the United Kingdom for U.K. and Guernsey tax purposes. It is possible that
in the future, whether as a result of a change in law or the practice of any relevant tax authorities or as a result of any change in
the conduct of our affairs or for any other reason, we could become, or be regarded as having become, a resident in a jurisdiction other
than the United Kingdom. If we cease to be a U.K. tax resident, we may be subject to a charge to U.K. corporation tax on chargeable gains
on our assets and to unexpected tax charges in other jurisdictions on our income. Similarly, if the tax residency of any of our subsidiaries
were to change from their current jurisdiction for any of the reasons listed above, we may be subject to a charge to local capital gains
tax on the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit
from favorable U.K. tax legislation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a U.K. resident trading entity, we are subject to U.K. corporate taxation. Due to the nature of our business, we have generated losses
since inception. As of March 31, 2022, we had cumulative carryforward tax losses of $15,870,525. Subject to any relevant restrictions,
we expect these to be available to carry forward and offset against future operating profits. As a company that carries out extensive
research and development activities, we benefit from the U.K. research and development tax credit regime for small and medium-sized companies,
whereby we are able to surrender the trading losses that arise from our qualifying research and development activities for a payable
tax credit of up to 33.35% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs
for research staff, consumables and certain internal overhead costs incurred as part of research projects. Certain subcontracted qualifying
research expenditures are eligible for a cash rebate of up to 21.67%. The majority of our pipeline research, clinical trials management
and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. Our ability to continue
to claim payable research and development tax credits in the future may be limited because we may no longer qualify as a small or medium-sized
company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may benefit in the future from the United Kingdom&#8217;s &#8220;patent box&#8221; regime, which allows certain profits attributable
to revenues from patented products to be taxed at an effective rate of 10%. We are the exclusive licensee or owner of several patent
applications which, if issued, would cover our product candidates, and accordingly, future upfront fees, milestone fees, product revenues
and royalties could be taxed at this tax rate. When taken in combination with the enhanced relief available on our research and development
expenditures, we expect a long-term lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to
the U.K. research and development tax credit regime or the &#8220;patent box&#8221; regime, or for any reason we are unable to qualify
for such advantageous tax legislation, or we are unable to use net operating loss and tax credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
and uncertainties in the tax system in the countries in which we have operations could materially adversely affect our financial condition
and results of operations and reduce net returns to our shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes
in the interpretation thereof by the tax authorities in the United Kingdom, the United States and other jurisdictions as well as being
affected by certain changes currently proposed by the Organization for Economic Co-operation and Development and their action plan on
Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which
we operate, particularly if such trends continue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future
effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues
arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities;
(4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with
acquisitions; (5) changes in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws,
and changes in generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, Her Majesty&#8217;s
Revenue &amp; Customs, or HMRC, the U.S. Internal Revenue Service, or IRS, or another tax authority could challenge our allocation of
income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer
pricing policies, including methodologies for valuing developed technology and amounts paid with respect to our intellectual property
development. Similarly, a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established
a taxable connection, often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion,
if successful, could increase our expected tax liability in one or more jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
tax authority may take the position that material income tax liabilities, interest and penalties are payable by us, for example where
there has been a technical violation of contradictory laws and regulations that are relatively new and have not been subject to extensive
review or interpretation, in which case we expect that we might contest such assessment. High-profile companies can be particularly vulnerable
to aggressive application of unclear requirements. Many companies must negotiate their tax bills with tax inspectors who may demand higher
taxes than applicable law appears to provide. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in
disputing the assessment, the implications could increase our anticipated effective tax rate, where applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties
do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for
or commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs,
to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs.
In engaging these third parties, we typically have to, and expect to have to, negotiate budgets and contracts, which may result in delays
to our development timelines and increases costs. Additionally, there is a limited number of qualified third-party service providers
that specialize or have the expertise required to achieve our business objectives, and so it may be challenging to find alternative investigators
or CROs, or do so on commercially reasonable terms. We rely on these parties for execution of our preclinical studies and clinical trials,
and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our preclinical studies
and clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required
to comply with GCP requirements, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States
of the European Economic Area and comparable foreign regulatory authorities for all of our product candidates in clinical development.
Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical
trial sites. If we fail to exercise adequate oversight over any of our CROs or if we or any of our CROs fail to comply with applicable
GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or other regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon a regulatory
inspection of us or our CROs or other third parties performing services in connection with our clinical trials, such regulatory authority
will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with
product produced under applicable cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials,
which would delay the regulatory approval process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
these investigators and CROs are not our employees, and we will not be able to control, other than by contract, the amount of resources,
including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote
sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise
the prospects for approval and commercialization of our product candidates. These investigators and CROs may also have relationships
with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development
activities, which could affect their performance on our behalf. In addition, the use of third-party service providers requires us to
disclose our proprietary information to these parties, which increases the risk that a competitor will discover them or that this information
will be misappropriated or disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or
to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected
deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure
to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results
of operations and commercial prospects would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repeating
clinical trials or switching or engaging additional CROs involves additional cost and requires our management&#8217;s time and focus.
In addition, there is a natural transition period when a clinical trial has to be repeated or when a new CRO commences work. As a result,
delays could occur, which could materially impact our ability to meet our desired clinical development timelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have engaged CROs specializing in ophthalmic drug development, to prepare and support the IND filing, and we must, at times, share
our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary
technology, in part, by entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative
research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and consultants
prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties
to use or disclose our confidential information. Despite the contractual provisions employed when working with third parties, the
need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements.
Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our
proprietary technology and confidential information or other unauthorized use or disclosure of such technology or information would
impair our competitive position and may have an adverse effect on our business, financial condition, results of operations and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of these agreements,
independent development or publication of information including our trade secrets by third parties. A competitor&#8217;s discovery of
our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition, results of operations
and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
utilize, and expect to continue to utilize, third parties to conduct our product manufacturing for the foreseeable future, and these
third parties may not perform satisfactorily.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will rely on contract manufacturing organizations (CMOs) for the manufacturing of clinical batches and intend to continue to rely on
third parties to manufacture our preclinical study and clinical trial product supplies. If our current CMOs, or any future third-party
manufacturers, do not successfully carry out their contractual duties, meet expected deadlines or manufacture our product candidates
in accordance with regulatory requirements, or if there are disagreements between us and our CMOs or any future third-party manufacturers,
we will not be able to complete, or may be delayed in completing, the preclinical studies required to support future investigational
new drug, or IND, submissions and the clinical trials required for approval of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to our current CMOs, we may rely on additional third parties to manufacture ingredients of our product candidates in the future
and to perform quality testing, and reliance on these third parties entails risks to which we would not be subject if we manufactured
the product candidates ourselves, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    control for certain aspects of manufacturing activities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    or nonrenewal of manufacturing and service agreements with third parties in a manner or at a time that is costly or damaging to us;
    and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
    to the operations of our third-party manufacturers and service providers caused by conditions unrelated to our business or operations,
    including the bankruptcy of the manufacturer or service provider.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize
any of our product candidates. Some of these events could be the basis for FDA, EMA or other regulatory authority action, including injunction,
recall, seizure or total or partial suspension of product manufacture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent we rely on a third-party manufacturing facility for commercial supply, that third party will be subject to significant regulatory
oversight with respect to manufacturing our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of therapeutics for clinical trials or commercial sale is subject to extensive regulation. Components of a finished therapeutic
product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP requirements.
These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality
systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes
can lead to the introduction of outside agents or other contaminants, or to inadvertent changes in the properties or stability of a product
candidate that may not be detectable in final product testing. To the extent that we utilize third-party facilities for commercial supply,
the third party&#8217;s facilities and quality systems must pass an inspection for compliance with the applicable regulations as a condition
of regulatory approval. In addition, the regulatory authorities may, at any time, audit or inspect the third-party manufacturing facility
or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If, for example,
these facilities do not pass a plant inspection, the FDA will not approve the applicable New Drug Application (&#8216;NDA&#8217;) or
biologics license application, or BLA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not directly control the manufacturing of, and are completely dependent on, our CMOs for compliance with cGMP requirements. If our
CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA,
EMA or other regulatory authorities, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities.
In addition, we have no direct control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified
personnel. Furthermore, all of our CMOs are engaged with other companies to supply and/or manufacture materials or products for such
companies, which exposes our CMOs to regulatory risks for the production of such materials and products. As a result, failure to meet
the regulatory requirements for the production of those materials and products may generally affect the regulatory clearance of our CMOs&#8217;
facilities. Our failure, or the failure of third parties, to comply with applicable regulations could result in sanctions being imposed
on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our products and product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
potential future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins
and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.85pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_005"></span>ITEM
4: INFORMATION ON THE COMPANY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.85pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
History and Development of the Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.85pt; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated in the British Virgin Islands as a British Virgin Islands Business Company on July 4, 2007 under the BVI
Business Companies Act 2004 with company number 1415559 under the name Jellon Enterprises, Inc. Our legal and commercial name was changed
to Minor Metals &amp; Mining, Inc. on October 24, 2007, to Emerging Metals Limited on November 28, 2007, to West African Minerals Corporation
on December 9, 2011, and to OKYO Pharma Corporation on January 10, 2018. On March 9, 2018, shareholders approved the cancellation of
our AIM listing and migration to Guernsey. On July 3, 2018, following the approval of the Guernsey Companies Registry, we were registered
under the Guernsey Companies Law under the name OKYO Pharma Limited, as a Guernsey company with limited liability, an indefinite life
and company number 65220. We are domiciled in Guernsey. On July 17, 2018, our Ordinary Shares were admitted to listing on the standard
segment of the Official List of the FCA and admitted to trading on the standard listing of the Main Market of the London Stock Exchange.
We are subject to the Takeover Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
registered office is located at Martello Court, Admiral Park, St. Peter Port, Guernsey GY1 3HB and our telephone number is +44 (0) 20
7495 2379. Our website address is www.okyopharma.com. The reference to our website is an inactive textual reference only and the information
contained in, or that can be accessed through, our website is not a part of this annual report. Our agent for service of process in the
United States is OKYO Pharma US, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers, such
as us, that file electronically, with the SEC at www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Business Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory
eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays
a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting
inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product
candidate, for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic
pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical
analogue candidate for the treatment of neuropathic ocular pain, and plan on maintaining this drug candidate at the exploratory level
while we focus our primary energy on the OK-101 program. We have not yet submitted an application to the Food and Drug Administration
(&#8220;FDA&#8221;) for any of our product candidates. We have however significantly advanced our ongoing Investigational New Drug (&#8220;IND)
enabling work on our lead candidate OK-101 during this past year for an IND submission for OK-101 to treat dry eye and are presently
on schedule to file an IND on OK-101 to treat dry eye disease in the fourth quarter of 2022. (see Figure 1 below).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1. OKYO Pipeline</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form20-f_001.jpg" alt="Chart&#10;&#10;Description automatically generated with medium confidence" style="height: 191px; width: 461px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*Anticipated
IND Submission date Q4, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>**Topical
drug delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
evidence from over 40 years of scientific literature suggests inflammation as the most common underlying cause of DED. An increase in
the levels of inflammatory cytokines in both conjunctiva and tears is known to cause the chronic inflammation associated with DED. Consequently,
development of new therapeutic agents that target inflammatory pathways is crucial in improving symptoms in DED patients. On February
21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license from OTT
to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our ophthalmic
disease drug programs. These licenses gave us the right to exploit the IP estate which is directed to compositions-of-matter and methodologies
for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We also have a license from TMC to a separate
IP estate for treating symptoms of ocular neuropathic pain, uveitis and associated pain. The scope of our use of the TMC IP granted to
us through the sublicense with OTT is commensurate with the scope of use of the IP granted to OTT from TMC. This intellectual property
forms the basis of our OK-101 program, which is discussed in greater detail below</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>OK-101</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101,
our lead preclinical product candidate, is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial
disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. DED is one
of the most common ophthalmic conditions encountered in clinical practice. Symptoms of DED include constant discomfort and irritation
accompanied by inflammation of the ocular surface, visual impairment and potential damage to the ocular surface. There are presently
approximately 20 million people suffering from DED in the U.S. alone (Farrand et al. AJO 2017; 182:90), with the disease affecting approximately
up to 34% of the population aged 50+ (Dana et al. AJO 2019; 202:47), and with women representing approximately two-thirds of those affected
(Matossian et al. J Womens Health (Larchmt) 2019; 28:502&#8211;514). Prevalence of DED is anticipated to increase substantially in the
next 10-20 years due to aging populations in the U.S., Europe, Japan and China and use of contact lenses in the younger population. We
believe this increase in prevalence of dry eye syndrome represents a major expanding economic burden to public healthcare. According
to Market Research Report, Dry Eye Syndrome, December 2020, the global DED market in 2019 was approximately $5.22 billion, with the market
size expected to reach $6.54 billion by 2027. In addition, DED causes approximately $3.8 billion annually in healthcare costs and represents
a major economic burden to public healthcare, accounting for more than $50 billion to the U.S. economy annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, there are essentially three major prescription drugs used to treat DED: 1) R Cyclosporine (Restasis&#174; &amp; Cequa&#174;),
2) Lifitegrast (Xiidra&#174;), and 3) Varenicline (Tyrvaya&#174;). However, DED continues to be a major unmet medical need due to the large
number of patients not well served by present-day treatments due to their lack of adequate efficacy, slow onset of action and poor side
effect profile. The development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient
population suffering from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease
in well-controlled clinical trials. The evidence from over 40 years of scientific literature, however, suggests inflammation as the most
common underlying cause of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is crucial in improving
symptoms in DED patients. OK-101 is focused on an anti-inflammatory pathway for treating dry eye.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
is designed to target a chemokine-like receptor 1, or CMKLR1, or CHEMR23, which is a G protein-coupled receptor expressed on macrophages,
neutrophils, monocytes, plasmacytoid/myeloid dendritic cells, natural killer cells and nonhemopoietic cell types, such as endothelial
and epithelial cells. Activation of CMKLR1 by its endogenous peptide ligand chemerin is known to modulate inflammation, but natural ligands
for CMKLR1 have short half-lives due to rapid inactivation. Discovery of OK-101, a stable, high potency CMKLR1 agonist by On Target Therapeutics
(Note: technology licensed to OKYO Pharma Limited) provided an important step toward the development of a new class of anti-inflammatory
therapeutics that can be applied to the treatment of ophthalmic diseases including DED, uveitis and ocular pain. (See Figure 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form20-f_002.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="height: 337px; width: 530px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
2</b>. OK-101 binds to CHEMR23 receptor producing an anti-inflammatory response</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key driver in the development of OK-101 to treat DED, uveitis and other ocular conditions was an analysis of the inherent advantages
and difficulties associated with the treatment of ocular conditions. One of the major issues with topical administration of any drug
designed for treating DED is the requirement that the drug have adequate drug &#8216;residence&#8217; time at the ocular site to afford
a pharmacologic benefit before being washed out through natural processes of tear enhancement and lacrimal tear drainage. The drug candidates
we have developed are designed to combat washout by including a lipid &#8216;anchor&#8217; within the candidate drug molecule to enhance
the residence time of the drug in the eye. We refer to our candidates for DED as &#8220;lipidated-chemerin&#8221; analogues to highlight
this pharmacologic characteristic. Figure 3 shows the significance of including a lipid anchor in the &#8220;chemerin&#8221; molecule
on drug potency and wash resistance conducted in a series of <i>in vitro</i> studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_003.jpg" alt="Diagram&#10;&#10;Description automatically generated" style="height: 579px; width: 514px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
3</b> shows the significance of including a lipid anchor in the &#8220;chemerin&#8221; molecule on drug potency and wash resistance conducted
in a series of <i>in vitro</i> studies. HEK293 cells were transiently transfected with cDNAs encoding human chemerin receptor CMKLR1.
Twenty-four hours after transfection, cells were stimulated with increasing concentrations of OK-101 for 15 min and luciferase activity
was determined as described (<i>Doyle J et al, J. Biol. Chem. 2014). </i>Data points represent the mean Standard Error. from at least three independent
experiments, each performed in triplicate. The lipidated stable chemerin analog OK-101 showed a 50-fold higher potency against human
chemerin receptor than the corresponding non-lipidated peptide (Figure 3 top panel). Signaling of the lipidated stable chemerin analog
OK-101 persisted despite serial washes, whereas activity of the non-lipidated peptide was markedly diminished (Figure 3 bottom panel).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potency of OK-101 was first determined in a cell-based PathHunter&#174; &#946;-Arrestin assay. This assay monitors the activation of a
GPCR in a homogenous, non-imaging assay format using a technology developed by DiscoverX called Enzyme Fragment Complementation (EFC)
with &#946;-galactosidase (&#946;-Gal) as the functional reporter. The enzyme is split into two inactive complementary portions (EA for
Enzyme Acceptor and PK for ProLink) expressed as fusion proteins in the cells. EA is fused to &#946;-Arrestin and PK is fused to human
Chemokine-like receptor 1, CMKLR1. Activation of CMKLR1-PK induces &#946;-Arrestin-EA recruitment, forcing complementation of the two
&#946;-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent
signal, which is measured using chemiluminescent PathHunter&#174; Detection Reagents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assay
Design: PathHunter cell lines co-expressing the ProLink&#8482; (PK) tagged GPCR (human Chemokine-like receptor 1, CMKLR1) and the Enzyme
Acceptor (EA) tagged &#946;-Arrestin were expanded from freezer stocks according to standard procedures. Cells were seeded in a total
volume of 20 &#956;L into white walled, 384-well microplates and incubated at 37&#176;C for the appropriate time prior to testing. For agonist
potency determination, cells were treated with various concentrations of peptide to induce response and incubated at 37&#176;C for 90
minutes. Assay signal was generated through a single addition of 12.5 or 15 &#956;L (50% v/v) of PathHunter Detection reagent cocktail,
followed by a one-hour incubation at room temperature. Microplates were read following signal generation with a PerkinElmer EnvisionTM
instrument for chemiluminescent signal detection. Compound activity was analyzed using CBIS data analysis suite (ChemInnovation, CA).
Figure 4 below shows the agonist activity of OK-101 against human chemerin receptor CMKLR1 determined using PathHunter&#174; &#946;-Arrestin
assay. OK-101 was shown to have a sub-nanomolar EC50 potency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_004.jpg" alt="" style="height: 237px; width: 339px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
4.</b> Agonist activity of OK-101 using PathHunter&#174; &#946;-Arrestin assay</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
further characterize the potential efficacy of OK-101 to treat DED, OK-101 was tested in a mouse model of acute DED. Animals were divided
into five separate cohorts that included: 1) non-stressed control animals untreated throughout the study, 2) animals treated with scopolamine
to induce acute DED, 3) animals treated with scopolamine to induce acute DED and treated with 0.1% cyclosporine as a positive control,
4) animals treated with scopolamine to induce acute DED and treated with phosphate buffer solution (the vehicle used for OK-101 delivery),
and 5) animals treated with scopolamine to induce acute DED and treated with OK-101 in phosphate buffered solution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Animals
in cohorts 1) and 2) were left untreated with test agents throughout the 5-day period, whereas animals in cohorts 3), 4) and 5) were
treated with either cyclosporine, or CS, vehicle or OK-101, respectively, twice a day during the 5-day period <i>via </i>bilateral topical
administration of the respective agents. On the fifth day, all of the animals were assessed for efficacy by evaluating corneal permeability,
a measure of dry-eye effectiveness, in live animals, as well as by exploring the impact of respective treatments on immune response.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5 shows the results from this animal study. Animals induced with scopolamine to generate acute DED showed a dramatic, statistically significant
increase in corneal permeability relative to na&#239;ve non-stressed animals. The addition of cyclosporine to scopolamine-induced DED
animals showed a statistically significant reduction of permeability (p &#8804; 0.001). Notably, OK-101 demonstrated a dramatic reduction
of DED-induced corneal permeability as well (p &#8804; 0.001). OK-101&#8217;s effect in reducing DED-induced corneal permeability was virtually
identical to that of the cyclosporine positive control and close to the baseline corneal permeability observed in non-stressed control
animals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_005.jpg" alt="Chart, bar chart&#10;&#10;Description automatically generated" style="height: 266px; width: 389px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
5</b>. Effect of various treatments on mouse corneal permeability. Corneal permeability was measured using Oregon Green Dextran (OGD)
staining followed by imaging. CS was positive control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the in-life portion of the study, immunohistochemistry was performed on frozen sections of enucleated mouse eyes to measure CD4+ T-cell
infiltration into the conjunctival epithelium of the eye (Figure 6). Animals induced to develop acute DED and not treated with drug (Vehicle
animals) showed significant infiltration of CD4+ T cells within the conjunctival epithelium, whereas OK-101 demonstrated a statistically
significant (p &#8804; 0.01) reduction in dry-eye-induced enhancement of CD4+ T-cells. In fact, the level of CD4+ T cells observed in OK-101
treated animals was equivalent to the CD4+ T cell level observed in na&#239;ve untreated animals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_006.jpg" alt="Chart&#10;&#10;Description automatically generated" style="height: 293px; width: 270px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
6</b>. CD4+ T cells in the conjunctival epithelium after acute DED induction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immunohistochemistry
was also performed on enucleated intact conjunctiva of mouse eyes fixed in 10% formalin, embedded in paraffin, and sectioned and stained.
DED typically leads to a loss of goblet cell density as was observed following induction of DED in the mice administered Vehicle (Figure
7). Whereas administration of OK-101 significantly rescued the DED-induced loss of Goblet Cells.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_007.jpg" alt="Chart&#10;&#10;Description automatically generated" style="height: 265px; width: 280px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
7</b>. Goblet Cell density following acute DED induction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in a separate set of animal model experiments, we evaluated pain-reducing activity of OK-101 in a ciliary nerve ligation mouse
model of corneal neuropathic pain. Neuropathic corneal pain is a severe, chronic and debilitating disease with no FDA approved commercially
available treatments currently available for this condition. In collaboration with Pedram Hamrah, MD, Professor of Ophthalmology, cornea
specialist, and clinician-scientist at Tufts Medical Center, Boston, we demonstrated that OK-101 suppresses neuropathic corneal pain
in a mouse model of neuropathic corneal pain developed in Dr. Hamrah&#8217;s laboratory. OK-101 was topically administered to mice in
comparison to the positive control gabapentin which was administered via intraperitoneal injection. Pain relief was evaluated by an eye-wipe
count, and OK-101 was shown to reduce corneal pain similar to that of gabapentin (Figure 8), a commonly used oral drug for neuropathic
pain. Notably, the drug concentration of OK-101 used in this study was identical to that used in mouse models of DED that demonstrated
ocular anti-inflammatory activity. OK-101 had no effect on corneal epithelial integrity compared to gabapentin or balanced salt solution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form20-f_008.jpg" alt="" style="height: 282px; width: 591px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Figure
8.</b> <i>OK-101 ameliorates neuropathic corneal pain in a mouse model of ciliary nerve ligation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
separate series of experiments were also performed to evaluate ocular tolerance of OK-101 in rabbits <i>via</i> repeated ocular instillation
followed by clinical ophthalmic observations. Rabbit ocular tolerance tests on OK-101 showed no adverse signs such as inflammation, chemosis
or hyperemia and no signs of local irritation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results from earlier DED animal model studies that have been performed with OK-101 as well as the additional animal study
illuminating the potential of OK-101 to reduce corneal neuropathic pain, we are moving forward with plans to file an IND in the
fourth quarter of 2022 on OK-101 to treat DED to enable us to begin clinical trials soon thereafter. During the second quarter of
2021 we successfully manufactured a 200-gram batch of OK-101 drug substance needed for the IND-enabling studies. To support the IND
preparatory work, we also signed an agreement in April 2021 with Ora Inc., a major CRO specializing in ophthalmic drug development who
is providing the following consulting services:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation
    of the OK-101 pre-IND briefing document</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    in requesting and preparing for the OK-101 pre-IND meeting with FDA</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for regulatory publishing and submission of IND in Electronic Common Technical Document (eCTD) format</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development of topical formulation for OK-101</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing
    quality oversight for development and qualification of a drug stability analysis method for OK-101 along with conducting stability
    studies to establish that the formulated drug product is stable for at least 90 days</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Support
    for completing animal toxicology studies in two animal species</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outlook
and Strategy for Development of OK-101 to Treat DED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development of new drugs to treat DED has been particularly challenging due to the heterogeneous nature of the patient population suffering
from DED, and due to the difficulties in demonstrating an improvement in both signs and symptoms of the disease in well-controlled clinical
trials. The evidence from over 40 years of scientific literature, however, suggests inflammation as the most common underlying cause
of DED. Consequently, development of new therapeutic agents that target inflammatory pathways is looking to be an attractive approach
in improving symptoms in DED patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022 we have significantly advanced our efforts to finish all IND-enabling activities and are presently on track to file an IND on OK-101
to treat DED in the fourth quarter of 2022. These ongoing activities have included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    topical formulation of the OK-101 drug product and initial stability studies</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finalizing
    the bioanalytical method development to support the OK-101 clinical program</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    batch manufacture of cGMP OK-101 for clinical trials</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicokinetic method development</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    toxicology studies in rabbits and dogs</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing
    stability studies of formulated OK-101</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on recent consultations with Ora, we plan to commence the first human study with OK-101 in the first quarter of 2023, and because
the drug is designed to be administered topically, we plan to skip the standard Phase 1 studies typically expected with orally
delivered or injectable drug candidates in non-life-threatening conditions. Consequently, this first trial is planned to be a
Phase 2 efficacy clinical trial in DED patients and is anticipated to be conducted in approximately 200 to 250 patients. The study
is being designed in conjunction with, and will be managed and monitored by Ora Inc. The Phase 2 trial is expected to be completed
in 6-8 months from enrollment of the first patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2022, we announced the successful completion of the pre-IND meeting facilitated by Ora with the FDA regarding development
plans for OK-101 to treat DED. Both nonclinical and clinical development milestones were covered in the pre-IND meeting, with the FDA
agreeing that our first human trial would be a Phase 2 safety and efficacy trial in DED patients. The FDA also provided guidance on the
planned protocol for this trial in DED patients, concurring with our decision to designate co-primary efficacy endpoints covering both
a sign and a symptom of DED in the clinical protocol of the trial. The decision to designate efficacy endpoints as primary endpoints
in this trial is highly significant as should this trial meet its prespecified primary endpoints, this result could accelerate the timeline
to an NDA filing with the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional
Applicable Disease Indications for OK-101</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ophthalmic
diseases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second related ophthalmic disease indication that is the target of our chemerin-based technology is uveitis. Uveitis is the third leading
cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis
can damage vital eye tissue, leading to permanent vision loss. Uveitis is currently treated with corticosteroid eyedrops and injections
that reduce inflammation, however, the long-term use of corticosteroids causes increased risk of cataracts and glaucoma, requiring close
monitoring for the drug&#8217;s potential side effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
we are in the clinic evaluating OK-101 to treat DED, we will also undertake the clinical plan to explore the drug candidate&#8217;s
potential to suppress the inflammation associated with uveitis. In support of this plan, we will also be exploring preclinical development
of OK-101 for the uveitis indication by first establishing &#8216;proof-of-concept&#8217; for this indication utilizing animal model
studies of anterior uveitis to evaluate the potential of OK-101 to suppress the inflammation associated with uveitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
third related ophthalmic disease indication that is the target of our chemerin-based technology is allergic conjunctivitis. Allergic
conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction that affects about 20% of the global population and
is typically treated with antihistamines, mast cell stabilizers and corticosteroids. Although there are effective drugs for the
treatment of ocular allergies, about one third of patients do not respond adequately to the currently marketed drugs. Further,
patients who display poor response to antihistamines appear to suffer from chronic and seasonal allergies. There is a lack of an
optimal treatment for the perennial and severe forms of ocular allergies. We plan on conducting &#8216;proof-of-concept&#8217;
studies using OK-101 for the treatment of chronic and seasonal allergic conjunctivitis using a conjunctival allergen challenge
animal model to investigate the potential of OK-101 to suppress the inflammation associated with allergic conjunctivitis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>OK-201</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 1, 2018, we obtained a license agreement from Tufts Medical Center for the right to exploit all the intellectual property claimed
in patent application PCT/US2016/0611101 &#8216;Lipidated BAM8-22 and methods of using same&#8217; including claims covering composition-of-matter
and methodology for treating symptoms of neuropathic chronic pain, ocular pain and uveitis-associated pain. OKYO began an effort to explore
BAM8-22 analogs that have potential to ameliorate inflammation and neuropathic pain. OK-201 is the lead compound from the license agreement
with Tufts Medical Center and was the focus of the Company&#8217;s initial efforts to develop a lipidated BAM8-22 analogue to treat neuropathic
pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 6, 2019, we signed a collaborative agreement with Tufts Medical Center, Boston and Pedram Hamrah, MD, Professor of Ophthalmology
at Tufts University School of Medicine, Boston, MA to evaluate OKYO&#8217;s BAM8-22 analogues, including OK-201, as non-opioid analgesics
to suppress corneal neuropathic pain using a mouse ocular pain model developed in Dr. Hamrah&#8217;s laboratory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 28, 2021, we announced positive results of OK-201, a non-opioid analgesic drug candidate delivered topically in Dr. Hamrah&#8217;s
mouse neuropathic corneal pain model, as a potential drug to treat acute and chronic ocular pain. Importantly, OK-201 demonstrated a
reduced corneal pain response equivalent to that of gabapentin, a commonly used oral drug for neuropathic pain. These observations demonstrated
preclinical &#8216;proof-of-concept&#8217; for the topical administration of OK-201 as a potential non-opioid analgesic for ocular pain.
Current treatments for corneal pain are limited to short term NSAIDs, steroids, and oral gabapentin and opioids in severe cases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the results with OK-201 were encouraging, due to subsequent success obtained with OK-101 (see section on OK-101) in follow-on animal
model studies utilizing the same mouse neuropathic corneal pain model as for OK-201, we have decided to maintain this drug candidate
at the exploratory level while we focus our primary energy on the OK-101 program to treat DED, based on OK-101&#8217;s combination of
anti-inflammatory and ocular pain-reducing activities in animal models of these conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers
the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical
element in the success of our business. As of August 10, 2022, our owned and licensed intellectual property included 8 issued patents
and 15 pending patent applications in the U.S. and abroad.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
United States patent directed to lipidated chemerin fragments or analogs has a statutory expiration date of March 13, 2034, with potential
patent term extension available until 2039, following the grant of marketing authorization. Issued United States patent directed to methods
of using lipidated chemerin fragments or analogs for treating neuropathic pain has a statutory expiration date of March 13, 2034 (plus
187 days of patent term adjustment, or PTA), with potential patent term extension available until 2039, following the grant of marketing
authorization. Issued United States patent directed to methods of using lipidated chemerin fragments or analogs for treating DED has
a statutory expiration date of January 23, 2037, with potential patent term extension available until 2041, following the grant of marketing
authorization. We have pending patent applications for lipidated chemerin fragments or analogs and methods of use thereof that, if issued,
would be expected to expire in the United States and in countries outside of the United States between 2034 and 2043, excluding any patent
term adjustment that might be available following the grant of the patent and any patent term extensions that might be available following
the grant of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
United States patent directed to lipidated BAM8-22 peptides or analogs and methods of use thereof has a statutory expiration date of
November 9, 2036 (plus 70 days of PTA), with potential patent term extension available until 2042, following the grant of marketing authorization.
We have pending patent applications for lipidated BAM8-22 peptides or analogs and methods of use thereof that, if issued, would be expected
to expire in the United States and in countries outside of the United States between 2036 and 2040, excluding any patent term adjustment
that might be available following the grant of the patent and any patent term extensions that might be available following the grant
of marketing authorizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to protect our intellectual property position by, among other things, licensing or filing our own U.S. and foreign patent applications
related to our proprietary technologies and products, and any inventions or improvements that are important to the development and implementation
of our business. We also may seek patent protection, if available, with respect to biomarkers and diagnostic methods that may be used
to determine optimal patient populations for use of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wherever
possible, we seek to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select
countries. Because patent applications in the U.S. are maintained in secrecy for at least 18 months after the applications are filed,
and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain
that we were the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first
to file for protection of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party
patents or other intellectual property rights, in which case continued development and marketing of our products would require a license.
Required licenses may not be available to us on commercially acceptable terms, if at all. If we do not obtain these licenses, we could
encounter delays in product introductions while we attempt to design around the patents, or we could find that the development, manufacture
or sale of products requiring such licenses are not possible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of
which can be difficult to protect. We seek to protect some of our proprietary technologies and processes by entering into confidentiality
agreements with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for
any breach and our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees
or our consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights
in related or resulting know-how and inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>License
Agreement for OK-101</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On Target Therapeutics (OTT)
and Tufts Medical Centre (TMC) entered into a license agreement on April 3, 2017, or the Master License, pursuant to which OTT licensed exclusive rights to
certain patent applications that describe and claim lipidated chemerin peptides and their uses in DED, or Chemerin. The Master License
remains in effect until they royalty term has expired with respect to all licensed products in all countries. The Master License may
be terminated by either party in the event of a material breach and in addition, OTT may terminate the Master License at any time upon
90 days&#8217; notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 22, 2017, OTT entered into a license and sublicense agreement with Panetta Partners Limited, one of our principal stockholders, relating
to Chemerin, or the Chemerin License Agreement, which was licensed from OTT and sublicensed from TMC. On May 1, 2018, we entered into
an assignment of the Sublicense with Panetta Partners Limited. Under the terms of the Chemerin License Agreement, we have exclusive rights
to Chemerin. Specifically, we have the benefit of the exclusive worldwide rights to a U.S. patent application (which if issued would
expire in 2036). In addition, we have exclusive worldwide rights to a Patent Cooperation Treaty, or PCT, patent which has been nationalized
in the U.S., Europe, Japan, Australia and Canada and if issued it would expire in 2037. The Chemerin License Agreement provides for the
payment by us of up to $4.9 million in development milestone payments and up to $37 million in sales milestones as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Development
milestone payments being:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$300,000
    upon first patient enrolled in a Phase I clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$600,000
    upon first patient enrolled on a Phase II clinical trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1,500,000
    upon first patient enrolled in a Phase III clinical trial; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,500,000
    upon first commercial sale of a licensed product.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
milestones payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2,000,000
    on first achievement of annual net sales of $50,000,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4,000,000
    on first achievement of annual net sales of $100,000,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$6,000,000
    on first achievement of annual net sales of $250,000,000;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10,000,000
    on first achievement of annual net sales of $500,000,000; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15,000,000
    on first achievement of annual net sales of $1,000,000,000.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above payments equate to low and declining single digit percentage royalties on net sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we have novel composition-of-matter coverage on the lipidated chemerin peptide lead analogues and novel method-of-use claims
in treating DED and other ophthalmic diseases. Each patent office has different patentability requirements, but we believe that the license
patent applications 16/070,467 (U.S. patent application entitled &#8220;Compounds and methods for treating inflammation&#8221;; applicant:
Tufts Medical Center / Trustees of Tufts College) and PCT/US2017/014605 (U.S. patent application entitled &#8220;Compounds and methods
for treating inflammation&#8221;; applicant Tufts Medical Center / Trustees of Tufts College) contain patentable subject matter. The
process for issuance of a patent involves a correspondence with each local patent office in the jurisdictions in which the patent application
is filed. That process, patent prosecution, involves a discussion of any relevant prior art and typically a discussion of the scope of
the claims. The patent prosecution process can take several years depending on the jurisdiction and is not in the control of the patent
owner, but in the control of the local patent office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
subject matter of the licensed IP may have been developed with government financial assistance and are subject to certain federal regulations
under the Bayh-Dole Act of 1980. In particular, the federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up
license&#8221; for its own benefit to inventions produced with its financial assistance. The Bayh-Dole Act also provides federal agencies
with &#8220;march-in rights&#8221; and allows the government certain rights to require products to be manufactured in the United States.
March-in rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant
a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the
patent owner refuses to do so, the government may grant the license itself.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>OK-201</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into a license agreement with TMC on May 1, 2018, relating to intellectual property and proprietary technology for the use
of certain lipidated BAM peptides in the treatment of neuropathic pain. Under the terms of the license agreement, we have acquired
an exclusive license to certain patents (pending and issued), inventions (including future patent filings on lipidated BAM molecules
related to the licensed patents). The license agreement requires an upfront license fee of $15,000 (&#163;11,000), which has been
paid by us and annual maintenance fees of $15,000 (&#163;11,000) commencing on the first anniversary of the license agreement. The
maintenance fees decrease to $10,000 after the three-year anniversary until the first commercial sale. The license agreement also
provides for further development and sales milestone payments and royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 23, 2021, we announced that patent No. 10,899,796 entitled &#8220;Compounds and Methods for Treating Pain&#8221; was issued
by the United States Patent and Trademark Office. The patent is directed to a class of BAM peptides linked to specific lipids that demonstrate
potential for treating symptoms of neuropathic pain, ocular pain, ocular inflammation and/or DED. The work recited in this patent lays
out the potential of this class of lipidated BAM analogues as non-opioid analgesics for ocular pain management without the side effects
and potential abuse associated with opioid medications and is the foundation of our OK-201 program. In addition to the license from TMC
we have a collaboration agreement with TMC pursuant to which TMC has agreed to make available the services of Dr Pedram Hamrah M.D. as
principal investigator and nominated reach associate to carry out investigative and research studies in furtherance of our OK-201 corneal
neuropathic pain program. The patent will expire in early 2036.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities in most jurisdictions extensively regulate the research, development, clinical testing, manufacture, distribution and marketing
of pharmaceutical products such as those that the company is developing. Obtaining regulatory approvals and ensuring subsequent compliance
with applicable laws and regulations requires the expenditure of substantial time and financial and managerial resources. Regulatory
requirements in different jurisdictions vary, and the timing and success of efforts to obtain regulatory approvals can be highly uncertain.
Development of a successful drug candidate, from identification of a candidate drug compound, through preclinical and clinical testing,
to filing of a marketing approval application, to registration, typically takes more than ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development is a highly structured process divided into two major stages, preclinical and clinical. In the preclinical stage, the toxicology
and mode of action of an active compound is evaluated. The clinical stage is designed to prove the safety of any new pharmaceutical,
determine dosage requirements and, predominantly in the later phases, prove its therapeutic utility. This stage is carried out in three
phases, which, as a developer moves through the phases, require increasingly large, complex, expensive and time-consuming clinical studies.
During Phase 1, the product candidate is initially given to a small number of healthy human subjects or patients and tested for safety,
tolerance, absorption, metabolism, distribution and excretion. During Phase 2, additional trials are conducted in a larger, but still
relatively limited, patient population to verify that the product candidate has the desired effect and to identify optimal dosage levels.
Furthermore, possible adverse effects and safety risks are identified. The therapeutic utility of the product candidate for specific
targeted diseases is also studied in more depth. During Phase 3, trials are undertaken to further evaluate dosage, to provide statistically
significant evidence of clinical effectiveness and to further study the safety in an expanded patient population at multiple clinical
trial sites. Phase 3 trials may require several hundreds or thousands of patients and are therefore the most expensive and time-consuming
to conduct. At any time during one of the phases, a trial may produce a negative result, in which case the developer may choose to end
the development project, or a regulator could force clinical trials to terminate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
completion of the Phase 3 trials, the developer submits all the preclinical and clinical trial documentation as well as extensive data
characterizing the manufacturing process to the regulator to seek regulatory approval to market the formulation as a pharmaceutical product.
The regulator reviews all the information related to the safety of the active compound, and whether the pharmacological effect claimed
by the developer on the proposed label can be substantiated by the results of the clinical trials. The regulator has the option to decide
to approve the application as requested, ask for changes to the claims made by the developer, ask for more information, require that
further clinical trials are undertaken, or refuse to approve the formulation for sale.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after initial regulatory approval has been obtained, further studies, including Phase 4 post-approval safety studies, may be required
to provide additional data on safety and will be required to gain approval for the use of a product as a treatment for clinical indications
other than those for which the product was initially tested. There are also continuing, annual user fee requirements for any marketed
products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications
with clinical data. In addition, regulatory authorities require post-marketing reporting to monitor the adverse effects of the product.
Results of post-approval programs may limit or expand the further marketing of the products. Further, if there are any modifications
to the product, including changes in indication, manufacturing process or labeling, or a change in the manufacturing facility, an application
seeking approval of such changes or, as the case may be, notification, must be submitted to the relevant regulatory authorities before
the modified product can be commercialized. Moreover, an approved drug product may be subject to a REMS, which could impose a number
of post-approval obligations, including (among other things) a communication plan for physicians regarding safe use of the drug, distribution
and use restrictions, and/or periodic assessments of the effectiveness of the REMS. Finally, studies may be required as a contingency
of regulatory approval (post-approval commitments), and completion of these studies within a regulator mandated time frame may be required.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>European
Union</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development, marketing and sale of medicinal products in the EU is subject to extensive pre- and post- marketing regulation by regulatory
authorities at both the EU and national levels. The requirements, regulatory approvals and processes governing the conduct of clinical
trials, product licensing, pricing and reimbursement vary from country to country, although there is some degree of EU wide harmonization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials of medicinal products in the EU must be conducted in accordance with EU and national regulations, focusing, in particular on traceability,
apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the EU,
it must appoint an entity within the EU to act as its legal representative. The sponsor must take out a clinical trial insurance policy
and, in most EU countries, the sponsor is liable to provide &#8216;no fault&#8217; compensation to any study subject injured in the clinical
trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to commencing a clinical trial, the sponsor must obtain a clinical trial authorization from the relevant regulatory authority, and a
positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things,
a copy of the trial protocol and an investigational medicinal product dossier containing information about the manufacture and quality
of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the regulatory
authority in each Member State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently
expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing
the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or
other information submitted with the clinical trial applications must be notified to or approved by the relevant competent authorities
and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU medicinal products can only be commercialized after obtaining marketing authorization, or MA. There are three procedures for obtaining
marketing approvals: the centralized procedure, the decentralized procedure and the mutual recognition procedure/national procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Community marketing authorization, which is issued by the European Commission through the centralized procedure, based on the opinion
of the Committee for Medicinal Products for Human Use (CHMP) of the EMA, is valid throughout the entire territory of the EU. The centralized procedure is mandatory for certain types
of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance
indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, autoimmune and viral diseases. The centralized procedure
is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant
therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the decentralized procedure are available for products not falling within the mandatory scope of the Centralized
Procedure. An identical dossier is submitted to the regulatory authorities of each of the Member States in which the marketing approval
is sought, one of which is selected by the applicant as the Reference Member State, or RMS. The competent authority of the RMS prepares
a draft assessment report, a draft summary of the product characteristics and a draft of the labeling and package leaflet, which are
sent to the other the concerned Member States, or CMSs, for their approval. A CMS can raise an objection, based on the assessment report,
the summary of product characteristics, the labeling and the package leaflet on the grounds of potential serious risk to public health.
If no such objections are raised the product will be granted a national marketing authorization in the RMS and all of the selected CMSs.
Where a product has already been authorized for marketing in a Member State, this decentralized procedure approval can be recognized
in other Member States through the mutual recognition procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketing
approvals obtained using the national procedure are issued by a single regulatory authority of one of the Member States and only apply
to the territory covered by the relevant regulatory authority. They are available for products not falling within the mandatory scope
of the centralized procedure. Once a product has been authorized for marketing in a Member State through the national procedure, any
application in another Member State must be by the mutual recognition procedure whereby the marketing approval can also be recognized
in other Member States through the mutual recognition procedure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the procedures described above, before granting the MA, the EMA or the relevant regulatory authority of the Member States of the EU makes
an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and therapeutic
utility.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holder of a marketing authorization in any Member State of the EU is subject to various obligations under applicable EU regulations,
such as pharmacovigilance obligations, requiring it to, among other things, report and maintain detailed records of adverse reactions,
and to submit periodic safety update reports to the regulatory authorities. The holder must also ensure that the manufacturing and batch
release of its product is in compliance with the applicable requirements. The marketing approval holder is further obligated to ensure
that the advertising and promotion of its products complies with applicable laws, which can differ from Member State to Member State
of the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Data
Exclusivity</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MAAs
for generic medicinal products in the EU do not need to include the results of preclinical and clinical trials, but instead can refer
to the data included in the marketing approval of a reference product for which regulatory data exclusivity has expired. If a marketing
approval is granted for a medicinal product containing a new active substance, that product benefits from eight years of data exclusivity,
during which generic MAAs referring to the data of that product may not be accepted by the regulatory authorities, and a further two
years of market exclusivity, during which such generic products may not be placed on the market. The two-year period may be extended
to three years if during the first eight years a new therapeutic indication with significant clinical benefit over existing therapies
is approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is a special regime for biosimilars, or biological medicinal products that are similar to a reference medicinal product but that do not
meet the definition of a generic medicinal product, for example, because of differences in raw materials or manufacturing processes.
For such products, the results of appropriate preclinical or clinical trials must be provided, and guidelines from the EMA detail the
type of quantity of supplementary data to be provided for different types of biological product. There are no such guidelines for complex
biological products, such as gene or cell therapy medicinal products, and so it is unlikely that biosimilars of those products will currently
be approved in the EU. However, guidance from the EMA states that they will be considered in the future in light of the scientific knowledge
and regulatory experience gained at the time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Medicinal Products</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EMA&#8217;s Committee for Orphan Medicinal Products, or COMP, may recommend orphan medicinal product designation to promote the development
of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting
not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention
or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely
that sales of the product in the EU would be sufficient to justify the necessary investment in developing the medicinal product. The
COMP may only recommend orphan medicinal product designation when the product in question offers a significant clinical benefit over
existing approved products for the relevant indication. Following a positive opinion by the COMP, the European Commission adopts a decision
granting orphan status. The COMP will reassess orphan status in parallel with EMA review of a marketing authorization application and
orphan status may be withdrawn at that stage if it no longer fulfills the orphan criteria (for instance because in the meantime a new
product was approved for the indication and no convincing data are available to demonstrate a significant benefit over that product).
Orphan medicinal product designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years
of market exclusivity is granted following marketing authorization. During this period, the competent authorities may not accept or approve
any similar medicinal product, unless it offers a significant clinical benefit. This period may be redacted to six years if the orphan
medicinal product designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not
to justify maintenance of market exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 17pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Standard
Procedure</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act of 1938 and its implementing regulations. The
process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs or BLAs, withdrawal of an approval, imposition of a clinical
hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of preclinical laboratory studies, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice
    regulations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an IND, which the FDA must approve before human clinical trials may begin;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of the human clinical trial by the institutional review board, or IRB, at each clinical site before each trial may be initiated;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations,
    sometimes referred to as GCPs to establish the safety and clinical utility of the proposed product candidate for its proposed indication;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of a BLA or NDA;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA pre-approval inspection of the production facility or facilities where the product is produced to assess compliance
    with the FDA&#8217;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s
    identity, strength, quality, purity and potency;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    review and approval of the BLA or NDA prior to any commercial marketing or sale of the product in the United States.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained
or if problems occur after the product reaches the market. Other potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on post-approval clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of products; or</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Clinical
Trials</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the IND to human patients under the supervision of qualified investigators in accordance with GCP
requirements, which include the requirement that all research patients provide their informed consent in writing for their participation
in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating
in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information about
certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on
their website. Regulatory authorities, IRBs or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research patients are being exposed to an unacceptable health risk.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Marketing
Approval</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed
information relating to the product&#8217;s chemistry, manufacture, controls, or CMC, and proposed labeling, among other things, are
submitted to the FDA as part of an NDA or BLA requesting approval to market the product for one or more indications. In most cases, the
submission of an NDA or BLA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act guidelines that
are currently in effect, the FDA has a goal of 10 months from the date of filing of a standard NDA for a new molecular entity to review
and act on the submission. This review typically takes 12 months from the date the NDA is submitted to the FDA because the FDA has approximately
two months to make a filing decision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act of 2003<b><i>, </i></b>certain NDAs or supplements to an NDA must contain data that
are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations,
and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on
its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval
of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine
whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an
NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also
subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive
review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which
it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and
purity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be
approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations
carefully when making decisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
approving a BLA or NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the
FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
evaluating the NDA or BLA and all related information, including the advisory committee recommendation, if any, and inspection reports
regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete
response letter (which generally contains a statement of specific conditions that must be met in order to secure final approval of the
NDA and may require additional clinical or preclinical testing in order for the FDA to reconsider the application). Even with submission
of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings
or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted
to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization,
or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially
affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding
new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and
approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Orphan
Drug Designation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act of 1983, the FDA may designate a biologic product as an &#8220;orphan drug&#8221; if it is intended to treat a rare
disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which
there is no reasonable expectation that the cost of developing and making a biologic product available in the United States for treatment
of the disease or condition will be recovered from sales of the product).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation, the product
is entitled to orphan product exclusivity, meaning that the FDA may not approve any other applications to market the same drug or biologic
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product
with orphan exclusivity or if the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug
to meet the needs of patients with the disease or condition for which the drug was designated. Competitors, however, may receive approval
of different products for the same indication for which the orphan product has exclusivity or obtain approval for the same product but
for a different indication for which the orphan product has exclusivity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Post-Approval
Requirements for the EU and United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and the relevant regulatory authorities in the EU strictly regulate marketing, labeling, advertising and promotion of products that
are placed on the market in their respective territories. Drugs may be promoted only for the approved indications and in accordance with
the provisions of the approved label. The regulatory authorities actively enforce the laws and regulations prohibiting the promotion
of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register
their establishments with the relevant regulatory authorities and are subject to periodic unannounced inspections by them to confirm
compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior approval of the
relevant regulatory authorities before being implemented. Regulations laid down by the FDA and the regulatory authorities in the EU also
require investigation and correction of any deviations from the requirements of cGMP and impose reporting and documentation requirements
upon the marketing approval holder and any third-party manufacturers that the marketing approval holder may decide to use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Healthcare Laws in the EU and United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company will also be subject to healthcare regulation and enforcement by the U.S. federal government and the state governments in
the EU and any other countries in which the company conducts its business, including its research, and the marketing and
distribution of its product candidates and products once they have obtained marketing approval. Failure to comply with these laws,
where applicable, can result in the imposition of significant civil penalties, criminal penalties, exclusion from participating in
health care programs, additional reporting requirements and oversight if the company becomes subject to a corporate integrity
agreement or similar agreement to resolve allegations of non-compliance with these laws and other sanctions. The healthcare laws and
regulations that may affect the Company&#8217;s ability to operate in the United States include: the federal fraud and abuse laws,
including the federal anti-kickback and false claims laws; federal data privacy and security laws; and federal transparency laws
related to payments and/or other transfers of value made to physicians and other healthcare professionals and teaching hospitals.
Many U.S. states have similar laws and regulations that may differ from each other and federal law in significant ways. Moreover,
several U.S. states have enacted legislation requiring pharmaceutical manufacturers to, among other things, establish marketing
compliance programs, file periodic reports with the state, and make periodic public disclosures on sales and marketing activities,
and prohibiting certain other sales and marketing practices. Rules and legislation covering more or less the same subject matter as
those in the United States apply to in countries in the EU and to other countries. These can differ between jurisdictions and can
sometimes result in lower or higher exposure in those countries than in the United States. Where a product is sold in a number of
countries compliance efforts can therefore be complicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement in the EU and United States</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of products developed from the Company&#8217;s product candidates, if approved, will depend, in part, on the extent to which such products
will be covered by third party payors, such as government health care authorities, government health care programs, commercial insurance
and managed healthcare organizations. These third-party payors are increasingly limiting coverage or reducing reimbursements for medical
products and services. In the United States, no uniform policy of coverage and reimbursement for products exists among third party payors.
Therefore, coverage and reimbursement for products can differ significantly from payor to payor. In addition, the U.S. government, state
legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governments
influence the price of medicinal products in the EU through their pricing and reimbursement rules and control of national healthcare
systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some
of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate
to currently available therapies. Other Member States allow companies to fix their own prices for medicines but monitor and control company
profits. The downward pressure on healthcare costs in general in the EU governments influence the price of medicinal products through
their pricing and reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adoption of price controls and cost-containment measures, and the adoption of more restrictive policies in jurisdictions with existing
controls and measures, could further limit the Company&#8217;s net revenue and results. Decreases in third party reimbursement for the
Company&#8217;s product candidates or a decision by a third-party payor to not cover the Company&#8217;s product candidates could reduce
physician usage of the Company&#8217;s product candidates, once approved, and have a material adverse effect on the Company&#8217;s sales,
results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Privacy
and Data Protection Laws in Europe</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to European laws relating to our and our suppliers&#8217;, partners&#8217; and subcontractors&#8217; collection, control,
processing and other use of personal data (i.e., any data relating to an identifiable living individual, whether that individual can
be identified directly or indirectly). We are subject to the supervision of local data protection authorities in those jurisdictions
where we are established, where we offer goods or services to EU residents and where we monitor the behavior of individuals in the EU
(i.e., undertaking clinical trials). We and our suppliers, partners and subcontractors process personal data including in relation to
our employees, employees of customers, clinical trial patients, healthcare professionals and employees of suppliers including health
and medical information. The data privacy regime in the EU includes the General Data Protection Regulation, or GDPR, the e-Privacy Directive
(2002/58/EC) and the e-Privacy Regulation (once in force) and the national laws and regulations implementing or supplementing each of
them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
GDPR requires that personal data is only collected for specified, explicit and legal purposes as set out in the GDPR or local laws, and
the data may then only be processed in a manner consistent with those purposes. The personal data collected and processed must be adequate,
relevant and not excessive in relation to the purposes for which it is collected and processed, it must be held securely, not transferred
outside of the EEA, (unless certain steps are taken to ensure an adequate level of protection) and must not be retained for longer than
necessary for the purposes for which it was collected. In addition, the GDPR requires companies processing personal data to take certain
organizational steps to ensure that they have adequate records, policies, security, training and governance frameworks in place to ensure
the protection of data subject rights, including as required to respond to complaints and requests from data subjects. For example, the
GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal
data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where
sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the
EU and imposes additional obligations on us when we are contracting with service providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, to the extent a company processes, controls or otherwise uses &#8220;special category&#8221; personal data (including patients&#8217;
health or medical information, genetic information and biometric information), more stringent rules apply, further limiting the circumstances
and the manner in which a company is legally permitted to process that data. Finally, the GDPR provides a broad right for Member States
to create supplemental national laws which may result in divergence across Europe making it harder to maintain a consistent operating
model or standard operating procedures. Such laws, for example, may relate to the processing of health, genetic and biometric data, which
could further limit our ability to use and share such data or could cause our costs to increase, and harm our business and financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on a number of third parties in relation to the provision of our services, a number of which process personal data on our behalf.
With each such provider we enter into contractual arrangements to ensure that they only process personal data according to our instructions,
and that they have sufficient technical and organizational security measures in place. Where we transfer personal data outside the EU,
we do so in compliance with the relevant data export requirements from time to time. We take our data protection obligations seriously,
as any improper, unlawful or accidental disclosure, loss, alteration or access to, personal data, particularly sensitive personal data
(i.e., special category), could negatively impact our business and/or our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also subject to EU laws on personal data export, as we may transfer personal data from the EU to other jurisdictions which are not
considered by the European Commission to offer adequate protection of personal data. Such transfers need to be legitimized by a valid
transfer mechanism under the GDPR. There is currently ongoing litigation challenging the commonly used transfer mechanisms, the European Commission
approved model clauses. In addition, the U.S. Privacy Shield is currently under review by the European Commission. As such, it is uncertain
whether the Privacy Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find
alternative bases for the compliant transfer of personal data from the EU to the United States and we are monitoring developments in
this area. Invalidation of any mechanism on which we rely could require operational changes and increased costs and may lead to governmental
enforcement actions, litigation, fines and penalties or adverse publicity that could have an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU is in the process of replacing the e-Privacy Directive with a new set of rules taking the form of a regulation, which will be directly
implemented in the laws of each Member State, without the need for further enactment. The draft e-Privacy Regulation imposes strict opt-in
marketing rules with limited exceptions for business-to-business communications and alters rules on third-party cookies, web beacons
and similar technology. Regulation of cookies and web beacons may lead to broader restrictions on online research activities, including
efforts to understand users&#8217; internet usage. The current draft also significantly increases fining powers to the same levels as
GDPR (i.e., the greater of 20 million Euros or 4% of total global annual revenue). The European Commission proposed the ePrivacy Regulation in January 2017. It was intended to take effect alongside
the EU GDPR (General Data Protection Regulation) on 25 May 2018.However, the final text is still to be agreed, with the Council of the
European Union and the European Parliament disagreeing about a number of issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are costs and administrative burdens associated with compliance with the GDPR and the resultant changes in the EU and EEA member states&#8217;
national laws and the introduction of the e-Privacy Regulation once it takes effect. Any failure or perceived failure to comply with
global privacy laws carries with it the risk of significant penalties and sanctions of up to &#8364;20 million or 4% of global turnover.
These laws or new interpretations, enactments or supplementary forms of these laws, could create liability for us, could impose additional
operational requirements on our business, could affect the manner in which we use and transmit patient information and could increase
our cost of doing business. Claims of violations of privacy rights or contractual breaches, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Organizational Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets out details of the Company&#8217;s only subsidiary:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    activity</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registered
    address</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    </b><br />
    <b>shareholding</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country
    of </b><br />
    <b>incorporation</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
    Pharma US Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
    stage biotechnology company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 19%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">420
                                            Lexington Avenue</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    1402</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10170</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Property, Plant and Equipment</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
below table contains information regarding existing or planned material tangible fixed assets owned or leased by OKYO Pharma Ltd and its Subsidiary.
We believe that suitable additional or substitute space will be available as needed to accommodate any future expansion of our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Location</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tenure</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    use</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">420
                                            Lexington Avenue</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
    1402</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, NY 10170</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6
    Months </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    Office</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_006"></span>ITEM
4A: UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_007"></span>ITEM
5: OPERATING AND FINANCIAL REVIEW AND PROSPECTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>You
should read the following discussion and analysis of our financial condition and results of operations together with &#8220;Selected
Consolidated Financial Data&#8221; and our consolidated financial statements and the related notes thereto appearing at the end of this
Annual Report. We present our consolidated financial statements in U.S. dollars and in accordance with International Financial Reporting
Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Some
information included in this discussion and analysis, including statements regarding industry outlook, our expectations regarding our
future performance, liquidity and capital resources and other statements regarding our plans and strategy for our business and related
financing, are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties. You should
read the &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that could cause actual results
to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion
and analysis.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>We
maintain our books and records in Pounds Sterling, and we prepare our financial statements in accordance with IFRS as issued by the IASB.
We report our financial results in U.S. dollars.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical biopharmaceutical company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory
eye diseases and ocular pain. Our research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which we believe plays
a key role in the pathology of these inflammatory eye diseases of high unmet medical need. Our therapeutic approach is focused on targeting
inflammatory and pain modulation pathways that drive these conditions. We are presently developing OK-101, our lead preclinical product
candidate, for the treatment of dry-eye disease. We also plan to evaluate its potential in benefiting patients with ocular neuropathic
pain, uveitis and allergic conjunctivitis. We have also been evaluating OK-201, a bovine adrenal medulla, or BAM, lipidated-peptide preclinical
analogue candidate for the treatment of neuropathic ocular pain, and plan on maintaining this drug candidate at the exploratory level
while we focus our primary energy on the OK-101 program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 21, 2018, we announced that we successfully obtained (via assignment from Panetta Partners Limited, a related party) a license
from OTT to patents owned or controlled by OTT and a sub-license from OTT to certain patents licensed by OTT from TMC to support our
ophthalmic disease drug programs. These licenses gave us the right to exploit the IP estate which is directed to compositions-of-matter
and methodologies for treating ocular inflammation, DED with chemerin or lipid-linked chemerin analogues. We also have a license from
TMC to a separate IP estate for treating symptoms of ocular neuropathic pain and uveitis associated pain. On August 6, 2019, we signed
a collaborative agreement with TMC on a research program focused on ocular neuropathic pain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2021 we announced the appointment of Mr. Gabriele Cerrone as Non-Executive Chairman and Director, and Gary S. Jacob, Ph.D.
as Chief Executive Officer and Director. The addition of these two individuals is a significant step for us, highlighting a careful realignment
of the strategic focus of our research and development program. We believe this realignment will allow us to file IND applications on
our drug candidates from with FDA in the shortest time possible. We have not yet submitted an application to the FDA for any of our product candidates. We have however significantly
advanced our ongoing IND enabling work on our lead candidate OK-101 during this past year for an IND submission for OK-101 to treat dry
eye and are presently on schedule to file an IND on OK-101 to treat dry eye disease in the fourth quarter of 2022. (see Figure 1 below)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1. OKYO Pipeline</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><img src="form20-f_009.jpg" alt="Chart&#10;&#10;Description automatically generated with medium confidence" style="height: 206px; width: 495px" /></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.05in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>*Anticipated
IND Submission date Q4, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.7pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>**Topical
drug delivery</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Foreign
currency translations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements are measured using the currency of the primary economic environment in which the entity operates
(the functional currency). The consolidated financial statements are presented in U.S. dollars, which is our presentation currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of overseas subsidiary undertakings are translated into our functional currency on the following basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Components
of Our Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the
near future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate
revenue in the future from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating
Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expenses consist primarily of costs incurred in connection with the R&amp;D of our product candidates and are expensed as incurred. These
expenses consist of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
    incurred under agreements with CROs, CMOs, as well as investigative sites and consultants that conduct our clinical trials, preclinical
    studies and other scientific development services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
    scale-up expenses and the cost of acquiring and manufacturing materials for preclinical studies and clinical trial materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
    expenses, including salaries, related benefits, travel and share-based compensation expense for employees engaged in R&amp;D functions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    related to compliance with regulatory requirements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
    costs, depreciation and other expenses, which include rent and utilities; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    for maintaining our third-party licensing agreements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided
to us by our service providers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
direct R&amp;D expenses are tracked on a program-by-program basis for our product candidates and consist primarily of external costs,
such as fees paid to outside consultants, CROs and CMOs in connection with our preclinical development, manufacturing and clinical development
activities. Our direct R&amp;D expenses by program also include fees incurred under our license agreements. We do not allocate employee
costs or facility expenses, including depreciation or other indirect costs, to specific programs because these costs are deployed across
multiple programs and, as such, are not separately classified. We use internal resources primarily to oversee the R&amp;D as well as
for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work
across multiple programs and, therefore, we do not track their costs by program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes our R&amp;D expenses incurred by program:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Direct research and development expense by program:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%">OK-101</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,300,664</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">170,417</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">449,580</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>OK-201</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">514</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,518</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Total direct research and development expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,301,178</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">173,821</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">518,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total research and development expense</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,301,178</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">173,821</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">518,098</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
activities are central to our business model. Product candidates in later stages of clinical development generally have higher development
costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical
trials and related product manufacturing expenses. As a result, we expect that our R&amp;D expenses will increase substantially over
the next several years as we increase personnel costs and prepare for regulatory filings related to our product candidates. We also expect
to incur additional expenses related to milestone, royalty payments and maintenance fees payable to third parties with whom we have entered
into license agreements to acquire the rights related to our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
successful development and commercialization of our product candidates is highly uncertain. At this time, we cannot reasonably estimate
or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any
of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty
is due to the numerous risks and uncertainties associated with development and commercialization, including the uncertainty of:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other R&amp;D activities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    an appropriate safety profile with IND- and CTA-enabling studies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    patient enrollment in, and the initiation and completion of, clinical trials;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    and timely delivery of commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining,
    maintaining, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    and changing government regulation;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">launching
    commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintaining
    a continued acceptable safety profile of the product candidates following approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical
trials. We may elect to discontinue, delay or modify clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, related benefits, travel and share-based compensation expense for personnel
in executive, finance and administrative functions. General and administrative expenses also include professional fees for legal, consulting,
accounting and audit services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research activities and development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal,
regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being
a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Taxation</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax expense for a period represents the total of current taxation and deferred taxation. The charges in respect of current taxation are
based on the estimated taxable profit for the relevant year. Taxable profit for the year is based on the profit as shown in the income
statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability
for the year is calculated using tax rates which have either been enacted or substantively enacted at the relevant balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
UK tax legislation, small and medium entity R&amp;D relief allows us to claim back up to 14.5% of our surrenderable losses as a tax cash
credit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of operations that follow reflect the historic periods under review and should not be taken as indicative of future performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Years Ended March 31, 2022 and 2021</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarizes our results of operations for the years ended March 31, 2022 and 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,301,178</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,127,357</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,916,388</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,192,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,724,003</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,217,566</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,366,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,851,360</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Income/ (Expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">786,521</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">761,527</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,431,045</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,353,507</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,077,538</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    comprehensive loss:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(837,152</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,183,517</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Comprehensive (Loss)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6,268,197</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,007,142</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,261,055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities were $1,301,178 for the year ended March 31, 2022 compared to $173,821 for the year ended March 31, 2021 an
increase of $1,127,357. The increase is due to an increase in R&amp;D activity after the temporary pause in R&amp;D activity in 2020 while
the Scientific Advisory Board and management team were established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses were $4,916,388 for the year ended March 31, 2022 as compared to $3,192,385 for the year ended March 31, 2021, an increase of
$1,724,003. The increase is predominantly due to the establishment of a management team and an increase in activity in the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Credit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credits of $786,521 and $24,994 are recognized for the years ended March 31, 2022 and 2021, respectively. The credits are obtained
at a rate of 14.5% of 230% of our qualifying research and development expenditure. The increase in the provision is due primarily to
an increase in qualifying research and development expenditure incurred in the year ending March 31, 2022, plus more qualifying research
and development expenditure identified for the year ending March 31, 2021 than was provided for.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comparison
of Years Ended March 31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables summarizes our results of operations for the years ended March 31, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(173,821</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(518,098</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">344,277</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,192,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,016,548</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,837</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,366,206</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,534,646</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,831,560</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Income/ (Expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(85,701</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73,407</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
    credit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,994</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76,289</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(51,295</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,353,507</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,544,059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,809,448</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    comprehensive loss:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">346,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">86,654</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,711</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Comprehensive (Loss)/Profit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,007,142</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,457,405</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,549,737</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development activities were $173,821 for the year ended March 31, 2021 compared to $518,098 for the year ended March 31, 2020. The
decrease of $344,277 is due to the temporary pause in R&amp;D activity in the year to March 31, 2021 while the Scientific Advisory Board
and team were established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses were $3,192,385 and $1,016,548 for the year ended March 31, 2021 and 2020. The increase of $2,175,837 is
predominantly due to bonuses accrued of approximately $1,200,000, additional share-based payment charges of approximately $485,000, additional
legal and audit costs of approximately $142,000 and realized foreign exchange approximately $466,000 offset by savings of approximately
$103,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Tax Credit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax credits of $24,994 and $76,288 are recognized for the years ended March 31, 2021 and 2020, respectively. The credits are obtained
at a rate of 14.5% of 230% of our qualifying research and development expenditure. The decrease in the provision is due primarily to
the decrease in qualifying research and development expenditure incurred in the year ending March 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Liquidity and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have not generated any revenue and have incurred operating losses and negative cash flows from our operations. We have
funded our operations to date primarily with proceeds from the sale of ordinary shares, American Depository Shares, or ADSs, and convertible
loan notes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, we had cash and cash equivalents of $2,700,724.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
March 31, 2022, we had received net cash proceeds of $1,378,387 from exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cash
Flows</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows for each of the periods presented:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="11" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,468,065</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,600,198</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,202,066</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,669</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,114</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(132,668</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,153,270</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,826,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">963,310</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of exchange rate changes on cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(872,141</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">445,217</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,708</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (decrease)/increase in cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,316,464</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,208,627</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(371,423</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Used in Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of cash in each of the years ended March 31, 2022, 2021 and 2020, resulted primarily from our net losses, adjusted for non-cash charges
and changes in components of working capital. Net cash used in operating activities of $5,468,065 during the year ended March 31, 2022
increased by $3,867,867 compared to the year ended March 31, 2021. The increase in net cash used in operating activities was primarily
due to increased activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
use of cash in each of the years ended March 31, 2021 and 2020 resulted primarily from our net losses, adjusted for non-cash charges
and changes in components of working capital. Net cash used in operating activities of $1,600,198 during the year ended March 31, 2021
increased by $398,132 compared to the year ended March 31, 2020. The increase in net cash used in operating activities was primarily
due to increased activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Used in Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2022, we used $1,669 of cash in investing activities for the purchases of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2021 we used $18,114 of cash in investing activities for the purchases of property and equipment and advances
under a loan facility to West African Minerals Ltd. During the year ended March 31, 2020, $132,668 was used for the same reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Cash Provided by Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended March 31, 2022 and 2021, net cash provided by financing activities was $1,378,387 and $7,826,938, respectively,
consisting of net cash proceeds from our sale and issuance of ordinary shares, entering into fixed term convertible loan agreements and
the exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended March 31, 2021, and 2020, net cash provided by financing activities was $7,826,938 and $963,310, respectively, consisting
of net cash proceeds from our sale and issuance of ordinary shares and entering into fixed term convertible loan agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Funding
Requirements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities,
manufacturing and clinical trials of our product candidates and as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing and distribution infrastructure in anticipation of commercializing any product candidates for which we may obtain
    marketing approval and intend to commercialize on our own or jointly;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
    additional clinical, medical and development personnel;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    our infrastructure and facilities to accommodate our growing employee base; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">maintain,
    expand and protect our intellectual property portfolio.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">We do not
believe that our existing cash, will enable us to fund our operating expenses and capital expenditure requirements for the foreseeable
future. We have experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as
of March 31, 2022, had an accumulated deficit of $112m , a net loss for the year ended March 31, 2022, of $5.4m and net cash used in operating
activities of $5.5m.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">We have prepared cash flow projections that include the costs
associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections,
we conclude significant doubt exists about the Group&#8217;s ability to continue as a going concern. We have based these estimates
on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. If we receive
regulatory approval for our other product candidates, we expect to incur significant commercialization expenses related to product
manufacturing, sales, marketing and distribution. See note 2 in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical product candidates,
we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could
increase significantly as a result of many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development
    activities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs, timing, receipt and terms of any marketing approvals from applicable regulatory authorities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of future activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates
    for which we receive marketing approval;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs and timing of hiring new employees to support our continued growth;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
    intellectual property-related claims; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    extent to which we acquire technologies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through
equity offerings and other financing activities such as debt arrangements. To the extent that we raise additional capital through the
sale of equity, your ownership interest will be diluted. If we raise additional funds through other third-party funding, collaboration
agreements, strategic alliances, licensing arrangements or marketing and distribution arrangements, we may have to relinquish valuable
rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to us. If we are unable to raise additional funds through equity financings when needed, we may be required to delay, limit,
reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product
candidates that we would otherwise prefer to develop and market ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Borrowings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 29, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $606,980 at an interest rate of 20%
per annum to be repaid no later than 48 months after the date of the agreement. On May 4, 2021, $167,434 of the fixed term loan agreement
plus the associated interest accrued, was converted and 62,920,000 shares were issued accordingly at a price of $0.006 per share. On
February 24, 2022, all remaining fixed term loan agreements plus the associated interest accrued were converted and 165,176,000 shares
were issued accordingly at a price of $0.006 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 27, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $4,828,250 at an interest rate of
2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021, the fixed term loan agreement plus
the associated interest accrued, was converted and 43,889,863 shares were issued accordingly at a price of $0.117 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 17, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $1,982,485 at an interest rate
of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 18,021,226 shares were issued accordingly at a price of $0.117 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 3, 2020, we entered into a fixed term unsecured loan agreement with existing shareholders for $689,750 at an interest rate
of 2.15% per annum to be repaid no later than 36 months after the date of the agreement. On May 4, 2021 the fixed term loan agreement
plus the associated interest accrued, was converted and 6,269,980 shares were issued accordingly at a price of $0.117 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
loans were converted into ordinary shares in May 2021 and February 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Research and Development Expenses, Patents and Licenses, etc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 4.B.&#8212;Business Overview,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Trend Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 5. Operating and Financial Review and Prospects&#8212;Trend Information.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Off-Balance Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules
and regulations of the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Tabular Disclosure of Contractual Obligations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our contractual commitments and obligations as of March 31, 2022 and 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    at March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than <br /> 1 Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
    1 and 5 Years</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
    than<br /> 5 Years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    at March 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="15" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than <br /> 1 Year</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
    1 and 5 Years</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
    than<br /> 5 Years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Borrowings</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,371</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,371</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease obligations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,478</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,371</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
refer to &#8220;Item 4 B. Business Overview&#8221; and &#8220;Item 10.C. Material Contracts&#8221; for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
Safe Harbor</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form&#160;20-F&#160;contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act
and Section&#160;21E of the Exchange Act and as defined in the Private Securities Litigation Reform Act of 1995.&#160;See the section
titled &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_008"></span>ITEM
6: DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Directors and Senior Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our directors and senior management as of the date of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Marco Antonio Cerrone MBA&#160;(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Gary S. Jacob</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    and Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Raj Patil</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Scientific Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon (1) (2) (3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Non-Executive Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio (1) (2) (3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer (1) (2) (3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">74</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remuneration
    Committee member</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination
    Committee member</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit,
    risk and disclosure Committee member</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gabriele
Marco Antonio Cerrone &#8211; <i>Non-Executive Chairman</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
Cerrone has been the Non-Executive Chairman of our company since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences Limited
and has been its Executive Chairman since April 2014. Mr. Cerrone has founded 10 biotechnology companies in oncology, infectious diseases
and molecular diagnostics, and has listed seven of these companies on Nasdaq, and two to the Main Market and AIM Market in London. Mr.
Cerrone co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman
of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies,
Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007
with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012.
Mr. Cerrone is the Executive Chairman and Founder of Nasdaq-listed Tiziana Life Sciences Limited, an oncology focused therapeutics company;
Co-Founder of Rasna Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals,
Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA
technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated
from New York University&#8217;s Stern School of Business with a master&#8217;s degree in business administration (MBA).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Gary S. Jacob</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Gary S. Jacob has served as Chief Executive Officer and a director of our company since January 2021. From November 2018 to March 2020,
Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until
December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where
he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December
12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. Since March 19, 2014,
Dr. Jacob has been Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive
Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May
2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Rasna Therapeutics,
Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology
industries across multiple disciplines including research &amp; development, operations and business development. Prior to 1999, Dr.
Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of
Functional Genomics, Corporate Science &amp; Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of
Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group
at Oxford University, England.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr.
Raj Patil</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Dr.
Raj Patil has served as Chief Scientific Officer of our company since March 2021. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Patil has over 15 years of ophthalmic drug development experience, <span style="background-color: white">including research &amp; development,
operations and business development. Dr. Patil </span>previously worked with Ora, as Vice President of Research &amp; Development, where
he was responsible for driving all anterior and posterior segment ocular research of Ora&#8217;s R&amp;D Institute. From 2013 until 2018,
Dr. Patil worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil&#8217;s tenure at iVeena
included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School, and
Principal Investigator at Singapore Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles at
Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma
and retina research. Prior to 2004, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology &amp; Genetics at the University
of Nebraska Medical Centre in Omaha from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology &amp; Pharmacology
at Washington University in St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University
of Pune, India, and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor,
MI. He is the recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director&#8217;s
New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for
numerous journals, and is frequently invited to lecture at academic and industry events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Keeren
Shah</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
Shah has served as our Chief Financial Officer since August 2020. Ms. Shah currently also serves as the Finance Director of Tiziana Life
Sciences Limited, Accustem Sciences Limited and Rasna Therapeutics Inc., having previously served as the Group Financial Controller for
all businesses from June 2016 to July 2020. Prior to joining us, Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance
team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as
leading and participating in key transformation programs and Visa Inc.&#8217;s initial public offering. Before joining Visa, Ms. Shah
also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor
of Arts with Honors in Economics and is a member of the Chartered Institute of Management Accountants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Willy
Simon &#8211; <i>Non-Executive Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
Jules Simon has been a director of our company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London
before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment
Management from 1999 to 2002. He acted as chairman of Bank Oyens &amp; van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3
plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a Nasdaq OTC listed
company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime
since 2015. He is also a non-executive director of Tiziana Life Sciences Limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>John
Brancaccio &#8211; <i>Non-Executive Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">John
Brancaccio, a retired CPA, has served as a director of our company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was
the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio served as a
director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and has
been a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004, as well as a director of Hepion Pharmaceuticals,
Inc. since December 2013, Rasna Therapeutics, Inc. since September 2016, Cardiff Oncology, Inc. since December 2005 and Tiziana Life
Sciences Limited since July 2020. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bernard
Denoyer&#8211; <i>Non-Executive Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Bernard
F. Denoyer has served as a director of our company since December 2021. Mr. Denoyer served as Senior Vice President, Finance and Secretary
of Synergy Pharmaceuticals, Inc, from July 2008 until his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently
served as Principal Financial Officer of Synergy&#8217;s former parent company, Callisto Pharmaceuticals, Inc. From October 2000 to December
2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President
of META Group, Inc. He is currently serving on the Board of Trustees for two not-for-profits, St. Edmunds Retreat, Inc. and Midwestern
Connecticut Council on Alcoholism, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships among any of our executive officers or directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Compensation</b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total
Compensation for the Non-Executive Chairman and Non-Executive Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets out the total remuneration received by the Non-Executive Chairman and the Non-Executive Directors for the year ended
March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees<br />
    earned<br /> or paid<br /> in cash<br /> ($000) (1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options<br />
    awarded<br /> ($000) (2)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<br />
    ($000)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total<br />
    ($000)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Chairman</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Executive
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    amounts have been translated into U.S. dollars from Pounds Sterling based upon the exchange rate as certified by the Federal Reserve
    Bank of New York for customs purposes as of March 31, 2022. These translations are merely for the convenience of the reader and should
    not be construed as representations that the Pounds Sterling amounts actually represent such U.S. dollar amounts or could be converted
    into U.S. dollars at the rate indicated.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the fair value of incentive stock options granted during the year to March 31, 2022 using the Black-Scholes model for computing stock-based
    compensation expense as of the date of grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to the Compensation table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gabriele
Cerrone</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an appointment agreement with Gabriele Cerrone on January 6, 2021 to serve as our Non-Executive Chairman. This agreement
entitles Mr. Cerrone to receive a consultancy fee of &#163;120,000 per year. On April 28, 2021 we entered into an agreement with the
Mr. Cerrone pursuant to which Mr. Cerrone was awarded a retrospective bonus of $687,273 for the financial year ended March 31, 2020 and
a further bonus of $554,400 for the financial year ended March 31, 2021, in each case for services prior to his agreeing to become a
director of the Company, on condition that Mr. Cerrone agreed that Panetta Partners Limited and Planwise Group Limited exercise a total
of 147,969,396 warrants at exercise prices between $0.006 and $0.0189 (being all of the warrants held by Mr. Cerrone and his associated
entities). Mr. Cerrone also agreed that his accrued but unpaid compensation from January 6, 2021 to May 4, 2021 and through to March
31, 2022, in the sum of $210,000 be waived and offset against the costs of the exercise of certain of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non
-Executive Director remuneration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration of our non-executive directors is determined by our board as a whole, based on a review of current practices in other companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation
of Executive Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets the remuneration of each of the Executive Directors for the financial year ended March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Position</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees
    <br /> earned or <br /> paid in <br /> cash <br /> ($000)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus
    <br /> earned or<br /> paid in<br /> cash <br /> ($000)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options<br />
    awarded <br /> ($000) (1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    <br /> ($000)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Director</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">517</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">942</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    the fair value of incentive stock options granted during the year to March 31, 2022 using an appropriate valuation model for computing
    stock-based compensation expense as of the date of grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative
Disclosure to the Compensation table</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into an employment agreement with Dr. Gary S. Jacob, our Chief Executive Officer, on December 21, 2020 and amended the agreement
on January 19, 2021. Pursuant to the agreement, Dr. Jacob has an annual salary of $350,000 and a cash bonus of up to 50% of his annual
salary based on annual performance goals. In addition, Dr. Jacob was granted options to purchase 40,000,000 ordinary shares. The options
will vest over 4 years in 4 equal tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 22.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jacob is also entitled to the same fringe benefits as we provide to our other executives from time to time and is eligible to receive
employee share incentives. If Dr. Jacob&#8217;s employment with the company is terminated without cause, or if he resigns for good reason,
Dr. Jacob will also be entitled to receive severance equal to continuation of his base salary as then currently in effect for 12 months
following his date of termination and will be eligible for a pro-rated bonus and for reimbursement for medical coverage premiums for
6 months following his date of termination. Dr. Jacob&#8217;s severance benefits are conditioned on, amongst other things, his execution
of our standard separation agreement and a general release of claims in our favor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides information regarding all outstanding equity awards for our directors, executive officers, and non-executive
directors, as of March 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary<br />
    Shares<br /> Underlying<br /> Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise<br />
    Price Per<br /> Ordinary<br /> Share (&#163;)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration<br />
    Date</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.05</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/01/2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">05/01/2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.049</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/08/2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30/08/2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.045</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/07/2018</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">06/07/2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">450,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.155</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20/08/2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20/08/2030</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">900,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.049</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/08/2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30/08/2031</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/01/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/01/2032</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/01/2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31/01/2032</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Share Option Plan with Non-Employee Sub-Plan and US Sub-Plan</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main features of the Unapproved Share Option Plan are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligibility</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
executive directors, officers and employees of the Company and any of its subsidiaries are eligible to participate in the Unapproved
Share Option Plan. The Remuneration Committee selects the individuals to whom share options are to be granted from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Grant
of options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may be granted at such time or times as the Remuneration Committee (or the Board, excluding any interested Director, until a Remuneration
Committee is formally established) determines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
price and adjustments to options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Ordinary Shares are admitted to trading on the Main Market of the London Stock Exchange, the exercise price per Ordinary Share may
not be less than the average of the middle market quotations for an Ordinary Share for the five dealing days immediately prior to the
date of grant. While the Ordinary Shares are not admitted to trading on the Main Market of the London Stock Exchange, the exercise price
will be the amount specified by the Remuneration Committee. If the Ordinary Shares are newly issued the exercise price may not, in any
event, be less than the nominal value of an Ordinary Share. In the event of any variation in the share capital of the Company the exercise
price and/or the number of Ordinary Shares comprised in each option may be adjusted as the Remuneration Committee determines. No adjustment
may be made which will reduce the exercise price below the nominal value of an Ordinary Share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
and restrictions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
option granted under the Unapproved Share Option Plan is not transferable. The option certificate will specify when the option will lapse,
and such date may not be later than the tenth anniversary of its date of grant. Except in the circumstances referred to below, an option
will only be exercisable on or after the date which is three years after the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the participant ceases to be employed by the Company by reason of injury, disability, ill-health or redundancy; or because the business
or company that employs them is transferred out of the ultimate ownership of the Company, their option may be exercised within six months
after such cessation or transfer provided that this limit may be further extended by the Remuneration Committee in the event that any
exercise of the options would trigger any requirement upon the holder to make a general offer to shareholders under Rule 9 of the Takeover
Code. In the event of the death of a participant, the personal representatives of a participant may exercise their option within six
months after the date of death. The extent to which an option may be exercised in these circumstances will be determined by reference
to any exercise conditions and time vesting provisions set out in the option certificate unless the Remuneration Committee decides otherwise
and is satisfied that any waiver of such provisions does not constitute a reward for failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
cessation of employment for any other reason (or when a participant serves or has been served with, notice of termination of such employment),
the option will lapse unless the Remuneration Committee exercises its discretion to allow the exercise of the option for a period not
exceeding 6 months from the date of such cessation or notice. In such circumstances and where exercise is permitted, the extent to which
an option may be exercised will be determined by reference to any exercise conditions and time vesting provisions set out in the option
certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions does not constitute
a reward for failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Corporate
events</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options,
to the extent not already exercisable, will become exercisable immediately prior to a change in control of the Company, in the event
of a takeover of the Company, in the event that an officer becomes entitled or bound to acquire Ordinary Shares or in the event that
the court sanctions a compromise or arrangement for the reconstruction of the Company or its amalgamation with any other company. In
such event, all share options may be exercised for a limited period and will lapse to the extent not exercised. Options, to the extent
not already exercisable, will become exercisable in the event that the Company is proposed to be voluntarily wound up and all share options
may be exercised within a limited period in connection with the winding up, failing which they will lapse. In such circumstances and
where exercise is permitted, the extent to which an option may be exercised will be determined by reference to any exercise conditions
set out in the option certificate unless the Remuneration Committee decides otherwise and is satisfied that any waiver of such provisions
does not constitute a reward for failure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
conditions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of share options may be subject to the satisfaction of such performance conditions, if any, as may be specified and subsequently
varied and/or waived by the Remuneration Committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance
of Ordinary Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Shares issued upon the exercise of share options granted under the Unapproved Share Option Plan will rank pari passu with the
Company&#8217;s issued Ordinary Shares on the date of exercise, save as regards any rights arising by reference to a record date prior
to the date of such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Plan
limit</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
may not be granted under the Unapproved Share Option Plan if such grant would result in the total number of &#8220;Dilutive Shares&#8221;
exceeding 15% of the Company&#8217;s issued share capital from time to time. &#8220;Dilutive Shares&#8221; means, on any date, all shares
of the Company which (a) have been issued, or transferred out of treasury, on the exercise of share options granted, or in satisfaction
of any other awards made, under any share incentive scheme (including the Unapproved Share Option Plan) in the shorter of the five years
ending on (and including) that date and the period since Admission; and (b) remain capable of issue, or transfer out of treasury, under
any subsisting share options granted by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alternative
settlement on exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Instead
of delivering the number of Ordinary Shares specified in the exercise notice, the Remuneration Committee may make a cash payment with
the option holder&#8217;s consent or deliver Ordinary Shares equal to the value of the Ordinary Shares over which the option is exercised,
less the relevant exercise price, or may deliver a combination of the above two.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Alteration</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may alter the Unapproved Share Option Plan except that (apart from minor amendments to benefit the administration
of the Share Option Plan, to correct typographical or other errors, to take account of a change in legislation or to obtain or maintain
favorable tax, exchange control or regulatory treatment for participants or the Company) no alteration to the advantage of participants
or to the Unapproved Share Option Plan limit described above can be made without the prior approval of Shareholders in general meeting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
amendment may have a materially adverse effect on share options granted before the amendment without the relevant option holder&#8217;s
consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Termination
and Plan period</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Remuneration Committee may terminate or suspend the operation of the Unapproved Share Option Plan at any time, whereupon no further share
options shall be granted but in all other respects the provisions of the Unapproved Share Option Plan shall remain in force. In any event,
no share options may be granted after the date which is five years after the date the Unapproved Share Option Plan is adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Board Practices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate
Governance Practices</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;foreign private issuer,&#8221; as defined by the SEC. As a result, in accordance with Nasdaq listing requirements, we may
rely on home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq corporate governance
standards. While we voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the following limited
exemptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from filing quarterly reports on Form 10-Q containing unaudited financial and other specified information or current reports on Form
    8-K upon the occurrence of specified significant events.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from Section 16 rules requiring insiders to file public reports of their stock ownership and trading activities and liability for
    insiders who profit from trades in a short period of time, which will provide less data in this regard than shareholders of U.S.
    companies that are subject to the Exchange Act.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the Nasdaq requirement requiring disclosure of any waivers of the code of business conduct and ethics for directors and officers.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement that our board have a compensation committee that is composed entirely of independent directors with a written
    charter addressing the committee&#8217;s purpose and responsibilities.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exemption
    from the requirement to have independent director oversight of director nominations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
follow the QCA code corporate governance practices in lieu of Nasdaq corporate governance requirements as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not follow Nasdaq Rule 5620(c) regarding quorum requirements applicable to meetings of shareholders. Such quorum requirements
    are not required under English law. In accordance with generally accepted business practice, our Articles of Association will provide
    alternative quorum requirements that are generally applicable to meetings of shareholders.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not follow Nasdaq Rule 5605(b)(2), which requires that independent directors regularly meet in executive sessions where only independent
    directors are present. Our independent directors may choose to meet in executive sessions at their discretion.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we may rely on certain home country corporate governance practices, we must comply with Nasdaq&#8217;s Notification of Noncompliance
requirement (Nasdaq Rule 5625) and the Voting Rights requirement (Nasdaq Rule 5640). Further, we must have an audit committee that satisfies
Nasdaq Rule 5605(c)(3), which addresses audit committee responsibilities and authority and requires that the audit committee consist
of members who meet the independence requirements of Nasdaq Rule 5605(c)(2)(A)(ii).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance
requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and Nasdaq listing rules. Accordingly, our shareholders will not
have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of Nasdaq.
For an overview of our corporate governance principles, see the section titled &#8220;Description of Share Capital and Articles of Association&#8212;Differences
in Corporate Law.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliance
with the Quoted Companies Alliance Corporate Governance Code</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
companies with securities admitted to trading on LSE are required to include on their website details of a recognized corporate governance
code that the board of directors of the company have decided to apply, how the company complies with that code, and where it departs
from its chosen corporate governance code an explanation of the reasons for doing so. This information is required to be reviewed annually.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company has decided to apply the Corporate Governance Code published by the Quoted Companies Alliance, or the QCA Code. The QCA Code
sets out a standard of minimum best practice for small and midsize quoted companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Composition
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors is currently composed of five members. Our board of directors has determined that, of our five directors, three
of the directors, Mr. John Brancaccio, Mr. Bernard Denoyer and Mr. Simon, each do not have a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined
under Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with our Articles, each of our directors for whom it is the third annual general meeting following the annual general meeting
at which they were elected or last re-elected, or who was appointed by the board since the previous annual general meeting, shall retire
from office but shall be eligible to stand for re-election. See &#8220;Description of Share Capital and Articles of Association&#8212;Articles
of Association&#8212;Board of Directors.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
expiration of the current terms of the members of the Board of Directors and the period each member has served in that term are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year&#160;Current<br />
    Term Began</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year&#160;Current<br />
    Term&#160;Expires</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2014</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted best practice for corporate governance in its country of incorporation so all directors will retire and stand for
re-election at each annual general meeting (as opposed to reliance upon rotational reappointment).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Committees
of Our Board of Directors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has three standing committees: an audit, risk and disclosure committee, a remuneration committee and a nomination committee.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Audit,
Risk and Disclosure Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit, risk and disclosure committee, which consists of John Brancaccio, Bernard Denoyer and Willy Simon, assists the board of directors
in overseeing our accounting and financial reporting processes. Mr. Brancaccio serves as chairman of the audit, risk and disclosure committee.
The audit, risk and disclosure committee consists exclusively of members of our board who are financially literate, and Mr. Brancaccio
is considered an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication
as defined under the applicable Nasdaq rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board has determined that all of the members of the audit, risk and disclosure committee satisfy the &#8220;independence&#8221; requirements
set forth in Rule 10A-3 under the Exchange Act. The audit, risk and disclosure committee will be governed by a charter that complies
with Nasdaq rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
audit, risk and disclosure committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    the appointment of the independent auditor to the general meeting of shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit
    report or performing other audit services;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
    the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such
    services;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    the independent auditor&#8217;s qualifications, performance and independence, and presenting its conclusions to the full board of
    directors on at least an annual basis;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and discussing with management and our independent registered public accounting firm our financial statements and our financial reporting
    process;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    approving or ratifying any related party transactions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remuneration
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee consists of Mr. Brancaccio, Mr. Denoyer and Mr. Simon. Mr. Simon serves as chairman of the remuneration committee.
Under SEC and Nasdaq rules, there are heightened independence standards for members of the remuneration committee, including a prohibition
against the receipt of any compensation from us other than standard board member fees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remuneration committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    reviewing and proposing policies relevant to the compensation and benefits of our directors and executive officers;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    each executive officer&#8217;s performance in light of such policies and reporting to the board; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering our employee share option scheme or equity incentive plans in operation from time to time.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nomination
Committee</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nomination committee consists of Mr. Denoyer, Mr. Brancaccio and Mr. Simon. Mr. Denoyer serves as chairman of the nomination committee.
The nomination committee&#8217;s responsibilities include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drawing
    up selection criteria and appointment procedures for directors;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    nominees for election to our board of directors and its corresponding committees;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
    the functioning of individual members of our board of directors and executive officers and reporting the results of such assessment
    to the board of directors; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    corporate governance guidelines.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our non-employee directors have any service contracts with Okyo Pharma Ltd or our subsidiary that provide for benefits upon termination
of employment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 31, 2022, we had 3 full time employees. Two of our employees were engaged in research and development and one employee was engaged
in management, administration and finance. One is located in England and two are located in the United States. None of our employees
are members of labor unions. None of our employees are covered by a collective bargaining agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance
and Indemnification</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent permitted by the Companies (Guernsey) Law, 2008, we are empowered to indemnify our directors against any liability they incur
by reason of their directorship. We maintain directors&#8217; and officers&#8217; insurance to insure such persons against certain liabilities.
We expect to enter into a deed of indemnity with each of our directors and executive officers prior to, or as soon as practicable, following
the filing of this annual report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to such indemnification, we provide our directors and executive officers with directors&#8217; and officers&#8217; liability
insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification of liabilities arising under the Securities Act may be permitted to our board of directors, executive officers, or
persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification
is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -9.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Share Ownership</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 7. Major Shareholders and Related Party Transactions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_009"></span>ITEM
7: MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Major Shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information relating to the beneficial ownership of our ordinary shares as of July 21, 2022 by:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding ordinary shares; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    member of our board of directors and each of our executive officers.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of ordinary shares beneficially owned by each entity, person, board member, or executive officer is determined in accordance with
the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules,
beneficial ownership includes any ordinary shares over which the individual has sole or shared voting power or investment power as well
as any ordinary shares that the individual has the right to acquire within 60 days of July 21, 2022 through the exercise of any option,
warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table
have sole voting and investment power with respect to all ordinary shares held by that person.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Ordinary<br /> Shares Beneficially<br /> Owned</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of beneficial owner</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5%
    or Greater Shareholders:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553,043,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officers and Directors:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553,043,715</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.08</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Willy
    Simon<sup>(2)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,807,100</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob <sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,000,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio<sup>(4)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">112,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
    Denoyer</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors and executive officers as a group (5 persons)<sup>(3)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">564,963,315</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">39.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    beneficial ownership of less than 1% of the total outstanding ordinary shares.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gabriele Cerrone is the ultimate beneficial owner of ordinary shares through Planwise Group Limited and Panetta Partners Limited.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 1,500,000 stock options which are currently exercisable or exercisable within 60 days of July 21, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 10,000,000 stock options which are currently exercisable or exercisable within 60 days of July 21, 2022</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 112,500 stock options which are currently exercisable or exercisable within 60 days of July 21, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a description of related party transactions we have entered into since April 1, 2021, with the beneficial owners of 5% or
more of our ordinary shares, which are our only voting securities, and senior management and members of our board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnity
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into deeds of indemnity with each of our directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shared
services Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;We
have entered into a Shared Services agreement with Tiziana whereby we are charged for shared services such as payroll
and rent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Person Transaction Policy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has adopted a written related person transaction policy, effective as of May 10, 2022. This policy covers, any transaction or proposed transactions between us and a related person
that are material to us or the related person, including without limitation, purchases of goods or services by or from the related person
or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related
person. In reviewing and approving any such transactions, our audit, risk and disclosure committee is tasked to consider all relevant
facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained
in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Interests of Experts and Counsel</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_010"></span>ITEM
8: FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Consolidated Statements and Other Financial Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&#8220;Item 18. Financial Statements&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal
Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
as disclosed in this paragraph, there are no governmental, legal or arbitration proceedings (including any such proceedings which
are pending or threatened of which the Company is aware), which may have, or have had during the 12 months prior to the date of this
annual report, a significant effect on the Company&#8217;s and/or our financial position or profitability. In addition to the
proceedings set out in this section, the Company is not involved in other legal proceedings and claims in the ordinary course of
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -10.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Significant Changes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 25 of our consolidated financial statements at the end of this Annual Report for a description of the significant changes since
March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_011"></span>ITEM
9: THE LISTING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Listing Details</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal trading market for our ordinary shares is the main market of the London Stock Exchange (LSE), where our ordinary shares have
been listed since July 17, 2018. Prior to this date we were listed on the AIM market of the London Stock Exchange since 2014. The following
table sets forth, for the periods indicated, the reported high and low closing prices on the London Stock Exchange for our ordinary shares
in pounds Sterling. See &#8220;Exchange Rate Information&#8221; on page 4 for the exchange rates applicable to the periods set forth
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares have been trading on the Main Market of the London Stock Exchange under the symbol &#8220;OKYO&#8221; since July 17,
2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents, for the periods indicated, the reported high and low sale prices, including intra-day sales, of our ordinary
shares on the Main Market of the London Stock Exchange in Pounds Sterling and U.S. dollars. For the convenience of the reader, we have
translated Pounds Sterling amounts in the table below into U.S. dollars at the noon buying rate of the Federal Reserve Bank of New York
on July 29, 2022 which was &#163;1.00 to $1.2183.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    Per<br /> Ordinary Share &#163;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    Per<br /> Ordinary Share $</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31, 2023</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.026</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.032</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Quarter (to August 3, 2022)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.028</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.020</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.033</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.024</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31, 2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.078</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.060</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.094</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.073</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.065</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.040</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.079</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.049</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.085</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.041</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.104</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.050</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.083</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.048</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.058</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.055</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.017</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.067</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.180</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.053</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.219</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.064</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.121</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.071</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.147</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.087</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.120</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.076</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.146</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.093</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31, 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.011</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.026</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.013</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.059</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.072</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.025</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.043</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.017</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.052</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth
    Quarter</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.013</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.027</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.015</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2022 the last reported sale price of our ordinary shares on LSE was &#163;0.019 per ordinary share ($0.023 per ordinary share
based on the exchange rate set forth above).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
American Depositary Shares, or ADSs, have been trading on the Nasdaq Capital Market under the symbol &#8220;OKYO&#8221; since May 17,
2022. The following table sets forth, for the periods indicated, the reported high and low closing sale prices of our ADSs on the Nasdaq
Capital Market in U.S. dollars.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price
    Per<br /> ADS $</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Low</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monthly:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.60</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.88</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
    2022</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.35</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.95</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    2022 (to August 3, 2022)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.96</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 3, 2022, the last reported sale price of our ADS&#8217;s on the Nasdaq Capital Market was $1.96 per ADS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Plan of Distribution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Markets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ordinary shares are listed on LSE under the symbol &#8220;OKYO&#8221; and our ADSs are listed on the Nasdaq Global Market under the symbol
&#8220;OKYO&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Selling Shareholders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Dilution</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Expenses of the Issue</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_012"></span>ITEM
10: ADDITIONAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Share Capital</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Memorandum and Articles of Association</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate by reference into this Annual Report the description of our amended articles of association contained in our Registration
Statement on Form F-1 originally filed with the SEC on March 4, 2022, as amended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Material Contracts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise disclosed in this Annual Report (including the exhibits hereto), we are not currently, and have not been in the last two
years, party to any material contract, other than contracts entered into in the ordinary course of business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
Exchange Controls</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of
capital, including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends,
interest, or other payments by us to non-resident holders of our ordinary shares or ADSs, other than withholding tax requirements.
There is no limitation imposed by English and our Guernsey law or our articles of association on the right of non-residents to hold
or participate in shareholders vote.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>E.
Taxation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material
U.S. Federal Income Tax Considerations for U.S. Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S.
Federal Income Tax Considerations for U.S. Holders</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ADSs
by U.S. Holders. This discussion applies to U.S. Holders that purchase our ADSs pursuant to this offering and hold such ADSs as capital
assets for tax purposes. This discussion is based on the Internal Revenue Code, U.S. Treasury regulations promulgated thereunder and
administrative and judicial interpretations thereof, and the income tax treaty between the United Kingdom and the United States, or the
Treaty, all as in effect on the date hereof and all of which are subject to change, possibly with retroactive effect. This discussion
does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light of their particular
circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain financial institutions,
insurance companies, dealers or traders in securities or other persons that generally mark their securities to market for U.S. federal
income tax purposes, tax-exempt entities or governmental organizations, retirement plans, regulated investment companies, real estate
investment trusts, grantor trusts, brokers, dealers or traders in securities, commodities, currencies or notional principal contracts,
certain former citizens or long-term residents of the United States, persons who hold our ADSs as part of a &#8220;straddle,&#8221; &#8220;hedge,&#8221;
&#8220;conversion transaction,&#8221; &#8220;synthetic security&#8221; or integrated investment, persons that have a &#8220;functional
currency&#8221; other than the U.S. dollar, persons who are subject to the tax accounting rules of Section 451(b) of the Internal Revenue
Code, persons that own directly, indirectly or through attribution 10% or more (by vote or value) of our equity, corporations that accumulate
earnings to avoid U.S. federal income tax, partnerships and other pass-through entities, and investors in such pass-through entities).
This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or alternative
minimum tax consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our ADSs that is, for U.S. federal income tax
purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation
for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District
of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (i) with
respect to which a court within the United States is able to exercise primary supervision over its administration and one or more United
States persons have the authority to control all of its substantial decisions or (ii) that has elected under applicable U.S. Treasury
regulations to be treated as a domestic trust for U.S. federal income tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an entity treated as a partnership for U.S. federal income tax purposes holds our ADSs, the U.S. federal income tax consequences relating
to an investment in such ADSs will depend upon the status and activities of such entity and the particular partner. Any such entity and
a partner in any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it (and,
as applicable, its partners) of the purchase, ownership and disposition of our ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not sought, nor will we seek, a ruling from the IRS with respect to the matters discussed below. There can be no assurance that
the IRS will not take a different position concerning the tax consequences of the purchase, ownership or disposition of the ADSs or that
any such position would not be sustained. Persons considering an investment in our ADSs should consult their own tax advisors as to the
particular tax consequences applicable to them relating to the purchase, ownership and disposition of our ADSs, including the applicability
of U.S. federal, state and local tax laws and non-U.S. tax laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Passive
Foreign Investment Company (PFIC) Rules</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, a corporation organized outside the United States will be treated as a PFIC for any taxable year in which either (1) at least
75% of its gross income is &#8220;passive income,&#8221; or the PFIC income test, or (2) on average at least 50% of its assets, determined
on a quarterly basis, are assets that produce passive income or are held for the production of passive income, or the PFIC asset test.
Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale
or exchange of property that give rise to passive income. Assets that produce or are held for the production of passive income generally
include cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce
passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of
each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature
of our current and expected income and the current and expected value and composition of our assets, we believe we were a PFIC for our
2017 tax year and we expect to be a PFIC for our current taxable year. There can be no assurance that we will not be a PFIC in future
taxable years. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the IRS will agree with
our conclusion and that the IRS would not successfully challenge our position. Because of the uncertainties involved in establishing
our PFIC status, our U.S. counsel expresses no opinion regarding our PFIC status, and also expresses no opinion with respect to our predictions
or past determinations regarding our PFIC status.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC in any taxable year during which a U.S. Holder owns our ADSs, the U.S. Holder could be liable for additional taxes and
interest charges under the &#8220;PFIC excess distribution regime&#8221; upon (1) a distribution paid during a taxable year that is greater
than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder&#8217;s holding
period for our ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including, under certain circumstances, a
pledge, of our ADSs, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution
or gain would be determined by allocating the distribution or gain ratably over the U.S. Holder&#8217;s holding period for our ADSs.
The amount allocated to the current taxable year (<i>i.e</i>., the year in which the distribution occurs or the gain is recognized) and
any year prior to the first taxable year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year.
The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as
applicable, to ordinary income for each such taxable year, and an interest charge, generally applicable to underpayments of tax, will
be added to the tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any year during which a U.S. Holder holds our ADSs, we must generally continue to be treated as a PFIC by that U.S.
Holder for all succeeding years during which the U.S. Holder holds such ADSs, unless we cease to meet the requirements for PFIC status
and the U.S. Holder makes a &#8220;deemed sale&#8221; election with respect to our ADSs. If the election is made, the U.S. Holder will
be deemed to sell our ADSs it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC,
and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime. After the deemed sale election,
the U.S. Holder&#8217;s ADSs would not be treated as shares of a PFIC unless we subsequently become a PFIC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC for any taxable year during which a U.S. Holder holds our ADSs and one of our non-United States subsidiaries is also a
PFIC (<i>i.e</i>., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares of
the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain
from the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions
or dispositions. Any of our non-United States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships
for U.S. federal income tax purposes would not be corporations under U.S. federal income tax law and accordingly, cannot be classified
as lower-tier PFICs. However, a non-United States subsidiary that has not made the election may be classified as a lower-tier PFIC if
we are a PFIC during your holding period and the subsidiary meets the PFIC income test or PFIC asset test.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized
on our ADSs if a valid &#8220;mark-to-market&#8221; election is made by the U.S. Holder for our ADSs. An electing U.S. Holder generally
would take into account as ordinary income each year, the excess of the fair market value of our ADSs held at the end of such taxable
year over the adjusted tax basis of such ADSs. The U.S. Holder would also take into account, as an ordinary loss each year, the excess
of the adjusted tax basis of such ADSs over their fair market value at the end of the taxable year, but only to the extent of the excess
of amounts previously included in income over ordinary losses deducted as a result of the mark-to-market election. The U.S. Holder&#8217;s
tax basis in our ADSs would be adjusted annually to reflect any income or loss recognized as a result of the mark-to-market election.
Any gain from a sale, exchange or other disposition of our ADSs in any taxable year in which we are a PFIC would be treated as ordinary
income and any loss from such sale, exchange or other disposition would be treated first as ordinary loss (to the extent of any net mark-to-market
gains previously included in income) and thereafter as capital loss. If, after having been a PFIC for a taxable year, we cease to be
classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder would not be required to take into
account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or exchange of the ADSs would
be classified as a capital gain or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
mark-to-market election is available to a U.S. Holder only for &#8220;marketable stock.&#8221; Generally, stock will be considered marketable
stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable U.S. Treasury regulations.
A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in de minimis quantities,
on at least 15 days during each calendar quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ADSs will be marketable stock as long as they remain listed on Nasdaq and are regularly traded. A mark-to-market election will not apply
to the ADSs for any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable year
in which we become a PFIC. Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S. Holder may continue
to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the U.S. Holder&#8217;s
mark-to-market election for our ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make
a valid Qualified Electing Fund (QEF) election. As we do not expect to provide U.S. Holders with the information necessary for a U.S.
Holder to make a QEF election, prospective investors should assume that a QEF election will not be available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The
U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own
tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of our ADSs, the consequences to them
of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with respect
to the purchase, ownership and disposition of ADSs of a PFIC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Distributions</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &#8220;Passive Foreign Investment Company Rules&#8221;, a U.S. Holder that receives a distribution with
respect to our ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend when actually
or constructively received by the U.S. Holder to the extent of the U.S. Holder&#8217;s pro rata share of our current and/or accumulated
earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder
is not a dividend because it exceeds the U.S. Holder&#8217;s pro rata share of our current and accumulated earnings and profits, it will
be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis of the U.S. Holder&#8217;s ADSs.
To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&#8217;s ADSs, the remainder will be taxed as a capital
gain. Because we may not account for our earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should
expect all distributions to be reported to them as dividends. The amount of a dividend will include any amounts withheld by the company
in respect of United Kingdom taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
on our ADSs that are treated as dividends generally will constitute income from sources outside the United States for foreign tax credit
purposes and generally will constitute passive category income. Subject to applicable limitations, some of which vary depending upon
the U.S. Holder&#8217;s particular circumstances, any United Kingdom income taxes withheld from dividends on ADSs at a rate not exceeding
the rate provided by the Treaty will be creditable against the U.S. Holder&#8217;s U.S. federal income tax liability. The rules governing
foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their
particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including
any United Kingdom income tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election
to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. The
amount of any dividend income paid in a currency other than the U.S. dollar will be the U.S. dollar amount calculated by reference to
the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into
U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. holder should not be required
to recognize foreign currency gain or loss in respect of the dividend amount. A U.S. Holder may have foreign currency gain or loss if
the dividend is converted into U.S. dollars after the date of receipt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions
paid on our ADSs will not be eligible for the &#8220;dividends received&#8221; deduction generally allowed to corporate shareholders
with respect to dividends received from U.S. corporations under the Internal Revenue Code. Dividends paid by a &#8220;qualified
foreign corporation&#8217;&#8217; to non-corporate U.S. Holders are eligible for taxation at a reduced capital gains rate rather
than the marginal tax rates generally applicable to ordinary income provided that a holding period requirement (more than 60 days of
ownership, without protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and
certain other requirements are met. Each U.S. Holder is advised to consult their tax advisors regarding the availability of the
reduced tax rate on dividends to their particular circumstances. However, if we are a PFIC for the taxable year in which the
dividend is paid or the preceding taxable year (see discussion above under &#8220;Passive Foreign Investment Company
Rules&#8217;&#8217;), we will not be treated as a qualified foreign corporation, and therefore the reduced capital gains tax rate
described above will not apply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-United States corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid
or the preceding taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays
on ADSs that are readily tradable on an established securities market in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of any dividend income that is paid in Pounds Sterling will be the U.S. dollar amount calculated by reference to the exchange
rate in effect on the date of receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted
into U.S. dollars on the date of receipt (actual or constructive), a U.S. Holder should not be required to recognize foreign currency
gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gains or losses if the dividend is converted
into U.S. dollars after the date of receipt (actual or constructive).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sale,
Exchange or Other Taxable Disposition of Our ADSs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion above under &#8220;Passive Foreign Investment Company Rules&#8221;, a U.S. Holder generally will recognize capital
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ADSs in an amount equal to the
difference, if any, between the amount realized (<i>i.e</i>., the amount of cash plus the fair market value of any property received)
on the sale, exchange or other disposition and such U.S. Holder&#8217;s adjusted tax basis in the ADSs. Such capital gain or loss generally
will be a long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or a long-term capital loss if, on the date
of sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate
U.S. Holder that is not a long-term capital gain is taxed at ordinary income tax rates. The deductibility of capital losses is subject
to limitations. Any gain or loss recognized from the sale or other disposition of our ADSs will generally be a gain or loss from sources
within the United States for U.S. foreign tax credit purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Medicare
Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax
on all or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition
of our ADSs. If you are a U.S. Holder that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding
the applicability of this Medicare tax to your income and gains in respect of your investment in our ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Information
Reporting and Backup Withholding</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ADSs, including,
among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). In addition, each U.S. Holder who is a shareholder of
a PFIC must file an annual report containing certain information. U.S. Holders paying more than $100,000 for our ADSs may be required
to file IRS Form 926 (Return by a U.S. Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties
and other adverse circumstances may be imposed upon a U.S. Holder that fails to comply with the required information reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
on and proceeds from the sale or other disposition of our ADSs generally have to be reported to the IRS unless the U.S. Holder establishes
a basis for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S.
taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons.
However, U.S. Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup
withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or
a credit against a U.S. Holder&#8217;s U.S. federal income tax liability if the required information is furnished by the U.S. Holder
on a timely basis to the IRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EACH
PROSPECTIVE INVESTOR IS URGED TO CONSULT THEIR OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO THEM OF AN INVESTMENT IN OUR ADSS IN LIGHT
OF THE INVESTOR&#8217;S OWN CIRCUMSTANCES. IN ADDITION, SIGNIFICANT CHANGES IN U.S. FEDERAL INCOME TAX LAWS WERE RECENTLY ENACTED. PROSPECTIVE
INVESTORS SHOULD ALSO CONSULT WITH THEIR TAX ADVISORS WITH RESPECT TO SUCH CHANGES IN U.S. TAX LAW AS WELL AS POTENTIAL CONFORMING CHANGES
IN STATE TAX LAWS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.K.
Taxation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is intended as a general guide to current U.K. tax law and Her Majesty&#8217;s Revenue&#160;&amp; Customs, or HMRC, published
practice applying as at the date of this annual report (both of which are subject to change at any time, possibly with retrospective
effect) relating to the holding of ADSs. It does not constitute legal or tax advice and does not purport to be a complete analysis of
all U.K. tax considerations relating to the holding of ADSs, or all of the circumstances in which holders of ADSs may benefit from an
exemption or relief from U.K. taxation. It is written on the basis that the company does not (and will not) directly or indirectly derive
75% or more of its qualifying asset value from U.K. land, and that the company is and remains solely resident in the U.K. for tax purposes
and will therefore be subject to the U.K. tax regime and not the U.S. tax regime save as set out above under &#8220;U.S. Federal Income
Taxation.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
to the extent that the position of non-U.K. resident persons is expressly referred to, this guide relates only to persons who are resident
(and, in the case of individuals, domiciled or deemed domiciled) for tax purposes solely in the U.K. and do not have a permanent establishment
or fixed base in any other jurisdiction with which the holding of the ADSs is connected, or U.K. Holders, who are absolute beneficial
owners of the ADSs (where the ADSs are not held through an Individual Savings Account or a Self-Invested Personal Pension) and who hold
the ADSs as investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
guide may not relate to certain classes of U.K. Holders, such as (but not limited to):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who are connected with the company;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    institutions;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insurance
    companies;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">charities
    or tax-exempt organizations;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collective
    investment schemes;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pension
    schemes;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    makers, intermediaries, brokers or dealers in securities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons
    who have (or are deemed to have) acquired their ADSs by virtue of an office or employment or who are or have been officers or employees
    of the company or any of its affiliates; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">individuals
    who are subject to U.K. taxation on a remittance basis.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
decision of the First-tier Tribunal (Tax Chamber) in <i>HSBC Holdings PLC and The Bank of New York Mellon Corporation v HMRC</i> (2012)
cast some doubt on whether a holder of a depositary receipt is the beneficial owner of the underlying shares. However, based on published
HMRC guidance we would expect that HMRC will regard a holder of ADSs as holding the beneficial interest in the underlying shares and
therefore these paragraphs assume that a holder of ADSs is the beneficial owner of the underlying ordinary shares and any dividends paid
in respect of the underlying ordinary shares (where the dividends are regarded for U.K. purposes as that person&#8217;s own income) for
U.K. direct tax purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THESE
PARAGRAPHS ARE A SUMMARY OF CERTAIN U.K. TAX CONSIDERATIONS AND ARE INTENDED AS A GENERAL GUIDE ONLY. IT IS RECOMMENDED THAT ALL HOLDERS
OF ADSs OBTAIN ADVICE AS TO THE CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSAL OF THE ADSs IN THEIR OWN SPECIFIC CIRCUMSTANCES
FROM THEIR OWN TAX ADVISORS. IN PARTICULAR, NON-U.K. RESIDENT OR DOMICILED PERSONS ARE ADVISED TO CONSIDER THE POTENTIAL IMPACT OF ANY
RELEVANT DOUBLE TAXATION AGREEMENTS.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dividends</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Withholding
Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
paid by the company will not be subject to any withholding or deduction for or on account of U.K. tax, irrespective of the residence
or particular circumstances of the holders of ADSs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Income
Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
individual U.K. Holder may, depending on his or her particular circumstances, be subject to U.K. tax on dividends received from the company.
An individual holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. income tax on
dividends received from the company unless he or she carries on (whether solely or in partnership) a trade, profession or vocation in
the U.K. through a branch or agency to which the ADSs are attributable. There are certain exceptions for trading in the U.K. through
independent agents, such as some brokers and investment managers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
dividends received by an individual U.K. Holder from us or from other sources will form part of that U.K. Holder&#8217;s total income
for income tax purposes and will constitute the top slice of that income. A nil rate of income tax will apply to the first &#163;2,000
of taxable dividend income received by the individual U.K. Holder in a tax year. Income within the nil-rate band will be taken into account
in determining whether income in excess of the &#163;2,000 tax-free allowance falls within the basic rate, higher rate or additional
rate tax bands. Dividend income in excess of the tax-free allowance will (subject to the availability of any income tax personal allowance)
be taxed at 7.5 per cent. to the extent that the excess amount falls within the basic rate tax band, 32.5 per cent. to the extent that
the excess amount falls within the higher rate tax band and 38.1 per cent. to the extent that the excess amount falls within the additional
rate tax band.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 19.55pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Corporation
Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
corporate holder of ADSs who is not resident for tax purposes in the United Kingdom should not be chargeable to U.K. corporation tax
on dividends received from the company unless it carries on (whether solely or in partnership) a trade in the United Kingdom through
a permanent establishment to which the ADSs are attributable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
U.K. Holders should not be subject to U.K. corporation tax on any dividend received from the company so long as the dividends qualify
for exemption, which should be the case, provided the dividends fall within an exempt class and certain conditions are met. If the conditions
for the exemption are not satisfied, or such U.K. Holder elects for an otherwise exempt dividend to be taxable, U.K. corporation tax
will be chargeable on the amount of any dividends (at the current rate of 19%).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Chargeable
Gains</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
disposal or deemed disposal of ADSs by a U.K. Holder may, depending on the U.K. Holder&#8217;s circumstances and subject to any available
exemptions or reliefs (such as the annual exemption), give rise to a chargeable gain or an allowable loss for the purposes of U.K. capital
gains tax and corporation tax on chargeable gains.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an individual U.K. Holder who is subject to U.K. income tax at either the higher or the additional rate is liable to U.K. capital gains
tax on the disposal of ADSs, the current applicable rate will be 20%. For an individual U.K. Holder who is subject to U.K. income tax
at the basic rate and liable to capital gains tax on such disposal, the current applicable rate would be 10%, save to the extent that
any capital gains when aggregated with the U.K. Holder&#8217;s other taxable income and gains in the relevant tax year exceed the unused
basic rate tax band. In that case, the rate currently applicable to the excess would be 20%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a corporate U.K. Holder becomes liable to U.K. corporation tax on the disposal (or deemed disposal) of ADSs, the main rate of U.K. corporation
tax (currently 19%) would apply. Indexation allowance is not available in respect of disposals of ADSs acquired on or after January 1,
2018 (and only covers the movement in the retail prices index up until 31 March 2017, in respect of assets acquired prior to that date).
A holder of ADSs which is not resident for tax purposes in the United Kingdom should not normally be liable to U.K. capital gains tax
or corporation tax on chargeable gains on a disposal (or deemed disposal) of ADSs unless the person is carrying on (whether solely or
in partnership) a trade, profession or vocation in the United Kingdom through a branch or agency (or, in the case of a corporate holder
of ADSs, through a permanent establishment) to which the ADSs are attributable. However, an individual holder of ADSs who is treated
as resident outside the United Kingdom for the purposes of a double tax treaty, or who has ceased to be resident for tax purposes in
the United Kingdom for a period of less than five years and who disposes of ADSs during that period may be liable on his or her return
to the United Kingdom to U.K. tax on any capital gain realized (subject to any available exemption or relief).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stamp
Duty and Stamp Duty Reserve Tax</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
discussion below relates to the holders of our ordinary shares or ADSs wherever resident, however it should be noted that special rules
may apply to certain persons such as market makers, brokers, dealers or intermediaries.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issue
of Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
U.K. stamp duty or stamp duty reserve tax, or SDRT, is payable on the issue of the underlying ordinary shares in the company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Transfers
of Shares</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfers
of the ordinary shares (including instruments transferring ordinary shares and agreements to transfer ordinary shares) are subject to
stamp duty or SDRT at a rate of 0.5% on the value of the transfer.:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ordinary shares are admitted to trading on LSE, but are not listed on any market (with the term &#8220;listed&#8221; being construed
    in accordance with section 99A of the Finance Act 1986), and this has been certified to Euroclear;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that either of the above requirements is not met, stamp duty or SDRT will generally apply to transfers of, or agreements to
transfer, ordinary shares. Where applicable, the purchaser normally pays the stamp duty or SDRT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issue
and Transfers of ADSs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.K.
stamp duty or SDRT is payable on the issue or transfer of (including an agreement to transfer) ADSs in the company at a rate of 0.5%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F.
Dividends and Paying Agents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>G.
Statements by Experts</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>H.
Documents on Display</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information
with the SEC, including annual reports on Form 20-F and reports on Form 6-K. You may inspect and copy reports and other information filed
with the SEC at the public reference facilities of the SEC located at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain
copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington,
DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains a website
at http://www.sec.gov from which certain filings may be accessed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also make available on our website, free of charge, our Annual Report and the text of our reports on Form 6-K, including any amendments
to these reports, as well as certain other SEC filings, as soon as reasonably practicable after they are electronically filed with or
furnished to the SEC. Our website address is <span style="text-decoration: underline">www.okyopharma.com</span>. The information contained on our website is not incorporated
by reference in this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.
Subsidiary Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
information on our subsidiaries, see &#8220;Item 4C. Organizational Structure.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_013"></span>ITEM
11: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business, which are principally limited to interest rate fluctuations and foreign
currency exchange rate fluctuations. We maintain significant amounts of cash and cash equivalents that are in excess of federally insured
limits in various currencies, placed with one or more financial institutions for varying periods according to expected liquidity requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Rate Risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to interest rate sensitivity is impacted by changes in the underlying U.S. and U.K. bank interest rates. Our surplus cash and
cash equivalents have been invested in interest-bearing savings and money market accounts from time to time. We have not entered into
investments for trading or speculative purposes. Due to the conservative nature of our investment portfolio, which is predicated on capital
preservation of investments with short-term maturities, we do not believe an immediate one percentage point change in interest rates
would have a material effect on the fair market value of our portfolio, and therefore we do not expect our operating results or cash
flows to be significantly affected by changes in market interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign
Currency Exchange Risk</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain our consolidated financial statements in the functional currency Pounds Sterling. Monetary assets and liabilities denominated
in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance
sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the
exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included
in the determination of net income (loss) for the respective periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
financial reporting purposes, our consolidated financial statements are prepared using the functional currency, and translated into the
U.S. dollar. Assets and liabilities are translated at the exchange rates at the balance sheet dates and revenue and expenses are translated
at the average exchange rates and shareholders&#8217; equity is translated based on historical exchange rates. Translation adjustments
are not included in determining net income (loss) but are included in foreign exchange adjustment to accumulate other comprehensive loss,
a component of shareholders&#8217; equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently engage in currency hedging activities in order to reduce our currency exposure, but we may begin to do so in the future.
Instruments that may be used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be
used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency fluctuations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_014"></span>ITEM
12: DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.
Debt Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.
Warrants and Rights</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.
Other Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>D.
American Depositary Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
and Expenses</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JPMorgan
Chase Bank, N.A., or JPMorgan, as depositary, registers and delivers the American Depositary Shares, also referred to as ADSs. Each ADS
represents an ownership interest in a designated number of ordinary shares that are on deposit with the custodian, as agent of the depositary,
under the deposit agreement among ourselves, the depositary and the ADS holders. Each ADS will also represent any securities, cash or
other property deposited with the depositary but which they have not distributed directly to the ADS holders. The depositary&#8217;s
office is located at 4 New York Plaza, Floor 12, New York, NY, 10004. A copy of the deposit agreement is incorporated by reference as
an exhibit to this Annual Report on Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares,
issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared
by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities,
and each person surrendering ADSs for withdrawal of deposited securities or whose ADSs are cancelled or reduced for any other reason,
$5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary
may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other
distribution prior to such deposit to pay such charge.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following additional charges shall be incurred by the American Depository Receipt (ADR) holders, by any party depositing or withdrawing
ordinary shares or by any party surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to
a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution
of ADSs), whichever is applicable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee of up to U.S.$0.05 per ADS for any cash distribution made pursuant to the deposit agreement;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
    aggregate fee of up to U.S.$0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering
    the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as
    of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in
    the next succeeding provision);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including,
    without limitation, the custodian and expenses incurred on behalf of holders in connection with compliance with foreign exchange
    control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the ordinary shares
    or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited
    securities or otherwise in connection with the depositary&#8217;s or its custodian&#8217;s compliance with applicable law, rule or
    regulation (which fees and charges shall be assessed on a proportionate basis against holders as of the record date or dates set
    by the depositary and shall be payable at the sole discretion of the depositary by billing such holders or by deducting such charge
    from one or more cash dividends or other cash distributions);</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount
    equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit
    of such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from
    the sale thereof are instead distributed by the depositary to those holders entitled thereto;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    transfer or other taxes and other governmental charges;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SWIFT,
    cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery
    of ordinary shares, ADRs or deposited securities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">transfer
    or registration fees for the registration or transfer of deposited securities on any applicable register in connection with the deposit
    or withdrawal of deposited securities;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    connection with the conversion of foreign currency into U.S. dollars, JPMorgan Chase Bank, N.A. (&#8220;JPMorgan&#8221;) shall deduct
    out of such foreign currency the fees, expenses and other charges charged by it and/or its agent (which may be a division, branch
    or affiliate) so appointed in connection with such conversion; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or
    private sale of securities under the deposit agreement.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.P.
Morgan,&#160;and/or its agent may act as principal for such conversion of foreign currency. For further details see https://www.adr.com.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements
from time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us
and the depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the
termination of the deposit agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise
upon such terms and conditions as we and the depositary may agree on from time to time. The depositary collects its fees for issuance
and cancellation of ADSs directly from investors depositing ordinary shares or surrendering ADSs for the purpose of withdrawal or from
intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts
distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary
services by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants
acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no
distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services
to holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary,
all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Payment
of Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian
or the depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon,
such tax or other governmental charge shall be paid by the holder thereof to the depositary and by holding or having held an ADR the
holder and all prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and
its agents in respect thereof. If an ADR holder owes any tax or other governmental charge, the depositary may (i)&#160;deduct the amount
thereof from any cash distributions, or (ii)&#160;sell deposited securities by public or private sale (after attempting by reasonable
means to notify the ADR holder hereof prior to such sale) and deduct the amount owing from the net proceeds of such sale. In either case
the ADR holder remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to affect
any registration, registration of transfer,&#160;split-up&#160;or combination of deposited securities or withdrawal of deposited securities
until such payment is made. If any tax or governmental charge is required to be withheld on any cash distribution, the depositary may
deduct the amount required to be withheld from any cash distribution or, in the case of a non-cash distribution, sell the distributed
property or securities (by public or private sale) in such amounts and in such manner as the depositary deems necessary and practicable
to pay such taxes and distribute any remaining net proceeds or the balance of any such property after deduction of such taxes to the
ADR holders entitled thereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective
officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority
with respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source
or other tax benefit obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_015"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_016"></span>ITEM
13: DEFAULTS, DIVIDEND ARREARAGES AN DELINQUENCIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_017"></span>ITEM
14: MATERIAL MODIF</b>IC<b>ATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_018"></span>ITEM
15: CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, have evaluated
the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and&#160;15d-15(e) under
the Securities Exchange Act of&#160;1934, as amended (the&#160;&#8220;Exchange Act&#8221;)) as of&#160;March 31, 2022. Based on that
evaluation, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer have concluded that as of&#160;March
31, 2022, due to the existence of the material weaknesses in the Company&#8217;s internal control over financial reporting described
below, the Company&#8217;s disclosure controls and procedures were not effective.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s management is responsible for establishing and maintaining adequate internal controls over financial reporting as defined
in Rules&#160;13a-15(f) and&#160;15d-15(f) under the Exchange Act. The Company&#8217;s internal control over financial reporting is a
process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting
Standards Board (IASB), and IFRIC interpretations as applicable to companies reporting under IFRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of their inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the supervision and with the participation of management, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief
Financial Officer, the Company conducted an informal evaluation, based on regular verbal discussions between management and the
audit committee, of the effectiveness of its internal control over financial reporting based on the framework described in Internal
Control-Integrated Framework issued by the Commission of Sponsoring Organizations of the Treadway Commission, as revised
in&#160;2013. Based on that evaluation, management has concluded that the Company did not maintain effective internal control over
financial reporting as of the period ended&#160;March 31, 2022&#160;due to the existence of the material weaknesses in internal
control over financial reporting described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Material
Weaknesses</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or
employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material
weakness is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable
possibility that a material misstatement of the Company&#8217;s annual or interim financial statements will not be prevented or detected
on a timely basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board and management have determined that the Company did not maintain effective internal control over financial reporting as of the
period ended&#160;March 31, 2022&#160;due to the existence of the following material weaknesses identified by management. A consequence
of the material weaknesses identified below did result in material errors , but these were identified during the audit phase and adjusted
for in the consolidated financial statements. Management therefore believes that our consolidated financial statements present fairly
the consolidated financial position, results of operations and cash flows for the periods covered. However, management recognizes that
the failure of the internal control over financial reporting to operate effectively as described below could result in a material misstatement
which may not have been detected by our controls:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Lack
of Accounting Resources</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the limited financial resources available for expenditure other than research and development, the Company had a lack of accounting
resources resulting in over reliance on key staff, professional opinions, a weakness in monitoring controls and other oversight procedures,
which resulted in corrected misstatements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Remediation
efforts</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
intends to remediate this item in the following manner:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    funds have been made available to enable the Company to address its lack of accounting resources and additional resources have been
    hired and formalized review controls have been implemented.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
    assessments will be performed to evaluate the sufficiency of the Company&#8217;s accounting resources and needs for recruiting additional
    personnel, in addition to providing our accounting personnel with regular training over applicable IFRS accounting standards, complex
    accounting and financial reporting subject matters, and SEC reporting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to complete the remediation of the material weaknesses discussed above as soon as practicable, but we can give no assurance that
we will be able to do so. Designing and implementing effective disclosure controls and procedures is a continuous effort that requires
us to anticipate and react to changes in our business and the economic and regulatory environments and to devote significant resources
to maintain a financial reporting system that adequately satisfies our reporting obligations. The remedial measures that we have taken
and intend to take may not fully address the material weaknesses that we have identified, and material weaknesses in our disclosure controls
and procedures may be identified in the future. Should we discover such conditions, we intend to remediate them as soon as practicable.
We are committed to taking appropriate steps for remediation, as needed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_019"></span>ITEM
16A: AUDIT COMMITTEE FINANCIAL EXPERT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
members of our audit, risk and disclosure committee are Mr John Brancaccio, Mr Bernard Denoyer and Mr. Willy Simon. Mr. John Brancaccio is the chair of the
audit, risk and disclosure committee. Each of our audit, risk and disclosure committee members satisfies the independence requirements of Rule 5605(a)(2) of the Nasdaq Stock Market
Marketplace Rules and the independence requirements of Rule 10A-3(b)(1) under the Exchange Act. Our board of directors has determined
that Mr. John Brancaccio is an &#8220;audit committee financial expert&#8221; as defined in Item 16A of Form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_020"></span>ITEM
16B: CODE OF ETHICS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Code of Business Conduct and Ethics is applicable to all of our employees, officers and directors and is available on our website at
https://www.okyopharma.com. Our Code of Business Conduct and Ethics provides that our directors and officers are expected to avoid any
action, position or interest that conflicts with the interests of our company or gives the appearance of a conflict. Our directors and
officers have an obligation under our Code of Business Conduct and Ethics to advance our company&#8217;s interests when the opportunity
to do so arises. We expect that any amendment to this code, or any waivers of its requirements, will be disclosed on our website. Information
contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report, and you should not
consider information on our website to be part of this Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_021"></span>ITEM
16C: PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth, for each of the years indicated, the aggregate fees billed to us for services rendered by Mazars LLP, our
independent registered public accounting firm.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ending March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    thousands)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit
    fees</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    assurance services<sup>(1)</sup></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">149</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">132</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    assurance services include interim reviews and audit opinions required for other filings</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_022"></span>ITEM
16D: EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_023"></span>ITEM
16E: PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_024"></span>ITEM
16F: CHANGE IN REGISTRANTS CERTIFYING ACCOUNTANT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_025"></span>ITEM
16G: CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including
our company, to comply with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may
follow home country practices in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent
that such exemptions would be contrary to U.S. federal securities laws. The home country practices followed by our company in lieu of
Nasdaq rules are described below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not follow Nasdaq&#8217;s quorum requirements applicable to meetings of shareholders. Such quorum requirements are not required
    under Guernsey law. In accordance with generally accepted business practice, our articles of association provide alternative quorum
    requirements that are generally applicable to meetings of shareholders.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not follow Nasdaq&#8217;s requirements that non-management directors meet on a regular basis without management present. Our board
    of directors may choose to meet in executive session at their discretion.</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not follow Nasdaq&#8217;s requirements to seek shareholder approval for the implementation of certain equity compensation plans,
    the issuances of ordinary shares under such plans, or in connection with certain private placements of equity securities. In accordance
    with Guernsey law, we are not required to seek shareholder approval to allot ordinary shares in connection with applicable employee
    equity compensation plans. We will follow Guernsey law with respect to any requirement to obtain shareholder approval prior to any
    private placements of equity securities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance
requirements of the Sarbanes-Oxley Act of 2002, the rules adopted by the SEC and Nasdaq&#8217;s listing standards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are a foreign private issuer, our directors and senior management are not subject to short-swing profit and insider trading reporting
obligations under Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or Exchange Act. They are, however, subject to
the obligations to report changes in share ownership under Section 13 of the Exchange Act and related SEC rules.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_026"></span>ITEM
16H: MINE SAFETY DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_027"></span>ITEM
16L: DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_028"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_029"></span>ITEM
17: FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to furnish financial statements and related information specified in Item 18.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_030"></span>ITEM
18: FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
the Financial Statements beginning on page F-1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_031"></span>ITEM
19: EXHIBITS</b>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex3-1.htm" style="-sec-extract: exhibit">Memorandum and Articles of Incorporation of OKYO Pharma Limited</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222007784/ex2-1.htm" style="-sec-extract: exhibit">Form of Deposit Agreement.&#160;(Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222007784/ex2-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of American Depositary Receipt (included in Exhibit 2.1).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">8.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex21-1.htm" style="-sec-extract: exhibit">List of Subsidiaries. (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-1.htm" style="-sec-extract: exhibit">OKYO Pharma Limited Share Option Plan With Non-Employee Sub-Plan And US Sub-Plan (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-2.htm" style="-sec-extract: exhibit">Executive Employment Agreement dated December 21, 2020 between Gary S. Jacob and OKYO Pharma Limited as amended on January 19, 2021. (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-3.htm" style="-sec-extract: exhibit">Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated June 4, 2018 (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-4.htm" style="-sec-extract: exhibit">Amendment to Collaboration Agreement between On Target Therapeutics, LLC and OKYO Pharma Limited dated October 22, 2018 (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-5.htm" style="-sec-extract: exhibit">License Agreement dated as of May 1, 2018 by and between Tufts Medical Center, Inc. and OKYO Pharma Limited (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-6.htm" style="-sec-extract: exhibit">Shared Services Agreement dated as of January 1, 2018 by and between OKYO Pharma Limited and Tiziana Life Sciences plc (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-7.htm" style="-sec-extract: exhibit">License and Sublicense Agreement dated May 22, 2017 by and between On Target Therapeutics, LLC and OKYO Pharma Limited (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-8.htm" style="-sec-extract: exhibit">First Amendment to the License and Sublicense Agreement dated March 25, 2021 by and between On Target Therapeutics, LLC and OKYO Pharma Limited. (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1849296/000149315222006119/ex10-9.htm" style="-sec-extract: exhibit">Collaboration Agreement dated August 6, 2019 between Tufts Medical Center, Inc. and OKYO Pharma Limited. (Incorporated by reference to Exhibit 4.1 to Amendment No. 6 to Form F-1 filed on May 13, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-1.htm">Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex12-2.htm">Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex13-1.htm">Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex13-2.htm">Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex15-1.htm">Consent of Mazars LLP.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    Herewith</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="Z_032"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized
the undersigned to sign this annual report on its behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: small-caps 10pt Times New Roman, Times, Serif"><b>OKYO
    Pharma Ltd</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Gary Jacob </i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief
    Executive Officer</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    15, 2022</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OKYO
PHARMA LIMITED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 92%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_033">Report of Independent Registered Public Accounting Firm</a> PCAOB ID: <span id="xdx_909_edei--AuditorFirmId_c20210401__20220331_z3MNLGzaWKs7"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorFirmId">1401</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_034">Consolidated Balance Sheets</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_035">Consolidated Statements of Comprehensive Income</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_036">Consolidated Statements of Changes in Shareholders&#8217; Equity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#Z_037">Consolidated Statement of Cash Flows</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">Notes to Consolidated Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 97; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="Z_033"></span>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the shareholders and Board of Directors of OKYO Pharma Limited</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Opinion
on the Consolidated Financial Statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of OKYO Pharma Limited and its subsidiary (the Group) as of March 31, 2022
and 2021, together with the related consolidated statements of operations and comprehensive loss, consolidated statements of
shareholders&#8217; equity, and consolidated statements of cash flows for each of the three years in the period ended March 31, 2022
and the related notes (collectively referred to as the &#8216;consolidated financial statements&#8217;). In our opinion, the consolidated
financial statements present fairly, in all material respects, the financial position of the Group as of March 31, 2022 and 2021,
and the results of its operations and its cash flows for each of the three years in the period ended March 31, 2022, in conformity
with International Financial Reporting Standards as issued by the International Accounting Standards Board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><i>Going Concern Uncertainty</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Group will continue as a going concern. As discussed
in Note 2 to the consolidated financial statements, the Group are pre-revenue, and its business model requires significant ongoing expenditure
on research and development. The forecast prepared by management indicates that the current cash held will be exhausted by October 2022
without additional financing facilities in place. The Group is in the final stages of its Investigational New Drug (IND) application
for OK101, due to be filed with the U.S. Food and Drug Administration (FDA) in mid-November 2022 after which there is a 30 day period
for the FDA to raise questions or issue a clinical hold. On completion of the IND application
process, management intends to raise sufficient funds to enable the Group to complete Phase II clinical trials for OK101. As management&#8217;s
forecasts indicate current cash held is not sufficient to complete the IND application process and cover working capital requirements
until further funds are raised for the Phase II clinical trials, to meet the short-term need, the Group has secured a $2 million short-term
credit facility with a related party, Tiziana Life Sciences Limited, which must be repaid six months after the initial draw-down. After
taking this facility into consideration the available cash position will be extended to approximately April 2023. If further funds for
the Phase II clinical trials are not raised before then, to continue operating, the Group will need to raise additional funds sufficient
to meet its ongoing working capital requirements as well as to repay the $2 million short-term credit facility. These conditions raise
substantial doubt about the Group&#8217;s ability to continue as a going concern. The consolidated financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis
for Opinion</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Group&#8217;s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. The Group is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we
are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Group&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--AuditorName_c20210401__20220331_zAiy2MqYdYk"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorName">Mazars
LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Group&#8217;s auditor since 2019.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--AuditorLocation_c20210401__20220331_zX2OAL1GGEy1"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" name="dei:AuditorLocation">London,
England</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 15, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="Z_034"></span>OKYO
Pharma Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_111_zq7wBMAUfpG6" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" id="xdx_490_20220331_ziCQYNu5VQ9f" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" id="xdx_495_20210331_zWcmYUEmpLa9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td></tr>
  <tr id="xdx_402_eifrs-full--AssetsAbstract_iB_zaB6BANKhh1k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--CurrentAssetsAbstract_i01B_zPH4XRHSp0Z8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--CashAndCashEquivalents_i02I_maCAzV2A_zHDBDVYyolI7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 62%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,724</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,889,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--RelatedPartyReceivables_i02I_maCAzV2A_zszdTDG9Jat3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0060">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:RelatedPartyReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,664</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--CurrentTaxationReceivable_i02I_maCAzV2A_zl5FGzY4BICg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    taxation receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:CurrentTaxationReceivable" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">781,688</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:CurrentTaxationReceivable" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,322</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--OtherReceivables_i02I_maCAzV2A_zmWF0aNpOEUc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,956</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,371</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eifrs-full--CurrentAssets_i02TI_mtCAzV2A_maAz2k4_z3AZg5xhh5F7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,295,368</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CurrentAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,986,686</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eifrs-full--PropertyPlantAndEquipment_i01I_maNAzqZv_z1I0WUTcF5Vh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,225</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,057</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eifrs-full--RightofuseAssets_i01I_maNAzqZv_z3L70W5P1QBe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Right
    of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0075">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,579</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--NoncurrentAssets_i01TI_mtNAzqZv_maAz2k4_zvuW9eaTfNqk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    non-current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,225</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NoncurrentAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,636</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--Assets_i01TI_mtAz2k4_zcej1z27XDE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,300,593</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Assets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,091,322</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eifrs-full--EquityAndLiabilitiesAbstract_iB_z1NFN9oYkJ24" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND SHAREHOLDERS&#8217; EQUITY</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--LiabilitiesAbstract_iB_z0imceF8Km5g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eifrs-full--CurrentLiabilitiesAbstract_i01B_zlCPTrgNLQPd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentPayables_i02I_maCLzqnM_zkGBcqgdz2o" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,306,150</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,673,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eifrs-full--TradeAndOtherCurrentPayablesToRelatedParties_i02I_maCLzqnM_z7fNZf211bCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related
    party payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,041</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0097">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_i02I_maCLzqnM_zdlfhO2zR0X6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liabilities - current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0099">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,148</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eifrs-full--CurrentLiabilities_i02TI_mtCLzqnM_maLz4KJ_z0tgO3JxoRD7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,353,191</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,707,302</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--NoncurrentLeaseLiabilities_i01I_maLz4KJ_zsgw94b16qS" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
    liabilities - non current</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,612</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--Liabilities_i01TI_mtLz4KJ_maEALzYYP_zBpOM00TIVK9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,353,191</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Liabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,771,914</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--EquityAbstract_i01B_zj5Us2LtaF13" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&#8217;
    Equity:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eifrs-full--SharePremium_i02I_maEz67c_zVDTzUPMsU81" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    premium</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,976,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:SharePremium" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,629,173</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eifrs-full--ReserveOfSharebasedPayments_i02I_maEz67c_zpdKZEPxQhQi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    options reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,355,040</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ReserveOfSharebasedPayments" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,313</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--WarrantReserve_i02I_maEz67c_zvOwFHNHKMSl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WarrantReserve" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,413</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WarrantReserve" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">861,214</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--ConvertibleLoanNoteReserve_i02I_maEz67c_zn5jltqa1mv3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Loan Note reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0123">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ConvertibleLoanNoteReserve" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,370,836</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ForeignCurrencyTranslationReserve_i02I_maEz67c_zQmicm1HX0Db" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
    currency translation reserve</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:ForeignCurrencyTranslationReserve" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,011,527</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:ForeignCurrencyTranslationReserve" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,174,375</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eifrs-full--RetainedEarnings_i02I_maEz67c_z9m0sdxT4wme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,426,034</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">106,003,753</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_402_eifrs-full--Equity_i01TI_mtEz67c_maEALzYYP_zr1LGT00aKtl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    shareholders&#8217; equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,947,402</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,319,408</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--EquityAndLiabilities_i01TI_mtEALzYYP_zLShsJt7Exth" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and shareholders&#8217; equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,300,593</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EquityAndLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,091,322</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="Z_035"></span>OKYO
Pharma Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Operations and Comprehensive Loss</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_113_zB01umfR3YBe" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_492_20210401__20220331_zxpDzpwjNOOh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20200401__20210331_zfGYTppt8E6f" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20190401__20200331_zfNrhV2nYVc" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eifrs-full--MaterialIncomeAndExpenseAbstract_iB_zR27Tx8txzp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eifrs-full--ResearchAndDevelopmentExpense_i01N_di_maOEzNzz_zTO7IQPeGtAg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,301,178</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,821</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ResearchAndDevelopmentExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">518,098</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eifrs-full--OperatingExpense_i01N_di_maOEzNzz_zjDXOJPqv2Jb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,916,388</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,192,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,016,548</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eifrs-full--OperatingExpenseExcludingCostOfSales_i01NT_di_mtOEzNzz_msPLBTzWn7_z1UDcSGgnJN2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpenseExcludingCostOfSales" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,217,566</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpenseExcludingCostOfSales" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,366,206</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OperatingExpenseExcludingCostOfSales" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,534,646</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income/(expense):</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eifrs-full--FinanceIncome_i01_maPLBTzWn7_zGLDyT09jrd1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    Income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0154">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="-sec-ix-hidden: xdx2ixbrl0155">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,125</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eifrs-full--FinanceCosts_i01N_di_msPLBTzWn7_zPqnOdH1EhQ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    (expense)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0158">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,158</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_ecustom--ImpairmentOfLoan_i01_maPLBTzWn7_zu2FkNBewWs" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    of loan</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0162">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:ImpairmentOfLoan" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,172</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:ImpairmentOfLoan" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,668</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLossBeforeTax_iT_mtPLBTzWn7_maPLzktc_zWVQs2cD53bk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,217,566</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,378,501</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,620,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_ecustom--IncomeTaxExpenseBenefitContinuingOperations_iN_di_msPLzktc_zWRYhOhJpwWh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
    tax provision</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncomeTaxExpenseBenefitContinuingOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">786,521</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncomeTaxExpenseBenefitContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,994</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncomeTaxExpenseBenefitContinuingOperations" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,288</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--ProfitLoss_iT_mtPLzktc_maOCIzhYt_zxfXmZjSvKh3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    for the year</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,431,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,353,507</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,544,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eifrs-full--OtherComprehensiveIncomeAbstract_iB_zwYJeSOMRQY4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Comprehensive loss:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eifrs-full--OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_i01_maOCIzhYt_zbs96CuvamW1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    differences on translating foreign operations</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,365</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ComprehensiveIncome_i01T_mtOCIzhYt_z5grckaPLol6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    loss</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,268,197</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,007,142</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,457,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders_zdcbNtpzHHNk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted loss per share attributable to common shareholders</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="Z_036"></span>OKYO
Pharma Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Shareholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zmwJV2YIbGh8" summary="xdx: Statement - Consolidated Statements of Shareholders&apos; Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No.
    of Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_ifrs-full--ComponentsOfEquityAxis_ifrs-full--IssuedCapitalMember_zR7DRnLQsZki" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    Capital</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_ifrs-full--ComponentsOfEquityAxis_ifrs-full--OtherReservesMember_zbfmfeZcFZl9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    reserve</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_ifrs-full--ComponentsOfEquityAxis_custom--WarrantReservesMember_zfmYI5kTbmJf" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    reserve</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_ifrs-full--ComponentsOfEquityAxis_custom--ConvertibleLoanNoteReserveMember_zk5lgOGx45t1" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Loan Note reserve</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_ifrs-full--ComponentsOfEquityAxis_ifrs-full--RetainedEarningsMember_zuJ1IMy0B1Zi" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
    Earnings</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_ifrs-full--ComponentsOfEquityAxis_custom--TranslationReserveMember_zmGKB4yJzKAb" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Translation
    Reserve</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_zfkFwNjQqCB9" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Equity</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_434_c20190401__20200331_eifrs-full--Equity_iS_zy6n0h4VX6Mf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at 31 March 2019</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20190401__20200331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zF9McaZpWLt2" title="Balance, beginning (shares)" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2019-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">524,108,283</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,741,860</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,101</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,242</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0197">&#8212;</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">100,888,643</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,607,394</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,166</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueNewIssue_zgpEPNgCfCrg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    of share capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesShareCapital_pid_c20190401__20200331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zf5hOdfFZU5f" title="Issuance of share capital, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodSharesShareCapital" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">112,188,766</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">965,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0205">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0206">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0207">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0208">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0209">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">965,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnConvertibleDebtAndWarrantInterest_zCoq1KudTQNj" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note and warrant interest</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Issuance of share capital, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueTransferBetweenEquityReserves_zjTdBX5F4Ff2" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer between equity reserves</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Issuance of share capital, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnOptionsCharge_zidsbgGCvTZk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0232">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0233">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0234">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_i_pn3n3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodShareslExerciseOfOptions_pid_zFSHIEAJBW12" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span>, shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseThroughExerciseOfForfeiture_zw74c2qJYFy2" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeiture</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_zjF5LYQHPP5d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnWarrantsExercisedShares_zc7SASOlmBp3" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercised</span>, shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsCharge_zXlxM0fXWA8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">627,047</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">609,661</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">17,386</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedOnConvertibleDebtConversion_z1oIHKifoNJa" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note issued</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnConvertibleDebtConversionShares_zTSmmUzEqFmj" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note issued</span>, shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedOnConvertibleDebtInterest_zmMr4ZzvhVV2" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note interest</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnTotalTransactions_z2CEhsYBZBza" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    transactions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">338,124</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">609,661</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">984,125</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--SharesIssuedOnTotalTransactionsShares_z4U3GqH7lQn7" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    transactions</span>, shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLoss_zpziu7Cw0Cz2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    for the period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,544,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,544,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40B_eifrs-full--OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_zGYQw5OSpdWf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0336">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--ComprehensiveIncome_zZhmXOt2n18d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    comprehensive income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0342">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0344">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,544,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,654</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,457,405</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_436_c20200401__20210331_eifrs-full--Equity_iS_z2k0KfsU962b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at 31 March 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zNa57nMQkBle" title="Balance, beginning (shares)" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">636,297,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,079,984</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">93,441</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,903</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">102,432,702</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,520,740</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">140,114</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueNewIssue_ztDLlpVVBUcb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    of share capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesShareCapital_pid_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zdpJZJWohcDg" title="Issuance of share capital, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodSharesShareCapital" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,269,253</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0363">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0364">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueNewIssue" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnOptionsCharge_zo4vbCXuirMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0373">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_zPko0CFPRmL4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--StockIssuedDuringPeriodShareslExerciseOfOptions_pid_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsLwMcqQYmm4" title="Options exercised, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodShareslExerciseOfOptions" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,870</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,515</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0380">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0381">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,515</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,870</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseThroughExerciseOfForfeiture_zC74v0jiWeId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeiture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,751</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,751</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsCharge_zPVSzI0rmDm1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">138,305</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,311</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,006</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--SharesIssuedOnConvertibleDebtConversion_zhHGID72VJy8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note issued</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">558,396</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,151,777</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,593,382</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedOnConvertibleDebtInterest_zMMOpyqKrpC6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0414">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">219,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtInterest" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">219,059</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnTotalTransactions_zaP5vK9UZvgg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    transactions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">450,811</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">542,872</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">221,311</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,370,836</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">217,544</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,466,664</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLoss_zFdeXf6fcQX9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    for the period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0431">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,353,507</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0433">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,353,507</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eifrs-full--OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_zXACw1Vz8Ckf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0440">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,365</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,365</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--ComprehensiveIncome_zvTi2dED8mIc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    comprehensive income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0447">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,353,507</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">346,365</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,007,142</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_43D_c20210401__20220331_eifrs-full--Equity_iS_z8pF9MpVgOaa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at 31 March 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zQPgjCXxVc4j" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">672,816,302</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,629,173</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,313</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">861,214</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,370,836</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">106,003,753</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,174,375</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,319,408</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_430_c20210401__20220331_eifrs-full--Equity_iS_zNuuphgylumf" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_eifrs-full--NumberOfSharesOutstanding_iS_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxZDxuBUQkUa" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">672,816,302</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,629,173</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">636,313</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">861,214</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,370,836</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">106,003,753</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,174,375</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,319,408</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--SharesIssuedOnConvertibleDebtAndWarrantInterest_z1n7GOGuRk3b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note and warrant interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,318</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">444,918</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">991,236</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0477">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--SharesIssuedOnConvertibleDebtConversion_zljCzz3j4TUh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    loan note conversion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--SharesIssuedOnConvertibleDebtConversionShares_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zRGT5u87ij27" title="Convertible debt conversion, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversionShares" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315,086,410</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,876,397</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0481">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnConvertibleDebtConversion" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,876,397</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0484">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_zMjS6Ab2IcH4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Currency translation on Convertible Loan note conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td title="Convertible debt conversion, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0490">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">654,833</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0494">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">654,833</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueTransferBetweenEquityReserves_zIl0C1TXoqt1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer between equity reserves</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0498">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">594,190</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">594,190</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0502">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--SharesIssuedOnOptionsCharge_zIsuPyHJINf4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,737,876</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnOptionsCharge" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,737,876</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--IncreaseDecreaseThroughExerciseOfForfeiture_zTPAzeQCwfC6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    forfeiture</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,149</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfForfeiture" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,149</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_zVpLj0anyTP6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--SharesIssuedOnWarrantsExercisedShares_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zEcoNDRBcBg3" title="Warrants exercised, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnWarrantsExercisedShares" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386,512,756</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,470,940</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,010,030</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0527">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,460,910</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsCharge_z1LHOg1Tz7Qh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0535">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--SharesIssuedOnTotalTransactions_zuQuJrfpA7a9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    transactions</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--SharesIssuedOnTotalTransactionsShares_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z1Jsu3h5jJd8" title="Total transactions, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactionsShares" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">701,599,166</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,347,337</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,718,727</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">807,801</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,370,836</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">991,236</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:SharesIssuedOnTotalTransactions" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,896,191</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Comprehensive
    income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--ProfitLoss_z9rSUgRsx3qc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    for the period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,431,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,431,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eifrs-full--OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_zwrGexDqemYg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currency
    translation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eifrs-full--ComprehensiveIncome_zJXJf65oXT8e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    comprehensive income</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0566">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,431,045</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">837,152</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ComprehensiveIncome" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,268,197</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_436_c20210401__20220331_eifrs-full--Equity_iE_ztMNa59Zry5c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    at 31 March 2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iE_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zXUA220l1IF1" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,415,468</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,976,510</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,355,040</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,413</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,426,034</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,011,527</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,947,402</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_43A_c20210401__20220331_eifrs-full--Equity_iE_zQOsrGjq9Edk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--NumberOfSharesOutstanding_iE_pid_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zojN3gijl42c" title="Balance, shares" style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,415,468</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,976,510</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_OtherReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,355,040</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_WarrantReservesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,413</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">112,426,034</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_custom_TranslationReserveMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">11,011,527</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,947,402</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="Z_037"></span>OKYO
Pharma Limited</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zcrszoc0UWp5" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20210401__20220331_z1N2pc6XyQY9" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20200401__20210331_zbrsQZUqzND7" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49C_20190401__20200331_zsNrdrFp42E8" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eifrs-full--CashFlowsFromUsedInOperatingActivitiesAbstract_iB" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM OPERATING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--ProfitLossBeforeTax_i01_ma001_zKlfJ6YpsAne" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from operations before income taxes</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,217,566</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,378,501</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:ProfitLossBeforeTax" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,620,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eifrs-full--AdjustmentsForReconcileProfitLossAbstract_i01B_zZJdtACz2MLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net cash used in operating activities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--AdjustmentsForSharebasedPayments_i02_ma001_zfS5z9nSDe0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    option charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,737,876</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550,138</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForSharebasedPayments" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,340</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--AdjustmentsForChangeInFairValueOfWarrantCharge_i02N_di_ms001_z74tNI9FntT1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    charge</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">61,721</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">83,006</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42,846</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AdjustmentsForChangeInFairValueOfForfeitureOfOptions_i02N_di_ms001_zWZTNseIiGjl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeiture
    of options</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,149</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,751</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--AdjustmentsForDepreciationExpense_i02_ma001_zLlYrjFBC4R6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    of fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,331</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,510</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForDepreciationExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">426</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eifrs-full--AdjustmentsForAmortisationExpense_i02_ma001_zlI44as8ys92" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    of right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,601</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForAmortisationExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,553</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForUnrealisedForeignExchangeLossesGains_i02_ma001_zuZIpmXvHMwl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)/Loss
    on foreign exchange</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,230</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,056</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,915</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances_i02_ma001_zgjt5dikJuGh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment
    of loan to West African Minerals Ltd</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0630">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,668</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_i02N_di_ms001_zn4267zFpoX3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain
    on disposal of right of use asset</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">179</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">818</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0636">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--AdjustmentsForDecreaseIncreaseRelatedPartyReceivables_i02_ma001_zXO7Wgz5JdA5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    decrease/(increase) in related party receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,376</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,862</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">543</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_ecustom--AdjustmentsForIncreaseDecreaseInRelatedPartyPayables_i02_ma001_zzDLkhHfxRn4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase/(decrease) in related party payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,900</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,311</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,049</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_i02_ma001_z5zLKARVpvp7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (increase)/decrease in operating assets/other receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">802,154</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">208,931</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">122,190</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eifrs-full--AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_i02_ma001_zA7kKtr4pSY" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (decrease)/increase in trade and other payables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">297,991</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886,093</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,218</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eifrs-full--AdjustmentsForReconcileProfitLoss_i02_ma001_znDqu9XSXPVj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    inflow from taxation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AdjustmentsForReconcileProfitLoss" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,540</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0656">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eifrs-full--CashFlowsFromUsedInOperatingActivities_i01T_mt001_maIDICAzqOp_zOOIVOQ4NbH2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,468,065</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,600,198</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,202,066</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--CashFlowsFromUsedInInvestingActivitiesAbstract_iB_z6xqldhY7tP8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM INVESTING ACTIVITIES</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eifrs-full--PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_i01N_di_msCFFUIzqf6_zu6rI26Dmz02" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisition
    of property, plant and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,669</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,943</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--CashAdvancesAndLoansMadeToRelatedParties_i01N_di_msCFFUIzqf6_zXqtxgjmlif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    to West African Minerals Ltd</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0670">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashAdvancesAndLoansMadeToRelatedParties" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,668</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_404_eifrs-full--CashFlowsFromUsedInInvestingActivities_i01T_mtCFFUIzqf6_maIDICAzqOp_z0fsVs9mfINi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in investing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,669</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,114</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:CashFlowsFromUsedInInvestingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">132,668</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eifrs-full--CashFlowsFromUsedInFinancingActivitiesAbstract_iB_zzjTeAUc3gmj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CASH
    FLOWS FROM FINANCING ACTIVITIES:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eifrs-full--ProceedsFromIssuingShares_i01_maCFFUIzVPV_zznWSPHxMKc3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of ordinary shares</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,019</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">990,639</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--ProceedsFromIssueOfBondsNotesAndDebentures_i01_maCFFUIzVPV_ze1hh4JCpDt" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of convertible loan notes</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0686">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,593,380</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0688">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ProcessedFromOptionsExercised_i01_maCFFUIzVPV_zDQwVE1kump1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processed
    from options exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ProcessedFromOptionsExercised" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,870</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0692">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--ProcessedFromWarrantsExercised_i01_maCFFUIzVPV_zgtZT75bU7qg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Processed
    from warrants exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ProcessedFromWarrantsExercised" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0695">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--CashAdvancesAndLoansToRelatedParties_i01_maCFFUIzVPV_zd9j6ock1Iac" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    to related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0699">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:CashAdvancesAndLoansToRelatedParties" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">518,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40D_eifrs-full--CashAdvancesAndLoansFromRelatedParties_i01_maCFFUIzVPV_zHynuudSwClf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan
    repayment from related party</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0702">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0703">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAdvancesAndLoansFromRelatedParties" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">496,810</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eifrs-full--PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_i01N_di_msCFFUIzVPV_zGzUZS0pddic" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment
    of leasing liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0706">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,331</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,139</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eifrs-full--CashFlowsFromUsedInFinancingActivities_i01T_mtCFFUIzVPV_maIDICAzqOp_zB4rxeT0Fy89" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,153,270</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,826,938</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInFinancingActivities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963,310</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eifrs-full--IncreaseDecreaseInCashAndCashEquivalents_iT_mtIDICAzqOp_z0WGilXDoMIl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    (decrease)/increase in cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,316,464</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,208,627</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">371,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_405_eifrs-full--CashAndCashEquivalents_iS_zRbpeRRiBNd1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalent, beginning of period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,889,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,485</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">627,616</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eifrs-full--EffectOfExchangeRateChangesOnCashAndCashEquivalents_zBwdf2OkKstk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
    difference</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,141</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,217</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">20,708</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eifrs-full--CashAndCashEquivalents_iE_z6H5P3C7NTV1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalent, end of period</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,700,724</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,889,329</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">235,485</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfReportingEntityExplanatory"><p id="xdx_807_ecustom--DisclosureOfReportingEntityExplanatory_zN3ed7cfS9gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>1.
<span id="xdx_822_zIrU2AH0WvJd">Reporting Entity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (the &#8220;Company&#8221; or &#8220;OKYO&#8221;) is a company domiciled in Guernsey and listed with a standard listing
on the main market of the London Stock Exchange (LSE) and on the Nasdaq Capital Market (LSE: OKYO, NASDAQ: OKYO).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate parent of the group is Panetta Partners Limited, incorporated in the British Virgin Islands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory"><p id="xdx_806_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zKGRXvat9wY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82C_zrPyXyik5nr8">ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years presented unless otherwise stated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory"><p id="xdx_843_ecustom--DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_zfHxssMul8de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zuiCtMYBwdSe">Basis
of preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements"><p id="xdx_84C_eifrs-full--ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_ze6rEvZvCdVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSHeKIf3gOw6">Basis
of measurement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfGoingConcernExplanatory"><p id="xdx_840_eifrs-full--DisclosureOfGoingConcernExplanatory_zyjwyoe4H8Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zIJXF9vULX97">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &#163;<span id="xdx_908_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20220331_znuD9gZzK7s8" title="Accumulated deficit"><ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="GBP">76.8</ix:nonFraction></span>m (&#163;<span id="xdx_90E_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20181231_zaW6Bco1JJu6"><ix:nonFraction name="ifrs-full:RetainedEarnings" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="GBP">64</ix:nonFraction></span>m of this accumulated loss relates to a discontinued business prior
to the reorganisation in 2018), a net loss for the year ended March 31, 2022, of &#163;<span id="xdx_905_eifrs-full--ProfitLoss_iN_pn5n6_di_uGBP_c20210401__20220331_zm0Cywblto74" title="Net loss"><ix:nonFraction name="ifrs-full:ProfitLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="GBP">4.0</ix:nonFraction></span>m and net cash used in operating activities
of &#163;<span id="xdx_908_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pn5n6_di_uGBP_c20210401__20220331_zSQLLI5hFUw2" title="Net cash used in operating activities"><ix:nonFraction name="ifrs-full:CashFlowsFromUsedInOperatingActivities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-5" scale="6" sign="-" unitRef="GBP">4.0</ix:nonFraction></span>m.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &#163;<span id="xdx_90A_eifrs-full--CashAndCashEquivalents_iI_pn5n6_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zp1LWwYLOLx9" title="Cash"><ix:nonFraction name="ifrs-full:CashAndCashEquivalents" contextRef="AsOf2022-08-01_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">1.5</ix:nonFraction></span>m, with current liabilities of &#163;<span id="xdx_90F_eifrs-full--CurrentLiabilities_iI_pn3n3_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_ze72JlAwVGUb" title="Current liabilities"><ix:nonFraction name="ifrs-full:CurrentLiabilities" contextRef="AsOf2022-08-01_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="GBP">978</ix:nonFraction></span>k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &#163;<span id="xdx_909_ecustom--CashBurnRate_pn5n6_uGBP_c20220801__20221231__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zYmIKoYjsO1" title="Rate of cash burn/spend"><ix:nonFraction name="OKYO:CashBurnRate" contextRef="From2022-08-012022-12-31_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="GBP">2.4</ix:nonFraction></span>m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took
strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential
liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are
more specialist investors focused on early-stage opportunities. The Directors are also confident that the nature of the OK101
clinical program is such that various inflection points arise over a relatively short period of time which should provide financing
opportunities, for example the FDA approval of the IND in December 2022 for OK101 in dry-eye and the return of headline data from
the Phase II registration trial to be held between July and December 2023; these pivotal events in the primary clinical program
for OK101 have the benefit of being near term events (which is unusual in the context of the normal timeframes for Phase II clinical
programs to deliver meaningful data points. The Directors have also consulted the Company&#8217;s investment bankers with a view to
planning a number of alternative financing strategies to ensure the Company has access to sufficient capital to finance its planned
R&amp;D activity in the coming 18 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To meet the Company&#8217;s short-term
liquidity needs, the Company has secured a $2m short-term credit facility with a related party in order to bridge any delays in the
occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for a period of 6 months upon first
draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the
6-month period. The loan will extend the Company&#8217;s fixed cost cash burn to April 2023 without the need to raise additional
funds. The Directors believe that this facility together with additional working capital management measures will be sufficient to
complete the IND application. The Directors also considered any risks to the short-term cash position of the company such as delay
in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash resources and
the additional financing strategies already disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="margin: 0pt; text-align: justify">On completion of the IND application the company will be in a position to raise funds on the market, via the financing
strategies being discussed with the Company&#8217;s investment bankers. The necessary steps are being taken to affect such a fundraise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Until and unless the Group and Company secures sufficient investment to
fund their clinical pipeline, there is a significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this significant
doubt, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident,
based on the previous fund-raising history as well as additional measures already put in place and being planned, that sufficient funds
will be forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
and Revised Standards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standards
in effect in 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfBasisOfConsolidationExplanatory"><p id="xdx_840_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_z8XuKH8VZHrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAEqUJeIcxTa">Basis
of consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&#8217;s return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zL1Tjuw6eBY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z9pHKU5FVQ77">Segment
reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_z8j7TbRaDvDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zZmLakyiYkc9">Taxation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"><p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zqPFx9fhSOq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zy5WsOrjQrJ1">Foreign
currency translation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentation currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are translated into US dollars on the following basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DescriptionOfAccountingPolicyForLicenseFeesExplanatory"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForLicenseFeesExplanatory_z4OBpo4q3jX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zm7114eoO8Gi">License
fees</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. Licence fees expenses are recognised as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory"><p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_zV4NMjY7ImUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zdB5ejYOmZq6">Research
and development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&#8217;s products, the criteria for development costs to be recognised as an asset, as set out
in IAS 38 &#8216;Intangible Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zmF6nZC13B7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zVywf64qjVV6">Financial
instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities include trade and other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_z9PMWq0U69aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zbwcn0sWvmfd">Cash
and cash equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents comprise cash on hand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory"><p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zu5Vz53LAPZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zSSUUkEJ16pj">Impairment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of financial assets measured at amortised cost</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognised at an amount equal to the lifetime expected credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Simplified
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of non-financial assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of
    fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DescriptionOfAccountingPolicyForShareCapitalExplanatory"><p id="xdx_84F_ecustom--DescriptionOfAccountingPolicyForShareCapitalExplanatory_zhKIP9EcIGAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zutNHNqPZix7">Share
capital</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the Company are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"><p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z3Tp1iH8qZEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_ziZ4K9iwOnRj">Property,
plant and equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognition
    and measurement</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalised as part of that equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfEstimatedUsefulLivesExplanatory"><p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zohpzScp5GKj" style="display: none">DISCLOSURE OF ESTIMATED USEFUL LIVES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures
    and fittings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_FurnitureAndFixtureMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">5</ix:nonNumeric></span>
    years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives"><ix:nonNumeric contextRef="From2021-04-012022-03-31_ifrs-full_ComputerEquipmentMember" format="ixt-sec:duryear" name="ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">3</ix:nonNumeric></span>
    years</b></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_ztfRBhkQeQtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DescriptionOfAccountingPolicyForLeaseExplanatory"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForLeaseExplanatory_z2MC8R5u546h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zKMh4tMa5WMa">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    of low value assets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&#8217;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
term leases&#160;exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit
and loss on a straight-line basis over the term of the lease.<b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_zWrtAKrce05d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOrTi2vaPpRa">Share
based payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&#8217;, Directors&#8217; or
advisers&#8217; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &#8211; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &#8211; warrants, in the case of warrants issued in return for services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForWarrantsExplanatory_zQwDNsR5fr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zbEsSZejhIv1">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued in return for services.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued as part of a financing transaction.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &#8216;fixed&#8217; test for non-derivatives, and the &#8216;fixed for fixed&#8217;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForBorrowingsExplanatory_zhziKifCc0wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
loan notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Where
the fixed for fixed condition is met</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve. The accrued interest on the principal amount is also recorded in the Convertible
loan note reserve as it is convertible into equity. Upon redemption of the instrument and the issue of share capital, the amount is reclassified
from the convertible loan note reserve to share capital and share premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z6QSFNFpPNkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><span id="xdx_86A_zGUsrfQMiDpk">Fair Value Measurement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management have assessed the categorization
of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the
basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 2 - valued by reference to valuation
techniques using observable inputs other than quoted prices included within Level 1;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 3 - valued by reference to valuation
techniques using inputs that are not based on observable market data.</p>
</ix:nonNumeric><p id="xdx_859_zWofBggxCs6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zyknLoeTuQ29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zDLKxXdOri22">CRITICAL
  ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being IFRS as
issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income
and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based
on historical experience and other factors, including expectations of future events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be the key sources of estimation uncertainty<b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-based
payments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes estimates as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest
rate for the term of the award and correlations and volatilities of the shares of peer group companies. The Group also makes estimates
as to the vesting period for awards that have performance-based criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resulting cost of an equity incentive award is recognised as expense over the requisite service period of the award, which is usually
the vesting period. Compensation expense is recognised over the vesting period using the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 27 to our consolidated financial
statements.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfOtherOperatingExpenseExplanatory_zKqq8zJDfqt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zXnleg6bN7Tl">OPERATING
                                            EXPENSES</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_zcJQPfshHF66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses are stated after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BA_zv5H4Zdb09P3" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_492_20210401_20220331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_490_20200401_20210331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_499_20190401_20200331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br />
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"></td></tr>
  <tr id="xdx_400_ecustom--KeyManagementPersonnelCompensationDirectorFees_zePbaRlnR1q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    fees including bonus (excluding Chairman&#8217;s bonus)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationDirectorFees" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">707,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationDirectorFees" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">278,224</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationDirectorFees" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,101</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--ChairmansBonus_zWNaBdmQhEBi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&#8217;s
    bonus</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0801">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ChairmansBonus" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,160,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemuneration_zOFBOtlnRyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s
    Remuneration (refer to Note 20) <span id="xdx_F4F_z1VPTCZ1HRX4">*</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2021-04-01to2022-03-31" id="Fact000805" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,665</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2020-04-012021-03-31" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,511</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2019-04-012020-03-31" id="Fact000807" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,402</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--ProfessionalFeesExpense_maOEz5cJ_zSKJSxSK2Ykd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    and Professional fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,143,300</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">343,422</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ProfessionalFeesExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,433</ix:nonFraction></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainlossOnDisposalOfLeases_zDCjm8fYgV8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)/Loss
    on disposal of leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:GainlossOnDisposalOfLeases" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">179</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ForeignExchangeLossesGains_zjHTgj2143v1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FX
    Gains and losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:ForeignExchangeLossesGains" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,577</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ForeignExchangeLossesGains" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,061</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:ForeignExchangeLossesGains" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,061</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--DepreciationAndAmortisationExpense_maOEz5cJ_zkqnZJ3zsXG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,423</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,512</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DepreciationAndAmortisationExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">212</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zas2XeaQKt8b" style="vertical-align: top; width: 15pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1D_z2RKUHb9dNke" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000824" xml:lang="en-US">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#8217;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#8217;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</ix:footnote></span></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8AA_zu24TZXfaBfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory"><p id="xdx_800_eifrs-full--DisclosureOfOperatingSegmentsExplanatory_zK7fl0qf2Pmi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_za9DJG2Orqyf">SEGMENTAL
                                            REPORTING</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year under review management identified the Group&#8217;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfEmployeeDetailsExplanatory"><p id="xdx_80B_ecustom--DisclosureOfEmployeeDetailsExplanatory_zNzKw4PJSRuk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zUwHzfcQaSGc">EMPLOYEES
                                            INCLUDING OFFICERS</span></b></span></td></tr></table>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory"><p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutEmployeesExplanatory_zZzhVfMhnC1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zCg3Dxgsfoia" style="display: none">DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210401__20220331_zJK1dSHpyP3d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200401__20210331_zS7V6fUe7wfg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20190401__20200331_zhysJddbD2dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended March 31,</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Group</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff
    costs comprised:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--DirectorsSalaries_zzJlwL2IxEI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalaries" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">707,385</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalaries" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,438,571</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalaries" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,101</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--WagesAndSalaries_zCbkmO9Xt7z4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,186</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,702</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WagesAndSalaries" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,347</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--SocialSecurityContributions_zMexCkPv3lt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    security costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,449</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,543</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:SocialSecurityContributions" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,740</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eifrs-full--OtherShorttermEmployeeBenefits_zzA113lNobYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruitment
    Costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,259</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:OtherShorttermEmployeeBenefits" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,922</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--EmployeeBenefitsExpense_zAc6HfaUaDle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    employee benefits expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129,279</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,582,739</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:EmployeeBenefitsExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,188</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March
    31, 2020 were:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zdWNXY20Uey9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2022-03-31_custom_ResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_z76vWoTxq5Hd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2021-03-31_custom_ResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zMCPgwZdQKmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2020-03-31_custom_ResearchAndDevelopmentMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    and administration</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zcb2NreUYGm4" title="Corporate and administration" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2022-03-31_custom_CorporateAndAdministrationMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zyXHP3ZnUfcg" title="Corporate and administration" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2021-03-31_custom_CorporateAndAdministrationMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zgRPVeAAnHEd" title="Corporate and administration" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2020-03-31_custom_CorporateAndAdministrationMember" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">3</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331_zKFobcgy3Io4" title="Total number of employees" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">7</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331_zn1tzEcmsRe2" title="Total number of employees" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">6</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331_zAprse49DnKg" title="Total number of employees" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:NumberOfEmployees" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Integer">4</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_z8nRwVEJndq9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company made $<span id="xdx_907_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20210401__20220331_zYQWoNgRX8Bb" title="Pension contribution"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,622</ix:nonFraction></span> of payments to a defined contribution pension schemes on behalf of Directors or employees during the year
ending March 31, 2022 (March 31, 2021: $<span id="xdx_909_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20200401__20210331_zk5BlBACdOd3" title="Pension contribution"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,904</ix:nonFraction></span>, March 31 2020: $<span id="xdx_901_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20190401__20200331_z0H3IhZ39aQ1" title="Pension contribution"><ix:nonFraction name="ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,774</ix:nonFraction></span>)</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_z1vAekVUCnMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zugKqiGQufXe">REMUNERATION
  OF KEY MANAGEMENT PERSONNEL</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"><p id="xdx_89E_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_z82Jw7rgipH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_z6eoRVcapVgd" style="display: none">SCHEDULE OF
REMUNERATION OF DIRECTORS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br />
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br />
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span id="xdx_F42_zoORemjkg0rk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
    Cerrone (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zJwRoQbTyQmc" title="Directors&apos; fees" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_GCerroneMember" id="Fact000877" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">164</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zA7MD3BExeDg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zuSVp0qrqYE4" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z1H6cleFajP5" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zaR8Ml2OXp1k" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_GCerroneMember" id="Fact000881" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zkoaGsrBKQN" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_GCerroneMember" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,160</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zFKhZNRw7PY9" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z6ZcLf6nkjJ8" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4A_zcmcM70NVUja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Jacob (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ziZY4SFDKuHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zchuBtXycHxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-012022-03-31_custom_GJacobMember" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zMfKmv9pg8zh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-012022-03-31_custom_GJacobMember" id="Fact000887" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zvYjB2pqWyd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_GJacobMember" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,579</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zjK7D1AO1h44" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zTkkst7XIcp9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31_custom_GJacobMember" id="Fact000890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ztB7f8Ln9vi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31_custom_GJacobMember" id="Fact000891" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zuYxRB6PDBal" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_GJacobMember" id="Fact000892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">468</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4E_zzaXpCDtM9a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">W
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zLvSegVwVCv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_z5G4arfld85e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zsY4YPBp8slk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zu5FvKgicT3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_zXh5gqSLKmMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_ziR4g5giYx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z2bJ593xY0sj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z9m3kUtwlUle" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F49_zFm9R05AmXLh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
    Shailubhai (6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zMwQRQ6AgnP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember" id="Fact000901" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zjYrUyzh4yo2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zDbKs9k3JB73" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zJ3ixkf2DDmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember" id="Fact000904" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zejh3HSzYFlb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember" id="Fact000905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z1GavsmgNkYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zwiEnKf05zP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z6SICVjSSkq3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember" id="Fact000908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zmGavRadwrci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J
    Brancaccio (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zJzQMAz59bGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember" id="Fact000909" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_znRNaQPTpSZ4" title="Bonus" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zHpFX7ehxCDl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zcWLYBo4WMna" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember" id="Fact000913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zkQwVkBcsUhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember" id="Fact000914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zs6xJcti6qb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zz5AMRnJ2gzi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zqFIbPAExZGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember" id="Fact000917" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zJLgUzqgODTb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Macrae (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zBGIHcmYZX6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z9Q2ETy3Eapl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zuJuf7xlGW37" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_ziIHzwa8a4Jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zx7BK1WLWAXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31_custom_GMacraeMember" id="Fact000922" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zNbrCVF1lWa1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z8Jqss0FDSnh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zcPMn6vhFdFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F46_zSCSXCjYZsBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
    Denoyer (5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zyZh9yANafg5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-012022-03-31_custom_BDenoyerMember" id="Fact000926" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zLwXKQg5EkV6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zdFhmkfHb2f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zRZ2rBN2k19k" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-012022-03-31_custom_BDenoyerMember" id="Fact000929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zAy5OlAa9cU3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zs7tjKo5mn6a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zkwRWpjCdBa9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_z7It9OMM0Je2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331_zOVK6I3VUsw1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">283</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20210401__20220331_zKEURchPa9m6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">75</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331_zO6pqSAbZNeh" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331_zivYpMRn1ZBa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,589</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331_z72j0IbuBhV6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--DirectorsBonus_pn3n3_c20200401__20210331_zT47m87MiwQj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsBonus" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,201</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20200401__20210331_zrWCboYkOuC7" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:DirectorsSalary" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">85</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331_zPwnrT4BIodj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">503</ix:nonFraction></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors<br /> fees</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based<br /> payment<br /> expenses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">W Simon</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zUk5yIMoiBg9" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2019-04-012020-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zmVN5YAfYlQg" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zyXHfCIzrGE2" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zi39PWSrFrJj" style="width: 10%; text-align: right"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2019-04-012020-03-31_custom_WSimonMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_zdgU0nltkua9" style="text-align: justify">K. Shailubhai (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zpx0UL5mnXqd" style="text-align: right"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember" id="Fact000946" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zrR0gXsz7Ehd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z64f6ExpMdM" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zOaOil4dS3J" style="text-align: right"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember" id="Fact000949" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_zlZ4vg1RPHdf" style="text-align: justify">G Macrae (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zI66tZZDBpRg" style="text-align: right"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2019-04-012020-03-31_custom_GMacraeMember" id="Fact000950" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zCkK2ZoKldPl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z14gZjqiWApe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zbca9H2gAQY5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F45_zhIBMzPADFN7" style="text-align: justify; padding-bottom: 1.5pt">L Zambeletti (7)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z9zhoSTwAuV" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2019-04-012020-03-31_custom_LZambelettiMember" id="Fact000954" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z6ZUQ1aqQt2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zHVKHhwti3E6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zrZJ4kZhznbk" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2019-04-012020-03-31_custom_LZambelettiMember" id="Fact000957" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331_zeBYIC885IU9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:DirectorsRemunerationExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">122</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20190401__20200331_ztO78z315hFl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20190401__20200331_zATpAnwJFwse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331_zNGjx3BII9G5" title="Share based payment expenses" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="OKYO:KeyManagementPersonnelCompensationSharebasedPayments" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0F_zdsAkDzx71u6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zFso84703sok" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000963" xml:lang="en-US">Gabriele
    Cerrone&#8217;s bonus awarded for $<span id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="OKYO:BonusAwarded" contextRef="From2021-04-012022-03-31_custom_GCerroneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,160</ix:nonFraction></span>k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhlu0tFfEE9h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zFtqJgI8lMA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000966" xml:lang="en-US">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zVGCkBTOFDal" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z5cPpMHsrvf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000967" xml:lang="en-US">John
    Brancaccio was appointed as Director on 10 June 2020</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0A_zPbxjDVQGxrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zb9U2ivUxQP4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000968" xml:lang="en-US">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zkAhLD19uhje" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zju9flrcZlI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000969" xml:lang="en-US">Bernard
Denoyer was appointed as Director on 24 November 2021</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zeRBkloR8v6h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zC93YuD6Dxp3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000970" xml:lang="en-US">K
    Shailubhai resigned as Director on 17 June 2021</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_zdKOOi2lXYZg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zpYeXyc5fTn2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote000971" xml:lang="en-US">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A0_z9ONIEZCOAg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:ScheduleOfShareOptionsGrantedToDirectorsExplanatory"><p id="xdx_89F_ecustom--ScheduleOfShareOptionsGrantedToDirectorsExplanatory_zycsLkTejWhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zHNq8SfTnDx9" style="display: none">SCHEDULE
OF SHARE OPTIONS GRANTED&#160;TO DIRECTORS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br /> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br /> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br /> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: justify">J Brancaccio</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zVeQ2fW9nZo2" title="Number of options" style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_JBrancaccioMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">325,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_z2gi1spW5x2" style="width: 11%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_JBrancaccioMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">450,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zHtMVMbte2k3" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">G Jacob</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_z2Qq0qXPnbf3" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_GJacobMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zJThVA8w4bMh" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_GJacobMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zSvKRuLfR4j1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">B Denoyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zJcYFhtLFxXl" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_BDenoyerMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zZIlA4YDQtgh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zW796tZZY3Fh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zkJGfGiPauX9" title="Number of options" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-04-012022-03-31_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,575,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zyFwmstGJsfg" title="Number of options" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31_custom_DirectorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,450,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzytfXWb2Vv6" title="Number of options" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zhfh3ZePpKo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director has yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Key Management Personnel of the Group are members of the leadership team who have the authority and responsibility for planning, directing
and controlling the activities of the Group either directly or indirectly. They include all Directors of the Board (executive and non-executive).
Key Management Personnel compensation is set out below.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfEmployeeBenefitsExplanatory"><p id="xdx_898_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_z2oWKmgIrQjj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z4iUaM102BYh" style="display: none">SCHEDULE OF KEY
MANAGEMENT PERSONNEL COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_ziOkPUmYBc6d" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_z17rap7c5xG8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_zvQIOP6tZaY4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_pn3n3_z4sLaAo65vX3" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: justify">Short-term employee benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,026</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,455</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">351</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_z6RayWBXrOr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,815</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">41</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--KeyManagementPersonnelCompensation_pn3n3_zoREdEZ3Q3Pk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,841</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:KeyManagementPersonnelCompensation" contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">392</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zw8oBPohzHif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfIncomeTaxExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfIncomeTaxExplanatory_zuvlOuF4IYze" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zATQaOhRAqnk">TAXATION</span></b></span></td></tr>
</table>


<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory"><p id="xdx_898_eifrs-full--DisclosureOfTaxReceivablesAndPayablesExplanatory_zTpr5AjWRcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zxO6z3GPQzgj" style="display: none">SCHEDULE
OF TAX CREDIT PERIOD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210401__20220331_zpZY4HvA90J9" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200401__20210331_zS2WhvN8YA5h" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20190401__20200331_zMtuGAxFmh4j" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="text-decoration: underline">Group</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_z3dkca1Qe6ja" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">Current year tax (credit)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">509,282</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncome" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,952</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AdjustmentsForCurrentTaxOfPriorPeriod_zHN85F7b3G3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments in respect of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">277,239</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_zWGOxkJy6ZA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Origination and reversal of timing differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zR5GhEgBM1yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,289</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossBeforeTaxation_zqgQa1G8Jf1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:LossBeforeTaxation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,045,372</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:LossBeforeTaxation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,378,501</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:LossBeforeTaxation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,620,347</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LossChargedAtStandardRateOfCorporationTax_zE24A79JgYul" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss charged at standard rate of corporation tax <span id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210401__20220331_z51STLB7nbFd" title="Corporation tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><span id="xdx_90E_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200401__20210331_z2R9xAUXttXc" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><span id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20190401__20200331_z7R3mreO1z53" title="Corporation tax rate" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="ifrs-full:ApplicableTaxRate" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19</ix:nonFraction></ix:nonFraction></ix:nonFraction>%</span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:LossChargedAtStandardRateOfCorporationTax" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,181,337</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:LossChargedAtStandardRateOfCorporationTax" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">641,915</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:LossChargedAtStandardRateOfCorporationTax" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">307,866</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_z8SiS2olBDH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax losses arising in the year not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">524,870</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">660,594</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TaxLossesSurrenderedForResearchAndDevelopment_zsGR3bFmOfF" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax losses surrendered for Research and Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OKYO:TaxLossesSurrenderedForResearchAndDevelopment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">667,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_z1zbXRnS5075" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">370,306</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">145</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_zeCGmHghSJY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax increase from effect of capital allowances and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">334</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentTaxClaim_zDLPsa4a8cM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:ResearchAndDevelopmentTaxClaim" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">509,282</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:ResearchAndDevelopmentTaxClaim" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,432</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ResearchAndDevelopmentEnhancedExpenditure_zDbTg4TDxT5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and Development enhanced expenditure</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:ResearchAndDevelopmentEnhancedExpenditure" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">377,187</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_zo30sWgWiie8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax credits claimed in respect of previous periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">277,240</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">42</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">76,289</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--IncreaseDecreaseThroughForeignExchangeFinancialAssets_zgfKklf11Lb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,983</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,504</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_zGPztcPidbjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loans written off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_znKrZf957KGi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,521</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:IncomeTaxExpenseContinuingOperations" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,289</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zkKGziTLr6ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will
be recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has tax losses of $<span id="xdx_906_eifrs-full--TaxEffectOfTaxLosses_c20210401__20220331_zlUu7w5u5KKa"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,870,525</ix:nonFraction></span> (2021: $<span id="xdx_909_eifrs-full--TaxEffectOfTaxLosses_c20200401__20210331_z5wzR174TGMe"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,411,521</ix:nonFraction></span>, 2020: $<span id="xdx_904_eifrs-full--TaxEffectOfTaxLosses_c20190401__20200331_zWe1gHUD8Vba"><ix:nonFraction name="ifrs-full:TaxEffectOfTaxLosses" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,421,886</ix:nonFraction></span>) to carry forward for use against future profits<b>.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory"><p id="xdx_80D_eifrs-full--DisclosureOfFinanceIncomeExpenseExplanatory_z6Bmt2CqwIfl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_z7U17UOkOUr7">FINANCE INCOME AND COSTS</span></b></span></td></tr>
</table>


<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfFinanceCostExplanatory"><p id="xdx_897_eifrs-full--DisclosureOfFinanceCostExplanatory_zVIwQP9Y7xAk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zFA0aooYeKH8" style="display: none">SCHEDULE
OF FINANCE COST</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; text-align: left">Interest income</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RevenueFromInterest_c20210401__20220331_z5BQSJecRC5k" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--RevenueFromInterest_c20200401__20210331_z9iOz0ATOuM8" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RevenueFromInterest_c20190401__20200331_zYoGULSQcRp9" style="width: 14%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:RevenueFromInterest" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,125</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Total finance income</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceIncome_c20210401__20220331_zfwiJKbvUMJg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinanceIncome_c20200401__20210331_z28upqv01yge" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinanceIncome_c20190401__20200331_z74SwCEBy9Ab" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:FinanceIncome" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20210401__20220331_zCXJBdK1vm5i" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20200401__20210331_zT89OdbrWguc" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20190401__20200331_zZYfP1t8ckU8" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:InterestExpenseOnLeaseLiabilities" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total finance expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinanceCosts_iN_di_c20210401__20220331_zlvnOnYSuWp" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iN_di_c20200401__20210331_zw3FQjmHFMWk" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,123</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceCosts_iN_di_c20190401__20200331_zpax2t3ux8lj" style="font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:FinanceCosts" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,158</ix:nonFraction></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zwhSVyHJp8Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory"><p id="xdx_803_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zYzidRpTvYKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_z5KRlV0SOcm5">PROPERTY, PLANT AND EQUIPMENT</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"><p id="xdx_89F_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zeehfFSYz9o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&#8217;s property, plant and equipment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B7_zk5p61NgWeBc" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbm3svaqAEf" title="Property and equipment, cost, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,343</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331_zYl7p3r5oW7" style="width: 12%; text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,343</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbyO3Phi8H9f" title="Additions" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,669</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zljr3IGPH9Bb" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,669</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zNphzel2GQFf" title="Disposals" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331_z3dls8PGuoFc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zWiB7NCRXNQf" title="Foreign exchange" style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">233</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zDuZKWpxjs0a" style="text-align: right">(<ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">233</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zTw55nHaBPq1" title="Property and equipment, cost, ending  balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331_zQvZiKya0EWb" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH3QgMQhPXgc" title="Depreciation, beginning balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331_zz1FiovGWAug" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,286</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z30av2cacJD8" title="Charge in year" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfChargeInYearDepreciation" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,331</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331_zPZFrWjdvkai" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfChargeInYearDepreciation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOD30thWAeMg" title="Foreign exchange" style="text-align: right">(<ix:nonFraction name="OKYO:EffectOfForeignExchangeDepreciation" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331_zbuWdloWm8Mf" style="text-align: right">(<ix:nonFraction name="OKYO:EffectOfForeignExchangeDepreciation" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">63</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zybgCEbakJy3" title="Depreciation, ending balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,554</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331_z8VmpTu2dWFl" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,554</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zdrMW5a86kQ4" title="Depreciation, net book value" style="text-align: right"><ix:nonFraction name="OKYO:DepreciationNetValue" contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331_zu4nnXM8hH2c" style="text-align: right"><ix:nonFraction name="OKYO:DepreciationNetValue" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zadJS1DdOrp9" title="Property and equipment, cost, beginning balance" style="width: 12%; text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2020-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331_zfZoEFLWnQUe" style="width: 12%; text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,257</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zb76uxQ6aUGj" title="Additions" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,944</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zz70dKhw6yj2" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,944</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zPShkp99A2Pb" title="Disposals" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331_zDIV8GM7OVW4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH9PfEb03lu9" title="Foreign exchange" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zchRCv1Ino7f" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">142</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z0Jhp0XXJQse" title="Property and equipment, cost, ending  balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,343</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331_zqh33mSfm1P6" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentCost" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,343</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z36KRN7x29i3" title="Depreciation, beginning balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2020-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331_zJrJ9WOy6cnl" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zDlS8NcyPw0f" title="Charge in year" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfChargeInYearDepreciation" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331_zQa0JJkJaGI7" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfChargeInYearDepreciation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,593</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOEYqzsBcGsf" title="Foreign exchange" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfForeignExchangeDepreciation" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331_zccQWkVKq5Fi" style="text-align: right"><ix:nonFraction name="OKYO:EffectOfForeignExchangeDepreciation" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zoUwEAla2oTd" title="Depreciation, ending balance" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331_zW8ydcV96hcc" style="text-align: right"><ix:nonFraction name="OKYO:PropertyPlantAndEquipmentDepreciation" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,286</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zcQ3Q7oQZbtf" title="Depreciation, net book value" style="text-align: right"><ix:nonFraction name="OKYO:DepreciationNetValue" contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,057</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331_zavxPSoOYXCf" style="text-align: right"><ix:nonFraction name="OKYO:DepreciationNetValue" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zTBboH1RkJzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory"><p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_zsV6hvqTV6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s property, plant and equipment is located in the following operating segments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span id="xdx_8B2_ztfOLp0m8fl1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zyPuhkpTFt8l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="text-align: right; margin-top: 0; margin-bottom: 0">Net
Book Value <br />
March 31 2022</p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UKMember_zWOGzuTdEE3d" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 78%; text-align: justify">UK</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-03-31_custom_UKMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UnitedStateMember_zpNO2hZ0Hnga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-03-31_custom_UnitedStateMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,289</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--PropertyPlantAndEquipment_iI_znRT2UPILrn9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--PropertyPlantAndEquipment_iI_zey57vwsNt1h" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property, plant and equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:PropertyPlantAndEquipment" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>
</ix:nonNumeric><p id="xdx_8A1_zeiPPVcibwk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zYmWNBzf8YH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zbe9wKy7Mzfa">OTHER RECEIVABLES</span></b></span></td></tr>
</table>


<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory"><p id="xdx_89D_ecustom--DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_zN4blPd07Ix8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zyB7ubYrYrAc" style="display: none">DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_z0Zkq71YyAOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210331_z3bCDh3xrjI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherCurrentReceivables_iI_zjcT4x8f4481" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Other receivables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,130</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:OtherCurrentReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CurrentValueAddedTaxReceivables_iI_zxMSIvnZ27L1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,617</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:CurrentValueAddedTaxReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Prepayments_iI_z3DDGg0OFeSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepayments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">711,209</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:Prepayments" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,072</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentReceivables_iI_zFxjurqPKIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">812,956</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,370</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zNdzfBV0xgj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
include $<span id="xdx_906_ecustom--PrepaymentsReceivables_iI_c20220331_znQ5zL13I7rg" title="Prepayments receivables"><ix:nonFraction name="OKYO:PrepaymentsReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,635</ix:nonFraction></span> of prepaid invoices relating to the OK-101 project.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zr8WRGgCFXn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zaHSkyisDEe7">TRADE AND OTHER PAYABLES</span></b></span></td></tr>
</table>


<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory"><p id="xdx_895_ecustom--DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_z1TpnBoBBfO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zti1IuYBWd81" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220331_zQuvyKgXtT07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210331_zzrruNLNF9jc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Year ended March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Group</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pn3n3_maTAOCPzjQt_zyDD0Inv5u74" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Trade payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">741,807</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">210,992</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Accruals_iI_pn3n3_zXnGmfDLkrta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457,773</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:Accruals" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">71,093</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--BonusAccrual_iI_pn3n3_zLDhyIfvkj7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Bonus accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OKYO:BonusAccrual" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">106,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OKYO:BonusAccrual" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,391,069</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_iI_pn3n3_zz0fbhgv4Mxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,306,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673,154</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_zpxjWuAEU5F" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zUATpX2dICt5">CAPITAL AND RESERVES</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Company&#8217;s capital management, capital includes called up share capital, share premium, share based payments
for options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern and to maximise
shareholder value through the optimisation of the debt and equity balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital to maximise the return to the shareholders through the optimisation of equity. The capital structure of the
Company as at 31 March 2022 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and
retained deficit as disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders.
To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders
or issue new shares and release the Company&#8217;s share premium account. No changes were made in the objectives, policies or processes
during the year ended 31 March 2022 and 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
capital and premium</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares
and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class
or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share in the Company confers upon the shareholder:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to one vote at a meeting of the shareholders or on any resolution of shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in any dividend paid by the Company; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in the distribution of the surplus assets of the Company on its liquidation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&#8217;s Articles of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory"><p id="xdx_892_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zQF1wsIWSUaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_z99m5UbcSvk1" style="display: none">SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Share capital</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issued ordinary shares of US$0.00 each</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify; padding-bottom: 2.5pt">At 31 March 2020 </td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zI2GyAWKAQ9" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">636,297,049</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Equity_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7HFLauLesEh" title="Beginning balance" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,079,984</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares issued - private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfSharesIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2QGkJBMHGKh" title="Shares issued - private placement, shares" style="text-align: right"><ix:nonFraction name="OKYO:NumberOfSharesIssuedPrivatePlacement" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,269,253</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfSharesIssuedPrivatePlacementValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2yvFVeXfPlh" title="Shares issued - private placement" style="text-align: right"><ix:nonFraction name="OKYO:NumberOfSharesIssuedPrivatePlacementValue" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">230,019</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Relative Fair value charge for warrants issued in conjunction with private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueWarrantsIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zPjL31xagFkk" title="Relative Fair value charge for warrants issued in conjunction with private placement" style="text-align: right">(<ix:nonFraction name="OKYO:FairValueWarrantsIssuedPrivatePlacement" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">138,305</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">CLNs issued in lieu of fundraising commission</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuedInLieuValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxLU4yt50RG9" title="CLNs issued in lieu of fundraising commission" style="text-align: right">(<ix:nonFraction name="OKYO:IssuedInLieuValue" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">558,395</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IncreaseDecreaseThroughExerciseOfOptionsShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbe89ng9kIXh" title="Options exercised, shares" style="text-align: right"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfOptionsShares" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgDwdCkblDO7" title="Options exercised" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zqz9DVicEiXe" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">672,816,302</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--Equity_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zWroLbqOyWH6" title="Beginning balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">111,629,173</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zTVXBueNSpCg" title="Exercise of warrants, shares" style="text-align: right"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">386,512,756</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsyCrb47nzv6" title="Exercise of warrants" style="text-align: right"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,470,940</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Conversion of CLN</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z6RoRHfYZqo8" title="Conversion of CLN, shares" style="text-align: right"><ix:nonFraction name="OKYO:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">315,086,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zU0cjhOvfMUd" title="Conversion of CLN" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,876,397</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2VDia2mobG" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfSharesOutstanding" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374,415,468</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Equity_iE_pp0p0_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zP07DWSELImc" title="Ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:Equity" contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">123,976,510</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zVsfw1SBhIjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Issuance
of ordinary shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, <span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zvQkPbvZIRx9" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2019-05-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,363,636</ix:nonFraction></span> ordinary shares were issued at an issue price of <span id="xdx_904_eifrs-full--ParValuePerShare_iI_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zAvLHx7KDi21" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2019-05-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1</ix:nonFraction></span>p per ordinary share by way of a placing of ordinary shares
to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, <span id="xdx_90B_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zXFtDu3Cgm4b" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2020-03-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,825,130</ix:nonFraction></span> ordinary shares were issued at an issue price of <span id="xdx_90E_eifrs-full--ParValuePerShare_iI_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z5ewCJ2923Pk" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2020-03-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1</ix:nonFraction></span>p per ordinary share by way of a further placing of ordinary
shares to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zZmcPvTNzp9c" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2020-06-30_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,269,253</ix:nonFraction></span> ordinary shares were issued at an issue price of <span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zmEgPBG9T614" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2020-06-30_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.005</ix:nonFraction></span>p per ordinary share by way of a placing of ordinary shares
to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, <span id="xdx_90C_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z4k7uTxdG2Bj" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-03-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> ordinary shares were issued in relation to an exercise of options at an issue price of <span id="xdx_901_eifrs-full--ParValuePerShare_iI_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zFMoZgOkJ3ue" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-03-31_ifrs-full_OrdinarySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.045</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_900_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTxpGskBJA4a" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,363,636</ix:nonFraction></span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_90A_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmYgCHrVA2Zb" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0135</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90F_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zob6Ry0UPcM4" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-05-31_custom_WarrantReserveOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,000,000</ix:nonFraction></span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zSWAUoKaoX6k" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-05-31_custom_WarrantReserveOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0055</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zFSNUmsCUKS" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-05-31_custom_LoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,605,760</ix:nonFraction></span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zZBYg7wCXC9a" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-05-31_custom_LoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.004</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zBUMPbDplosh" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-05-31_custom_LoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,304,650</ix:nonFraction></span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zFVdryIG5KEk" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-05-31_custom_LoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.085</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zFUKUWP7cXAa" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-05-31_custom_WarrantReserveTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,605,760</ix:nonFraction></span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zWZE0DwgONXj" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2021-05-31_custom_WarrantReserveTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.004</ix:nonFraction></span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, <span id="xdx_905_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zujPVugIqpU3" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-02-28_custom_LoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,176,000</ix:nonFraction></span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zwzazQpbMKx7" title="Ordinary shares were issued, per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2022-02-28_custom_LoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.004</ix:nonFraction></span>p per ordinary
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, <span id="xdx_907_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zj13tyNNzYE9" title="Ordinary shares were issued"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-02-28_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">238,543,360</ix:nonFraction></span> ordinary shares were issued in relation to a cashless exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
options reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for options represents the cost to issue share-based compensation, primarily share options, based on their
grant date fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
warrants reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for warrants represent the cost to issue warrants based on their grant date fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Loan Note reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible loan note reserve represents the proceeds received on issuance of convertible loan notes classified as equity instruments,
accrued interest and any relative fair value adjustments. .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Retained
Deficit reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
deficit represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Translation
reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors paid <span id="xdx_908_eifrs-full--DividendPayables_iI_do_c20220331_zfUL2ZAntQDi" title="Payment of dividend"><span id="xdx_906_eifrs-full--DividendPayables_iI_do_c20210331_z8taAzLLzEqb" title="Payment of dividend"><ix:nonFraction name="ifrs-full:DividendPayables" contextRef="AsOf2022-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="ifrs-full:DividendPayables" contextRef="AsOf2021-03-31" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> dividend during the year to 31 March 2022 and 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
between equity reserves</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company affected a transfer between reserves in equity in order to align the values of the equity reserves on a relative fair value basis.
The total amount recorded in equity remains unaltered.</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><p id="xdx_805_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zYYBEu6vihkh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zTJfekQNeT35">SHARE OPTIONS AND WARRANTS</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory"><p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_zDs6kwvTCsJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_zKJ43HynaNn2" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> exercise price <br /> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br /> Average <br /> exercise price <br /> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20210401__20220331_zBnXx2Z27wW" title="Beginning balance, Options outstanding" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,750,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331_z9OF1qsv9bIc" title="Beginning balance, Weighted Average Exercise price, outstanding" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20200401__20210331_zB2lpLNRsLP1" title="Beginning balance, Options outstanding" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,500,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331_zbVxm1ZqgWn3" title="Beginning balance, Weighted Average Exercise price, outstanding" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zgtZUPpn810d" title="Options, granted" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zWqMuyLjpJqf" title="Weighted Average Exercise price, Granted" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.41</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zwbxypGNTnqj" title="Options, granted" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">42,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zUEKoj2yvXIf" title="Weighted Average Exercise price, Granted" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.31</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zVqtXqqkOXCj" title="Options, forfeited" style="text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,500,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zDgk82hgVKI6" title="Weighted Average Exercise price, Forfeited" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.91</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_z2pUMhy3BoYd" title="Options, forfeited" style="text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zAmdrblhBC06" title="Weighted Average Exercise price, Forfeited" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.21</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zzGlESPEcPCe" title="Options, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_z2O4EzirWGUg" title="Weighted Average Exercise price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_zguc3dEIz887" title="Options, exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zX2p4vyKAlpl" title="Weighted Average Exercise price, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20210401__20220331_zIVtBWlbq5Lg" title="Ending balance, Options outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">72,400,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEiE7je0Vt8e" title="Ending balance, Weighted Average Exercise price, outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.49</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20200401__20210331_zpaele3kquh1" title="Ending balance, Options outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,750,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zarLvtiYX6Hk" title="Ending balance, Weighted Average Exercise price, outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331_zaRay0yWGRqc" title="Options, Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,437,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEaNhtLb5dYi" title="Ending balance, Weighted Average Exercise price, Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.36</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331_zhPyMEFPupUg" title="Options, Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,250,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zoTKjZIqPjn5" title="Ending balance, Weighted Average Exercise price, Exercisable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted <br /> Average <br /> exercise price <br /> (cents)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-size: 10pt">Outstanding at 1 April</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20190401__20200331_z9Nw9D1OGcEl" style="width: 18%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20190401__20200331_zwHisMhbOz6l" style="width: 18%; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,000,000</ix:nonFraction></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zqco43H2poE3" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zsoFPIjxFTzj" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_iN_di_uUSDPShares_c20190401__20200331_zdLpMC1qYEul" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20190401__20200331_zx1dEbBXrQhi" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zOFfw5ZCGXaj" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zNJeFfoReAR" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zRj9AxlQi7Xd" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20190401__20200331_z9jNGPiKdZqk" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zWFnhmT6OLY2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.58</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20190401__20200331_zbTd2cBcpCsg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,875,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A3_zPGI9W9vkCy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending 31 March 2022, <span id="xdx_90C_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_doxL_uShares_c20210401__20220331_zbK9xRcJ7hl9" title="Number of option were exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1351">no</span></span> options were exercised. During the year ending 31 March 2021, <span id="xdx_905_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zBubgi1X0D2l" title="Number of option were exercised"><ix:nonFraction name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250,000</ix:nonFraction></span> options were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total outstanding fair value charge of the share option instruments is deemed to be approximately $<span id="xdx_90A_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20220331_zch50rZS3538" title="Fair value charge of share option instruments deemed"><ix:nonFraction name="ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,072,515</ix:nonFraction></span> (2021: $<span id="xdx_904_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20210331_zPvOT2e8E1Aj" title="Fair value charge of share option instruments deemed"><ix:nonFraction name="ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,682,050</ix:nonFraction></span>). A
share-based payment charge for the year of $<span id="xdx_907_ecustom--ShareBasedPaymentCharge_c20210401__20220331_zSROmK3WHol4" title="Share based payment charge"><ix:nonFraction name="OKYO:ShareBasedPaymentCharge" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,718,727</ix:nonFraction></span> (2021: $<span id="xdx_90A_ecustom--ShareBasedPaymentCharge_c20200401__20210331_zFRLxmK5XLeg" title="Share based payment charge"><ix:nonFraction name="OKYO:ShareBasedPaymentCharge" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">545,582</ix:nonFraction></span>) has been expensed in the statement of comprehensive income.
The share based payment charge in the year to March 31, 2022 includes a forfeiture of $<span id="xdx_909_ecustom--ShareBasedPaymentChargeForfeiture_c20210401__20220331_z9oewG7J2JWk" title="Share based payment charge forfeiture"><ix:nonFraction name="OKYO:ShareBasedPaymentChargeForfeiture" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,149</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average contractual life of options outstanding at March 31, 2022 is <span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20220331_z60myUIhSgn9" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">7.77</ix:nonNumeric></span> years. (2021: <span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20210331_zA5Ql33Zv8Z6" title="Weighted average contractual life of options outstanding"><ix:nonNumeric contextRef="From2020-04-012021-03-31" format="ixt-sec:duryear" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">8.07</ix:nonNumeric></span> years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"><p id="xdx_89F_eifrs-full--DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_zRmrjLvVy22l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options outstanding at the end of the year have the following expiry dates and exercise prices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zCYvDr4CdPn3" style="display: none">SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiry Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">Share Options as at 31 March 2022<br /> (&#8216;000)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">6 July 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center"><span id="xdx_905_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_za11cw4SeNB1" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">6 July 2025</ix:nonNumeric></span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: center"><span id="xdx_900_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zcUiaNFlUpji" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.5</ix:nonFraction>p</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zBIvgID3y0X9" title="Share Options, Outstanding" style="width: 18%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_SixJulyTwoThousandEighteenMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">20 August 2020</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zMApVVo1CtZh" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">19 August 2028</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zjvqLyWDj0v1" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.5</ix:nonFraction>p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zuVt2gcyCy1i" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_TwentyAugustTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">6 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_zitoPfFeUB66" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">5 January 2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90B_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_ztF25WaesvWh" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5</ix:nonFraction>p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_z6jsGPECbxr3" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">40,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">12 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_z1kF1A6642vi" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">11 January 2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_ziw5ZqV5aZka" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.9</ix:nonFraction>p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_zMNA5wJYgMbc" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">15 April 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zbem14aMRwtl" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">15 April 2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zVqV0CatIzwd" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.88</ix:nonFraction>p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zzHQBf3ff3C6" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">5,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">31 August 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zllwEzpr4cok" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">31 August 2031</ix:nonNumeric></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90E_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_z2kZzFfu4gk5" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.9</ix:nonFraction>p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zDSOG95UtpO3" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">14,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90E_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zPyxLg3Cazqb" title="Expiration date of outstanding"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember" format="ixt:datedaymonthyearen" name="OKYO:ExpirationDateOfOutstanding">30 January 2032</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zm1SfpQal5if" title="Exercise Price"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.0</ix:nonFraction>p</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zHI2Chh2B1Mh" title="Share Options, Outstanding" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">8,750</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331_zvIv48WGKnmc" title="Share Options, Outstanding" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOutstandingShareOptions" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">72,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zYZ39ohDi5B2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
value of options granted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory"><p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_zoVLXy2sWdXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zcceEqQFlaP5" style="display: none">SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">15 April 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 August 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zsLcnQuMbr3a" title="Grant date share price" style="width: 14%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2021-04-122021-04-15" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.7</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zaLPnKmd1Uyl" title="Grant date share price" style="width: 14%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2021-08-292021-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.9</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zb8gctmMfPt5" title="Grant date share price" style="width: 14%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2022-01-292022-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.8</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zdjSH7JJC00d" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-04-122021-04-15" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.9</ix:nonFraction></td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zsbofvgW7Us7" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-08-292021-08-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.9</ix:nonFraction></td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zpLZauYinPC4" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2022-01-292022-01-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.0</ix:nonFraction></td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--VestingPeriodsDescription_c20210412__20210415_z2z9YUvsxFl" title="Vesting periods"><ix:nonNumeric contextRef="From2021-04-122021-04-15" name="OKYO:VestingPeriodsDescription">25% each year</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210829__20210831_zs9Yfz0ZvKfj" title="Vesting periods"><ix:nonNumeric contextRef="From2021-08-292021-08-31" name="OKYO:VestingPeriodsDescription">25% each year</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--VestingPeriodsDescription_c20220129__20220131_zWJ3KSD4V5ib" title="Vesting periods"><ix:nonNumeric contextRef="From2022-01-292022-01-31" name="OKYO:VestingPeriodsDescription">1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions</ix:nonNumeric></span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210412__20210415_z998cjLwqlXd" title="Risk free rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2021-04-122021-04-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.35</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210829__20210831_zVLgQdNLfxI7" title="Risk free rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2021-08-292021-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.30</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20220129__20220131_zmBAxFFACaFb" title="Risk free rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2022-01-292022-01-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.97</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210412__20210415_zQdmFb5a1mB9" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2021-04-122021-04-15" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80.20</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210829__20210831_zpI3ijoVB1j1" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2021-08-292021-08-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.7</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20220129__20220131_zF2ahJF1mIZ2" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2022-01-292022-01-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--OptionLifePeriod_dtY_c20210412__20210415_z6eKbMSRO7al" title="Option life"><ix:nonNumeric contextRef="From2021-04-122021-04-15" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210829__20210831_zqlQyvD4L5Cl" title="Option life"><ix:nonNumeric contextRef="From2021-08-292021-08-31" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--OptionLifePeriod_dtY_c20220129__20220131_zRz3C4PGVnZd" title="Option life"><ix:nonNumeric contextRef="From2022-01-292022-01-31" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">5</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20 August</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6 January</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 January <br /> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20200815__20200820_zzxSqmk2EUa2" title="Grant date share price" style="width: 14%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2020-08-152020-08-20" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.5</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210104__20210106_zDt7RmgVTqMb" title="Grant date share price" style="width: 14%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2021-01-042021-01-06" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.8</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210110__20210112_z5N1pvF4QuSg" title="Grant date share price" style="width: 18%; text-align: right"><ix:nonFraction name="OKYO:GrantDateShareOptionsGranted2019" contextRef="From2021-01-102021-01-12" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.79</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200815__20200820_z8UYAWz5qj6g" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2020-08-152020-08-20" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.5</ix:nonFraction></td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210104__20210106_z63tdn6KGE0h" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-01-042021-01-06" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5</ix:nonFraction></td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210110__20210112_zjqb5DMz09m2" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2021-01-102021-01-12" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.79</ix:nonFraction></td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--VestingPeriodsDescription_c20200815__20200820_zeiP75ECJm84" title="Vesting periods"><ix:nonNumeric contextRef="From2020-08-152020-08-20" name="OKYO:VestingPeriodsDescription">25%
each year</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--VestingPeriodsDescription_c20210104__20210106_z1VFiJ4SXayc" title="Vesting periods"><ix:nonNumeric contextRef="From2021-01-042021-01-06" name="OKYO:VestingPeriodsDescription">25% each year</ix:nonNumeric></span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210110__20210112_zGrWABE0LFZ3" title="Vesting periods"><ix:nonNumeric contextRef="From2021-01-102021-01-12" name="OKYO:VestingPeriodsDescription">33% in 6 months and 67% in 1 year</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20200815__20200820_z1DYsNgaii7j" title="Risk free rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-08-152020-08-20" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.15</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210104__20210106_zYitdBolAlh7" title="Risk free rate" style="text-align: right">-<ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2021-01-042021-01-06" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.01</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhcYUU7Y3edg" title="Risk free rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.4</ix:nonFraction></span>%,
<span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_znJdygR1QQI1" title="Risk free rate"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.6</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20200815__20200820_zo4CinQ71S92" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2020-08-152020-08-20" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.4</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210104__20210106_zgVo52FLcWec" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2021-01-042021-01-06" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">77.5</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zv1xdkcnz4f5" title="Expected volatility"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">66.7</ix:nonFraction></span>%,
<span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zIz42KB2JfR8" title="Expected volatility"><ix:nonFraction name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">83.7</ix:nonFraction></span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--OptionLifePeriod_dtY_c20200815__20200820_zWWcqGk15Hz4" title="Option life"><ix:nonNumeric contextRef="From2020-08-152020-08-20" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">5</ix:nonNumeric></span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210104__20210106_z8zjROfjGeSj" title="Option life"><ix:nonNumeric contextRef="From2021-01-042021-01-06" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">5</ix:nonNumeric></span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--OptionLifePeriod_dtM_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zKNeCysJyrxj" title="Option life"><ix:nonNumeric contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember" format="ixt-sec:durmonth" name="OKYO:OptionLifePeriod">6</ix:nonNumeric></span> months to <span id="xdx_90B_ecustom--OptionLifePeriod_dtY_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zp3z6D4jbUE2" title="Option life"><ix:nonNumeric contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember" format="ixt-sec:duryear" name="OKYO:OptionLifePeriod">1</ix:nonNumeric></span> year</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zfDmXVbCLzKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the acquisition of the OK-101 project, the underlying scientific founders of the OK-101 Project (inukshuk Holdings), who
will continue to be involved in the development of the Project, received <span id="xdx_905_eifrs-full--ConsiderationPaidReceived_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zBPFWTl4tTE6" title="Consideration received"><ix:nonFraction name="ifrs-full:ConsiderationPaidReceived" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,000,000</ix:nonFraction></span> warrants as consideration. The warrants are exercisable
at a price of <span id="xdx_901_ecustom--WarrantsExercisablePricePerShare_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJ7ZHZDRRrzl" title="Warrants exercisable price per share"><ix:nonFraction name="OKYO:WarrantsExercisablePricePerShare" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.5</ix:nonFraction></span> pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until <span id="xdx_906_ecustom--WarrantsExercisableDate_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember" title="Warrants exercisable date"><ix:nonNumeric contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:datedaymonthyearen" name="OKYO:WarrantsExercisableDate">17 July 2023</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, warrants were granted over <span id="xdx_90A_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z0SvPoL0lsxa" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2019-05-012019-05-31_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,363,636</ix:nonFraction></span> shares at an exercise price of <span id="xdx_902_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2019-05-012019-05-31_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.35</ix:nonFraction></span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over <span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z6nFfXTp1IO9" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000,000</ix:nonFraction></span> shares at an exercise price of <span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>p per share in connection with a private placement.
These warrants were exercised on a cashless basis in February 2022 (post a price reduction offer to <span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2022-02-012022-02-28_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></span>p), resulting in the issuance
of <span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zbDn8LswJH3g" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2022-02-012022-02-28_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,400,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over <span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_zMF7RuyLVWni" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,825,130</ix:nonFraction> </span>shares at an exercise price of <span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, warrants were granted over <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zLJ09Q3MNLOd" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-04-012020-04-30_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,174,870</ix:nonFraction> </span>shares at an exercise price of <span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012020-04-30_custom_PrivatePlacementsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.55</ix:nonFraction></span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, warrants were granted over <span id="xdx_909_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_z5kAoOD3wSi4" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">909,090</ix:nonFraction> </span>shares at an exercise price of <span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span>p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, warrants were granted over <span id="xdx_90C_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zJ6QpUsUUMil" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares at an exercise price of <span id="xdx_904_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zDihcs8nbAS1" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14</ix:nonFraction></span>p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, warrants were granted over <span id="xdx_908_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zOLIsy6W2rfi" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">76,605,760</ix:nonFraction></span> shares at an exercise price of <span id="xdx_903_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p per share in connection with the conversion of convertible
loan notes. <span id="xdx_903_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zlJ9X3uUPN56" title="Warrants exercised"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,605,760</ix:nonFraction></span> were exercised immediately and the remaining <span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zbA8ZWrtiIw5" title="Warrants exercised on cashless basic"><ix:nonFraction name="OKYO:WarrantsExercisedOnCashlessBasic" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,000,000</ix:nonFraction></span> were exercised on a cashless basis in February 2022 (post
a price reduction offer to <span id="xdx_90B_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on price reduction offer"><ix:nonFraction name="OKYO:WarrantsExercisedOnPriceReductionOffer" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></span>p), resulting in the issuance of <span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on issuances"><ix:nonFraction name="OKYO:WarrantsExercisedOnIssuances" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,445,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, warrants were granted over <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zfetb7hcwlYg" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,176,000</ix:nonFraction></span> shares at an exercise price of <span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Weighted average exercise price, granted"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p per share in connection with the conversion
of convertible loan notes. <span id="xdx_90C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_z6oNkzBJdwt8" title="Warrants exercised"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">165,176,000</ix:nonFraction></span> were exercised on a cashless basis in February 2022(post a price reduction offer to <span id="xdx_906_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Warrants exercised on price reduction offer"><ix:nonFraction name="OKYO:WarrantsExercisedOnPriceReductionOffer" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.012</ix:nonFraction></span>p), resulting
in the issuance of <span id="xdx_902_ecustom--WarrantsExercisedOnIssuances_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zJXrJtrSstLc" title="Warrants exercised on issuances"><ix:nonFraction name="OKYO:WarrantsExercisedOnIssuances" contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,698,360</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, during the year, <span id="xdx_900_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zdOf3TMbLfNe" title="Warrants exercised"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,969,396</ix:nonFraction></span> warrants were exercised for proceeds of &#163;<span id="xdx_906_eifrs-full--ProceedsFromExerciseOfWarrants_pp0p0_uGBP_c20210401__20220331_zujDEkWG8lVf" title="Proceeds from warrants exercised"><ix:nonFraction name="ifrs-full:ProceedsFromExerciseOfWarrants" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="GBP">1,045,332</ix:nonFraction></span>, resulting in the issuance of <span id="xdx_904_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331_zEUw6hBb6cl9" title="Warrants granted"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,969,396</ix:nonFraction></span>
shares. <span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20210401__20220331_zdYLGe8kXR1l" title="Warrants exercised on cashless basic"><ix:nonFraction name="OKYO:WarrantsExercisedOnCashlessBasic" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">242,716,000</ix:nonFraction></span> warrants were also exercised on a cashless basis resulting in the issuance of <span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_uShares_c20210401__20220331_zCaWfxjAaRQ9" title="Warrants exercised on issuances"><ix:nonFraction name="OKYO:WarrantsExercisedOnIssuances" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">238,543,360</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"><p id="xdx_89C_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_z1LLvaPTGXg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_z90HQYpTPNWg" style="display: none"><span>SCHEDULE OF WARRANTS
OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcd7KVh6AHU" title="Warrants outstanding, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,022,726</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z73YajK94nLj" title="Weighted average exercise price, outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zQm9Dv1h3CFb" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="AsOf2020-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">147,188,766</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zF1t7WDV96Lh" style="width: 10%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2020-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.1</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zNm8htQqtqq8" title="Warrants granted" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,781,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zuP7UXhDHn9b" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1b5WkEd1382" style="text-align: right"><ix:nonFraction name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,833,960</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJBsp9LjITQk" style="text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.2</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1En4jVLMUil" title="Warrants exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">390,145,396</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTyz7CgI7q1" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbfxILNOzhl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1ZvTvKfiZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at 31 March</span></p></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEhXslULHNR7" title="Warrants outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">36,659,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziAiKkBwPyCe" title="Weighted average exercise price, outstanding ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zofZ5ZpVf4rc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">185,022,726</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zawgODp3KTmf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercisable at 31 March</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zXxAO9XzX8b4" title="Warrants exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,659,090</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z0BdExgerH6c" title="Weighted average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.30</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zUes8Z2X6lyb" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,568,181</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzEs9LlpqhB6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zLqsxtpHPZNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for warrants granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model included:</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory"><p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_zTfcGa6qE8Ek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zfr88tv0EsF9" style="display: none">SCHEDULE OF INPUTS FOR
WARRANTS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">29 May 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEsfwntYcTod" title="Grant date share price" style="width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.75</ix:nonFraction></td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbbL5oIcUDy7" title="Exercise share price" style="text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTxlwpqoxfj" title="Risk free rate" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.25</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zsFN4GAfFsq3" title="Expected volatility" style="text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.6</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ExpectedLifeOfWarrants_dtY_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zq5wRgYwpVP5" title="Expected life"><ix:nonNumeric contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember" format="ixt-sec:duryear" name="OKYO:ExpectedLifeOfWarrants">3</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zzFu9tfNCPWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory"><p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_zurTi4FfrK1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zvhWhCbxZyNa" style="display: none">SCHEDULE OF FAIR VALUE
OF WARRANTS IN SERVICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 2020</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%">Grant date share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTpJqRf9hMEe" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.3</ix:nonFraction>p</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zvkI8JK1i6ej" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8</ix:nonFraction>p</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zHxclxQs4x52" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019" contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.8</ix:nonFraction>p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise share price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zPtfrlpk9lX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14</ix:nonFraction>p</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmRiSa4pNCAk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.8</ix:nonFraction>p</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zrlDZCTpjmJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="ifrs-full:ExercisePriceShareOptionsGranted2019" contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.5</ix:nonFraction>p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting periods</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantsVestingPeriod_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zoCvgeiTKvyk" title="Vesting periods"><ix:nonNumeric contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" name="OKYO:WarrantsVestingPeriod">Fully vested</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--WarrantsVestingPeriod_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zdPnB7Qb9Id"><ix:nonNumeric contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" name="OKYO:WarrantsVestingPeriod">50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)</ix:nonNumeric></span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--WarrantsVestingPeriod_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zelhksSHOXI9"><ix:nonNumeric contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" name="OKYO:WarrantsVestingPeriod">Fully
    vested</ix:nonNumeric> </span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free rate </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zqUxxQCSCECi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.68</ix:nonFraction>%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zOYKlyvnL8X1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.95</ix:nonFraction>%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zLShQVeV3NTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.22</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1F1LpH6qFG" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.1</ix:nonFraction>%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zV4GtEvwhMr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.6</ix:nonFraction>%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_983_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcatnTJgkge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.4</ix:nonFraction>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ExpectedLifeOfWarrants_dtY_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziHcC6IoaUa7"><ix:nonNumeric contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember" format="ixt-sec:duryear" name="OKYO:ExpectedLifeOfWarrants">2</ix:nonNumeric></span> years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--ExpectedLifeOfWarrants_dtY_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zyBlZXykt1Ch"><ix:nonNumeric contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember" format="ixt-sec:duryear" name="OKYO:ExpectedLifeOfWarrants">3</ix:nonNumeric></span> years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ExpectedLifeOfWarrants_dtY_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzKYE5UDPTee"><ix:nonNumeric contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember" format="ixt-sec:duryear" name="OKYO:ExpectedLifeOfWarrants">5</ix:nonNumeric></span> years</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zp3OWSjNidCd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining fair value of the warrant instruments is deemed to be approximately $<span id="xdx_906_ecustom--FairValueOfWarrants_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjP4zzdj6DZ9" title="Fair value of warrants"><ix:nonFraction name="OKYO:FairValueOfWarrants" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,348</ix:nonFraction></span> (2021: $<span id="xdx_904_ecustom--FairValueOfWarrants_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjoIo1i8tWsh" title="Fair value of warrants"><ix:nonFraction name="OKYO:FairValueOfWarrants" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,873</ix:nonFraction></span>). For the consideration warrants,
the charge has been expensed over the vesting period. For all other warrants, the charge has been expensed over the service period. A
share-based payment charge for the year of $<span id="xdx_909_ecustom--ShareBasedPaymentCharge_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzNi3rYUTn05"><ix:nonFraction name="OKYO:ShareBasedPaymentCharge" contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,721</ix:nonFraction></span> (2021: $<span id="xdx_905_ecustom--ShareBasedPaymentCharge_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmjZFi3iYiEk"><ix:nonFraction name="OKYO:ShareBasedPaymentCharge" contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,914</ix:nonFraction></span>) has been expensed in the statement of comprehensive income.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfDebtSecuritiesExplanatory"><p id="xdx_803_eifrs-full--DisclosureOfDebtSecuritiesExplanatory_zcflQnmUxUJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zKSogIdq5Mxk">CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has raised convertible equity finance via the issuance of convertible loan notes as per the table below. All notes are not convertible
into cash and are convertible on the fourth anniversary of the date of issue of the Notes, or at the election of the noteholder on completion
of the next non-qualifying equity financing or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers
and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming,
unconditional.</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory"><p id="xdx_894_ecustom--DisclosureOfIssuanceOfConvertibleNotesExplanatory_z9WXST82QuX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zGA5tD6eUa82" style="display: none">SCHEDULE OF ISSUANCE OF
CONVERTIBLE LOAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Terms</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">$</p></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 26%; text-align: left">29 May 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 54%; text-align: left">&#9679; <span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zlC1BgpyZjid" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% coupon per annum <br />&#9679; Conversion price of <span id="xdx_905_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zMFSsu4bwI5b" title="Conversion price"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p <br />&#9679; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_907_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjZqVnhHKUll" title="Warrant exercise share"><ix:nonFraction name="OKYO:WarrantExercisePricePerShare" contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p with a maximum life of <span id="xdx_90B_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zPTxfShu5g6c" title="Debt term"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt-sec:durwordsen" name="OKYO:DebtTerm">5 years</ix:nonNumeric></span> from the
    date of the conversion of the loan note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zu9wOhWF6Ow" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">541,239</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fees relating to equity fundraise 29 May 2020 issued as CLN</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_90A_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zcGIUh42aq2e" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%
    coupon per annum <br />&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_z0BRA6hDBFJh" title="Conversion price per share"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p <br />&#9679;
    Upon conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_908_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zpLBCFncD9k9" title="Warrant Exercise per share"><ix:nonFraction name="OKYO:WarrantExercisePricePerShare" contextRef="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4</ix:nonFraction></span>p
    with a maximum life of <span title="Debt term"></span><span id="xdx_907_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjl3ZONpf4I6" title="Debt term"><ix:nonNumeric contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember" format="ixt-sec:durwordsen" name="OKYO:DebtTerm">5 years</ix:nonNumeric></span> from the date of the conversion of the loan note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zwz1bGTftRQ9" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,474</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">27 July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zDhybC3xgKDe" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.15</ix:nonFraction></span>% coupon per annum <br />Conversion price of <span id="xdx_908_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zg5p2KPUZNU2" title="Conversion price per share"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.5</ix:nonFraction></span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zX2Ergjjb9ll" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,506,446</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">17 August 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zvbBhLid24w4" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.15</ix:nonFraction></span>% coupon per annum <br />&#9679; Conversion price of <span id="xdx_900_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zUQPz20QAzp9" title="Conversion price per share"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.5</ix:nonFraction></span>p <br /></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zNMjjZgsDsi4" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,882,641</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                            September 2020</span></p></td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zpS8ngSKuhwj" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.15</ix:nonFraction></span>% coupon per annum <br />&#9679; Conversion price of <span id="xdx_90D_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_z551mFfXGer5" title="Conversion price per share"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.5</ix:nonFraction></span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zBVNjOa54Sba" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,055</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: left">Fees relating to all other equity fundraise issued as CLN</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zUD9vOcyMPYk" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.15</ix:nonFraction></span>% coupon per annum <br />&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_znrjvJTeSUV2" title="Conversion price per share"><ix:nonFraction name="OKYO:ConversionPricePerShares" contextRef="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.5</ix:nonFraction></span>p</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zCyWyWRMn8wl" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-012022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">525,922</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331_z11jltf6xKta" title="Issue of convertible instruments"><ix:nonFraction name="ifrs-full:IssueOfConvertibleInstruments" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,151,777</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zTU2Qis7oQbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
noteholders were offered the option to convert during the year and any conversions took place on May 7, 2021 and February 21, 2022. Loan
note holders were offered conversions including the full interest that would have been accrued had the note reached its full term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory"><p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zitXUuwKIzY1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zy2z7wiDF0Bc">FINANCIAL INSTRUMENTS</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main risks arising from the Group&#8217;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory"><p id="xdx_895_ecustom--DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_zoqKyLA0m1F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted
payments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BF_zmr1ZUhD4BX9" style="display: none">SUMMARY OF FINANCIAL
LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_z4B59WqIDKKi" style="font-weight: bold; text-align: center">Less than 3<br /> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zDAwKHUJfTwc" style="font-weight: bold; text-align: center">3 to 12<br /> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_zTfHCzYKtARb" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br /> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br /> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzENJ_zfcbbF2ZWT3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2022-03-31_custom_LessThanThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">649,624</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,186</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">741,810</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzENJ_zyruebiDfWv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2022-03-31_custom_LessThanThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,041</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzENJ_zEFc68Ej9Lmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-03-31_custom_LessThanThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">696,665</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,186</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">788,851</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_zNEXJ5qt8gM1" style="font-weight: bold; text-align: center">Less than 3<br /> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20210331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zAbLSq6XX4W5" style="font-weight: bold; text-align: center">3 to 12<br /> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210331_z2XoYnqigSy7" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br /> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br /> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzjzM_zQwrY98YGIzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2021-03-31_custom_LessThanThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,179</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,813</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:TradeAndOtherPayables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,992</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzjzM_zmDdJcjuV88g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzjzM_zJOtu1pTyPN6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2021-03-31_custom_LessThanThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,179</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">100,813</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:FinancialLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">210,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zDrJvqdzcl04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and currently
has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their
internal reporting and assess outstanding receivables for ability to be repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
rate risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has limited exposure to interest-rate risk arising from its bank deposits and convertible loan note instruments. These deposit
accounts are held at variable interest rates based on Barclays bank &amp; Penn base rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2022 or 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfRelatedPartyExplanatory"><p id="xdx_801_eifrs-full--DisclosureOfRelatedPartyExplanatory_zlpdhyDU4FP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_828_ztD4Awd4yjLl">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions occurred in the normal course of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>West
African Minerals Limited (&#8220;WAML&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, the Group disposed of its Cameroon operations by way of an in-specie distribution of all of its shares in West African Minerals
Limited (formerly Ferrum Resources Limited) to shareholders. As part of this transaction, the Group had agreed to a deed of release with
WAML whereby it agreed to write off $<span id="xdx_905_ecustom--WriteOffExchangeOfLoan_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zNkvIcnw6H6l" title="Write off related party exchange of loan"><ix:nonFraction name="OKYO:WriteOffExchangeOfLoan" contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,056,070</ix:nonFraction></span> of loans in exchange for shares in WAML to be distributed as part of the in-specie distribution.
A remaining amount of $<span id="xdx_904_eifrs-full--RevenueFromSaleOfGoodsRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zSuJzUgCLFD2"><ix:nonFraction name="ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions" contextRef="From2021-04-012022-03-31_custom_WestAfricanMineralsLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,400,000</ix:nonFraction></span> was outstanding from WAML, however, after careful consideration of the operations of WAML and its subsidiaries,
the Group decided to impair this receivable down to $nil in 2018 as it did not expect to recover any of this outstanding debt. In addition
to the $<span id="xdx_903_eifrs-full--NetDebt_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zgLgRnKOGAm9"><ix:nonFraction name="ifrs-full:NetDebt" contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,400,000</ix:nonFraction></span> outstanding was a working capital loan advance of $<span id="xdx_90E_eifrs-full--Borrowings_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_z6FP8JHGPwB2"><ix:nonFraction name="ifrs-full:Borrowings" contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span> which was also impaired as the Group does not expect to
recover any of this outstanding debt. During the year ended March 31, 2022, the Group had funded $<span id="xdx_907_eifrs-full--LoansAndReceivables_iI_do_c20220331_zOlc6rNCXH3d" title="Loans receivable"><ix:nonFraction name="ifrs-full:LoansAndReceivables" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> (2021: $<span id="xdx_905_eifrs-full--LoansAndReceivables_iI_c20210331_zDLLsSV0Da6h" title="Loans receivable"><ix:nonFraction name="ifrs-full:LoansAndReceivables" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,172</ix:nonFraction></span>) towards this $<span id="xdx_904_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_ztWtGN05J9L6"><ix:nonFraction name="ifrs-full:TradeAndOtherPayablesToRelatedParties" contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span>
loan facility and as at the year-end no further amounts were payable under this facility. The amounts funded in the year have been immediately
written off as the Group has no reasonable expectation of recovering the contractual cash flows of the loan in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tiziana
Life Sciences Ltd</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. The Company
shares premises and other resources with Tiziana Life Sciences Ltd and there is a shared services agreement in place between the Company and
Tiziana Life Sciences PLC. As at 31<sup>st</sup> March 2022, the Company had incurred $<span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zpnVKbHZo1O3" title="Service received related party transaction"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2021-04-012022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,132</ix:nonFraction></span> (2021: $<span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20200401__20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zlYezFQwC8eh" title="Service received related party transaction"><ix:nonFraction name="ifrs-full:ServicesReceivedRelatedPartyTransactions" contextRef="From2020-04-012021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,567</ix:nonFraction></span>) worth of costs in relation
to this agreement and at 31 March 2022 $<span id="xdx_90E_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zJ6LSJcb5ffi" title="Amounts Payable related party transaction"><ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="AsOf2022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,041</ix:nonFraction></span> was due to Tiziana Life Sciences Ltd. At 31 March 2021, $<span id="xdx_90A_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zsnK6ra2YE6b" title="Amounts Payable related party transaction"><ix:nonFraction name="ifrs-full:AmountsPayableRelatedPartyTransactions" contextRef="AsOf2021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,664</ix:nonFraction></span> was receivable from Tiziana
Life Sciences Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfEarningsPerShareExplanatory_zRUZ2SWf9eri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zUnyPY1x2PWd">BASIC AND DILUTED LOSS PER SHARE</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:EarningsPerShareExplanatory"><p id="xdx_896_eifrs-full--EarningsPerShareExplanatory_zSm0U7stgkp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwF8RUz40iXi" style="display: none">SUMMARY
OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br /> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20210401__20220331_zNqmuav90nh5" title="(Loss) attributable to equity holders of the company" style="width: 12%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,268,197</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20200401__20210331_pp0p0" title="(Loss) attributable to equity holders of the company" style="width: 12%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,353,507</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageShares_c20210401__20220331_z6IzBFm1oPH" title="Weighted average number of ordinary shares in issue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">979,212,888</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--WeightedAverageShares_c20200401__20210331_pdd" title="Weighted average number of ordinary shares in issue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">672,767,629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--BasicAndDilutedEarningsLossPerShare_c20210401__20220331_z1WozRvrawSb" title="Basic and dilutive loss per share (cents per share)" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShare" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--BasicAndDilutedEarningsLossPerShare_c20200401__20210331_pdd" title="Basic and dilutive loss per share (cents per share)" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShare" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br /> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20190401__20200331_z4l19vmKMoP8" title="(Loss) attributable to equity holders of the company" style="width: 16%; text-align: right">(<ix:nonFraction name="ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,544,059</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageShares_c20190401__20200331_zEvPIGB4F4oi" title="Weighted average number of ordinary shares in issue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:WeightedAverageShares" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">595,474,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BasicAndDilutedEarningsLossPerShare_c20190401__20200331_z9B8BNlE3wnc" title="Basic and dilutive loss per share (cents per share)" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:BasicAndDilutedEarningsLossPerShare" contextRef="From2019-04-012020-03-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zk7lwaU07q04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered
dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented
on the face of the Statement of comprehensive income are therefore identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfLeasesExplanatory"><p id="xdx_80F_eifrs-full--DisclosureOfLeasesExplanatory_zWskv507RpI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_82E_z3P6cgdVDPji">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is a lessee and does not have any leases as a lessor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Leases of low value assets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based
on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its
right-of-use assets in a consistent manner to its property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties
in their original condition at the end of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year to March 31, 2022, the Group entered
into new lease agreement on its existing office. The new leases has a term shorter than 12 months, so the Group has applied the exemption
allowed by paragraph 5a in IFRS 16 in respect of short term leases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year to March 31, 2021, the group terminated from its lease early resulting in the right of use asset of $<span id="xdx_90C_ecustom--DisposalsRightOfUseAssets_c20200401__20210331_zLfqCQB2D4ck" title="Early Termination write off right of use of assets"><ix:nonFraction name="OKYO:DisposalsRightOfUseAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,069</ix:nonFraction></span> and lease liability
of $<span id="xdx_90A_ecustom--DisposalsLeaseLiabilities_c20200401__20210331_zjvcN10sMuxg" title="Early Termination write off lease liability"><ix:nonFraction name="OKYO:DisposalsLeaseLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,887</ix:nonFraction></span> being written off to the profit and loss. A new lease was subsequently entered into in January 2021. The initial recognition
resulted in a right of use asset and a lease liability of $<span id="xdx_904_ecustom--InitialRecognitionForRightOfUseAssetAndLeaseLiability_c20200401__20210331_pp0p0" title="initial recognition for right of use asset and lease liability"><ix:nonFraction name="OKYO:InitialRecognitionForRightOfUseAssetAndLeaseLiability" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,377</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"><p id="xdx_89C_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_zZKJgd98QZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVZpiUE9kMs8" style="display: none">SCHEDULE
OF RIGHT OF USE ASSETS AND LEASE LIABILITY</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">Right-of-use assets</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property <br />$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RightofuseAssets_iS_c20210401__20220331_zzxDfJZQtynj" title="Right-of-use assets, balance as at the beginning of the year" style="width: 18%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,579</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Derecognition of right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--DisposalsRightOfUseAssets_c20210401__20220331_zD1HO3XrvGSh" title="Derecognition of right of use asset" style="text-align: right">(<ix:nonFraction name="OKYO:DisposalsRightOfUseAssets" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,553</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_iN_di_c20210401__20220331_zzQyo0Jwr6ak" title="Impact of Foreign exchange" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:ImpactOfForeignExchange" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,026</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--RightofuseAssets_iE_c20210401__20220331_zvgcnVyaIU1" title="Right-of-use assets, balance as at the end of the year" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1768">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RightofuseAssets_iS_c20200401__20210331_zUznAy0hxQgc" title="Right-of-use assets, balance as at the beginning of the year" style="width: 18%; text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,099</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation of early terminated lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DepreciationOfEarlyTerminatedLease_c20200401__20210331_zMR2gPGEmIF3" title="Depreciation of early terminated lease" style="text-align: right">(<ix:nonFraction name="OKYO:DepreciationOfEarlyTerminatedLease" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,060</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Termination write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DisposalsRightOfUseAssets_iN_di_c20200401__20210331_zmJPyy0U421f" title="Early Termination write off" style="text-align: right">(<ix:nonFraction name="OKYO:DisposalsRightOfUseAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,069</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_c20200401__20210331_zA078dNHUbzc" title="Impact of Foreign exchange" style="text-align: right"><ix:nonFraction name="OKYO:ImpactOfForeignExchange" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,030</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsToRightofuseAssets_c20200401__20210331_zMQcUq9qXCd2" title="Additions" style="text-align: right"><ix:nonFraction name="ifrs-full:AdditionsToRightofuseAssets" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,377</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of new lease</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DepreciationOfNewLease_c20200401__20210331_zjlwxfOcTG7f" title="Depreciation of new lease" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:DepreciationOfNewLease" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,799</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_c20200401__20210331_zQH9Uk8SKbP9" title="Right-of-use assets, balance as at the end of the year" style="text-align: right"><ix:nonFraction name="ifrs-full:RightofuseAssets" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,579</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Lease Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zxT5lM2DB388" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20210331_zAc7Rrn5SjU6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160; &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--LeaseLiabilities_iS_zZmBklQvjOTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%">At 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,760</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,689</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LeaseLiabilities_iS_zTo2iwDz0etj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Liabilities, balance as at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,760</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,689</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--LeaseLiabilitiesInterestExpense_zPIrqOS9pajd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OKYO:LeaseLiabilitiesInterestExpense" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LeasePayments_zNa5PCDQm2n8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:LeasePayments" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,542</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpactOfForeignExchangeLeaseLiabilities_zKImhhjwP1v8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:ImpactOfForeignExchangeLeaseLiabilities" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,207</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1797">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerecognitionOfLeaseLiability_zsLlWUqHIva1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derecognition of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="OKYO:DerecognitionOfLeaseLiability" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97,553</ix:nonFraction></p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1800">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalsLeaseLiabilities_iN_di_zA5gJ4qrPJ5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Early Termination write off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="OKYO:DisposalsLeaseLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,887</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AdditionsToLeaseLiabilities_zTBcNDgE6xAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OKYO:AdditionsToLeaseLiabilities" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LeaseLiabilitiesInterestExpenses_zhiVgAqdY6Qc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="OKYO:LeaseLiabilitiesInterestExpenses" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeasePayment_zh6mgGmMfmv3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="OKYO:LeasePayment" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--LeaseLiabilities_iE_zupJ8UUubTB" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    30 April</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1814">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--LeaseLiabilities_iE_zeKKkfpgmXl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span style="font-size: 10pt">Lease Liabilities, balance as at the beginning of the year</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A9_zvwFanj0gUL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory"><p id="xdx_897_ecustom--DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_zB5CKFgNe3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zbmjPqrG3F3c" style="display: none">SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20220331_zmKwmnIBhzo8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210331_zlyPh0jhynRh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$ &#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$
&#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zv7XaDQkJUWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Current </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CurrentLeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,148</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--NoncurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zl2kQG5N0vVc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Non-current </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="ifrs-full:NoncurrentLeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,612</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--LeaseLiabilities_iTI_mtLLzex8_ztlPC1rZi9Rk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:LeaseLiabilities" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,760</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



</ix:nonNumeric><p id="xdx_8A0_zrbiYpZWRDi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory"><p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_z9RZTlXFUeD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B4_zcQfZaCgGKG6" style="display: none">SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Operating leases which expire:</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 68%; text-align: justify">Within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zDu9wXXbjjK9" title="Within one year" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:GrossLeaseLiabilities" contextRef="AsOf2022-03-31_ifrs-full_NotLaterThanOneYearMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,713</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_z6tAvFmpciOf" title="Within one year" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1835">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331_zzpMOaiax946" title="Within one year" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:GrossLeaseLiabilities" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,713</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331_ziHlYPfIZQk" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z2dKXGvMBz56" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfAuditorsRemunerationExplanatory"><p id="xdx_804_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_zXZQkSQqwA0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_82A_zcZrAJzYJQhg">Auditor&#8217;s Remuneration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory"><p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_zD2gkHE1hTxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period, the group obtained the following services from the company&#8217;s auditors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQMzkE6Qo47b">SCHEDULE
OF COMPANY AUDITORS FEES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zbf5K3wx0Av3" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20210331_zOUzJkwP8mp" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemunerationForAuditServices_zNfxNk36Cayc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Fees payable to the company&#8217;s auditors for the audit of the parent company and consolidated financial statements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,773</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForAuditServices" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,874</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fees payable to the company&#8217;s auditors for other services:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AuditorsRemunerationForOtherServices_zn1lZdfN4mR3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Audit-related assurance services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,892</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemunerationForOtherServices" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,637</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zgB2fVZqwwth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total auditor&#8217;s remuneration</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:AuditorsRemuneration" contextRef="From2020-04-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,511</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zecrDmusrV1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory"><p id="xdx_80B_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_zkmTECTLSrkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
<span id="xdx_826_zlmiUo2epTI6">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory"><p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_zNxGs8zLiU9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B1_zYWdwGwZDKU7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160; </b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash at bank and in hand:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify">GBP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--GBPMember_pp0p0" title="Cash at bank and in hand" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2022-03-31_custom_GBPMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,400,817</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--GBPMember_pp0p0" title="Cash at bank and in hand" style="width: 12%; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2021-03-31_custom_GBPMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,344,740</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">USD</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--USDMember_pp0p0" title="Cash at bank and in hand" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2022-03-31_custom_USDMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">299,907</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--USDMember_pp0p0" title="Cash at bank and in hand" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2021-03-31_custom_USDMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,544,589</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--CashOnHand_c20220331_pp0p0" title="Cash at bank and in hand" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,700,724</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CashOnHand_c20210331_pp0p0" title="Cash at bank and in hand" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="ifrs-full:CashOnHand" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,889,329</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_z2imog4U0SEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"><p id="xdx_80E_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zCve7pILUbRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.
<span id="xdx_828_zbqJ9fOVtSX9">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialisation of the products of this research
and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that
the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    &#8211; We are obligated to pay to On Target Therapeutics the following additional amounts in respect of the first licensed product
    or service which achieves the stated development milestones:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.65in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase I Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_907_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIHumanClinicalTrialMember_zXzDW5cGvOHa" title="Amount of licensed product or service"><ix:nonFraction name="OKYO:AmountOfLicensedProductOrService" contextRef="From2021-04-012022-03-31_custom_PhaseIHumanClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase II Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90B_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIHumanClinicalTrialMember_zG3J3HDW16S5"><ix:nonFraction name="OKYO:AmountOfLicensedProductOrService" contextRef="From2021-04-012022-03-31_custom_PhaseIIHumanClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">600,000</ix:nonFraction></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase III Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIIHumanClinicalTrialMember_zcK21OsPDhr"><ix:nonFraction name="OKYO:AmountOfLicensedProductOrService" contextRef="From2021-04-012022-03-31_custom_PhaseIIIHumanClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,500,000</ix:nonFraction></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAM8
    &#8211; The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
    fee is $<span id="xdx_900_ecustom--AnnualLicenseMaintenanceFee_c20210401__20220331_pp0p0" title="Annual license maintenance fee"><ix:nonFraction name="OKYO:AnnualLicenseMaintenanceFee" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000</ix:nonFraction></span> until May 2021, and $<span id="xdx_90A_ecustom--AnnualLicenseMaintenanceFeeTherafter_c20210401__20220331_pp0p0" title="Annual license maintenance fee, therafter"><ix:nonFraction name="OKYO:AnnualLicenseMaintenanceFeeTherafter" contextRef="From2021-04-01to2022-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-04-01to2022-03-31" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory"><p id="xdx_809_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_znWjsdIHUESc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.
<span id="xdx_828_zzNJreRL2kGl">Post Balance Sheet Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022, OKYO announced the closing of its underwritten public offering of <span id="xdx_906_eifrs-full--NumberOfSharesIssued_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_z7hh2Ya6rUF3"><ix:nonFraction name="ifrs-full:NumberOfSharesIssued" contextRef="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">625,000</ix:nonFraction></span> American Depository Shares (the &#8220;ADSs&#8221;)
at a public offering price of $<span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_znIYxZab1sAk" title="Price per share"><ix:nonFraction name="ifrs-full:ParValuePerShare" contextRef="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per ADS, for gross proceeds of $<span id="xdx_909_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20220502__20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_zGm8DDxjg789" title="Gross proceeds from public offering"><ix:nonFraction name="ifrs-full:ProceedsFromIssuingShares" contextRef="From2022-05-022022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million, before deducting underwriting discounts and offering
expenses. As a result, the Company is now listed on the Nasdaq stock exchange and is therefore a dual listed Company with its existing
listing on the London Stock Exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022, the Remuneration committee awarded the Non-Executive Chairman a bonus of $<span id="xdx_902_ecustom--Bonus_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z6kbkZgenBSk"><ix:nonFraction name="OKYO:Bonus" contextRef="AsOf2022-05-19_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The committee noted that in order to support the offering the Non-Executive Chairman participated in the offering. It was noted that
the offering may have failed without this subscription, so it was agreed to compensate Mr Cerrone for this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Group secured a short-term credit facility from Tiziana Life Sciences, a related party, for $<span id="xdx_908_ecustom--ShorttermCreditFacility_iI_pn6n6_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zk6EoyVv3Hal"><ix:nonFraction name="OKYO:ShorttermCreditFacility" contextRef="AsOf2022-08-15_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">2</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m
in order to support short term liquidity. The loan is available for a period of 6 months upon first draw-down and carries an interest
rate of <span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z5q1Xg9p2Z4c" title="Interest rate"><ix:nonFraction name="ifrs-full:BorrowingsInterestRate" contextRef="AsOf2022-08-15_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% per annum, with additional default interest of <span id="xdx_907_ecustom--AdditionalBorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z70UCXqKYT39" title="Additional interest rate"><ix:nonFraction name="OKYO:AdditionalBorrowingsInterestRate" contextRef="AsOf2022-08-15_custom_NonadjustingEventMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>% if the loan is not repaid after the 6-month period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_813_zHCpMZtZZtC2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 126; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>ex12-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 12.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Gary Jacob, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">1.</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">I have reviewed this annual report on Form 20-F of OKYO Pharma Ltd;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">2.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">3.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">4.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">The company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the company and have:</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">a.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">b.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">c.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Evaluated the effectiveness of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">d.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period
covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal
control over financial reporting; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">5.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">The company&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the
equivalent functions):</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">a.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in">b.</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal
control over financial reporting.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 15, 2022</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary Jacob</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>ex12-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Keeren Shah, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 20-F of OKYO Pharma
Ltd;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the company as of, and for, the periods presented in this report;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company&rsquo;s other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the company&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the company&rsquo;s
internal control over financial reporting that occurred during the period covered by the annual report that has materially affected,
or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the
audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s
ability to record, process, summarize and report financial information; and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 15, 2022</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren Shah</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>ex13-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certification set forth below is being submitted in connection with OKYO Pharma Ltd&rsquo;s Annual Report on Form 20-F for the fiscal
year ended March 31, 2022 (the &ldquo;Report&rdquo;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Jacob, Chief Executive Officer of OKYO Pharma Ltd, certifies that, to the best of his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of OKYO Pharma Ltd</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 15, 2022</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Gary Jacob</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Gary Jacob</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>5
<FILENAME>ex13-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
13.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
certification set forth below is being submitted in connection with OKYO Pharma Ltd&rsquo;s Annual Report on Form 20-F for the fiscal
year ended March 31, 2022 (the &ldquo;Report&rdquo;) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) and Section 1350 of Chapter 63 of Title 18 of the United States Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
Shah, Chief Financial Officer of OKYO Pharma Ltd, certifies that, to the best of his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Report fully complies with the requirements of Section
13(a) or 15(d) of the Exchange Act; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the information contained in the Report fairly presents, in
all material respects, the financial condition and results of operations of OKYO Pharma Ltd</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
August 15, 2022</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Keeren Shah</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>6
<FILENAME>ex15-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Consent of Independent Registered Public Accounting Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Board of Directors of OKYO Pharma Ltd:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference of our
report dated August 15, 2022 with respect to the consolidated balance sheets for the years ended March 31, 2022 and March 31, 2021 and
the related consolidated statements of operations and comprehensive loss, cash flows and shareholders&rsquo; equity for each of the years
in the three-year period ended March 31, 2022, and the related notes, for OKYO Pharma Ltd, which report appears in the March 31, 2022
annual report on Form 20-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>/s/ Mazars LLP.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mazars LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">London</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">August 15, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form20-f_001.jpg
<TEXT>
begin 644 form20-f_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "_ <T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN(\:?
M$1/!^J6]DVF/=&:'S=XF"8Y(QC!]*N%.51\L=R9SC!<TMCMZ*\D_X7A%_P!
M"3_P*'_Q-'_"\(O^@!)_X%#_ .)K;ZG6_E_(Q^M4>YZW17DG_"\(O^@!)_X%
M#_XFC_A>$7_0 D_\"A_\31]3K?R_D'UJCW/6Z*\D_P"%X1?] "3_ ,"A_P#$
MU/;?&>*X2Y;^PI%\B$R_\?(Y^8#'W?>CZI67V0^M4NYZI17DG_"\(O\ H 2?
M^!0_^)H_X7A%_P! "3_P*'_Q-'U.M_+^0?6J/<];HKR3_A>$7_0 D_\  H?_
M !-'_"\(O^@!)_X%#_XFCZG6_E_(/K5'N>MT5Y)_PO"+_H 2?^!0_P#B:/\
MA>$7_0 D_P# H?\ Q-'U.M_+^0?6J/<];HKR3_A>$7_0 D_\"A_\31_PO"+_
M * $G_@4/_B:/J=;^7\@^M4>YZW17E]Y\8X[2"QE_L.1OM5OY^/M(&WYV7'W
M>?NY_&JG_"\(O^@!)_X%#_XFA82L_L@\5274];HKR3_A>$7_ $ )/_ H?_$T
M?\+PB_Z $G_@4/\ XFCZG6_E_(/K5'N>MT5Y)_PO"+_H 2?^!0_^)H_X7A%_
MT )/_ H?_$T?4ZW\OY!]:H]SUNBO)/\ A>$7_0 D_P# H?\ Q-'_  O"+_H
M2?\ @4/_ (FCZG6_E_(/K5'N>MT5Y79_&B*[O;>V&A2+YTBQ[OM(.,G&?NU"
MWQOB5B/[ DX)'_'T/_B:/JE;^4/K5+N>M45Y)_PO"+_H 2?^!0_^)H_X7A%_
MT )/_ H?_$T?4ZW\OY!]:H]SUNBO)/\ A>$7_0 D_P# H?\ Q-'_  O"+_H
M2?\ @4/_ (FCZG6_E_(/K5'N>MT5Y)_PO"+_ * $G_@4/_B:/^%X1?\ 0 D_
M\"A_\31]3K?R_D'UJCW/6Z*\D_X7A%_T )/_  *'_P 31_PO"+_H 2?^!0_^
M)H^IUOY?R#ZU1[GK=%>2'XXQ $_V!)Q_T]#_ .)JQ??&>*RO9+8Z%(^S'S?:
M0,Y /]WWH^J5OY0^M4NYZG17DG_"\(O^@!)_X%#_ .)H_P"%X1?] "3_ ,"A
M_P#$T?4ZW\OY!]:H]SUNBO)/^%X1?] "3_P*'_Q-'_"\(O\ H 2?^!0_^)H^
MIUOY?R#ZU1[GK=%>2?\ "\(O^@!)_P"!0_\ B:G@^,\4\%U+_84@\B,/C[2/
MFRRKC[O^U1]4K?RA]:I=SU2BO)/^%X1?] "3_P "A_\ $T?\+PB_Z $G_@4/
M_B:/J=;^7\@^M4>YZW17DG_"\(O^@!)_X%#_ .)H_P"%X1?] "3_ ,"A_P#$
MT?4ZW\OY!]:H]SUNBO)/^%X1?] "3_P*'_Q-'_"\(O\ H 2?^!0_^)H^IUOY
M?R#ZU1[GK=%>2?\ "\(O^@!)_P"!0_\ B:GE^,\45G;7']A2'SRXV_:1QM('
M]WWH^J5OY0^M4NYZI17DG_"\(O\ H 2?^!0_^)H_X7A%_P! "3_P*'_Q-'U.
MM_+^0?6J/<];HKR3_A>$7_0 D_\  H?_ !-'_"\(O^@!)_X%#_XFCZG6_E_(
M/K5'N>MT5Y)_PO"+_H 2?^!0_P#B:/\ A>$7_0 D_P# H?\ Q-'U.M_+^0?6
MJ/<];HKS[PK\48_$_B"'2ETA[<R([>89PV-HSTP*]!K&I3E3=I(UA4C-7BPK
MP[XU?\C3I_\ UY?^SM7N->'?&K_D:=/_ .O+_P!G:NG _P 9?,PQG\)_(\UH
MI55G9412SL0JJ.Y/05WFN_#O[%<:1;VDLD)N93:W$UY\L8F"AMRG'*'Y@/4B
MO7E4C%I/J>7&$I)M'!45UL7@&\EO;VV^V(K6B([*;:7S"&STCQN(&.2,CTS3
MK3P!>26]C=75U'##<-"74(VY8Y'V @D8+=/EZ@$$U/MJ?<?LI]CD*OZ;_J-2
M_P"O-O\ T-*36;.'3]<O[*WE,L-O</$CL,$A21S[]J73?]1J7_7FW_H:5;=X
MW)2L[%"B@]*[63P+%<&V>VU!+6)X++=]H5G+37 . -HX&?7I1*<8?$$8.6QQ
M5%=C9^"HXH+MM3O$$ZV-S<PVT.=Q\IMFXMC&,@\=<5'X@\'1:3<W;-J%O9P"
M1X[6.=F=IBB*S#<% '+ #(&3^=0JT&[7*=*:5[')45W.F_#MI+K36U"^V6EV
M[H0D+I(&6(R8PPZ8!YQV]Q52?P=$;2SO%OX;6SDM())+B;<X>25F50%"Y&=N
M>^!WH]O"]KC]C.U['(T5UDO@&]M[61Y[ZU2Y2*YE^S;6)(@;#_-C'N/6N3JX
MSC+X61*$H[HUM9_X\-"_[!__ +6EK)K6UG_CPT+_ +!__M:6NFM/">B-X3LM
M2O&F@:XLI;A[HWD:JCJ2%41$;FS@=*CVBA%7_K<OD<V['!T5V$'P^NI[B2!-
M2MRT*0M.1#(1$TH!13@<\')/0 <U7TOPA<B>^N-:M;N+3;&"69Y(1_KRAV[8
MW/!Y[^@I^VAW%[*?8Y>BNOT_1- UJ&]N+!-0B2%;7$=Q(O#R3B-@& ^9<'@X
M&#3K_P !RPF[DM[Z !!=2Q6S;BYC@D*-E\ 9[CIFE[:%[/0/92M=:G'45UNO
M>#X=+NKMSJ-M9VZRF*V2X9G:5EC5V&X* /O  D#DX]ZMZ9\/V:ZTN2_N"UI>
M.\;(B-%(K"%I!]X<CC&<?XT>WA:]Q^QG>UCE-'_Y#FG_ /7S'_Z$*CMK5[[4
MXK2-D62>;RU+G"@DX&34FC?\AO3_ /KYC_\ 0A523_6O_O'^=7U(Z'7VWP\O
M+C4TL?[1M [W<EJ'4%ERD0EW9]""!CM4</@.Y"(U_?Q60^SW,\P>%G,0AD",
M"!USG(QVJGHGBN31+2"W2S280SS3!C(5)\R'RL=.PYK1_P"%A3SQ6J:CIZ78
MBT^2PE)G*&97*Y8D#@X0?7.:P?M[Z;&R]C;4P]6T-M+O+&)+R&ZMKY%DMKF,
M$*ZEMO0\@@]16QJ_@"\TVX2TMIYKV\>;R5B6QDB5C@DE9'^1N!V/-5+GQG=R
M/%'8V]O9V$,*P1VH42X0$G[[@G)).2,5I2^/XGUN/5TT:1;I9C*0^HR/&25*
MD!",+U[4VZVEA+V6IA+X6UMKQ;46)\YXUD0&5 &5CM&#NP<GC .<U8N/!VJP
MZ/;:DL1D21)7FC  >#RWV-N!.3CJ<#CO5W2?';:5;V40TN"5[.!(8Y?-*O\
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MY_T#=._\?_QHYD:?V7B>R^\]NHKQ'_A=&N?] W3O_'_\:/\ A=&N?] W3O\
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M2.2_X4_X8_O7_P#W_P#_ *U'_"G_  Q_>O\ _O\ _P#UJZW[3IO_ $$D_P#
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M>?+_ ,^LOYK_ (T>?+_SZR_FO^- $]%0>?+_ ,^LOYK_ (T>?+_SZR_FO^-
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M9Q116X\LI'%]U<QJ2!^)-;_PD_Y'N/\ Z]9?Z5PV,=*[GX2?\CW'_P!>LO\
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M'VVV_P">Z?G1]MMO^>Z?G18/K%;^=_>SG_\ A7?A'_H!V_YM_C1_PKOPC_T
M[?\ -O\ &N@^VVW_ #W3\Z/MMM_SW3\Z+!]8K?SO[V<EIOPWTC3_ !3-JZP1
MB! GV2U4$K&P'+G/4YZ>G\NTJ#[;;?\ /=/SH^VVW_/=/SH)J59U&G-W)Z*@
M^VVW_/=/SH^VVW_/=/SH,R>BH/MMM_SW3\Z/MMM_SW3\Z )Z*@^VVW_/=/SH
M^VVW_/=/SH GHJ#[;;?\]T_.C[;;?\]T_.@">BH/MMM_SW3\Z/MMM_SW3\Z
M)Z*@^VVW_/=/SH^VVW_/=/SH GHJ#[;;?\]T_.C[;;?\]T_.@">BH/MMM_SW
M3\Z/MMM_SW3\Z )Z*@^VVW_/=/SH^VVW_/=/SH GHJ#[;;?\]T_.C[;;?\]T
M_.@">BH/MMM_SW3\Z/MMM_SW3\Z )Z*@^VVW_/=/SH^VVW_/=/SH GHJ#[;;
M?\]T_.C[;;?\]T_.@">BH/MMM_SW3\Z/MMM_SW3\Z )Z*@^VVW_/=/SH^VVW
M_/=/SH 2ZZ0_]=5JQ5*>YAE:!4E5F\U> :NT %>(_&?_ )&BP_Z\_P#V=J]N
MKQ'XS_\ (T6'_7G_ .SM2EL>AE?^\KT9YO1114'TP4444 %=S\)/^1[3_KUE
M_I7#5W/PD_Y'N/\ Z]9?Z4+<Y\7_ +O/T9[[56+4[">]ELH;VVDNXO\ 60)*
MI=/JN<BK5<%:^%-8B:VM%BL+463SR1ZG$Y,TS.K@97;QRX+9)R5&*Z(1B[W=
MCXZ<I*UE<[VHXIX9C((I4<QML<*P.UNN#Z'D5PDGAK6UTN)+2SB@E6*XA>+[
M>[!C)$JB3)''S*3@>N>N:BU'PGKTN\6_E &Y,ZLMP496VQ ,3@_W'&.O(YQF
MK5*'\Q#J2_E/0)YX;:!YYY4BBC&YW=@JJ/4D]*BLM0LM2@\^QNX+J(';OAD#
MKGTR*YM_#5TWA77;,*GV[4))V#-(2"K.Q0$GIA2..U9VM>"+X6!ATNYDN)IW
M:6>:6587\P(%C(V*% &.<#/O2C"#T<AN<UJHG=QS13;_ "I%?8Q1MISAAU!]
MZ?7G]YX2UFYDNY=Z^8?.>W/VAAMD:6-E/'HJM]/QKT"HG%1V=RH2;W5C#O=?
MTOP^MQ/JMVMM%+<[$8JS9;8IQP#V%4/^%E>$/^@U'_WZD_\ B:R_'GAG4O%&
MG_9M-$)DAO\ S&\U]HQY0'H?6N"_X5'XJ_N6/_@1_P#8UFVSU<-A\+.FI59V
M?K_P#U'_ (65X0_Z#4?_ 'ZD_P#B:/\ A97A#_H-1_\ ?J3_ .)KR[_A4?BK
M^Y8_^!'_ -C1_P *C\5?W+'_ ,"/_L:5V;_5,#_S\_%?Y'J/_"RO"'_0:C_[
M]2?_ !-'_"RO"'_0:C_[]2?_ !->7?\ "H_%7]RQ_P# C_[&C_A4?BK^Y8_^
M!'_V-%V'U3 _\_/Q7^1ZC_PLKPA_T&H_^_4G_P 31_PLKPA_T&H_^_4G_P 3
M7EW_  J/Q5_<L?\ P(_^QH_X5'XJ_N6/_@1_]C1=A]4P/_/S\5_D>AZ;\3-(
MOO%4VE>?&;239]DNP"JNQ'*-GH<]#^%=S7SOIWPZUF]\3R:),J1?9PKW5PAW
M)&K#(P>,L1T%?0-E:K8V,%JDDDBPH$#RMN9@!C)/<TU<Y<=1H4W'V3OI_3^9
M/1113. **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML/\ OX*/-N?^?8?]_!5BB@"OYMS_ ,^P_P"_@H\VY_Y]A_W\%6** *_FW/\
MS[#_ +^"CS;G_GV'_?P58HH K^;<_P#/L/\ OX*/-N?^?8?]_!5BB@"OYMS_
M ,^P_P"_@H\VY_Y]A_W\%6** *_FW/\ S[#_ +^"CS;G_GV'_?P58HH K^;<
M_P#/L/\ OX*/-N?^?8?]_!5BB@"OYMS_ ,^P_P"_@H\VY_Y]A_W\%6** *_F
MW/\ S[#_ +^"CS;G_GV'_?P58HH K^;<_P#/L/\ OX*/-N?^?8?]_!5BB@"O
MYMS_ ,^P_P"_@H\VY_Y]A_W\%6** *_FW/\ S[#_ +^"CS;G_GV'_?P58HH
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M@_Z M]_WY-?0=%;?69=CS_[(I_S/\#Y\_P"$6\0?] 6^_P"_)H_X1;Q!_P!
M6^_[\FOH.BCZS+L']D4_YG^!\^?\(MX@_P"@+??]^373^ =&U32_%"W-_IUU
M;P"!U\R2(@9.,"O7**F6(<E:QI2RN%.:FI/3T*_VV#^\W_?#?X4?;8/[S?\
M?#?X58HK ],K_;8/[S?]\-_A0;RW(P68C_</^%6** *_VV#^\W_?#?X4?;8/
M[S?]\-_A5BB@"O\ ;8/[S?\ ?#?X4?;8/[S?]\-_A5BB@#/M;F));HL6 :;<
MOR-R-JCT]JL?;8/[S?\ ?#?X58HH K_;8/[S?]\-_A1]M@_O-_WPW^%6** *
M_P!M@_O-_P!\-_A1]M@_O-_WPW^%6** *_VV#^\W_?#?X4?;8/[S?]\-_A5B
MB@"O]M@_O-_WPW^%'VV#^\W_ 'PW^%6** *_VV#^\W_?#?X4?;8/[S?]\-_A
M5BB@"O\ ;8/[S?\ ?#?X4?;8/[S?]\-_A5BB@"O]M@_O-_WPW^%'VV#^\W_?
M#?X58HH K_;8/[S?]\-_A1]M@_O-_P!\-_A5BB@"O]M@_O-_WPW^%'VV#^\W
M_?#?X58HH K_ &V#^\W_ 'PW^%'VV#^\W_?#?X58HH K_;8/[S?]\-_A1]M@
M_O-_WPW^%6** *_VV#^\W_?#?X4?;8/[S?\ ?#?X58HH K_;8/[S?]\-_A1]
MM@_O-_WPW^%6** *_P!M@_O-_P!\-_A1]M@_O-_WPW^%6** *_VV#^\W_?#?
MX4?;8/[S?]\-_A5BB@"O]M@_O-_WPW^%'VV#^\W_ 'PW^%6** *_VV#^\W_?
M#?X4?;8/[S?]\-_A5BB@"O\ ;8/[S?\ ?#?X4?;8/[S?]\-_A5BB@"O]M@_O
G-_WPW^%'VV#^\W_?#?X58HH I37$<S0K&6)\U3]P_P"%7:** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form20-f_002.jpg
<TEXT>
begin 644 form20-f_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 A(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBF^8G]]?SH =13?,3^^OYT>8G]
M]?SH =13?,3^^OYT>8G]]?SH =13?,3^^OYT!T)P'7\Z '45@ZOKEY::Q!IU
MA9I<RF W4JLQ!,8=5(3 Y;YL\\<5S\_C^Y6V@:&VLS+*)MP>4XC*7*PC=CD
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MI[@B9;:(;IG&21T1?[Q_IZ_G0 V29KBY-M#]Q/\ 72>G^R/?^0^M,_L72_\
MH'6O_?E?\*MPPI!$(XUPH_4^OUI],5NY1_L72_\ H'6O_?E?\*/[%TO_ *!U
MK_WY7_"KU%%V%EV*/]BZ7_T#K7_ORO\ A1_8NE_] ZU_[\K_ (5>HHNPLNQ1
M_L72_P#H'6O_ 'Y7_"G)I.G12+)'86RNIRK")00?7I5RBE<+(P-8T*\O-8AU
M&PO$MI?L[6LA922$+JV5P>&^4CGCFL27P#,8+=8KJV$D(ESNB.)"]RLPSST
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MV*!W)J*A^UVW_/Q%_P!]BD:\MPORS1NW0*K DGT% 7%GG$6V-2#-)PB^OO\
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M*BLISQM.TD?6NQHI\[)5&",_1K"73]#M=/NI$F:"(1%@.&4<#K[8J7^R]/\
M^?&U_P"_*_X5;HI7+LK6*G]EZ?\ \^-M_P!^5_PH_LO3_P#GQMO^_*_X5;HI
M7"R*G]EZ?_SXVW_?E?\ "GQ6%G#()(K2"-QT9(P"/QJQ10%D%1RG"5)44Y^6
M@I;E>BBJ\HDGF$2,4B4YD<'DG^Z/3W/X4C5NQ7=?/UG:[MLB0$)V)-:%4;21
MKF]N)67:J':OJ>U7JX, E*,ZJ^U)Z^2T7Y.QK5W2[(*N*<K5.K49R@^E>@83
M'T444&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4UW6*-G=@J*,DGH!3JRO$4;2:)/M)&W#$
M#N :4G9-BD[)LYR_OFU2\,YR(4XB0^GK]:H2@/+_  84=QG)IEU)(ELKQG&,
M9QV%9\%VT][&S28"GN,"O-UDW)GS^(Q"<^61JQR;T&1M8<$&EV*'+X^8]352
MZ1GMV,I$:*<Y R>M4;.YE^= ZX"Y#.<8I)&,JZA)1DOZ]"WJEP(K<)S^\.TD
M=AWK-7S()!*KAO[K$9!J2>5ID@ADE09');IG-7X$$%D  "0I;ZFM+)(YIKV]
M1R3M9$,.HH\BQR#:S<;L\9KJ="832I"[$#=D'/=>1_6N):5[MXXW5 =V-P&*
MZC2)O)OHSG@,#^'2M:>DT=67UY.I=NZ.PDL0D8-KB.96W!CSN/?/K1]@5H'!
M.V9SO,@ZAO6KE%=9],4WL@UM( 1Y[C)D[[NU17,<T2?:Y;AB8\'RUX7&>>.]
M:-(RJZE6 (/8T 1K=6[R>6D\3/\ W0X)_*I:H3B&._M_D2,*"S/C'L!G_/2K
M] !1110 4444 %%%% !1110 4444 %%%% !4$YZ5/6??7#1,J1KOF?(1#T]R
M?0"@<=R*XDD9A;P'$C#+28XC7U^OH/QJ0"*UM^NV.,<DG/XGU-$,7E1[2Y=S
MRSG^(^M4KN?[3YMG&KAU(W''7OQ7-B\2J%-RZ]%W?1&].'-(?IVUQ+/'GRY6
M+#/<YYJ]3401QJ@& !CBG486BZ-&,'OU]7J_Q8YRYI7"K,/W*K58@/RUT&4M
MA+F[MK.,275Q%!&3C=*X49^IH-W; 9-Q%CR_-SO'W/[WT]ZQ-6ACN/%^B1S(
MLD8BN&V.,C.$&<?B:\_@E?['ID+AS:RV[074JG_50?:L'\.B_0T7.[#X"-:"
M?-9[_G_D_P #U_S$$?F;U\O&[=GC'KFH)-1L88XI);VW2.;_ %;-*H#_ $.>
M:H7D^FZE'?:2\9D,$>9(WC8)P,CG&#VZ5QL4<<VDVPE17">&)&4,,[3E>1Z'
MWH,Z&$4U>;:_R:T_,]'\Z(3"$RIYI7<$W#<1ZX]*?7&:+!$OB#1+H(//N='+
MS2=W/[H<UV=,PKTE2DDG?3]6OT"BBB@P"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHI#TH ,@4C.%ZTTL#WJ/S!G:<_2G8ER)&DQT&137E. 4Q^-0"
M0APNWDU$9)$D7Y0<G'%-(AS++S%E 4X:F/.S)MR0X].]59#+$^[(;#=*9.)8
M6+A\D'=@U21FYLM/.QB,;9WCCCO36N&6)HGSD=".]5)HY5;?YIW'YMIZ4R2&
M1E64RD-)\P7J!Z522(<Y%S[0T4312%L]<_TJ)IB;.6VFR/,0CGG (Z54:.66
M/SWE*[S@*.14;K<W2R3&0(H.S&,Y]31RI[D.I(YZV >#9)TY4YK&_<0RDX(B
MW?4XK;?*ZC=QX  ;/'3FL.>&,W92%7;)Y5N>:\I1LVF>+C=U8TA/'J5M)%&2
MC$8 ;K]:RX(9I'>$1_O4X8=,5&\RQ,=NX/C'R\8%2VLSP6=S(ORN67YQS@52
MCH<4JJJM<_2_W$:6TD[M& -RDY!-7KJ/SH$MC*BR* 64GKQ52&1HG2ZR&7)Q
MSG<>^:EO_LLLCOYC"8CMR ?>GU%!Q5-]_7H5()B I(4*I"Y"\CGN:Z6T!-QQ
MZ5SL,MVENP96,( R-HZ>QKI+  72X/''\Q515Y(VP#[^1Z$/NCZ4M1+<PO,8
MED4R#JM2UU'V":>P4444#(+N5(H#NC,A;Y50#.XFBT@^S6J1<\#IG./:DNYH
M(X]DSX+\*H^\?H*C2=[33T>Z):0?* H^9SV 'J: )KBZM[50UQ/%"K' ,CA<
M_G3(=1LKF3RX+RWE?&=J2!C^0-%M#)@RW.#*_)4<A!V4?X]ZL!5!R% /TH%J
M<KXA\1WNF:N]I;)%Y8TZ:8.ZDXF"LR#Z81ZR[?Q7K6L306VG_9X;B6,R8DCS
MM=(E+1GGN[8SV K8UCP59ZQJ,]_+.Z7,@55D51E$",A4>QW$U%=>";4W$D]M
MJ,UG//(=S(%.0T81P >[!0<]0>:T3C8QDJE_(RCXVU!#>Q,(1=6\EV#&8VVJ
M$"[!NZ'!)SCK[5!>>,-:L=4&GO<0230S21#%L?\ 2V#1;%X/R9$A&>G K;_X
M133#%)9+J;9F>X95WJ6'F  X]=NW^>:9'X0M)IW=]8>>_E1WDD&P$LS1L'"C
MH!Y:@=J=XDN-3N4O[?UFX*BWU.%9);VXA*M9G$(C61@,Y&[.P9(Z5UMKJUN^
MEV5U=SP6[W,"2[7D"C)4$@9^M8LWA"YD5437)HUBN)9H,6Z$QB3?O7GK]\X)
MZ5T=M:16EG!:QC,<,:QINY. ,#^53)KH:04D]2'^V-,_Z"-I_P!_E_QH_MC3
M/^@C:?\ ?Y?\:M[$_N+^5&Q/[B_E4Z&FI4_MC3/^@C:?]_E_QH_MC3/^@C:?
M]_E_QJWL3^XOY4;$_N+^5&@:E-M8T_&(KN&>0_=CBD#,Q]  ::B.&,DH7SF'
MS;>@']T'VJ]L4=% /L*8T()S2*CIN5Z*E,!IIB84C2Z&45((F-/$ [T Y(@Z
MU8A! YIX11VIU,ARN9NIZ0FHS6UPMQ-;7-L6\N:+&0&&&!!!!!X_*J4?A'3H
MK;[.#*8OL3694D<JS;BW^]GFM^B@TCB*L8J,9:(@CMMEBMLTCOB,1EV^\W&,
MGWK%F\(VLEG:V\=W=0^1:FS+QD9DB/56R/;M70T4"A7J0=XNQ032;>/4+6[C
M+J;:W-O&@/R[25_7Y15^BB@B4Y2^)A11102%%%% !1110 4444 %%%% !111
M0 4444 %%%% !32>M./2H7/% FQ-R[B?:H?- <,1[4CG@U6<\$5:1C*0XW)#
M@\'!S5>2Z8ON!SSD9IK'K5<GGKVJTC"4V/DNF>0G)&:ADN7ED))()'KVJ,G)
M';VJ(-\^#ZG_ /55)&,IL?+=22R#)Y&1G/I44MS(^Q2?N< YIK<OR<'=5>9\
M-M[D_D*I(RE)CIKZ0HL74*>#FHVU*583"6+ MNZX.35:7EB,X/ %0RG);/''
M!J[(P<Y=QT,K/+/(QRS-UK*OD5KQF3>3GD=L^U:-K_J2?5C6;/F&^\V"8EBV
M&4C]*\6+NVSAQCO:_<FFA6WL5/EJ&;_6.>M9]O<.BR*C#:YP01P:V[C)@90H
M8XZ'I6((U\Q.!DL,#UYJHVZG%B%R3318:V6UMRTKA&Z*@YR:0>1=WD9@5U.<
MR(1\IJUJ#)Y2[T#_ #<<XJ.PV)+(R)L! RN<TUW8W!1J<BV_$AEB:.\D!D4,
M/NC=@8/:N@L602@D_,V-O/H>E<Z[FXO6R0H<\#KS6PS C [#@U<'RR39IAVD
MY-'06M[=M>?;'B00I)L5@<9[&K]KK:R:KY0N0R9"NK<8/M6/<>9;V44<%P7\
MI=Y!QAN_/I387CAT^&1[8QRS-YC2%1QSD9[@=*]-Q3/;IUYQMKYO^D=A%J,,
MMV;;#*^,@GH:N5P]C]L0C4'N R-)^[4KD[>1^M6M/UN.36&(9U7=L8-DACC_
M !K*5+L=E/&;*?7\C=U*Y^RS0/@ <LSGT'4?K4]MYEPWVB6/8/\ EDC#E1ZG
MT)].P_&LV*\34]16.1%$0.8\\Y*G/]*VE=6)"L"1UP>E>;A*LJKG/[-]/1:/
MY7N>E-)677K_ %Z#J***ZR K#\02QPW>B22R)&@ON6=@ /W4G<UN5'-;PW*;
M)X8Y4SG:ZAAG\::%)75CR?1=+.K^*;B..2&,1^9.9MFZ10M[*W[L]B<8)]":
MN:']G^WZ,R"(7GFV@!&/,\O[*^X>NWI[5Z8D$,1S'%&AQC*J!QUIJVMNDHE6
M")9 NT.$ ('IGTJW,Q5&Q-11169N%%%% !1110 4444 %%%% !1110 4444
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M$W;<DG'7MUJO]HUG_H'6?_@8W_QN@#2HK-^T:S_T#K/_ ,#&_P#C='VC6?\
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M?B+3;JU5M:GC2YC=Y')4C?DYR,=3[>U<88Z:8O:@/4[V+3HM;*WMIAH;AV8
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MZG@>E)$"6&2>_P"7:K QN ]<_I4W-$A O#\CZU+&N">.0,#Z4*%X4#CFIE0
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M2V2V<M]HM_M$9XQM&W(.#PPW+D>]:=<=X:\/WFC:I:I+&GEQVTH9X_N;F\D
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M6/VJ;FB152/VJPD=3+"/2IDBI7*2&)'5A4 IRJ!2U)204444#"BBB@ HHHH
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M_:91@&9TE@8DX!Z$EO?\:J)97$.GW5DK29E@:QD."V,32RDG\$?GWKVK8O\
M='ITHV+_ '1^5/VA/L/,\LOI?M-UXHN# QAOK9C&[X*OY#*@VC.1@,<U'J:6
MZW6JQ*L:WBW5^77'SB+[,-N1UV?=QVZ5ZMY:8 V+@>U-\B+S6E\I/,9=I?:,
MD>F?2CG&Z-^IYI;Z3)=7-B9?)CEFU6>WOHHX]J;%(E"J/3]TIY_OFJ_B"!I/
M'-^[[5@ @W.%^??]GFVJ#V4\@^O%>JE%ZX&?I33$I_A7\J.<3H:6/*U>SM;+
M0;B5[2>4V4"/;11XWC< K1MG_6HQ!9>X/-4;?2ULM,T#4+Z2#[+<V4B.NP)$
MI6W<1EL]7))Y]L"O7C:194^3'\IW*=@^4GC(]#2/;)(NQXT=,@[64$<<CBG[
M0GV!XY;VD^[9J;W*VDT#^<Z+N>&1;2+<<=\@@D?[)KHO#K))XB@$2V$92WE2
M0Q\I,XFY>#G #9S@=.17HGE#/09/?%,6UBC5%2*-53A J ;?IZ4.=QQHV96\
MOVICP_-G%7O+]J0Q9[5%S7E*/E4OE5<\JE\KVHN'*4_*IXBJV(O:G".BX^4J
MB*G>55D1BG;1Z4KCY2N(J>(JFHI7'8:$ IV,444#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &NB2HR2*KHPP589!
M%5?[)TW_ *!]I_WY7_"KE% %/^R=-_Z!]I_WY7_"C^R=-_Z!]I_WY7_"KE%
M%/\ LG3?^@?:?]^5_P */[)TW_H'VG_?E?\ "KE% %/^R=-_Z!]I_P!^5_PH
M_LG3?^@?:?\ ?E?\*N44 4_[)TW_ *!]I_WY7_"C^R=-_P"@?:?]^5_PJY10
M!3_LG3?^@?:?]^5_PH_LG3?^@?:?]^5_PJY10!3_ +)TW_H'VG_?E?\ "K@
M P.!110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form20-f_003.jpg
<TEXT>
begin 644 form20-f_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )# @(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS!0Z$\,N2/SH [BBL;_A*-,/B*ST-)'DO+NU-Y'L7*B(<;B>V>U;- !1110
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M<;/(?F)&V,JN">"<M@=J>_B[4OMDP&G6XLA?OIT<OGGS/-VY5BN.%SP><]Z
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M[[_KWD_]!-&E_P#()LO^N"?^@B@"W1110 4444 %%%% !1110 4444 %%%%
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MO_D$V7_7!/\ T$4 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3@#DF@16;]]J"+QMA7>?]X\#],_F*M53MW6*SDNY?E#YF;V7''Z 40:E!+#
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M48R>_O4$/^DW)N/^6<>4B]SW;^@_'UJW0 4444 %%%% !1110 4444 %%%%
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MZC-KK/:PM)%*5*R[ONGN6/ZT',=^JJB!% "J, #L*6FQJ4B16;<P4 GU-.H
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M_P#",:3_ ,\9O_ F3_XJC_A&-)_YXS?^!,G_ ,50!L45C_\ ",:3_P \9?\
MP)D_^*K/T30-.N](@FF29Y&W98W$G.&(_O4 =116/_PC&D_\\9O_  )D_P#B
MJ/\ A&-)_P">,W_@3)_\50!L45C_ /",:3_SQF_\"9/_ (JC_A&-)_YXS?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M32=*>T\-6FDZC.=0:.U6WGEE&?.^7#$@^OO6+I_PS\(:7>6UW9Z0L=Q:S>=
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MVO(VBBV;/,#97J<XV]: .MHKQGPYK&I:1I&J7L+D3-Y*)')*9 P>5A]H.XX
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M?T 5[BV,US:RA@!"Y8CURI']:I)9Z@)[F9VM6EDX1B"<*#PF.PZY/J<UJT4
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M/^_#_P"BQ0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5"/\
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M-6BR#O8MP6^[D#IGWKO*YS0%\,1W<4.A"!I$M-RF$E@L3-GD]B3SSSQ[5T=
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M !<_B0:TZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *KW\@BTZYD+L@2)FW*1D8!Y&>,U8K,\07
MZ:;HES<2V%S?1[=KV]LF]V4\'CT]: .5\"_8[?5)(;/3=3TY;BS6Y:.[D5EN
M"6 \W@D[SGGH.1Q7>UP/P_\ )N+J>[A1S&L AB-QJ(N)H4!XCV #8/KD\"N^
MH **** "LG3O^0]K/^_#_P"BQ6M63IW_ "'M9_WX?_18H UJ*** "BBB@ HI
M"0H))  Y)-5DU*QEE\N.\@9^FT2 F@"U1110 4444 %%%(S*BEG8*HY))P!0
M M%5I-1LHD+O=P@#_;!JJ5GU7AT>"Q/56XDF'H?[J_J?:@N,+ZO1"H?[4N5E
M_P"7*%LQ_P#39Q_%_NCMZGGL*DO])MM2>)KAI\Q'*>7,R 'UX/6KJJJ*%4 *
M!@ #@"@LJXW,!DX&3UH'[1IWCI8$4(BJ"2%&,DY-+1109A14=Q/':V\D\S;8
MXU+,?85E:-XDL]:FEAA22.1!N"R8^9?48H V:**1F5%+,P4#N3B@!:*XW7?&
M%Q8ZMY%FL+P1@%R>=^>>#VKI8C=7D*2%Q;QNH8*GS/@CU/ _*@"Q-<0VX!ED
M"YZ#N?H.]9.NB^U#1;F&SMY%++U8[689Y '7GWQ6K#:PP$LB?.>KL<L?Q-34
M <CX(T^^LTNFN8I(8GVA$<8)(SDXKKJ** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L;Q/+
M+'HQC@UB+29YI%BBNI4# ,>W/ )P>:V:ANK2WOK9[:[@CG@<8:.10RGZ@T <
M7X8L$\-ZF[ZI-IDEY?;8UODN7>>Y<GA2K?GP<5W59&G>%M"TFX^T6&DVL$W0
M2)&-P^A[5KT %5-1>1+95C<HTDB1[QU4$@$CWJW4<\$=S"T4H)1O0X(]"#V-
M &1<7(BT>]ANA/<J'>W&Q&=F!7C.WGOC->?Z:E]!J$4D<4OFVY!_>12R!&Q@
M;E4@GCIFO5K>WCM81'$#C))+$DDGJ23U-5;.TEAU74KAP/+G:,I@\\( <_C0
M!SEIXBU5+Z$7Q5[<YW+#ILRL>.V2:TKWQ-$ME,UM;WHF"_(9+1PN??BMQX5>
M:.4YW1Y YXYHGA6X@>%\[7&#CK0!RG_"4:I_T#F_\!9?\*7_ (2C4_\ H'/_
M . LM==107S^2^XY ^)]38;?[.?GCFUEKF-.AOK'64G%M+YL69"#"QR#D= ,
MX->K516UE&N279 \IK98P<\[@S'^HH$Y7Z'/?\)/JG_/@P_[=)J3_A)M5/\
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MM6MQ.VFR730+;@&TE#HH1NYQN(P>>/I5^?Q%K%I?2:7>ZW;VL<5V\;:G);*
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LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form20-f_004.jpg
<TEXT>
begin 644 form20-f_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #M 5,# 2(  A$! Q$!_\0
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M=?+;^5<#\*X_#"Z#8/I_V#^V3;?Z3Y3 R_>YW#KUQ0!Z)1110 4444 %%%%
M!1110 44A( ))  ZDU7LM1LM2MOM-C=0W$&XKYD3AER.HR* +-%9FH>(M%TF
M98=0U2TMI67<J2RA6(]0*YG5/BCI%E;XM[/4YKN5O+MX38R+YK^Q(Y '/T%
M'<T5P-AX^U>XN18?\(O=75ZL N'>!UCC9"2 0)"&'((P>>*TO^$H\0?]"3J'
M_@5#_P#%4 =917)_\)1X@_Z$G4/_  *A_P#BJ/\ A*/$'_0DZA_X%0__ !5
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M<T =G7FFJW-R-5O&O[F[@\11RD:-;6Y)CDC_ (<#HV?X\_=[5O\ _"4>(/\
MH2=0_P# J'_XJFGQ+KQ8,? ]^6'0_:8<C_QZ@#J+,W#64#7:(ER8U,JQG*A\
M<@'TSFIJYJR\1:W<WL,,_A*]MHG8*\SW$1"#U(!R:Z6@ HHHH **** "BBB@
M HI#G!QU[9KSK3D\0VOQ7A36=76ZCFT^:2*WMT*11@.N.">3SU-1*:BTGU_R
M;_0'M<]&HKQS1X;O3;_^UO$VB:FBOJ3+'=MJ#_+ER(_W.?N]*747O'TO6/&"
MZC>)J-CK!@@42$1"$.J;"GW3PQYQFGS)-)]?^!_F3SQN[;*_W:Z_A_F>N7?_
M !Y3_P#7-OY5Q_PS?23X/TI;9K(WPMOWHB*>9U/WL<_G76RN9=,DD (+PDX]
M,BO-? /B/P1H_A?3GDO--M=2\C9<.$VR$Y.0Q R:IZ#BU))KJ>IT4R&6.>%)
MHF#QR*&5AT(/(-/H&%%%% !1110 44U)$D!*.K8.#M.<'TK!\2ZO<V\::7I!
M636;K B3&?+3/S2-Z #.,]3@4 9WC._COT30+"9YM2:1)'M(@=LL8^\DC]$4
M]SG/M6#X9\.7_B6\N=2U816&CRKY?]DV9"K*R\?O&0X8+V(P3WKI-4\-36WA
M=K#1G8RF59;K<^)+Q?XU+]0S=,]NE0>%[.1M:EU#3]/FTC1S#Y;64T>PRR@_
M?"?P@#(S_%G- &U8>%-!TR$Q6NE6RJ6W?.OF'/U;)K,\>V%QJ.AQP".1K#S0
MU]]GXG6(=XCV(.,^V:ZNB@#@OAWI46G37KZ2US+H4RJT-Q?$F>67HQ!(!\O
M  /?-=[110!RWB[Q'>:/=Z786D<49U%WC:^GR8[7 !#,.^<]R![U;\+ZO=:I
M;3QW025[:3ROMD(Q#<_[2?U[>A-5_%]G=SBRN/)>]TRW=FO=/C&6G7'!'][:
M>=O\5'A"SNK<7MP87L],N'5[+3Y!AH%QR3_=W'G;_#0!TU<;XU=4N[+^V';_
M (1IE*W*1$[FE_AW <E,9X7G..U=E7.:_I5\=6L]=TZ);RXM(VC%E,^U'#'[
MRD\*X]3VR* $\%O>2:3*\LC/8&4_V>9&W2^1VWGUSG'?&,\UTE8?AG1I])MK
MJ2Y=?/O9S<201?ZJ D#Y4'IQD^I)-;E %#5=&T[6[9;?4K1+B)6#*&R,'V(Y
MJ['&D,2QQ(J1H,*JC  ] *=10 4444 %%%% $<EO#,\;RPQN\9W(S*"5/J/2
MI*** "BBB@ HHHH **** "BBL76O%N@>'65-5U6WMY6^[$6W2'Z(N6/Y4 ;5
M%<C;_$[P?<7"P-JXMG<X7[9!);J?^!.H'ZUUB.DL:R1LKHPRK*<@CU!H =6)
M-X;BF\70^(?M4PEBM6MO)_A(8@Y]CQ6W12<4[-]/^&#I8X]?!5[+-#%?^([N
M]TV&X%PEK-$N[<&W*#)U(![5!=?#F&YU6XD_M>[32;JZ%Y<:8 "CRCG(;J 2
M 2!Z5V]%-:*W]?UH#=Y<W4ANQ_H4X'_/-OY5POPRU?3+_P +Z;IJ6LWVF"VS
M(\EHRH<$CAR,'\#7=7?-E/\ ]<V_E7%_#'5YKGPKIE@^DW\"0VW%U*BB*3!_
MA.<_I0!W0    P!VHHHH **** "LKQ'#J=QH-U%H\JQ7K*-K'J1GY@#V)&0#
MV)%:M% 'F5I?PZ%(^JZ/IUY9Z;;Q,E]:SJ5>[N3PJQ@]9,]6'WO>NP\,Z/+I
MT%Q>7T@EU&^D,T[X^X#]V,$\[5Z"LZY'_"2>-8K3&_3=%(EF[K)<GE%/<%!A
M@?\ :KKJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KF-8M/$%MJ[7?AS2] 8SH/M%Q>,\<SL.,913D  =3
M73UR^MC5[[7_ +!H_B>'398K59I;9]/$Y*EF ?<6']TC'M[T 5(]9UR'4K/2
MO%VBZ8;34G,$,]G,98_,VE@CHZ@\A6P1D9'O776UM!9VT=M;0QPP1*$CCC4*
MJ@=  .@KCM!T*ZUFYTS7]3\4G6[:WS-8QPVBV\0<@KYA )+$ L!GIFNVH **
M*A:ZMUNEM6GC%PREUB+#<5'4X]* )J*I+K&FOJ;::E_;-?*,M;B4>8!U^[UH
M?6--CU--->_MEOG&5MS*!(1[+UH GN^;*?\ ZYM_*N*^&&MQW?A73-.6QU"-
MH+;F>6W*Q/AC]UN]=K=_\>4__7-OY5Q7PPU*^G\+:99S:-<6]M%;?)=O(A27
MGL <C\: .[HHHH **** "L/QAJ5[I/A:]O=/$)NXU'EK*^T,20, _P![GCWQ
M6Y7(^+_^)KJNC^'$Q(EQ+]IO(NA\B,Y# ]L/LZ<T 8'P\BN+.\BCL+N6_CG$
MDVM3S@Y2<_=&>\@X5AT  KTVD5%3.U0,G)P.II: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/%\']G>(
MX=93QE8Z!+=6RV>R[@202A79@1N88^_S^%=W7">)M&U>7Q>VJ6?A_3]:MI--
M%F4N[H1^4=[,V 5;(8%<_2@"EX>AG\*ZMI/AJ;QW:700%(],73U\UUVD\LK$
MJ.^2*](KSGX?Z/K_ (8MK/3)_"NG6\>,7>HQWX>64X/S$;,MS@8)X_"O1@<]
M* $(R",XSW%>::?H%OH?Q@B>.\N[RYN=,FDDDNI=[9WK@#T%>F50?1=/?6X]
M9:W7[?'$85FR<["<D?I6=2#DU9VM?\FO\@Z-'D5O!:KX/T34X4B.L?\ "1%?
M.!S(Q,S!E)ZD8P,'M3]3@LW\(>(]2D6+^UH?$)V39_>HWFH H/4#!/%>D0^!
M_#MOKS:U%IR+>%S)D,=@<C!<)G:&]\9HF\#^'KC7_P"VY-.0WI<2,=Q",X&
MS)G:6&>I%4H[:O\ KE_'3R_,5M;WZ?=OM]YL2EFTR0R##F$[O8XYKSSP3?\
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M* "D*JV-P!P<C(Z&EHH :D:1@A$5022=HQDGJ:=110 4@55SM &3DX'>EHH
2**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>form20-f_005.jpg
<TEXT>
begin 644 form20-f_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $* 84# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH'_@7-_\;H\WQK_SYZ!_X%S?_&Z .CHKG/-\:_\ /GH'_@7-_P#&Z/-\:_\
M/GH'_@7-_P#&Z .CHKG/-\:_\^>@?^!<W_QNCS?&O_/GH'_@7-_\;H Z.BN<
M\WQK_P ^>@?^!<W_ ,;H\WQK_P ^>@?^!<W_ ,;H Z.BN<\WQK_SYZ!_X%S?
M_&Z/-\:_\^>@?^!<W_QN@#HZ*YSS?&O_ #YZ!_X%S?\ QNCS?&O_ #YZ!_X%
MS?\ QN@#HZ*YSS?&O_/GH'_@7-_\;H\WQK_SYZ!_X%S?_&Z .CHKG/-\:_\
M/GH'_@7-_P#&Z/-\:_\ /GH'_@7-_P#&Z .CHKG/-\:_\^>@?^!<W_QNCS?&
MO_/GH'_@7-_\;H Z.BN<\WQK_P ^>@?^!<W_ ,;H\WQK_P ^>@?^!<W_ ,;H
M Z.BN<\WQK_SYZ!_X%S?_&Z/-\:_\^>@?^!<W_QN@#HZ*Q?#6KW>KV=V;ZWA
M@N;2[DM9! Y="4QR"0#W]*VJ "BBB@ HHHH **** "BLO4M0NK615C6SB1F"
M++=S[0['^%0 23^56K"XFN8-\T,:'^%HI1(CCLRGCCZB@"U1110!A7O_ ".^
MC?\ 7C>?^A05NUA7O_([Z-_UXWG_ *%!6[0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% ',W'B2XM)G@EB626WF99U13DJS
M!8<=<;MX.>?NMQ4$GB^:-;F9[-E@6,;3N&Y'VR$C!ZC]WUXZ_EU#VMO)YOF0
M1-YJA9-R [P.@/J.3^=,^P6?E^7]D@\O &WRQC ! &/H3^= '/7WBTVT<5PM
MOBV\YU8[@7=463=A>JG<@P>1CTJ^/$ _LI[M[8QR+.(/*=L98XZ'&3P?3/M5
MJ_M+>.TNKB*"!)]AD\SRE))"GKZ\9'T)J:+3[5;%;4VT!AX)3RE"D^NW&* .
M?M_&'G)),+;=%Y0G"EPI2,(I;D_>;+<#BGCQBI"@:?+OE;;  V=X#NI)P"5_
MU9/0]16]_9UCM1?L=OM1@RCREPI'0CC@TKV%G)&8WM(&1A@JT8(/.?Y\_6@!
M;*Y6]L8+I49%FC5PK=1D9P:GI%544*H"J!@ #  I: "BBB@ HHHH **** .9
M\&]-?_[#-S_[+735S/@WIK__ &&;G_V6NFH **** "BBB@ HHHH Y7Q;+M>W
M:4_9A&X,,YEC^8Y5B-K#U5?\FMS11$-&M/():,Q J2P;.><Y''Y50\1&$/:_
M:)3;HPD7[1O*A#@%1T/)8*1G'W?PJ[H8(T2SW(ZL8@2'/.?7H.O7H* *^I3:
MM%/<"S0R)Y2%,(/E.6W=?O' '';-53=:SYORI-C?T,0QNW?=SC[FWG=Z]^U=
M%10!A7O_ ".^C?\ 7C>?^A05NUA7O_([Z-_UXWG_ *%!6[0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16)>^+-*L+Z:S
MF>X,T) <1V[N 2 <9 QT(J#_ (3;1O6\_P# 23_XF@#9U'_D&7?_ %Q?_P!!
M-6%^Z/I7,W7C#2;BSGA0W6]XV5=UK(!D@]R*E_X331E^4M=''&1:2$?^@T =
M%17._P#";:-_>N__  $D_P#B:MZ;XETS5;S[);/-YVPR!9('3(! ."0/44 :
M]%%% !1110 4444 %%%% ',^#>FO_P#89N?_ &6NFKF?!O37_P#L,W/_ ++7
M34 %%%% !1110 4444 96LZ=/J)MXXKH1)EA*A+#>AQG&".<#'? 8]ZN:?;R
M6EA!!+)YCQH%9N>?IGG'UK'\5,ACM8FB=RS$YBB1I%' RK,P"\L.>>M7M"5Q
MIR2&YN9HY &1;DAI(^.0S#J<YH TZ*QM3O;VVGF5&V1;(_*98"_SDL"">F.!
MD]A[D55_M+5MX&PGYQD" XW;L>7GTV_-NH FO?\ D=]&_P"O&\_]"@K=K"O?
M^1WT;_KQO/\ T*"MV@ HHHH **** "BBB@ HHHH S=<N9[6QC-O,L$DEQ%%Y
MC*&VAG )P>.AK .LZK)?+9QW)D$;2JT]O%%^]VE,'YV &-Q!QGD?A76S00W,
M1BGB26,]4=0P/X&JT]CI@@07%K:"*+A!)&NU,]AGI0!C6VJWO]I)OO(IHYK^
M6U%J(P&15W88$'/&WG/K7357BL[..8W,-O LKCF5$ 9A]1UJQ0 4444 %%%%
M !1110 4444 %%%% 'F6M?\ (S:M_P!=T_\ 14=4ZMZU_P C/J__ %W7_P!%
M1U4H **** "M;PI_R-</_7K-_P"A1UDUK>%/^1JA_P"O6;_T*.@#T.BBB@ H
MHHH **** "BBB@#F?!O37_\ L,W/_LM=-7,^#>FO_P#89N?YK734 %%%% !1
M110 4444 <WXBNE:98XDBG:#"2PR6YD#&7Y5 ((PW7OT/TK7TAXI-'M&A6-8
MS$NU8E*J!CH >1]*IW]FT-Z]Q;ZK%9-<XWI+&KAF P&7)&&Q@=QP.*TK.UCL
M;.&UB+%(E"@L<D^Y]Z )Z*** ,*]_P"1WT;_ *\;S_T*"MVL*]_Y'?1O^O&\
M_P#0H*W: "BBB@ HHHH **** "BBN#O+J_EU._QJ=[&J7#(J1NH55 & .* .
M\JGJJAM+N R@C9T(S7%>;?\ _07U'_OZO_Q-([7DB%'U74&4C!!E'/\ X[0!
MZ$  ,#@45Y]YM]_T%]0_[^K_ /$T>;??]!?4?^_J_P#Q- 'H-%<CX;N;PZ[+
M;S7UQ<1&U\S;,P.&WXR, =JZZ@ HHHH **** "BBB@ HHHH \QUK_D9]7_Z[
MI_Z*2JE6]:_Y&?5O^NZ_^BHZJ4 %%%% !6MX4_Y&N'_KUF_]"CK)K6\*?\C5
M#_UZS?\ H4= 'H=%%% !1110 4444 %%%% ',^#>FO\ _89N?_9:Z:N9\&]-
M?_[#-S_[+734 %%%% !1110 4444 <EJKI::OJ$]Y8Z?>1N(@IGF&^-"-H7;
ML;@MNZ=<UNZ$K)H5DK.K_NEPR/O&.V#W&,5BZO.UAJ\YMUBN6E\N>2-X97,#
M*,*^44\8'0XZ$CK6[I$,4&D6D<$PGC$8*RKT?/.1[&@"IJ6J7-G=2QJL*QK&
MC+(^3R=^0>G4J /<_A5-/$%V_EYAB!8C*8.0Q;'E=?O@<Y_2NDHH PKW_D=]
M&_Z\;S_T*"MVL*]_Y'?1O^O&\_\ 0H*W: "BBB@ HHHH **** "N F_Y"6H_
M]?;_ -*[^N F_P"0EJ/_ %]R?TH 2DHHH *6DHH O^&_^1ED_P"O+_V<5V5<
M;X<_Y&63_KR_]J5U-WJ%G8!/M=S'#YA(3>V-V!DXH LT4V.1)HEEB=7C<!E9
M3D$'N#3'N(8V*O(JD=03[9_E0!+1110 444U'21=R,K+TRIR* '44Q)8Y&=4
M=6:-MK@'[IP#@_@0?QI] 'F.M?\ (SZM_P!=U_\ 14=5*N:U_P C/JW_ %W7
M_P!%1U3H **** "M;PI_R-</_7K-_P"A1UDUK>%/^1KA_P"O6;_T*.@#T.BB
MB@ HHHH **** "BBB@#F?!O37_\ L,W/\UKIJYGP;TU__L,W/\UKIJ "BBB@
M HHHH **** .<U&6ZTW4[B:U?RDN=A=I;229=P&,J8SD' '!].#6GHH6/3(H
M8X[A8XE"J\Z;&D]6V]1SZ@4S6+J\MA!]A4R3L3B'R=X<>[9&S'J?7H:FTR]G
MO8&:XM#;R+@';()$;(SE6'7TZ=10!=HK.UK4)=-LA-"B.Q<+\YP ,$^H]/7\
M^E9T7B&XDN(T\F+:Y![Y&6"^7_O@'<?;MWH EO?^1WT;_KQO/_0H*W:PKW_D
M=]&_Z\;S_P!"@K=H **** "BBB@ HHHH *X";_D):C_U]O\ TKOZX"?_ )"6
MH_\ 7V_]* &TM)2T %%)2T 7O#?_ ",LG_7E_P"SBMW5-)?4;^PG%R\*6QD+
M>6VUCN7'!K"\-_\ (RR?]>7_ +.*[*@#EYO"\X,D=K,L4/W4(E<,(]@41^F,
MC=GGZ=::?#%\T<9DNXFEBR(V 8>6-A7(]^GI^%=52-G:=O7'% '+7GAF\F8A
M-1./,?RT,A&$P=G//*DMS[CGBKNH:1=7=T9(KM01 L2.S,&@?YLNH4C).1U_
MNBLS3[*X*1R3Z:UY)(D/ER.X7[.Z_P"L#'.X'?N;*@YSBH/[.O+6/4&6SDB+
MHPC=]A<S&0%-KJ<N,\Y< CCWH T%\,W!#DSI'@$PQI(Y6)OW?S D_P"PQ_'Z
MTD?A66$';)$R!P1%N=59-\C%3CIG>I^J^E=110!F:)IL^F6TL=Q.)I)'5BPS
MV15QSR?NUIT44 >9:U_R,VK?]=T_]%1U3JYK7_(S:O\ ]=T_]%1U3H ****
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M8^7]IM8#)'YB[ESD=10!T%%?*O\ PT'XV]-,_P# 8_\ Q5'_  T'XV]-,_\
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M(?\ KT/\Q0!\7T444 %%%% !7VK\-?\ DFGAS_KPB_E7Q57VK\-?^2:>'/\
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M^SUV5 ',^/\ _D3;O_KI#_Z-6O)*];\?_P#(FW?_ %TA_P#1JUY)0 4M%)0
M4V3_ %3_ .Z?Y4^F2?ZI_P#=/\J /<?#_P#R+6E?]></_H K2K-\/_\ (M:5
M_P!></\ Z *TJ /,=:_Y&;5_^NZ_^BHZJ5;UK_D9M7_Z[K_Z*CJI0 E+110
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MSG_ZYM_(U] VO_'I#_US7^5 $M<!-_R$M1_Z^W_I7?UP$W_(2U'_ *^W_I0
MVBBB@ HHHH O^'/^1FD_Z\C_ .C*[*N-\.?\C-)_UY'_ -&5V5 ',^/_ /D3
M;O\ ZZ0_^C5KR2O6_'__ ")MW_UTA_\ 1JUY)0 M)110 M,D_P!4_P#NG^5.
MILO^J?\ W3_*@#W+P_\ \BUI7_7G#_Z *T:SO#__ "+6E?\ 7G%_Z *T: /,
M=:_Y&?5O^NZ_^BHZJ5<UK_D9]6_Z[K_Z*CJG0 44E+0 5K>%/^1KA_Z]9O\
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M/[I/>JO]I6'_ #_VG_?]?\: +-+57^TK#_G_ +3_ +_K_C1_:5A_S_VG_?\
M7_&@"U6MX4_Y&N'_ *]9O_0HZY_^TM/_ .?^T_[_ *_XUI^&=7TN#Q/#)+J5
MDB?991N:X0#.Z/CK0!ZA7(?%/_DE_B'_ *]#_,5M_P#"2:%_T&M._P# I/\
M&N4^)NO:/<_#77X8-6L997M2%1+E&9CD<  \T ?']%%% !1110 5]J_#7_DF
MGAS_ *\(OY5\55]B_#O7M&M_AUX?AFU:PCE2QC#(]R@*G'0C/% &IX-Z:_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form20-f_006.jpg
<TEXT>
begin 644 form20-f_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E 0X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0I8[2UL9].LRMY?"4_:F=1N2-U^56'^UU/UH ]?HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KEH/ASX2MM9_M:#18
M8[O>9 59@@<_Q!,[0>>N*ZFB@#E=*^&_A+1=0AOK'2$2Y@),+/+)((R>ZAF(
M!]P*UM0\/:7JE[I]W=VJO-I\IFMR"5V.1C.!U_&M2B@"K%IUG!J%Q?Q6\:W=
MPJI-,!\SA<[03[9/YU%JNC66LI;)?1&1;:X2YB 8KB1/NGCKUZ5?HH S];T7
M3_$.D3Z7J< GM)P Z9(/!R"".000#FN>;X9^'6LX(2+_ ,^WG,\5[]MD^T(Y
M4*2),YQA0,=.*[&B@#EY/ .B3) LWVR5H;.>R5Y;IW<QS9WY8DDGGKVJ _#C
M0VFL2TVHM;V0A\NS-XY@)B ",R="1@?7O77T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !37=8T+NP50,DDX %.KG/'<!N
MO"-W;B%Y_->)?*6)I!)^\7Y65?F*GHV.<9H W;>[MKO?]FN(IMAVOY;AMIQG
M!QT."/SJ:N-^'&B-HNC7B!-,2">Y,D T\':4"JN6R =Q()(/3.*O>)IM7;]U
M9:G;:)9(F^XU.X17QDX"(&(4'N6;U& <\ '1G.TX&3V%<YX?U/69YM9M]46T
MN)+*11')9*RJQ*!C'AB?F7(&>^1P*C\):E?WBW=M<:K9ZS! VV+4[10H8X!*
M.H)7< 5.5X(/0$5/I7AN[TJ!HAX@OIPTCR$RQQ9)8'/1!GYCNR><@#IQ0!6T
MCQA8C2(KC6]6LK:XDD=?+E7[.R%2 R%78G*GJ>AXKIXI8YHDEB=7C=0RLIR&
M!Z$&L34=%L8]"OFN((;F;RI96FFB4DN4Y;IQT'3TJ7PB-O@S0Q_TX0?^BQ0!
MLT444 %%-D<1Q/(0Q"@G"C)./05YY_PN;P_NVG3]9!]#;+_\50!Z+17G/_"Z
MO#0SFTU88];8?_%4+\:O"[?\L-4'UMA_\50!UWB3Q':>&-,%[=I*ZLVQ%1>"
MV"0"W11QU.!5O2=4MM:TV*_L_,\B7.PRQM&W!(^ZP!'2O.M5^*?@;6+06VIV
M>H3P+(LGEO;G!9>03AN?H>*GM/C#X+L+.&T@&H1P0HL<:F MA0, 9))Z4 >E
MT5YX/C5X.)P9[P?6V-.7XT>#6_Y>[D?6V:@#T&BN/T7XF^&-?U>#2]/NII+J
M;=L4P,!P"3DXXX%=A0 4444 %%<V?'?AT:S/I;:@BW$"N7)'RY3<77/]Y0A)
M]L5;T/Q7HWB*2>/3+Q)I(>64==I) <?[)P<&@#9HHHH **** "BBB@ HHHH
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M:?;#TB3^0K@/%/A1[3P!>E-7U*V2TLY]MI#/B(H2S*C @Y !"]>@KT&S&+*
M>D:_RH FHHJG?ZOINEA#J%_;6GF9">?*J;L>F3S0!<HK&_X2WPY_T'],_P#
MM/\ &E'BOPZ?^8]IG_@6G^- &Q14-K=VU];K<6EQ%<0M]V2)PRG\14U !111
M0!\]7IW>/O%[#'_'\H_):1N,$GO3;C!\<^+CR?\ B8D'CV-/<G8H[Y&*3W 1
MB X_K4NX$%N,>M0LA8Y/<4X)A?;O0 ]F^4C/-3^&U)^*'AG/)S<GZ?NS5; (
MS@#U-6_"J@_%/P[CDB*Z/_CE 'O-%%%, HHHH **** "BBB@ HHHH **** "
MN(^),MK/H"P-]@G:"\@>:"\NQ!$%.['F'^Z<'COCVKMZR=9LM#FB1M8@LS&\
MT>#< 8>09V Y^\1DX!H R/ART+^%,P6NGVT?VJ8"/3I?-@'SGE&[Y]?7-9?Q
M&TW2[6*WU673]*5YKN);R]O+1)3Y8XVY8$+D#&>PSWKK?#YT9](CFT 6W]G3
M,TD9MAB,DD[B .G.:S/%%T66UE@2^O(+&[#7UKIV&E;Y"55DZLN64E>X(/:@
M!_@62UF\*PS6-C'9V<D\[6\<2%%:/S6VN%/0,,-CWKI*YWP;/<MH,-MJ&8[Y
M TK6LC[I((G=C$K^X0 ?A714 <]X\_Y$/7/^O.3^5;MN,6\0]$'\JPO'8SX$
MUL>MH_\ *MZ+B)!_LB@#%N?&GAFTNI;:XUW3XIXF*21O.H*L.H(]:P=<O?AM
MXEFADU?4-)NY(5*QE[K&T'&1P1Z"O-(](TW4M>\337EI',ZZO<*I8D8&<XX/
MO4P\+:$Q!.F19'^T_P#C0!I>-])^&]MX*U2;0FTTZFD(-N(;LN^[<.B[CGC-
M:^F>'?A7+I5G)<OI7VAH$,NZ_(.[:,Y&_CFN5?PKH'ED_P!G(#USN?\ QI$\
M):"5'_$M0D]_,?\ QHN!ZKH-WX'\-V;VND:GI5M!(YD91>JV6P!GECV K=L]
M>TC49_(LM4LKF;!;RX9U=L>N :\+;PCH(8_\2]>G&)'_ ,:M>%-+LM)^+'AV
M.QM_)66WN6?YRV2$..M 'O5%%% 'SO*?^*W\7 _]!-L?D:>P&Y0,CZU%(V?%
MOBU^<?VJXI[2?.M+J(5CSGT-2Y''7D5!R0>._7\:FYR .>*!B./ER.F*N^$Q
MGXJ>'N>1;W9_\=%4LX3&,FM#P@=WQ6T3(Y6TNCG\!0![G1113 *AN+RVM%5K
MFXAA5C@&5PN3^-8%S\0/"=G=36MSKUG'/"YCD1GY5@<$&N9\3:G\,_&!MCJV
MNVDGV?<(]MR4QG&?Y"@#OO[7TS_H(VG_ '_7_&E_M73C_P O]K_W^7_&O"?%
MFA?"^S\*ZE<Z-J=O-J4<):WC%YO+/G@;>_TJUI'A?X3W&CV,U[K4$=[);HTR
M?;PN'*C<,=N<\4 >ZQ313H'AD21#_$C C]*?7 >%M1\ >$K&6RTKQ'9"&67S
M2);U6PV ./3I74V/BC0=3NDMK'6;&YG<$K%#.K,<<G@&@#6HHHH **** "O/
M_'NM6=PSZ&]KXA,T061I],L//4*ZLI7/3)4L/;K7H%>?>/+%[6[34VUSQ%&;
MEX[>&QTNX6)1@$L[$@\ 9)/MCO0!N^!7BD\,QO##/"AFEQ'<0>2ZX<@ ID[<
M  ?AFG:]X4CU:Z^VVFJW^D7Q4))<6,@4RJ.@<$$-C)P<9&:F\)VR6>B&V2_N
M;[RKF=&GNCF5F$C ACW(((S[5B_$&UCO9M!MGTB;5RUV["R641QOB)LEV) X
MZ@=S0!OZ#IEAH^G2"TN);HN[/<7<TGFR32#@EF[D8Q@=,8 J6WU_3;K04UN*
MY!T]T\Q964C(SCH1G.>,8S5+PA"++PI;Q#3#IPB:8"Q63S?*_>-\H;O_ /7K
MG+33K]_A[IFE'3[N*ZMQ'=.C( #Y4X8Q]?O$9('>@#9\9W<-[\.=5N;=P\4E
MJQ5L>^.G8^U=/'_JU^@KR_Q/H>M1^!KRZ;69;.UV/++IOV="&WS%\%NH.& .
M.F*]17A1]* /!-*?_B;>)#CKK%P?UK1'!)(['O65HAW7FO\ J=6N3U_VJTB0
M">N :3W DVD1]3C'K2*^W'7I2;PL??;CUHR&P<=* %QE21S[4S1%S\7_  UU
M&+.Y)_[Y-*N#O_$4WP^"WQAT#/;3[C^M 'M]%%%,#YV W>)O%3>NJRTYP$=1
M3%X\0^)^^=6F/ZT$9(^;GU-)[@2$Y YR/_KTXM@J0#@@<YJ-<$\$4_' Y!H
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M=RI-X#OY(G5XW$6UE.009%Z&NHKS+Q1%XG7P="A71X-)6.U2:)(W67/F("4
M^51G&!Z5Z;0!\]^'3FWU)B>6U.Z/7K\];!RIR..*Q?#'_'A>,>AU&Z_]#-:Y
M.&!7FEU$2-R@YQWI=V5.#]:;_=ST]*02 @D#ISQ2 7D;CGCTIOA<9^,VF 9P
MNES'G_>H;)&3T-.\*<_&6PY_YA$O'_ Z:&>V#I1113 ^;=-^>^UT\X.J7'_H
M576SOX&.>]4-)?==:V1G_D*7/3_?J\[#()).?:D]Q  0>?7M3F))S[4BX#
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MUIUJVZT;&3F60\_[QH8$JN5!H$-QN(&.V>:.N?4BE$?W1ST]<TQA@'YSP.U
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M.V01@@XQ6[I=@VFV0MWNYKM]Q8RRJBDY]D4 #\* +M%%% ".RHA=B%51DD]
M*Y*S^(6G7<MC)]@U&'3;^?[/::C+$HAFD/"C[VX!B,*2H!KJ+NV6\LI[5R0D
MT;1L1U (Q_6O/;+PGXCETG0?#6H1V,>FZ/<03-?13%GN4A.8U$>WY"<+N))Z
M''6@#IM/\9Z;J=];65K'<R7,[S@QA!^Z2)V1I'Y^52RX'<YZ=<6=7\3Z?HVI
M:?I]RMPT]_,L,7EPEE4L2 6;H!D'OGVKDM!\$ZQHMY--#<")-5EG&I"&;#Q_
MO'>&:)B#\P5@K+TYSU'.AXDTC6FBT*TTZU?4X]/O8[V2XN[Q5D?86^4_+R?F
M'/M0!HR^.-,BU<V)AO#$MVMB]Z(OW"7#8Q&6SG.2!G& 2!FKND^)=/UK4]0L
M+/SS)8[/-9XBBMNW8VD]1E6YZ<=ZY)_#&O/-<:1]E@_LZYUQ=5:^\X96/S%E
M,>S&2^Y=N>F#G/:M?1+;6H_&^LW]YI(@L[Z.%(Y1<HY7RMPY4<_-NS[8H ZZ
MBBB@ HHHH **** "BBB@ HHHH **** .(U7X@&P\3S:3;Z7+=):S00W+IO+Y
MEP0455((4$$[F7C.,XJ"Y^)D5G:-)-IKF:WBN7O84ER83%*(E7..=[L,=.,F
MNFN/#&FSZP=5 N8+M]GG-;W+Q+/L^[YBJ0&QTY[<=*SX/!5@]]XDGU".*X36
MY$\R,*5"QJ@ &<YSG+9&.2/2@";PKXFD\1+>K-9^1+:R*I>,NT4@89!5F52<
M<@C'!'O7150TO2H]*A>..YO+C>VXM=W+S,.,8!8G J_0 4444 %%%% !7%:O
MXUN=-\76NF11VUQ:R7D%G,$27S(FE7(+/CRP>AVYR0<UVM8\_A70[G5QJLVG
MQO>B1)1*2WWU&%?&<;@.,XSCB@#@_#OBW6T\/QVUG'!>74$%Y?W$M_.PW1K<
MR(J*1DY^4\G@ "M2X^(5[YC7%IIL#:=##83S&68K*5NCM 48QE>O)YKH+CP1
MX<N;>&"33$$4*R*JH[IE9&WNIP1N5FY*G(JU<>&=&NC=&6PC/VH0B;!(W"$Y
MC'!XVGTH Y[3/'-YJ7B@6,6D2-IS74]I]H1)2T9BW#>Y*;-I92  V1D9]*[>
MLFW\-Z9::K)J5O#+%/)(TKJMQ((R[<,WE[MNX^N/>M:@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form20-f_007.jpg
<TEXT>
begin 644 form20-f_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $) 1@# 2(  A$! Q$!_\0
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MK7'"J.I/%+;^/_'UU;Q7$'@$O#*@>-Q<<,I&0?RH N?\(!XN'_-1=0/UA_\
MLJ/^$!\7X_Y*)?Y]?(_^RK5\)^(O%>KZG+#K?A;^RK5(MRSF;=E\C"X^F?RK
MLJ /./\ A /%^,?\+%U#_OQ_]E0/ /B\=?B)?G_MA_\ 95Z/10!YLWP_\9$_
M+\1[\#_KW_\ LJ>/ 7C$?\U#O3_V[_\ V5>C44 >=?\ "">,?^BA7G_@/_\
M95J^'/"OB'2=5%WJGC"[U.!4*BV:(*I)[DY/3VKL** "BBB@ HHHH **** .
M)UOXJ>&= UBXTN]DN_M-N0)!';E@"0#U_&LX_&SP<P(+WY!X(-HU>8>-R/\
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M[FD"Y.><T.6QD'!Z&FEV0G)SQ0(,97OUJ3[RJ#D >M0[CL![$T\'*KD#&>E
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M80"P//:CYLKC)Z\T,F7S^M+@GMT]#3$1\@9QWZ5,K$JH[5&& P,=.*>,DC
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M:,*$!]C0IX&!C/- #UY)QC@54U;']B:D#WMI/_035H$9R>IXJGK/.AZH,?\
M+M)S_P !- (].^'@Q\._#X_Z<8_Y5TU<U\/?^2>>'_\ KQB_]!KI:; CN/\
MCVE_W#_*OF?PRRC0(?FY\V3_ -#-?2]U_P >DW_7-OY5\R^&0IT"#@ ^9(?_
M !XT@-DC,G7BEQVS]<TN<-D 4C $_*,9H %P2,<\4$?,OUH7 *Y]Z<?OX YS
M0!-&N'Z8KLO@UG^S?$!)_P"8K(/_ !U:XV-@LF203TQ79?!GG2M>;UU63_T%
M:$!Z72'H:6D/2F!\S>,&W?$?Q(O_ $\K_P"@"L4@\9QZYK7\79_X63XFSVNE
MQ[_(*R3\R],8H!@1T^8X-([<8W>N*>S'Y<#-!"MGUH$0Y!P1Q]:DC7D#/'KW
MHVCA< ]Z$&<':,4 =M\'"/\ A95Z!G_D%'_T8M>^UX'\'4Q\2;YL_P#,*QCT
M_>+7OE PHHHH **** /-_'^B>'7GDNVT^PO=:O98;8B\O&BCA'9W"L"% ';D
M\"MSX?6=GI^@W%K9VUO;^7=NLR6UPTT)DPN61FYVD8.#T.1VK,^(/A;P]/;M
MJM]9V,,T\T<=WJ=Q;B4P1 'YL-P.BKDC W9/2M3X>?8U\++#INQ].BGD2UG2
M 0B=,YW[1Q]XL,@ '&<<T 1>+DT.?5=+M[RYM;;4#/%,DTD@61$1\X3)SEC\
MN!UR?2L+PP-39Y!HSVJ:BNG@7?VI6*?:/M#D^9MYW8W_ )CMBO2'MH))!))#
M&SKT9E!(_&GK&B%BJJ"QRQ QD^IH X;P0-2'B[Q=_:S6K7OF6GF&T#"/_5'&
M-W/2D^,H)^%>L8](^O\ UT6KWAO_ )'SQEQ_RTM.?^V-4/C, ?A7K()[1_\
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M5EL&*KT% ,:Q&<>M!!.<\ '\Z.QX&0:<6!."<9]*!" +C/6E5AA1T/I2[05
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M4)VJ!@#D>E3_ /"->)/^AWO/_ *#_"F!T>H?\@VZ_P"N+_R-?./A:)1X;LP
M<9;_ -"->TR>%O$DD;QOXWNRKC:1]A@Z?E7.VGP>-C;+;V_B:Z2)#E5^RQG'
M>@#DV7YQ[4@154D#G'<UV9^%-R6)_P"$JNN?^G2.D_X51=$8_P"$KNO_  #C
MI <:5Y&3@'BG@XDYYQ6OX6\"7WB+08=4E\17%N\CRIY8M$( 5V4'GU"Y_&MD
M?"FZ!S_PE5SG_KSCH Y-!D_=]*Z[X,KM\/:P/^HO,?T6A?A;>*21XIGZYYLX
MS5K1/A]J_AVVGM]+\73PQ3S-/(IL(FR[8R>?H.*8'?45RO\ PC_BG'_(ZR_^
M"V&D_P"$?\5?]#M)_P""R&@#Q'Q,I;Q_XFX/_']_[**SN1@@=N]>LW/P>EO+
M^ZOIO$\S7%U)YDSBS0;FQC.,\5$?@L3C_BI9N/\ IT3_ !H \JVDG!'?K2%
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M TJ*** "BBB@ HKD-=\4S^'M?O(+K:UK)I;W=D-N"9HCAX\]R0T9'XU1L?B
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M*0ZK]U3QR!V':KE% $%I9VUA;);6=O%;P)]V.) JK] *GHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form20-f_008.jpg
<TEXT>
begin 644 form20-f_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $: D\# 2(  A$! Q$!_\0
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M)Y8I94D9&:."2 \=-T4GS(<$<$GL<X-:E)JPUJ%%%%( HHHH **** "BBB@
MHHK/UV2XAT"_DM"RSK Y1E&2#CJ!ZT :%%<HMCI&FZEHLVAQP12WDAWM;8_T
MJ'RV)=R/OX.T[SDY/7YCG,T>6:2:.VU6U0:-)?720,'W+)/Y[D"5<< ]%&2-
MPYY*U7**YWU%9%R+C6-/NH)8-1TM5.-XDB#2KSG:R,Y4'U^5O3%<[8VMG?:9
MX:M-2BBFL_[':58YL,OF*L6&P?X@"V#U&30D%SN:*XB[@N+SPKX<O[J\N_,2
M2Q+1;\+(YDC^9^,L<$\$XYSC(!'56-JUM<WS'?MFF$BEG+9^10>IX&0>*&K
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M7FI:A!X@$C75PE@)XX0(5@D@4LH^24$^:LA9N"N5 *DCK5#3=<U:'1X-0FU
M:C)<Z7+=F#RD41O'MQMV@'')#9)Y'&.E'*PN=U17&76H:K9+-91ZNURY:R9;
MN2&,L@FEV,,*H4C R.,\G)/%0SW^MK+=6$.HWEP;.>16DMQ:BZ=?+C8,RR!4
M* NP.T _<]Z.0+G<T5Q&L:_JIFA?3#<20QV$=X)(1;QQ2EB?];Y[!E3"C[AR
M-W)Z5VRG*@D8)'2DU8$[BT444AA1110 5'/!'<Q>7*NY,AL9(Y!!'3W%253U
M5S%I%XZW!MV6%R)A&7,?'WMHY..N* )FM86O([LH?/1&C5@Q'RL02,=#RHZU
MEW>F:%'JT4]W(L=U<R9CA>[=4FD ZB+=M9@ .=I(P#V%<IINM16LMK,VI*NG
M17H$]RNKO>6N&AD !FD (.X+E"2 2F.34FFQ)JNL6EU/<7<A:VU)5874J947
M 5> P_A/'T7T&-.5HF]S3O?#EGX@M+6/2M1LUTV&$VC>3YDK,@X*;UE"G'HZ
MN ><5OG1K I(I@R))TN'^=N9$V[6Z]MB\=.*\Z\^[L-)T.""\2W3^S(9+0W.
MJ3Q%YR<L JJ_GX^0>6> #@#GCMM%1YM;UNXFGN':*Y$,<9G?RT7RHV("9QG)
M)SC/-$DUU!#XM+T"^%S;PB&?RQ-;SI'<%BGFMOD5L-P2<'U';%6IM"TZXOUO
M)87,H*DJ)G$;E?NLT8.QB.,$@D8'H*Y+3;(1V.EV<=U?1PW.L7BS;+R4,RKY
M^!NW9 RH/!'//4FK=I>,?$4:+?S-J9O)DN[/[0S+'; /L;RB<(.(B' R2V,G
M-#3[C-A/"6C()%^SS,CPO!LDNY75(VQN1 6(1>!PN,8&*LWVDZ7<&5KM &G$
M:,WG,A/EL63!!!!!).1@US.GZ>]T-*\[4]587MB\MP!?RKO9=FT@@Y3&X_<V
MY_BS6YHL2ZQX;TBZOC))/]GCD+B1E); .3M(SR :3OO<"QK.B0ZT+))Y'2.V
MG\XA&96;Y&4892"I!;.0<\5-:Z18V3V[P0;6MXVBC8NQ.UB&;))^8DJ"2<G/
M?DUR]VUPNHZA?K>WGFV^KV]O#']H<1"-Q"&4H#M.=[=0<=1BLC3[_5I].U<K
M>HUV-.F>XB@U&:>6*<'CY"@$!'S#8K<XX!VYIJ+MN*^IV4_A;3VL=0@ME>&2
M\@DAWO(\HB#YR$5FPJY.=JX!P/04Z+POI45F]L(IB'*L9/M,OF*5^[M?=N0#
MG 4@#)QU-<Y?:RNJ7=W_ &=JKRVC'3HQ+:7!VC?.ROM93@$C@XY_*IKN?[+K
MC6ZW]RFHQ7-O%8VANW;S;<[-[&,M^\ZRY<@D;<Y&*+/N&AU%OH]A:M T,&UH
M(GA0EF)VL06SD_,25!).23WY-0II&DZ;;([1K'!:V\D(:>9F5(F(+*2Q/R_*
M.O0# P*Y?1[Y9-; 35[J?4?[1NDFM#.S!+93)C]V>  0N'QG/RYQQ6)=:@FI
M6VJVT%W-+!/I5Q+(AU5YIA(I0@21C"P,,ME$.#R".,4*+;W"YW]GH>C)%+;P
M*9=DT;2;[EY75TPZ*69BP X(7..>G-7K.*S5KB>S*-]HE+RNC[@S@!#WX(V@
M8'I7$6\<<,UYJ5C?73!=5M(HBMX[1O&Z0*21NQ)E6^\V3T(-3?;HW@MAK6JS
MVFG--?!KC[8T'[Q9R(U,@8'[N["YP<=.*'%]P3.E3PSI*)=(+9RERC1R*\\C
M!4;EE0%OW8/HN!P/05=O;"VU"V^SW",4!#*4D9&4CH592&4^X(K,UBX>/PL)
M8;B<1E8O-N&!CE6$LHD<\ JP3<>@Q[8K!%]%]BP-4G_X1[^T-GV[[8W^I\K/
M_'QNW;?-XW;O]G.*5FQG3V6@Z?INQK&#RI(UD",SN^/,8,Y.3SE@"<\^_-2:
M1;Q6=FUJD\,TL<C-<&(!1YKG>WRY.W[V<$DX(Y/6N,O];@L++5DAUJX:.72U
M.FO-.V^5@9<F,G!<@;/F&21M))ZU'J5]#;WVJ0S7#PF2]+(9-2:PA9A!!P94
M&XOR=JC@\YZ"GRMBNCMI]#T^XU)-0EB<SJ5.!,X1BOW2R [6([$@D8&.@I;+
M31 EY]H,4TEY*9)BL6Q6&T*!@D_PJ >>>>G0<]X7GGU74+>ZNKNY=H]*M)0@
MF94\QQ(')48#'@=1VJMXFO8XO$5Y%-K%U:2)I\<EC!%<,@DN"\@&%!P[' &P
MY![@XX7*[V'?J=5IVD6.D))]E20;\;WFG>5L#H-SDD*.<#.!D^M4-'\.Z;;2
M-J$<GVJ2>66X202L8L2,6RJ;BF=IV[P,D>QQ7-^(=9-MK:^7=O%>13P(\<NI
M-$0C%-QCME&V5,,V7;D'.#\HQ")[NXT2>]DU&_$MGH5K=1;+IU'FD2$LP!^?
M.T9#9![BFHNU[[BNCJ+;P]X>,T\$.9G6)X'A:]DD$4;8W(%+D(.!P ,8&*N'
MP]IK6DEL8IMDDBRLXN9!)O50H82;MP.% R#D\^IJY#:01RO<(F)90-[9//\
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MD:15#@QMM.Y"H)P#P2.1SU&1V[4I*VPT/HHHJ1A1110 4444 %%%% !1110
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M4 %%8]S>ZA'XOT^PCDMA8SV<\\BM"QEW1M&N ^\  ^:I^Z?NG^]QL4 %%%%
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MC'6NT^%__)/=._WIO_1KU,J;BKLI23V.PHHHK,H**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.:>&VB,L\J11KU=V"@?B:
MDJCK%Y]@TR6X'F94J/W8!(RP'3N.>1UQTYH G@O;6YD>."XBDD0 NBN"RYZ9
M'45@1Z#?1!@&@?,+0?/,Q^]D%_N\=OE'')Y];.@6UVS2WE\\[F<B:&*>/!AW
M9) R25." 5XQM[\LV[3:L"(Y%E^SNL+HLNPA'=2RAL<$@$9'MD?6L+24O8_%
M>J"_N+>>7[#:$-! T2A=]QQ@NW/7G/X5T-8]M_R.6I_]@^T_]&7-(#8HHHH
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M;H.H7T*HTMM;R2H'!*DJI(SCMQ4-[K2V%M9,;6>ZN;LA8K>V"[F.TL<;V50
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MA)!S%(L@'WCP2@!]B:V]%^+.O:EKVG6,UIIJQ7-U'"Y2-PP#, <9?KS7F'Z
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M!X5&B923[N,C_P =JQ;7T5P[1X,<JYRC8SQZ$9![=#QD9Q0%BS1110(****
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M]YC)Y[=A].E7XX!)'M(*\@],$'J#Z5' O0E"N.Y_^M6A&G?'/>F(A((MF+[
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M! T2A=]QQ@NW/7G/X5(SH:*** .&^*O_ "*]M_U^K_Z ]>/U[!\5?^17MO\
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MU.-VKLFI92:1T8<R#=YA(R#@'&/\^AI0H48  'M60LS1$$-@]/K6M&7,8,@
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M=T15^"7H_P F?/-1S_\ 'O)_N'^5:6EZ9)JDTD<<BH8TWG*LV>0. H)[UG7
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M:QJD3F2]F(AF8-@JID((^4D9'L??+$[GU7#T'+ TVE]J7;NNYK_!G_D<+O\
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MBF489@PZ8!YI+6;Y1&5.23CC&/K5@0Q#I&G_ 'R*<%4=% ^@H "0HR2 /4T
M@@$'(/0BEHH **** "BBB@ I"JDYQR>XZTM% '.Q6RSZ4+:ZN1+=6^U'6%-K
M%TP?N_,0#@'Z,#WJJFB-&TEZ9;LSD(OEA!@J&)X^3.<,1R!R.PKH[BU,D@G@
ME,-P%*AL95AS@,.X!.>"#UP1DY5UNS"41X5EV\2,A*[O]S(X_P"!55R.1&5#
M!]BM[&QL;E'D4QHPEC).Q<%LX^[\H."1C) [BMQ_N-]*BAMA$79G:61R27?'
M3.0 !P .G\\G),CCY&Y/2DRDK#JYZ_TI[5VGMUWQ9Y4=5_\ K?Y[9KH.:7-(
MI.QRMO.H8'/(7A5.X8X]JU(;@$=?SXJS<:5:W#;\/&^<EHFVYYR<CI^/6HET
MMU)Q<97L-O\ 7- ,E$OR]<&I0X]:A-@^S:LP4GJ2N?ZU.MK&OWLOZ!N@_"@0
MU"9S\N1'C.\'[WT_Q_R+  4    < "EHH **** "BBB@ JCK%R]II4\D4GES
ML!'"VW=^\8[4X/'WB.O%7JKWMC;ZC:M;7*LT3$-\CLA!!!!#*0000#D&A 8?
MA1+]S>7-W<>>CN8T=XXU?*NX(.U1T&T<YY#8XP3LSZ;:7)8RQDECN8AV7/ 7
M!P>F ..E1Z7I%OH\3Q6KW!B9B^R:=I<,222"Q)Y)R<FK]-N[$ADL,4\#P31I
M)%(I1XW4%64C!!!ZC%8.DZ?9:;XKU2&PL[>UB:QM'*01*BEM]P,X Z\#\JVC
M>0"Z%L7_ 'I'3:<>N,],XYQUQ6=;?\CEJ?\ V#[3_P!&7-(9Y7^T'_S+O_;S
M_P"TJ\>NM+O+&VM[BZMY(5N,F/S(V4LN <C(P0<C_.*]B_: ^_X;Y YN>6&0
M/]5UKB?'NYM.T.5K1%+P'_2XT55N,!1E0/FQQ_$JX["NZD[0B<D]9LP/#G_(
M0D_ZY'^8KTV^M/*\%VDRW(D5W'R[QD'+Y^4C< ./;.?:O,O#G_(0D_ZY'^8K
MT._N]..A16]JQ\TNCE 9/EPN&W9.W[V2,>IZ=*TGT]3Q\0TJTK_RG,:A_J%_
MWQ_(UVVI:1IUCX?N;^RLK!KB[1S-;RZE&\5J0I^:)0?G;EMN22O3'KQ.H?ZA
M<_WQ_(UU5]JD;17URWB*&?1[B"2.VTD%RT9*XC7RR-J;#M.X'^'@G-<F)W/K
MN'E)X"%OYI=]=5_P_P#5BQ\&?^1PN_\ KP?_ -&1U[E7AOP9_P"1PN_^O!__
M $9'7N58&V:_[R_1!6)XR_Y$?Q!_V#;C_P!%-6W6)XR_Y$?Q!_V#;C_T4U..
MZ/->S/FSPY;V3>'=7N+BV$LD:GRY'6+:C^6X R[;CG).%&<JISQBN=L/^0A;
M?]=5_F*ZSPM<:G%X4UN.RA6\A:%C-'YY0VR[2"Y#+@@YZ*<\<]JY.P_Y"%M_
MUU7^8KTE\3^1Y]3^%]YZUX/M1<W\_P#I"Q,L8.UG"AAN&<E@1T['OCMFN;N\
MA)P<YPW6MOP_=:?:2/+>-LD5@5.9 2N#D#81SG:1GCCJ.^%<D&*8C."K8S4O
M=^AY&':YJ2Z\R_-'2> -.M-7T^X@O+6UNA;R--"K03.\<A48+>6N#&<?=)_A
M_/,ADGE^*&GFYGAFF&HVZ,T$)B0891M"E01C&.1VJCIL^EW>BC2]1O[BP\JX
M:X66.#S4DW*JX90P((V\'G[QZ5:L;^+4OB-I%S )?*^VVD:M-C>X0HNYL=SM
MR?K7GO<_4N1J523[/^OGOI\SZ/HHHI'RH5XI^T -S>&QSR;D<#)_Y95[77BO
MQ_7?)X:7YN3<CY1D_P#++H.];4/XB,ZWP,X3QQ;266G:-!)*[D1Y8-;/'@[(
MP,DD@D*%4A< ;?7FLOPS_P O7_ /ZU>\9V]M:6FE000V43QQ%9!'M6XR !^^
MC RC=\%F/7FJ/AG_ )>O^ ?UKLI[?>>9COX+^1Z-?6GE>"[29;D2*[CY=XR#
ME\_*1N ''MG/M7%:CUB_'^E=7?W>G'0HK>U8^:71R@,GRX7#;LG;][)&/4].
ME<IJ76+\?Z5G/X7ZEY&U_:=&W9_^DL]&U>RCMO"LVKV::?;75W$WVN[6SG*R
MJPP!$63:F_)SP.3P?3/^#/\ R.%W_P!>#_\ HR.LFZU;1C<W^M17][)=WT,L
M1L&APL9=2N#)NP47.5 &>%X&*UO@S_R.%W_UX/\ ^C(ZX>I]O.#CA*B?;_+\
MMOR/<J***#YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@>PY-9$GBG3(]4@TXB_:XG4-'LTZX9&4XYWA-N!N7)S@9YQ0!LT44P2J9FB
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MM0!?FABN(C%-$DL9ZHZA@?P-/  &!P*RG\1Z6EPT'GR/(DX@;RX)'"N?4JI
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M^8],^U;T(E$$8G*-+M&\H"%+=\ YP*?10 4444 %%%% !1110 4444 %%%%
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M1G*&&4(69MWSKM.X@*I&T]<\ '3VGAO3;.-HXA=M&7201S7LTJH4.Y=BNY"
M''"X' '05+_86G^;!((75H))94VS.H)D)+[@#A@2<[6R.G' K'\%75M=:!>$
MWUK?QB\N#+=0!O(DW,6)4NSY7#=F8#D=L#GKK4TD\(6,>B6$M_I44ZXETN>W
M$:LMP-L9S(I QC@ CD9P,T =G8^&=*T^X2>"&8RQMNC::ZEE\O@KM7>QVKAF
M^48 STI9/#>F23P3!+J)H%5%$%Y-$K*O0.JN X&3]X'J?6G6Q,>NSQ1HR1RV
MZSR(6!V2%B.@Z$@<XXRN?4UJ4 9%IX8TNSB>...Y=6:-OW]Y-,08VW( 7<D
M'G X]JMC2[(79NA#^^,WG[MQ^_Y?EYQG'W1C'3\:N44 8,GA:UN)Y/M#N(%2
M..V6VEE@DA5 W_+5'#$G>W3''!!ZU<30K%+RVNU-V)K>,1JWVR;#J 0/,&[$
MI&3R^X\UI44 8T?A72(K66W2&<)*JJ3]KEWJ%8LNQMVY-I8XVD8[< 5/!H.G
M6\"Q)"Y4120[I)G=F5R"^YF)+$D#DDGWK2HH J65C]DLVMVFDD#.[ F1R0&)
M. 68L,9QUX[8& *">%-(2UM[;R[IHX'9T,E].['<<LK,7)9"0,HQ*G'(K:HH
M HC1[%=5.IB)Q<L,']Z^S.,;O+SLWXXW8W8XSCBH6\/:<UV;DK<^:;G[5D7D
MP'F;-F<;L8V\;<8]JU** .4T?P8='U2:2._D;32C1QV?G73%00!\Q>=D/ ZA
M%/OUSI:GX8T[5))YY5G6YD50LBW,R["H;:5"N-OWF!VXR"0>#6S10!A^&=#N
MM"LI8+K4&O&=P5.Z<JH Q@>=-*P_!@/;J3N444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5[VRAOX!#.9M@
M8-B*9XR<=B5()'J#P>X-6    !@#M110!&T*-.DQ#%T4JOS' SC/'3/'7KU]
M32S1+/"\3[MCJ5.UBIP?0CD?A3Z* $ "J% P , "FS1+/"\3[MCJ5.UBIP?0
MCD?A3Z* $ "J% P , "EHHH **** (HK>*!Y7C0!Y6W.W4L>G)^G'M4M%% !
>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form20-f_009.jpg
<TEXT>
begin 644 form20-f_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #. >\# 2(  A$! Q$!_\0
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M_P"_*_\ Q5'_  N?PW_S[:C_ -^5_P#BJ/JU;^5A]8I?S(]%HKSK_A<_AO\
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M?5JW\K#ZQ2_F1Z+17G7_  N?PW_S[:C_ -^5_P#BJ/\ A<_AO_GVU'_ORO\
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MY7_XJCZM6_E8?6*7\R/1:*\Z_P"%S^&_^?;4?^_*_P#Q530?%[P]<+.R6^H
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M:M_*P^L4OYD>BT5YU_PN?PW_ ,^VH_\ ?E?_ (JC_A<_AO\ Y]M1_P"_*_\
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MN9]1TV"X-M]J6QEGVS&/&0<8QDCD#.:'.*Z@H2?0YZBM^[\(:C:F5%*7$J-
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M_P#B:]"^T0?\]H_^^A1]H@_Y[1_]]"CZU6_F8?5J?\IY[_PI?P[_ ,_FI?\
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M_P"^A6D:LHJR.65-2=V<MX7TF2'Q#JER8W2QMI'@T]7B*;5=O,EP#VWX /3
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M[5]  8 '/'K31Q8^E2IU;4GZKL+1113.$**** "BBB@ HHHH **** "BBB@
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M^_\ UJL44 5_-NO^?9?^_O\ ]:CS;K_GV7_O[_\ 6JQ10!7\VZ_Y]E_[^_\
MUJ/-NO\ GV7_ +^__6JQ10!7\VZ_Y]E_[^__ %J/-NO^?9?^_O\ ]:K%% %?
MS;K_ )]E_P"_O_UJ/-NO^?9?^_O_ -:K%% %?S;K_GV7_O[_ /6H\VZ_Y]E_
M[^__ %JL44 5_-NO^?9?^_O_ -:CS;K_ )]E_P"_O_UJL44 5_-NO^?9?^_O
M_P!:CS;K_GV7_O[_ /6JQ10!7\VZ_P"?9?\ O[_]:CS;K_GV7_O[_P#6JQ10
M!7\VZ_Y]E_[^_P#UJ/-NO^?9?^_O_P!:K%% %?S;K_GV7_O[_P#6H\VZ_P"?
M9?\ O[_]:K%% %?S;K_GV7_O[_\ 6H\VZ_Y]E_[^_P#UJL44 5_-NO\ GV7_
M +^__6H\VZ_Y]E_[^_\ UJL44 5_-NO^?9?^_O\ ]:CS;K_GV7_O[_\ 6JQ1
M0!7\VZ_Y]E_[^_\ UJ/-NO\ GV7_ +^__6JQ10!1NY+DV<P-NH&QLGS/;Z5=
M'W14-Y_QY3_]<V_E4P^Z/I0 M>1_&WKHO_;;_P!EKURO(_C;UT7_ +;?^RTG
ML=V7?[S'Y_D>2TF!Z"EHJ#Z@*,#THHH **** /HGX9_\D^TOZ/\ ^AM76UR7
MPS_Y)[I>/[LG_H;5AZ-<2P-/,BZW-XG2WN&N891)]G:0 [00?EQG&W96].GS
M)L^-QD^6O+U?YG;Z]IDFLZ+<:='<&W%P!')(!DA"1N ]RN1GWK!A\$/:R%(=
M4FDMC=I=@7(WN'$;1M\W'!!7MQM]ZS[76->O'M[>&_N&MY;I(_MILU5\&!W=
M=I7 "NJC..^.:K:=XBU47$-Y=,Z!S8F]Q 255XY-Q*X)7+!>@K>,*D59,XI3
MA)W:-&U^'WV:12;N*0"W5"SQON618?*#+A]H&.>03U&>:JZ]X9U-5MK/3H#.
MLFGV]E++L38/*D# C+ KW/1NW>H[/7?$D\-M=/<3*$CLV>$V@'F&2=D?/RY&
M% /&,=:2\U76+K3;POJ5[!<17,1G@BL]HMD^T;3A]OS#9@XYSC/0XJU[3FNV
MB'[/ET3-J'PA=6EV+BVOX-SO()A-;>8-C3F8;03PPSC)SV/85UM>?6>HZ]'/
M:VUOYIAO[V:(2&'_ %&R<LSG(Z-%D#/&0,5ES7>KJN6FO CV[^7;^6=C,+T@
M]LYV8/7I[5#I2F]6BU4C%:(]5KF_%>IW&C:?J.HVNSS[>Q+IO&5SN[BJWAK5
MM5NO$6IV=_(\T4>YHW6+9&GSD!>55@V,<'=G!(-:NJZ9;ZS+<:==[_L]Q:;'
MV-@XW=C7/.#B['51G%R4FM+GCW_"W_%']W3_ /OPW_Q5'_"W_%']W3_^_#?_
M !5=Y_PJ#PM_=O?_  (/^%'_  J#PM_=O?\ P(/^%9V9[7UG+_Y/P_X)P?\
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M5-'%F%2C4JWI+U?<****9PA1110 4444 %%%% !1110 4444 %%%% !1110
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M/L</I)_W\;_&@">BH/L</I)_W\;_ !H^QP^DG_?QO\: )Z*@^QP^DG_?QO\
M&C['#Z2?]_&_QH GHJ#['#Z2?]_&_P :/L</I)_W\;_&@">BH/L</I)_W\;_
M !H^QP^DG_?QO\: )Z*@^QP^DG_?QO\ &C['#Z2?]_&_QH GHJ#['#Z2?]_&
M_P :/L</I)_W\;_&@">BH/L</I)_W\;_ !H^QP^DG_?QO\: "\_X\I_^N;?R
MJ8?='TJG=VD*V<Q ?(1C_K&]/K5P=!0 M>1_&WKHO_;;_P!EKURO(_C;UT7_
M +;?^RTGL=V6_P"\Q^?Y'DM%&1ZT9'K69]38**,CUHR/6@+!11D>M&1ZT!8^
MB?AG_P D^TOZ/_Z&U:'B_4+G3= :>VG^S;IHHY;G9N^SQLX#28]@>]9_PS_Y
M)]I?T?\ ]#:NL90RE6 *D8(/0UM!I--GQN+5ZLUYO\SSZU\375DUU:VFKPZI
M:"Y@@AU.ZVF.)G5BX=DVAL;5QC'+@$U=7QG<"^CM7;3W:26Q2-HG)$JS9WLF
M3D@8X./K77"SM1;&V%M"+<]8M@VG\.E*;2V:1)&MXB\8 1B@RH'0 ]JV=2#^
MR<BA-=3S[2O&VH*^BVDCP7'GM&ER\O$F9'< KR,X"CHI]R*T+K7=6N?AG-K1
MEBANYE1H?LB[2@+JN,L2"3SSTYKL/L5IN1OLL.Y!A3Y8RHSGCTYYI_D0^2(?
M*C\H?P;1M_*AU(73405.=FG(\[N/$/B+PQH[M>C=-+)+);)J3QM)Y4<89@S1
ME5R6Z=3CL:FF\7ZI#<7BVOV9L-<2C[1N8*L<$<FT8(ZEC_.N^FMX+@*)X8Y0
MIR ZAL'UYIOV2V'_ "[Q<@C[@[C!_0 4_:PZQU%[.720VPN?MNG6UT5V^=$D
MFT'.,@''ZUS/CR:2#P_K$L4CQ2+IY*NC%2#O'0CI76JH50J@!0, #H*I21I-
MJS1R(KHUM@JPR#\WI7.SIIRY)*3UM8^8O[<U+_H+WO\ X%/_ (T?VYJ7_07O
M?_ I_P#&OJ#^RM._Y\+7_ORO^%']E:=_SX6O_?E?\*GE/9_M6G_S[_+_ "/E
M_P#MS4O^@O>_^!3_ .-']N:E_P!!>]_\"G_QKZ@_LK3O^?"U_P"_*_X4?V5I
MW_/A:_\ ?E?\*.4/[5I_\^_R_P CY?\ [<U+_H+WO_@4_P#C1_;FI?\ 07O?
M_ I_\:^H/[*T[_GPM?\ ORO^%']E:=_SX6O_ 'Y7_"CE#^U:?_/O\O\ (^7_
M .W-2_Z"][_X%/\ XT?VYJ7_ $%[W_P*?_&OJ#^RM._Y\+7_ +\K_A1_96G?
M\^%K_P!^5_PHY0_M6G_S[_+_ "/GCP1J.N6GBB#^Q%:XN)VQ+"Q^25,\ESVQ
MUW=J^D1G R,'N*PO#7A2P\-)<M;J'N;F1I)IRN"<DD*/11GI6]32L<..Q,*]
M2\%M^(4444SB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_OFIZ* (/L5K_P ^\?\ WS1]BM?^?>/_ +YJ>B@"#[%:_P#/O'_WS1]BM?\
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MS1]BM?\ GWC_ .^:GHH @^Q6O_/O'_WS1]BM?^?>/_OFIZ* (/L5K_S[Q_\
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1K NI4$NO<?6K@X HHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>okyo-20220331.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaCLqbP9z5Z8yekhvWB6bWk6Py0kzodXdSMAMRImkeMB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:OKYO="http://okyopharma.com/20220331" elementFormDefault="qualified" targetNamespace="http://okyopharma.com/20220331">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://okyopharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/StatementsOfShareholdersEquity" id="StatementsOfShareholdersEquity">
	  <link:definition>00000004 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ReportingEntity" id="ReportingEntity">
	  <link:definition>00000006 - Disclosure - Reporting Entity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AccountingPolicies" id="AccountingPolicies">
	  <link:definition>00000007 - Disclosure - ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" id="CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty">
	  <link:definition>00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/OperatingExpenses" id="OperatingExpenses">
	  <link:definition>00000009 - Disclosure - OPERATING EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/SegmentalReporting" id="SegmentalReporting">
	  <link:definition>00000010 - Disclosure - SEGMENTAL REPORTING</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/EmployeesIncludingOfficers" id="EmployeesIncludingOfficers">
	  <link:definition>00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" id="RemunerationOfKeyManagementPersonnel">
	  <link:definition>00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/Taxation" id="Taxation">
	  <link:definition>00000013 - Disclosure - TAXATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/FinanceIncomeAndCosts" id="FinanceIncomeAndCosts">
	  <link:definition>00000014 - Disclosure - FINANCE INCOME AND COSTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
	  <link:definition>00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/OtherReceivables" id="OtherReceivables">
	  <link:definition>00000016 - Disclosure - OTHER RECEIVABLES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/TradeAndOtherPayables" id="TradeAndOtherPayables">
	  <link:definition>00000017 - Disclosure - TRADE AND OTHER PAYABLES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CapitalAndReserves" id="CapitalAndReserves">
	  <link:definition>00000018 - Disclosure - CAPITAL AND RESERVES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ShareOptionsAndWarrants" id="ShareOptionsAndWarrants">
	  <link:definition>00000019 - Disclosure - SHARE OPTIONS AND WARRANTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" id="ConvertibleInstrumentsClassifiedAsEquity">
	  <link:definition>00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/FinancialInstruments" id="FinancialInstruments">
	  <link:definition>00000021 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000022 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShare" id="BasicAndDilutedLossPerShare">
	  <link:definition>00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/Leases" id="Leases">
	  <link:definition>00000024 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AuditorsRemuneration" id="AuditorsRemuneration">
	  <link:definition>00000025 - Disclosure - Auditor&#8217;s Remuneration</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
	  <link:definition>00000026 - Disclosure - Cash and Cash Equivalents</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000027 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/PostBalanceSheetEvents" id="PostBalanceSheetEvents">
	  <link:definition>00000028 - Disclosure - Post Balance Sheet Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AccountingPoliciesPolicies" id="AccountingPoliciesPolicies">
	  <link:definition>00000029 - Disclosure - ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AccountingPoliciesTables" id="AccountingPoliciesTables">
	  <link:definition>00000030 - Disclosure - ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/OperatingExpensesTables" id="OperatingExpensesTables">
	  <link:definition>00000031 - Disclosure - OPERATING EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersTables" id="EmployeesIncludingOfficersTables">
	  <link:definition>00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" id="RemunerationOfKeyManagementPersonnelTables">
	  <link:definition>00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/TaxationTables" id="TaxationTables">
	  <link:definition>00000034 - Disclosure - TAXATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/FinanceIncomeAndCostsTables" id="FinanceIncomeAndCostsTables">
	  <link:definition>00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
	  <link:definition>00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/OtherReceivablesTables" id="OtherReceivablesTables">
	  <link:definition>00000037 - Disclosure - OTHER RECEIVABLES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/TradeAndOtherPayablesTables" id="TradeAndOtherPayablesTables">
	  <link:definition>00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CapitalAndReservesTables" id="CapitalAndReservesTables">
	  <link:definition>00000039 - Disclosure - CAPITAL AND RESERVES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" id="ShareOptionsAndWarrantsTables">
	  <link:definition>00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" id="ConvertibleInstrumentsClassifiedAsEquityTables">
	  <link:definition>00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/FinancialInstrumentsTables" id="FinancialInstrumentsTables">
	  <link:definition>00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" id="BasicAndDilutedLossPerShareTables">
	  <link:definition>00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000044 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AuditorsRemunerationTables" id="AuditorsRemunerationTables">
	  <link:definition>00000045 - Disclosure - Auditor&#8217;s Remuneration (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CashAndCashEquivalentsTables" id="CashAndCashEquivalentsTables">
	  <link:definition>00000046 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" id="DisclosureOfEstimatedUsefulLivesDetails">
	  <link:definition>00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" id="AccountingPoliciesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" id="DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails">
	  <link:definition>00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" id="DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails">
	  <link:definition>00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" id="EmployeesIncludingOfficersDetailsNarrative">
	  <link:definition>00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" id="ScheduleOfRemunerationOfDirectorsDetails">
	  <link:definition>00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" id="ScheduleOfRemunerationOfDirectorsDetailsParenthetical">
	  <link:definition>00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" id="ScheduleOfShareOptionsGrantedToDirectorsDetails">
	  <link:definition>00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" id="ScheduleOfKeyManagementPersonnelCompensationDetails">
	  <link:definition>00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" id="ScheduleOfTaxCreditPeriodDetails">
	  <link:definition>00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" id="ScheduleOfTaxCreditPeriodDetailsParenthetical">
	  <link:definition>00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/TaxationDetailsNarrative" id="TaxationDetailsNarrative">
	  <link:definition>00000058 - Disclosure - TAXATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" id="ScheduleOfFinanceCostDetails">
	  <link:definition>00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" id="ScheduleOfPropertyPlantAndEquipmentDetails">
	  <link:definition>00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" id="ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails">
	  <link:definition>00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" id="DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails">
	  <link:definition>00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" id="OtherReceivablesDetailsNarrative">
	  <link:definition>00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" id="DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails">
	  <link:definition>00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" id="ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails">
	  <link:definition>00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" id="CapitalAndReservesDetailsNarrative">
	  <link:definition>00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" id="ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails">
	  <link:definition>00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" id="ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails">
	  <link:definition>00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" id="ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails">
	  <link:definition>00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" id="ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails">
	  <link:definition>00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" id="ScheduleOfInputsForWarrantsGrantedDetails">
	  <link:definition>00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" id="ScheduleOfFairValueOfWarrantsInServicesDetails">
	  <link:definition>00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" id="ShareOptionsAndWarrantsDetailsNarrative">
	  <link:definition>00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" id="ScheduleOfIssuanceOfConvertibleLoanDetails">
	  <link:definition>00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" id="SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails">
	  <link:definition>00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" id="SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails">
	  <link:definition>00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" id="ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails">
	  <link:definition>00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" id="ScheduleOfLeaseLiabilitiesByClassificationDetails">
	  <link:definition>00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" id="ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails">
	  <link:definition>00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000081 - Disclosure - Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" id="ScheduleOfCompanyAuditorsFeesDetails">
	  <link:definition>00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" id="ScheduleOfCashAndCashEquivalentDetails">
	  <link:definition>00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000084 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" id="PostBalanceSheetEventsDetailsNarrative">
	  <link:definition>00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="okyo-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="okyo-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="okyo-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="okyo-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="OKYO_WarrantReservesMember" name="WarrantReservesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ConvertibleLoanNoteReserveMember" name="ConvertibleLoanNoteReserveMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TranslationReserveMember" name="TranslationReserveMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_NonadjustingEventMember" name="NonadjustingEventMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FurnitureAndFixtureMember" name="FurnitureAndFixtureMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_CorporateAndAdministrationMember" name="CorporateAndAdministrationMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GCerroneMember" name="GCerroneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GJacobMember" name="GJacobMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WSimonMember" name="WSimonMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_KShailubhaiMember" name="KShailubhaiMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_JBrancaccioMember" name="JBrancaccioMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GMacraeMember" name="GMacraeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_BDenoyerMember" name="BDenoyerMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LZambelettiMember" name="LZambelettiMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DirectorsMember" name="DirectorsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ITEquipmentMember" name="ITEquipmentMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_UKMember" name="UKMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_UnitedStateMember" name="UnitedStateMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantReserveOneMember" name="WarrantReserveOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LoanNotesMember" name="LoanNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LoanNotesOneMember" name="LoanNotesOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantReserveTwoMember" name="WarrantReserveTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PrivatePlacementsMember" name="PrivatePlacementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PrivatePlacementsOneMember" name="PrivatePlacementsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LieuOfProfessionalFeesMember" name="LieuOfProfessionalFeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LieuOfBrokerFeesMember" name="LieuOfBrokerFeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ConvertibleLoanNotesMember" name="ConvertibleLoanNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ConvertibleLoanNotesOneMember" name="ConvertibleLoanNotesOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SixJulyTwoThousandEighteenMember" name="SixJulyTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TwentyAugustTwoThousandTwentyMember" name="TwentyAugustTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SixJanuaryTwoThousandTwentyOneMember" name="SixJanuaryTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TwelveJanuaryTwoThousandTwentyOneMember" name="TwelveJanuaryTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FifteenAprilTwoThousandTwentyOneMember" name="FifteenAprilTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" name="ThirtyFirstAugustTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" name="ThirtyFirstAugustTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TwentyNineMayTwoThousandAndTwentyMember" name="TwentyNineMayTwoThousandAndTwentyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" name="FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TwentySevenJulyTwoThousandTwentyMember" name="TwentySevenJulyTwoThousandTwentyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SeventeenthAugustTwoThousandAndTwentyMember" name="SeventeenthAugustTwoThousandAndTwentyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ThreeSeptemberTwoThousandAndTwentyMember" name="ThreeSeptemberTwoThousandAndTwentyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" name="FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LessThanThreeMember" name="LessThanThreeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ThreeToTwelveMonthsMember" name="ThreeToTwelveMonthsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WestAfricanMineralsLimitedMember" name="WestAfricanMineralsLimitedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TizianaLifeSciencesLtdMember" name="TizianaLifeSciencesLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GBPMember" name="GBPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_USDMember" name="USDMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PhaseIHumanClinicalTrialMember" name="PhaseIHumanClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PhaseIIHumanClinicalTrialMember" name="PhaseIIHumanClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PhaseIIIHumanClinicalTrialMember" name="PhaseIIIHumanClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_RelatedPartyReceivables" name="RelatedPartyReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_CurrentTaxationReceivable" name="CurrentTaxationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ConvertibleLoanNoteReserve" name="ConvertibleLoanNoteReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ForeignCurrencyTranslationReserve" name="ForeignCurrencyTranslationReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ImpairmentOfLoan" name="ImpairmentOfLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncomeTaxExpenseBenefitContinuingOperations" name="IncomeTaxExpenseBenefitContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" name="BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IfrsStatementLineItems" name="IfrsStatementLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_StockIssuedDuringPeriodValueNewIssue" name="StockIssuedDuringPeriodValueNewIssue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_StockIssuedDuringPeriodSharesShareCapital" name="StockIssuedDuringPeriodSharesShareCapital" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" name="SharesIssuedOnConvertibleDebtAndWarrantInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" name="StockIssuedDuringPeriodValueTransferBetweenEquityReserves" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnOptionsCharge" name="SharesIssuedOnOptionsCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" name="StockIssuedDuringPeriodShareslExerciseOfOptions" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" name="IncreaseDecreaseThroughExerciseOfForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnWarrantsExercisedShares" name="SharesIssuedOnWarrantsExercisedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" name="IncreaseDecreaseThroughExerciseOfWarrantsCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnConvertibleDebtConversion" name="SharesIssuedOnConvertibleDebtConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnConvertibleDebtConversionShares" name="SharesIssuedOnConvertibleDebtConversionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnConvertibleDebtInterest" name="SharesIssuedOnConvertibleDebtInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnTotalTransactions" name="SharesIssuedOnTotalTransactions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnTotalTransactionsShares" name="SharesIssuedOnTotalTransactionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" name="SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" name="AdjustmentsForChangeInFairValueOfWarrantCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" name="AdjustmentsForChangeInFairValueOfForfeitureOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" name="AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" name="AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ProcessedFromOptionsExercised" name="ProcessedFromOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ProcessedFromWarrantsExercised" name="ProcessedFromWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_CashAdvancesAndLoansToRelatedParties" name="CashAdvancesAndLoansToRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureReportingEntityAbstract" name="DisclosureReportingEntityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfReportingEntityExplanatory" name="DisclosureOfReportingEntityExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureAccountingPoliciesAbstract" name="DisclosureAccountingPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" name="DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOperatingExpensesAbstract" name="DisclosureOperatingExpensesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureSegmentalReportingAbstract" name="DisclosureSegmentalReportingAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureEmployeesIncludingOfficersAbstract" name="DisclosureEmployeesIncludingOfficersAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfEmployeeDetailsExplanatory" name="DisclosureOfEmployeeDetailsExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" name="DisclosureRemunerationOfKeyManagementPersonnelAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureTaxationAbstract" name="DisclosureTaxationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureFinanceIncomeAndCostsAbstract" name="DisclosureFinanceIncomeAndCostsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosurePropertyPlantAndEquipmentAbstract" name="DisclosurePropertyPlantAndEquipmentAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOtherReceivablesAbstract" name="DisclosureOtherReceivablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureTradeAndOtherPayablesAbstract" name="DisclosureTradeAndOtherPayablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureCapitalAndReservesAbstract" name="DisclosureCapitalAndReservesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureShareOptionsAndWarrantsAbstract" name="DisclosureShareOptionsAndWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" name="DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureFinancialInstrumentsAbstract" name="DisclosureFinancialInstrumentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureRelatedPartyTransactionsAbstract" name="DisclosureRelatedPartyTransactionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" name="DisclosureBasicAndDilutedLossPerShareAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureCashAndCashEquivalentsAbstract" name="DisclosureCashAndCashEquivalentsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureCommitmentsAndContingenciesAbstract" name="DisclosureCommitmentsAndContingenciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosurePostBalanceSheetEventsAbstract" name="DisclosurePostBalanceSheetEventsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" name="DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" name="DescriptionOfAccountingPolicyForLicenseFeesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" name="DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" name="DescriptionOfAccountingPolicyForShareCapitalExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" name="DescriptionOfAccountingPolicyForLeaseExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" name="DisclosureOfEstimatedUsefulLivesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" name="DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" name="DisclosureOfDetailedInformationAboutEmployeesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" name="ScheduleOfShareOptionsGrantedToDirectorsExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" name="DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" name="DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" name="DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" name="DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" name="DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" name="DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" name="DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" name="DisclosureOfIssuanceOfConvertibleNotesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" name="DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" name="DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" name="DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" name="DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" name="DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_CashBurnRate" name="CashBurnRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_KeyManagementPersonnelCompensationDirectorFees" name="KeyManagementPersonnelCompensationDirectorFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ChairmansBonus" name="ChairmansBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GainlossOnDisposalOfLeases" name="GainlossOnDisposalOfLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ForeignExchangeLossesGains" name="ForeignExchangeLossesGains" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DirectorsSalaries" name="DirectorsSalaries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IfrsStatementTable" name="IfrsStatementTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="OKYO_DirectorsBonus" name="DirectorsBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DirectorsSalary" name="DirectorsSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_KeyManagementPersonnelCompensationSharebasedPayments" name="KeyManagementPersonnelCompensationSharebasedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_BonusAwarded" name="BonusAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LossBeforeTaxation" name="LossBeforeTaxation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LossChargedAtStandardRateOfCorporationTax" name="LossChargedAtStandardRateOfCorporationTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TaxLossesSurrenderedForResearchAndDevelopment" name="TaxLossesSurrenderedForResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" name="TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ResearchAndDevelopmentTaxClaim" name="ResearchAndDevelopmentTaxClaim" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ResearchAndDevelopmentEnhancedExpenditure" name="ResearchAndDevelopmentEnhancedExpenditure" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PropertyPlantAndEquipmentCost" name="PropertyPlantAndEquipmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PropertyPlantAndEquipmentDepreciation" name="PropertyPlantAndEquipmentDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_EffectOfChargeInYearDepreciation" name="EffectOfChargeInYearDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_EffectOfForeignExchangeDepreciation" name="EffectOfForeignExchangeDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DepreciationNetValue" name="DepreciationNetValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_PrepaymentsReceivables" name="PrepaymentsReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_BonusAccrual" name="BonusAccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" name="TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_NumberOfSharesIssuedPrivatePlacement" name="NumberOfSharesIssuedPrivatePlacement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_NumberOfSharesIssuedPrivatePlacementValue" name="NumberOfSharesIssuedPrivatePlacementValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FairValueWarrantsIssuedPrivatePlacement" name="FairValueWarrantsIssuedPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IssuedInLieuValue" name="IssuedInLieuValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" name="IncreaseDecreaseThroughExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" name="IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" name="IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GrantDateAxis" name="GrantDateAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="OKYO_GrantDateDomain" name="GrantDateDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ExpirationDateOfOutstanding" name="ExpirationDateOfOutstanding" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GrantDateShareOptionsGranted2019" name="GrantDateShareOptionsGranted2019" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_VestingPeriodsDescription" name="VestingPeriodsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_OptionLifePeriod" name="OptionLifePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ExpectedLifeOfWarrants" name="ExpectedLifeOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsVestingPeriod" name="WarrantsVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ShareBasedPaymentCharge" name="ShareBasedPaymentCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ShareBasedPaymentChargeForfeiture" name="ShareBasedPaymentChargeForfeiture" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsExercisablePricePerShare" name="WarrantsExercisablePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsExercisableDate" name="WarrantsExercisableDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsExercisedOnCashlessBasic" name="WarrantsExercisedOnCashlessBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsExercisedOnPriceReductionOffer" name="WarrantsExercisedOnPriceReductionOffer" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantsExercisedOnIssuances" name="WarrantsExercisedOnIssuances" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_FairValueOfWarrants" name="FairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ConversionPricePerShares" name="ConversionPricePerShares" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WarrantExercisePricePerShare" name="WarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DebtTerm" name="DebtTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_WriteOffExchangeOfLoan" name="WriteOffExchangeOfLoan" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_BasicAndDilutedEarningsLossPerShare" name="BasicAndDilutedEarningsLossPerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisposalsRightOfUseAssets" name="DisposalsRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ImpactOfForeignExchange" name="ImpactOfForeignExchange" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DepreciationOfEarlyTerminatedLease" name="DepreciationOfEarlyTerminatedLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DepreciationOfNewLease" name="DepreciationOfNewLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LeaseLiabilitiesInterestExpense" name="LeaseLiabilitiesInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LeasePayments" name="LeasePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ImpactOfForeignExchangeLeaseLiabilities" name="ImpactOfForeignExchangeLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DerecognitionOfLeaseLiability" name="DerecognitionOfLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_DisposalsLeaseLiabilities" name="DisposalsLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdditionsToLeaseLiabilities" name="AdditionsToLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LeaseLiabilitiesInterestExpenses" name="LeaseLiabilitiesInterestExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_LeasePayment" name="LeasePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" name="InitialRecognitionForRightOfUseAssetAndLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AllCurrenciesDomain" name="AllCurrenciesDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AmountOfLicensedProductOrService" name="AmountOfLicensedProductOrService" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AnnualLicenseMaintenanceFee" name="AnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AnnualLicenseMaintenanceFeeTherafter" name="AnnualLicenseMaintenanceFeeTherafter" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_Bonus" name="Bonus" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_ShorttermCreditFacility" name="ShorttermCreditFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_AdditionalBorrowingsInterestRate" name="AdditionalBorrowingsInterestRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_USMember" name="USMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OKYO_GeographicalAreaAxis" name="GeographicalAreaAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" name="WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>okyo-20220331_cal.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://okyopharma.com/role/Cover" xlink:href="okyo-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BalanceSheets" xlink:href="okyo-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="okyo-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:href="okyo-20220331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfCashFlows" xlink:href="okyo-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ReportingEntity" xlink:href="okyo-20220331.xsd#ReportingEntity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPolicies" xlink:href="okyo-20220331.xsd#AccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:href="okyo-20220331.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpenses" xlink:href="okyo-20220331.xsd#OperatingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SegmentalReporting" xlink:href="okyo-20220331.xsd#SegmentalReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficers" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnel" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Taxation" xlink:href="okyo-20220331.xsd#Taxation" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivables" xlink:href="okyo-20220331.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReserves" xlink:href="okyo-20220331.xsd#CapitalAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstruments" xlink:href="okyo-20220331.xsd#FinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactions" xlink:href="okyo-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Leases" xlink:href="okyo-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemuneration" xlink:href="okyo-20220331.xsd#AuditorsRemuneration" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalents" xlink:href="okyo-20220331.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:href="okyo-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:href="okyo-20220331.xsd#PostBalanceSheetEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:href="okyo-20220331.xsd#AccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesTables" xlink:href="okyo-20220331.xsd#AccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpensesTables" xlink:href="okyo-20220331.xsd#OperatingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnelTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationTables" xlink:href="okyo-20220331.xsd#TaxationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesTables" xlink:href="okyo-20220331.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesTables" xlink:href="okyo-20220331.xsd#CapitalAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:href="okyo-20220331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesTables" xlink:href="okyo-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:href="okyo-20220331.xsd#AuditorsRemunerationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:href="okyo-20220331.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:href="okyo-20220331.xsd#AccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:href="okyo-20220331.xsd#TaxationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFinanceCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:href="okyo-20220331.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:href="okyo-20220331.xsd#CapitalAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfInputsForWarrantsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:href="okyo-20220331.xsd#ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="okyo-20220331.xsd#SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="okyo-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:href="okyo-20220331.xsd#SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:href="okyo-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCompanyAuditorsFeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCashAndCashEquivalentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="okyo-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:href="okyo-20220331.xsd#PostBalanceSheetEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_RelatedPartyReceivables" xlink:label="loc_OKYORelatedPartyReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_OKYORelatedPartyReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CurrentTaxationReceivable" xlink:label="loc_OKYOCurrentTaxationReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_OKYOCurrentTaxationReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-fullOtherReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentAssets" xlink:to="loc_ifrs-fullOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullNoncurrentAssets" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullAssets" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCurrentLiabilities" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLiabilities" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-fullSharePremium" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullSharePremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="loc_ifrs-fullReserveOfSharebasedPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullReserveOfSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-fullWarrantReserve" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullWarrantReserve" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserve" xlink:label="loc_OKYOConvertibleLoanNoteReserve" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_OKYOConvertibleLoanNoteReserve" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ForeignCurrencyTranslationReserve" xlink:label="loc_OKYOForeignCurrencyTranslationReserve" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_OKYOForeignCurrencyTranslationReserve" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquity" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullEquityAndLiabilities" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpenseExcludingCostOfSales" xlink:label="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-fullOperatingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" xlink:to="loc_ifrs-fullOperatingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-fullFinanceIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullFinanceIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpairmentOfLoan" xlink:label="loc_OKYOImpairmentOfLoan" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLossBeforeTax" xlink:to="loc_OKYOImpairmentOfLoan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_OKYOIncomeTaxExpenseBenefitContinuingOperations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullProfitLoss" xlink:to="loc_OKYOIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullComprehensiveIncome" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000004 - Statement - Consolidated Statements of Shareholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:label="loc_OKYOAdjustmentsForChangeInFairValueOfWarrantCharge" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_OKYOAdjustmentsForChangeInFairValueOfWarrantCharge" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:label="loc_OKYOAdjustmentsForChangeInFairValueOfForfeitureOfOptions" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_OKYOAdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForAmortisationExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForAmortisationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:label="loc_ifrs-fullAdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:label="loc_OKYOAdjustmentsForDecreaseIncreaseRelatedPartyReceivables" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_OKYOAdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:label="loc_OKYOAdjustmentsForIncreaseDecreaseInRelatedPartyPayables" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_OKYOAdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLoss" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansMadeToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:to="loc_ifrs-fullCashAdvancesAndLoansMadeToRelatedParties" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullProceedsFromIssuingShares" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="loc_ifrs-fullProceedsFromIssueOfBondsNotesAndDebentures" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullProceedsFromIssueOfBondsNotesAndDebentures" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromOptionsExercised" xlink:label="loc_OKYOProcessedFromOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_OKYOProcessedFromOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromWarrantsExercised" xlink:label="loc_OKYOProcessedFromWarrantsExercised" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_OKYOProcessedFromWarrantsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashAdvancesAndLoansToRelatedParties" xlink:label="loc_OKYOCashAdvancesAndLoansToRelatedParties" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_OKYOCashAdvancesAndLoansToRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ReportingEntity" xlink:title="00000006 - Disclosure - Reporting Entity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPolicies" xlink:title="00000007 - Disclosure - ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:title="00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpenses" xlink:title="00000009 - Disclosure - OPERATING EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SegmentalReporting" xlink:title="00000010 - Disclosure - SEGMENTAL REPORTING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:title="00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:title="00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Taxation" xlink:title="00000013 - Disclosure - TAXATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:title="00000014 - Disclosure - FINANCE INCOME AND COSTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivables" xlink:title="00000016 - Disclosure - OTHER RECEIVABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayables" xlink:title="00000017 - Disclosure - TRADE AND OTHER PAYABLES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReserves" xlink:title="00000018 - Disclosure - CAPITAL AND RESERVES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:title="00000019 - Disclosure - SHARE OPTIONS AND WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:title="00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstruments" xlink:title="00000021 - Disclosure - FINANCIAL INSTRUMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:title="00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Leases" xlink:title="00000024 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemuneration" xlink:title="00000025 - Disclosure - Auditor&#8217;s Remuneration" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalents" xlink:title="00000026 - Disclosure - Cash and Cash Equivalents" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:title="00000027 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:title="00000028 - Disclosure - Post Balance Sheet Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesTables" xlink:title="00000030 - Disclosure - ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpensesTables" xlink:title="00000031 - Disclosure - OPERATING EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:title="00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:title="00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationTables" xlink:title="00000034 - Disclosure - TAXATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:title="00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesTables" xlink:title="00000037 - Disclosure - OTHER RECEIVABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:title="00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesTables" xlink:title="00000039 - Disclosure - CAPITAL AND RESERVES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:title="00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:title="00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:title="00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:title="00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesTables" xlink:title="00000044 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:title="00000045 - Disclosure - Auditor&#8217;s Remuneration (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:title="00000046 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:title="00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:title="00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:title="00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:title="00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:title="00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:title="00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:title="00000058 - Disclosure - TAXATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:title="00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:title="00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:title="00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:title="00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:title="00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-fullFinancialLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullFinancialLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherPayables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullFinancialLiabilities" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:title="00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-fullLeaseLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLeaseLiabilities" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-fullLeaseLiabilities" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:title="00000081 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000084 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:title="00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>okyo-20220331_def.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://okyopharma.com/role/Cover" xlink:href="okyo-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BalanceSheets" xlink:href="okyo-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="okyo-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:href="okyo-20220331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfCashFlows" xlink:href="okyo-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ReportingEntity" xlink:href="okyo-20220331.xsd#ReportingEntity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPolicies" xlink:href="okyo-20220331.xsd#AccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:href="okyo-20220331.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpenses" xlink:href="okyo-20220331.xsd#OperatingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SegmentalReporting" xlink:href="okyo-20220331.xsd#SegmentalReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficers" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnel" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Taxation" xlink:href="okyo-20220331.xsd#Taxation" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivables" xlink:href="okyo-20220331.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReserves" xlink:href="okyo-20220331.xsd#CapitalAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstruments" xlink:href="okyo-20220331.xsd#FinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactions" xlink:href="okyo-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Leases" xlink:href="okyo-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemuneration" xlink:href="okyo-20220331.xsd#AuditorsRemuneration" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalents" xlink:href="okyo-20220331.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:href="okyo-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:href="okyo-20220331.xsd#PostBalanceSheetEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:href="okyo-20220331.xsd#AccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesTables" xlink:href="okyo-20220331.xsd#AccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpensesTables" xlink:href="okyo-20220331.xsd#OperatingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnelTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationTables" xlink:href="okyo-20220331.xsd#TaxationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesTables" xlink:href="okyo-20220331.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesTables" xlink:href="okyo-20220331.xsd#CapitalAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:href="okyo-20220331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesTables" xlink:href="okyo-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:href="okyo-20220331.xsd#AuditorsRemunerationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:href="okyo-20220331.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:href="okyo-20220331.xsd#AccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:href="okyo-20220331.xsd#TaxationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFinanceCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:href="okyo-20220331.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:href="okyo-20220331.xsd#CapitalAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfInputsForWarrantsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:href="okyo-20220331.xsd#ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="okyo-20220331.xsd#SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="okyo-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:href="okyo-20220331.xsd#SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:href="okyo-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCompanyAuditorsFeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCashAndCashEquivalentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="okyo-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:href="okyo-20220331.xsd#PostBalanceSheetEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName_40" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId_40" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName_40" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation_40" xlink:type="arc" order="61" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000004 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-fullOtherReservesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullOtherReservesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReservesMember" xlink:label="loc_OKYOWarrantReservesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOWarrantReservesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserveMember" xlink:label="loc_OKYOConvertibleLoanNoteReserveMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOConvertibleLoanNoteReserveMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TranslationReserveMember" xlink:label="loc_OKYOTranslationReserveMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOTranslationReserveMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueNewIssue" xlink:label="loc_OKYOStockIssuedDuringPeriodValueNewIssue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodValueNewIssue_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodSharesShareCapital" xlink:label="loc_OKYOStockIssuedDuringPeriodSharesShareCapital_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodSharesShareCapital_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtAndWarrantInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtAndWarrantInterest_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:label="loc_OKYOStockIssuedDuringPeriodValueTransferBetweenEquityReserves_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodValueTransferBetweenEquityReserves_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnOptionsCharge" xlink:label="loc_OKYOSharesIssuedOnOptionsCharge_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnOptionsCharge_80" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions_80" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" xlink:label="loc_OKYOStockIssuedDuringPeriodShareslExerciseOfOptions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodShareslExerciseOfOptions_80" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfForfeiture_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfForfeiture_80" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity_80" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnWarrantsExercisedShares" xlink:label="loc_OKYOSharesIssuedOnWarrantsExercisedShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnWarrantsExercisedShares_80" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsCharge_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsCharge_80" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversion" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtConversion_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtConversion_80" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversionShares" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtConversionShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtConversionShares_80" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtInterest" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtInterest_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtInterest_80" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactions" xlink:label="loc_OKYOSharesIssuedOnTotalTransactions_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnTotalTransactions_80" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactionsShares" xlink:label="loc_OKYOSharesIssuedOnTotalTransactionsShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnTotalTransactionsShares_80" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_80" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_80" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullComprehensiveIncome_80" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:label="loc_OKYOSharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_80" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ReportingEntity" xlink:title="00000006 - Disclosure - Reporting Entity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPolicies" xlink:title="00000007 - Disclosure - ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:title="00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpenses" xlink:title="00000009 - Disclosure - OPERATING EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SegmentalReporting" xlink:title="00000010 - Disclosure - SEGMENTAL REPORTING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:title="00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:title="00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Taxation" xlink:title="00000013 - Disclosure - TAXATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:title="00000014 - Disclosure - FINANCE INCOME AND COSTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivables" xlink:title="00000016 - Disclosure - OTHER RECEIVABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayables" xlink:title="00000017 - Disclosure - TRADE AND OTHER PAYABLES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReserves" xlink:title="00000018 - Disclosure - CAPITAL AND RESERVES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:title="00000019 - Disclosure - SHARE OPTIONS AND WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:title="00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstruments" xlink:title="00000021 - Disclosure - FINANCIAL INSTRUMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:title="00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Leases" xlink:title="00000024 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemuneration" xlink:title="00000025 - Disclosure - Auditor&#8217;s Remuneration" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalents" xlink:title="00000026 - Disclosure - Cash and Cash Equivalents" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:title="00000027 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:title="00000028 - Disclosure - Post Balance Sheet Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesTables" xlink:title="00000030 - Disclosure - ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpensesTables" xlink:title="00000031 - Disclosure - OPERATING EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:title="00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:title="00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationTables" xlink:title="00000034 - Disclosure - TAXATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:title="00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesTables" xlink:title="00000037 - Disclosure - OTHER RECEIVABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:title="00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesTables" xlink:title="00000039 - Disclosure - CAPITAL AND RESERVES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:title="00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:title="00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:title="00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:title="00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesTables" xlink:title="00000044 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:title="00000045 - Disclosure - Auditor&#8217;s Remuneration (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:title="00000046 - Disclosure - Cash and Cash Equivalents (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:title="00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FurnitureAndFixtureMember" xlink:label="loc_OKYOFurnitureAndFixtureMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_OKYOFurnitureAndFixtureMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-fullComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_ifrs-fullComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NonadjustingEventMember" xlink:label="loc_OKYONonadjustingEventMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_OKYONonadjustingEventMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullRetainedEarnings_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentLiabilities_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashBurnRate" xlink:label="loc_OKYOCashBurnRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOCashBurnRate_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:title="00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:title="00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentMember" xlink:label="loc_OKYOResearchAndDevelopmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" xlink:to="loc_OKYOResearchAndDevelopmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CorporateAndAdministrationMember" xlink:label="loc_OKYOCorporateAndAdministrationMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" xlink:to="loc_OKYOCorporateAndAdministrationMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalaries" xlink:label="loc_OKYODirectorsSalaries_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsSalaries_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWagesAndSalaries_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-fullSocialSecurityContributions_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullSocialSecurityContributions_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="loc_ifrs-fullOtherShorttermEmployeeBenefits_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherShorttermEmployeeBenefits_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-fullEmployeeBenefitsExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEmployeeBenefitsExpense_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees" xlink:label="loc_ifrs-fullNumberOfEmployees_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfEmployees_130" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:title="00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GCerroneMember" xlink:label="loc_OKYOGCerroneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGCerroneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GJacobMember" xlink:label="loc_OKYOGJacobMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGJacobMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WSimonMember" xlink:label="loc_OKYOWSimonMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOWSimonMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KShailubhaiMember" xlink:label="loc_OKYOKShailubhaiMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOKShailubhaiMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_JBrancaccioMember" xlink:label="loc_OKYOJBrancaccioMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOJBrancaccioMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GMacraeMember" xlink:label="loc_OKYOGMacraeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGMacraeMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BDenoyerMember" xlink:label="loc_OKYOBDenoyerMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOBDenoyerMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LZambelettiMember" xlink:label="loc_OKYOLZambelettiMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOLZambelettiMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-fullDirectorsRemunerationExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDirectorsRemunerationExpense_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsBonus" xlink:label="loc_OKYODirectorsBonus_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsBonus_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalary" xlink:label="loc_OKYODirectorsSalary_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsSalary_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KeyManagementPersonnelCompensationSharebasedPayments" xlink:label="loc_OKYOKeyManagementPersonnelCompensationSharebasedPayments_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOKeyManagementPersonnelCompensationSharebasedPayments_220" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:title="00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GCerroneMember" xlink:label="loc_OKYOGCerroneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGCerroneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BonusAwarded" xlink:label="loc_OKYOBonusAwarded_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOBonusAwarded_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsMember" xlink:label="loc_OKYODirectorsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_OKYODirectorsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_JBrancaccioMember" xlink:label="loc_OKYOJBrancaccioMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOJBrancaccioMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GJacobMember" xlink:label="loc_OKYOGJacobMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGJacobMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BDenoyerMember" xlink:label="loc_OKYOBDenoyerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOBDenoyerMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="loc_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationShorttermEmployeeBenefits_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationShorttermEmployeeBenefits_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensation_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:title="00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:title="00000058 - Disclosure - TAXATION (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ITEquipmentMember" xlink:label="loc_OKYOITEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_OKYOITEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentCost" xlink:label="loc_OKYOPropertyPlantAndEquipmentCost_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentCost_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDisposalsPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisposalsPropertyPlantAndEquipment_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentDepreciation" xlink:label="loc_OKYOPropertyPlantAndEquipmentDepreciation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentDepreciation_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfChargeInYearDepreciation" xlink:label="loc_OKYOEffectOfChargeInYearDepreciation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOEffectOfChargeInYearDepreciation_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfForeignExchangeDepreciation" xlink:label="loc_OKYOEffectOfForeignExchangeDepreciation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOEffectOfForeignExchangeDepreciation_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationNetValue" xlink:label="loc_OKYODepreciationNetValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODepreciationNetValue_110" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveLineItems" xlink:label="loc_srtRealEstateWriteDownOrReserveLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveTable" xlink:label="loc_srtRealEstateWriteDownOrReserveTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtRealEstateWriteDownOrReserveLineItems" xlink:to="loc_srtRealEstateWriteDownOrReserveTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtRealEstateWriteDownOrReserveTable" xlink:to="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UKMember" xlink:label="loc_OKYOUKMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="loc_OKYOUKMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UnitedStateMember" xlink:label="loc_OKYOUnitedStateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="loc_OKYOUnitedStateMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRealEstateWriteDownOrReserveLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:title="00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:title="00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacement" xlink:label="loc_OKYONumberOfSharesIssuedPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYONumberOfSharesIssuedPrivatePlacement_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacementValue" xlink:label="loc_OKYONumberOfSharesIssuedPrivatePlacementValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYONumberOfSharesIssuedPrivatePlacementValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueWarrantsIssuedPrivatePlacement" xlink:label="loc_OKYOFairValueWarrantsIssuedPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOFairValueWarrantsIssuedPrivatePlacement_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IssuedInLieuValue" xlink:label="loc_OKYOIssuedInLieuValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIssuedInLieuValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfOptionsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfOptionsShares_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsEquityShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsEquityShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:label="loc_OKYOIncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:title="00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-fullOrdinarySharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ifrs-fullOrdinarySharesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveOneMember" xlink:label="loc_OKYOWarrantReserveOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOWarrantReserveOneMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveTwoMember" xlink:label="loc_OKYOWarrantReserveTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOWarrantReserveTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesMember" xlink:label="loc_OKYOLoanNotesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsMember" xlink:to="loc_OKYOLoanNotesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesOneMember" xlink:label="loc_OKYOLoanNotesOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsMember" xlink:to="loc_OKYOLoanNotesOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendPayables" xlink:label="loc_ifrs-fullDividendPayables_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDividendPayables_140" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateAxis" xlink:label="loc_OKYOGrantDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOGrantDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateDomain" xlink:label="loc_OKYOGrantDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_OKYOGrantDateAxis" xlink:to="loc_OKYOGrantDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateDomain" xlink:label="loc_OKYOGrantDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_OKYOGrantDateAxis" xlink:to="loc_OKYOGrantDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJulyTwoThousandEighteenMember" xlink:label="loc_OKYOSixJulyTwoThousandEighteenMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOSixJulyTwoThousandEighteenMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyAugustTwoThousandTwentyMember" xlink:label="loc_OKYOTwentyAugustTwoThousandTwentyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOTwentyAugustTwoThousandTwentyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJanuaryTwoThousandTwentyOneMember" xlink:label="loc_OKYOSixJanuaryTwoThousandTwentyOneMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOSixJanuaryTwoThousandTwentyOneMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwelveJanuaryTwoThousandTwentyOneMember" xlink:label="loc_OKYOTwelveJanuaryTwoThousandTwentyOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOTwelveJanuaryTwoThousandTwentyOneMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FifteenAprilTwoThousandTwentyOneMember" xlink:label="loc_OKYOFifteenAprilTwoThousandTwentyOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOFifteenAprilTwoThousandTwentyOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" xlink:label="loc_OKYOThirtyFirstAugustTwoThousandTwentyOneMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOThirtyFirstAugustTwoThousandTwentyOneMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:label="loc_OKYOThirtyFirstAugustTwoThousandTwentyTwoMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOThirtyFirstAugustTwoThousandTwentyTwoMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpirationDateOfOutstanding" xlink:label="loc_OKYOExpirationDateOfOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpirationDateOfOutstanding_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions_160" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateShareOptionsGranted2019" xlink:label="loc_OKYOGrantDateShareOptionsGranted2019_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOGrantDateShareOptionsGranted2019_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_VestingPeriodsDescription" xlink:label="loc_OKYOVestingPeriodsDescription_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOVestingPeriodsDescription_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_OptionLifePeriod" xlink:label="loc_OKYOOptionLifePeriod_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOOptionLifePeriod_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpectedLifeOfWarrants" xlink:label="loc_OKYOExpectedLifeOfWarrants_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpectedLifeOfWarrants_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsVestingPeriod" xlink:label="loc_OKYOWarrantsVestingPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsVestingPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpectedLifeOfWarrants" xlink:label="loc_OKYOExpectedLifeOfWarrants_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpectedLifeOfWarrants_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:title="00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsMember" xlink:label="loc_OKYOPrivatePlacementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOPrivatePlacementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsOneMember" xlink:label="loc_OKYOPrivatePlacementsOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOPrivatePlacementsOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="loc_ifrs-fullTypesOfContractsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullTypesOfContractsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfProfessionalFeesMember" xlink:label="loc_OKYOLieuOfProfessionalFeesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOLieuOfProfessionalFeesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfBrokerFeesMember" xlink:label="loc_OKYOLieuOfBrokerFeesMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOLieuOfBrokerFeesMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-fullBorrowingsByNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullBorrowingsByNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-fullBorrowingsByNameMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullBorrowingsByNameAxis" xlink:to="loc_ifrs-fullBorrowingsByNameMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-fullBorrowingsByNameMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullBorrowingsByNameAxis" xlink:to="loc_ifrs-fullBorrowingsByNameMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesMember" xlink:label="loc_OKYOConvertibleLoanNotesMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullBorrowingsByNameMember" xlink:to="loc_OKYOConvertibleLoanNotesMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesOneMember" xlink:label="loc_OKYOConvertibleLoanNotesOneMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullBorrowingsByNameMember" xlink:to="loc_OKYOConvertibleLoanNotesOneMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" xlink:label="loc_ifrs-fullDeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentCharge" xlink:label="loc_OKYOShareBasedPaymentCharge_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShareBasedPaymentCharge_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentChargeForfeiture" xlink:label="loc_OKYOShareBasedPaymentChargeForfeiture_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShareBasedPaymentChargeForfeiture_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-fullConsiderationPaidReceived_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullConsiderationPaidReceived_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisablePricePerShare" xlink:label="loc_OKYOWarrantsExercisablePricePerShare_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisablePricePerShare_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisableDate" xlink:label="loc_OKYOWarrantsExercisableDate_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisableDate_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnCashlessBasic" xlink:label="loc_OKYOWarrantsExercisedOnCashlessBasic_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnCashlessBasic_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnPriceReductionOffer" xlink:label="loc_OKYOWarrantsExercisedOnPriceReductionOffer_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnPriceReductionOffer_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnIssuances" xlink:label="loc_OKYOWarrantsExercisedOnIssuances_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnIssuances_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-fullProceedsFromExerciseOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromExerciseOfWarrants_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueOfWarrants" xlink:label="loc_OKYOFairValueOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOFairValueOfWarrants_170" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-fullClassesOfAssetsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullClassesOfAssetsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-fullClassesOfAssetsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfAssetsAxis" xlink:to="loc_ifrs-fullClassesOfAssetsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-fullClassesOfAssetsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfAssetsAxis" xlink:to="loc_ifrs-fullClassesOfAssetsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyNineMayTwoThousandAndTwentyMember" xlink:label="loc_OKYOTwentyNineMayTwoThousandAndTwentyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOTwentyNineMayTwoThousandAndTwentyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:label="loc_OKYOFeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOFeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentySevenJulyTwoThousandTwentyMember" xlink:label="loc_OKYOTwentySevenJulyTwoThousandTwentyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOTwentySevenJulyTwoThousandTwentyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SeventeenthAugustTwoThousandAndTwentyMember" xlink:label="loc_OKYOSeventeenthAugustTwoThousandAndTwentyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOSeventeenthAugustTwoThousandAndTwentyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeSeptemberTwoThousandAndTwentyMember" xlink:label="loc_OKYOThreeSeptemberTwoThousandAndTwentyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOThreeSeptemberTwoThousandAndTwentyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:label="loc_OKYOFeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOFeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConversionPricePerShares" xlink:label="loc_OKYOConversionPricePerShares_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOConversionPricePerShares_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantExercisePricePerShare" xlink:label="loc_OKYOWarrantExercisePricePerShare_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantExercisePricePerShare_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DebtTerm" xlink:label="loc_OKYODebtTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODebtTerm_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="loc_ifrs-fullIssueOfConvertibleInstruments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfConvertibleInstruments_140" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:title="00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LessThanThreeMember" xlink:label="loc_OKYOLessThanThreeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_OKYOLessThanThreeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeToTwelveMonthsMember" xlink:label="loc_OKYOThreeToTwelveMonthsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_OKYOThreeToTwelveMonthsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-fullFinancialLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullFinancialLiabilities_70" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WestAfricanMineralsLimitedMember" xlink:label="loc_OKYOWestAfricanMineralsLimitedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_OKYOWestAfricanMineralsLimitedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TizianaLifeSciencesLtdMember" xlink:label="loc_OKYOTizianaLifeSciencesLtdMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_OKYOTizianaLifeSciencesLtdMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="loc_ifrs-fullTypesOfContractsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullTypesOfContractsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ServiceAgreementMember" xlink:label="loc_OKYOServiceAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOServiceAgreementMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WriteOffExchangeOfLoan" xlink:label="loc_OKYOWriteOffExchangeOfLoan_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWriteOffExchangeOfLoan_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:label="loc_ifrs-fullRevenueFromSaleOfGoodsRelatedPartyTransactions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenueFromSaleOfGoodsRelatedPartyTransactions_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-fullNetDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetDebt_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LoansAndReceivables" xlink:label="loc_ifrs-fullLoansAndReceivables_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansAndReceivables_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:label="loc_ifrs-fullServicesReceivedRelatedPartyTransactions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullServicesReceivedRelatedPartyTransactions_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-fullAmountsPayableRelatedPartyTransactions_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountsPayableRelatedPartyTransactions_90" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:title="00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-fullNotLaterThanOneYearMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_ifrs-fullNotLaterThanOneYearMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-fullGrossLeaseLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullGrossLeaseLiabilities_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:title="00000081 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIfrsStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AllCurrenciesDomain" xlink:label="loc_OKYOAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_OKYOAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AllCurrenciesDomain" xlink:label="loc_OKYOAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_OKYOAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GBPMember" xlink:label="loc_OKYOGBPMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOAllCurrenciesDomain" xlink:to="loc_OKYOGBPMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_USDMember" xlink:label="loc_OKYOUSDMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOAllCurrenciesDomain" xlink:to="loc_OKYOUSDMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOnHand_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000084 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-fullProductsAndServicesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullProductsAndServicesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-fullProductsAndServicesMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-fullProductsAndServicesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIHumanClinicalTrialMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIHumanClinicalTrialMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIIHumanClinicalTrialMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIIHumanClinicalTrialMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIIIHumanClinicalTrialMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIIIHumanClinicalTrialMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmountOfLicensedProductOrService" xlink:label="loc_OKYOAmountOfLicensedProductOrService_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAmountOfLicensedProductOrService_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFee" xlink:label="loc_OKYOAnnualLicenseMaintenanceFee_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAnnualLicenseMaintenanceFee_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFeeTherafter" xlink:label="loc_OKYOAnnualLicenseMaintenanceFeeTherafter_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAnnualLicenseMaintenanceFeeTherafter_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:title="00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NonadjustingEventMember" xlink:label="loc_OKYONonadjustingEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_OKYONonadjustingEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmericanDepositorySharesMember" xlink:label="loc_OKYOAmericanDepositorySharesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_OKYOAmericanDepositorySharesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_Bonus" xlink:label="loc_OKYOBonus_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOBonus_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShorttermCreditFacility" xlink:label="loc_OKYOShorttermCreditFacility_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShorttermCreditFacility_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdditionalBorrowingsInterestRate" xlink:label="loc_OKYOAdditionalBorrowingsInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAdditionalBorrowingsInterestRate_50" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>okyo-20220331_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="ifrs-full_OtherReservesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Other reserves [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReservesMember" xlink:label="OKYO_WarrantReservesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReservesMember" xlink:to="OKYO_WarrantReservesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantReservesMember_lbl" xml:lang="en-US">Warrant Reserves [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserveMember" xlink:label="OKYO_ConvertibleLoanNoteReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNoteReserveMember" xlink:to="OKYO_ConvertibleLoanNoteReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ConvertibleLoanNoteReserveMember_lbl" xml:lang="en-US">Convertible loan note reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Retained earnings [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TranslationReserveMember" xlink:label="OKYO_TranslationReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TranslationReserveMember" xlink:to="OKYO_TranslationReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TranslationReserveMember_lbl" xml:lang="en-US">Translation reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NonadjustingEventMember" xlink:label="OKYO_NonadjustingEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NonadjustingEventMember" xlink:to="OKYO_NonadjustingEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_NonadjustingEventMember_lbl" xml:lang="en-US">Non-adjusting event [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FurnitureAndFixtureMember" xlink:label="OKYO_FurnitureAndFixtureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FurnitureAndFixtureMember" xlink:to="OKYO_FurnitureAndFixtureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FurnitureAndFixtureMember_lbl" xml:lang="en-US">Furniture and fixtures [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer equipment [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_lbl" xml:lang="en-US">Classes of intangible assets other than goodwill [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentMember" xlink:label="OKYO_ResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentMember" xlink:to="OKYO_ResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research and development [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CorporateAndAdministrationMember" xlink:label="OKYO_CorporateAndAdministrationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CorporateAndAdministrationMember" xlink:to="OKYO_CorporateAndAdministrationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_CorporateAndAdministrationMember_lbl" xml:lang="en-US">Corporate and administration [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GCerroneMember" xlink:label="OKYO_GCerroneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GCerroneMember" xlink:to="OKYO_GCerroneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GCerroneMember_lbl" xml:lang="en-US">G Cerrone [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GJacobMember" xlink:label="OKYO_GJacobMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GJacobMember" xlink:to="OKYO_GJacobMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GJacobMember_lbl" xml:lang="en-US">G Jacob [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WSimonMember" xlink:label="OKYO_WSimonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WSimonMember" xlink:to="OKYO_WSimonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WSimonMember_lbl" xml:lang="en-US">W Simon [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KShailubhaiMember" xlink:label="OKYO_KShailubhaiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KShailubhaiMember" xlink:to="OKYO_KShailubhaiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_KShailubhaiMember_lbl" xml:lang="en-US">K Shailubhai [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_JBrancaccioMember" xlink:label="OKYO_JBrancaccioMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_JBrancaccioMember" xlink:to="OKYO_JBrancaccioMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_JBrancaccioMember_lbl" xml:lang="en-US">J Brancaccio [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GMacraeMember" xlink:label="OKYO_GMacraeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GMacraeMember" xlink:to="OKYO_GMacraeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GMacraeMember_lbl" xml:lang="en-US">G Macrae [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BDenoyerMember" xlink:label="OKYO_BDenoyerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BDenoyerMember" xlink:to="OKYO_BDenoyerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_BDenoyerMember_lbl" xml:lang="en-US">B Denoyer [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LZambelettiMember" xlink:label="OKYO_LZambelettiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LZambelettiMember" xlink:to="OKYO_LZambelettiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LZambelettiMember_lbl" xml:lang="en-US">L Z ambeletti [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US">Categories of related parties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsMember" xlink:label="OKYO_DirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsMember" xlink:to="OKYO_DirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DirectorsMember_lbl" xml:lang="en-US">Directors [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ITEquipmentMember" xlink:label="OKYO_ITEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ITEquipmentMember" xlink:to="OKYO_ITEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ITEquipmentMember_lbl" xml:lang="en-US">IT equipment [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US">Name of Property [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UKMember" xlink:label="OKYO_UKMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_UKMember" xlink:to="OKYO_UKMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_UKMember_lbl" xml:lang="en-US">UK [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UnitedStateMember" xlink:label="OKYO_UnitedStateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_UnitedStateMember" xlink:to="OKYO_UnitedStateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_UnitedStateMember_lbl" xml:lang="en-US">US [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary shares [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="ifrs-full_WarrantReserveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserveMember" xlink:to="ifrs-full_WarrantReserveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserveMember_lbl" xml:lang="en-US">Warrant reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveOneMember" xlink:label="OKYO_WarrantReserveOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReserveOneMember" xlink:to="OKYO_WarrantReserveOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantReserveOneMember_lbl" xml:lang="en-US">Warrant reserve one [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesMember" xlink:label="OKYO_LoanNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LoanNotesMember" xlink:to="OKYO_LoanNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LoanNotesMember_lbl" xml:lang="en-US">Loan notes [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesOneMember" xlink:label="OKYO_LoanNotesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LoanNotesOneMember" xlink:to="OKYO_LoanNotesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LoanNotesOneMember_lbl" xml:lang="en-US">Loan notes one [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveTwoMember" xlink:label="OKYO_WarrantReserveTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReserveTwoMember" xlink:to="OKYO_WarrantReserveTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantReserveTwoMember_lbl" xml:lang="en-US">Warrant reserve two [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsMember" xlink:label="OKYO_PrivatePlacementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrivatePlacementsMember" xlink:to="OKYO_PrivatePlacementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PrivatePlacementsMember_lbl" xml:lang="en-US">Private placements [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsOneMember" xlink:label="OKYO_PrivatePlacementsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrivatePlacementsOneMember" xlink:to="OKYO_PrivatePlacementsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PrivatePlacementsOneMember_lbl" xml:lang="en-US">Private placements one [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US">Types of contracts [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfProfessionalFeesMember" xlink:label="OKYO_LieuOfProfessionalFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LieuOfProfessionalFeesMember" xlink:to="OKYO_LieuOfProfessionalFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LieuOfProfessionalFeesMember_lbl" xml:lang="en-US">Lieu of professional fees [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfBrokerFeesMember" xlink:label="OKYO_LieuOfBrokerFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LieuOfBrokerFeesMember" xlink:to="OKYO_LieuOfBrokerFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LieuOfBrokerFeesMember_lbl" xml:lang="en-US">Lieu of broker-fees [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US">Borrowings by name [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesMember" xlink:label="OKYO_ConvertibleLoanNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNotesMember" xlink:to="OKYO_ConvertibleLoanNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ConvertibleLoanNotesMember_lbl" xml:lang="en-US">Convertible loan notes [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesOneMember" xlink:label="OKYO_ConvertibleLoanNotesOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNotesOneMember" xlink:to="OKYO_ConvertibleLoanNotesOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ConvertibleLoanNotesOneMember_lbl" xml:lang="en-US">Convertible loan notes one [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateAxis" xlink:label="OKYO_GrantDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GrantDateAxis" xlink:to="OKYO_GrantDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GrantDateAxis_lbl" xml:lang="en-US">Grant Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJulyTwoThousandEighteenMember" xlink:label="OKYO_SixJulyTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SixJulyTwoThousandEighteenMember" xlink:to="OKYO_SixJulyTwoThousandEighteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SixJulyTwoThousandEighteenMember_lbl" xml:lang="en-US">6 July 2018 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyAugustTwoThousandTwentyMember" xlink:label="OKYO_TwentyAugustTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentyAugustTwoThousandTwentyMember" xlink:to="OKYO_TwentyAugustTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TwentyAugustTwoThousandTwentyMember_lbl" xml:lang="en-US">20 August 2020 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJanuaryTwoThousandTwentyOneMember" xlink:label="OKYO_SixJanuaryTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SixJanuaryTwoThousandTwentyOneMember" xlink:to="OKYO_SixJanuaryTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SixJanuaryTwoThousandTwentyOneMember_lbl" xml:lang="en-US">6 January 2021 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwelveJanuaryTwoThousandTwentyOneMember" xlink:label="OKYO_TwelveJanuaryTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwelveJanuaryTwoThousandTwentyOneMember" xlink:to="OKYO_TwelveJanuaryTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TwelveJanuaryTwoThousandTwentyOneMember_lbl" xml:lang="en-US">12 January 2021 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FifteenAprilTwoThousandTwentyOneMember" xlink:label="OKYO_FifteenAprilTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FifteenAprilTwoThousandTwentyOneMember" xlink:to="OKYO_FifteenAprilTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FifteenAprilTwoThousandTwentyOneMember_lbl" xml:lang="en-US">15 April 2021 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" xlink:to="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember_lbl" xml:lang="en-US">31 August 2021 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:to="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">31 January 2022 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US">Range [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US">Bottom of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US">Top of range [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US">Classes of assets [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyNineMayTwoThousandAndTwentyMember" xlink:label="OKYO_TwentyNineMayTwoThousandAndTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentyNineMayTwoThousandAndTwentyMember" xlink:to="OKYO_TwentyNineMayTwoThousandAndTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TwentyNineMayTwoThousandAndTwentyMember_lbl" xml:lang="en-US">29 May 2020 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:label="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:to="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_lbl" xml:lang="en-US">Fees relating to equity fundraise 29 May 2020 issued as CLN [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentySevenJulyTwoThousandTwentyMember" xlink:label="OKYO_TwentySevenJulyTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentySevenJulyTwoThousandTwentyMember" xlink:to="OKYO_TwentySevenJulyTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TwentySevenJulyTwoThousandTwentyMember_lbl" xml:lang="en-US">27 July 2020 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SeventeenthAugustTwoThousandAndTwentyMember" xlink:label="OKYO_SeventeenthAugustTwoThousandAndTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SeventeenthAugustTwoThousandAndTwentyMember" xlink:to="OKYO_SeventeenthAugustTwoThousandAndTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SeventeenthAugustTwoThousandAndTwentyMember_lbl" xml:lang="en-US">17 August 2020 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeSeptemberTwoThousandAndTwentyMember" xlink:label="OKYO_ThreeSeptemberTwoThousandAndTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThreeSeptemberTwoThousandAndTwentyMember" xlink:to="OKYO_ThreeSeptemberTwoThousandAndTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ThreeSeptemberTwoThousandAndTwentyMember_lbl" xml:lang="en-US">03 September 2022 [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:label="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:to="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_lbl" xml:lang="en-US">Fees relating to all other equity fundraise issued as CLN [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US">Maturity [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LessThanThreeMember" xlink:label="OKYO_LessThanThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LessThanThreeMember" xlink:to="OKYO_LessThanThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LessThanThreeMember_lbl" xml:lang="en-US">Less Than Three [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeToTwelveMonthsMember" xlink:label="OKYO_ThreeToTwelveMonthsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThreeToTwelveMonthsMember" xlink:to="OKYO_ThreeToTwelveMonthsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ThreeToTwelveMonthsMember_lbl" xml:lang="en-US">Three to Twelve Months [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US">Counterparties [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WestAfricanMineralsLimitedMember" xlink:label="OKYO_WestAfricanMineralsLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WestAfricanMineralsLimitedMember" xlink:to="OKYO_WestAfricanMineralsLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WestAfricanMineralsLimitedMember_lbl" xml:lang="en-US">West African Minerals Limited [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TizianaLifeSciencesLtdMember" xlink:label="OKYO_TizianaLifeSciencesLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TizianaLifeSciencesLtdMember" xlink:to="OKYO_TizianaLifeSciencesLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TizianaLifeSciencesLtdMember_lbl" xml:lang="en-US">Tiziana Life Sciences Ltd [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ServiceAgreementMember" xlink:label="OKYO_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ServiceAgreementMember" xlink:to="OKYO_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ServiceAgreementMember_lbl" xml:lang="en-US">Service agreement [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US">Not later than one year [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GBPMember" xlink:label="OKYO_GBPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GBPMember" xlink:to="OKYO_GBPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GBPMember_lbl" xml:lang="en-US">GBP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_USDMember" xlink:label="OKYO_USDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_USDMember" xlink:to="OKYO_USDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_USDMember_lbl" xml:lang="en-US">USD [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US">Products and services [axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIHumanClinicalTrialMember" xlink:label="OKYO_PhaseIHumanClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIHumanClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PhaseIHumanClinicalTrialMember_lbl" xml:lang="en-US">Phase I Human Clinical Trial [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIHumanClinicalTrialMember" xlink:label="OKYO_PhaseIIHumanClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIIHumanClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PhaseIIHumanClinicalTrialMember_lbl" xml:lang="en-US">Phase II Human Clinical Trial [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIIHumanClinicalTrialMember" xlink:label="OKYO_PhaseIIIHumanClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIIIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIIIHumanClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PhaseIIIHumanClinicalTrialMember_lbl" xml:lang="en-US">Phase III Human Clinical Trial [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmericanDepositorySharesMember" xlink:label="OKYO_AmericanDepositorySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AmericanDepositorySharesMember" xlink:to="OKYO_AmericanDepositorySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AmericanDepositorySharesMember_lbl" xml:lang="en-US">American depository shares [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US">Entity Addresses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_RelatedPartyReceivables" xlink:label="OKYO_RelatedPartyReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_RelatedPartyReceivables" xlink:to="OKYO_RelatedPartyReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_RelatedPartyReceivables_lbl" xml:lang="en-US">Related party receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CurrentTaxationReceivable" xlink:label="OKYO_CurrentTaxationReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CurrentTaxationReceivable" xlink:to="OKYO_CurrentTaxationReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_CurrentTaxationReceivable_lbl" xml:lang="en-US">Current taxation receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and Equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US">Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties_lbl" xml:lang="en-US">Related party payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities - current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities - non current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share premium</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="ifrs-full_ReserveOfSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPayments" xlink:to="ifrs-full_ReserveOfSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfSharebasedPayments_lbl" xml:lang="en-US">Share options reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserve" xlink:label="ifrs-full_WarrantReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WarrantReserve" xlink:to="ifrs-full_WarrantReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WarrantReserve_lbl" xml:lang="en-US">Warrants reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserve" xlink:label="OKYO_ConvertibleLoanNoteReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNoteReserve" xlink:to="OKYO_ConvertibleLoanNoteReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ConvertibleLoanNoteReserve_lbl" xml:lang="en-US">Convertible Loan Note reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ForeignCurrencyTranslationReserve" xlink:label="OKYO_ForeignCurrencyTranslationReserve" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ForeignCurrencyTranslationReserve" xlink:to="OKYO_ForeignCurrencyTranslationReserve_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ForeignCurrencyTranslationReserve_lbl" xml:lang="en-US">Foreign currency translation reserve</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Retained deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US">Profit or loss [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:label="ifrs-full_MaterialIncomeAndExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:to="ifrs-full_MaterialIncomeAndExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaterialIncomeAndExpenseAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpenseExcludingCostOfSales" xlink:label="ifrs-full_OperatingExpenseExcludingCostOfSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpenseExcludingCostOfSales" xlink:to="ifrs-full_OperatingExpenseExcludingCostOfSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpenseExcludingCostOfSales_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpairmentOfLoan" xlink:label="OKYO_ImpairmentOfLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpairmentOfLoan" xlink:to="OKYO_ImpairmentOfLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ImpairmentOfLoan_lbl" xml:lang="en-US">Impairment of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:label="OKYO_IncomeTaxExpenseBenefitContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:to="OKYO_IncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_IncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">Income tax provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Loss for the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other Comprehensive loss:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Exchange differences on translating foreign operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" xlink:to="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders_lbl" xml:lang="en-US">Basic and diluted loss per share attributable to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="OKYO_IfrsStatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IfrsStatementLineItems" xlink:to="OKYO_IfrsStatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IfrsStatementLineItems_lbl" xml:lang="en-US">IfrsStatementLineItems [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueNewIssue" xlink:label="OKYO_StockIssuedDuringPeriodValueNewIssue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodValueNewIssue" xlink:to="OKYO_StockIssuedDuringPeriodValueNewIssue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_StockIssuedDuringPeriodValueNewIssue_lbl" xml:lang="en-US">Issue of share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodSharesShareCapital" xlink:label="OKYO_StockIssuedDuringPeriodSharesShareCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodSharesShareCapital" xlink:to="OKYO_StockIssuedDuringPeriodSharesShareCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_StockIssuedDuringPeriodSharesShareCapital_lbl" xml:lang="en-US">Issuance of share capital, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:label="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:to="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest_lbl" xml:lang="en-US">Convertible loan note and warrant interest</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:label="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:to="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves_lbl" xml:lang="en-US">Transfer between equity reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnOptionsCharge" xlink:label="OKYO_SharesIssuedOnOptionsCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnOptionsCharge" xlink:to="OKYO_SharesIssuedOnOptionsCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnOptionsCharge_lbl" xml:lang="en-US">Options charge</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" xlink:label="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" xlink:to="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions_lbl" xml:lang="en-US">Options exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture_lbl" xml:lang="en-US">Options forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US">Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnWarrantsExercisedShares" xlink:label="OKYO_SharesIssuedOnWarrantsExercisedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnWarrantsExercisedShares" xlink:to="OKYO_SharesIssuedOnWarrantsExercisedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnWarrantsExercisedShares_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge_lbl" xml:lang="en-US">Warrants charge</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversion" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtConversion" xlink:to="OKYO_SharesIssuedOnConvertibleDebtConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversion_lbl" xml:lang="en-US">Convertible loan note conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversionShares" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtConversionShares" xlink:to="OKYO_SharesIssuedOnConvertibleDebtConversionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversionShares_lbl" xml:lang="en-US">Convertible debt conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtInterest" xlink:label="OKYO_SharesIssuedOnConvertibleDebtInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtInterest" xlink:to="OKYO_SharesIssuedOnConvertibleDebtInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnConvertibleDebtInterest_lbl" xml:lang="en-US">Convertible loan note interest</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactions" xlink:label="OKYO_SharesIssuedOnTotalTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnTotalTransactions" xlink:to="OKYO_SharesIssuedOnTotalTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnTotalTransactions_lbl" xml:lang="en-US">Total transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactionsShares" xlink:label="OKYO_SharesIssuedOnTotalTransactionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnTotalTransactionsShares" xlink:to="OKYO_SharesIssuedOnTotalTransactionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnTotalTransactionsShares_lbl" xml:lang="en-US">Total transactions, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_2_lbl" xml:lang="en-US">Loss for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US">Currency translation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_2_lbl" xml:lang="en-US">Total comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:label="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:to="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_lbl" xml:lang="en-US">Currency translation on Convertible Loan note conversion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_2_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US">Share option charge</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_lbl" xml:lang="en-US">Warrant charge</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_lbl" xml:lang="en-US">Forfeiture of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xml:lang="en-US">Amortization of right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_lbl" xml:lang="en-US">(Gain)/Loss on foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances_lbl" xml:lang="en-US">Impairment of loan to West African Minerals Ltd</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Gain on disposal of right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:label="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:to="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables_lbl" xml:lang="en-US">Net decrease/(increase) in related party receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:label="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:to="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables_lbl" xml:lang="en-US">Net increase/(decrease) in related party payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US">Net (increase)/decrease in operating assets/other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US">Net (decrease)/increase in trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss_lbl" xml:lang="en-US">Cash inflow from taxation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Acquisition of property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_lbl" xml:lang="en-US">Loan to West African Minerals Ltd</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US">Proceeds from issuance of ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US">Proceeds from issuance of convertible loan notes</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromOptionsExercised" xlink:label="OKYO_ProcessedFromOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ProcessedFromOptionsExercised" xlink:to="OKYO_ProcessedFromOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ProcessedFromOptionsExercised_lbl" xml:lang="en-US">Processed from options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromWarrantsExercised" xlink:label="OKYO_ProcessedFromWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ProcessedFromWarrantsExercised" xlink:to="OKYO_ProcessedFromWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ProcessedFromWarrantsExercised_lbl" xml:lang="en-US">Processed from warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashAdvancesAndLoansToRelatedParties" xlink:label="OKYO_CashAdvancesAndLoansToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CashAdvancesAndLoansToRelatedParties" xlink:to="OKYO_CashAdvancesAndLoansToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_CashAdvancesAndLoansToRelatedParties_lbl" xml:lang="en-US">Loan to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="ifrs-full_CashAdvancesAndLoansFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAdvancesAndLoansFromRelatedParties_lbl" xml:lang="en-US">Loan repayment from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US">Repayment of leasing liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net (decrease)/increase in cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalent, beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Exchange difference</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_3_lbl" xml:lang="en-US">Cash and cash equivalent, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureReportingEntityAbstract" xlink:label="OKYO_DisclosureReportingEntityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureReportingEntityAbstract" xlink:to="OKYO_DisclosureReportingEntityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureReportingEntityAbstract_lbl" xml:lang="en-US">Reporting Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfReportingEntityExplanatory" xlink:label="OKYO_DisclosureOfReportingEntityExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfReportingEntityExplanatory" xlink:to="OKYO_DisclosureOfReportingEntityExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureOfReportingEntityExplanatory_lbl" xml:lang="en-US">Reporting Entity</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="OKYO_DisclosureAccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureAccountingPoliciesAbstract" xlink:to="OKYO_DisclosureAccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureAccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US">ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" xlink:label="OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" xlink:to="OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract_lbl" xml:lang="en-US">Critical Accounting Judgements And Key Sources Of Estimation Uncertainty</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US">CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOperatingExpensesAbstract" xlink:label="OKYO_DisclosureOperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOperatingExpensesAbstract" xlink:to="OKYO_DisclosureOperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureSegmentalReportingAbstract" xlink:label="OKYO_DisclosureSegmentalReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureSegmentalReportingAbstract" xlink:to="OKYO_DisclosureSegmentalReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureSegmentalReportingAbstract_lbl" xml:lang="en-US">Segmental Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">SEGMENTAL REPORTING</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:label="OKYO_DisclosureEmployeesIncludingOfficersAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:to="OKYO_DisclosureEmployeesIncludingOfficersAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureEmployeesIncludingOfficersAbstract_lbl" xml:lang="en-US">Employees Including Officers</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfEmployeeDetailsExplanatory" xlink:label="OKYO_DisclosureOfEmployeeDetailsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfEmployeeDetailsExplanatory" xlink:to="OKYO_DisclosureOfEmployeeDetailsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfEmployeeDetailsExplanatory_lbl" xml:lang="en-US">EMPLOYEES INCLUDING OFFICERS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract_lbl" xml:lang="en-US">Remuneration Of Key Management Personnel</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_lbl" xml:lang="en-US">REMUNERATION OF KEY MANAGEMENT PERSONNEL</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="OKYO_DisclosureTaxationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureTaxationAbstract" xlink:to="OKYO_DisclosureTaxationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureTaxationAbstract_lbl" xml:lang="en-US">Taxation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US">TAXATION</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:label="OKYO_DisclosureFinanceIncomeAndCostsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:to="OKYO_DisclosureFinanceIncomeAndCostsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureFinanceIncomeAndCostsAbstract_lbl" xml:lang="en-US">Finance Income And Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US">FINANCE INCOME AND COSTS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="OKYO_DisclosurePropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:to="OKYO_DisclosurePropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosurePropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property Plant And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOtherReceivablesAbstract" xlink:label="OKYO_DisclosureOtherReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOtherReceivablesAbstract" xlink:to="OKYO_DisclosureOtherReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOtherReceivablesAbstract_lbl" xml:lang="en-US">Other Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">OTHER RECEIVABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:label="OKYO_DisclosureTradeAndOtherPayablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:to="OKYO_DisclosureTradeAndOtherPayablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureTradeAndOtherPayablesAbstract_lbl" xml:lang="en-US">Trade And Other Payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US">TRADE AND OTHER PAYABLES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCapitalAndReservesAbstract" xlink:label="OKYO_DisclosureCapitalAndReservesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureCapitalAndReservesAbstract" xlink:to="OKYO_DisclosureCapitalAndReservesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureCapitalAndReservesAbstract_lbl" xml:lang="en-US">Capital And Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">CAPITAL AND RESERVES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="OKYO_DisclosureShareOptionsAndWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:to="OKYO_DisclosureShareOptionsAndWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureShareOptionsAndWarrantsAbstract_lbl" xml:lang="en-US">Share Options And Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">SHARE OPTIONS AND WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:label="OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:to="OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract_lbl" xml:lang="en-US">Convertible Instruments Classified As Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="ifrs-full_DisclosureOfDebtSecuritiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:to="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDebtSecuritiesExplanatory_lbl" xml:lang="en-US">CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinancialInstrumentsAbstract" xlink:label="OKYO_DisclosureFinancialInstrumentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureFinancialInstrumentsAbstract" xlink:to="OKYO_DisclosureFinancialInstrumentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureFinancialInstrumentsAbstract_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">FINANCIAL INSTRUMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRelatedPartyTransactionsAbstract" xlink:label="OKYO_DisclosureRelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureRelatedPartyTransactionsAbstract" xlink:to="OKYO_DisclosureRelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:label="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract_lbl" xml:lang="en-US">Basic And Diluted Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="OKYO_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureLeasesAbstract" xlink:to="OKYO_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US">Disclosure of notes and other explanatory information [text block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:to="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAuditorsRemunerationExplanatory_lbl" xml:lang="en-US">Auditor&#8217;s Remuneration</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCashAndCashEquivalentsAbstract" xlink:label="OKYO_DisclosureCashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureCashAndCashEquivalentsAbstract" xlink:to="OKYO_DisclosureCashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash And Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCommitmentsAndContingenciesAbstract" xlink:label="OKYO_DisclosureCommitmentsAndContingenciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureCommitmentsAndContingenciesAbstract" xlink:to="OKYO_DisclosureCommitmentsAndContingenciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureCommitmentsAndContingenciesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePostBalanceSheetEventsAbstract" xlink:label="OKYO_DisclosurePostBalanceSheetEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosurePostBalanceSheetEventsAbstract" xlink:to="OKYO_DisclosurePostBalanceSheetEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosurePostBalanceSheetEventsAbstract_lbl" xml:lang="en-US">Post Balance Sheet Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Post Balance Sheet Events</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" xlink:label="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" xlink:to="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_lbl" xml:lang="en-US">Basis of preparation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:to="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_lbl" xml:lang="en-US">Basis of measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:to="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGoingConcernExplanatory_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory_lbl" xml:lang="en-US">Basis of consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US">Segment reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US">Taxation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_lbl" xml:lang="en-US">Foreign currency translation</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" xlink:label="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory_lbl" xml:lang="en-US">License fees</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" xlink:label="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">Financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US">Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" xlink:label="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" xlink:label="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_lbl" xml:lang="en-US">Share based payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory_lbl" xml:lang="en-US">Convertible loan notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US">Fair Value Measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" xlink:label="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" xlink:to="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory_lbl" xml:lang="en-US">DISCLOSURE OF ESTIMATED USEFUL LIVES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_lbl" xml:lang="en-US">DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory_lbl" xml:lang="en-US">DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF REMUNERATION OF DIRECTORS</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" xlink:label="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" xlink:to="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF TAX CREDIT PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceCostExplanatory_lbl" xml:lang="en-US">SCHEDULE OF FINANCE COST</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" xlink:label="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" xlink:to="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US">DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_lbl" xml:lang="en-US">DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US">SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_lbl" xml:lang="en-US">SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_lbl" xml:lang="en-US">SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_lbl" xml:lang="en-US">SCHEDULE OF INPUTS FOR WARRANTS GRANTED</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" xlink:label="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" xlink:to="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US">SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US">SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_lbl" xml:lang="en-US">SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_lbl" xml:lang="en-US">SCHEDULE OF COMPANY AUDITORS FEES</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">SCHEDULE OF CASH AND CASH EQUIVALENT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:to="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RetainedEarnings_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_4_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_2_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashBurnRate" xlink:label="OKYO_CashBurnRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CashBurnRate" xlink:to="OKYO_CashBurnRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_CashBurnRate_lbl" xml:lang="en-US">Rate of cash burn/spend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOperatingExpensesAbstract" xlink:to="OKYO_DisclosureOperatingExpensesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureOperatingExpensesAbstract_2_lbl" xml:lang="en-US">Disclosure Of Detailed Information About Operating Expenses Explanatory</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KeyManagementPersonnelCompensationDirectorFees" xlink:label="OKYO_KeyManagementPersonnelCompensationDirectorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KeyManagementPersonnelCompensationDirectorFees" xlink:to="OKYO_KeyManagementPersonnelCompensationDirectorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_KeyManagementPersonnelCompensationDirectorFees_lbl" xml:lang="en-US">Director fees including bonus (excluding Chairman&#8217;s bonus)</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ChairmansBonus" xlink:label="OKYO_ChairmansBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ChairmansBonus" xlink:to="OKYO_ChairmansBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ChairmansBonus_lbl" xml:lang="en-US">Chairman&#8217;s bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemuneration" xlink:label="ifrs-full_AuditorsRemuneration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemuneration_lbl" xml:lang="en-US">Auditor&#8217;s Remuneration (refer to Note 20)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US">Legal and Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GainlossOnDisposalOfLeases" xlink:label="OKYO_GainlossOnDisposalOfLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GainlossOnDisposalOfLeases" xlink:to="OKYO_GainlossOnDisposalOfLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GainlossOnDisposalOfLeases_lbl" xml:lang="en-US">(Gain)/Loss on disposal of leases</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ForeignExchangeLossesGains" xlink:label="OKYO_ForeignExchangeLossesGains" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ForeignExchangeLossesGains" xlink:to="OKYO_ForeignExchangeLossesGains_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ForeignExchangeLossesGains_lbl" xml:lang="en-US">FX Gains and losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US">Disclosure of detailed information about intangible assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalaries" xlink:label="OKYO_DirectorsSalaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsSalaries" xlink:to="OKYO_DirectorsSalaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DirectorsSalaries_lbl" xml:lang="en-US">Directors&#8217; salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US">Wages and salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US">Social security costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherShorttermEmployeeBenefits" xlink:to="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherShorttermEmployeeBenefits_lbl" xml:lang="en-US">Recruitment Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">&#160;Total employee benefits expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees" xlink:label="ifrs-full_NumberOfEmployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfEmployees" xlink:to="ifrs-full_NumberOfEmployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfEmployees_lbl" xml:lang="en-US">Total number of employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:to="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans_lbl" xml:lang="en-US">Pension contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="OKYO_IfrsStatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IfrsStatementTable" xlink:to="OKYO_IfrsStatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IfrsStatementTable_lbl" xml:lang="en-US">IfrsStatementTable [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="ifrs-full_DirectorsRemunerationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DirectorsRemunerationExpense" xlink:to="ifrs-full_DirectorsRemunerationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DirectorsRemunerationExpense_lbl" xml:lang="en-US">Directors' fees</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsBonus" xlink:label="OKYO_DirectorsBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsBonus" xlink:to="OKYO_DirectorsBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DirectorsBonus_lbl" xml:lang="en-US">Bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalary" xlink:label="OKYO_DirectorsSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsSalary" xlink:to="OKYO_DirectorsSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DirectorsSalary_lbl" xml:lang="en-US">[custom:DirectorsSalary]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KeyManagementPersonnelCompensationSharebasedPayments" xlink:label="OKYO_KeyManagementPersonnelCompensationSharebasedPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KeyManagementPersonnelCompensationSharebasedPayments" xlink:to="OKYO_KeyManagementPersonnelCompensationSharebasedPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_KeyManagementPersonnelCompensationSharebasedPayments_lbl" xml:lang="en-US">Share based payment expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BonusAwarded" xlink:label="OKYO_BonusAwarded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BonusAwarded" xlink:to="OKYO_BonusAwarded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_BonusAwarded_lbl" xml:lang="en-US">Bonus awarded</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US">Disclosure of transactions between related parties [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US">Short-term employee benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US">Share based payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureTaxationAbstract" xlink:to="OKYO_DisclosureTaxationAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureTaxationAbstract_2_lbl" xml:lang="en-US">Schedule Of Tax Credit Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="ifrs-full_CurrentTaxExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncome" xlink:to="ifrs-full_CurrentTaxExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncome_lbl" xml:lang="en-US">Current year tax (credit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:to="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod_lbl" xml:lang="en-US">Adjustments in respect of prior periods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_lbl" xml:lang="en-US">Origination and reversal of timing differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Total tax (credit) for the period</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LossBeforeTaxation" xlink:label="OKYO_LossBeforeTaxation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LossBeforeTaxation" xlink:to="OKYO_LossBeforeTaxation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LossBeforeTaxation_lbl" xml:lang="en-US">Loss before taxation</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LossChargedAtStandardRateOfCorporationTax" xlink:label="OKYO_LossChargedAtStandardRateOfCorporationTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LossChargedAtStandardRateOfCorporationTax" xlink:to="OKYO_LossChargedAtStandardRateOfCorporationTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LossChargedAtStandardRateOfCorporationTax_lbl" xml:lang="en-US">Loss charged at standard rate of corporation tax 19%</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_lbl" xml:lang="en-US">Tax losses arising in the year not recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TaxLossesSurrenderedForResearchAndDevelopment" xlink:label="OKYO_TaxLossesSurrenderedForResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TaxLossesSurrenderedForResearchAndDevelopment" xlink:to="OKYO_TaxLossesSurrenderedForResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TaxLossesSurrenderedForResearchAndDevelopment_lbl" xml:lang="en-US">Tax losses surrendered for Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:to="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_lbl" xml:lang="en-US">Expenses not deductible for taxation</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" xlink:label="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" xlink:to="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_lbl" xml:lang="en-US">Tax increase from effect of capital allowances and depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentTaxClaim" xlink:label="OKYO_ResearchAndDevelopmentTaxClaim" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentTaxClaim" xlink:to="OKYO_ResearchAndDevelopmentTaxClaim_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ResearchAndDevelopmentTaxClaim_lbl" xml:lang="en-US">Research and Development tax claim</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentEnhancedExpenditure" xlink:label="OKYO_ResearchAndDevelopmentEnhancedExpenditure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentEnhancedExpenditure" xlink:to="OKYO_ResearchAndDevelopmentEnhancedExpenditure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ResearchAndDevelopmentEnhancedExpenditure_lbl" xml:lang="en-US">Research and Development enhanced expenditure</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:to="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_lbl" xml:lang="en-US">Research and Development tax credits claimed in respect of previous periods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:to="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets_lbl" xml:lang="en-US">Consolidation adjustment in relation to foreign exchange movements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" xlink:label="ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" xlink:to="ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_lbl" xml:lang="en-US">Loans written off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureTaxationAbstract" xlink:to="OKYO_DisclosureTaxationAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="OKYO_DisclosureTaxationAbstract_3_lbl" xml:lang="en-US">Schedule Of Tax Credit Period Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US">Corporation tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="ifrs-full_TaxEffectOfTaxLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectOfTaxLosses" xlink:to="ifrs-full_TaxEffectOfTaxLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxEffectOfTaxLosses_lbl" xml:lang="en-US">Tax effect of tax losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:to="OKYO_DisclosureFinanceIncomeAndCostsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureFinanceIncomeAndCostsAbstract_2_lbl" xml:lang="en-US">Schedule Of Finance Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinanceIncome_2_lbl" xml:lang="en-US">Finance income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_FinanceCosts_2_lbl" xml:lang="en-US">Finance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentCost" xlink:label="OKYO_PropertyPlantAndEquipmentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentCost" xlink:to="OKYO_PropertyPlantAndEquipmentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="OKYO_PropertyPlantAndEquipmentCost_lbl" xml:lang="en-US">Property and equipment, cost, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Disposals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Foreign exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentCost" xlink:to="OKYO_PropertyPlantAndEquipmentCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="OKYO_PropertyPlantAndEquipmentCost_2_lbl" xml:lang="en-US">Property and equipment, cost, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentDepreciation" xlink:label="OKYO_PropertyPlantAndEquipmentDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentDepreciation" xlink:to="OKYO_PropertyPlantAndEquipmentDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="OKYO_PropertyPlantAndEquipmentDepreciation_lbl" xml:lang="en-US">Depreciation, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfChargeInYearDepreciation" xlink:label="OKYO_EffectOfChargeInYearDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_EffectOfChargeInYearDepreciation" xlink:to="OKYO_EffectOfChargeInYearDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_EffectOfChargeInYearDepreciation_lbl" xml:lang="en-US">Charge in year</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfForeignExchangeDepreciation" xlink:label="OKYO_EffectOfForeignExchangeDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_EffectOfForeignExchangeDepreciation" xlink:to="OKYO_EffectOfForeignExchangeDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_EffectOfForeignExchangeDepreciation_lbl" xml:lang="en-US">Foreign exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentDepreciation" xlink:to="OKYO_PropertyPlantAndEquipmentDepreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="OKYO_PropertyPlantAndEquipmentDepreciation_2_lbl" xml:lang="en-US">Depreciation, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationNetValue" xlink:label="OKYO_DepreciationNetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationNetValue" xlink:to="OKYO_DepreciationNetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DepreciationNetValue_lbl" xml:lang="en-US">Depreciation, net book value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveTable" xlink:label="srt_RealEstateWriteDownOrReserveTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateWriteDownOrReserveTable" xlink:to="srt_RealEstateWriteDownOrReserveTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateWriteDownOrReserveTable_lbl" xml:lang="en-US">SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveLineItems" xlink:label="srt_RealEstateWriteDownOrReserveLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RealEstateWriteDownOrReserveLineItems" xlink:to="srt_RealEstateWriteDownOrReserveLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RealEstateWriteDownOrReserveLineItems_lbl" xml:lang="en-US">SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOtherReceivablesAbstract" xlink:to="OKYO_DisclosureOtherReceivablesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureOtherReceivablesAbstract_2_lbl" xml:lang="en-US">Disclosure Of Detailed Trade And Other Receivables Explanatory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables_lbl" xml:lang="en-US">VAT receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Prepayments" xlink:label="ifrs-full_Prepayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Prepayments" xlink:to="ifrs-full_Prepayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Prepayments_lbl" xml:lang="en-US">Prepayments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US">Trade and other receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrepaymentsReceivables" xlink:label="OKYO_PrepaymentsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrepaymentsReceivables" xlink:to="OKYO_PrepaymentsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PrepaymentsReceivables_lbl" xml:lang="en-US">Prepayments receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:to="OKYO_DisclosureTradeAndOtherPayablesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureTradeAndOtherPayablesAbstract_2_lbl" xml:lang="en-US">Disclosure Of Detailed Information About Payables And Accrued Liabilities Explanatory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US">Trade payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals" xlink:label="ifrs-full_Accruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Accruals" xlink:to="ifrs-full_Accruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Accruals_lbl" xml:lang="en-US">Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BonusAccrual" xlink:label="OKYO_BonusAccrual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BonusAccrual" xlink:to="OKYO_BonusAccrual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_BonusAccrual_lbl" xml:lang="en-US">Bonus accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:label="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:to="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacement" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NumberOfSharesIssuedPrivatePlacement" xlink:to="OKYO_NumberOfSharesIssuedPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacement_lbl" xml:lang="en-US">Shares issued - private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacementValue" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacementValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NumberOfSharesIssuedPrivatePlacementValue" xlink:to="OKYO_NumberOfSharesIssuedPrivatePlacementValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacementValue_lbl" xml:lang="en-US">Shares issued - private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueWarrantsIssuedPrivatePlacement" xlink:label="OKYO_FairValueWarrantsIssuedPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FairValueWarrantsIssuedPrivatePlacement" xlink:to="OKYO_FairValueWarrantsIssuedPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FairValueWarrantsIssuedPrivatePlacement_lbl" xml:lang="en-US">Relative Fair value charge for warrants issued in conjunction with private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IssuedInLieuValue" xlink:label="OKYO_IssuedInLieuValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IssuedInLieuValue" xlink:to="OKYO_IssuedInLieuValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IssuedInLieuValue_lbl" xml:lang="en-US">CLNs issued in lieu of fundraising commission</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_lbl" xml:lang="en-US">Options exercised, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_lbl" xml:lang="en-US">Exercise of warrants, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_2_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:label="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:to="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_lbl" xml:lang="en-US">Conversion of CLN, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments_lbl" xml:lang="en-US">Conversion of CLN</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_lbl" xml:lang="en-US">Ordinary shares were issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US">Ordinary shares were issued, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendPayables" xlink:label="ifrs-full_DividendPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DividendPayables" xlink:to="ifrs-full_DividendPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DividendPayables_lbl" xml:lang="en-US">Payment of dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:to="OKYO_DisclosureShareOptionsAndWarrantsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureShareOptionsAndWarrantsAbstract_2_lbl" xml:lang="en-US">Schedule Of Options Outstanding And Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_2_lbl" xml:lang="en-US">Beginning balance, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Beginning balance, Weighted Average Exercise price, outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Options, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise price, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted Average Exercise price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_3_lbl" xml:lang="en-US">Ending balance, Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Ending balance, Weighted Average Exercise price, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Options, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Ending balance, Weighted Average Exercise price, Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GrantDateAxis" xlink:to="OKYO_GrantDateAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_GrantDateAxis_2_lbl" xml:lang="en-US">GrantDateAxis [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpirationDateOfOutstanding" xlink:label="OKYO_ExpirationDateOfOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ExpirationDateOfOutstanding" xlink:to="OKYO_ExpirationDateOfOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ExpirationDateOfOutstanding_lbl" xml:lang="en-US">Expiration date of outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfOutstandingShareOptions_4_lbl" xml:lang="en-US">Share Options, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US">Disclosure of detailed information about borrowings [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateShareOptionsGranted2019" xlink:label="OKYO_GrantDateShareOptionsGranted2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GrantDateShareOptionsGranted2019" xlink:to="OKYO_GrantDateShareOptionsGranted2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_GrantDateShareOptionsGranted2019_lbl" xml:lang="en-US">Grant date share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_2_lbl" xml:lang="en-US">Exercise share price</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_VestingPeriodsDescription" xlink:label="OKYO_VestingPeriodsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_VestingPeriodsDescription" xlink:to="OKYO_VestingPeriodsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_VestingPeriodsDescription_lbl" xml:lang="en-US">Vesting periods</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_OptionLifePeriod" xlink:label="OKYO_OptionLifePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_OptionLifePeriod" xlink:to="OKYO_OptionLifePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_OptionLifePeriod_lbl" xml:lang="en-US">Option life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Weighted average exercise price, outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Warrants exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US">Weighted average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_lbl" xml:lang="en-US">Grant date share price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpectedLifeOfWarrants" xlink:label="OKYO_ExpectedLifeOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ExpectedLifeOfWarrants" xlink:to="OKYO_ExpectedLifeOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ExpectedLifeOfWarrants_lbl" xml:lang="en-US">Expected life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019_2_lbl" xml:lang="en-US">Weighted average share price, share options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_3_lbl" xml:lang="en-US">Exercise price, share options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsVestingPeriod" xlink:label="OKYO_WarrantsVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsVestingPeriod" xlink:to="OKYO_WarrantsVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_WarrantsVestingPeriod_lbl" xml:lang="en-US">Vesting periods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_2_lbl" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_2_lbl" xml:lang="en-US">Expected volatility, share options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ExpectedLifeOfWarrants" xlink:to="OKYO_ExpectedLifeOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_ExpectedLifeOfWarrants_2_lbl" xml:lang="en-US">[custom:ExpectedLifeOfWarrants]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_3_lbl" xml:lang="en-US">Number of option were exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" xlink:label="ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" xlink:to="ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_lbl" xml:lang="en-US">Fair value charge of share option instruments deemed</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentCharge" xlink:label="OKYO_ShareBasedPaymentCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShareBasedPaymentCharge" xlink:to="OKYO_ShareBasedPaymentCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ShareBasedPaymentCharge_lbl" xml:lang="en-US">Share based payment charge</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentChargeForfeiture" xlink:label="OKYO_ShareBasedPaymentChargeForfeiture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShareBasedPaymentChargeForfeiture" xlink:to="OKYO_ShareBasedPaymentChargeForfeiture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ShareBasedPaymentChargeForfeiture_lbl" xml:lang="en-US">Share based payment charge forfeiture</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US">Weighted average contractual life of options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="ifrs-full_ConsiderationPaidReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConsiderationPaidReceived" xlink:to="ifrs-full_ConsiderationPaidReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConsiderationPaidReceived_lbl" xml:lang="en-US">Consideration received</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisablePricePerShare" xlink:label="OKYO_WarrantsExercisablePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisablePricePerShare" xlink:to="OKYO_WarrantsExercisablePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsExercisablePricePerShare_lbl" xml:lang="en-US">Warrants exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisableDate" xlink:label="OKYO_WarrantsExercisableDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisableDate" xlink:to="OKYO_WarrantsExercisableDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsExercisableDate_lbl" xml:lang="en-US">Warrants exercisable date</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnCashlessBasic" xlink:label="OKYO_WarrantsExercisedOnCashlessBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnCashlessBasic" xlink:to="OKYO_WarrantsExercisedOnCashlessBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsExercisedOnCashlessBasic_lbl" xml:lang="en-US">Warrants exercised on cashless basic</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnPriceReductionOffer" xlink:label="OKYO_WarrantsExercisedOnPriceReductionOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnPriceReductionOffer" xlink:to="OKYO_WarrantsExercisedOnPriceReductionOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsExercisedOnPriceReductionOffer_lbl" xml:lang="en-US">Warrants exercised on price reduction offer</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnIssuances" xlink:label="OKYO_WarrantsExercisedOnIssuances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnIssuances" xlink:to="OKYO_WarrantsExercisedOnIssuances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsExercisedOnIssuances_lbl" xml:lang="en-US">Warrants exercised on issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US">Proceeds from warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueOfWarrants" xlink:label="OKYO_FairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FairValueOfWarrants" xlink:to="OKYO_FairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_FairValueOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US">Disclosure of fair value measurement of assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConversionPricePerShares" xlink:label="OKYO_ConversionPricePerShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConversionPricePerShares" xlink:to="OKYO_ConversionPricePerShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ConversionPricePerShares_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantExercisePricePerShare" xlink:label="OKYO_WarrantExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantExercisePricePerShare" xlink:to="OKYO_WarrantExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantExercisePricePerShare_lbl" xml:lang="en-US">Warrant Exercise per share</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DebtTerm" xlink:label="OKYO_DebtTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DebtTerm" xlink:to="OKYO_DebtTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DebtTerm_lbl" xml:lang="en-US">Debt term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US">Issue of convertible instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable_lbl" xml:lang="en-US">Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Trade and other payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherPayablesToRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherPayablesToRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesToRelatedParties_lbl" xml:lang="en-US">Related party payables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialLiabilities_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable_lbl" xml:lang="en-US">Disclosure of offsetting of financial assets [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WriteOffExchangeOfLoan" xlink:label="OKYO_WriteOffExchangeOfLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WriteOffExchangeOfLoan" xlink:to="OKYO_WriteOffExchangeOfLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WriteOffExchangeOfLoan_lbl" xml:lang="en-US">Write off related party exchange of loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:label="ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:to="ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions_lbl" xml:lang="en-US">Revenue from sale of goods, related party transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDebt" xlink:label="ifrs-full_NetDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDebt" xlink:to="ifrs-full_NetDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDebt_lbl" xml:lang="en-US">Net debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US">Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LoansAndReceivables" xlink:label="ifrs-full_LoansAndReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LoansAndReceivables" xlink:to="ifrs-full_LoansAndReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LoansAndReceivables_lbl" xml:lang="en-US">Loans receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherPayablesToRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherPayablesToRelatedParties_2_lbl" xml:lang="en-US">Payables to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:label="ifrs-full_ServicesReceivedRelatedPartyTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:to="ifrs-full_ServicesReceivedRelatedPartyTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ServicesReceivedRelatedPartyTransactions_lbl" xml:lang="en-US">Service received related party transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:to="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmountsPayableRelatedPartyTransactions_lbl" xml:lang="en-US">Amounts Payable related party transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureBasicAndDilutedLossPerShareAbstract_2_lbl" xml:lang="en-US">Summary Of Income And Share Data Used In Basic And Diluted Loss Per Share Computations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:to="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_lbl" xml:lang="en-US">(Loss) attributable to equity holders of the company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of ordinary shares in issue</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BasicAndDilutedEarningsLossPerShare" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BasicAndDilutedEarningsLossPerShare" xlink:to="OKYO_BasicAndDilutedEarningsLossPerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US">Basic and dilutive loss per share (cents per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureLeasesAbstract" xlink:to="OKYO_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Right Of Use Assets And Lease Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_RightofuseAssets_2_lbl" xml:lang="en-US">Right-of-use assets, balance as at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsRightOfUseAssets" xlink:label="OKYO_DisposalsRightOfUseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsRightOfUseAssets" xlink:to="OKYO_DisposalsRightOfUseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisposalsRightOfUseAssets_lbl" xml:lang="en-US">Derecognition of right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpactOfForeignExchange" xlink:label="OKYO_ImpactOfForeignExchange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpactOfForeignExchange" xlink:to="OKYO_ImpactOfForeignExchange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_ImpactOfForeignExchange_lbl" xml:lang="en-US">Impact of Foreign exchange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_RightofuseAssets_3_lbl" xml:lang="en-US">Right-of-use assets, balance as at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationOfEarlyTerminatedLease" xlink:label="OKYO_DepreciationOfEarlyTerminatedLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationOfEarlyTerminatedLease" xlink:to="OKYO_DepreciationOfEarlyTerminatedLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DepreciationOfEarlyTerminatedLease_lbl" xml:lang="en-US">Depreciation of early terminated lease</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsRightOfUseAssets" xlink:to="OKYO_DisposalsRightOfUseAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_DisposalsRightOfUseAssets_2_lbl" xml:lang="en-US">Early Termination write off</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpactOfForeignExchange" xlink:to="OKYO_ImpactOfForeignExchange_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ImpactOfForeignExchange_2_lbl" xml:lang="en-US">Impact of Foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationOfNewLease" xlink:label="OKYO_DepreciationOfNewLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationOfNewLease" xlink:to="OKYO_DepreciationOfNewLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DepreciationOfNewLease_lbl" xml:lang="en-US">Depreciation of new lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease Liabilities, balance as at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeaseLiabilitiesInterestExpense" xlink:label="OKYO_LeaseLiabilitiesInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeaseLiabilitiesInterestExpense" xlink:to="OKYO_LeaseLiabilitiesInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LeaseLiabilitiesInterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeasePayments" xlink:label="OKYO_LeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeasePayments" xlink:to="OKYO_LeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LeasePayments_lbl" xml:lang="en-US">Lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpactOfForeignExchangeLeaseLiabilities" xlink:label="OKYO_ImpactOfForeignExchangeLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpactOfForeignExchangeLeaseLiabilities" xlink:to="OKYO_ImpactOfForeignExchangeLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ImpactOfForeignExchangeLeaseLiabilities_lbl" xml:lang="en-US">Impact of foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DerecognitionOfLeaseLiability" xlink:label="OKYO_DerecognitionOfLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DerecognitionOfLeaseLiability" xlink:to="OKYO_DerecognitionOfLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DerecognitionOfLeaseLiability_lbl" xml:lang="en-US">Derecognition of lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsLeaseLiabilities" xlink:label="OKYO_DisposalsLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsLeaseLiabilities" xlink:to="OKYO_DisposalsLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="OKYO_DisposalsLeaseLiabilities_lbl" xml:lang="en-US">Early Termination write off</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdditionsToLeaseLiabilities" xlink:label="OKYO_AdditionsToLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdditionsToLeaseLiabilities" xlink:to="OKYO_AdditionsToLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_AdditionsToLeaseLiabilities_lbl" xml:lang="en-US">Additions</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeaseLiabilitiesInterestExpenses" xlink:label="OKYO_LeaseLiabilitiesInterestExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeaseLiabilitiesInterestExpenses" xlink:to="OKYO_LeaseLiabilitiesInterestExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_LeaseLiabilitiesInterestExpenses_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeasePayment" xlink:label="OKYO_LeasePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeasePayment" xlink:to="OKYO_LeasePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_LeasePayment_lbl" xml:lang="en-US">Lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LeaseLiabilities_2_lbl" xml:lang="en-US">Lease Liabilities, balance as at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureLeasesAbstract" xlink:to="OKYO_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="OKYO_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Lease Liabilities By Classification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_2_lbl" xml:lang="en-US">Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_2_lbl" xml:lang="en-US">Non-current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_LeaseLiabilities_3_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US">Within one year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsRightOfUseAssets" xlink:to="OKYO_DisposalsRightOfUseAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="OKYO_DisposalsRightOfUseAssets_3_lbl" xml:lang="en-US">Early Termination write off right of use of assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsLeaseLiabilities" xlink:to="OKYO_DisposalsLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisposalsLeaseLiabilities_2_lbl" xml:lang="en-US">Early Termination write off lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" xlink:label="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" xlink:to="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability_lbl" xml:lang="en-US">initial recognition for right of use asset and lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForAuditServices" xlink:to="ifrs-full_AuditorsRemunerationForAuditServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemunerationForAuditServices_lbl" xml:lang="en-US">Fees payable to the company&#8217;s auditors for the audit of the parent company and consolidated financial statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemunerationForOtherServices" xlink:to="ifrs-full_AuditorsRemunerationForOtherServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AuditorsRemunerationForOtherServices_lbl" xml:lang="en-US">Audit-related assurance services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AuditorsRemuneration" xlink:to="ifrs-full_AuditorsRemuneration_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AuditorsRemuneration_2_lbl" xml:lang="en-US">Total auditor&#8217;s remuneration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOnHand" xlink:label="ifrs-full_CashOnHand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOnHand" xlink:to="ifrs-full_CashOnHand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOnHand_lbl" xml:lang="en-US">Cash at bank and in hand</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US">Disclosure of disaggregation of revenue from contracts with customers [table]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmountOfLicensedProductOrService" xlink:label="OKYO_AmountOfLicensedProductOrService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AmountOfLicensedProductOrService" xlink:to="OKYO_AmountOfLicensedProductOrService_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AmountOfLicensedProductOrService_lbl" xml:lang="en-US">Amount of licensed product or service</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFee" xlink:label="OKYO_AnnualLicenseMaintenanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AnnualLicenseMaintenanceFee" xlink:to="OKYO_AnnualLicenseMaintenanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AnnualLicenseMaintenanceFee_lbl" xml:lang="en-US">Annual license maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFeeTherafter" xlink:label="OKYO_AnnualLicenseMaintenanceFeeTherafter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AnnualLicenseMaintenanceFeeTherafter" xlink:to="OKYO_AnnualLicenseMaintenanceFeeTherafter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AnnualLicenseMaintenanceFeeTherafter_lbl" xml:lang="en-US">Annual license maintenance fee, therafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US">Number of shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_2_lbl" xml:lang="en-US">Price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_2_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_Bonus" xlink:label="OKYO_Bonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_Bonus" xlink:to="OKYO_Bonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_Bonus_lbl" xml:lang="en-US">[custom:Bonus-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShorttermCreditFacility" xlink:label="OKYO_ShorttermCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShorttermCreditFacility" xlink:to="OKYO_ShorttermCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_ShorttermCreditFacility_lbl" xml:lang="en-US">[custom:ShorttermCreditFacility-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdditionalBorrowingsInterestRate" xlink:label="OKYO_AdditionalBorrowingsInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdditionalBorrowingsInterestRate" xlink:to="OKYO_AdditionalBorrowingsInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdditionalBorrowingsInterestRate_lbl" xml:lang="en-US">Additional interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfReportingEntityExplanatory" xlink:to="OKYO_DisclosureOfReportingEntityExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfReportingEntityExplanatory_doc" xml:lang="en-US">Disclosure of Reporting Entity Explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtConversion" xlink:to="OKYO_SharesIssuedOnConvertibleDebtConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversion_doc" xml:lang="en-US">Shares issued on convertible debt, conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtConversionShares" xlink:to="OKYO_SharesIssuedOnConvertibleDebtConversionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnConvertibleDebtConversionShares_doc" xml:lang="en-US">Shares issued on convertible debt conversion, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about operating expenses explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfEmployeeDetailsExplanatory" xlink:to="OKYO_DisclosureOfEmployeeDetailsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfEmployeeDetailsExplanatory_doc" xml:lang="en-US">Disclosure of employee details explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about employees explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" xlink:to="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_doc" xml:lang="en-US">Detailed trade and other receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentCost" xlink:to="OKYO_PropertyPlantAndEquipmentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PropertyPlantAndEquipmentCost_doc" xml:lang="en-US">Property and equipment, cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationNetValue" xlink:to="OKYO_DepreciationNetValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DepreciationNetValue_doc" xml:lang="en-US">Depreciation net value.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentDepreciation" xlink:to="OKYO_PropertyPlantAndEquipmentDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PropertyPlantAndEquipmentDepreciation_doc" xml:lang="en-US">Property plant and equipment depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_EffectOfForeignExchangeDepreciation" xlink:to="OKYO_EffectOfForeignExchangeDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_EffectOfForeignExchangeDepreciation_doc" xml:lang="en-US">Effect of foreign exchange depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_EffectOfChargeInYearDepreciation" xlink:to="OKYO_EffectOfChargeInYearDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_EffectOfChargeInYearDepreciation_doc" xml:lang="en-US">Effect of charge in year depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_doc" xml:lang="en-US">Disclosure of Detailed Information About Property Plant And Equipment Located Operating Segment Explanatory [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CurrentTaxationReceivable" xlink:to="OKYO_CurrentTaxationReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_CurrentTaxationReceivable_doc" xml:lang="en-US">Current taxation receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsBonus" xlink:to="OKYO_DirectorsBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DirectorsBonus_doc" xml:lang="en-US">Directors bonus</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNoteReserve" xlink:to="OKYO_ConvertibleLoanNoteReserve_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ConvertibleLoanNoteReserve_doc" xml:lang="en-US">Convertible loan note reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ForeignCurrencyTranslationReserve" xlink:to="OKYO_ForeignCurrencyTranslationReserve_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ForeignCurrencyTranslationReserve_doc" xml:lang="en-US">Foreign currency translation reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsSalary" xlink:to="OKYO_DirectorsSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DirectorsSalary_doc" xml:lang="en-US">Directors salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpairmentOfLoan" xlink:to="OKYO_ImpairmentOfLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ImpairmentOfLoan_doc" xml:lang="en-US">Impairment of loan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NumberOfSharesIssuedPrivatePlacement" xlink:to="OKYO_NumberOfSharesIssuedPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacement_doc" xml:lang="en-US">Number of shares issued private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NumberOfSharesIssuedPrivatePlacementValue" xlink:to="OKYO_NumberOfSharesIssuedPrivatePlacementValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_NumberOfSharesIssuedPrivatePlacementValue_doc" xml:lang="en-US">Number of shares issued private placement value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodValueNewIssue" xlink:to="OKYO_StockIssuedDuringPeriodValueNewIssue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_StockIssuedDuringPeriodValueNewIssue_doc" xml:lang="en-US">Stock issued during period value new issue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodSharesShareCapital" xlink:to="OKYO_StockIssuedDuringPeriodSharesShareCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_StockIssuedDuringPeriodSharesShareCapital_doc" xml:lang="en-US">Stock issued during period shares share capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FairValueWarrantsIssuedPrivatePlacement" xlink:to="OKYO_FairValueWarrantsIssuedPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FairValueWarrantsIssuedPrivatePlacement_doc" xml:lang="en-US">Fair value warrants issued private placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnOptionsCharge" xlink:to="OKYO_SharesIssuedOnOptionsCharge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnOptionsCharge_doc" xml:lang="en-US">Shares issued on options charge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IssuedInLieuValue" xlink:to="OKYO_IssuedInLieuValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IssuedInLieuValue_doc" xml:lang="en-US">Issued in lieu value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnTotalTransactions" xlink:to="OKYO_SharesIssuedOnTotalTransactions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnTotalTransactions_doc" xml:lang="en-US">Shares issued on total transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_doc" xml:lang="en-US">Increase decrease through exercise of warrants equity shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:to="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_doc" xml:lang="en-US">Increase decrease through conversion of convertible instruments shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_doc" xml:lang="en-US">Increase decrease through exercise of options shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" xlink:to="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions_doc" xml:lang="en-US">Stock issued during period shares exercise of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfForfeiture_doc" xml:lang="en-US">Increase decrease through exercise of forfeiture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge_doc" xml:lang="en-US">Increase decrease through exercise of warrants charge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_doc" xml:lang="en-US">Description of Accounting Policy For Lease Explanatory [PolicyText Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory_doc" xml:lang="en-US">Description of Accounting Policy For License Fees Explanatory [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_doc" xml:lang="en-US">Description of accounting policy for research and development explanatory [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory_doc" xml:lang="en-US">Description of accounting policy for share capital explanatory [Policy Text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BonusAwarded" xlink:to="OKYO_BonusAwarded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_BonusAwarded_doc" xml:lang="en-US">Bonus awarded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" xlink:to="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory_doc" xml:lang="en-US">Schedule of share options granted to directors explanatory [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LossChargedAtStandardRateOfCorporationTax" xlink:to="OKYO_LossChargedAtStandardRateOfCorporationTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LossChargedAtStandardRateOfCorporationTax_doc" xml:lang="en-US">Loss charged at standard rate of corporation tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentTaxClaim" xlink:to="OKYO_ResearchAndDevelopmentTaxClaim_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ResearchAndDevelopmentTaxClaim_doc" xml:lang="en-US">Research and Development tax claim.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentEnhancedExpenditure" xlink:to="OKYO_ResearchAndDevelopmentEnhancedExpenditure_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ResearchAndDevelopmentEnhancedExpenditure_doc" xml:lang="en-US">Research and Development enhanced expenditure.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TaxLossesSurrenderedForResearchAndDevelopment" xlink:to="OKYO_TaxLossesSurrenderedForResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TaxLossesSurrenderedForResearchAndDevelopment_doc" xml:lang="en-US">Tax losses surrendered for Research and Development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsRightOfUseAssets" xlink:to="OKYO_DisposalsRightOfUseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisposalsRightOfUseAssets_doc" xml:lang="en-US">Early Termination write off.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpactOfForeignExchange" xlink:to="OKYO_ImpactOfForeignExchange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ImpactOfForeignExchange_doc" xml:lang="en-US">Impact of Foreign exchange.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationOfEarlyTerminatedLease" xlink:to="OKYO_DepreciationOfEarlyTerminatedLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DepreciationOfEarlyTerminatedLease_doc" xml:lang="en-US">Depreciation of early terminated lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeasePayments" xlink:to="OKYO_LeasePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LeasePayments_doc" xml:lang="en-US">Lease payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ExpectedLifeOfWarrants" xlink:to="OKYO_ExpectedLifeOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ExpectedLifeOfWarrants_doc" xml:lang="en-US">Expected life.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisposalsLeaseLiabilities" xlink:to="OKYO_DisposalsLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisposalsLeaseLiabilities_doc" xml:lang="en-US">Disposals Lease Liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ImpactOfForeignExchangeLeaseLiabilities" xlink:to="OKYO_ImpactOfForeignExchangeLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ImpactOfForeignExchangeLeaseLiabilities_doc" xml:lang="en-US">Impact of foreign exchange lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsVestingPeriod" xlink:to="OKYO_WarrantsVestingPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsVestingPeriod_doc" xml:lang="en-US">Vesting periods.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdditionsToLeaseLiabilities" xlink:to="OKYO_AdditionsToLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdditionsToLeaseLiabilities_doc" xml:lang="en-US">Additions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WestAfricanMineralsLimitedMember" xlink:to="OKYO_WestAfricanMineralsLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WestAfricanMineralsLimitedMember_doc" xml:lang="en-US">West African Minerals Limited [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TranslationReserveMember" xlink:to="OKYO_TranslationReserveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TranslationReserveMember_doc" xml:lang="en-US">Translation reserve [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ResearchAndDevelopmentMember" xlink:to="OKYO_ResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ResearchAndDevelopmentMember_doc" xml:lang="en-US">Research and development [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CorporateAndAdministrationMember" xlink:to="OKYO_CorporateAndAdministrationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_CorporateAndAdministrationMember_doc" xml:lang="en-US">Corporate and administration [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FurnitureAndFixtureMember" xlink:to="OKYO_FurnitureAndFixtureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FurnitureAndFixtureMember_doc" xml:lang="en-US">Furniture and fixtures [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ITEquipmentMember" xlink:to="OKYO_ITEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ITEquipmentMember_doc" xml:lang="en-US">IT equipment [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNoteReserveMember" xlink:to="OKYO_ConvertibleLoanNoteReserveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ConvertibleLoanNoteReserveMember_doc" xml:lang="en-US">Convertible loan note reserve [member]</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_USMember" xlink:label="OKYO_USMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_USMember" xlink:to="OKYO_USMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_USMember_doc" xml:lang="en-US">US [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_UKMember" xlink:to="OKYO_UKMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_UKMember_doc" xml:lang="en-US">UK [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GCerroneMember" xlink:to="OKYO_GCerroneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GCerroneMember_doc" xml:lang="en-US">G Cerrone [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GJacobMember" xlink:to="OKYO_GJacobMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GJacobMember_doc" xml:lang="en-US">G Jacob [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WSimonMember" xlink:to="OKYO_WSimonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WSimonMember_doc" xml:lang="en-US">W Simon [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KShailubhaiMember" xlink:to="OKYO_KShailubhaiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_KShailubhaiMember_doc" xml:lang="en-US">K Shailubhai [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_JBrancaccioMember" xlink:to="OKYO_JBrancaccioMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_JBrancaccioMember_doc" xml:lang="en-US">J Brancaccio [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GMacraeMember" xlink:to="OKYO_GMacraeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GMacraeMember_doc" xml:lang="en-US">G Macrae [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BDenoyerMember" xlink:to="OKYO_BDenoyerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_BDenoyerMember_doc" xml:lang="en-US">B Denoyer [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LZambelettiMember" xlink:to="OKYO_LZambelettiMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LZambelettiMember_doc" xml:lang="en-US">L Z ambeletti [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReservesMember" xlink:to="OKYO_WarrantReservesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantReservesMember_doc" xml:lang="en-US">Warrant Reserves [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentyNineMayTwoThousandAndTwentyMember" xlink:to="OKYO_TwentyNineMayTwoThousandAndTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TwentyNineMayTwoThousandAndTwentyMember_doc" xml:lang="en-US">29 May 2020 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:to="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_doc" xml:lang="en-US">Fees relating to equity fundraise 29 May 2020 issued as CLN [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AmountOfLicensedProductOrService" xlink:to="OKYO_AmountOfLicensedProductOrService_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AmountOfLicensedProductOrService_doc" xml:lang="en-US">Amount of Licensed Product or Service.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AmericanDepositorySharesMember" xlink:to="OKYO_AmericanDepositorySharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AmericanDepositorySharesMember_doc" xml:lang="en-US">American depository shares [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_Bonus" xlink:to="OKYO_Bonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_Bonus_doc" xml:lang="en-US">Bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeaseLiabilitiesInterestExpenses" xlink:to="OKYO_LeaseLiabilitiesInterestExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LeaseLiabilitiesInterestExpenses_doc" xml:lang="en-US">Lease liabilities interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeasePayment" xlink:to="OKYO_LeasePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LeasePayment_doc" xml:lang="en-US">Lease Payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_RelatedPartyReceivables" xlink:to="OKYO_RelatedPartyReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_RelatedPartyReceivables_doc" xml:lang="en-US">Related party receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtInterest" xlink:to="OKYO_SharesIssuedOnConvertibleDebtInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnConvertibleDebtInterest_doc" xml:lang="en-US">Shares issued on convertible debt interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:to="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest_doc" xml:lang="en-US">Shares issued on convertible debt and warrant interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:to="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves_doc" xml:lang="en-US">Stock issued during period value transfer between equisty reserves.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnWarrantsExercisedShares" xlink:to="OKYO_SharesIssuedOnWarrantsExercisedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnWarrantsExercisedShares_doc" xml:lang="en-US">Shares issued on warrants exercised shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnTotalTransactionsShares" xlink:to="OKYO_SharesIssuedOnTotalTransactionsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnTotalTransactionsShares_doc" xml:lang="en-US">Shares issued on total transactions shares,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_doc" xml:lang="en-US">Adjustments for change in fair value of warrant charge.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_doc" xml:lang="en-US">Adjustments for change in fair value of forfeiture of options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:to="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables_doc" xml:lang="en-US">Adjustments for decrease increase related party receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:to="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables_doc" xml:lang="en-US">Adjustments for increase decrease in related party payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CashAdvancesAndLoansToRelatedParties" xlink:to="OKYO_CashAdvancesAndLoansToRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_CashAdvancesAndLoansToRelatedParties_doc" xml:lang="en-US">Cash advances and loans to related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ProcessedFromOptionsExercised" xlink:to="OKYO_ProcessedFromOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ProcessedFromOptionsExercised_doc" xml:lang="en-US">Processed from options exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ProcessedFromWarrantsExercised" xlink:to="OKYO_ProcessedFromWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ProcessedFromWarrantsExercised_doc" xml:lang="en-US">Processed from warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShareBasedPaymentChargeForfeiture" xlink:to="OKYO_ShareBasedPaymentChargeForfeiture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ShareBasedPaymentChargeForfeiture_doc" xml:lang="en-US">Share based payment charge forfeiture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GainlossOnDisposalOfLeases" xlink:to="OKYO_GainlossOnDisposalOfLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GainlossOnDisposalOfLeases_doc" xml:lang="en-US">Gain loss on disposal of leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ForeignExchangeLossesGains" xlink:to="OKYO_ForeignExchangeLossesGains_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ForeignExchangeLossesGains_doc" xml:lang="en-US">Foreign exchange loss gain.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ChairmansBonus" xlink:to="OKYO_ChairmansBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ChairmansBonus_doc" xml:lang="en-US">Chairman bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KeyManagementPersonnelCompensationDirectorFees" xlink:to="OKYO_KeyManagementPersonnelCompensationDirectorFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_KeyManagementPersonnelCompensationDirectorFees_doc" xml:lang="en-US">Director fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ExpirationDateOfOutstanding" xlink:to="OKYO_ExpirationDateOfOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ExpirationDateOfOutstanding_doc" xml:lang="en-US">Expiration date of outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GrantDateShareOptionsGranted2019" xlink:to="OKYO_GrantDateShareOptionsGranted2019_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GrantDateShareOptionsGranted2019_doc" xml:lang="en-US">Grant date share options granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_VestingPeriodsDescription" xlink:to="OKYO_VestingPeriodsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_VestingPeriodsDescription_doc" xml:lang="en-US">Vesting period description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsSalaries" xlink:to="OKYO_DirectorsSalaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DirectorsSalaries_doc" xml:lang="en-US">Directors salaries.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_OptionLifePeriod" xlink:to="OKYO_OptionLifePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_OptionLifePeriod_doc" xml:lang="en-US">Options life period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisablePricePerShare" xlink:to="OKYO_WarrantsExercisablePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsExercisablePricePerShare_doc" xml:lang="en-US">Warrants exercisable price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrepaymentsReceivables" xlink:to="OKYO_PrepaymentsReceivables_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PrepaymentsReceivables_doc" xml:lang="en-US">Prepayments receivables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_doc" xml:lang="en-US">Detailed information about payables and accrued liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BonusAccrual" xlink:to="OKYO_BonusAccrual_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_BonusAccrual_doc" xml:lang="en-US">Bonus accrual.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:to="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_doc" xml:lang="en-US">Trade and current payables.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BasicAndDilutedEarningsLossPerShare" xlink:to="OKYO_BasicAndDilutedEarningsLossPerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShare_doc" xml:lang="en-US">Basic and diluted earnings loss per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" xlink:to="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory_doc" xml:lang="en-US">Disclosure Of Issuance Of Convertible Notes Explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeaseLiabilitiesInterestExpense" xlink:to="OKYO_LeaseLiabilitiesInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LeaseLiabilitiesInterestExpense_doc" xml:lang="en-US">Lease liabilities interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantExercisePricePerShare" xlink:to="OKYO_WarrantExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantExercisePricePerShare_doc" xml:lang="en-US">Warrants exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DebtTerm" xlink:to="OKYO_DebtTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DebtTerm_doc" xml:lang="en-US">Debt term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConversionPricePerShares" xlink:to="OKYO_ConversionPricePerShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ConversionPricePerShares_doc" xml:lang="en-US">Conversion price per shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LessThanThreeMember" xlink:to="OKYO_LessThanThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LessThanThreeMember_doc" xml:lang="en-US">Less Than Three [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThreeToTwelveMonthsMember" xlink:to="OKYO_ThreeToTwelveMonthsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ThreeToTwelveMonthsMember_doc" xml:lang="en-US">Three to Twelve Months [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DirectorsMember" xlink:to="OKYO_DirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DirectorsMember_doc" xml:lang="en-US">Directors [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentySevenJulyTwoThousandTwentyMember" xlink:to="OKYO_TwentySevenJulyTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TwentySevenJulyTwoThousandTwentyMember_doc" xml:lang="en-US">27 July 2020 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SeventeenthAugustTwoThousandAndTwentyMember" xlink:to="OKYO_SeventeenthAugustTwoThousandAndTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SeventeenthAugustTwoThousandAndTwentyMember_doc" xml:lang="en-US">17 August 2020 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThreeSeptemberTwoThousandAndTwentyMember" xlink:to="OKYO_ThreeSeptemberTwoThousandAndTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ThreeSeptemberTwoThousandAndTwentyMember_doc" xml:lang="en-US">03 September 2022 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:to="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_doc" xml:lang="en-US">Fees relating to all other equity fundraise issued as CLN [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WriteOffExchangeOfLoan" xlink:to="OKYO_WriteOffExchangeOfLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WriteOffExchangeOfLoan_doc" xml:lang="en-US">Write off exchange of loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIHumanClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PhaseIHumanClinicalTrialMember_doc" xml:lang="en-US">Phase I Human Clinical Trial [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIIIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIIIHumanClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PhaseIIIHumanClinicalTrialMember_doc" xml:lang="en-US">Phase III Human Clinical Trial [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PhaseIIHumanClinicalTrialMember" xlink:to="OKYO_PhaseIIHumanClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PhaseIIHumanClinicalTrialMember_doc" xml:lang="en-US">Phase II Human Clinical Trial [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TizianaLifeSciencesLtdMember" xlink:to="OKYO_TizianaLifeSciencesLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TizianaLifeSciencesLtdMember_doc" xml:lang="en-US">Tiziana Life Sciences Ltd [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ServiceAgreementMember" xlink:to="OKYO_ServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ServiceAgreementMember_doc" xml:lang="en-US">Service agreement [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" xlink:to="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_doc" xml:lang="en-US">Tax increase from effect of capital allowances and depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SixJulyTwoThousandEighteenMember" xlink:to="OKYO_SixJulyTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SixJulyTwoThousandEighteenMember_doc" xml:lang="en-US">6 July 2018 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwentyAugustTwoThousandTwentyMember" xlink:to="OKYO_TwentyAugustTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TwentyAugustTwoThousandTwentyMember_doc" xml:lang="en-US">20 August 2020 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SixJanuaryTwoThousandTwentyOneMember" xlink:to="OKYO_SixJanuaryTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SixJanuaryTwoThousandTwentyOneMember_doc" xml:lang="en-US">6 January 2021 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TwelveJanuaryTwoThousandTwentyOneMember" xlink:to="OKYO_TwelveJanuaryTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_TwelveJanuaryTwoThousandTwentyOneMember_doc" xml:lang="en-US">12 January 2021 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FifteenAprilTwoThousandTwentyOneMember" xlink:to="OKYO_FifteenAprilTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FifteenAprilTwoThousandTwentyOneMember_doc" xml:lang="en-US">15 April 2021 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" xlink:to="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember_doc" xml:lang="en-US">31 August 2021 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:to="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember_doc" xml:lang="en-US">31 January 2022 [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GrantDateAxis" xlink:to="OKYO_GrantDateAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GrantDateAxis_doc" xml:lang="en-US">Grant Date Axis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DepreciationOfNewLease" xlink:to="OKYO_DepreciationOfNewLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DepreciationOfNewLease_doc" xml:lang="en-US">Depreciation of new lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_KeyManagementPersonnelCompensationSharebasedPayments" xlink:to="OKYO_KeyManagementPersonnelCompensationSharebasedPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_KeyManagementPersonnelCompensationSharebasedPayments_doc" xml:lang="en-US">The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LossBeforeTaxation" xlink:to="OKYO_LossBeforeTaxation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LossBeforeTaxation_doc" xml:lang="en-US">Loss before taxation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:to="OKYO_IncomeTaxExpenseBenefitContinuingOperations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_IncomeTaxExpenseBenefitContinuingOperations_doc" xml:lang="en-US">Income tax expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about cash and cash equivalents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about company auditors fees explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_doc" xml:lang="en-US">The disclosure of detailed information of maturities of financial instruments explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about contractual maturities of lease liabilities explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_doc" xml:lang="en-US">The disclosure of detailed information abou lease liabilities by classification explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" xlink:to="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_doc" xml:lang="en-US">The disclosure of accounting policies of basis of preparation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" xlink:to="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfEstimatedUsefulLivesExplanatory_doc" xml:lang="en-US">The tabular disclosure for estimated useful lives explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DerecognitionOfLeaseLiability" xlink:to="OKYO_DerecognitionOfLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DerecognitionOfLeaseLiability_doc" xml:lang="en-US">Derecognition of lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" xlink:to="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability_doc" xml:lang="en-US">Initial recognition for right of use asset and lease liability .</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GBPMember" xlink:to="OKYO_GBPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GBPMember_doc" xml:lang="en-US">GBP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_USDMember" xlink:to="OKYO_USDMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_USDMember_doc" xml:lang="en-US">USD [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AnnualLicenseMaintenanceFee" xlink:to="OKYO_AnnualLicenseMaintenanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AnnualLicenseMaintenanceFee_doc" xml:lang="en-US">Annual license maintenance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AnnualLicenseMaintenanceFeeTherafter" xlink:to="OKYO_AnnualLicenseMaintenanceFeeTherafter_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AnnualLicenseMaintenanceFeeTherafter_doc" xml:lang="en-US">Annual license maintenance fee, therafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_NonadjustingEventMember" xlink:to="OKYO_NonadjustingEventMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_NonadjustingEventMember_doc" xml:lang="en-US">Non-adjusting event [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShorttermCreditFacility" xlink:to="OKYO_ShorttermCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ShorttermCreditFacility_doc" xml:lang="en-US">Short-term credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about options outstanding and weighted average exercise price explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_doc" xml:lang="en-US">Disclosure of detailed information about share-based payment award model inputs options granted explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about inputs for warrants granted explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" xlink:to="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_doc" xml:lang="en-US">The disclosure of detailed information about fair value of warrants in services explanatory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReserveOneMember" xlink:to="OKYO_WarrantReserveOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantReserveOneMember_doc" xml:lang="en-US">Warrant reserve one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LoanNotesMember" xlink:to="OKYO_LoanNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LoanNotesMember_doc" xml:lang="en-US">Loan notes [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LoanNotesOneMember" xlink:to="OKYO_LoanNotesOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LoanNotesOneMember_doc" xml:lang="en-US">Loan notes one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantReserveTwoMember" xlink:to="OKYO_WarrantReserveTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantReserveTwoMember_doc" xml:lang="en-US">Warrant reserve two [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisableDate" xlink:to="OKYO_WarrantsExercisableDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsExercisableDate_doc" xml:lang="en-US">Warrants exercisable date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrivatePlacementsMember" xlink:to="OKYO_PrivatePlacementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PrivatePlacementsMember_doc" xml:lang="en-US">Private placements [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PrivatePlacementsOneMember" xlink:to="OKYO_PrivatePlacementsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_PrivatePlacementsOneMember_doc" xml:lang="en-US">Private placements one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LieuOfProfessionalFeesMember" xlink:to="OKYO_LieuOfProfessionalFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LieuOfProfessionalFeesMember_doc" xml:lang="en-US">Lieu of professional fees [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LieuOfBrokerFeesMember" xlink:to="OKYO_LieuOfBrokerFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_LieuOfBrokerFeesMember_doc" xml:lang="en-US">Lieu of broker-fees [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNotesMember" xlink:to="OKYO_ConvertibleLoanNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ConvertibleLoanNotesMember_doc" xml:lang="en-US">Convertible loan notes [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ConvertibleLoanNotesOneMember" xlink:to="OKYO_ConvertibleLoanNotesOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ConvertibleLoanNotesOneMember_doc" xml:lang="en-US">Convertible loan notes one [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnCashlessBasic" xlink:to="OKYO_WarrantsExercisedOnCashlessBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsExercisedOnCashlessBasic_doc" xml:lang="en-US">Warrants exercised on cashless basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnIssuances" xlink:to="OKYO_WarrantsExercisedOnIssuances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsExercisedOnIssuances_doc" xml:lang="en-US">Warrants exercised on issuances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_FairValueOfWarrants" xlink:to="OKYO_FairValueOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_FairValueOfWarrants_doc" xml:lang="en-US">Fair value of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_ShareBasedPaymentCharge" xlink:to="OKYO_ShareBasedPaymentCharge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_ShareBasedPaymentCharge_doc" xml:lang="en-US">Share based payment charge.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsExercisedOnPriceReductionOffer" xlink:to="OKYO_WarrantsExercisedOnPriceReductionOffer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WarrantsExercisedOnPriceReductionOffer_doc" xml:lang="en-US">Warrants exercised on price reduction offer .</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GeographicalAreaAxis" xlink:label="OKYO_GeographicalAreaAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_GeographicalAreaAxis" xlink:to="OKYO_GeographicalAreaAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_GeographicalAreaAxis_doc" xml:lang="en-US">Geographical Area [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_UnitedStateMember" xlink:to="OKYO_UnitedStateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_UnitedStateMember_doc" xml:lang="en-US">US [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_CashBurnRate" xlink:to="OKYO_CashBurnRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_CashBurnRate_doc" xml:lang="en-US">Rate of cash burn/spend.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:to="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion_doc" xml:lang="en-US">Shares issued on currency translation on convertible loan note conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" xlink:to="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders_doc" xml:lang="en-US">Basic and diluted earnings loss per share attributable to common shareholders.</link:label>
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement_doc" xml:lang="en-US">Weighted average exercise price of share options forfeited in sharebased payment arrangement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdditionalBorrowingsInterestRate" xlink:to="OKYO_AdditionalBorrowingsInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="OKYO_AdditionalBorrowingsInterestRate_doc" xml:lang="en-US">Additional interest rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_2_lbl" xml:lang="en-US">Current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_2_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_4_lbl" xml:lang="en-US">Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_2_lbl" xml:lang="en-US">Equity and liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_2_lbl" xml:lang="en-US">Operating expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpenseExcludingCostOfSales" xlink:to="ifrs-full_OperatingExpenseExcludingCostOfSales_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpenseExcludingCostOfSales_2_lbl" xml:lang="en-US">Operating expense excluding cost of sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_3_lbl" xml:lang="en-US">Finance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:to="OKYO_IncomeTaxExpenseBenefitContinuingOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncomeTaxExpenseBenefitContinuingOperations_3_lbl" xml:lang="en-US">IncomeTaxExpenseBenefitContinuingOperations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_3_lbl" xml:lang="en-US">Number of shares outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge_3_lbl" xml:lang="en-US">AdjustmentsForChangeInFairValueOfWarrantCharge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:to="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions_3_lbl" xml:lang="en-US">AdjustmentsForChangeInFairValueOfForfeitureOfOptions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Adjustments for gain (loss) on disposals, property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_3_lbl" xml:lang="en-US">Cash flows from (used in) operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_2_lbl" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:to="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAdvancesAndLoansMadeToRelatedParties_2_lbl" xml:lang="en-US">Cash advances and loans made to related parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_2_lbl" xml:lang="en-US">Payments of lease liabilities, classified as financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_2_lbl" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_2_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DisclosureOfReportingEntityExplanatory" xlink:to="OKYO_DisclosureOfReportingEntityExplanatory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DisclosureOfReportingEntityExplanatory_3_lbl" xml:lang="en-US">DisclosureOfReportingEntityExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_2_lbl" xml:lang="en-US">Disclosure of leases [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_2_lbl" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_2_lbl" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_2_lbl" xml:lang="en-US">Description of accounting policy for restricted cash and cash equivalents [text block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" xlink:to="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory_3_lbl" xml:lang="en-US">DescriptionOfAccountingPolicyForLeaseExplanatory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_2_lbl" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_2_lbl" xml:lang="en-US">Tax expense (income)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_2_lbl" xml:lang="en-US">Interest expense on lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentCost" xlink:to="OKYO_PropertyPlantAndEquipmentCost_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PropertyPlantAndEquipmentCost_4_lbl" xml:lang="en-US">PropertyPlantAndEquipmentCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_PropertyPlantAndEquipmentDepreciation" xlink:to="OKYO_PropertyPlantAndEquipmentDepreciation_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_PropertyPlantAndEquipmentDepreciation_4_lbl" xml:lang="en-US">PropertyPlantAndEquipmentDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_EffectOfForeignExchangeDepreciation" xlink:to="OKYO_EffectOfForeignExchangeDepreciation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_EffectOfForeignExchangeDepreciation_3_lbl" xml:lang="en-US">EffectOfForeignExchangeDepreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_2_lbl" xml:lang="en-US">Other current receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:to="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_3_lbl" xml:lang="en-US">TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:to="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares_3_lbl" xml:lang="en-US">IncreaseDecreaseThroughExerciseOfOptionsShares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3_lbl" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3_lbl" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_3_lbl" xml:lang="en-US">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_2_lbl" xml:lang="en-US">Number of other equity instruments exercisable in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_2_lbl" xml:lang="en-US">Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_WarrantsVestingPeriod" xlink:to="OKYO_WarrantsVestingPeriod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_WarrantsVestingPeriod_3_lbl" xml:lang="en-US">WarrantsVestingPeriod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_2_lbl" xml:lang="en-US">Trade and other payables [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilities_2_lbl" xml:lang="en-US">Financial liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_2_lbl" xml:lang="en-US">Additions to right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_4_lbl" xml:lang="en-US">Lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_AdditionsToLeaseLiabilities" xlink:to="OKYO_AdditionsToLeaseLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_AdditionsToLeaseLiabilities_3_lbl" xml:lang="en-US">AdditionsToLeaseLiabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeaseLiabilitiesInterestExpenses" xlink:to="OKYO_LeaseLiabilitiesInterestExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LeaseLiabilitiesInterestExpenses_3_lbl" xml:lang="en-US">LeaseLiabilitiesInterestExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OKYO_LeasePayment" xlink:to="OKYO_LeasePayment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OKYO_LeasePayment_3_lbl" xml:lang="en-US">LeasePayment</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>okyo-20220331_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.15b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://okyopharma.com/role/Cover" xlink:href="okyo-20220331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BalanceSheets" xlink:href="okyo-20220331.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="okyo-20220331.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:href="okyo-20220331.xsd#StatementsOfShareholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/StatementsOfCashFlows" xlink:href="okyo-20220331.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ReportingEntity" xlink:href="okyo-20220331.xsd#ReportingEntity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPolicies" xlink:href="okyo-20220331.xsd#AccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:href="okyo-20220331.xsd#CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpenses" xlink:href="okyo-20220331.xsd#OperatingExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SegmentalReporting" xlink:href="okyo-20220331.xsd#SegmentalReporting" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficers" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnel" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Taxation" xlink:href="okyo-20220331.xsd#Taxation" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCosts" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivables" xlink:href="okyo-20220331.xsd#OtherReceivables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReserves" xlink:href="okyo-20220331.xsd#CapitalAndReserves" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstruments" xlink:href="okyo-20220331.xsd#FinancialInstruments" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactions" xlink:href="okyo-20220331.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/Leases" xlink:href="okyo-20220331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemuneration" xlink:href="okyo-20220331.xsd#AuditorsRemuneration" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalents" xlink:href="okyo-20220331.xsd#CashAndCashEquivalents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:href="okyo-20220331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:href="okyo-20220331.xsd#PostBalanceSheetEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:href="okyo-20220331.xsd#AccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesTables" xlink:href="okyo-20220331.xsd#AccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OperatingExpensesTables" xlink:href="okyo-20220331.xsd#OperatingExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:href="okyo-20220331.xsd#RemunerationOfKeyManagementPersonnelTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationTables" xlink:href="okyo-20220331.xsd#TaxationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:href="okyo-20220331.xsd#FinanceIncomeAndCostsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:href="okyo-20220331.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesTables" xlink:href="okyo-20220331.xsd#OtherReceivablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:href="okyo-20220331.xsd#TradeAndOtherPayablesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesTables" xlink:href="okyo-20220331.xsd#CapitalAndReservesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:href="okyo-20220331.xsd#ConvertibleInstrumentsClassifiedAsEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:href="okyo-20220331.xsd#FinancialInstrumentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:href="okyo-20220331.xsd#BasicAndDilutedLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesTables" xlink:href="okyo-20220331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:href="okyo-20220331.xsd#AuditorsRemunerationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:href="okyo-20220331.xsd#CashAndCashEquivalentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:href="okyo-20220331.xsd#AccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:href="okyo-20220331.xsd#EmployeesIncludingOfficersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:href="okyo-20220331.xsd#ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:href="okyo-20220331.xsd#TaxationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFinanceCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:href="okyo-20220331.xsd#OtherReceivablesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:href="okyo-20220331.xsd#DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:href="okyo-20220331.xsd#CapitalAndReservesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="okyo-20220331.xsd#ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:href="okyo-20220331.xsd#ScheduleOfInputsForWarrantsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:href="okyo-20220331.xsd#ShareOptionsAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:href="okyo-20220331.xsd#ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:href="okyo-20220331.xsd#SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="okyo-20220331.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:href="okyo-20220331.xsd#SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:href="okyo-20220331.xsd#ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:href="okyo-20220331.xsd#ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:href="okyo-20220331.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCompanyAuditorsFeesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:href="okyo-20220331.xsd#ScheduleOfCashAndCashEquivalentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="okyo-20220331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:href="okyo-20220331.xsd#PostBalanceSheetEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesTable" xlink:label="loc_deiEntityAddressesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesLineItems" xlink:label="loc_deiEntityAddressesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_deiEntityAddressesAddressTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesTable" xlink:to="loc_deiEntityAddressesAddressTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="loc_deiAddressTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesAddressTypeAxis" xlink:to="loc_deiAddressTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="loc_deiBusinessContactMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiAddressTypeDomain" xlink:to="loc_deiBusinessContactMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="loc_deiContactPersonnelName" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiContactPersonnelName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityAddressesLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="loc_ifrs-fullStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="loc_ifrs-fullAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="loc_ifrs-fullCurrentAssetsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_RelatedPartyReceivables" xlink:label="loc_OKYORelatedPartyReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_OKYORelatedPartyReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CurrentTaxationReceivable" xlink:label="loc_OKYOCurrentTaxationReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_OKYOCurrentTaxationReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReceivables" xlink:label="loc_ifrs-fullOtherReceivables" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="loc_ifrs-fullCurrentAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentAssetsAbstract" xlink:to="loc_ifrs-fullCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="loc_ifrs-fullNoncurrentAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="loc_ifrs-fullAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAssetsAbstract" xlink:to="loc_ifrs-fullAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="loc_ifrs-fullEquityAndLiabilitiesAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="loc_ifrs-fullLiabilitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfFinancialPositionAbstract" xlink:to="loc_ifrs-fullLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="loc_ifrs-fullCurrentLiabilitiesAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCurrentLiabilitiesAbstract" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="loc_ifrs-fullLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="loc_ifrs-fullEquityAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="loc_ifrs-fullSharePremium" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullSharePremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfSharebasedPayments" xlink:label="loc_ifrs-fullReserveOfSharebasedPayments" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullReserveOfSharebasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserve" xlink:label="loc_ifrs-fullWarrantReserve" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullWarrantReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserve" xlink:label="loc_OKYOConvertibleLoanNoteReserve" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_OKYOConvertibleLoanNoteReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ForeignCurrencyTranslationReserve" xlink:label="loc_OKYOForeignCurrencyTranslationReserve" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_OKYOForeignCurrencyTranslationReserve" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityAbstract" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="loc_ifrs-fullEquityAndLiabilities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullLiabilitiesAbstract" xlink:to="loc_ifrs-fullEquityAndLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="loc_ifrs-fullIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaterialIncomeAndExpenseAbstract" xlink:label="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="loc_ifrs-fullResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_ifrs-fullResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="loc_ifrs-fullOperatingExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_ifrs-fullOperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpenseExcludingCostOfSales" xlink:label="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_ifrs-fullOperatingExpenseExcludingCostOfSales" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-fullFinanceIncome" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_ifrs-fullFinanceIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpairmentOfLoan" xlink:label="loc_OKYOImpairmentOfLoan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaterialIncomeAndExpenseAbstract" xlink:to="loc_OKYOImpairmentOfLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_OKYOIncomeTaxExpenseBenefitContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_OKYOIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullOtherComprehensiveIncomeAbstract" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" xlink:label="loc_OKYOBasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIncomeStatementAbstract" xlink:to="loc_OKYOBasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfShareholdersEquity" xlink:title="00000004 - Statement - Consolidated Statements of Shareholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="loc_ifrs-fullStatementOfChangesInEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReservesMember" xlink:label="loc_ifrs-fullOtherReservesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullOtherReservesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReservesMember" xlink:label="loc_OKYOWarrantReservesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_OKYOWarrantReservesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNoteReserveMember" xlink:label="loc_OKYOConvertibleLoanNoteReserveMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_OKYOConvertibleLoanNoteReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="loc_ifrs-fullRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TranslationReserveMember" xlink:label="loc_OKYOTranslationReserveMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_OKYOTranslationReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueNewIssue" xlink:label="loc_OKYOStockIssuedDuringPeriodValueNewIssue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodValueNewIssue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodSharesShareCapital" xlink:label="loc_OKYOStockIssuedDuringPeriodSharesShareCapital" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodSharesShareCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtAndWarrantInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtAndWarrantInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:label="loc_OKYOStockIssuedDuringPeriodValueTransferBetweenEquityReserves" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodValueTransferBetweenEquityReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnOptionsCharge" xlink:label="loc_OKYOSharesIssuedOnOptionsCharge" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnOptionsCharge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions" xlink:label="loc_OKYOStockIssuedDuringPeriodShareslExerciseOfOptions" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOStockIssuedDuringPeriodShareslExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfForfeiture" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfForfeiture" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnWarrantsExercisedShares" xlink:label="loc_OKYOSharesIssuedOnWarrantsExercisedShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnWarrantsExercisedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsCharge" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsCharge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversion" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtConversion" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtConversionShares" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtConversionShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtConversionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnConvertibleDebtInterest" xlink:label="loc_OKYOSharesIssuedOnConvertibleDebtInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnConvertibleDebtInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactions" xlink:label="loc_OKYOSharesIssuedOnTotalTransactions" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnTotalTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnTotalTransactionsShares" xlink:label="loc_OKYOSharesIssuedOnTotalTransactionsShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnTotalTransactionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="loc_ifrs-fullComprehensiveIncome" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullComprehensiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:label="loc_OKYOSharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOSharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="loc_ifrs-fullStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="loc_ifrs-fullProfitLossBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullProfitLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="loc_ifrs-fullAdjustmentsForSharebasedPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForSharebasedPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge" xlink:label="loc_OKYOAdjustmentsForChangeInFairValueOfWarrantCharge" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_OKYOAdjustmentsForChangeInFairValueOfWarrantCharge" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:label="loc_OKYOAdjustmentsForChangeInFairValueOfForfeitureOfOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_OKYOAdjustmentsForChangeInFairValueOfForfeitureOfOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="loc_ifrs-fullAdjustmentsForDepreciationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDepreciationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="loc_ifrs-fullAdjustmentsForAmortisationExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForAmortisationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:label="loc_ifrs-fullAdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:label="loc_OKYOAdjustmentsForDecreaseIncreaseRelatedPartyReceivables" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_OKYOAdjustmentsForDecreaseIncreaseRelatedPartyReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:label="loc_OKYOAdjustmentsForIncreaseDecreaseInRelatedPartyPayables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_OKYOAdjustmentsForIncreaseDecreaseInRelatedPartyPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="loc_ifrs-fullAdjustmentsForReconcileProfitLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAdjustmentsForReconcileProfitLossAbstract" xlink:to="loc_ifrs-fullAdjustmentsForReconcileProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullPurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansMadeToRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansMadeToRelatedParties" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashAdvancesAndLoansMadeToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromIssuingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="loc_ifrs-fullProceedsFromIssueOfBondsNotesAndDebentures" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullProceedsFromIssueOfBondsNotesAndDebentures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromOptionsExercised" xlink:label="loc_OKYOProcessedFromOptionsExercised" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_OKYOProcessedFromOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ProcessedFromWarrantsExercised" xlink:label="loc_OKYOProcessedFromWarrantsExercised" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_OKYOProcessedFromWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashAdvancesAndLoansToRelatedParties" xlink:label="loc_OKYOCashAdvancesAndLoansToRelatedParties" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_OKYOCashAdvancesAndLoansToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAdvancesAndLoansFromRelatedParties" xlink:label="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashAdvancesAndLoansFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullPaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="loc_ifrs-fullCashFlowsFromUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="loc_ifrs-fullEffectOfExchangeRateChangesOnCashAndCashEquivalents" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullEffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents_2" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfCashFlowsAbstract" xlink:to="loc_ifrs-fullCashAndCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ReportingEntity" xlink:title="00000006 - Disclosure - Reporting Entity">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureReportingEntityAbstract" xlink:label="loc_OKYODisclosureReportingEntityAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfReportingEntityExplanatory" xlink:label="loc_OKYODisclosureOfReportingEntityExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureReportingEntityAbstract" xlink:to="loc_OKYODisclosureOfReportingEntityExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPolicies" xlink:title="00000007 - Disclosure - ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="loc_OKYODisclosureAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty" xlink:title="00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" xlink:label="loc_OKYODisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract" xlink:to="loc_ifrs-fullDisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpenses" xlink:title="00000009 - Disclosure - OPERATING EXPENSES">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOperatingExpensesAbstract" xlink:label="loc_OKYODisclosureOperatingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOtherOperatingExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_ifrs-fullDisclosureOfOtherOperatingExpenseExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SegmentalReporting" xlink:title="00000010 - Disclosure - SEGMENTAL REPORTING">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureSegmentalReportingAbstract" xlink:label="loc_OKYODisclosureSegmentalReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfOperatingSegmentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureSegmentalReportingAbstract" xlink:to="loc_ifrs-fullDisclosureOfOperatingSegmentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficers" xlink:title="00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:label="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfEmployeeDetailsExplanatory" xlink:label="loc_OKYODisclosureOfEmployeeDetailsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" xlink:to="loc_OKYODisclosureOfEmployeeDetailsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel" xlink:title="00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="loc_ifrs-fullDisclosureOfInformationAboutKeyManagementPersonnelExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_ifrs-fullDisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Taxation" xlink:title="00000013 - Disclosure - TAXATION">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="loc_OKYODisclosureTaxationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullDisclosureOfIncomeTaxExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCosts" xlink:title="00000014 - Disclosure - FINANCE INCOME AND COSTS">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:label="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinanceIncomeExpenseExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipment" xlink:title="00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivables" xlink:title="00000016 - Disclosure - OTHER RECEIVABLES">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOtherReceivablesAbstract" xlink:label="loc_OKYODisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTradeAndOtherReceivablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayables" xlink:title="00000017 - Disclosure - TRADE AND OTHER PAYABLES">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_OKYODisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTradeAndOtherPayablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullDisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReserves" xlink:title="00000018 - Disclosure - CAPITAL AND RESERVES">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCapitalAndReservesAbstract" xlink:label="loc_OKYODisclosureCapitalAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="loc_ifrs-fullDisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCapitalAndReservesAbstract" xlink:to="loc_ifrs-fullDisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrants" xlink:title="00000019 - Disclosure - SHARE OPTIONS AND WARRANTS">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullDisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity" xlink:title="00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:label="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDebtSecuritiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDebtSecuritiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:to="loc_ifrs-fullDisclosureOfDebtSecuritiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstruments" xlink:title="00000021 - Disclosure - FINANCIAL INSTRUMENTS">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_OKYODisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinancialInstrumentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactions" xlink:title="00000022 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_OKYODisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfRelatedPartyExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShare" xlink:title="00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:label="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="loc_ifrs-fullDisclosureOfEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="loc_ifrs-fullDisclosureOfEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/Leases" xlink:title="00000024 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfLeasesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDisclosureOfLeasesExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemuneration" xlink:title="00000025 - Disclosure - Auditor&#8217;s Remuneration">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAuditorsRemunerationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfAuditorsRemunerationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="loc_ifrs-fullDisclosureOfAuditorsRemunerationExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalents" xlink:title="00000026 - Disclosure - Cash and Cash Equivalents">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_OKYODisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCashAndCashEquivalentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingencies" xlink:title="00000027 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCommitmentsAndContingenciesAbstract" xlink:label="loc_OKYODisclosureCommitmentsAndContingenciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCommitmentsAndContingenciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEvents" xlink:title="00000028 - Disclosure - Post Balance Sheet Events">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePostBalanceSheetEventsAbstract" xlink:label="loc_OKYODisclosurePostBalanceSheetEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="loc_ifrs-fullDisclosureOfEventsAfterReportingPeriodExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePostBalanceSheetEventsAbstract" xlink:to="loc_ifrs-fullDisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesPolicies" xlink:title="00000029 - Disclosure - ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="loc_OKYODisclosureAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" xlink:label="loc_OKYODisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODisclosureOfAccountingPoliciesBasisOfPresentationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:label="loc_ifrs-fullExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullExplanationOfMeasurementBasesUsedInPreparingFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfGoingConcernExplanatory" xlink:label="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfGoingConcernExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForSegmentReportingExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory" xlink:label="loc_OKYODescriptionOfAccountingPolicyForLicenseFeesExplanatory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODescriptionOfAccountingPolicyForLicenseFeesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" xlink:label="loc_OKYODescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory" xlink:label="loc_OKYODescriptionOfAccountingPolicyForShareCapitalExplanatory" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODescriptionOfAccountingPolicyForShareCapitalExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory" xlink:label="loc_OKYODescriptionOfAccountingPolicyForLeaseExplanatory" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODescriptionOfAccountingPolicyForLeaseExplanatory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForWarrantsExplanatory" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForWarrantsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForBorrowingsExplanatory" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForBorrowingsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="loc_ifrs-fullDescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesTables" xlink:title="00000030 - Disclosure - ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="loc_OKYODisclosureAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfEstimatedUsefulLivesExplanatory" xlink:label="loc_OKYODisclosureOfEstimatedUsefulLivesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_OKYODisclosureOfEstimatedUsefulLivesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OperatingExpensesTables" xlink:title="00000031 - Disclosure - OPERATING EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOperatingExpensesAbstract" xlink:label="loc_OKYODisclosureOperatingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutOperatingExpensesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersTables" xlink:title="00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:label="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutEmployeesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutEmployeesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables" xlink:title="00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory" xlink:label="loc_OKYOScheduleOfShareOptionsGrantedToDirectorsExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_OKYOScheduleOfShareOptionsGrantedToDirectorsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfEmployeeBenefitsExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_ifrs-fullDisclosureOfEmployeeBenefitsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationTables" xlink:title="00000034 - Disclosure - TAXATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="loc_OKYODisclosureTaxationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory" xlink:label="loc_ifrs-fullDisclosureOfTaxReceivablesAndPayablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullDisclosureOfTaxReceivablesAndPayablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinanceIncomeAndCostsTables" xlink:title="00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:label="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceCostExplanatory" xlink:label="loc_ifrs-fullDisclosureOfFinanceCostExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullDisclosureOfFinanceCostExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PropertyPlantAndEquipmentTables" xlink:title="00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesTables" xlink:title="00000037 - Disclosure - OTHER RECEIVABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOtherReceivablesAbstract" xlink:label="loc_OKYODisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedTradeAndOtherReceivablesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_OKYODisclosureOfDetailedTradeAndOtherReceivablesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TradeAndOtherPayablesTables" xlink:title="00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_OKYODisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesTables" xlink:title="00000039 - Disclosure - CAPITAL AND RESERVES (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCapitalAndReservesAbstract" xlink:label="loc_OKYODisclosureCapitalAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="loc_ifrs-fullDisclosureOfClassesOfShareCapitalExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCapitalAndReservesAbstract" xlink:to="loc_ifrs-fullDisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsTables" xlink:title="00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullDisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullDisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables" xlink:title="00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:label="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory" xlink:label="loc_OKYODisclosureOfIssuanceOfConvertibleNotesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:to="loc_OKYODisclosureOfIssuanceOfConvertibleNotesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/FinancialInstrumentsTables" xlink:title="00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_OKYODisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinancialInstrumentsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/BasicAndDilutedLossPerShareTables" xlink:title="00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:label="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="loc_ifrs-fullEarningsPerShareExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="loc_ifrs-fullEarningsPerShareExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesTables" xlink:title="00000044 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AuditorsRemunerationTables" xlink:title="00000045 - Disclosure - Auditor&#8217;s Remuneration (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CashAndCashEquivalentsTables" xlink:title="00000046 - Disclosure - Cash and Cash Equivalents (Tables)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_OKYODisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:label="loc_OKYODisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_OKYODisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails" xlink:title="00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="loc_OKYODisclosureAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FurnitureAndFixtureMember" xlink:label="loc_OKYOFurnitureAndFixtureMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_OKYOFurnitureAndFixtureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="loc_ifrs-fullComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_ifrs-fullComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:label="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullUsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/AccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureAccountingPoliciesAbstract" xlink:label="loc_OKYODisclosureAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureAccountingPoliciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NonadjustingEventMember" xlink:label="loc_OKYONonadjustingEventMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_OKYONonadjustingEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="loc_ifrs-fullRetainedEarnings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullRetainedEarnings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="loc_ifrs-fullProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashFlowsFromUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="loc_ifrs-fullCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="loc_ifrs-fullCurrentLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CashBurnRate" xlink:label="loc_OKYOCashBurnRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOCashBurnRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails" xlink:title="00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOperatingExpensesAbstract" xlink:label="loc_OKYODisclosureOperatingExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KeyManagementPersonnelCompensationDirectorFees" xlink:label="loc_OKYOKeyManagementPersonnelCompensationDirectorFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_OKYOKeyManagementPersonnelCompensationDirectorFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ChairmansBonus" xlink:label="loc_OKYOChairmansBonus" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_OKYOChairmansBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-fullAuditorsRemuneration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_ifrs-fullAuditorsRemuneration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="loc_ifrs-fullProfessionalFeesExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_ifrs-fullProfessionalFeesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GainlossOnDisposalOfLeases" xlink:label="loc_OKYOGainlossOnDisposalOfLeases" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_OKYOGainlossOnDisposalOfLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ForeignExchangeLossesGains" xlink:label="loc_OKYOForeignExchangeLossesGains" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_OKYOForeignExchangeLossesGains" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="loc_ifrs-fullDepreciationAndAmortisationExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOperatingExpensesAbstract" xlink:to="loc_ifrs-fullDepreciationAndAmortisationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails" xlink:title="00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:label="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" xlink:to="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfIntangibleAssetsTable" xlink:to="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentMember" xlink:label="loc_OKYOResearchAndDevelopmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" xlink:to="loc_OKYOResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_CorporateAndAdministrationMember" xlink:label="loc_OKYOCorporateAndAdministrationMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullIntangibleAssetsOtherThanGoodwillMember" xlink:to="loc_OKYOCorporateAndAdministrationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalaries" xlink:label="loc_OKYODirectorsSalaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsSalaries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WagesAndSalaries" xlink:label="loc_ifrs-fullWagesAndSalaries" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWagesAndSalaries" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SocialSecurityContributions" xlink:label="loc_ifrs-fullSocialSecurityContributions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullSocialSecurityContributions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherShorttermEmployeeBenefits" xlink:label="loc_ifrs-fullOtherShorttermEmployeeBenefits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullOtherShorttermEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="loc_ifrs-fullEmployeeBenefitsExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEmployeeBenefitsExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfEmployees" xlink:label="loc_ifrs-fullNumberOfEmployees" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfEmployees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative" xlink:title="00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureEmployeesIncludingOfficersAbstract" xlink:label="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans" xlink:label="loc_ifrs-fullPostemploymentBenefitExpenseDefinedContributionPlans" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureEmployeesIncludingOfficersAbstract" xlink:to="loc_ifrs-fullPostemploymentBenefitExpenseDefinedContributionPlans" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails" xlink:title="00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_OKYOIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GCerroneMember" xlink:label="loc_OKYOGCerroneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGCerroneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GJacobMember" xlink:label="loc_OKYOGJacobMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGJacobMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WSimonMember" xlink:label="loc_OKYOWSimonMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOWSimonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KShailubhaiMember" xlink:label="loc_OKYOKShailubhaiMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOKShailubhaiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_JBrancaccioMember" xlink:label="loc_OKYOJBrancaccioMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOJBrancaccioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GMacraeMember" xlink:label="loc_OKYOGMacraeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGMacraeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BDenoyerMember" xlink:label="loc_OKYOBDenoyerMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOBDenoyerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LZambelettiMember" xlink:label="loc_OKYOLZambelettiMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOLZambelettiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DirectorsRemunerationExpense" xlink:label="loc_ifrs-fullDirectorsRemunerationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDirectorsRemunerationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsBonus" xlink:label="loc_OKYODirectorsBonus" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsSalary" xlink:label="loc_OKYODirectorsSalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODirectorsSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_KeyManagementPersonnelCompensationSharebasedPayments" xlink:label="loc_OKYOKeyManagementPersonnelCompensationSharebasedPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOKeyManagementPersonnelCompensationSharebasedPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical" xlink:title="00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_OKYOIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GCerroneMember" xlink:label="loc_OKYOGCerroneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGCerroneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BonusAwarded" xlink:label="loc_OKYOBonusAwarded" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOBonusAwarded" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails" xlink:title="00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DirectorsMember" xlink:label="loc_OKYODirectorsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_OKYODirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_JBrancaccioMember" xlink:label="loc_OKYOJBrancaccioMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOJBrancaccioMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GJacobMember" xlink:label="loc_OKYOGJacobMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOGJacobMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BDenoyerMember" xlink:label="loc_OKYOBDenoyerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_OKYOBDenoyerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails" xlink:title="00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:label="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRemunerationOfKeyManagementPersonnelAbstract" xlink:to="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCategoriesOfRelatedPartiesAxis" xlink:to="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="loc_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEntitysTotalForRelatedPartiesMember" xlink:to="loc_ifrs-fullKeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationShorttermEmployeeBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="loc_ifrs-fullKeyManagementPersonnelCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullKeyManagementPersonnelCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails" xlink:title="00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="loc_OKYODisclosureTaxationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncome" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncome" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod" xlink:label="loc_ifrs-fullAdjustmentsForCurrentTaxOfPriorPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullAdjustmentsForCurrentTaxOfPriorPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="loc_ifrs-fullDeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullDeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullIncomeTaxExpenseContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LossBeforeTaxation" xlink:label="loc_OKYOLossBeforeTaxation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOLossBeforeTaxation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LossChargedAtStandardRateOfCorporationTax" xlink:label="loc_OKYOLossChargedAtStandardRateOfCorporationTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOLossChargedAtStandardRateOfCorporationTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:label="loc_ifrs-fullTaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullTaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TaxLossesSurrenderedForResearchAndDevelopment" xlink:label="loc_OKYOTaxLossesSurrenderedForResearchAndDevelopment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOTaxLossesSurrenderedForResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:label="loc_ifrs-fullTaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullTaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" xlink:label="loc_OKYOTaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOTaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentTaxClaim" xlink:label="loc_OKYOResearchAndDevelopmentTaxClaim" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOResearchAndDevelopmentTaxClaim" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ResearchAndDevelopmentEnhancedExpenditure" xlink:label="loc_OKYOResearchAndDevelopmentEnhancedExpenditure" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_OKYOResearchAndDevelopmentEnhancedExpenditure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:label="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullCurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughForeignExchangeFinancialAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughForeignExchangeFinancialAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" xlink:label="loc_ifrs-fullGainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullGainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical" xlink:title="00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="loc_OKYODisclosureTaxationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ApplicableTaxRate" xlink:label="loc_ifrs-fullApplicableTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullApplicableTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/TaxationDetailsNarrative" xlink:title="00000058 - Disclosure - TAXATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTaxationAbstract" xlink:label="loc_OKYODisclosureTaxationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TaxEffectOfTaxLosses" xlink:label="loc_ifrs-fullTaxEffectOfTaxLosses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTaxationAbstract" xlink:to="loc_ifrs-fullTaxEffectOfTaxLosses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFinanceCostDetails" xlink:title="00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinanceIncomeAndCostsAbstract" xlink:label="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromInterest" xlink:label="loc_ifrs-fullRevenueFromInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullRevenueFromInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="loc_ifrs-fullFinanceIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullFinanceIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullInterestExpenseOnLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="loc_ifrs-fullFinanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinanceIncomeAndCostsAbstract" xlink:to="loc_ifrs-fullFinanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfPropertyPlantAndEquipmentTable" xlink:to="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="loc_ifrs-fullPropertyPlantAndEquipmentMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfPropertyPlantAndEquipmentAxis" xlink:to="loc_ifrs-fullPropertyPlantAndEquipmentMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ITEquipmentMember" xlink:label="loc_OKYOITEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullPropertyPlantAndEquipmentMember" xlink:to="loc_OKYOITEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentCost" xlink:label="loc_OKYOPropertyPlantAndEquipmentCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullAdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullDisposalsPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDisposalsPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentCost" xlink:label="loc_OKYOPropertyPlantAndEquipmentCost_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentCost_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentDepreciation" xlink:label="loc_OKYOPropertyPlantAndEquipmentDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfChargeInYearDepreciation" xlink:label="loc_OKYOEffectOfChargeInYearDepreciation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOEffectOfChargeInYearDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_EffectOfForeignExchangeDepreciation" xlink:label="loc_OKYOEffectOfForeignExchangeDepreciation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOEffectOfForeignExchangeDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PropertyPlantAndEquipmentDepreciation" xlink:label="loc_OKYOPropertyPlantAndEquipmentDepreciation_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOPropertyPlantAndEquipmentDepreciation_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationNetValue" xlink:label="loc_OKYODepreciationNetValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODepreciationNetValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails" xlink:title="00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePropertyPlantAndEquipmentAbstract" xlink:label="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveTable" xlink:label="loc_srtRealEstateWriteDownOrReserveTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePropertyPlantAndEquipmentAbstract" xlink:to="loc_srtRealEstateWriteDownOrReserveTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateWriteDownOrReserveLineItems" xlink:label="loc_srtRealEstateWriteDownOrReserveLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateWriteDownOrReserveTable" xlink:to="loc_srtRealEstateWriteDownOrReserveLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateWriteDownOrReserveTable" xlink:to="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UKMember" xlink:label="loc_OKYOUKMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="loc_OKYOUKMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_UnitedStateMember" xlink:label="loc_OKYOUnitedStateMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="loc_OKYOUnitedStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="loc_ifrs-fullPropertyPlantAndEquipment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRealEstateWriteDownOrReserveLineItems" xlink:to="loc_ifrs-fullPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails" xlink:title="00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOtherReceivablesAbstract" xlink:label="loc_OKYODisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="loc_ifrs-fullOtherCurrentReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_ifrs-fullOtherCurrentReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="loc_ifrs-fullCurrentValueAddedTaxReceivables" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_ifrs-fullCurrentValueAddedTaxReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Prepayments" xlink:label="loc_ifrs-fullPrepayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_ifrs-fullPrepayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="loc_ifrs-fullTradeAndOtherCurrentReceivables" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/OtherReceivablesDetailsNarrative" xlink:title="00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureOtherReceivablesAbstract" xlink:label="loc_OKYODisclosureOtherReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrepaymentsReceivables" xlink:label="loc_OKYOPrepaymentsReceivables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureOtherReceivablesAbstract" xlink:to="loc_OKYOPrepaymentsReceivables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails" xlink:title="00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureTradeAndOtherPayablesAbstract" xlink:label="loc_OKYODisclosureTradeAndOtherPayablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="loc_ifrs-fullTradeAndOtherCurrentPayablesToTradeSuppliers" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullTradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Accruals" xlink:label="loc_ifrs-fullAccruals" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_ifrs-fullAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BonusAccrual" xlink:label="loc_OKYOBonusAccrual" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_OKYOBonusAccrual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:label="loc_OKYOTradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureTradeAndOtherPayablesAbstract" xlink:to="loc_OKYOTradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails" xlink:title="00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCapitalAndReservesAbstract" xlink:label="loc_OKYODisclosureCapitalAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCapitalAndReservesAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="loc_ifrs-fullIssuedCapitalMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullIssuedCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacement" xlink:label="loc_OKYONumberOfSharesIssuedPrivatePlacement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYONumberOfSharesIssuedPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NumberOfSharesIssuedPrivatePlacementValue" xlink:label="loc_OKYONumberOfSharesIssuedPrivatePlacementValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYONumberOfSharesIssuedPrivatePlacementValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueWarrantsIssuedPrivatePlacement" xlink:label="loc_OKYOFairValueWarrantsIssuedPrivatePlacement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOFairValueWarrantsIssuedPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IssuedInLieuValue" xlink:label="loc_OKYOIssuedInLieuValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIssuedInLieuValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfOptionsShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfOptionsShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:label="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsEquityShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughExerciseOfWarrantsEquityShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:label="loc_OKYOIncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOIncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="loc_ifrs-fullNumberOfSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="loc_ifrs-fullEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CapitalAndReservesDetailsNarrative" xlink:title="00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCapitalAndReservesAbstract" xlink:label="loc_OKYODisclosureCapitalAndReservesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCapitalAndReservesAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="loc_ifrs-fullOrdinarySharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_ifrs-fullOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveOneMember" xlink:label="loc_OKYOWarrantReserveOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOWarrantReserveOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantReserveTwoMember" xlink:label="loc_OKYOWarrantReserveTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOWarrantReserveTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="loc_ifrs-fullClassesOfFinancialInstrumentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsAxis" xlink:to="loc_ifrs-fullClassesOfFinancialInstrumentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesMember" xlink:label="loc_OKYOLoanNotesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsMember" xlink:to="loc_OKYOLoanNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LoanNotesOneMember" xlink:label="loc_OKYOLoanNotesOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfFinancialInstrumentsMember" xlink:to="loc_OKYOLoanNotesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DividendPayables" xlink:label="loc_ifrs-fullDividendPayables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDividendPayables" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails" xlink:title="00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_OKYOIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateAxis" xlink:label="loc_OKYOGrantDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOGrantDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateDomain" xlink:label="loc_OKYOGrantDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateAxis" xlink:to="loc_OKYOGrantDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJulyTwoThousandEighteenMember" xlink:label="loc_OKYOSixJulyTwoThousandEighteenMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOSixJulyTwoThousandEighteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyAugustTwoThousandTwentyMember" xlink:label="loc_OKYOTwentyAugustTwoThousandTwentyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOTwentyAugustTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SixJanuaryTwoThousandTwentyOneMember" xlink:label="loc_OKYOSixJanuaryTwoThousandTwentyOneMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOSixJanuaryTwoThousandTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwelveJanuaryTwoThousandTwentyOneMember" xlink:label="loc_OKYOTwelveJanuaryTwoThousandTwentyOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOTwelveJanuaryTwoThousandTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FifteenAprilTwoThousandTwentyOneMember" xlink:label="loc_OKYOFifteenAprilTwoThousandTwentyOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOFifteenAprilTwoThousandTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember" xlink:label="loc_OKYOThirtyFirstAugustTwoThousandTwentyOneMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOThirtyFirstAugustTwoThousandTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:label="loc_OKYOThirtyFirstAugustTwoThousandTwentyTwoMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOGrantDateDomain" xlink:to="loc_OKYOThirtyFirstAugustTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpirationDateOfOutstanding" xlink:label="loc_OKYOExpirationDateOfOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpirationDateOfOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="loc_ifrs-fullNumberOfOutstandingShareOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOutstandingShareOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails" xlink:title="00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="loc_ifrs-fullRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="loc_ifrs-fullRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="loc_ifrs-fullRangesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangeAxis" xlink:to="loc_ifrs-fullRangesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="loc_ifrs-fullBottomOfRangeMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullBottomOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="loc_ifrs-fullTopOfRangeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullRangesMember" xlink:to="loc_ifrs-fullTopOfRangeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GrantDateShareOptionsGranted2019" xlink:label="loc_OKYOGrantDateShareOptionsGranted2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOGrantDateShareOptionsGranted2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_VestingPeriodsDescription" xlink:label="loc_OKYOVestingPeriodsDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOVestingPeriodsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_OptionLifePeriod" xlink:label="loc_OKYOOptionLifePeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOOptionLifePeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails" xlink:title="00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpectedLifeOfWarrants" xlink:label="loc_OKYOExpectedLifeOfWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpectedLifeOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails" xlink:title="00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageSharePriceShareOptionsGranted2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="loc_ifrs-fullExercisePriceShareOptionsGranted2019" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullExercisePriceShareOptionsGranted2019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsVestingPeriod" xlink:label="loc_OKYOWarrantsVestingPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsVestingPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ExpectedLifeOfWarrants" xlink:label="loc_OKYOExpectedLifeOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOExpectedLifeOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative" xlink:title="00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureShareOptionsAndWarrantsAbstract" xlink:label="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="loc_ifrs-fullStatementOfChangesInEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureShareOptionsAndWarrantsAbstract" xlink:to="loc_ifrs-fullStatementOfChangesInEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="loc_ifrs-fullComponentsOfEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullComponentsOfEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="loc_ifrs-fullEquityMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullComponentsOfEquityAxis" xlink:to="loc_ifrs-fullEquityMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WarrantReserveMember" xlink:label="loc_ifrs-fullWarrantReserveMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_ifrs-fullWarrantReserveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsMember" xlink:label="loc_OKYOPrivatePlacementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOPrivatePlacementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PrivatePlacementsOneMember" xlink:label="loc_OKYOPrivatePlacementsOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullEquityMember" xlink:to="loc_OKYOPrivatePlacementsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="loc_ifrs-fullTypesOfContractsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullTypesOfContractsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfProfessionalFeesMember" xlink:label="loc_OKYOLieuOfProfessionalFeesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOLieuOfProfessionalFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LieuOfBrokerFeesMember" xlink:label="loc_OKYOLieuOfBrokerFeesMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOLieuOfBrokerFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="loc_ifrs-fullBorrowingsByNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullStatementOfChangesInEquityTable" xlink:to="loc_ifrs-fullBorrowingsByNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="loc_ifrs-fullBorrowingsByNameMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBorrowingsByNameAxis" xlink:to="loc_ifrs-fullBorrowingsByNameMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesMember" xlink:label="loc_OKYOConvertibleLoanNotesMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBorrowingsByNameMember" xlink:to="loc_OKYOConvertibleLoanNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConvertibleLoanNotesOneMember" xlink:label="loc_OKYOConvertibleLoanNotesOneMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullBorrowingsByNameMember" xlink:to="loc_OKYOConvertibleLoanNotesOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" xlink:label="loc_ifrs-fullDeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullDeemedCostOfInvestmentsForWhichDeemedCostIsFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentCharge" xlink:label="loc_OKYOShareBasedPaymentCharge" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShareBasedPaymentCharge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShareBasedPaymentChargeForfeiture" xlink:label="loc_OKYOShareBasedPaymentChargeForfeiture" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShareBasedPaymentChargeForfeiture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ConsiderationPaidReceived" xlink:label="loc_ifrs-fullConsiderationPaidReceived" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullConsiderationPaidReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisablePricePerShare" xlink:label="loc_OKYOWarrantsExercisablePricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisablePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisableDate" xlink:label="loc_OKYOWarrantsExercisableDate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisableDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullWeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnCashlessBasic" xlink:label="loc_OKYOWarrantsExercisedOnCashlessBasic" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnCashlessBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnPriceReductionOffer" xlink:label="loc_OKYOWarrantsExercisedOnPriceReductionOffer" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnPriceReductionOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantsExercisedOnIssuances" xlink:label="loc_OKYOWarrantsExercisedOnIssuances" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantsExercisedOnIssuances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="loc_ifrs-fullProceedsFromExerciseOfWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FairValueOfWarrants" xlink:label="loc_OKYOFairValueOfWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOFairValueOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails" xlink:title="00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:label="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureConvertibleInstrumentsClassifiedAsEquityAbstract" xlink:to="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="loc_ifrs-fullClassesOfAssetsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="loc_ifrs-fullClassesOfAssetsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="loc_ifrs-fullClassesOfAssetsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsAxis" xlink:to="loc_ifrs-fullClassesOfAssetsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentyNineMayTwoThousandAndTwentyMember" xlink:label="loc_OKYOTwentyNineMayTwoThousandAndTwentyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOTwentyNineMayTwoThousandAndTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:label="loc_OKYOFeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOFeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TwentySevenJulyTwoThousandTwentyMember" xlink:label="loc_OKYOTwentySevenJulyTwoThousandTwentyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOTwentySevenJulyTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_SeventeenthAugustTwoThousandAndTwentyMember" xlink:label="loc_OKYOSeventeenthAugustTwoThousandAndTwentyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOSeventeenthAugustTwoThousandAndTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeSeptemberTwoThousandAndTwentyMember" xlink:label="loc_OKYOThreeSeptemberTwoThousandAndTwentyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOThreeSeptemberTwoThousandAndTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:label="loc_OKYOFeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfAssetsMember" xlink:to="loc_OKYOFeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ConversionPricePerShares" xlink:label="loc_OKYOConversionPricePerShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOConversionPricePerShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WarrantExercisePricePerShare" xlink:label="loc_OKYOWarrantExercisePricePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWarrantExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DebtTerm" xlink:label="loc_OKYODebtTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYODebtTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="loc_ifrs-fullIssueOfConvertibleInstruments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullIssueOfConvertibleInstruments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails" xlink:title="00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureFinancialInstrumentsAbstract" xlink:label="loc_OKYODisclosureFinancialInstrumentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureFinancialInstrumentsAbstract" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LessThanThreeMember" xlink:label="loc_OKYOLessThanThreeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_OKYOLessThanThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ThreeToTwelveMonthsMember" xlink:label="loc_OKYOThreeToTwelveMonthsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_OKYOThreeToTwelveMonthsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="loc_ifrs-fullTradeAndOtherPayables" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilities" xlink:label="loc_ifrs-fullFinancialLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullFinancialLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureRelatedPartyTransactionsAbstract" xlink:label="loc_OKYODisclosureRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable" xlink:label="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureRelatedPartyTransactionsAbstract" xlink:to="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="loc_ifrs-fullCounterpartiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullCounterpartiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="loc_ifrs-fullCounterpartiesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesAxis" xlink:to="loc_ifrs-fullCounterpartiesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WestAfricanMineralsLimitedMember" xlink:label="loc_OKYOWestAfricanMineralsLimitedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_OKYOWestAfricanMineralsLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_TizianaLifeSciencesLtdMember" xlink:label="loc_OKYOTizianaLifeSciencesLtdMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullCounterpartiesMember" xlink:to="loc_OKYOTizianaLifeSciencesLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="loc_ifrs-fullTypesOfContractsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfOffsettingOfFinancialAssetsTable" xlink:to="loc_ifrs-fullTypesOfContractsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="loc_ifrs-fullTypesOfContractsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfContractsAxis" xlink:to="loc_ifrs-fullTypesOfContractsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ServiceAgreementMember" xlink:label="loc_OKYOServiceAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullTypesOfContractsMember" xlink:to="loc_OKYOServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_WriteOffExchangeOfLoan" xlink:label="loc_OKYOWriteOffExchangeOfLoan" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOWriteOffExchangeOfLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:label="loc_ifrs-fullRevenueFromSaleOfGoodsRelatedPartyTransactions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullRevenueFromSaleOfGoodsRelatedPartyTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDebt" xlink:label="loc_ifrs-fullNetDebt" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNetDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Borrowings" xlink:label="loc_ifrs-fullBorrowings" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LoansAndReceivables" xlink:label="loc_ifrs-fullLoansAndReceivables" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullLoansAndReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherPayablesToRelatedParties" xlink:label="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullTradeAndOtherPayablesToRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ServicesReceivedRelatedPartyTransactions" xlink:label="loc_ifrs-fullServicesReceivedRelatedPartyTransactions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullServicesReceivedRelatedPartyTransactions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AmountsPayableRelatedPartyTransactions" xlink:label="loc_ifrs-fullAmountsPayableRelatedPartyTransactions" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullAmountsPayableRelatedPartyTransactions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails" xlink:title="00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureBasicAndDilutedLossPerShareAbstract" xlink:label="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:label="loc_ifrs-fullProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="loc_ifrs-fullProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="loc_ifrs-fullWeightedAverageShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="loc_ifrs-fullWeightedAverageShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_BasicAndDilutedEarningsLossPerShare" xlink:label="loc_OKYOBasicAndDilutedEarningsLossPerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureBasicAndDilutedLossPerShareAbstract" xlink:to="loc_OKYOBasicAndDilutedEarningsLossPerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails" xlink:title="00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsRightOfUseAssets" xlink:label="loc_OKYODisposalsRightOfUseAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisposalsRightOfUseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpactOfForeignExchange" xlink:label="loc_OKYOImpactOfForeignExchange" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOImpactOfForeignExchange" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="loc_ifrs-fullRightofuseAssets_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullRightofuseAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationOfEarlyTerminatedLease" xlink:label="loc_OKYODepreciationOfEarlyTerminatedLease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODepreciationOfEarlyTerminatedLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsRightOfUseAssets" xlink:label="loc_OKYODisposalsRightOfUseAssets_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisposalsRightOfUseAssets_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpactOfForeignExchange" xlink:label="loc_OKYOImpactOfForeignExchange_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOImpactOfForeignExchange_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="loc_ifrs-fullAdditionsToRightofuseAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullAdditionsToRightofuseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DepreciationOfNewLease" xlink:label="loc_OKYODepreciationOfNewLease" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODepreciationOfNewLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-fullLeaseLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeaseLiabilitiesInterestExpense" xlink:label="loc_OKYOLeaseLiabilitiesInterestExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOLeaseLiabilitiesInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeasePayments" xlink:label="loc_OKYOLeasePayments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ImpactOfForeignExchangeLeaseLiabilities" xlink:label="loc_OKYOImpactOfForeignExchangeLeaseLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOImpactOfForeignExchangeLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DerecognitionOfLeaseLiability" xlink:label="loc_OKYODerecognitionOfLeaseLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODerecognitionOfLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsLeaseLiabilities" xlink:label="loc_OKYODisposalsLeaseLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisposalsLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdditionsToLeaseLiabilities" xlink:label="loc_OKYOAdditionsToLeaseLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOAdditionsToLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeaseLiabilitiesInterestExpenses" xlink:label="loc_OKYOLeaseLiabilitiesInterestExpenses" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOLeaseLiabilitiesInterestExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_LeasePayment" xlink:label="loc_OKYOLeasePayment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOLeasePayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-fullLeaseLiabilities_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullLeaseLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails" xlink:title="00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="loc_ifrs-fullCurrentLeaseLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullCurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="loc_ifrs-fullNoncurrentLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullNoncurrentLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="loc_ifrs-fullLeaseLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullLeaseLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails" xlink:title="00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:label="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="loc_ifrs-fullMaturityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable" xlink:to="loc_ifrs-fullMaturityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="loc_ifrs-fullAggregatedTimeBandsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullMaturityAxis" xlink:to="loc_ifrs-fullAggregatedTimeBandsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="loc_ifrs-fullNotLaterThanOneYearMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullAggregatedTimeBandsMember" xlink:to="loc_ifrs-fullNotLaterThanOneYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="loc_ifrs-fullGrossLeaseLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullGrossLeaseLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/LeasesDetailsNarrative" xlink:title="00000081 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureLeasesAbstract" xlink:label="loc_OKYODisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsRightOfUseAssets" xlink:label="loc_OKYODisposalsRightOfUseAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisposalsRightOfUseAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisposalsLeaseLiabilities" xlink:label="loc_OKYODisposalsLeaseLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYODisposalsLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability" xlink:label="loc_OKYOInitialRecognitionForRightOfUseAssetAndLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureLeasesAbstract" xlink:to="loc_OKYOInitialRecognitionForRightOfUseAssetAndLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails" xlink:title="00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemunerationForAuditServices" xlink:label="loc_ifrs-fullAuditorsRemunerationForAuditServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="loc_ifrs-fullAuditorsRemunerationForAuditServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemunerationForOtherServices" xlink:label="loc_ifrs-fullAuditorsRemunerationForOtherServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="loc_ifrs-fullAuditorsRemunerationForOtherServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AuditorsRemuneration" xlink:label="loc_ifrs-fullAuditorsRemuneration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="loc_ifrs-fullAuditorsRemuneration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails" xlink:title="00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCashAndCashEquivalentsAbstract" xlink:label="loc_OKYODisclosureCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementTable" xlink:label="loc_OKYOIfrsStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCashAndCashEquivalentsAbstract" xlink:to="loc_OKYOIfrsStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementTable" xlink:to="loc_srtCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AllCurrenciesDomain" xlink:label="loc_OKYOAllCurrenciesDomain_2" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_OKYOAllCurrenciesDomain_2" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_GBPMember" xlink:label="loc_OKYOGBPMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOAllCurrenciesDomain_2" xlink:to="loc_OKYOGBPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_USDMember" xlink:label="loc_OKYOUSDMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOAllCurrenciesDomain_2" xlink:to="loc_OKYOUSDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashOnHand" xlink:label="loc_ifrs-fullCashOnHand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullCashOnHand" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000084 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosureCommitmentsAndContingenciesAbstract" xlink:label="loc_OKYODisclosureCommitmentsAndContingenciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosureCommitmentsAndContingenciesAbstract" xlink:to="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="loc_ifrs-fullProductsAndServicesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="loc_ifrs-fullProductsAndServicesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="loc_ifrs-fullProductsAndServicesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesAxis" xlink:to="loc_ifrs-fullProductsAndServicesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIHumanClinicalTrialMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIHumanClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIIHumanClinicalTrialMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIIHumanClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_PhaseIIIHumanClinicalTrialMember" xlink:label="loc_OKYOPhaseIIIHumanClinicalTrialMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullProductsAndServicesMember" xlink:to="loc_OKYOPhaseIIIHumanClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmountOfLicensedProductOrService" xlink:label="loc_OKYOAmountOfLicensedProductOrService" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAmountOfLicensedProductOrService" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFee" xlink:label="loc_OKYOAnnualLicenseMaintenanceFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAnnualLicenseMaintenanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AnnualLicenseMaintenanceFeeTherafter" xlink:label="loc_OKYOAnnualLicenseMaintenanceFeeTherafter" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAnnualLicenseMaintenanceFeeTherafter" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative" xlink:title="00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_DisclosurePostBalanceSheetEventsAbstract" xlink:label="loc_OKYODisclosurePostBalanceSheetEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYODisclosurePostBalanceSheetEventsAbstract" xlink:to="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_IfrsStatementLineItems" xlink:label="loc_OKYOIfrsStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_OKYOIfrsStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="loc_ifrs-fullNonadjustingEventsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsAfterReportingPeriodAxis" xlink:to="loc_ifrs-fullNonadjustingEventsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_NonadjustingEventMember" xlink:label="loc_OKYONonadjustingEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullNonadjustingEventsMember" xlink:to="loc_OKYONonadjustingEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="loc_ifrs-fullClassesOfShareCapitalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullDisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="loc_ifrs-fullClassesOfShareCapitalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="loc_ifrs-fullClassesOfShareCapitalMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalAxis" xlink:to="loc_ifrs-fullClassesOfShareCapitalMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AmericanDepositorySharesMember" xlink:label="loc_OKYOAmericanDepositorySharesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-fullClassesOfShareCapitalMember" xlink:to="loc_OKYOAmericanDepositorySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="loc_ifrs-fullNumberOfSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullNumberOfSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="loc_ifrs-fullParValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullParValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="loc_ifrs-fullProceedsFromIssuingShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullProceedsFromIssuingShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_Bonus" xlink:label="loc_OKYOBonus" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_ShorttermCreditFacility" xlink:label="loc_OKYOShorttermCreditFacility" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOShorttermCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="loc_ifrs-fullBorrowingsInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_ifrs-fullBorrowingsInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="okyo-20220331.xsd#OKYO_AdditionalBorrowingsInterestRate" xlink:label="loc_OKYOAdditionalBorrowingsInterestRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OKYOIfrsStatementLineItems" xlink:to="loc_OKYOAdditionalBorrowingsInterestRate" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677713936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OKYO
Pharma Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001849296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Y7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Martello
Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Admiral
Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">St.
Peter Port<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">GY1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,374,415,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Mazars
LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">London,
England<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">107
Cheapside<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">London<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">GB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">EC2V 6DN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">+44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">20 7495 2379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Chief
Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874678833776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets<br> &#163; in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,700,724<span></span>
</td>
<td class="nump">$ 6,889,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_RelatedPartyReceivables', window );">Related party receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_CurrentTaxationReceivable', window );">Current taxation receivable</a></td>
<td class="nump">781,688<span></span>
</td>
<td class="nump">26,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">812,956<span></span>
</td>
<td class="nump">43,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">4,295,368<span></span>
</td>
<td class="nump">6,986,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and Equipment, net</a></td>
<td class="nump">5,225<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,579<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">5,225<span></span>
</td>
<td class="nump">104,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">4,300,593<span></span>
</td>
<td class="nump">7,091,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">1,306,150<span></span>
</td>
<td class="nump">1,673,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Related party payable</a></td>
<td class="nump">47,041<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities - current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">34,148<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">1,353,191<span></span>
</td>
<td class="nump">1,707,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities - non current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,353,191<span></span>
</td>
<td class="nump">1,771,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">123,976,510<span></span>
</td>
<td class="nump">111,629,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReserveOfSharebasedPayments', window );">Share options reserve</a></td>
<td class="nump">2,355,040<span></span>
</td>
<td class="nump">636,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantReserve', window );">Warrants reserve</a></td>
<td class="nump">53,413<span></span>
</td>
<td class="nump">861,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConvertibleLoanNoteReserve', window );">Convertible Loan Note reserve</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,370,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ForeignCurrencyTranslationReserve', window );">Foreign currency translation reserve</a></td>
<td class="num">(11,011,527)<span></span>
</td>
<td class="num">(10,174,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained deficit</a></td>
<td class="num">(112,426,034)<span></span>
</td>
<td class="num">(106,003,753)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">2,947,402<span></span>
</td>
<td class="nump">5,319,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 4,300,593<span></span>
</td>
<td class="nump">$ 7,091,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ConvertibleLoanNoteReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible loan note reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ConvertibleLoanNoteReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_CurrentTaxationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current taxation receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_CurrentTaxationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ForeignCurrencyTranslationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ForeignCurrencyTranslationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_RelatedPartyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_RelatedPartyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReserveOfSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReserveOfSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874684029520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaterialIncomeAndExpenseAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">$ (1,301,178)<span></span>
</td>
<td class="num">$ (173,821)<span></span>
</td>
<td class="num">$ (518,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating Expenses</a></td>
<td class="num">(4,916,388)<span></span>
</td>
<td class="num">(3,192,385)<span></span>
</td>
<td class="num">(1,016,548)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OperatingExpenseExcludingCostOfSales', window );">Total operating expenses</a></td>
<td class="num">(6,217,566)<span></span>
</td>
<td class="num">(3,366,206)<span></span>
</td>
<td class="num">(1,534,646)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance Income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance (expense)</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,123)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ImpairmentOfLoan', window );">Impairment of loan</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,172)<span></span>
</td>
<td class="num">(132,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss from operations before income taxes</a></td>
<td class="num">(6,217,566)<span></span>
</td>
<td class="num">(3,378,501)<span></span>
</td>
<td class="num">(1,620,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncomeTaxExpenseBenefitContinuingOperations', window );">Income tax provision</a></td>
<td class="nump">786,521<span></span>
</td>
<td class="nump">24,994<span></span>
</td>
<td class="nump">76,288<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the year</a></td>
<td class="num">(5,431,045)<span></span>
</td>
<td class="num">(3,353,507)<span></span>
</td>
<td class="num">(1,544,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="num">(837,152)<span></span>
</td>
<td class="nump">346,365<span></span>
</td>
<td class="nump">86,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="num">$ (6,268,197)<span></span>
</td>
<td class="num">$ (3,007,142)<span></span>
</td>
<td class="num">$ (1,457,405)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders', window );">Basic and diluted loss per share attributable to common shareholders | $ / shares</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings loss per share attributable to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ImpairmentOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of loan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ImpairmentOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaterialIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaterialIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpenseExcludingCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating expense excluding the cost of sales. [Refer: Cost of sales]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpenseExcludingCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676308848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity<br> &#163; in Millions</strong></div></th>
<th class="th">
<div>Issued capital [member] </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Other reserves [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Warrant Reserves [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Convertible loan note reserve [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Retained earnings [member] </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Translation reserve [member] </div>
<div>USD ($)</div>
</th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>GBP (&#163;)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 111,741,860<span></span>
</td>
<td class="nump">$ 57,101<span></span>
</td>
<td class="nump">$ 30,242<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (100,888,643)<span></span>
</td>
<td class="num">$ (10,607,394)<span></span>
</td>
<td class="nump">$ 333,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2019 | shares</a></td>
<td class="nump">524,108,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodValueNewIssue', window );">Issue of share capital</a></td>
<td class="nump">$ 965,171<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">965,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodSharesShareCapital', window );">Issuance of share capital, shares | shares</a></td>
<td class="nump">112,188,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnOptionsCharge', window );">Options charge</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">36,340<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge', window );">Warrants charge</a></td>
<td class="num">(627,047)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">609,661<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnTotalTransactions', window );">Total transactions</a></td>
<td class="nump">338,124<span></span>
</td>
<td class="nump">36,340<span></span>
</td>
<td class="nump">609,661<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">984,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,544,059)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,544,059)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86,654<span></span>
</td>
<td class="nump">86,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,544,059)<span></span>
</td>
<td class="nump">86,654<span></span>
</td>
<td class="num">(1,457,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 112,079,984<span></span>
</td>
<td class="nump">93,441<span></span>
</td>
<td class="nump">639,903<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(102,432,702)<span></span>
</td>
<td class="num">(10,520,740)<span></span>
</td>
<td class="num">(140,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2020 | shares</a></td>
<td class="nump">636,297,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodValueNewIssue', window );">Issue of share capital</a></td>
<td class="nump">$ 230,019<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">230,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodSharesShareCapital', window );">Issuance of share capital, shares | shares</a></td>
<td class="nump">36,269,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnOptionsCharge', window );">Options charge</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550,138<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">550,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Options exercised</a></td>
<td class="nump">$ 15,870<span></span>
</td>
<td class="num">(1,515)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,515<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions', window );">Options exercised, shares | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfForfeiture', window );">Options forfeiture</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,751)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge', window );">Warrants charge</a></td>
<td class="num">(138,305)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">221,311<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">83,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnConvertibleDebtConversion', window );">Convertible loan note conversion</a></td>
<td class="num">(558,396)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,151,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,593,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnConvertibleDebtInterest', window );">Convertible loan note interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">219,059<span></span>
</td>
<td class="num">(219,059)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnTotalTransactions', window );">Total transactions</a></td>
<td class="num">(450,811)<span></span>
</td>
<td class="nump">542,872<span></span>
</td>
<td class="nump">221,311<span></span>
</td>
<td class="nump">8,370,836<span></span>
</td>
<td class="num">(217,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,466,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,353,507)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,353,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">346,365<span></span>
</td>
<td class="nump">346,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,353,507)<span></span>
</td>
<td class="nump">346,365<span></span>
</td>
<td class="num">(3,007,142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 111,629,173<span></span>
</td>
<td class="nump">636,313<span></span>
</td>
<td class="nump">861,214<span></span>
</td>
<td class="nump">8,370,836<span></span>
</td>
<td class="num">(106,003,753)<span></span>
</td>
<td class="num">(10,174,375)<span></span>
</td>
<td class="nump">5,319,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2021 | shares</a></td>
<td class="nump">672,816,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest', window );">Convertible loan note and warrant interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">546,318<span></span>
</td>
<td class="nump">444,918<span></span>
</td>
<td class="num">(991,236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves', window );">Transfer between equity reserves</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">594,190<span></span>
</td>
<td class="num">(594,190)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnOptionsCharge', window );">Options charge</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,737,876<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,737,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfForfeiture', window );">Options forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants Exercised</a></td>
<td class="nump">$ 3,470,940<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,010,030)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,460,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnWarrantsExercisedShares', window );">Warrants exercised, shares | shares</a></td>
<td class="nump">386,512,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge', window );">Warrants charge</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,721<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">61,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnConvertibleDebtConversion', window );">Convertible loan note conversion</a></td>
<td class="nump">$ 8,876,397<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,876,397)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnConvertibleDebtConversionShares', window );">Convertible debt conversion, shares | shares</a></td>
<td class="nump">315,086,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnTotalTransactions', window );">Total transactions</a></td>
<td class="nump">$ 12,347,337<span></span>
</td>
<td class="nump">1,718,727<span></span>
</td>
<td class="num">(807,801)<span></span>
</td>
<td class="num">(8,370,836)<span></span>
</td>
<td class="num">(991,236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,896,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnTotalTransactionsShares', window );">Total transactions, shares | shares</a></td>
<td class="nump">701,599,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,431,045)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,431,045)<span></span>
</td>
<td class="num">&#163; (4.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Currency translation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(837,152)<span></span>
</td>
<td class="num">(837,152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,431,045)<span></span>
</td>
<td class="num">(837,152)<span></span>
</td>
<td class="num">(6,268,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion', window );">Currency translation on Convertible Loan note conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">654,833<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">654,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 123,976,510<span></span>
</td>
<td class="nump">$ 2,355,040<span></span>
</td>
<td class="nump">$ 53,413<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (112,426,034)<span></span>
</td>
<td class="num">$ (11,011,527)<span></span>
</td>
<td class="nump">$ 2,947,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares at Mar. 31, 2022 | shares</a></td>
<td class="nump">1,374,415,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncreaseDecreaseThroughExerciseOfForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of forfeiture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncreaseDecreaseThroughExerciseOfForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of warrants charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on convertible debt and warrant interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnConvertibleDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on convertible debt, conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnConvertibleDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnConvertibleDebtConversionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on convertible debt conversion, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnConvertibleDebtConversionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnConvertibleDebtInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on convertible debt interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnConvertibleDebtInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on currency translation on convertible loan note conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnOptionsCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on options charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnOptionsCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnTotalTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on total transactions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnTotalTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnTotalTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on total transactions shares,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnTotalTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_SharesIssuedOnWarrantsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issued on warrants exercised shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_SharesIssuedOnWarrantsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_StockIssuedDuringPeriodSharesShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares share capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_StockIssuedDuringPeriodSharesShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_StockIssuedDuringPeriodValueNewIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value new issue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_StockIssuedDuringPeriodValueNewIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value transfer between equisty reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683554928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss from operations before income taxes</a></td>
<td class="num">$ (6,217,566)<span></span>
</td>
<td class="num">$ (3,378,501)<span></span>
</td>
<td class="num">$ (1,620,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share option charge</a></td>
<td class="nump">1,737,876<span></span>
</td>
<td class="nump">550,138<span></span>
</td>
<td class="nump">36,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge', window );">Warrant charge</a></td>
<td class="nump">61,721<span></span>
</td>
<td class="nump">83,006<span></span>
</td>
<td class="nump">42,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions', window );">Forfeiture of options</a></td>
<td class="num">(19,149)<span></span>
</td>
<td class="num">(5,751)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of fixed assets</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">1,510<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of right of use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,601<span></span>
</td>
<td class="nump">5,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">(Gain)/Loss on foreign exchange</a></td>
<td class="num">(9,230)<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
<td class="nump">13,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances', window );">Impairment of loan to West African Minerals Ltd</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,171<span></span>
</td>
<td class="nump">132,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Gain on disposal of right of use asset</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(818)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables', window );">Net decrease/(increase) in related party receivables</a></td>
<td class="nump">27,376<span></span>
</td>
<td class="num">(3,862)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables', window );">Net increase/(decrease) in related party payables</a></td>
<td class="nump">48,900<span></span>
</td>
<td class="num">(46,311)<span></span>
</td>
<td class="nump">38,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Net (increase)/decrease in operating assets/other receivables</a></td>
<td class="num">(802,154)<span></span>
</td>
<td class="nump">208,931<span></span>
</td>
<td class="num">(122,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Net (decrease)/increase in trade and other payables</a></td>
<td class="num">(297,991)<span></span>
</td>
<td class="nump">886,093<span></span>
</td>
<td class="nump">271,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Cash inflow from taxation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78,540<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,468,065)<span></span>
</td>
<td class="num">(1,600,198)<span></span>
</td>
<td class="num">(1,202,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="num">(1,669)<span></span>
</td>
<td class="num">(6,943)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties', window );">Loan to West African Minerals Ltd</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,171)<span></span>
</td>
<td class="num">(132,668)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,669)<span></span>
</td>
<td class="num">(18,114)<span></span>
</td>
<td class="num">(132,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of ordinary shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">230,019<span></span>
</td>
<td class="nump">990,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issuance of convertible loan notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,593,380<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ProcessedFromOptionsExercised', window );">Processed from options exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,870<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ProcessedFromWarrantsExercised', window );">Processed from warrants exercised</a></td>
<td class="nump">2,153,270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_CashAdvancesAndLoansToRelatedParties', window );">Loan to related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(518,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties', window );">Loan repayment from related party</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">496,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of leasing liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12,331)<span></span>
</td>
<td class="num">(6,139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,153,270<span></span>
</td>
<td class="nump">7,826,938<span></span>
</td>
<td class="nump">963,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net (decrease)/increase in cash and cash equivalents</a></td>
<td class="num">(3,316,464)<span></span>
</td>
<td class="nump">6,208,627<span></span>
</td>
<td class="num">(371,423)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalent, beginning of period</a></td>
<td class="nump">6,889,329<span></span>
</td>
<td class="nump">235,485<span></span>
</td>
<td class="nump">627,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange difference</a></td>
<td class="num">(872,141)<span></span>
</td>
<td class="nump">445,217<span></span>
</td>
<td class="num">(20,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalent, end of period</a></td>
<td class="nump">$ 2,700,724<span></span>
</td>
<td class="nump">$ 6,889,329<span></span>
</td>
<td class="nump">$ 235,485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for change in fair value of forfeiture of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for change in fair value of warrant charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease increase related party receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase decrease in related party payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_CashAdvancesAndLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash advances and loans to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_CashAdvancesAndLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ProcessedFromOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Processed from options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ProcessedFromOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ProcessedFromWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Processed from warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ProcessedFromWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on loans and advances recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A__IAS07_IE_A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAdvancesAndLoansMadeToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loans and advances made to related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAdvancesAndLoansMadeToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680769696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reporting Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureReportingEntityAbstract', window );"><strong>Reporting Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfReportingEntityExplanatory', window );">Reporting Entity</a></td>
<td class="text"><p id="xdx_807_ecustom--DisclosureOfReportingEntityExplanatory_zN3ed7cfS9gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"/>1.
<span id="xdx_822_zIrU2AH0WvJd">Reporting Entity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (the &#8220;Company&#8221; or &#8220;OKYO&#8221;) is a company domiciled in Guernsey and listed with a standard listing
on the main market of the London Stock Exchange (LSE) and on the Nasdaq Capital Market (LSE: OKYO, NASDAQ: OKYO).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ultimate parent of the group is Panetta Partners Limited, incorporated in the British Virgin Islands.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfReportingEntityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Reporting Entity Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfReportingEntityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680792592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zKGRXvat9wY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span id="xdx_82C_zrPyXyik5nr8">ACCOUNTING POLICIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years presented unless otherwise stated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_ecustom--DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_zfHxssMul8de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zuiCtMYBwdSe">Basis
of preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84C_eifrs-full--ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_ze6rEvZvCdVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSHeKIf3gOw6">Basis
of measurement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eifrs-full--DisclosureOfGoingConcernExplanatory_zyjwyoe4H8Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zIJXF9vULX97">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &#163;<span id="xdx_908_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20220331_znuD9gZzK7s8" title="Accumulated deficit">76.8</span>m (&#163;<span id="xdx_90E_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20181231_zaW6Bco1JJu6">64</span>m of this accumulated loss relates to a discontinued business prior
to the reorganisation in 2018), a net loss for the year ended March 31, 2022, of &#163;<span id="xdx_905_eifrs-full--ProfitLoss_iN_pn5n6_di_uGBP_c20210401__20220331_zm0Cywblto74" title="Net loss">4.0</span>m and net cash used in operating activities
of &#163;<span id="xdx_908_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pn5n6_di_uGBP_c20210401__20220331_zSQLLI5hFUw2" title="Net cash used in operating activities">4.0</span>m.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &#163;<span id="xdx_90A_eifrs-full--CashAndCashEquivalents_iI_pn5n6_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zp1LWwYLOLx9" title="Cash">1.5</span>m, with current liabilities of &#163;<span id="xdx_90F_eifrs-full--CurrentLiabilities_iI_pn3n3_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_ze72JlAwVGUb" title="Current liabilities">978</span>k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &#163;<span id="xdx_909_ecustom--CashBurnRate_pn5n6_uGBP_c20220801__20221231__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zYmIKoYjsO1" title="Rate of cash burn/spend">2.4</span>m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took
strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential
liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are
more specialist investors focused on early-stage opportunities. The Directors are also confident that the nature of the OK101
clinical program is such that various inflection points arise over a relatively short period of time which should provide financing
opportunities, for example the FDA approval of the IND in December 2022 for OK101 in dry-eye and the return of headline data from
the Phase II registration trial to be held between July and December 2023; these pivotal events in the primary clinical program
for OK101 have the benefit of being near term events (which is unusual in the context of the normal timeframes for Phase II clinical
programs to deliver meaningful data points. The Directors have also consulted the Company&#8217;s investment bankers with a view to
planning a number of alternative financing strategies to ensure the Company has access to sufficient capital to finance its planned
R&amp;D activity in the coming 18 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To meet the Company&#8217;s short-term
liquidity needs, the Company has secured a $2m short-term credit facility with a related party in order to bridge any delays in the
occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for a period of 6 months upon first
draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the
6-month period. The loan will extend the Company&#8217;s fixed cost cash burn to April 2023 without the need to raise additional
funds. The Directors believe that this facility together with additional working capital management measures will be sufficient to
complete the IND application. The Directors also considered any risks to the short-term cash position of the company such as delay
in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash resources and
the additional financing strategies already disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="margin: 0pt; text-align: justify">On completion of the IND application the company will be in a position to raise funds on the market, via the financing
strategies being discussed with the Company&#8217;s investment bankers. The necessary steps are being taken to affect such a fundraise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Until and unless the Group and Company secures sufficient investment to
fund their clinical pipeline, there is a significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this significant
doubt, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident,
based on the previous fund-raising history as well as additional measures already put in place and being planned, that sufficient funds
will be forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
and Revised Standards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standards
in effect in 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_z8XuKH8VZHrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAEqUJeIcxTa">Basis
of consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&#8217;s return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zL1Tjuw6eBY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z9pHKU5FVQ77">Segment
reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_z8j7TbRaDvDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zZmLakyiYkc9">Taxation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zqPFx9fhSOq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zy5WsOrjQrJ1">Foreign
currency translation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentation currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are translated into US dollars on the following basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForLicenseFeesExplanatory_z4OBpo4q3jX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zm7114eoO8Gi">License
fees</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. Licence fees expenses are recognised as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_zV4NMjY7ImUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zdB5ejYOmZq6">Research
and development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&#8217;s products, the criteria for development costs to be recognised as an asset, as set out
in IAS 38 &#8216;Intangible Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zmF6nZC13B7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zVywf64qjVV6">Financial
instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities include trade and other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_z9PMWq0U69aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zbwcn0sWvmfd">Cash
and cash equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents comprise cash on hand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zu5Vz53LAPZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zSSUUkEJ16pj">Impairment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of financial assets measured at amortised cost</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognised at an amount equal to the lifetime expected credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Simplified
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of non-financial assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of
    fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_ecustom--DescriptionOfAccountingPolicyForShareCapitalExplanatory_zhKIP9EcIGAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zutNHNqPZix7">Share
capital</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the Company are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z3Tp1iH8qZEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_ziZ4K9iwOnRj">Property,
plant and equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognition
    and measurement</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalised as part of that equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zohpzScp5GKj" style="display: none">DISCLOSURE OF ESTIMATED USEFUL LIVES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures
    and fittings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives">5</span>
    years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives">3</span>
    years</b></span></td></tr>
  </table>
<p id="xdx_8A8_ztfRBhkQeQtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForLeaseExplanatory_z2MC8R5u546h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zKMh4tMa5WMa">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    of low value assets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&#8217;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
term leases&#160;exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit
and loss on a straight-line basis over the term of the lease.<b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_zWrtAKrce05d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOrTi2vaPpRa">Share
based payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&#8217;, Directors&#8217; or
advisers&#8217; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &#8211; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &#8211; warrants, in the case of warrants issued in return for services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForWarrantsExplanatory_zQwDNsR5fr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zbEsSZejhIv1">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued in return for services.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued as part of a financing transaction.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &#8216;fixed&#8217; test for non-derivatives, and the &#8216;fixed for fixed&#8217;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForBorrowingsExplanatory_zhziKifCc0wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
loan notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Where
the fixed for fixed condition is met</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve. The accrued interest on the principal amount is also recorded in the Convertible
loan note reserve as it is convertible into equity. Upon redemption of the instrument and the issue of share capital, the amount is reclassified
from the convertible loan note reserve to share capital and share premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z6QSFNFpPNkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><span id="xdx_86A_zGUsrfQMiDpk">Fair Value Measurement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management have assessed the categorization
of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the
basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 2 - valued by reference to valuation
techniques using observable inputs other than quoted prices included within Level 1;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 3 - valued by reference to valuation
techniques using inputs that are not based on observable market data.</p>
<p id="xdx_859_zWofBggxCs6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680909168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract', window );"><strong>Critical Accounting Judgements And Key Sources Of Estimation Uncertainty</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zyknLoeTuQ29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zDLKxXdOri22">CRITICAL
  ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being IFRS as
issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income
and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based
on historical experience and other factors, including expectations of future events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are considered to be the key sources of estimation uncertainty<b>:</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share-based
payments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group makes estimates as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest
rate for the term of the award and correlations and volatilities of the shares of peer group companies. The Group also makes estimates
as to the vesting period for awards that have performance-based criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resulting cost of an equity incentive award is recognised as expense over the requisite service period of the award, which is usually
the vesting period. Compensation expense is recognised over the vesting period using the straight-line method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 27 to our consolidated financial
statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680023856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory', window );">OPERATING EXPENSES</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfOtherOperatingExpenseExplanatory_zKqq8zJDfqt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zXnleg6bN7Tl">OPERATING
                                            EXPENSES</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_zcJQPfshHF66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses are stated after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BA_zv5H4Zdb09P3" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_492_20210401_20220331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_490_20200401_20210331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_499_20190401_20200331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/></tr>
  <tr id="xdx_400_ecustom--KeyManagementPersonnelCompensationDirectorFees_zePbaRlnR1q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    fees including bonus (excluding Chairman&#8217;s bonus)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">707,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--ChairmansBonus_zWNaBdmQhEBi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&#8217;s
    bonus</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0801">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,160,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemuneration_zOFBOtlnRyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s
    Remuneration (refer to Note 20) <span id="xdx_F4F_z1VPTCZ1HRX4">*</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">349,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--ProfessionalFeesExpense_maOEz5cJ_zSKJSxSK2Ykd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    and Professional fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,143,300</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">343,422</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,433</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainlossOnDisposalOfLeases_zDCjm8fYgV8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)/Loss
    on disposal of leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(179</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ForeignExchangeLossesGains_zjHTgj2143v1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FX
    Gains and losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,577</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,061</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,061</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--DepreciationAndAmortisationExpense_maOEz5cJ_zkqnZJ3zsXG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,423</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,512</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">212</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zas2XeaQKt8b" style="vertical-align: top; width: 15pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1D_z2RKUHb9dNke" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#8217;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#8217;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</span></td>
</tr></table>

<p id="xdx_8AA_zu24TZXfaBfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680420448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTAL REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureSegmentalReportingAbstract', window );"><strong>Segmental Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">SEGMENTAL REPORTING</a></td>
<td class="text"><p id="xdx_800_eifrs-full--DisclosureOfOperatingSegmentsExplanatory_zK7fl0qf2Pmi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_za9DJG2Orqyf">SEGMENTAL
                                            REPORTING</span></b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year under review management identified the Group&#8217;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureSegmentalReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureSegmentalReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680674336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEES INCLUDING OFFICERS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract', window );"><strong>Employees Including Officers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfEmployeeDetailsExplanatory', window );">EMPLOYEES INCLUDING OFFICERS</a></td>
<td class="text"><p id="xdx_80B_ecustom--DisclosureOfEmployeeDetailsExplanatory_zNzKw4PJSRuk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zUwHzfcQaSGc">EMPLOYEES
                                            INCLUDING OFFICERS</span></b></span></td></tr></table>

<p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutEmployeesExplanatory_zZzhVfMhnC1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zCg3Dxgsfoia" style="display: none">DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210401__20220331_zJK1dSHpyP3d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200401__20210331_zS7V6fUe7wfg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20190401__20200331_zhysJddbD2dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended March 31,</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Group</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff
    costs comprised:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--DirectorsSalaries_zzJlwL2IxEI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">707,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,438,571</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--WagesAndSalaries_zCbkmO9Xt7z4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--SocialSecurityContributions_zMexCkPv3lt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    security costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,449</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eifrs-full--OtherShorttermEmployeeBenefits_zzA113lNobYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruitment
    Costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,259</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,922</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--EmployeeBenefitsExpense_zAc6HfaUaDle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    employee benefits expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,129,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,582,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">420,188</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March
    31, 2020 were:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zdWNXY20Uey9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_z76vWoTxq5Hd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zMCPgwZdQKmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    and administration</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zcb2NreUYGm4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zyXHP3ZnUfcg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zgRPVeAAnHEd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331_zKFobcgy3Io4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331_zn1tzEcmsRe2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331_zAprse49DnKg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p id="xdx_8A1_z8nRwVEJndq9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group and Company made $<span id="xdx_907_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20210401__20220331_zYQWoNgRX8Bb" title="Pension contribution">2,622</span> of payments to a defined contribution pension schemes on behalf of Directors or employees during the year
ending March 31, 2022 (March 31, 2021: $<span id="xdx_909_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20200401__20210331_zk5BlBACdOd3" title="Pension contribution">2,904</span>, March 31 2020: $<span id="xdx_901_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20190401__20200331_z0H3IhZ39aQ1" title="Pension contribution">2,774</span>)</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureEmployeesIncludingOfficersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfEmployeeDetailsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of employee details explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfEmployeeDetailsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680645264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REMUNERATION OF KEY MANAGEMENT PERSONNEL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract', window );"><strong>Remuneration Of Key Management Personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">REMUNERATION OF KEY MANAGEMENT PERSONNEL</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_z1vAekVUCnMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zugKqiGQufXe">REMUNERATION
  OF KEY MANAGEMENT PERSONNEL</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_z82Jw7rgipH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_z6eoRVcapVgd" style="display: none">SCHEDULE OF
REMUNERATION OF DIRECTORS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br/>
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br/>
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span id="xdx_F42_zoORemjkg0rk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
    Cerrone (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zJwRoQbTyQmc" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Directors' fees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zA7MD3BExeDg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zuSVp0qrqYE4" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z1H6cleFajP5" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zaR8Ml2OXp1k" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zkoaGsrBKQN" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zFKhZNRw7PY9" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z6ZcLf6nkjJ8" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4A_zcmcM70NVUja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Jacob (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ziZY4SFDKuHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zchuBtXycHxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zMfKmv9pg8zh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zvYjB2pqWyd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,579</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zjK7D1AO1h44" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zTkkst7XIcp9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ztB7f8Ln9vi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zuYxRB6PDBal" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4E_zzaXpCDtM9a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">W
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zLvSegVwVCv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_z5G4arfld85e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zsY4YPBp8slk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zu5FvKgicT3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_zXh5gqSLKmMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_ziR4g5giYx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z2bJ593xY0sj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z9m3kUtwlUle" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F49_zFm9R05AmXLh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
    Shailubhai (6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zMwQRQ6AgnP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zjYrUyzh4yo2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zDbKs9k3JB73" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zJ3ixkf2DDmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zejh3HSzYFlb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z1GavsmgNkYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zwiEnKf05zP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z6SICVjSSkq3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zmGavRadwrci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J
    Brancaccio (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zJzQMAz59bGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_znRNaQPTpSZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Bonus"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zHpFX7ehxCDl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zcWLYBo4WMna" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zkQwVkBcsUhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zs6xJcti6qb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zz5AMRnJ2gzi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zqFIbPAExZGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zJLgUzqgODTb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Macrae (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zBGIHcmYZX6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z9Q2ETy3Eapl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zuJuf7xlGW37" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_ziIHzwa8a4Jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zx7BK1WLWAXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zNbrCVF1lWa1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z8Jqss0FDSnh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zcPMn6vhFdFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F46_zSCSXCjYZsBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
    Denoyer (5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zyZh9yANafg5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zLwXKQg5EkV6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zdFhmkfHb2f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zRZ2rBN2k19k" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zAy5OlAa9cU3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zs7tjKo5mn6a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zkwRWpjCdBa9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_z7It9OMM0Je2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331_zOVK6I3VUsw1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">283</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20210401__20220331_zKEURchPa9m6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331_zO6pqSAbZNeh" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331_zivYpMRn1ZBa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,589</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331_z72j0IbuBhV6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--DirectorsBonus_pn3n3_c20200401__20210331_zT47m87MiwQj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,201</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20200401__20210331_zrWCboYkOuC7" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331_zPwnrT4BIodj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">503</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors<br/> fees</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based<br/> payment<br/> expenses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">W Simon</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zUk5yIMoiBg9" style="width: 10%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zmVN5YAfYlQg" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zyXHfCIzrGE2" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zi39PWSrFrJj" style="width: 10%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_zdgU0nltkua9" style="text-align: justify">K. Shailubhai (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zpx0UL5mnXqd" style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zrR0gXsz7Ehd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z64f6ExpMdM" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zOaOil4dS3J" style="text-align: right">31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_zlZ4vg1RPHdf" style="text-align: justify">G Macrae (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zI66tZZDBpRg" style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zCkK2ZoKldPl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z14gZjqiWApe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zbca9H2gAQY5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F45_zhIBMzPADFN7" style="text-align: justify; padding-bottom: 1.5pt">L Zambeletti (7)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z9zhoSTwAuV" style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z6ZUQ1aqQt2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zHVKHhwti3E6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zrZJ4kZhznbk" style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331_zeBYIC885IU9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">122</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20190401__20200331_ztO78z315hFl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20190401__20200331_zATpAnwJFwse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331_zNGjx3BII9G5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Share based payment expenses">41</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0F_zdsAkDzx71u6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zFso84703sok" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone&#8217;s bonus awarded for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded">1,160</span>k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhlu0tFfEE9h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zFtqJgI8lMA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zVGCkBTOFDal" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z5cPpMHsrvf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio was appointed as Director on 10 June 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0A_zPbxjDVQGxrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zb9U2ivUxQP4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zkAhLD19uhje" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zju9flrcZlI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
Denoyer was appointed as Director on 24 November 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zeRBkloR8v6h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zC93YuD6Dxp3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K
    Shailubhai resigned as Director on 17 June 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_zdKOOi2lXYZg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zpYeXyc5fTn2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</span></td></tr>
  </table>
<p id="xdx_8A0_z9ONIEZCOAg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_ecustom--ScheduleOfShareOptionsGrantedToDirectorsExplanatory_zycsLkTejWhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zHNq8SfTnDx9" style="display: none">SCHEDULE
OF SHARE OPTIONS GRANTED&#160;TO DIRECTORS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: justify">J Brancaccio</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zVeQ2fW9nZo2" style="width: 11%; text-align: right" title="Number of options">325,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_z2gi1spW5x2" style="width: 11%; text-align: right">450,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zHtMVMbte2k3" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">G Jacob</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_z2Qq0qXPnbf3" style="text-align: right">3,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zJThVA8w4bMh" style="text-align: right">40,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zSvKRuLfR4j1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">B Denoyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zJcYFhtLFxXl" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zZIlA4YDQtgh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zW796tZZY3Fh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zkJGfGiPauX9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">4,575,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zyFwmstGJsfg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">40,450,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzytfXWb2Vv6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zhfh3ZePpKo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
director has yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Key Management Personnel of the Group are members of the leadership team who have the authority and responsibility for planning, directing
and controlling the activities of the Group either directly or indirectly. They include all Directors of the Board (executive and non-executive).
Key Management Personnel compensation is set out below.</span></p>

<p id="xdx_898_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_z2oWKmgIrQjj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z4iUaM102BYh" style="display: none">SCHEDULE OF KEY
MANAGEMENT PERSONNEL COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_ziOkPUmYBc6d" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_z17rap7c5xG8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_zvQIOP6tZaY4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_pn3n3_z4sLaAo65vX3" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: justify">Short-term employee benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,026</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">351</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_z6RayWBXrOr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--KeyManagementPersonnelCompensation_pn3n3_zoREdEZ3Q3Pk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,841</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">392</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zw8oBPohzHif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677572016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTaxationAbstract', window );"><strong>Taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">TAXATION</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfIncomeTaxExplanatory_zuvlOuF4IYze" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82C_zATQaOhRAqnk">TAXATION</span></b></span></td></tr>
</table>


<p id="xdx_898_eifrs-full--DisclosureOfTaxReceivablesAndPayablesExplanatory_zTpr5AjWRcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zxO6z3GPQzgj" style="display: none">SCHEDULE
OF TAX CREDIT PERIOD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210401__20220331_zpZY4HvA90J9" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200401__20210331_zS2WhvN8YA5h" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20190401__20200331_zMtuGAxFmh4j" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="text-decoration: underline">Group</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_z3dkca1Qe6ja" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">Current year tax (credit)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(509,282</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(24,952</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AdjustmentsForCurrentTaxOfPriorPeriod_zHN85F7b3G3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments in respect of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277,239</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,289</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_zWGOxkJy6ZA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Origination and reversal of timing differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zR5GhEgBM1yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(786,521</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,289</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossBeforeTaxation_zqgQa1G8Jf1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,045,372</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,378,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,620,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LossChargedAtStandardRateOfCorporationTax_zE24A79JgYul" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss charged at standard rate of corporation tax <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210401__20220331_z51STLB7nbFd" title="Corporation tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200401__20210331_z2R9xAUXttXc"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20190401__20200331_z7R3mreO1z53" title="Corporation tax rate">19%</span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,181,337</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(641,915</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(307,866</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_z8SiS2olBDH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax losses arising in the year not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">524,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">660,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TaxLossesSurrenderedForResearchAndDevelopment_zsGR3bFmOfF" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax losses surrendered for Research and Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">667,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_z1zbXRnS5075" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_zeCGmHghSJY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax increase from effect of capital allowances and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentTaxClaim_zDLPsa4a8cM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(509,282</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ResearchAndDevelopmentEnhancedExpenditure_zDbTg4TDxT5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and Development enhanced expenditure</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(377,187</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_zo30sWgWiie8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax credits claimed in respect of previous periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,289</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--IncreaseDecreaseThroughForeignExchangeFinancialAssets_zgfKklf11Lb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,983</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32,504</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_zGPztcPidbjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loans written off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_znKrZf957KGi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(786,521</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,289</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_zkKGziTLr6ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will
be recoverable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has tax losses of $<span id="xdx_906_eifrs-full--TaxEffectOfTaxLosses_c20210401__20220331_zlUu7w5u5KKa">15,870,525</span> (2021: $<span id="xdx_909_eifrs-full--TaxEffectOfTaxLosses_c20200401__20210331_z5wzR174TGMe">9,411,521</span>, 2020: $<span id="xdx_904_eifrs-full--TaxEffectOfTaxLosses_c20190401__20200331_zWe1gHUD8Vba">4,421,886</span>) to carry forward for use against future profits<b>.</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680595216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND COSTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract', window );"><strong>Finance Income And Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">FINANCE INCOME AND COSTS</a></td>
<td class="text"><p id="xdx_80D_eifrs-full--DisclosureOfFinanceIncomeExpenseExplanatory_z6Bmt2CqwIfl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_z7U17UOkOUr7">FINANCE INCOME AND COSTS</span></b></span></td></tr>
</table>


<p id="xdx_897_eifrs-full--DisclosureOfFinanceCostExplanatory_zVIwQP9Y7xAk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zFA0aooYeKH8" style="display: none">SCHEDULE
OF FINANCE COST</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; text-align: left">Interest income</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RevenueFromInterest_c20210401__20220331_z5BQSJecRC5k" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--RevenueFromInterest_c20200401__20210331_z9iOz0ATOuM8" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RevenueFromInterest_c20190401__20200331_zYoGULSQcRp9" style="width: 14%; font-size: 10pt; text-align: right">48,125</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Total finance income</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceIncome_c20210401__20220331_zfwiJKbvUMJg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinanceIncome_c20200401__20210331_z28upqv01yge" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinanceIncome_c20190401__20200331_z74SwCEBy9Ab" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">48,125</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20210401__20220331_zCXJBdK1vm5i" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20200401__20210331_zT89OdbrWguc" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,122</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20190401__20200331_zZYfP1t8ckU8" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,158</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total finance expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinanceCosts_iN_di_c20210401__20220331_zlvnOnYSuWp" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iN_di_c20200401__20210331_zw3FQjmHFMWk" style="font-size: 10pt; text-align: right">(1,123</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceCosts_iN_di_c20190401__20200331_zpax2t3ux8lj" style="font-size: 10pt; text-align: right">(1,158</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  </table>
<p id="xdx_8A9_zwhSVyHJp8Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureFinanceIncomeAndCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680650464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosurePropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_803_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zYzidRpTvYKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_z5KRlV0SOcm5">PROPERTY, PLANT AND EQUIPMENT</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zeehfFSYz9o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&#8217;s property, plant and equipment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B7_zk5p61NgWeBc" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbm3svaqAEf" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance">8,343</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331_zYl7p3r5oW7" style="width: 12%; text-align: right">8,343</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbyO3Phi8H9f" style="text-align: right" title="Additions">1,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zljr3IGPH9Bb" style="text-align: right">1,669</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zNphzel2GQFf" style="text-align: right" title="Disposals"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331_z3dls8PGuoFc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zWiB7NCRXNQf" style="text-align: right" title="Foreign exchange">(233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zDuZKWpxjs0a" style="text-align: right">(233</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zTw55nHaBPq1" style="text-align: right" title="Property and equipment, cost, ending  balance">9,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331_zQvZiKya0EWb" style="text-align: right">9,779</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH3QgMQhPXgc" style="text-align: right" title="Depreciation, beginning balance">2,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331_zz1FiovGWAug" style="text-align: right">2,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z30av2cacJD8" style="text-align: right" title="Charge in year">2,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331_zPZFrWjdvkai" style="text-align: right">2,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOD30thWAeMg" style="text-align: right" title="Foreign exchange">(63</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331_zbuWdloWm8Mf" style="text-align: right">(63</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zybgCEbakJy3" style="text-align: right" title="Depreciation, ending balance">4,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331_z8VmpTu2dWFl" style="text-align: right">4,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zdrMW5a86kQ4" style="text-align: right" title="Depreciation, net book value">5,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331_zu4nnXM8hH2c" style="text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zadJS1DdOrp9" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance">1,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331_zfZoEFLWnQUe" style="width: 12%; text-align: right">1,257</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zb76uxQ6aUGj" style="text-align: right" title="Additions">6,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zz70dKhw6yj2" style="text-align: right">6,944</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zPShkp99A2Pb" style="text-align: right" title="Disposals"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331_zDIV8GM7OVW4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH9PfEb03lu9" style="text-align: right" title="Foreign exchange">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zchRCv1Ino7f" style="text-align: right">142</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z0Jhp0XXJQse" style="text-align: right" title="Property and equipment, cost, ending  balance">8,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331_zqh33mSfm1P6" style="text-align: right">8,343</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z36KRN7x29i3" style="text-align: right" title="Depreciation, beginning balance">622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331_zJrJ9WOy6cnl" style="text-align: right">622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zDlS8NcyPw0f" style="text-align: right" title="Charge in year">1,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331_zQa0JJkJaGI7" style="text-align: right">1,593</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOEYqzsBcGsf" style="text-align: right" title="Foreign exchange">71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331_zccQWkVKq5Fi" style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zoUwEAla2oTd" style="text-align: right" title="Depreciation, ending balance">2,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331_zW8ydcV96hcc" style="text-align: right">2,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zcQ3Q7oQZbtf" style="text-align: right" title="Depreciation, net book value">6,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331_zavxPSoOYXCf" style="text-align: right">6,057</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zTBboH1RkJzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_zsV6hvqTV6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s property, plant and equipment is located in the following operating segments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span id="xdx_8B2_ztfOLp0m8fl1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zyPuhkpTFt8l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="text-align: right; margin-top: 0; margin-bottom: 0">Net
Book Value <br/>
March 31 2022</p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UKMember_zWOGzuTdEE3d" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 78%; text-align: justify">UK</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UnitedStateMember_zpNO2hZ0Hnga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--PropertyPlantAndEquipment_iI_znRT2UPILrn9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--PropertyPlantAndEquipment_iI_zey57vwsNt1h" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property, plant and equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
</table>
<p id="xdx_8A1_zeiPPVcibwk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosurePropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosurePropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680889056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOtherReceivablesAbstract', window );"><strong>Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">OTHER RECEIVABLES</a></td>
<td class="text"><p id="xdx_805_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zYmWNBzf8YH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zbe9wKy7Mzfa">OTHER RECEIVABLES</span></b></span></td></tr>
</table>


<p id="xdx_89D_ecustom--DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_zN4blPd07Ix8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zyB7ubYrYrAc" style="display: none">DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_z0Zkq71YyAOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210331_z3bCDh3xrjI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherCurrentReceivables_iI_zjcT4x8f4481" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Other receivables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">19,130</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CurrentValueAddedTaxReceivables_iI_zxMSIvnZ27L1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,799</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Prepayments_iI_z3DDGg0OFeSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepayments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">711,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentReceivables_iI_zFxjurqPKIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">812,956</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,370</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zNdzfBV0xgj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepayments
include $<span id="xdx_906_ecustom--PrepaymentsReceivables_iI_c20220331_znQ5zL13I7rg" title="Prepayments receivables">639,635</span> of prepaid invoices relating to the OK-101 project.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680788896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND OTHER PAYABLES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">TRADE AND OTHER PAYABLES</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zr8WRGgCFXn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_827_zaHSkyisDEe7">TRADE AND OTHER PAYABLES</span></b></span></td></tr>
</table>


<p id="xdx_895_ecustom--DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_z1TpnBoBBfO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zti1IuYBWd81" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220331_zQuvyKgXtT07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210331_zzrruNLNF9jc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Year ended March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Group</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pn3n3_maTAOCPzjQt_zyDD0Inv5u74" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Trade payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">741,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">210,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Accruals_iI_pn3n3_zXnGmfDLkrta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--BonusAccrual_iI_pn3n3_zLDhyIfvkj7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Bonus accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,391,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_iI_pn3n3_zz0fbhgv4Mxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,306,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,673,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680137968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL AND RESERVES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCapitalAndReservesAbstract', window );"><strong>Capital And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">CAPITAL AND RESERVES</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_zpxjWuAEU5F" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zUATpX2dICt5">CAPITAL AND RESERVES</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital
Management</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purpose of the Company&#8217;s capital management, capital includes called up share capital, share premium, share based payments
for options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s objectives when managing capital are to safeguard the Company&#8217;s ability to continue as a going concern and to maximise
shareholder value through the optimisation of the debt and equity balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital to maximise the return to the shareholders through the optimisation of equity. The capital structure of the
Company as at 31 March 2022 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and
retained deficit as disclosed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders.
To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders
or issue new shares and release the Company&#8217;s share premium account. No changes were made in the objectives, policies or processes
during the year ended 31 March 2022 and 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
capital and premium</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares
and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class
or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
share in the Company confers upon the shareholder:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to one vote at a meeting of the shareholders or on any resolution of shareholders;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in any dividend paid by the Company; and</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    right to an equal share in the distribution of the surplus assets of the Company on its liquidation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&#8217;s Articles of Incorporation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Authorized</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zQF1wsIWSUaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_z99m5UbcSvk1" style="display: none">SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Share capital</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issued ordinary shares of US$0.00 each</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify; padding-bottom: 2.5pt">At 31 March 2020 </td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zI2GyAWKAQ9" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance, shares">636,297,049</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Equity_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7HFLauLesEh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance">112,079,984</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares issued - private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfSharesIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2QGkJBMHGKh" style="text-align: right" title="Shares issued - private placement, shares">36,269,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfSharesIssuedPrivatePlacementValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2yvFVeXfPlh" style="text-align: right" title="Shares issued - private placement">230,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Relative Fair value charge for warrants issued in conjunction with private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueWarrantsIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zPjL31xagFkk" style="text-align: right" title="Relative Fair value charge for warrants issued in conjunction with private placement">(138,305</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">CLNs issued in lieu of fundraising commission</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuedInLieuValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxLU4yt50RG9" style="text-align: right" title="CLNs issued in lieu of fundraising commission">(558,395</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IncreaseDecreaseThroughExerciseOfOptionsShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbe89ng9kIXh" style="text-align: right" title="Options exercised, shares">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgDwdCkblDO7" style="text-align: right" title="Options exercised">15,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zqz9DVicEiXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance, shares">672,816,302</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--Equity_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zWroLbqOyWH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">111,629,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zTVXBueNSpCg" style="text-align: right" title="Exercise of warrants, shares">386,512,756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsyCrb47nzv6" style="text-align: right" title="Exercise of warrants">3,470,940</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Conversion of CLN</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z6RoRHfYZqo8" style="text-align: right" title="Conversion of CLN, shares">315,086,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zU0cjhOvfMUd" style="text-align: right" title="Conversion of CLN"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,876,397</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2VDia2mobG" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">1,374,415,468</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Equity_iE_pp0p0_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zP07DWSELImc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">123,976,510</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zVsfw1SBhIjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Issuance
of ordinary shares</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, <span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zvQkPbvZIRx9" title="Ordinary shares were issued">36,363,636</span> ordinary shares were issued at an issue price of <span id="xdx_904_eifrs-full--ParValuePerShare_iI_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zAvLHx7KDi21" title="Ordinary shares were issued, per share">1.1</span>p per ordinary share by way of a placing of ordinary shares
to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, <span id="xdx_90B_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zXFtDu3Cgm4b" title="Ordinary shares were issued">75,825,130</span> ordinary shares were issued at an issue price of <span id="xdx_90E_eifrs-full--ParValuePerShare_iI_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z5ewCJ2923Pk" title="Ordinary shares were issued, per share">1.1</span>p per ordinary share by way of a further placing of ordinary
shares to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2020, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zZmcPvTNzp9c" title="Ordinary shares were issued">36,269,253</span> ordinary shares were issued at an issue price of <span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zmEgPBG9T614" title="Ordinary shares were issued, per share">0.005</span>p per ordinary share by way of a placing of ordinary shares
to raise finance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2021, <span id="xdx_90C_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z4k7uTxdG2Bj" title="Ordinary shares were issued">250,000</span> ordinary shares were issued in relation to an exercise of options at an issue price of <span id="xdx_901_eifrs-full--ParValuePerShare_iI_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zFMoZgOkJ3ue" title="Ordinary shares were issued, per share">0.045</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_900_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTxpGskBJA4a" title="Ordinary shares were issued">36,363,636</span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_90A_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmYgCHrVA2Zb" title="Ordinary shares were issued, per share">0.0135</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90F_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zob6Ry0UPcM4" title="Ordinary shares were issued">72,000,000</span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zSWAUoKaoX6k" title="Ordinary shares were issued, per share">0.0055</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zFSNUmsCUKS" title="Ordinary shares were issued">76,605,760</span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zZBYg7wCXC9a" title="Ordinary shares were issued, per share">0.004</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zBUMPbDplosh" title="Ordinary shares were issued">73,304,650</span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zFVdryIG5KEk" title="Ordinary shares were issued, per share">0.085</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, <span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zFUKUWP7cXAa" title="Ordinary shares were issued">39,605,760</span> ordinary shares were issued in relation to an exercise of warrants at an issue price of <span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zWZE0DwgONXj" title="Ordinary shares were issued, per share">0.004</span>p per ordinary share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, <span id="xdx_905_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zujPVugIqpU3" title="Ordinary shares were issued">165,176,000</span> ordinary shares were issued in relation to a conversion of loan notes at an issue price of <span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zwzazQpbMKx7" title="Ordinary shares were issued, per share">0.004</span>p per ordinary
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, <span id="xdx_907_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zj13tyNNzYE9" title="Ordinary shares were issued">238,543,360</span> ordinary shares were issued in relation to a cashless exercise of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
options reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for options represents the cost to issue share-based compensation, primarily share options, based on their
grant date fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share
warrants reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
share-based payment reserve for warrants represent the cost to issue warrants based on their grant date fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Loan Note reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
convertible loan note reserve represents the proceeds received on issuance of convertible loan notes classified as equity instruments,
accrued interest and any relative fair value adjustments. .</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Retained
Deficit reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retained
deficit represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Translation
reserve</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors paid <span id="xdx_908_eifrs-full--DividendPayables_iI_do_c20220331_zfUL2ZAntQDi" title="Payment of dividend"><span id="xdx_906_eifrs-full--DividendPayables_iI_do_c20210331_z8taAzLLzEqb" title="Payment of dividend">no</span></span> dividend during the year to 31 March 2022 and 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer
between equity reserves</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
company affected a transfer between reserves in equity in order to align the values of the equity reserves on a relative fair value basis.
The total amount recorded in equity remains unaltered.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCapitalAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCapitalAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680791712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE OPTIONS AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract', window );"><strong>Share Options And Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE OPTIONS AND WARRANTS</a></td>
<td class="text"><p id="xdx_805_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zYYBEu6vihkh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td>
  <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zTJfekQNeT35">SHARE OPTIONS AND WARRANTS</span></b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Options</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_zDs6kwvTCsJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_zKJ43HynaNn2" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20210401__20220331_zBnXx2Z27wW" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding">60,750,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331_z9OF1qsv9bIc" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding">6.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20200401__20210331_zB2lpLNRsLP1" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding">19,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331_zbVxm1ZqgWn3" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding">5.58</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zgtZUPpn810d" style="text-align: right" title="Options, granted">28,150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zWqMuyLjpJqf" style="text-align: right" title="Weighted Average Exercise price, Granted">8.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zwbxypGNTnqj" style="text-align: right" title="Options, granted">42,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zUEKoj2yvXIf" style="text-align: right" title="Weighted Average Exercise price, Granted">7.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zVqtXqqkOXCj" style="text-align: right" title="Options, forfeited">(16,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zDgk82hgVKI6" style="text-align: right" title="Weighted Average Exercise price, Forfeited">5.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_z2pUMhy3BoYd" style="text-align: right" title="Options, forfeited">(750,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zAmdrblhBC06" style="text-align: right" title="Weighted Average Exercise price, Forfeited">6.21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zzGlESPEcPCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_z2O4EzirWGUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_zguc3dEIz887" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zX2p4vyKAlpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised">6.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20210401__20220331_zIVtBWlbq5Lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding">72,400,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEiE7je0Vt8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding">7.49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20200401__20210331_zpaele3kquh1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding">60,750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zarLvtiYX6Hk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding">6.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331_zaRay0yWGRqc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable">14,437,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEaNhtLb5dYi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable">7.36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331_zhPyMEFPupUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable">9,250,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zoTKjZIqPjn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable">6.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-size: 10pt">Outstanding at 1 April</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20190401__20200331_z9Nw9D1OGcEl" style="width: 18%; font-size: 10pt; text-align: right">5.58</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20190401__20200331_zwHisMhbOz6l" style="width: 18%; font-size: 10pt; text-align: right">23,000,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zqco43H2poE3" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zsoFPIjxFTzj" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_iN_di_uUSDPShares_c20190401__20200331_zdLpMC1qYEul" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20190401__20200331_zx1dEbBXrQhi" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(3,500,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zOFfw5ZCGXaj" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zNJeFfoReAR" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zRj9AxlQi7Xd" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20190401__20200331_z9jNGPiKdZqk" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">19,500,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zWFnhmT6OLY2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20190401__20200331_zbTd2cBcpCsg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">4,875,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A3_zPGI9W9vkCy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ending 31 March 2022, <span id="xdx_90C_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_doxL_uShares_c20210401__20220331_zbK9xRcJ7hl9" title="Number of option were exercised::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1351">no</span></span> options were exercised. During the year ending 31 March 2021, <span id="xdx_905_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zBubgi1X0D2l" title="Number of option were exercised">250,000</span> options were exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total outstanding fair value charge of the share option instruments is deemed to be approximately $<span id="xdx_90A_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20220331_zch50rZS3538" title="Fair value charge of share option instruments deemed">2,072,515</span> (2021: $<span id="xdx_904_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20210331_zPvOT2e8E1Aj" title="Fair value charge of share option instruments deemed">2,682,050</span>). A
share-based payment charge for the year of $<span id="xdx_907_ecustom--ShareBasedPaymentCharge_c20210401__20220331_zSROmK3WHol4" title="Share based payment charge">1,718,727</span> (2021: $<span id="xdx_90A_ecustom--ShareBasedPaymentCharge_c20200401__20210331_zFRLxmK5XLeg" title="Share based payment charge">545,582</span>) has been expensed in the statement of comprehensive income.
The share based payment charge in the year to March 31, 2022 includes a forfeiture of $<span id="xdx_909_ecustom--ShareBasedPaymentChargeForfeiture_c20210401__20220331_z9oewG7J2JWk" title="Share based payment charge forfeiture">19,149</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average contractual life of options outstanding at March 31, 2022 is <span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20220331_z60myUIhSgn9" title="Weighted average contractual life of options outstanding">7.77</span> years. (2021: <span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20210331_zA5Ql33Zv8Z6" title="Weighted average contractual life of options outstanding">8.07</span> years).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eifrs-full--DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_zRmrjLvVy22l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options outstanding at the end of the year have the following expiry dates and exercise prices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zCYvDr4CdPn3" style="display: none">SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiry Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">Share Options as at 31 March 2022<br/> (&#8216;000)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">6 July 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center"><span id="xdx_905_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_za11cw4SeNB1" title="Expiration date of outstanding">6 July 2025</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: center"><span id="xdx_900_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zcUiaNFlUpji" title="Exercise Price">4.5p</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zBIvgID3y0X9" style="width: 18%; text-align: right" title="Share Options, Outstanding">2,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">20 August 2020</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zMApVVo1CtZh" title="Expiration date of outstanding">19 August 2028</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zjvqLyWDj0v1" title="Exercise Price">15.5p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zuVt2gcyCy1i" style="text-align: right" title="Share Options, Outstanding">750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">6 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_zitoPfFeUB66" title="Expiration date of outstanding">5 January 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90B_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_ztF25WaesvWh" title="Exercise Price">5p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_z6jsGPECbxr3" style="text-align: right" title="Share Options, Outstanding">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">12 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_z1kF1A6642vi" title="Expiration date of outstanding">11 January 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_ziw5ZqV5aZka" title="Exercise Price">7.9p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_zMNA5wJYgMbc" style="text-align: right" title="Share Options, Outstanding">1,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">15 April 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zbem14aMRwtl" title="Expiration date of outstanding">15 April 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zVqV0CatIzwd" title="Exercise Price">7.88p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zzHQBf3ff3C6" style="text-align: right" title="Share Options, Outstanding">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">31 August 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zllwEzpr4cok" title="Expiration date of outstanding">31 August 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90E_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_z2kZzFfu4gk5" title="Exercise Price">4.9p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zDSOG95UtpO3" style="text-align: right" title="Share Options, Outstanding">14,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90E_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zPyxLg3Cazqb" title="Expiration date of outstanding">30 January 2032</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zm1SfpQal5if" title="Exercise Price">8.0p</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zHI2Chh2B1Mh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share Options, Outstanding">8,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331_zvIv48WGKnmc" style="text-align: right" title="Share Options, Outstanding">72,400</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zYZ39ohDi5B2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fair
value of options granted</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has estimated a forfeiture rate of zero.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_zoVLXy2sWdXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zcceEqQFlaP5" style="display: none">SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">15 April 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 August 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zsLcnQuMbr3a" style="width: 14%; text-align: right" title="Grant date share price">7.7</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zaLPnKmd1Uyl" style="width: 14%; text-align: right" title="Grant date share price">4.9</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zb8gctmMfPt5" style="width: 14%; text-align: right" title="Grant date share price">4.8</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zdjSH7JJC00d" style="text-align: right" title="Exercise share price">7.9</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zsbofvgW7Us7" style="text-align: right" title="Exercise share price">4.9</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zpLZauYinPC4" style="text-align: right" title="Exercise share price">8.0</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--VestingPeriodsDescription_c20210412__20210415_z2z9YUvsxFl" title="Vesting periods">25% each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210829__20210831_zs9Yfz0ZvKfj" title="Vesting periods">25% each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--VestingPeriodsDescription_c20220129__20220131_zWJ3KSD4V5ib" title="Vesting periods">1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions</span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210412__20210415_z998cjLwqlXd" style="text-align: right" title="Risk free rate">0.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210829__20210831_zVLgQdNLfxI7" style="text-align: right" title="Risk free rate">0.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20220129__20220131_zmBAxFFACaFb" style="text-align: right" title="Risk free rate">0.97</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210412__20210415_zQdmFb5a1mB9" style="text-align: right" title="Expected volatility">80.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210829__20210831_zpI3ijoVB1j1" style="text-align: right" title="Expected volatility">77.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20220129__20220131_zF2ahJF1mIZ2" style="text-align: right" title="Expected volatility">83.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--OptionLifePeriod_dtY_c20210412__20210415_z6eKbMSRO7al" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210829__20210831_zqlQyvD4L5Cl" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--OptionLifePeriod_dtY_c20220129__20220131_zRz3C4PGVnZd" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20 August</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6 January</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 January <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20200815__20200820_zzxSqmk2EUa2" style="width: 14%; text-align: right" title="Grant date share price">15.5</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210104__20210106_zDt7RmgVTqMb" style="width: 14%; text-align: right" title="Grant date share price">0.8</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210110__20210112_z5N1pvF4QuSg" style="width: 18%; text-align: right" title="Grant date share price">0.79</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200815__20200820_z8UYAWz5qj6g" style="text-align: right" title="Exercise share price">15.5</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210104__20210106_z63tdn6KGE0h" style="text-align: right" title="Exercise share price">0.5</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210110__20210112_zjqb5DMz09m2" style="text-align: right" title="Exercise share price">0.79</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--VestingPeriodsDescription_c20200815__20200820_zeiP75ECJm84" title="Vesting periods">25%
each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--VestingPeriodsDescription_c20210104__20210106_z1VFiJ4SXayc" title="Vesting periods">25% each year</span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210110__20210112_zGrWABE0LFZ3" title="Vesting periods">33% in 6 months and 67% in 1 year</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20200815__20200820_z1DYsNgaii7j" style="text-align: right" title="Risk free rate">0.15</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210104__20210106_zYitdBolAlh7" style="text-align: right" title="Risk free rate">-0.01</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhcYUU7Y3edg" title="Risk free rate">0.4</span>%,
<span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_znJdygR1QQI1" title="Risk free rate">0.6</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20200815__20200820_zo4CinQ71S92" style="text-align: right" title="Expected volatility">77.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210104__20210106_zgVo52FLcWec" style="text-align: right" title="Expected volatility">77.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zv1xdkcnz4f5" title="Expected volatility">66.7</span>%,
<span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zIz42KB2JfR8" title="Expected volatility">83.7</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--OptionLifePeriod_dtY_c20200815__20200820_zWWcqGk15Hz4" title="Option life">5</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210104__20210106_z8zjROfjGeSj" title="Option life">5</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--OptionLifePeriod_dtM_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zKNeCysJyrxj" title="Option life">6</span> months to <span id="xdx_90B_ecustom--OptionLifePeriod_dtY_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zp3z6D4jbUE2" title="Option life">1</span> year</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zfDmXVbCLzKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the acquisition of the OK-101 project, the underlying scientific founders of the OK-101 Project (inukshuk Holdings), who
will continue to be involved in the development of the Project, received <span id="xdx_905_eifrs-full--ConsiderationPaidReceived_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zBPFWTl4tTE6" title="Consideration received">35,000,000</span> warrants as consideration. The warrants are exercisable
at a price of <span id="xdx_901_ecustom--WarrantsExercisablePricePerShare_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJ7ZHZDRRrzl" title="Warrants exercisable price per share">4.5</span> pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until <span id="xdx_906_ecustom--WarrantsExercisableDate_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember" title="Warrants exercisable date">17 July 2023</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, warrants were granted over <span id="xdx_90A_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z0SvPoL0lsxa" title="Warrants granted">36,363,636</span> shares at an exercise price of <span id="xdx_902_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted">1.35</span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over <span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z6nFfXTp1IO9" title="Warrants granted">40,000,000</span> shares at an exercise price of <span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted">0.55</span>p per share in connection with a private placement.
These warrants were exercised on a cashless basis in February 2022 (post a price reduction offer to <span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted">0.012</span>p), resulting in the issuance
of <span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zbDn8LswJH3g" title="Warrants granted">39,400,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2020, warrants were granted over <span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_zMF7RuyLVWni" title="Warrants granted">35,825,130 </span>shares at an exercise price of <span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_pdd" title="Weighted average exercise price, granted">0.55</span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2020, warrants were granted over <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zLJ09Q3MNLOd" title="Warrants granted">36,174,870 </span>shares at an exercise price of <span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted">0.55</span>p per share in connection with a private placement.
These warrants were exercised in May 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2020, warrants were granted over <span id="xdx_909_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_z5kAoOD3wSi4" title="Warrants granted">909,090 </span>shares at an exercise price of <span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_pdd" title="Weighted average exercise price, granted">2.75</span>p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2020, warrants were granted over <span id="xdx_90C_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zJ6QpUsUUMil" title="Warrants granted">750,000</span> shares at an exercise price of <span id="xdx_904_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zDihcs8nbAS1" title="Weighted average exercise price, granted">14</span>p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, warrants were granted over <span id="xdx_908_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zOLIsy6W2rfi" title="Warrants granted">76,605,760</span> shares at an exercise price of <span id="xdx_903_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Weighted average exercise price, granted">0.4</span>p per share in connection with the conversion of convertible
loan notes. <span id="xdx_903_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zlJ9X3uUPN56" title="Warrants exercised">39,605,760</span> were exercised immediately and the remaining <span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zbA8ZWrtiIw5" title="Warrants exercised on cashless basic">37,000,000</span> were exercised on a cashless basis in February 2022 (post
a price reduction offer to <span id="xdx_90B_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on price reduction offer">0.012</span>p), resulting in the issuance of <span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on issuances">36,445,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022, warrants were granted over <span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zfetb7hcwlYg" title="Warrants granted">165,176,000</span> shares at an exercise price of <span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Weighted average exercise price, granted">0.4</span>p per share in connection with the conversion
of convertible loan notes. <span id="xdx_90C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_z6oNkzBJdwt8" title="Warrants exercised">165,176,000</span> were exercised on a cashless basis in February 2022(post a price reduction offer to <span id="xdx_906_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Warrants exercised on price reduction offer">0.012</span>p), resulting
in the issuance of <span id="xdx_902_ecustom--WarrantsExercisedOnIssuances_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zJXrJtrSstLc" title="Warrants exercised on issuances">162,698,360</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
summary, during the year, <span id="xdx_900_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zdOf3TMbLfNe" title="Warrants exercised">147,969,396</span> warrants were exercised for proceeds of &#163;<span id="xdx_906_eifrs-full--ProceedsFromExerciseOfWarrants_pp0p0_uGBP_c20210401__20220331_zujDEkWG8lVf" title="Proceeds from warrants exercised">1,045,332</span>, resulting in the issuance of <span id="xdx_904_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331_zEUw6hBb6cl9" title="Warrants granted">147,969,396</span>
shares. <span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20210401__20220331_zdYLGe8kXR1l" title="Warrants exercised on cashless basic">242,716,000</span> warrants were also exercised on a cashless basis resulting in the issuance of <span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_uShares_c20210401__20220331_zCaWfxjAaRQ9" title="Warrants exercised on issuances">238,543,360</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_89C_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_z1LLvaPTGXg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_z90HQYpTPNWg" style="display: none"><span>SCHEDULE OF WARRANTS
OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcd7KVh6AHU" style="width: 10%; text-align: right" title="Warrants outstanding, beginning balance">185,022,726</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z73YajK94nLj" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">2.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zQm9Dv1h3CFb" style="width: 10%; text-align: right">147,188,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zF1t7WDV96Lh" style="width: 10%; text-align: right">2.1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zNm8htQqtqq8" style="text-align: right" title="Warrants granted">241,781,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zuP7UXhDHn9b" style="text-align: right" title="Weighted average exercise price, granted">0.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1b5WkEd1382" style="text-align: right">37,833,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJBsp9LjITQk" style="text-align: right">1.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1En4jVLMUil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercised">(390,145,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTyz7CgI7q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbfxILNOzhl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1ZvTvKfiZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at 31 March</span></p></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEhXslULHNR7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">36,659,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziAiKkBwPyCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">6.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zofZ5ZpVf4rc" style="border-bottom: Black 2.5pt double; text-align: right">185,022,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zawgODp3KTmf" style="border-bottom: Black 2.5pt double; text-align: right">2.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercisable at 31 March</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zXxAO9XzX8b4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">1,659,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z0BdExgerH6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">10.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zUes8Z2X6lyb" style="border-bottom: Black 2.5pt double; text-align: right">149,568,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzEs9LlpqhB6" style="border-bottom: Black 2.5pt double; text-align: right">1.1</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zLqsxtpHPZNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for warrants granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model included:</span></p>

<p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_zTfcGa6qE8Ek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zfr88tv0EsF9" style="display: none">SCHEDULE OF INPUTS FOR
WARRANTS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">29 May 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEsfwntYcTod" style="width: 16%; text-align: right" title="Grant date share price">1.75</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbbL5oIcUDy7" style="text-align: right" title="Exercise share price">0.4</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTxlwpqoxfj" style="text-align: right" title="Risk free rate">0.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zsFN4GAfFsq3" style="text-align: right" title="Expected volatility">79.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ExpectedLifeOfWarrants_dtY_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zq5wRgYwpVP5" title="Expected life">3</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zzFu9tfNCPWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_zurTi4FfrK1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zvhWhCbxZyNa" style="display: none">SCHEDULE OF FAIR VALUE
OF WARRANTS IN SERVICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 2020</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%">Grant date share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTpJqRf9hMEe" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">8.3p</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zvkI8JK1i6ej" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right">2.8p</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zHxclxQs4x52" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise share price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zPtfrlpk9lX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">14p</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmRiSa4pNCAk" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.8p</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zrlDZCTpjmJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting periods</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantsVestingPeriod_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zoCvgeiTKvyk" title="Vesting periods">Fully vested</span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--WarrantsVestingPeriod_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zdPnB7Qb9Id">50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--WarrantsVestingPeriod_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zelhksSHOXI9">Fully
    vested </span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free rate </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zqUxxQCSCECi" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.68%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zOYKlyvnL8X1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.95%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zLShQVeV3NTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.22%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1F1LpH6qFG" style="font: 10pt Times New Roman, Times, Serif; text-align: right">88.1%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zV4GtEvwhMr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right">79.6%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_983_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcatnTJgkge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">82.4%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ExpectedLifeOfWarrants_dtY_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziHcC6IoaUa7">2</span> years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--ExpectedLifeOfWarrants_dtY_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zyBlZXykt1Ch">3</span> years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ExpectedLifeOfWarrants_dtY_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzKYE5UDPTee">5</span> years</td></tr>
  </table>

<p id="xdx_8A8_zp3OWSjNidCd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining fair value of the warrant instruments is deemed to be approximately $<span id="xdx_906_ecustom--FairValueOfWarrants_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjP4zzdj6DZ9" title="Fair value of warrants">43,348</span> (2021: $<span id="xdx_904_ecustom--FairValueOfWarrants_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjoIo1i8tWsh" title="Fair value of warrants">108,873</span>). For the consideration warrants,
the charge has been expensed over the vesting period. For all other warrants, the charge has been expensed over the service period. A
share-based payment charge for the year of $<span id="xdx_909_ecustom--ShareBasedPaymentCharge_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzNi3rYUTn05">61,721</span> (2021: $<span id="xdx_905_ecustom--ShareBasedPaymentCharge_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmjZFi3iYiEk">81,914</span>) has been expensed in the statement of comprehensive income.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureShareOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680852720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract', window );"><strong>Convertible Instruments Classified As Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory', window );">CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</a></td>
<td class="text"><p id="xdx_803_eifrs-full--DisclosureOfDebtSecuritiesExplanatory_zcflQnmUxUJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zKSogIdq5Mxk">CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has raised convertible equity finance via the issuance of convertible loan notes as per the table below. All notes are not convertible
into cash and are convertible on the fourth anniversary of the date of issue of the Notes, or at the election of the noteholder on completion
of the next non-qualifying equity financing or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers
and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming,
unconditional.</span></p>

<p id="xdx_894_ecustom--DisclosureOfIssuanceOfConvertibleNotesExplanatory_z9WXST82QuX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zGA5tD6eUa82" style="display: none">SCHEDULE OF ISSUANCE OF
CONVERTIBLE LOAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Terms</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">$</p></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 26%; text-align: left">29 May 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 54%; text-align: left">&#9679; <span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zlC1BgpyZjid" title="Interest rate">20</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_905_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zMFSsu4bwI5b" title="Conversion price">0.4</span>p <br/>&#9679; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_907_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjZqVnhHKUll" title="Warrant exercise share">0.4</span>p with a maximum life of <span id="xdx_90B_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zPTxfShu5g6c" title="Debt term">5 years</span> from the
    date of the conversion of the loan note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zu9wOhWF6Ow" title="Issue of convertible instruments">541,239</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fees relating to equity fundraise 29 May 2020 issued as CLN</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_90A_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zcGIUh42aq2e" title="Interest rate">20</span>%
    coupon per annum <br/>&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_z0BRA6hDBFJh" title="Conversion price per share">0.4</span>p <br/>&#9679;
    Upon conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_908_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zpLBCFncD9k9" title="Warrant Exercise per share">0.4</span>p
    with a maximum life of <span title="Debt term"/><span id="xdx_907_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjl3ZONpf4I6" title="Debt term">5 years</span> from the date of the conversion of the loan note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zwz1bGTftRQ9" title="Issue of convertible instruments">32,474</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">27 July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zDhybC3xgKDe" title="Interest rate">2.15</span>% coupon per annum <br/>Conversion price of <span id="xdx_908_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zg5p2KPUZNU2" title="Conversion price per share">8.5</span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zX2Ergjjb9ll" title="Issue of convertible instruments">4,506,446</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">17 August 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zvbBhLid24w4" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_900_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zUQPz20QAzp9" title="Conversion price per share">8.5</span>p <br/></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zNMjjZgsDsi4" title="Issue of convertible instruments">1,882,641</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                            September 2020</span></p></td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zpS8ngSKuhwj" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_90D_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_z551mFfXGer5" title="Conversion price per share">8.5</span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zBVNjOa54Sba" title="Issue of convertible instruments">663,055</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: left">Fees relating to all other equity fundraise issued as CLN</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zUD9vOcyMPYk" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_znrjvJTeSUV2" title="Conversion price per share">8.5</span>p</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zCyWyWRMn8wl" title="Issue of convertible instruments">525,922</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331_z11jltf6xKta" title="Issue of convertible instruments">8,151,777</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zTU2Qis7oQbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
noteholders were offered the option to convert during the year and any conversions took place on May 7, 2021 and February 21, 2022. Loan
note holders were offered conversions including the full interest that would have been accrued had the note reached its full term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDebtSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDebtSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874681027472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureFinancialInstrumentsAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zitXUuwKIzY1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_828_zy2z7wiDF0Bc">FINANCIAL INSTRUMENTS</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
main risks arising from the Group&#8217;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarized below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_ecustom--DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_zoqKyLA0m1F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted
payments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BF_zmr1ZUhD4BX9" style="display: none">SUMMARY OF FINANCIAL
LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_z4B59WqIDKKi" style="font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zDAwKHUJfTwc" style="font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_zTfHCzYKtARb" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzENJ_zfcbbF2ZWT3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">649,624</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">92,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">741,810</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzENJ_zyruebiDfWv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzENJ_zEFc68Ej9Lmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">696,665</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,186</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">788,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_zNEXJ5qt8gM1" style="font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20210331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zAbLSq6XX4W5" style="font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210331_z2XoYnqigSy7" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzjzM_zQwrY98YGIzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">110,179</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">100,813</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">210,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzjzM_zmDdJcjuV88g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzjzM_zJOtu1pTyPN6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">110,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zDrJvqdzcl04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Credit
risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and currently
has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their
internal reporting and assess outstanding receivables for ability to be repaid.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Interest
rate risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has limited exposure to interest-rate risk arising from its bank deposits and convertible loan note instruments. These deposit
accounts are held at variable interest rates based on Barclays bank &amp; Penn base rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2022 or 31 March 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680913840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureRelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_801_eifrs-full--DisclosureOfRelatedPartyExplanatory_zlpdhyDU4FP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_828_ztD4Awd4yjLl">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
related party transactions occurred in the normal course of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>West
African Minerals Limited (&#8220;WAML&#8221;)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2018, the Group disposed of its Cameroon operations by way of an in-specie distribution of all of its shares in West African Minerals
Limited (formerly Ferrum Resources Limited) to shareholders. As part of this transaction, the Group had agreed to a deed of release with
WAML whereby it agreed to write off $<span id="xdx_905_ecustom--WriteOffExchangeOfLoan_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zNkvIcnw6H6l" title="Write off related party exchange of loan">17,056,070</span> of loans in exchange for shares in WAML to be distributed as part of the in-specie distribution.
A remaining amount of $<span id="xdx_904_eifrs-full--RevenueFromSaleOfGoodsRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zSuJzUgCLFD2">3,400,000</span> was outstanding from WAML, however, after careful consideration of the operations of WAML and its subsidiaries,
the Group decided to impair this receivable down to $nil in 2018 as it did not expect to recover any of this outstanding debt. In addition
to the $<span id="xdx_903_eifrs-full--NetDebt_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zgLgRnKOGAm9">3,400,000</span> outstanding was a working capital loan advance of $<span id="xdx_90E_eifrs-full--Borrowings_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_z6FP8JHGPwB2">600,000</span> which was also impaired as the Group does not expect to
recover any of this outstanding debt. During the year ended March 31, 2022, the Group had funded $<span id="xdx_907_eifrs-full--LoansAndReceivables_iI_do_c20220331_zOlc6rNCXH3d" title="Loans receivable">0</span> (2021: $<span id="xdx_905_eifrs-full--LoansAndReceivables_iI_c20210331_zDLLsSV0Da6h" title="Loans receivable">11,172</span>) towards this $<span id="xdx_904_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_ztWtGN05J9L6">600,000</span>
loan facility and as at the year-end no further amounts were payable under this facility. The amounts funded in the year have been immediately
written off as the Group has no reasonable expectation of recovering the contractual cash flows of the loan in its entirety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tiziana
Life Sciences Ltd</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. The Company
shares premises and other resources with Tiziana Life Sciences Ltd and there is a shared services agreement in place between the Company and
Tiziana Life Sciences PLC. As at 31<sup>st</sup> March 2022, the Company had incurred $<span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zpnVKbHZo1O3" title="Service received related party transaction">107,132</span> (2021: $<span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20200401__20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zlYezFQwC8eh" title="Service received related party transaction">86,567</span>) worth of costs in relation
to this agreement and at 31 March 2022 $<span id="xdx_90E_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zJ6LSJcb5ffi" title="Amounts Payable related party transaction">47,041</span> was due to Tiziana Life Sciences Ltd. At 31 March 2021, $<span id="xdx_90A_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zsnK6ra2YE6b" title="Amounts Payable related party transaction">27,664</span> was receivable from Tiziana
Life Sciences Ltd.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureRelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureRelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680860288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract', window );"><strong>Basic And Diluted Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">BASIC AND DILUTED LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfEarningsPerShareExplanatory_zRUZ2SWf9eri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zUnyPY1x2PWd">BASIC AND DILUTED LOSS PER SHARE</span></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eifrs-full--EarningsPerShareExplanatory_zSm0U7stgkp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwF8RUz40iXi" style="display: none">SUMMARY
OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20210401__20220331_zNqmuav90nh5" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company">(6,268,197</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20200401__20210331_pp0p0" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company">(3,353,507</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageShares_c20210401__20220331_z6IzBFm1oPH" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">979,212,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--WeightedAverageShares_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">672,767,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--BasicAndDilutedEarningsLossPerShare_c20210401__20220331_z1WozRvrawSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--BasicAndDilutedEarningsLossPerShare_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20190401__20200331_z4l19vmKMoP8" style="width: 16%; text-align: right" title="(Loss) attributable to equity holders of the company">(1,544,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageShares_c20190401__20200331_zEvPIGB4F4oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">595,474,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BasicAndDilutedEarningsLossPerShare_c20190401__20200331_z9B8BNlE3wnc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8A3_zk7lwaU07q04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered
dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented
on the face of the Statement of comprehensive income are therefore identical.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureBasicAndDilutedLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683502144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p id="xdx_80F_eifrs-full--DisclosureOfLeasesExplanatory_zWskv507RpI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_82E_z3P6cgdVDPji">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group is a lessee and does not have any leases as a lessor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    Leases of low value assets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based
on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its
right-of-use assets in a consistent manner to its property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties
in their original condition at the end of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year to March 31, 2022, the Group entered
into new lease agreement on its existing office. The new leases has a term shorter than 12 months, so the Group has applied the exemption
allowed by paragraph 5a in IFRS 16 in respect of short term leases.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year to March 31, 2021, the group terminated from its lease early resulting in the right of use asset of $<span id="xdx_90C_ecustom--DisposalsRightOfUseAssets_c20200401__20210331_zLfqCQB2D4ck" title="Early Termination write off right of use of assets">27,069</span> and lease liability
of $<span id="xdx_90A_ecustom--DisposalsLeaseLiabilities_c20200401__20210331_zjvcN10sMuxg" title="Early Termination write off lease liability">27,887</span> being written off to the profit and loss. A new lease was subsequently entered into in January 2021. The initial recognition
resulted in a right of use asset and a lease liability of $<span id="xdx_904_ecustom--InitialRecognitionForRightOfUseAssetAndLeaseLiability_c20200401__20210331_pp0p0" title="initial recognition for right of use asset and lease liability">104,377</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p id="xdx_89C_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_zZKJgd98QZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVZpiUE9kMs8" style="display: none">SCHEDULE
OF RIGHT OF USE ASSETS AND LEASE LIABILITY</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">Right-of-use assets</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property <br/>$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RightofuseAssets_iS_c20210401__20220331_zzxDfJZQtynj" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year">98,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Derecognition of right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--DisposalsRightOfUseAssets_c20210401__20220331_zD1HO3XrvGSh" style="text-align: right" title="Derecognition of right of use asset">(97,553</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_iN_di_c20210401__20220331_zzQyo0Jwr6ak" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impact of Foreign exchange">(1,026</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--RightofuseAssets_iE_c20210401__20220331_zvgcnVyaIU1" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"><span style="-sec-ix-hidden: xdx2ixbrl1768">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RightofuseAssets_iS_c20200401__20210331_zUznAy0hxQgc" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year">30,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation of early terminated lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DepreciationOfEarlyTerminatedLease_c20200401__20210331_zMR2gPGEmIF3" style="text-align: right" title="Depreciation of early terminated lease">(4,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Termination write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DisposalsRightOfUseAssets_iN_di_c20200401__20210331_zmJPyy0U421f" style="text-align: right" title="Early Termination write off">(27,069</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_c20200401__20210331_zA078dNHUbzc" style="text-align: right" title="Impact of Foreign exchange">1,030</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsToRightofuseAssets_c20200401__20210331_zMQcUq9qXCd2" style="text-align: right" title="Additions">104,377</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of new lease</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DepreciationOfNewLease_c20200401__20210331_zjlwxfOcTG7f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation of new lease">(5,799</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_c20200401__20210331_zQH9Uk8SKbP9" style="text-align: right" title="Right-of-use assets, balance as at the end of the year">98,579</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Lease Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zxT5lM2DB388" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20210331_zAc7Rrn5SjU6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160; &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--LeaseLiabilities_iS_zZmBklQvjOTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%">At 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">98,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">31,689</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LeaseLiabilities_iS_zTo2iwDz0etj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Liabilities, balance as at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,689</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--LeaseLiabilitiesInterestExpense_zPIrqOS9pajd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LeasePayments_zNa5PCDQm2n8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,542</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpactOfForeignExchangeLeaseLiabilities_zKImhhjwP1v8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1797">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerecognitionOfLeaseLiability_zsLlWUqHIva1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derecognition of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(97,553</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1800">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalsLeaseLiabilities_iN_di_zA5gJ4qrPJ5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Early Termination write off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,887</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AdditionsToLeaseLiabilities_zTBcNDgE6xAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,378</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LeaseLiabilitiesInterestExpenses_zhiVgAqdY6Qc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeasePayment_zh6mgGmMfmv3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--LeaseLiabilities_iE_zupJ8UUubTB" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    30 April</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1814">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--LeaseLiabilities_iE_zeKKkfpgmXl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span style="font-size: 10pt">Lease Liabilities, balance as at the beginning of the year</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A9_zvwFanj0gUL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_zB5CKFgNe3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zbmjPqrG3F3c" style="display: none">SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20220331_zmKwmnIBhzo8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210331_zlyPh0jhynRh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$ &#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$
&#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zv7XaDQkJUWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Current </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34,148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--NoncurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zl2kQG5N0vVc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Non-current </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--LeaseLiabilities_iTI_mtLLzex8_ztlPC1rZi9Rk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,760</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p id="xdx_8A0_zrbiYpZWRDi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
leases</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_z9RZTlXFUeD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B4_zcQfZaCgGKG6" style="display: none">SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Operating leases which expire:</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 68%; text-align: justify">Within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zDu9wXXbjjK9" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year">18,713</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_z6tAvFmpciOf" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"><span style="-sec-ix-hidden: xdx2ixbrl1835">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331_zzpMOaiax946" style="border-bottom: Black 2.5pt double; text-align: right" title="Within one year">18,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331_ziHlYPfIZQk" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z2dKXGvMBz56" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677586640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auditor&#8217;s Remuneration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory', window );">Auditor&#8217;s Remuneration</a></td>
<td class="text"><p id="xdx_804_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_zXZQkSQqwA0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20.
<span id="xdx_82A_zcZrAJzYJQhg">Auditor&#8217;s Remuneration</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_zD2gkHE1hTxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period, the group obtained the following services from the company&#8217;s auditors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQMzkE6Qo47b">SCHEDULE
OF COMPANY AUDITORS FEES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zbf5K3wx0Av3" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20210331_zOUzJkwP8mp" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemunerationForAuditServices_zNfxNk36Cayc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Fees payable to the company&#8217;s auditors for the audit of the parent company and consolidated financial statements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">200,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fees payable to the company&#8217;s auditors for other services:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AuditorsRemunerationForOtherServices_zn1lZdfN4mR3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Audit-related assurance services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">148,892</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,637</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zgB2fVZqwwth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total auditor&#8217;s remuneration</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">131,511</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zecrDmusrV1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAuditorsRemunerationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of compensation to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAuditorsRemunerationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874684060896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_80B_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_zkmTECTLSrkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
<span id="xdx_826_zlmiUo2epTI6">Cash and Cash Equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_zNxGs8zLiU9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B1_zYWdwGwZDKU7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160; </b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash at bank and in hand:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify">GBP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand">2,400,817</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand">4,344,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">USD</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">299,907</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">2,544,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"/><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--CashOnHand_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">2,700,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CashOnHand_c20210331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">6,889,329</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_z2imog4U0SEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677789808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCommitmentsAndContingenciesAbstract', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zCve7pILUbRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22.
<span id="xdx_828_zbqJ9fOVtSX9">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialisation of the products of this research
and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that
the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OK-101
    &#8211; We are obligated to pay to On Target Therapeutics the following additional amounts in respect of the first licensed product
    or service which achieves the stated development milestones:</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.65in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase I Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_907_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIHumanClinicalTrialMember_zXzDW5cGvOHa" title="Amount of licensed product or service">300,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase II Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90B_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIHumanClinicalTrialMember_zG3J3HDW16S5">600,000</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Patient Enrolled in a Phase III Human Clinical trial</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_90D_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIIHumanClinicalTrialMember_zcK21OsPDhr">1,500,000</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BAM8
    &#8211; The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
    fee is $<span id="xdx_900_ecustom--AnnualLicenseMaintenanceFee_c20210401__20220331_pp0p0" title="Annual license maintenance fee">15,000</span> until May 2021, and $<span id="xdx_90A_ecustom--AnnualLicenseMaintenanceFeeTherafter_c20210401__20220331_pp0p0" title="Annual license maintenance fee, therafter">10,000</span> thereafter.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCommitmentsAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCommitmentsAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677766032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post Balance Sheet Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosurePostBalanceSheetEventsAbstract', window );"><strong>Post Balance Sheet Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Post Balance Sheet Events</a></td>
<td class="text"><p id="xdx_809_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_znWjsdIHUESc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>23.
<span id="xdx_828_zzNJreRL2kGl">Post Balance Sheet Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022, OKYO announced the closing of its underwritten public offering of <span id="xdx_906_eifrs-full--NumberOfSharesIssued_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_z7hh2Ya6rUF3">625,000</span> American Depository Shares (the &#8220;ADSs&#8221;)
at a public offering price of $<span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_znIYxZab1sAk" title="Price per share">4.00</span> per ADS, for gross proceeds of $<span id="xdx_909_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20220502__20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_zGm8DDxjg789" title="Gross proceeds from public offering">2.5</span> million, before deducting underwriting discounts and offering
expenses. As a result, the Company is now listed on the Nasdaq stock exchange and is therefore a dual listed Company with its existing
listing on the London Stock Exchange.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 19, 2022, the Remuneration committee awarded the Non-Executive Chairman a bonus of $<span id="xdx_902_ecustom--Bonus_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z6kbkZgenBSk">150,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The committee noted that in order to support the offering the Non-Executive Chairman participated in the offering. It was noted that
the offering may have failed without this subscription, so it was agreed to compensate Mr Cerrone for this transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2022, the Group secured a short-term credit facility from Tiziana Life Sciences, a related party, for $<span id="xdx_908_ecustom--ShorttermCreditFacility_iI_pn6n6_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zk6EoyVv3Hal">2</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m
in order to support short term liquidity. The loan is available for a period of 6 months upon first draw-down and carries an interest
rate of <span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z5q1Xg9p2Z4c" title="Interest rate">16</span>% per annum, with additional default interest of <span id="xdx_907_ecustom--AdditionalBorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z70UCXqKYT39" title="Additional interest rate">4</span>% if the loan is not repaid after the 6-month period.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosurePostBalanceSheetEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosurePostBalanceSheetEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677845264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p id="xdx_843_ecustom--DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_zfHxssMul8de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zuiCtMYBwdSe">Basis
of preparation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements', window );">Basis of measurement</a></td>
<td class="text"><p id="xdx_84C_eifrs-full--ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_ze6rEvZvCdVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSHeKIf3gOw6">Basis
of measurement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGoingConcernExplanatory', window );">Going Concern</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DisclosureOfGoingConcernExplanatory_zyjwyoe4H8Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zIJXF9vULX97">Going
Concern</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &#163;<span id="xdx_908_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20220331_znuD9gZzK7s8" title="Accumulated deficit">76.8</span>m (&#163;<span id="xdx_90E_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20181231_zaW6Bco1JJu6">64</span>m of this accumulated loss relates to a discontinued business prior
to the reorganisation in 2018), a net loss for the year ended March 31, 2022, of &#163;<span id="xdx_905_eifrs-full--ProfitLoss_iN_pn5n6_di_uGBP_c20210401__20220331_zm0Cywblto74" title="Net loss">4.0</span>m and net cash used in operating activities
of &#163;<span id="xdx_908_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pn5n6_di_uGBP_c20210401__20220331_zSQLLI5hFUw2" title="Net cash used in operating activities">4.0</span>m.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &#163;<span id="xdx_90A_eifrs-full--CashAndCashEquivalents_iI_pn5n6_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zp1LWwYLOLx9" title="Cash">1.5</span>m, with current liabilities of &#163;<span id="xdx_90F_eifrs-full--CurrentLiabilities_iI_pn3n3_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_ze72JlAwVGUb" title="Current liabilities">978</span>k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &#163;<span id="xdx_909_ecustom--CashBurnRate_pn5n6_uGBP_c20220801__20221231__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zYmIKoYjsO1" title="Rate of cash burn/spend">2.4</span>m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&#8217;s ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took
strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential
liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are
more specialist investors focused on early-stage opportunities. The Directors are also confident that the nature of the OK101
clinical program is such that various inflection points arise over a relatively short period of time which should provide financing
opportunities, for example the FDA approval of the IND in December 2022 for OK101 in dry-eye and the return of headline data from
the Phase II registration trial to be held between July and December 2023; these pivotal events in the primary clinical program
for OK101 have the benefit of being near term events (which is unusual in the context of the normal timeframes for Phase II clinical
programs to deliver meaningful data points. The Directors have also consulted the Company&#8217;s investment bankers with a view to
planning a number of alternative financing strategies to ensure the Company has access to sufficient capital to finance its planned
R&amp;D activity in the coming 18 months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">To meet the Company&#8217;s short-term
liquidity needs, the Company has secured a $2m short-term credit facility with a related party in order to bridge any delays in the
occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for a period of 6 months upon first
draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the
6-month period. The loan will extend the Company&#8217;s fixed cost cash burn to April 2023 without the need to raise additional
funds. The Directors believe that this facility together with additional working capital management measures will be sufficient to
complete the IND application. The Directors also considered any risks to the short-term cash position of the company such as delay
in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash resources and
the additional financing strategies already disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="margin: 0pt; text-align: justify">On completion of the IND application the company will be in a position to raise funds on the market, via the financing
strategies being discussed with the Company&#8217;s investment bankers. The necessary steps are being taken to affect such a fundraise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Until and unless the Group and Company secures sufficient investment to
fund their clinical pipeline, there is a significant doubt on the Group and Company&#8217;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this significant
doubt, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident,
based on the previous fund-raising history as well as additional measures already put in place and being planned, that sufficient funds
will be forthcoming and accordingly they have prepared these financial statements on a going concern basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>New
and Revised Standards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Standards
in effect in 2022</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Basis of consolidation</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_z8XuKH8VZHrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zAEqUJeIcxTa">Basis
of consolidation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&#8217;s return.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inter-company
transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Segment reporting</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zL1Tjuw6eBY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z9pHKU5FVQ77">Segment
reporting</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Taxation</a></td>
<td class="text"><p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_z8j7TbRaDvDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zZmLakyiYkc9">Taxation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zqPFx9fhSOq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zy5WsOrjQrJ1">Foreign
currency translation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
included in the financial statements of each of the Group&#8217;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements are presented in US dollars, which is the Group&#8217;s presentation currency.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are translated into US dollars on the following basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets
    and liabilities at the rate of exchange ruling at the year-end date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Profit
    and loss account items at the average rate of exchange for the year.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory', window );">License fees</a></td>
<td class="text"><p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForLicenseFeesExplanatory_z4OBpo4q3jX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zm7114eoO8Gi">License
fees</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. Licence fees expenses are recognised as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory', window );">Research and development</a></td>
<td class="text"><p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_zV4NMjY7ImUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zdB5ejYOmZq6">Research
and development</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&#8217;s products, the criteria for development costs to be recognised as an asset, as set out
in IAS 38 &#8216;Intangible Assets&#8217;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial instruments</a></td>
<td class="text"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zmF6nZC13B7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zVywf64qjVV6">Financial
instruments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            assets, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            liabilities, initial recognition and measurement and subsequent measurement</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s financial liabilities include trade and other payables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_z9PMWq0U69aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zbwcn0sWvmfd">Cash
and cash equivalents</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents comprise cash on hand.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zu5Vz53LAPZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zSSUUkEJ16pj">Impairment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Impairment
of financial assets measured at amortised cost</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>General
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognised at an amount equal to the lifetime expected credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Simplified
approach</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
simplified approach is applied to the impairment assessment of trade receivables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Impairment
of non-financial assets</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-financial
    assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of
    fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory', window );">Share capital</a></td>
<td class="text"><p id="xdx_84F_ecustom--DescriptionOfAccountingPolicyForShareCapitalExplanatory_zhKIP9EcIGAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zutNHNqPZix7">Share
capital</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares of the Company are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property, plant and equipment</a></td>
<td class="text"><p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z3Tp1iH8qZEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_ziZ4K9iwOnRj">Property,
plant and equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(i)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Recognition
    and measurement</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalised as part of that equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zohpzScp5GKj" style="display: none">DISCLOSURE OF ESTIMATED USEFUL LIVES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures
    and fittings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives">5</span>
    years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives">3</span>
    years</b></span></td></tr>
  </table>
<p id="xdx_8A8_ztfRBhkQeQtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory', window );">Leases</a></td>
<td class="text"><p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForLeaseExplanatory_z2MC8R5u546h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zKMh4tMa5WMa">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    of low value assets; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
    with a duration of 12 months or less.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&#8217;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
term leases&#160;exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit
and loss on a straight-line basis over the term of the lease.<b/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share based payments</a></td>
<td class="text"><p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_zWrtAKrce05d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zOrTi2vaPpRa">Share
based payments</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#8217;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&#8217;, Directors&#8217; or
advisers&#8217; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &#8211; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &#8211; warrants, in the case of warrants issued in return for services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory', window );">Warrants</a></td>
<td class="text"><p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForWarrantsExplanatory_zQwDNsR5fr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zbEsSZejhIv1">Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
are issued by the Group in return for services and as part of a financing transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued in return for services.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrants
issued as part of a financing transaction.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification
of these instruments is governed by the so-called &#8216;fixed&#8217; test for non-derivatives, and the &#8216;fixed for fixed&#8217;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory', window );">Convertible loan notes</a></td>
<td class="text"><p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForBorrowingsExplanatory_zhziKifCc0wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
loan notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Where
the fixed for fixed condition is met</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve. The accrued interest on the principal amount is also recorded in the Convertible
loan note reserve as it is convertible into equity. Upon redemption of the instrument and the issue of share capital, the amount is reclassified
from the convertible loan note reserve to share capital and share premium.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z6QSFNFpPNkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b><span id="xdx_86A_zGUsrfQMiDpk">Fair Value Measurement</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management have assessed the categorization
of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the
basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 1 - valued using quoted prices in active
markets for identical assets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 2 - valued by reference to valuation
techniques using observable inputs other than quoted prices included within Level 1;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Level 3 - valued by reference to valuation
techniques using inputs that are not based on observable market data.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Accounting Policy For Lease Explanatory [PolicyText Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of Accounting Policy For License Fees Explanatory [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for research and development explanatory [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for share capital explanatory [Policy Text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policies of basis of preparation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGoingConcernExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGoingConcernExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the measurement basis (or bases) used in preparing the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677759488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureAccountingPoliciesAbstract', window );"><strong>Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfEstimatedUsefulLivesExplanatory', window );">DISCLOSURE OF ESTIMATED USEFUL LIVES</a></td>
<td class="text"><p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated useful lives for the current period and the comparative period are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_8B2_zohpzScp5GKj" style="display: none">DISCLOSURE OF ESTIMATED USEFUL LIVES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixtures
    and fittings</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives">5</span>
    years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IT
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives">3</span>
    years</b></span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfEstimatedUsefulLivesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for estimated useful lives explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfEstimatedUsefulLivesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677766032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory', window );">DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY</a></td>
<td class="text"><p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_zcJQPfshHF66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
expenses are stated after charging:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BA_zv5H4Zdb09P3" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_492_20210401_20220331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_490_20200401_20210331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_499_20190401_20200331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: italic 10pt Times New Roman, Times, Serif; width: 52%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020<br/>
                                            $</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/></tr>
  <tr id="xdx_400_ecustom--KeyManagementPersonnelCompensationDirectorFees_zePbaRlnR1q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    fees including bonus (excluding Chairman&#8217;s bonus)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">707,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">278,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--ChairmansBonus_zWNaBdmQhEBi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman&#8217;s
    bonus</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0801">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,160,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemuneration_zOFBOtlnRyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Auditor&#8217;s
    Remuneration (refer to Note 20) <span id="xdx_F4F_z1VPTCZ1HRX4">*</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">349,665</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">131,511</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53,402</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eifrs-full--ProfessionalFeesExpense_maOEz5cJ_zSKJSxSK2Ykd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    and Professional fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,143,300</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">343,422</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">195,433</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--GainlossOnDisposalOfLeases_zDCjm8fYgV8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Gain)/Loss
    on disposal of leases</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(179</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0815">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--ForeignExchangeLossesGains_zjHTgj2143v1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FX
    Gains and losses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,577</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,061</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">200,061</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eifrs-full--DepreciationAndAmortisationExpense_maOEz5cJ_zkqnZJ3zsXG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,423</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,512</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">212</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0D_zas2XeaQKt8b" style="vertical-align: top; width: 15pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1D_z2RKUHb9dNke" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#8217;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#8217;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</span></td>
</tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about operating expenses explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680403264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEES INCLUDING OFFICERS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract', window );"><strong>Employees Including Officers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory', window );">DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY</a></td>
<td class="text"><p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutEmployeesExplanatory_zZzhVfMhnC1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zCg3Dxgsfoia" style="display: none">DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20210401__20220331_zJK1dSHpyP3d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_494_20200401__20210331_zS7V6fUe7wfg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20190401__20200331_zhysJddbD2dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year
    ended March 31,</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Group</span></span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Staff
    costs comprised:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--DirectorsSalaries_zzJlwL2IxEI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;
    salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">707,385</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,438,571</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eifrs-full--WagesAndSalaries_zCbkmO9Xt7z4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages
    and salaries</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">323,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">121,702</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">229,347</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eifrs-full--SocialSecurityContributions_zMexCkPv3lt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Social
    security costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,449</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,543</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,740</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eifrs-full--OtherShorttermEmployeeBenefits_zzA113lNobYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recruitment
    Costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,259</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,922</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eifrs-full--EmployeeBenefitsExpense_zAc6HfaUaDle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Total
    employee benefits expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,129,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,582,739</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">420,188</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March
    31, 2020 were:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zdWNXY20Uey9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_z76vWoTxq5Hd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zMCPgwZdQKmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    and administration</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zcb2NreUYGm4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zyXHP3ZnUfcg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zgRPVeAAnHEd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331_zKFobcgy3Io4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331_zn1tzEcmsRe2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331_zAprse49DnKg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureEmployeesIncludingOfficersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about employees explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677760864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract', window );"><strong>Remuneration Of Key Management Personnel</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">SCHEDULE OF REMUNERATION OF DIRECTORS</a></td>
<td class="text"><p id="xdx_89E_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_z82Jw7rgipH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B4_z6eoRVcapVgd" style="display: none">SCHEDULE OF
REMUNERATION OF DIRECTORS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended March 31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br/>
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors&#8217;<br/>
    fees</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bonus</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Salary</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    based payment expenses</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span id="xdx_F42_zoORemjkg0rk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.
    Cerrone (1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zJwRoQbTyQmc" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Directors' fees"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">164</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zA7MD3BExeDg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0878">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zuSVp0qrqYE4" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0879">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z1H6cleFajP5" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0880">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zaR8Ml2OXp1k" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zkoaGsrBKQN" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,160</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zFKhZNRw7PY9" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z6ZcLf6nkjJ8" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4A_zcmcM70NVUja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Jacob (2)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ziZY4SFDKuHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zchuBtXycHxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zMfKmv9pg8zh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zvYjB2pqWyd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,579</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zjK7D1AO1h44" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zTkkst7XIcp9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ztB7f8Ln9vi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zuYxRB6PDBal" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">468</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F4E_zzaXpCDtM9a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">W
    Simon</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zLvSegVwVCv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_z5G4arfld85e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zsY4YPBp8slk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zu5FvKgicT3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_zXh5gqSLKmMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_ziR4g5giYx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0898">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_980_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z2bJ593xY0sj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z9m3kUtwlUle" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F49_zFm9R05AmXLh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.
    Shailubhai (6)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zMwQRQ6AgnP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zjYrUyzh4yo2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0902">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zDbKs9k3JB73" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zJ3ixkf2DDmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zejh3HSzYFlb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z1GavsmgNkYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0906">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zwiEnKf05zP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z6SICVjSSkq3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zmGavRadwrci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J
    Brancaccio (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zJzQMAz59bGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_znRNaQPTpSZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Bonus"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zHpFX7ehxCDl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zcWLYBo4WMna" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zkQwVkBcsUhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zs6xJcti6qb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zz5AMRnJ2gzi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zqFIbPAExZGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F41_zJLgUzqgODTb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G
    Macrae (4)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zBGIHcmYZX6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z9Q2ETy3Eapl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_987_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zuJuf7xlGW37" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_ziIHzwa8a4Jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0921">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zx7BK1WLWAXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zNbrCVF1lWa1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z8Jqss0FDSnh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zcPMn6vhFdFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F46_zSCSXCjYZsBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B
    Denoyer (5)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zyZh9yANafg5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zLwXKQg5EkV6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0927">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zdFhmkfHb2f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0928">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zRZ2rBN2k19k" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zAy5OlAa9cU3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_983_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zs7tjKo5mn6a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0931">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zkwRWpjCdBa9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98C_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_z7It9OMM0Je2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0933">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331_zOVK6I3VUsw1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">283</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20210401__20220331_zKEURchPa9m6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331_zO6pqSAbZNeh" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">350</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331_zivYpMRn1ZBa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,589</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331_z72j0IbuBhV6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_984_ecustom--DirectorsBonus_pn3n3_c20200401__20210331_zT47m87MiwQj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,201</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20200401__20210331_zrWCboYkOuC7" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331_zPwnrT4BIodj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">503</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$&#8217;000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Directors<br/> fees</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Bonus</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Share based<br/> payment<br/> expenses</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">W Simon</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zUk5yIMoiBg9" style="width: 10%; text-align: right">41</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zmVN5YAfYlQg" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zyXHfCIzrGE2" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0944">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zi39PWSrFrJj" style="width: 10%; text-align: right">4</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F42_zdgU0nltkua9" style="text-align: justify">K. Shailubhai (6)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zpx0UL5mnXqd" style="text-align: right">38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zrR0gXsz7Ehd" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0947">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z64f6ExpMdM" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zOaOil4dS3J" style="text-align: right">31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_F43_zlZ4vg1RPHdf" style="text-align: justify">G Macrae (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zI66tZZDBpRg" style="text-align: right">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zCkK2ZoKldPl" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0951">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z14gZjqiWApe" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zbca9H2gAQY5" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0953">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td id="xdx_F45_zhIBMzPADFN7" style="text-align: justify; padding-bottom: 1.5pt">L Zambeletti (7)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z9zhoSTwAuV" style="border-bottom: Black 1.5pt solid; text-align: right">36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z6ZUQ1aqQt2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zHVKHhwti3E6" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zrZJ4kZhznbk" style="border-bottom: Black 1.5pt solid; text-align: right">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331_zeBYIC885IU9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">122</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20190401__20200331_ztO78z315hFl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0959">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20190401__20200331_zATpAnwJFwse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331_zNGjx3BII9G5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Share based payment expenses">41</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span id="xdx_F0F_zdsAkDzx71u6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_zFso84703sok" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gabriele
    Cerrone&#8217;s bonus awarded for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded">1,160</span>k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F07_zhlu0tFfEE9h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zFtqJgI8lMA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F00_zVGCkBTOFDal" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F16_z5cPpMHsrvf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Brancaccio was appointed as Director on 10 June 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0A_zPbxjDVQGxrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F11_zb9U2ivUxQP4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0E_zkAhLD19uhje" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zju9flrcZlI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bernard
Denoyer was appointed as Director on 24 November 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F0F_zeRBkloR8v6h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zC93YuD6Dxp3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K
    Shailubhai resigned as Director on 17 June 2021</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F05_zdKOOi2lXYZg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F12_zpYeXyc5fTn2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory', window );">SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfShareOptionsGrantedToDirectorsExplanatory_zycsLkTejWhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following share options were granted to Directors in the year:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zHNq8SfTnDx9" style="display: none">SCHEDULE
OF SHARE OPTIONS GRANTED&#160;TO DIRECTORS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/> options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; text-align: justify">J Brancaccio</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zVeQ2fW9nZo2" style="width: 11%; text-align: right" title="Number of options">325,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_z2gi1spW5x2" style="width: 11%; text-align: right">450,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zHtMVMbte2k3" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">G Jacob</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_z2Qq0qXPnbf3" style="text-align: right">3,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zJThVA8w4bMh" style="text-align: right">40,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zSvKRuLfR4j1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">B Denoyer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zJcYFhtLFxXl" style="text-align: right">1,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zZIlA4YDQtgh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zW796tZZY3Fh" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zkJGfGiPauX9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">4,575,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zyFwmstGJsfg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">40,450,000</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzytfXWb2Vv6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0989">-</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION</a></td>
<td class="text"><p id="xdx_898_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_z2oWKmgIrQjj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_z4iUaM102BYh" style="display: none">SCHEDULE OF KEY
MANAGEMENT PERSONNEL COMPENSATION</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_ziOkPUmYBc6d" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_z17rap7c5xG8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_zvQIOP6tZaY4" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$&#8217;000</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">$<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8217;000</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_pn3n3_z4sLaAo65vX3" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: justify">Short-term employee benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,026</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">1,455</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">351</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_z6RayWBXrOr9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Share based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,815</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">515</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--KeyManagementPersonnelCompensation_pn3n3_zoREdEZ3Q3Pk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,841</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,970</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">392</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share options granted to directors explanatory [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680433808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTaxationAbstract', window );"><strong>Taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory', window );">SCHEDULE OF TAX CREDIT PERIOD</a></td>
<td class="text"><p id="xdx_898_eifrs-full--DisclosureOfTaxReceivablesAndPayablesExplanatory_zTpr5AjWRcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zxO6z3GPQzgj" style="display: none">SCHEDULE
OF TAX CREDIT PERIOD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210401__20220331_zpZY4HvA90J9" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20200401__20210331_zS2WhvN8YA5h" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20190401__20200331_zMtuGAxFmh4j" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="text-decoration: underline">Group</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_z3dkca1Qe6ja" style="vertical-align: bottom; background-color: White">
    <td style="width: 58%; text-align: left">Current year tax (credit)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(509,282</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">(24,952</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AdjustmentsForCurrentTaxOfPriorPeriod_zHN85F7b3G3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments in respect of prior periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277,239</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,289</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_zWGOxkJy6ZA5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Origination and reversal of timing differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1017">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1018">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zR5GhEgBM1yk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(786,521</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,289</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--LossBeforeTaxation_zqgQa1G8Jf1j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loss before taxation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,045,372</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,378,501</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,620,347</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LossChargedAtStandardRateOfCorporationTax_zE24A79JgYul" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss charged at standard rate of corporation tax <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210401__20220331_z51STLB7nbFd" title="Corporation tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200401__20210331_z2R9xAUXttXc"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20190401__20200331_z7R3mreO1z53" title="Corporation tax rate">19%</span></span></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,181,337</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(641,915</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(307,866</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_z8SiS2olBDH7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax losses arising in the year not recognized</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">524,870</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">660,594</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">340,114</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--TaxLossesSurrenderedForResearchAndDevelopment_zsGR3bFmOfF" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax losses surrendered for Research and Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">667,335</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_z1zbXRnS5075" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expenses not deductible for taxation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">370,306</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">145</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_zeCGmHghSJY4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Tax increase from effect of capital allowances and depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(334</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">81</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ResearchAndDevelopmentTaxClaim_zDLPsa4a8cM4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax claim</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(509,282</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(43,432</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1056">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ResearchAndDevelopmentEnhancedExpenditure_zDbTg4TDxT5f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and Development enhanced expenditure</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(377,187</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_zo30sWgWiie8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development tax credits claimed in respect of previous periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(277,240</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(76,289</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eifrs-full--IncreaseDecreaseThroughForeignExchangeFinancialAssets_zgfKklf11Lb5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Consolidation adjustment in relation to foreign exchange movements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,983</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">135</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(32,504</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eifrs-full--GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_zGPztcPidbjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Loans written off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1071">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_znKrZf957KGi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total tax (credit) for the period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(786,521</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,994</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(76,289</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of tax receivables and payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680403520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME AND COSTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract', window );"><strong>Finance Income And Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceCostExplanatory', window );">SCHEDULE OF FINANCE COST</a></td>
<td class="text"><p id="xdx_897_eifrs-full--DisclosureOfFinanceCostExplanatory_zVIwQP9Y7xAk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zFA0aooYeKH8" style="display: none">SCHEDULE
OF FINANCE COST</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2022</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2021</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2020</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>$</b></p></td><td style="padding-bottom: 1.5pt; font-size: 10pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 46%; font-size: 10pt; text-align: left">Interest income</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--RevenueFromInterest_c20210401__20220331_z5BQSJecRC5k" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--RevenueFromInterest_c20200401__20210331_z9iOz0ATOuM8" style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1085">-</span></td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RevenueFromInterest_c20190401__20200331_zYoGULSQcRp9" style="width: 14%; font-size: 10pt; text-align: right">48,125</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Total finance income</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceIncome_c20210401__20220331_zfwiJKbvUMJg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1087">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--FinanceIncome_c20200401__20210331_z28upqv01yge" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--FinanceIncome_c20190401__20200331_z74SwCEBy9Ab" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">48,125</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-size: 10pt; text-align: left">Finance Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt">Interest expense on lease liabilities</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20210401__20220331_zCXJBdK1vm5i" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1090">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20200401__20210331_zT89OdbrWguc" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,122</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20190401__20200331_zZYfP1t8ckU8" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(1,158</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total finance expenses</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--FinanceCosts_iN_di_c20210401__20220331_zlvnOnYSuWp" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1093">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--FinanceCosts_iN_di_c20200401__20210331_zw3FQjmHFMWk" style="font-size: 10pt; text-align: right">(1,123</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--FinanceCosts_iN_di_c20190401__20200331_zpax2t3ux8lj" style="font-size: 10pt; text-align: right">(1,158</td><td style="font-size: 10pt; text-align: left">)</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureFinanceIncomeAndCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceCostExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance cost. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceCostExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677864704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosurePropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_89F_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zeehfFSYz9o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Details
of the Group&#8217;s property, plant and equipment are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B7_zk5p61NgWeBc" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbm3svaqAEf" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance">8,343</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331_zYl7p3r5oW7" style="width: 12%; text-align: right">8,343</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbyO3Phi8H9f" style="text-align: right" title="Additions">1,669</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zljr3IGPH9Bb" style="text-align: right">1,669</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zNphzel2GQFf" style="text-align: right" title="Disposals"><span style="-sec-ix-hidden: xdx2ixbrl1107">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331_z3dls8PGuoFc" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zWiB7NCRXNQf" style="text-align: right" title="Foreign exchange">(233</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zDuZKWpxjs0a" style="text-align: right">(233</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zTw55nHaBPq1" style="text-align: right" title="Property and equipment, cost, ending  balance">9,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331_zQvZiKya0EWb" style="text-align: right">9,779</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH3QgMQhPXgc" style="text-align: right" title="Depreciation, beginning balance">2,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331_zz1FiovGWAug" style="text-align: right">2,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z30av2cacJD8" style="text-align: right" title="Charge in year">2,331</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331_zPZFrWjdvkai" style="text-align: right">2,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOD30thWAeMg" style="text-align: right" title="Foreign exchange">(63</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331_zbuWdloWm8Mf" style="text-align: right">(63</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zybgCEbakJy3" style="text-align: right" title="Depreciation, ending balance">4,554</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331_z8VmpTu2dWFl" style="text-align: right">4,554</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zdrMW5a86kQ4" style="text-align: right" title="Depreciation, net book value">5,225</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331_zu4nnXM8hH2c" style="text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">IT equipment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zadJS1DdOrp9" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance">1,257</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331_zfZoEFLWnQUe" style="width: 12%; text-align: right">1,257</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zb76uxQ6aUGj" style="text-align: right" title="Additions">6,944</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zz70dKhw6yj2" style="text-align: right">6,944</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Disposals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zPShkp99A2Pb" style="text-align: right" title="Disposals"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331_zDIV8GM7OVW4" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH9PfEb03lu9" style="text-align: right" title="Foreign exchange">142</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zchRCv1Ino7f" style="text-align: right">142</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z0Jhp0XXJQse" style="text-align: right" title="Property and equipment, cost, ending  balance">8,343</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331_zqh33mSfm1P6" style="text-align: right">8,343</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">At 1 April 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z36KRN7x29i3" style="text-align: right" title="Depreciation, beginning balance">622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331_zJrJ9WOy6cnl" style="text-align: right">622</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Charge in year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zDlS8NcyPw0f" style="text-align: right" title="Charge in year">1,593</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331_zQa0JJkJaGI7" style="text-align: right">1,593</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOEYqzsBcGsf" style="text-align: right" title="Foreign exchange">71</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331_zccQWkVKq5Fi" style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zoUwEAla2oTd" style="text-align: right" title="Depreciation, ending balance">2,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331_zW8ydcV96hcc" style="text-align: right">2,286</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify">Net Book Value as at 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zcQ3Q7oQZbtf" style="text-align: right" title="Depreciation, net book value">6,057</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331_zavxPSoOYXCf" style="text-align: right">6,057</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory', window );">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT</a></td>
<td class="text"><p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_zsV6hvqTV6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Group&#8217;s property, plant and equipment is located in the following operating segments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"><span id="xdx_8B2_ztfOLp0m8fl1" style="display: none">SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20220331_zyPuhkpTFt8l" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="text-align: right; margin-top: 0; margin-bottom: 0">Net
Book Value <br/>
March 31 2022</p></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"/><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UKMember_zWOGzuTdEE3d" style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; width: 78%; text-align: justify">UK</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">2,937</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UnitedStateMember_zpNO2hZ0Hnga" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">US</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,289</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--PropertyPlantAndEquipment_iI_znRT2UPILrn9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eifrs-full--PropertyPlantAndEquipment_iI_zey57vwsNt1h" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Property, plant and equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,225</td><td style="text-align: left">&#160;</td></tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Detailed Information About Property Plant And Equipment Located Operating Segment Explanatory [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosurePropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosurePropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677818944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER RECEIVABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOtherReceivablesAbstract', window );"><strong>Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory', window );">DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY</a></td>
<td class="text"><p id="xdx_89D_ecustom--DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_zN4blPd07Ix8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_zyB7ubYrYrAc" style="display: none">DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20220331_z0Zkq71YyAOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20210331_z3bCDh3xrjI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify">Group</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--OtherCurrentReceivables_iI_zjcT4x8f4481" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: justify">Other receivables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">19,130</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">4,499</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--CurrentValueAddedTaxReceivables_iI_zxMSIvnZ27L1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">VAT receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">82,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,799</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--Prepayments_iI_z3DDGg0OFeSb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepayments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">711,209</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,072</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentReceivables_iI_zFxjurqPKIth" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other receivables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">812,956</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,370</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680420304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE AND OTHER PAYABLES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory', window );">DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY</a></td>
<td class="text"><p id="xdx_895_ecustom--DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_z1TpnBoBBfO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span id="xdx_8B8_zti1IuYBWd81" style="display: none">DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20220331_zQuvyKgXtT07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210331_zzrruNLNF9jc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>Year ended March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$000</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Group</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pn3n3_maTAOCPzjQt_zyDD0Inv5u74" style="vertical-align: bottom; background-color: White">
    <td style="width: 68%; text-align: left">Trade payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">741,807</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">210,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--Accruals_iI_pn3n3_zXnGmfDLkrta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">457,773</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,093</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--BonusAccrual_iI_pn3n3_zLDhyIfvkj7f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Bonus accrual</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,391,069</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_iI_pn3n3_zz0fbhgv4Mxh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt; padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    and other payables</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,306,150</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,673,154</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed information about payables and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680674160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CAPITAL AND RESERVES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCapitalAndReservesAbstract', window );"><strong>Capital And Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES</a></td>
<td class="text"><p id="xdx_892_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zQF1wsIWSUaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is authorized to issue an unlimited number of nil par value shares of a single class.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B1_z99m5UbcSvk1" style="display: none">SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Share capital</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Issued ordinary shares of US$0.00 each</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify; padding-bottom: 2.5pt">At 31 March 2020 </td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zI2GyAWKAQ9" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance, shares">636,297,049</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--Equity_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7HFLauLesEh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance">112,079,984</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Shares issued - private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--NumberOfSharesIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2QGkJBMHGKh" style="text-align: right" title="Shares issued - private placement, shares">36,269,253</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--NumberOfSharesIssuedPrivatePlacementValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2yvFVeXfPlh" style="text-align: right" title="Shares issued - private placement">230,019</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Relative Fair value charge for warrants issued in conjunction with private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--FairValueWarrantsIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zPjL31xagFkk" style="text-align: right" title="Relative Fair value charge for warrants issued in conjunction with private placement">(138,305</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">CLNs issued in lieu of fundraising commission</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuedInLieuValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxLU4yt50RG9" style="text-align: right" title="CLNs issued in lieu of fundraising commission">(558,395</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--IncreaseDecreaseThroughExerciseOfOptionsShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbe89ng9kIXh" style="text-align: right" title="Options exercised, shares">250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgDwdCkblDO7" style="text-align: right" title="Options exercised">15,870</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zqz9DVicEiXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance, shares">672,816,302</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--Equity_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zWroLbqOyWH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance">111,629,173</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exercise of warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zTVXBueNSpCg" style="text-align: right" title="Exercise of warrants, shares">386,512,756</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsyCrb47nzv6" style="text-align: right" title="Exercise of warrants">3,470,940</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Conversion of CLN</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z6RoRHfYZqo8" style="text-align: right" title="Conversion of CLN, shares">315,086,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zU0cjhOvfMUd" style="text-align: right" title="Conversion of CLN"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,876,397</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt">At 31 March 2022</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2VDia2mobG" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares">1,374,415,468</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--Equity_iE_pp0p0_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zP07DWSELImc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance">123,976,510</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCapitalAndReservesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCapitalAndReservesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676322432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE OPTIONS AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract', window );"><strong>Share Options And Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory', window );">SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</a></td>
<td class="text"><p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_zDs6kwvTCsJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B7_zKJ43HynaNn2" style="display: none">SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: justify">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20210401__20220331_zBnXx2Z27wW" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding">60,750,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331_z9OF1qsv9bIc" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding">6.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20200401__20210331_zB2lpLNRsLP1" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding">19,500,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331_zbVxm1ZqgWn3" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding">5.58</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zgtZUPpn810d" style="text-align: right" title="Options, granted">28,150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zWqMuyLjpJqf" style="text-align: right" title="Weighted Average Exercise price, Granted">8.41</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zwbxypGNTnqj" style="text-align: right" title="Options, granted">42,250,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zUEKoj2yvXIf" style="text-align: right" title="Weighted Average Exercise price, Granted">7.31</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zVqtXqqkOXCj" style="text-align: right" title="Options, forfeited">(16,500,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zDgk82hgVKI6" style="text-align: right" title="Weighted Average Exercise price, Forfeited">5.91</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_z2pUMhy3BoYd" style="text-align: right" title="Options, forfeited">(750,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zAmdrblhBC06" style="text-align: right" title="Weighted Average Exercise price, Forfeited">6.21</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zzGlESPEcPCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"><span style="-sec-ix-hidden: xdx2ixbrl1315">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_z2O4EzirWGUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_zguc3dEIz887" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised">(250,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zX2p4vyKAlpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised">6.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20210401__20220331_zIVtBWlbq5Lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding">72,400,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEiE7je0Vt8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding">7.49</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20200401__20210331_zpaele3kquh1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding">60,750,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zarLvtiYX6Hk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding">6.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331_zaRay0yWGRqc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable">14,437,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEaNhtLb5dYi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable">7.36</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331_zhPyMEFPupUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable">9,250,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zoTKjZIqPjn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable">6.21</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted <br/> Average <br/> exercise price <br/> (cents)</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-size: 10pt">Outstanding at 1 April</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20190401__20200331_z9Nw9D1OGcEl" style="width: 18%; font-size: 10pt; text-align: right">5.58</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20190401__20200331_zwHisMhbOz6l" style="width: 18%; font-size: 10pt; text-align: right">23,000,000</td><td style="width: 1%; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt">Granted</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zqco43H2poE3" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zsoFPIjxFTzj" style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1341">-</span></td><td style="font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Forfeited</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_iN_di_uUSDPShares_c20190401__20200331_zdLpMC1qYEul" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20190401__20200331_zx1dEbBXrQhi" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(3,500,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercised</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zOFfw5ZCGXaj" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1344">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zNJeFfoReAR" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1345">-</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Outstanding at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zRj9AxlQi7Xd" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20190401__20200331_z9jNGPiKdZqk" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">19,500,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1.5pt">Exercisable at 31 March</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zWFnhmT6OLY2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">5.58</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20190401__20200331_zbTd2cBcpCsg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">4,875,000</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES</a></td>
<td class="text"><p id="xdx_89F_eifrs-full--DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_zRmrjLvVy22l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
options outstanding at the end of the year have the following expiry dates and exercise prices:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BE_zCYvDr4CdPn3" style="display: none">SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">Expiry Date</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise Price</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right">Share Options as at 31 March 2022<br/> (&#8216;000)</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: justify">6 July 2018</td><td style="width: 2%">&#160;</td>
    <td style="width: 24%; text-align: center"><span id="xdx_905_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_za11cw4SeNB1" title="Expiration date of outstanding">6 July 2025</span></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: center"><span id="xdx_900_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zcUiaNFlUpji" title="Exercise Price">4.5p</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zBIvgID3y0X9" style="width: 18%; text-align: right" title="Share Options, Outstanding">2,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">20 August 2020</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90A_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zMApVVo1CtZh" title="Expiration date of outstanding">19 August 2028</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zjvqLyWDj0v1" title="Exercise Price">15.5p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zuVt2gcyCy1i" style="text-align: right" title="Share Options, Outstanding">750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">6 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_zitoPfFeUB66" title="Expiration date of outstanding">5 January 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90B_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_ztF25WaesvWh" title="Exercise Price">5p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_z6jsGPECbxr3" style="text-align: right" title="Share Options, Outstanding">40,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">12 January 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_z1kF1A6642vi" title="Expiration date of outstanding">11 January 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_ziw5ZqV5aZka" title="Exercise Price">7.9p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_zMNA5wJYgMbc" style="text-align: right" title="Share Options, Outstanding">1,500</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">15 April 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zbem14aMRwtl" title="Expiration date of outstanding">15 April 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zVqV0CatIzwd" title="Exercise Price">7.88p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zzHQBf3ff3C6" style="text-align: right" title="Share Options, Outstanding">5,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">31 August 2021</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_903_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zllwEzpr4cok" title="Expiration date of outstanding">31 August 2031</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span id="xdx_90E_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_z2kZzFfu4gk5" title="Exercise Price">4.9p</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zDSOG95UtpO3" style="text-align: right" title="Share Options, Outstanding">14,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_90E_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zPyxLg3Cazqb" title="Expiration date of outstanding">30 January 2032</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center"><span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zm1SfpQal5if" title="Exercise Price">8.0p</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zHI2Chh2B1Mh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share Options, Outstanding">8,750</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331_zvIv48WGKnmc" style="text-align: right" title="Share Options, Outstanding">72,400</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory', window );">SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED</a></td>
<td class="text"><p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_zoVLXy2sWdXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zcceEqQFlaP5" style="display: none">SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Grant Date</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">15 April 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 August 2021</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 January 2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zsLcnQuMbr3a" style="width: 14%; text-align: right" title="Grant date share price">7.7</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zaLPnKmd1Uyl" style="width: 14%; text-align: right" title="Grant date share price">4.9</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zb8gctmMfPt5" style="width: 14%; text-align: right" title="Grant date share price">4.8</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zdjSH7JJC00d" style="text-align: right" title="Exercise share price">7.9</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zsbofvgW7Us7" style="text-align: right" title="Exercise share price">4.9</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zpLZauYinPC4" style="text-align: right" title="Exercise share price">8.0</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--VestingPeriodsDescription_c20210412__20210415_z2z9YUvsxFl" title="Vesting periods">25% each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210829__20210831_zs9Yfz0ZvKfj" title="Vesting periods">25% each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_ecustom--VestingPeriodsDescription_c20220129__20220131_zWJ3KSD4V5ib" title="Vesting periods">1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions</span> </span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210412__20210415_z998cjLwqlXd" style="text-align: right" title="Risk free rate">0.35</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210829__20210831_zVLgQdNLfxI7" style="text-align: right" title="Risk free rate">0.30</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20220129__20220131_zmBAxFFACaFb" style="text-align: right" title="Risk free rate">0.97</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210412__20210415_zQdmFb5a1mB9" style="text-align: right" title="Expected volatility">80.20</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210829__20210831_zpI3ijoVB1j1" style="text-align: right" title="Expected volatility">77.7</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20220129__20220131_zF2ahJF1mIZ2" style="text-align: right" title="Expected volatility">83.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_ecustom--OptionLifePeriod_dtY_c20210412__20210415_z6eKbMSRO7al" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210829__20210831_zqlQyvD4L5Cl" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_ecustom--OptionLifePeriod_dtY_c20220129__20220131_zRz3C4PGVnZd" title="Option life">5</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>20 August</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6 January</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">12 January <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20200815__20200820_zzxSqmk2EUa2" style="width: 14%; text-align: right" title="Grant date share price">15.5</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210104__20210106_zDt7RmgVTqMb" style="width: 14%; text-align: right" title="Grant date share price">0.8</td><td style="width: 1%; text-align: left">p</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210110__20210112_z5N1pvF4QuSg" style="width: 18%; text-align: right" title="Grant date share price">0.79</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200815__20200820_z8UYAWz5qj6g" style="text-align: right" title="Exercise share price">15.5</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210104__20210106_z63tdn6KGE0h" style="text-align: right" title="Exercise share price">0.5</td><td style="text-align: left">p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210110__20210112_zjqb5DMz09m2" style="text-align: right" title="Exercise share price">0.79</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Vesting periods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--VestingPeriodsDescription_c20200815__20200820_zeiP75ECJm84" title="Vesting periods">25%
each year</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_ecustom--VestingPeriodsDescription_c20210104__20210106_z1VFiJ4SXayc" title="Vesting periods">25% each year</span> </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_ecustom--VestingPeriodsDescription_c20210110__20210112_zGrWABE0LFZ3" title="Vesting periods">33% in 6 months and 67% in 1 year</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20200815__20200820_z1DYsNgaii7j" style="text-align: right" title="Risk free rate">0.15</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210104__20210106_zYitdBolAlh7" style="text-align: right" title="Risk free rate">-0.01</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhcYUU7Y3edg" title="Risk free rate">0.4</span>%,
<span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_znJdygR1QQI1" title="Risk free rate">0.6</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20200815__20200820_zo4CinQ71S92" style="text-align: right" title="Expected volatility">77.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210104__20210106_zgVo52FLcWec" style="text-align: right" title="Expected volatility">77.5</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zv1xdkcnz4f5" title="Expected volatility">66.7</span>%,
<span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zIz42KB2JfR8" title="Expected volatility">83.7</span></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected option life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecustom--OptionLifePeriod_dtY_c20200815__20200820_zWWcqGk15Hz4" title="Option life">5</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210104__20210106_z8zjROfjGeSj" title="Option life">5</span>
years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--OptionLifePeriod_dtM_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zKNeCysJyrxj" title="Option life">6</span> months to <span id="xdx_90B_ecustom--OptionLifePeriod_dtY_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zp3z6D4jbUE2" title="Option life">1</span> year</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</a></td>
<td class="text"><p id="xdx_89C_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_z1LLvaPTGXg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B6_z90HQYpTPNWg" style="display: none"><span>SCHEDULE OF WARRANTS
OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Warrants</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted Average exercise price (cents)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Outstanding at 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcd7KVh6AHU" style="width: 10%; text-align: right" title="Warrants outstanding, beginning balance">185,022,726</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z73YajK94nLj" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding beginning balance">2.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zQm9Dv1h3CFb" style="width: 10%; text-align: right">147,188,766</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zF1t7WDV96Lh" style="width: 10%; text-align: right">2.1</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zNm8htQqtqq8" style="text-align: right" title="Warrants granted">241,781,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zuP7UXhDHn9b" style="text-align: right" title="Weighted average exercise price, granted">0.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1b5WkEd1382" style="text-align: right">37,833,960</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJBsp9LjITQk" style="text-align: right">1.2</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1En4jVLMUil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercised">(390,145,396</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTyz7CgI7q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">0.7</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbfxILNOzhl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1ZvTvKfiZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1579">-</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at 31 March</span></p></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEhXslULHNR7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance">36,659,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziAiKkBwPyCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance">6.11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zofZ5ZpVf4rc" style="border-bottom: Black 2.5pt double; text-align: right">185,022,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zawgODp3KTmf" style="border-bottom: Black 2.5pt double; text-align: right">2.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercisable at 31 March</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zXxAO9XzX8b4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable">1,659,090</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z0BdExgerH6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable">10.30</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zUes8Z2X6lyb" style="border-bottom: Black 2.5pt double; text-align: right">149,568,181</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzEs9LlpqhB6" style="border-bottom: Black 2.5pt double; text-align: right">1.1</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory', window );">SCHEDULE OF INPUTS FOR WARRANTS GRANTED</a></td>
<td class="text"><p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_zTfcGa6qE8Ek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zfr88tv0EsF9" style="display: none">SCHEDULE OF INPUTS FOR
WARRANTS GRANTED</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">29 May 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Grant date share price</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEsfwntYcTod" style="width: 16%; text-align: right" title="Grant date share price">1.75</td><td style="width: 1%; text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Exercise share price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbbL5oIcUDy7" style="text-align: right" title="Exercise share price">0.4</td><td style="text-align: left">p</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk free rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTxlwpqoxfj" style="text-align: right" title="Risk free rate">0.25</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zsFN4GAfFsq3" style="text-align: right" title="Expected volatility">79.6</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected life</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_ecustom--ExpectedLifeOfWarrants_dtY_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zq5wRgYwpVP5" title="Expected life">3</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory', window );">SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES</a></td>
<td class="text"><p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_zurTi4FfrK1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zvhWhCbxZyNa" style="display: none">SCHEDULE OF FAIR VALUE
OF WARRANTS IN SERVICES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 2020</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">May 2020</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%">Grant date share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_984_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTpJqRf9hMEe" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right">8.3p</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zvkI8JK1i6ej" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right">2.8p</td><td style="width: 2%; font-size: 10pt">&#160;</td>
    <td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zHxclxQs4x52" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise share price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zPtfrlpk9lX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">14p</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmRiSa4pNCAk" style="font: 10pt Times New Roman, Times, Serif; text-align: right">2.8p</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zrlDZCTpjmJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.5p</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting periods</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_ecustom--WarrantsVestingPeriod_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zoCvgeiTKvyk" title="Vesting periods">Fully vested</span></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_ecustom--WarrantsVestingPeriod_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zdPnB7Qb9Id">50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)</span></td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_ecustom--WarrantsVestingPeriod_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zelhksSHOXI9">Fully
    vested </span></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk free rate </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zqUxxQCSCECi" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.68%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zOYKlyvnL8X1" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.95%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zLShQVeV3NTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.22%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility </td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1F1LpH6qFG" style="font: 10pt Times New Roman, Times, Serif; text-align: right">88.1%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td id="xdx_98C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zV4GtEvwhMr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right">79.6%</td><td style="font-size: 10pt">&#160;</td>
    <td id="xdx_983_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcatnTJgkge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right">82.4%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ExpectedLifeOfWarrants_dtY_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziHcC6IoaUa7">2</span> years</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_ecustom--ExpectedLifeOfWarrants_dtY_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zyBlZXykt1Ch">3</span> years</td><td style="font-size: 10pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_ecustom--ExpectedLifeOfWarrants_dtY_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzKYE5UDPTee">5</span> years</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about fair value of warrants in services explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about inputs for warrants granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about options outstanding and weighted average exercise price explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about share-based payment award model inputs options granted explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureShareOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680074400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract', window );"><strong>Convertible Instruments Classified As Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory', window );">SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN</a></td>
<td class="text"><p id="xdx_894_ecustom--DisclosureOfIssuanceOfConvertibleNotesExplanatory_z9WXST82QuX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zGA5tD6eUa82" style="display: none">SCHEDULE OF ISSUANCE OF
CONVERTIBLE LOAN</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Date</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Terms</td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">$</p></td><td style="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center"/><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 26%; text-align: left">29 May 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 54%; text-align: left">&#9679; <span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zlC1BgpyZjid" title="Interest rate">20</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_905_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zMFSsu4bwI5b" title="Conversion price">0.4</span>p <br/>&#9679; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_907_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjZqVnhHKUll" title="Warrant exercise share">0.4</span>p with a maximum life of <span id="xdx_90B_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zPTxfShu5g6c" title="Debt term">5 years</span> from the
    date of the conversion of the loan note</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_907_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zu9wOhWF6Ow" title="Issue of convertible instruments">541,239</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Fees relating to equity fundraise 29 May 2020 issued as CLN</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_90A_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zcGIUh42aq2e" title="Interest rate">20</span>%
    coupon per annum <br/>&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_z0BRA6hDBFJh" title="Conversion price per share">0.4</span>p <br/>&#9679;
    Upon conversion the shares will be issued with a warrant attached at an exercise price of <span id="xdx_908_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zpLBCFncD9k9" title="Warrant Exercise per share">0.4</span>p
    with a maximum life of <span title="Debt term"/><span id="xdx_907_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjl3ZONpf4I6" title="Debt term">5 years</span> from the date of the conversion of the loan note</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zwz1bGTftRQ9" title="Issue of convertible instruments">32,474</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">27 July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zDhybC3xgKDe" title="Interest rate">2.15</span>% coupon per annum <br/>Conversion price of <span id="xdx_908_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zg5p2KPUZNU2" title="Conversion price per share">8.5</span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zX2Ergjjb9ll" title="Issue of convertible instruments">4,506,446</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">17 August 2020</td><td style="font-weight: bold">&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zvbBhLid24w4" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_900_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zUQPz20QAzp9" title="Conversion price per share">8.5</span>p <br/></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zNMjjZgsDsi4" title="Issue of convertible instruments">1,882,641</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3
                                            September 2020</span></p></td><td>&#160;</td>
    <td style="text-align: left">&#9679; <span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zpS8ngSKuhwj" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_90D_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_z551mFfXGer5" title="Conversion price per share">8.5</span>p</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zBVNjOa54Sba" title="Issue of convertible instruments">663,055</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; vertical-align: top; text-align: left">Fees relating to all other equity fundraise issued as CLN</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#9679; <span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zUD9vOcyMPYk" title="Interest rate">2.15</span>% coupon per annum <br/>&#9679; Conversion price of <span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_znrjvJTeSUV2" title="Conversion price per share">8.5</span>p</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zCyWyWRMn8wl" title="Issue of convertible instruments">525,922</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331_z11jltf6xKta" title="Issue of convertible instruments">8,151,777</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Issuance Of Convertible Notes Explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676419104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureFinancialInstrumentsAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory', window );">SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS</a></td>
<td class="text"><p id="xdx_895_ecustom--DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_zoqKyLA0m1F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below summarizes the maturity profile of the Group&#8217;s financial liabilities based on contractual undiscounted
payments:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BF_zmr1ZUhD4BX9" style="display: none">SUMMARY OF FINANCIAL
LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20220331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_z4B59WqIDKKi" style="font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20220331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zDAwKHUJfTwc" style="font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_494_20220331_zTfHCzYKtARb" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzENJ_zfcbbF2ZWT3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">649,624</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">92,186</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">741,810</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzENJ_zyruebiDfWv6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1691">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">47,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzENJ_zEFc68Ej9Lmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">696,665</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">92,186</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">788,851</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_zNEXJ5qt8gM1" style="font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20210331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zAbLSq6XX4W5" style="font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210331_z2XoYnqigSy7" style="font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">Group</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Less than 3<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">3 to 12<br/> months</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzjzM_zQwrY98YGIzj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Trade and other payables</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">110,179</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">100,813</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">210,992</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzjzM_zmDdJcjuV88g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party payables</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1702">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1703">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzjzM_zJOtu1pTyPN6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">110,179</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">100,813</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">210,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information of maturities of financial instruments explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680378640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract', window );"><strong>Basic And Diluted Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS</a></td>
<td class="text"><p id="xdx_896_eifrs-full--EarningsPerShareExplanatory_zSm0U7stgkp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zwF8RUz40iXi" style="display: none">SUMMARY
OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20210401__20220331_zNqmuav90nh5" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company">(6,268,197</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20200401__20210331_pp0p0" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company">(3,353,507</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--WeightedAverageShares_c20210401__20220331_z6IzBFm1oPH" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">979,212,888</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--WeightedAverageShares_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">672,767,629</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--BasicAndDilutedEarningsLossPerShare_c20210401__20220331_z1WozRvrawSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--BasicAndDilutedEarningsLossPerShare_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Year ended<br/> March 31,</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">(Loss) attributable to equity holders of the company ($)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20190401__20200331_z4l19vmKMoP8" style="width: 16%; text-align: right" title="(Loss) attributable to equity holders of the company">(1,544,059</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Weighted average number of ordinary shares in issue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--WeightedAverageShares_c20190401__20200331_zEvPIGB4F4oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue">595,474,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Basic and dilutive loss per share (cents per share)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--BasicAndDilutedEarningsLossPerShare_c20190401__20200331_z9B8BNlE3wnc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureBasicAndDilutedLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874681027344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY</a></td>
<td class="text"><p id="xdx_89C_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_zZKJgd98QZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zVZpiUE9kMs8" style="display: none">SCHEDULE
OF RIGHT OF USE ASSETS AND LEASE LIABILITY</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">Right-of-use assets</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Property <br/>$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eifrs-full--RightofuseAssets_iS_c20210401__20220331_zzxDfJZQtynj" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year">98,579</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Derecognition of right of use asset</p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--DisposalsRightOfUseAssets_c20210401__20220331_zD1HO3XrvGSh" style="text-align: right" title="Derecognition of right of use asset">(97,553</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_iN_di_c20210401__20220331_zzQyo0Jwr6ak" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impact of Foreign exchange">(1,026</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eifrs-full--RightofuseAssets_iE_c20210401__20220331_zvgcnVyaIU1" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"><span style="-sec-ix-hidden: xdx2ixbrl1768">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">$</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: left">At 1 April 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--RightofuseAssets_iS_c20200401__20210331_zUznAy0hxQgc" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year">30,099</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Depreciation of early terminated lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DepreciationOfEarlyTerminatedLease_c20200401__20210331_zMR2gPGEmIF3" style="text-align: right" title="Depreciation of early terminated lease">(4,060</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Early Termination write off</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--DisposalsRightOfUseAssets_iN_di_c20200401__20210331_zmJPyy0U421f" style="text-align: right" title="Early Termination write off">(27,069</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of Foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ImpactOfForeignExchange_c20200401__20210331_zA078dNHUbzc" style="text-align: right" title="Impact of Foreign exchange">1,030</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eifrs-full--AdditionsToRightofuseAssets_c20200401__20210331_zMQcUq9qXCd2" style="text-align: right" title="Additions">104,377</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of new lease</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--DepreciationOfNewLease_c20200401__20210331_zjlwxfOcTG7f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation of new lease">(5,799</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">At 31 March 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eifrs-full--RightofuseAssets_iE_c20200401__20210331_zQH9Uk8SKbP9" style="text-align: right" title="Right-of-use assets, balance as at the end of the year">98,579</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">Lease Liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zxT5lM2DB388" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20200401__20210331_zAc7Rrn5SjU6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160; &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$</b> &#160;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eifrs-full--LeaseLiabilities_iS_zZmBklQvjOTb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; width: 60%">At 1 April</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">98,760</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">31,689</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eifrs-full--LeaseLiabilities_iS_zTo2iwDz0etj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease Liabilities, balance as at the beginning of the year</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98,760</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31,689</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_ecustom--LeaseLiabilitiesInterestExpense_zPIrqOS9pajd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">740</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--LeasePayments_zNa5PCDQm2n8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1793">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,542</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--ImpactOfForeignExchangeLeaseLiabilities_zKImhhjwP1v8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Impact of foreign exchange</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,207</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1797">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DerecognitionOfLeaseLiability_zsLlWUqHIva1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Derecognition of lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(97,553</p></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1800">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DisposalsLeaseLiabilities_iN_di_zA5gJ4qrPJ5l" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Early Termination write off</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1802">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"/><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(27,887</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AdditionsToLeaseLiabilities_zTBcNDgE6xAk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Additions</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1805">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,378</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--LeaseLiabilitiesInterestExpenses_zhiVgAqdY6Qc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1808">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">382</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--LeasePayment_zh6mgGmMfmv3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1811">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eifrs-full--LeaseLiabilities_iE_zupJ8UUubTB" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">At
    30 April</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1814">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eifrs-full--LeaseLiabilities_iE_zeKKkfpgmXl" style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/><span style="font-size: 10pt">Lease Liabilities, balance as at the beginning of the year</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1817">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">98,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory', window );">SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION</a></td>
<td class="text"><p id="xdx_897_ecustom--DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_zB5CKFgNe3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease
liabilities are presented in the statement of financial position as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zbmjPqrG3F3c" style="display: none">SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20220331_zmKwmnIBhzo8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20210331_zlyPh0jhynRh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">31 March 2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$ &#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>$
&#160;</b></span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zv7XaDQkJUWf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%">Current </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1822">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34,148</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--NoncurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zl2kQG5N0vVc" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Non-current </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64,612</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td>
    <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eifrs-full--LeaseLiabilities_iTI_mtLLzex8_ztlPC1rZi9Rk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-size: 11pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">98,760</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory', window );">SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_z9RZTlXFUeD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B4_zcQfZaCgGKG6" style="display: none">SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: justify">Operating leases which expire:</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 68%; text-align: justify">Within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_982_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zDu9wXXbjjK9" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year">18,713</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_z6tAvFmpciOf" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"><span style="-sec-ix-hidden: xdx2ixbrl1835">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331_zzpMOaiax946" style="border-bottom: Black 2.5pt double; text-align: right" title="Within one year">18,713</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331_ziHlYPfIZQk" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information abou lease liabilities by classification explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about contractual maturities of lease liabilities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874678901712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Auditor&#8217;s Remuneration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory', window );">SCHEDULE OF COMPANY AUDITORS FEES</a></td>
<td class="text"><p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_zD2gkHE1hTxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the period, the group obtained the following services from the company&#8217;s auditors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zQMzkE6Qo47b">SCHEDULE
OF COMPANY AUDITORS FEES</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20210401__20220331_zbf5K3wx0Av3" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" id="xdx_496_20200401__20210331_zOUzJkwP8mp" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: center">&#160;</td></tr>
  <tr id="xdx_406_eifrs-full--AuditorsRemunerationForAuditServices_zNfxNk36Cayc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: left">Fees payable to the company&#8217;s auditors for the audit of the parent company and consolidated financial statements</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">200,773</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,874</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Fees payable to the company&#8217;s auditors for other services:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eifrs-full--AuditorsRemunerationForOtherServices_zn1lZdfN4mR3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Audit-related assurance services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">148,892</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">72,637</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zgB2fVZqwwth" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif">Total auditor&#8217;s remuneration</span></td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">349,665</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">131,511</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about company auditors fees explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680702672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureCashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory', window );">SCHEDULE OF CASH AND CASH EQUIVALENT</a></td>
<td class="text"><p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_zNxGs8zLiU9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<span id="xdx_8B1_zYWdwGwZDKU7" style="display: none">SCHEDULE OF CASH AND CASH EQUIVALENT</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160; </b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2022</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">31 March 2021</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$ </span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cash at bank and in hand:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 68%; text-align: justify">GBP</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand">2,400,817</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand">4,344,740</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: justify">USD</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">299,907</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">2,544,589</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"/><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eifrs-full--CashOnHand_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">2,700,724</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eifrs-full--CashOnHand_c20210331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand">6,889,329</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureCashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureCashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676333120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_FurnitureAndFixtureMember', window );">Furniture and fixtures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_FurnitureAndFixtureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_FurnitureAndFixtureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683464624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (Details Narrative)<br> &#163; in Thousands</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,426,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,003,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 76,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 64,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,431,045<span></span>
</td>
<td class="nump">&#163; 4,000<span></span>
</td>
<td class="nump">3,353,507<span></span>
</td>
<td class="nump">$ 1,544,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,468,065<span></span>
</td>
<td class="nump">&#163; 4,000<span></span>
</td>
<td class="nump">1,600,198<span></span>
</td>
<td class="nump">1,202,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,889,329<span></span>
</td>
<td class="nump">$ 235,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 627,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,353,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,707,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember', window );">Non-adjusting event [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_CashBurnRate', window );">Rate of cash burn/spend</a></td>
<td class="nump">&#163; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_CashBurnRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of cash burn/spend.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_CashBurnRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683572848">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationDirectorFees', window );">Director fees including bonus (excluding Chairman&#8217;s bonus)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 707,385<span></span>
</td>
<td class="nump">$ 278,224<span></span>
</td>
<td class="nump">$ 122,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ChairmansBonus', window );">Chairman&#8217;s bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,160,347<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Auditor&#8217;s Remuneration (refer to Note 20)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">349,665<span></span>
</td>
<td class="nump">131,511<span></span>
</td>
<td class="nump">53,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and Professional fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,143,300<span></span>
</td>
<td class="nump">343,422<span></span>
</td>
<td class="nump">195,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GainlossOnDisposalOfLeases', window );">(Gain)/Loss on disposal of leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(179)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ForeignExchangeLossesGains', window );">FX Gains and losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13,577)<span></span>
</td>
<td class="nump">200,061<span></span>
</td>
<td class="nump">200,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,423<span></span>
</td>
<td class="nump">$ 1,512<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#8217;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#8217;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ChairmansBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Chairman bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ChairmansBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange loss gain.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GainlossOnDisposalOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on disposal of leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GainlossOnDisposalOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_KeyManagementPersonnelCompensationDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Director fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_KeyManagementPersonnelCompensationDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676372608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>Integer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalaries', window );">Directors&#8217; salaries</a></td>
<td class="nump">$ 707,385<span></span>
</td>
<td class="nump">$ 1,438,571<span></span>
</td>
<td class="nump">$ 122,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">323,186<span></span>
</td>
<td class="nump">121,702<span></span>
</td>
<td class="nump">229,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">84,449<span></span>
</td>
<td class="nump">9,543<span></span>
</td>
<td class="nump">68,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherShorttermEmployeeBenefits', window );">Recruitment Costs</a></td>
<td class="nump">14,259<span></span>
</td>
<td class="nump">12,922<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">&#160;Total employee benefits expense</a></td>
<td class="nump">$ 1,129,279<span></span>
</td>
<td class="nump">$ 1,582,739<span></span>
</td>
<td class="nump">$ 420,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Total number of employees | Integer</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_ResearchAndDevelopmentMember', window );">Research and development [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Total number of employees | Integer</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_CorporateAndAdministrationMember', window );">Corporate and administration [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfEmployees', window );">Total number of employees | Integer</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DirectorsSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors salaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DirectorsSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of personnel employed by the entity at a date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_CorporateAndAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=OKYO_CorporateAndAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676306096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEES INCLUDING OFFICERS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract', window );"><strong>Employees Including Officers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans', window );">Pension contribution</a></td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="nump">$ 2,904<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureEmployeesIncludingOfficersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureEmployeesIncludingOfficersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676800640">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REMUNERATION OF DIRECTORS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">1,201<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">350<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_GCerroneMember', window );">G Cerrone [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">164<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_GJacobMember', window );">G Jacob [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">350<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,579<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_WSimonMember', window );">W Simon [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_KShailubhaiMember', window );">K Shailubhai [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">18<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_JBrancaccioMember', window );">J Brancaccio [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">42<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">20<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_GMacraeMember', window );">G Macrae [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_BDenoyerMember', window );">B Denoyer [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_LZambelettiMember', window );">L Z ambeletti [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DirectorsRemunerationExpense', window );">Directors' fees</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsBonus', window );">Bonus</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DirectorsSalary', window );">[custom:DirectorsSalary]</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments', window );">Share based payment expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Gabriele
    Cerrone&#8217;s bonus awarded for $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded">1,160</span>k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">K
    Shailubhai resigned as Director on 17 June 2021</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">John
    Brancaccio was appointed as Director on 10 June 2020</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Bernard
Denoyer was appointed as Director on 24 November 2021</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DirectorsBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DirectorsBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DirectorsSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Directors salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DirectorsSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_KeyManagementPersonnelCompensationSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_KeyManagementPersonnelCompensationSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DirectorsRemunerationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of remuneration paid or payable to the entity's directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DirectorsRemunerationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_GCerroneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_GCerroneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_GJacobMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_GJacobMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_WSimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_WSimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_KShailubhaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_KShailubhaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_JBrancaccioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_JBrancaccioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_GMacraeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_GMacraeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_BDenoyerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_BDenoyerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_LZambelettiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_LZambelettiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677665520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=OKYO_GCerroneMember', window );">G Cerrone [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_BonusAwarded', window );">Bonus awarded</a></td>
<td class="nump">$ 1,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_BonusAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus awarded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_BonusAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_GCerroneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_GCerroneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683473728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options</a></td>
<td class="nump">28,150,000<span></span>
</td>
<td class="nump">42,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember', window );">Directors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options</a></td>
<td class="nump">4,575,000<span></span>
</td>
<td class="nump">40,450,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember', window );">Directors [member] | J Brancaccio [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember', window );">Directors [member] | G Jacob [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options</a></td>
<td class="nump">3,250,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember', window );">Directors [member] | B Denoyer [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=OKYO_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_JBrancaccioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_JBrancaccioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_GJacobMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_GJacobMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=OKYO_BDenoyerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=OKYO_BDenoyerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683363808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details) - Key management personnel of entity or parent [member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">$ 1,026<span></span>
</td>
<td class="nump">$ 1,455<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share based payments</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">515<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total</a></td>
<td class="nump">$ 2,841<span></span>
</td>
<td class="nump">$ 1,970<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676599152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF TAX CREDIT PERIOD (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTaxationAbstract', window );"><strong>Taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current year tax (credit)</a></td>
<td class="num">$ (509,282)<span></span>
</td>
<td class="num">$ (24,952)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod', window );">Adjustments in respect of prior periods</a></td>
<td class="num">(277,239)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(76,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences', window );">Origination and reversal of timing differences</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total tax (credit) for the period</a></td>
<td class="num">(786,521)<span></span>
</td>
<td class="num">(24,994)<span></span>
</td>
<td class="num">(76,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LossBeforeTaxation', window );">Loss before taxation</a></td>
<td class="num">(6,045,372)<span></span>
</td>
<td class="num">(3,378,501)<span></span>
</td>
<td class="num">(1,620,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LossChargedAtStandardRateOfCorporationTax', window );">Loss charged at standard rate of corporation tax 19%</a></td>
<td class="num">(1,181,337)<span></span>
</td>
<td class="num">(641,915)<span></span>
</td>
<td class="num">(307,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense', window );">Tax losses arising in the year not recognized</a></td>
<td class="nump">524,870<span></span>
</td>
<td class="nump">660,594<span></span>
</td>
<td class="nump">340,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_TaxLossesSurrenderedForResearchAndDevelopment', window );">Tax losses surrendered for Research and Development</a></td>
<td class="nump">667,335<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss', window );">Expenses not deductible for taxation</a></td>
<td class="nump">370,306<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation', window );">Tax increase from effect of capital allowances and depreciation</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(334)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ResearchAndDevelopmentTaxClaim', window );">Research and Development tax claim</a></td>
<td class="num">(509,282)<span></span>
</td>
<td class="num">(43,432)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ResearchAndDevelopmentEnhancedExpenditure', window );">Research and Development enhanced expenditure</a></td>
<td class="num">(377,187)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods', window );">Research and Development tax credits claimed in respect of previous periods</a></td>
<td class="num">(277,240)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="num">(76,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets', window );">Consolidation adjustment in relation to foreign exchange movements</a></td>
<td class="num">(3,983)<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="num">(32,504)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff', window );">Loans written off</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LossBeforeTaxation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss before taxation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LossBeforeTaxation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LossChargedAtStandardRateOfCorporationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss charged at standard rate of corporation tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LossChargedAtStandardRateOfCorporationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ResearchAndDevelopmentEnhancedExpenditure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development enhanced expenditure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ResearchAndDevelopmentEnhancedExpenditure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ResearchAndDevelopmentTaxClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development tax claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ResearchAndDevelopmentTaxClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax increase from effect of capital allowances and depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_TaxLossesSurrenderedForResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax losses surrendered for Research and Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_TaxLossesSurrenderedForResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments of tax expense (income) recognised in the period for current tax of prior periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gain on the recovery of loans and advances previously written off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph IG20B<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG20B&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 80<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_80_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680860544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTaxationAbstract', window );"><strong>Taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Corporation tax rate</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874681027344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTaxationAbstract', window );"><strong>Taxation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfTaxLosses', window );">Tax effect of tax losses</a></td>
<td class="nump">$ 15,870,525<span></span>
</td>
<td class="nump">$ 9,411,521<span></span>
</td>
<td class="nump">$ 4,421,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTaxationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTaxationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfTaxLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfTaxLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680633904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FINANCE COST (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract', window );"><strong>Finance Income And Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 48,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,122)<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (1,123)<span></span>
</td>
<td class="num">$ (1,158)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureFinanceIncomeAndCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureFinanceIncomeAndCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683412512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentCost', window );">Property and equipment, cost, beginning balance</a></td>
<td class="nump">$ 8,343<span></span>
</td>
<td class="nump">$ 1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">6,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentCost', window );">Property and equipment, cost, ending balance</a></td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentDepreciation', window );">Depreciation, beginning balance</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_EffectOfChargeInYearDepreciation', window );">Charge in year</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_EffectOfForeignExchangeDepreciation', window );">Foreign exchange</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentDepreciation', window );">Depreciation, ending balance</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DepreciationNetValue', window );">Depreciation, net book value</a></td>
<td class="nump">5,225<span></span>
</td>
<td class="nump">6,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_ITEquipmentMember', window );">IT equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentCost', window );">Property and equipment, cost, beginning balance</a></td>
<td class="nump">8,343<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">1,669<span></span>
</td>
<td class="nump">6,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment', window );">Foreign exchange</a></td>
<td class="num">(233)<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentCost', window );">Property and equipment, cost, ending balance</a></td>
<td class="nump">9,779<span></span>
</td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentDepreciation', window );">Depreciation, beginning balance</a></td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_EffectOfChargeInYearDepreciation', window );">Charge in year</a></td>
<td class="nump">2,331<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_EffectOfForeignExchangeDepreciation', window );">Foreign exchange</a></td>
<td class="num">(63)<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PropertyPlantAndEquipmentDepreciation', window );">Depreciation, ending balance</a></td>
<td class="nump">4,554<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DepreciationNetValue', window );">Depreciation, net book value</a></td>
<td class="nump">$ 5,225<span></span>
</td>
<td class="nump">$ 6,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DepreciationNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation net value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DepreciationNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_EffectOfChargeInYearDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of charge in year depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_EffectOfChargeInYearDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_EffectOfForeignExchangeDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect of foreign exchange depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_EffectOfForeignExchangeDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_PropertyPlantAndEquipmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment, cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_PropertyPlantAndEquipmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_PropertyPlantAndEquipmentDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_PropertyPlantAndEquipmentDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_ITEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=OKYO_ITEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874678906320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateWriteDownOrReserveLineItems', window );"><strong>SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 5,225<span></span>
</td>
<td class="nump">$ 6,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UKMember', window );">UK [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateWriteDownOrReserveLineItems', window );"><strong>SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">2,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UnitedStateMember', window );">US [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateWriteDownOrReserveLineItems', window );"><strong>SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateWriteDownOrReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateWriteDownOrReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UnitedStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=OKYO_UnitedStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677627616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOtherReceivablesAbstract', window );"><strong>Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">$ 19,130<span></span>
</td>
<td class="nump">$ 4,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">VAT receivable</a></td>
<td class="nump">82,617<span></span>
</td>
<td class="nump">17,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Prepayments', window );">Prepayments</a></td>
<td class="nump">711,209<span></span>
</td>
<td class="nump">21,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">$ 812,956<span></span>
</td>
<td class="nump">$ 43,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Prepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables that represent amounts paid for goods and services before they have been delivered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Prepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677875536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER RECEIVABLES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureOtherReceivablesAbstract', window );"><strong>Other Receivables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_PrepaymentsReceivables', window );">Prepayments receivables</a></td>
<td class="nump">$ 639,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_PrepaymentsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_PrepaymentsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677543888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureTradeAndOtherPayablesAbstract', window );"><strong>Trade And Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payable</a></td>
<td class="nump">$ 741,807<span></span>
</td>
<td class="nump">$ 210,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Accruals', window );">Accruals</a></td>
<td class="nump">457,773<span></span>
</td>
<td class="nump">71,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_BonusAccrual', window );">Bonus accrual</a></td>
<td class="nump">106,570<span></span>
</td>
<td class="nump">1,391,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent', window );">Trade and other payables</a></td>
<td class="nump">$ 1,306,150<span></span>
</td>
<td class="nump">$ 1,673,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_BonusAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus accrual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_BonusAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureTradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureTradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trade and current payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Accruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Accruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683656080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance</a></td>
<td class="nump">$ 5,319,408<span></span>
</td>
<td class="num">$ (140,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="nump">1,460,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance</a></td>
<td class="nump">$ 2,947,402<span></span>
</td>
<td class="nump">$ 5,319,408<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Issued capital [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares</a></td>
<td class="nump">672,816,302<span></span>
</td>
<td class="nump">636,297,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance</a></td>
<td class="nump">$ 111,629,173<span></span>
</td>
<td class="nump">$ 112,079,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_NumberOfSharesIssuedPrivatePlacement', window );">Shares issued - private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,269,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_NumberOfSharesIssuedPrivatePlacementValue', window );">Shares issued - private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_FairValueWarrantsIssuedPrivatePlacement', window );">Relative Fair value charge for warrants issued in conjunction with private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IssuedInLieuValue', window );">CLNs issued in lieu of fundraising commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (558,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares', window );">Options exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares', window );">Exercise of warrants, shares</a></td>
<td class="nump">386,512,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="nump">$ 3,470,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares', window );">Conversion of CLN, shares</a></td>
<td class="nump">315,086,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Conversion of CLN</a></td>
<td class="nump">$ 8,876,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance, shares</a></td>
<td class="nump">1,374,415,468<span></span>
</td>
<td class="nump">672,816,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance</a></td>
<td class="nump">$ 123,976,510<span></span>
</td>
<td class="nump">$ 111,629,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_FairValueWarrantsIssuedPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value warrants issued private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_FairValueWarrantsIssuedPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through conversion of convertible instruments shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of options shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease through exercise of warrants equity shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IssuedInLieuValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issued in lieu value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IssuedInLieuValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_NumberOfSharesIssuedPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued private placement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_NumberOfSharesIssuedPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_NumberOfSharesIssuedPrivatePlacementValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued private placement value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_NumberOfSharesIssuedPrivatePlacementValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677030976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CAPITAL AND RESERVES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="nump">72,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DividendPayables', window );">Payment of dividend | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesMember', window );">Loan notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,176,000<span></span>
</td>
<td class="nump">76,605,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesOneMember', window );">Loan notes one [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,304,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,543,360<span></span>
</td>
<td class="nump">36,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveOneMember', window );">Warrant reserve one [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveTwoMember', window );">Warrant reserve two [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,605,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ordinary shares were issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">36,269,253<span></span>
</td>
<td class="nump">75,825,130<span></span>
</td>
<td class="nump">36,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Ordinary shares were issued, per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.045<span></span>
</td>
<td class="nump">$ 0.005<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DividendPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of dividends that the company has declared but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DividendPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=OKYO_LoanNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=OKYO_WarrantReserveTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874678950832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract', window );"><strong>Share Options And Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Beginning balance, Options outstanding | shares</a></td>
<td class="nump">60,750,000<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning balance, Weighted Average Exercise price, outstanding | $ / shares</a></td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Options, granted | shares</a></td>
<td class="nump">28,150,000<span></span>
</td>
<td class="nump">42,250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise price, Granted | $ / shares</a></td>
<td class="nump">$ 8.41<span></span>
</td>
<td class="nump">$ 7.31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options, forfeited | shares</a></td>
<td class="num">(16,500,000)<span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
<td class="num">(3,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise price, Forfeited | $ / shares</a></td>
<td class="nump">$ 5.91<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Options, exercised | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise price, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Ending balance, Options outstanding | shares</a></td>
<td class="nump">72,400,000<span></span>
</td>
<td class="nump">60,750,000<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance, Weighted Average Exercise price, outstanding | $ / shares</a></td>
<td class="nump">$ 7.49<span></span>
</td>
<td class="nump">$ 6.90<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options, Exercisable | shares</a></td>
<td class="nump">14,437,500<span></span>
</td>
<td class="nump">9,250,000<span></span>
</td>
<td class="nump">4,875,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Ending balance, Weighted Average Exercise price, Exercisable | $ / shares</a></td>
<td class="nump">$ 7.36<span></span>
</td>
<td class="nump">$ 6.21<span></span>
</td>
<td class="nump">$ 5.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price of share options forfeited in share-based payment arrangement | $ / shares</a></td>
<td class="num">$ (5.91)<span></span>
</td>
<td class="num">$ (6.21)<span></span>
</td>
<td class="num">$ (5.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised in share-based payment arrangement | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureShareOptionsAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureShareOptionsAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874675539216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 15, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 12, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 06, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 20, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,400,000<span></span>
</td>
<td class="nump">60,750,000<span></span>
</td>
<td class="nump">19,500,000<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_SixJulyTwoThousandEighteenMember', window );">6 July 2018 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  06,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_TwentyAugustTwoThousandTwentyMember', window );">20 August 2020 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 19,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_SixJanuaryTwoThousandTwentyOneMember', window );">6 January 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  05,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_TwelveJanuaryTwoThousandTwentyOneMember', window );">12 January 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 11,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_FifteenAprilTwoThousandTwentyOneMember', window );">15 April 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 15,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember', window );">31 August 2021 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember', window );">31 January 2022 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpirationDateOfOutstanding', window );">Expiration date of outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 30,  2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Share Options, Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ExpirationDateOfOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ExpirationDateOfOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_SixJulyTwoThousandEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_SixJulyTwoThousandEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_TwentyAugustTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_TwentyAugustTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_SixJanuaryTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_SixJanuaryTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_TwelveJanuaryTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_TwelveJanuaryTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_FifteenAprilTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_FifteenAprilTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateAxis=OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676721344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_GrantDateShareOptionsGranted2019', window );">Grant date share price</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_VestingPeriodsDescription', window );">Vesting periods</a></td>
<td class="text">1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions<span></span>
</td>
<td class="text">25% each year<span></span>
</td>
<td class="text">25% each year<span></span>
</td>
<td class="text">33% in 6 months and 67% in 1 year<span></span>
</td>
<td class="text">25% each year<span></span>
</td>
<td class="text">25%
each year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">77.70%<span></span>
</td>
<td class="nump">80.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.50%<span></span>
</td>
<td class="nump">77.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_OptionLifePeriod', window );">Option life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_OptionLifePeriod', window );">Option life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_OptionLifePeriod', window );">Option life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_GrantDateShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant date share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_GrantDateShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_OptionLifePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options life period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_OptionLifePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_VestingPeriodsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting period description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_VestingPeriodsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683447648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="nump">147,969,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="nump">147,969,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">185,022,726<span></span>
</td>
<td class="nump">147,188,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="nump">241,781,760<span></span>
</td>
<td class="nump">37,833,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="num">(390,145,396)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">36,659,090<span></span>
</td>
<td class="nump">185,022,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 6.11<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement', window );">Warrants exercisable</a></td>
<td class="nump">1,659,090<span></span>
</td>
<td class="nump">149,568,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, exercisable | $ / shares</a></td>
<td class="nump">$ 10.30<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683393536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Grant date share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">88.10%<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpectedLifeOfWarrants', window );">Expected life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ExpectedLifeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ExpectedLifeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676770816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Apr. 15, 2021</div></th>
<th class="th"><div>Jan. 12, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Aug. 20, 2020</div></th>
<th class="th"><div>May 29, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted</a></td>
<td class="nump">$ 8.0<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate, share options granted</a></td>
<td class="nump">0.97%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019', window );">Weighted average share price, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsVestingPeriod', window );">Vesting periods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Fully vested<span></span>
</td>
<td class="text">50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)<span></span>
</td>
<td class="text">Fully
    vested<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk free interest rate, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">88.10%<span></span>
</td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ExpectedLifeOfWarrants', window );">[custom:ExpectedLifeOfWarrants]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ExpectedLifeOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ExpectedLifeOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Vesting periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874674338656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE OPTIONS AND WARRANTS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>GBP (&#163;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of option were exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue', window );">Fair value charge of share option instruments deemed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,072,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,682,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ShareBasedPaymentCharge', window );">Share based payment charge | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,718,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ShareBasedPaymentChargeForfeiture', window );">Share based payment charge forfeiture | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average contractual life of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
<td class="text">7 years 9 months 7 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,969,396<span></span>
</td>
<td class="nump">147,969,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,969,396<span></span>
</td>
<td class="nump">147,969,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnCashlessBasic', window );">Warrants exercised on cashless basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,716,000<span></span>
</td>
<td class="nump">242,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnIssuances', window );">Warrants exercised on issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,543,360<span></span>
</td>
<td class="nump">238,543,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from warrants exercised | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,045,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesMember', window );">Convertible loan notes [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,605,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="nump">39,605,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnCashlessBasic', window );">Warrants exercised on cashless basic</a></td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnPriceReductionOffer', window );">Warrants exercised on price reduction offer | $ / shares</a></td>
<td class="nump">$ 0.012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnIssuances', window );">Warrants exercised on issuances</a></td>
<td class="nump">36,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesOneMember', window );">Convertible loan notes one [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="nump">165,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="nump">165,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnPriceReductionOffer', window );">Warrants exercised on price reduction offer | $ / shares</a></td>
<td class="nump">$ 0.012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisedOnIssuances', window );">Warrants exercised on issuances</a></td>
<td class="nump">162,698,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=OKYO_LieuOfProfessionalFeesMember', window );">Lieu of professional fees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfContractsAxis=OKYO_LieuOfBrokerFeesMember', window );">Lieu of broker-fees [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember', window );">Warrant reserve [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ShareBasedPaymentCharge', window );">Share based payment charge | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ConsiderationPaidReceived', window );">Consideration received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisablePricePerShare', window );">Warrants exercisable price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantsExercisableDate', window );">Warrants exercisable date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 17,  2023<span></span>
</td>
<td class="text">Jul. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,781,760<span></span>
</td>
<td class="nump">241,781,760<span></span>
</td>
<td class="nump">37,833,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390,145,396)<span></span>
</td>
<td class="num">(390,145,396)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_FairValueOfWarrants', window );">Fair value of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsMember', window );">Private placements [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="nump">39,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,174,870<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">36,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 0.012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsOneMember', window );">Private placements one [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Warrants granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,825,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ShareBasedPaymentCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ShareBasedPaymentCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ShareBasedPaymentChargeForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment charge forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ShareBasedPaymentChargeForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsExercisableDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsExercisableDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsExercisablePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsExercisablePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsExercisedOnCashlessBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised on cashless basic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsExercisedOnCashlessBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsExercisedOnIssuances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised on issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsExercisedOnIssuances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantsExercisedOnPriceReductionOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised on price reduction offer .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantsExercisedOnPriceReductionOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ConsiderationPaidReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 40<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_40_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ConsiderationPaidReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate deemed cost of investments in subsidiaries, joint ventures or associates for which deemed cost is fair value in the entity's first IFRS financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=OKYO_ConvertibleLoanNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=OKYO_LieuOfProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=OKYO_LieuOfProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=OKYO_LieuOfBrokerFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=OKYO_LieuOfBrokerFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_WarrantReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=OKYO_PrivatePlacementsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683420464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 8,151,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_TwentyNineMayTwoThousandAndTwentyMember', window );">29 May 2020 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantExercisePricePerShare', window );">Warrant Exercise per share</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DebtTerm', window );">Debt term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 541,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember', window );">Fees relating to equity fundraise 29 May 2020 issued as CLN [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WarrantExercisePricePerShare', window );">Warrant Exercise per share</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 32,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_TwentySevenJulyTwoThousandTwentyMember', window );">27 July 2020 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 4,506,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_SeventeenthAugustTwoThousandAndTwentyMember', window );">17 August 2020 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 1,882,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_ThreeSeptemberTwoThousandAndTwentyMember', window );">03 September 2022 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 663,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember', window );">Fees relating to all other equity fundraise issued as CLN [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="nump">2.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ConversionPricePerShares', window );">Conversion price per share</a></td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of convertible instruments | $</a></td>
<td class="nump">$ 525,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ConversionPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ConversionPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_TwentyNineMayTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_TwentyNineMayTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_TwentySevenJulyTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_TwentySevenJulyTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_SeventeenthAugustTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_SeventeenthAugustTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_ThreeSeptemberTwoThousandAndTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_ThreeSeptemberTwoThousandAndTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874674331264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">$ 741,810<span></span>
</td>
<td class="nump">$ 210,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Related party payables</a></td>
<td class="nump">47,041<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">788,851<span></span>
</td>
<td class="nump">210,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=OKYO_LessThanThreeMember', window );">Less Than Three [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">649,624<span></span>
</td>
<td class="nump">110,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Related party payables</a></td>
<td class="nump">47,041<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">696,665<span></span>
</td>
<td class="nump">110,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=OKYO_ThreeToTwelveMonthsMember', window );">Three to Twelve Months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">92,186<span></span>
</td>
<td class="nump">100,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Related party payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total</a></td>
<td class="nump">$ 92,186<span></span>
</td>
<td class="nump">$ 100,813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables due to related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=OKYO_LessThanThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=OKYO_LessThanThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=OKYO_ThreeToTwelveMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=OKYO_ThreeToTwelveMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677411088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LoansAndReceivables', window );">Loans receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Payables to related parties</a></td>
<td class="nump">47,041<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=OKYO_WestAfricanMineralsLimitedMember', window );">West African Minerals Limited [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_WriteOffExchangeOfLoan', window );">Write off related party exchange of loan</a></td>
<td class="nump">17,056,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions', window );">Revenue from sale of goods, related party transactions</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDebt', window );">Net debt</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToRelatedParties', window );">Payables to related parties</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=OKYO_TizianaLifeSciencesLtdMember', window );">Tiziana Life Sciences Ltd [member] | Service agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ServicesReceivedRelatedPartyTransactions', window );">Service received related party transaction</a></td>
<td class="nump">107,132<span></span>
</td>
<td class="nump">86,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmountsPayableRelatedPartyTransactions', window );">Amounts Payable related party transaction</a></td>
<td class="nump">$ 47,041<span></span>
</td>
<td class="nump">$ 27,664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_WriteOffExchangeOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off exchange of loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_WriteOffExchangeOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmountsPayableRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts payable resulting from related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmountsPayableRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LoansAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than: (a) those that the entity intends to sell immediately or in the near term, which shall be classified as held for trading, and those that the entity, upon initial recognition, designates as at fair value through profit or loss; (b) those that the entity, upon initial recognition, designates as available for sale; or (c) those for which the holder may not recover substantially all of its initial investment, other than because of credit deterioration, which shall be classified as available for sale. An interest acquired in a pool of assets that are not loans or receivables (for example, an interest in a mutual fund or a similar fund) is not a loan or receivable. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 8<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_c&amp;doctype=Standard&amp;book=b<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LoansAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net debt of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ServicesReceivedRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of services received in related party transactions. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Paragraph 21<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_21_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ServicesReceivedRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payables due to related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=OKYO_WestAfricanMineralsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=OKYO_WestAfricanMineralsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=OKYO_TizianaLifeSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=OKYO_TizianaLifeSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfContractsAxis=OKYO_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfContractsAxis=OKYO_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680240592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract', window );"><strong>Basic And Diluted Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity', window );">(Loss) attributable to equity holders of the company</a></td>
<td class="num">$ (6,268,197)<span></span>
</td>
<td class="num">$ (3,353,507)<span></span>
</td>
<td class="num">$ (1,544,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of ordinary shares in issue</a></td>
<td class="nump">979,212,888<span></span>
</td>
<td class="nump">672,767,629<span></span>
</td>
<td class="nump">595,474,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_BasicAndDilutedEarningsLossPerShare', window );">Basic and dilutive loss per share (cents per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="nump">$ (0.00)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings loss per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureBasicAndDilutedLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureBasicAndDilutedLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683495648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, balance as at the beginning of the year</a></td>
<td class="nump">$ 98,579<span></span>
</td>
<td class="nump">$ 30,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisposalsRightOfUseAssets', window );">Derecognition of right of use asset</a></td>
<td class="num">(97,553)<span></span>
</td>
<td class="nump">27,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ImpactOfForeignExchange', window );">Impact of Foreign exchange</a></td>
<td class="num">(1,026)<span></span>
</td>
<td class="num">(1,030)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, balance as at the end of the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">98,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DepreciationOfEarlyTerminatedLease', window );">Depreciation of early terminated lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisposalsRightOfUseAssets', window );">Early Termination write off</a></td>
<td class="nump">97,553<span></span>
</td>
<td class="num">(27,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ImpactOfForeignExchange', window );">Impact of Foreign exchange</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DepreciationOfNewLease', window );">Depreciation of new lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease Liabilities, balance as at the beginning of the year</a></td>
<td class="nump">98,760<span></span>
</td>
<td class="nump">31,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LeaseLiabilitiesInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LeasePayments', window );">Lease payments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ImpactOfForeignExchangeLeaseLiabilities', window );">Impact of foreign exchange</a></td>
<td class="num">(1,207)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DerecognitionOfLeaseLiability', window );">Derecognition of lease liability</a></td>
<td class="num">(97,553)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisposalsLeaseLiabilities', window );">Early Termination write off</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(27,887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdditionsToLeaseLiabilities', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">104,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LeaseLiabilitiesInterestExpenses', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_LeasePayment', window );">Lease payments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease Liabilities, balance as at the beginning of the year</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 98,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdditionsToLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdditionsToLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DepreciationOfEarlyTerminatedLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of early terminated lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DepreciationOfEarlyTerminatedLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DepreciationOfNewLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation of new lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DepreciationOfNewLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DerecognitionOfLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derecognition of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DerecognitionOfLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisposalsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisposalsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisposalsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Termination write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisposalsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ImpactOfForeignExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of Foreign exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ImpactOfForeignExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ImpactOfForeignExchangeLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impact of foreign exchange lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ImpactOfForeignExchangeLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LeaseLiabilitiesInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LeaseLiabilitiesInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LeaseLiabilitiesInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liabilities interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LeaseLiabilitiesInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LeasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LeasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_LeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_LeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683377040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 34,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 98,760<span></span>
</td>
<td class="nump">$ 31,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874680878368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Within one year</a></td>
<td class="nump">$ 18,713<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Within one year</a></td>
<td class="nump">$ 18,713<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677475664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisposalsRightOfUseAssets', window );">Early Termination write off right of use of assets</a></td>
<td class="num">$ (97,553)<span></span>
</td>
<td class="nump">$ 27,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_DisposalsLeaseLiabilities', window );">Early Termination write off lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability', window );">initial recognition for right of use asset and lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisposalsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposals Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisposalsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_DisposalsRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Termination write off.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_DisposalsRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial recognition for right of use asset and lease liability .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874677714768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF COMPANY AUDITORS FEES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForAuditServices', window );">Fees payable to the company&#8217;s auditors for the audit of the parent company and consolidated financial statements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 200,773<span></span>
</td>
<td class="nump">$ 58,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemunerationForOtherServices', window );">Audit-related assurance services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,892<span></span>
</td>
<td class="nump">72,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AuditorsRemuneration', window );">Total auditor&#8217;s remuneration</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 349,665<span></span>
</td>
<td class="nump">$ 131,511<span></span>
</td>
<td class="nump">$ 53,402<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#8217;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#8217;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemuneration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemuneration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForAuditServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for auditing services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForAuditServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AuditorsRemunerationForOtherServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AuditorsRemunerationForOtherServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683627120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF CASH AND CASH EQUIVALENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash at bank and in hand</a></td>
<td class="nump">$ 2,700,724<span></span>
</td>
<td class="nump">$ 6,889,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=OKYO_GBPMember', window );">GBP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash at bank and in hand</a></td>
<td class="nump">2,400,817<span></span>
</td>
<td class="nump">4,344,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=OKYO_USDMember', window );">USD [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOnHand', window );">Cash at bank and in hand</a></td>
<td class="nump">$ 299,907<span></span>
</td>
<td class="nump">$ 2,544,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOnHand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash held by the entity. This does not include demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOnHand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=OKYO_GBPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=OKYO_GBPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=OKYO_USDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=OKYO_USDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874683618864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AnnualLicenseMaintenanceFeeTherafter', window );">Annual license maintenance fee, therafter</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIHumanClinicalTrialMember', window );">Phase I Human Clinical Trial [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AmountOfLicensedProductOrService', window );">Amount of licensed product or service</a></td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIHumanClinicalTrialMember', window );">Phase II Human Clinical Trial [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AmountOfLicensedProductOrService', window );">Amount of licensed product or service</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIIHumanClinicalTrialMember', window );">Phase III Human Clinical Trial [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AmountOfLicensedProductOrService', window );">Amount of licensed product or service</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AmountOfLicensedProductOrService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Licensed Product or Service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AmountOfLicensedProductOrService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AnnualLicenseMaintenanceFeeTherafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fee, therafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AnnualLicenseMaintenanceFeeTherafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIHumanClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIHumanClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIHumanClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIHumanClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIIHumanClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=OKYO_PhaseIIIHumanClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139874676739728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Post Balance Sheet Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 19, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Aug. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 230,019<span></span>
</td>
<td class="nump">$ 990,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember', window );">Non-adjusting event [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_Bonus', window );">[custom:Bonus-0]</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_ShorttermCreditFacility', window );">[custom:ShorttermCreditFacility-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_AdditionalBorrowingsInterestRate', window );">Additional interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember', window );">Non-adjusting event [member] | American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_OKYO_IfrsStatementLineItems', window );"><strong>IfrsStatementLineItems [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Price per share</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Gross proceeds from public offering</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_AdditionalBorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_AdditionalBorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_Bonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_Bonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_IfrsStatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_IfrsStatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_OKYO_ShorttermCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">OKYO_ShorttermCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>OKYO_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=OKYO_NonadjustingEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=OKYO_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=OKYO_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>form20-f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:OKYO="http://okyopharma.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="okyo-20220331.xsd" xlink:type="simple"/>
    <context id="From2021-04-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_dei_BusinessContactMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-07-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_IssuedCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_OtherReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_WarrantReservesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:ConvertibleLoanNoteReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TranslationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:TranslationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-08-01_custom_NonadjustingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="From2022-08-012022-12-31_custom_NonadjustingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FurnitureAndFixtureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:FurnitureAndFixtureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_CorporateAndAdministrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_CorporateAndAdministrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_CorporateAndAdministrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">OKYO:CorporateAndAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_GCerroneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GCerroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_GCerroneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GCerroneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_GJacobMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_GJacobMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_WSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_WSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_KShailubhaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_KShailubhaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_JBrancaccioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_JBrancaccioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_GMacraeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_GMacraeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_BDenoyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_BDenoyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_WSimonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:WSimonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_KShailubhaiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:KShailubhaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_GMacraeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GMacraeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_LZambelettiMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:LZambelettiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_JBrancaccioMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:JBrancaccioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_GJacobMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_GJacobMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_GJacobMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:GJacobMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_DirectorsMember_custom_BDenoyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_DirectorsMember_custom_BDenoyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_DirectorsMember_custom_BDenoyerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">OKYO:BDenoyerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_DirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">OKYO:DirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_ITEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ITEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ITEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_ITEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_ITEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">OKYO:ITEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_UKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">OKYO:UKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_UnitedStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">OKYO:UnitedStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-05-31_ifrs-full_OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_ifrs-full_OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_OrdinarySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_WarrantReserveOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReserveOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_LoanNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_LoanNotesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2021-05-31_custom_WarrantReserveTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:WarrantReserveTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_custom_LoanNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">OKYO:LoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="AsOf2022-02-28_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2019-05-012019-05-31_custom_PrivatePlacementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="From2020-03-012020-03-31_custom_PrivatePlacementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_PrivatePlacementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-04-30_custom_PrivatePlacementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">OKYO:PrivatePlacementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:LieuOfProfessionalFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:LieuOfBrokerFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">OKYO:ConvertibleLoanNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJulyTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SixJulyTwoThousandEighteenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJulyTwoThousandEighteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwentyAugustTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwentyAugustTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwentyAugustTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:SixJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwelveJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:TwelveJanuaryTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:FifteenAprilTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:FifteenAprilTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="OKYO:GrantDateAxis">OKYO:ThirtyFirstAugustTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-122021-04-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-15</endDate>
        </period>
    </context>
    <context id="From2021-08-292021-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2021-08-29</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="From2022-01-292022-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2022-01-29</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="From2020-08-152020-08-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2020-08-15</startDate>
            <endDate>2020-08-20</endDate>
        </period>
    </context>
    <context id="From2021-01-042021-01-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="From2021-01-102021-01-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-10</startDate>
            <endDate>2021-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-28</startDate>
            <endDate>2020-05-29</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentyNineMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentyNineMayTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentySevenJulyTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:TwentySevenJulyTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:SeventeenthAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:SeventeenthAugustTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:ThreeSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:ThreeSeptemberTwoThousandAndTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">OKYO:FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_LessThanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:LessThanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:ThreeToTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_LessThanThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:LessThanThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">OKYO:ThreeToTwelveMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:WestAfricanMineralsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_WestAfricanMineralsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:WestAfricanMineralsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2020-04-012021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">OKYO:TizianaLifeSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfContractsAxis">OKYO:ServiceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_ifrs-full_NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_ifrs-full_NotLaterThanOneYearMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_GBPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:GBPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_GBPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:GBPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_USDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_USDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">OKYO:USDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_PhaseIHumanClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIHumanClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_PhaseIIHumanClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIIHumanClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_PhaseIIIHumanClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">OKYO:PhaseIIIHumanClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">OKYO:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="From2022-05-022022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">OKYO:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-19_custom_NonadjustingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="AsOf2022-08-15_custom_NonadjustingEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001849296</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">OKYO:NonadjustingEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-15</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Integer">
        <measure>OKYO:Integer</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-04-01to2022-03-31">0001849296</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-04-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-04-01to2022-03-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentRegistrationStatement contextRef="From2021-04-01to2022-03-31">false</dei:DocumentRegistrationStatement>
    <OKYO:RelatedPartyReceivables
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0060"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0075"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl0097"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ConvertibleLoanNoteReserve
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0154"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ImpairmentOfLoan
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0162"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0205"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0206"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0207"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0208"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0209"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0232"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0233"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0234"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0342"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0344"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0363"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0364"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0380"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0381"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0477"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0481"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0490"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0527"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_ConvertibleLoanNoteReserveMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0668"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ProcessedFromOptionsExercised
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ProcessedFromOptionsExercised
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0692"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ProcessedFromWarrantsExercised
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ProcessedFromWarrantsExercised
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:CashAdvancesAndLoansToRelatedParties
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:CashAdvancesAndLoansToRelatedParties
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ChairmansBonus
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl0801"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ChairmansBonus
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:GainlossOnDisposalOfLeases
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:GainlossOnDisposalOfLeases
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0815"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_GCerroneMember"
      id="xdx2ixbrl0878"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_GCerroneMember"
      id="xdx2ixbrl0879"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_GCerroneMember"
      id="xdx2ixbrl0880"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_GCerroneMember"
      id="xdx2ixbrl0883"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_GCerroneMember"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_GJacobMember"
      id="xdx2ixbrl0885"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_GJacobMember"
      id="xdx2ixbrl0889"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_WSimonMember"
      id="xdx2ixbrl0894"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_WSimonMember"
      id="xdx2ixbrl0895"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_WSimonMember"
      id="xdx2ixbrl0898"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_WSimonMember"
      id="xdx2ixbrl0899"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0906"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0907"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember"
      id="xdx2ixbrl0911"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember"
      id="xdx2ixbrl0912"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember"
      id="xdx2ixbrl0915"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0918"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0919"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0920"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0921"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0923"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0925"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0927"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0928"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0931"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0932"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_BDenoyerMember"
      id="xdx2ixbrl0933"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2019-04-012020-03-31_custom_WSimonMember"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2019-04-012020-03-31_custom_WSimonMember"
      id="xdx2ixbrl0944"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0947"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2019-04-012020-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0951"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2019-04-012020-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2019-04-012020-03-31_custom_GMacraeMember"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2019-04-012020-03-31_custom_LZambelettiMember"
      id="xdx2ixbrl0955"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2019-04-012020-03-31_custom_LZambelettiMember"
      id="xdx2ixbrl0956"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsBonus
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DirectorsSalary
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl0960"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_JBrancaccioMember"
      id="xdx2ixbrl0977"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_GJacobMember"
      id="xdx2ixbrl0980"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_BDenoyerMember"
      id="xdx2ixbrl0982"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31_custom_DirectorsMember_custom_BDenoyerMember"
      id="xdx2ixbrl0983"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31_custom_DirectorsMember"
      id="xdx2ixbrl0989"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1011"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1017"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1018"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1019"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:TaxLossesSurrenderedForResearchAndDevelopment
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1043"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:TaxLossesSurrenderedForResearchAndDevelopment
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1044"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1047"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ResearchAndDevelopmentTaxClaim
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1056"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ResearchAndDevelopmentEnhancedExpenditure
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1059"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ResearchAndDevelopmentEnhancedExpenditure
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1060"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1071"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromInterest
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1084"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RevenueFromInterest
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1085"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1087"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceIncome
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1088"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1090"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:FinanceCosts
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1093"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      id="xdx2ixbrl1107"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1108"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      id="xdx2ixbrl1137"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1138"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1315"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1317"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1340"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1341"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1344"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31"
      id="xdx2ixbrl1345"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1351"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      id="xdx2ixbrl1578"
      unitRef="Shares"
      xsi:nil="true"/>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      id="xdx2ixbrl1579"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember"
      id="xdx2ixbrl1691"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2021-03-31_custom_LessThanThreeMember"
      id="xdx2ixbrl1702"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember"
      id="xdx2ixbrl1703"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl1704"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:RightofuseAssets
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1768"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:LeasePayments
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1793"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:ImpactOfForeignExchangeLeaseLiabilities
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1797"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DerecognitionOfLeaseLiability
      contextRef="From2020-04-012021-03-31"
      id="xdx2ixbrl1800"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:DisposalsLeaseLiabilities
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1802"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:AdditionsToLeaseLiabilities
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1805"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:LeaseLiabilitiesInterestExpenses
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1808"
      unitRef="USD"
      xsi:nil="true"/>
    <OKYO:LeasePayment
      contextRef="From2021-04-01to2022-03-31"
      id="xdx2ixbrl1811"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1814"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1817"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1822"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1825"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:LeaseLiabilities
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl1828"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="AsOf2021-03-31_ifrs-full_NotLaterThanOneYearMember"
      id="xdx2ixbrl1835"
      unitRef="USD"
      xsi:nil="true"/>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="AsOf2021-03-31"
      id="xdx2ixbrl1838"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-04-01to2022-03-31">20-F</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2021-04-01to2022-03-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-04-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-04-01to2022-03-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-04-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-04-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="From2021-04-01to2022-03-31">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="From2021-04-01to2022-03-31">001-41386</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-04-01to2022-03-31">OKYO Pharma Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-04-01to2022-03-31">Y7</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-01to2022-03-31">Martello Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-04-01to2022-03-31">Admiral Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-01to2022-03-31">St. Peter Port</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="From2021-04-01to2022-03-31">GG</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-01to2022-03-31">GY1</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">Chief Financial Officer</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">107 Cheapside</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">London</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">EC2V 6DN</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">GB</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">+44</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-04-012022-03-31_dei_BusinessContactMember">20 7495 2379</dei:LocalPhoneNumber>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-07-21" decimals="INF" unitRef="Shares">1374415468</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2021-04-01to2022-03-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-04-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-04-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-04-01to2022-03-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-04-01to2022-03-31">false</dei:EntityExTransitionPeriod>
    <dei:DocumentAccountingStandard contextRef="From2021-04-01to2022-03-31">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="From2021-04-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="From2021-04-01to2022-03-31">1401</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2021-04-01to2022-03-31">Mazars LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2021-04-01to2022-03-31">London, England</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2700724</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6889329</ifrs-full:CashAndCashEquivalents>
    <OKYO:RelatedPartyReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">27664</OKYO:RelatedPartyReceivables>
    <OKYO:CurrentTaxationReceivable contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">781688</OKYO:CurrentTaxationReceivable>
    <OKYO:CurrentTaxationReceivable contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">26322</OKYO:CurrentTaxationReceivable>
    <ifrs-full:OtherReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">812956</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">43371</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentAssets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4295368</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6986686</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5225</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6057</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98579</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5225</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">104636</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4300593</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">7091322</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1306150</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1673154</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">47041</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
    <ifrs-full:CurrentLeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">34148</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1353191</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1707302</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">64612</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1353191</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">1771914</ifrs-full:Liabilities>
    <ifrs-full:SharePremium contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">123976510</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">111629173</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2355040</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">636313</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:WarrantReserve contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">53413</ifrs-full:WarrantReserve>
    <ifrs-full:WarrantReserve contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">861214</ifrs-full:WarrantReserve>
    <OKYO:ConvertibleLoanNoteReserve contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">8370836</OKYO:ConvertibleLoanNoteReserve>
    <OKYO:ForeignCurrencyTranslationReserve contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-11011527</OKYO:ForeignCurrencyTranslationReserve>
    <OKYO:ForeignCurrencyTranslationReserve contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-10174375</OKYO:ForeignCurrencyTranslationReserve>
    <ifrs-full:RetainedEarnings contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-112426034</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-106003753</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2947402</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5319408</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4300593</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">7091322</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1301178</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">173821</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">518098</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:OperatingExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">4916388</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">3192385</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1016548</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpenseExcludingCostOfSales
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">6217566</ifrs-full:OperatingExpenseExcludingCostOfSales>
    <ifrs-full:OperatingExpenseExcludingCostOfSales
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">3366206</ifrs-full:OperatingExpenseExcludingCostOfSales>
    <ifrs-full:OperatingExpenseExcludingCostOfSales
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1534646</ifrs-full:OperatingExpenseExcludingCostOfSales>
    <ifrs-full:FinanceIncome
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">48125</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1123</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1158</ifrs-full:FinanceCosts>
    <OKYO:ImpairmentOfLoan
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-11172</OKYO:ImpairmentOfLoan>
    <OKYO:ImpairmentOfLoan
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-132668</OKYO:ImpairmentOfLoan>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6217566</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3378501</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1620347</ifrs-full:ProfitLossBeforeTax>
    <OKYO:IncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-786521</OKYO:IncomeTaxExpenseBenefitContinuingOperations>
    <OKYO:IncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-24994</OKYO:IncomeTaxExpenseBenefitContinuingOperations>
    <OKYO:IncomeTaxExpenseBenefitContinuingOperations
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-76288</OKYO:IncomeTaxExpenseBenefitContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-5431045</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3353507</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1544059</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-837152</ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">346365</ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">86654</ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6268197</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3007142</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1457405</ifrs-full:ComprehensiveIncome>
    <OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders>
    <OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders>
    <OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</OKYO:BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2019-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">524108283</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">111741860</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">57101</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">30242</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-100888643</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2019-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-10607394</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">333166</ifrs-full:Equity>
    <OKYO:StockIssuedDuringPeriodSharesShareCapital
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">112188766</OKYO:StockIssuedDuringPeriodSharesShareCapital>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">965171</OKYO:StockIssuedDuringPeriodValueNewIssue>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">965171</OKYO:StockIssuedDuringPeriodValueNewIssue>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">36340</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">36340</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-627047</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">609661</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-17386</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">338124</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">36340</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">609661</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">984125</OKYO:SharesIssuedOnTotalTransactions>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1544059</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1544059</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">86654</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">86654</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-1544059</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">86654</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1457405</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">636297049</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">112079984</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">93441</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">639903</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-102432702</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-10520740</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-140114</ifrs-full:Equity>
    <OKYO:StockIssuedDuringPeriodSharesShareCapital
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">36269253</OKYO:StockIssuedDuringPeriodSharesShareCapital>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">230019</OKYO:StockIssuedDuringPeriodValueNewIssue>
    <OKYO:StockIssuedDuringPeriodValueNewIssue
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">230019</OKYO:StockIssuedDuringPeriodValueNewIssue>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">550138</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">550138</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:StockIssuedDuringPeriodShareslExerciseOfOptions
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">250000</OKYO:StockIssuedDuringPeriodShareslExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">15870</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">-1515</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">1515</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">15870</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">-5751</OKYO:IncreaseDecreaseThroughExerciseOfForfeiture>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-5751</OKYO:IncreaseDecreaseThroughExerciseOfForfeiture>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-138305</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">221311</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">83006</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-558396</OKYO:SharesIssuedOnConvertibleDebtConversion>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">8151777</OKYO:SharesIssuedOnConvertibleDebtConversion>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7593382</OKYO:SharesIssuedOnConvertibleDebtConversion>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">219059</OKYO:SharesIssuedOnConvertibleDebtInterest>
    <OKYO:SharesIssuedOnConvertibleDebtInterest
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-219059</OKYO:SharesIssuedOnConvertibleDebtInterest>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-450811</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">542872</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">221311</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">8370836</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-217544</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">8466664</OKYO:SharesIssuedOnTotalTransactions>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3353507</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3353507</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">346365</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">346365</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3353507</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">346365</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3007142</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">672816302</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">111629173</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">636313</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">861214</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">8370836</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-106003753</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-10174375</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5319408</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">672816302</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">111629173</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">636313</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">861214</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">8370836</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-106003753</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-10174375</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">5319408</ifrs-full:Equity>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">546318</OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">444918</OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest>
    <OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-991236</OKYO:SharesIssuedOnConvertibleDebtAndWarrantInterest>
    <OKYO:SharesIssuedOnConvertibleDebtConversionShares
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">315086410</OKYO:SharesIssuedOnConvertibleDebtConversionShares>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">8876397</OKYO:SharesIssuedOnConvertibleDebtConversion>
    <OKYO:SharesIssuedOnConvertibleDebtConversion
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">-8876397</OKYO:SharesIssuedOnConvertibleDebtConversion>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">654833</OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion>
    <OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">654833</OKYO:SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">594190</OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves>
    <OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">-594190</OKYO:StockIssuedDuringPeriodValueTransferBetweenEquityReserves>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">1737876</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:SharesIssuedOnOptionsCharge
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1737876</OKYO:SharesIssuedOnOptionsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">-19149</OKYO:IncreaseDecreaseThroughExerciseOfForfeiture>
    <OKYO:IncreaseDecreaseThroughExerciseOfForfeiture
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-19149</OKYO:IncreaseDecreaseThroughExerciseOfForfeiture>
    <OKYO:SharesIssuedOnWarrantsExercisedShares
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">386512756</OKYO:SharesIssuedOnWarrantsExercisedShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">3470940</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">-2010030</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1460910</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">61721</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">61721</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsCharge>
    <OKYO:SharesIssuedOnTotalTransactionsShares
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">701599166</OKYO:SharesIssuedOnTotalTransactionsShares>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">12347337</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">1718727</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">-807801</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_custom_ConvertibleLoanNoteReserveMember"
      decimals="0"
      unitRef="USD">-8370836</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-991236</OKYO:SharesIssuedOnTotalTransactions>
    <OKYO:SharesIssuedOnTotalTransactions
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">3896191</OKYO:SharesIssuedOnTotalTransactions>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5431045</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-5431045</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-837152</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-837152</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5431045</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-012022-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-837152</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6268197</ifrs-full:ComprehensiveIncome>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">1374415468</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">123976510</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">2355040</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">53413</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-112426034</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-11011527</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2947402</ifrs-full:Equity>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">1374415468</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">123976510</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_OtherReservesMember"
      decimals="0"
      unitRef="USD">2355040</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_WarrantReservesMember"
      decimals="0"
      unitRef="USD">53413</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-112426034</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_custom_TranslationReserveMember"
      decimals="0"
      unitRef="USD">-11011527</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2947402</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6217566</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3378501</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1620347</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1737876</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">550138</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">36340</ifrs-full:AdjustmentsForSharebasedPayments>
    <OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-61721</OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge>
    <OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-83006</OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge>
    <OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-42846</OKYO:AdjustmentsForChangeInFairValueOfWarrantCharge>
    <OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">19149</OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions>
    <OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">5751</OKYO:AdjustmentsForChangeInFairValueOfForfeitureOfOptions>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2331</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1510</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">426</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">11601</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">5553</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-9230</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">4056</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">13915</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">11171</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">132668</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">179</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">818</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
    <OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">27376</OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables>
    <OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3862</OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables>
    <OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-543</OKYO:AdjustmentsForDecreaseIncreaseRelatedPartyReceivables>
    <OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">48900</OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables>
    <OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-46311</OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables>
    <OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">38049</OKYO:AdjustmentsForIncreaseDecreaseInRelatedPartyPayables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-802154</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">208931</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-122190</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-297991</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">886093</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">271218</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForReconcileProfitLoss
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">78540</ifrs-full:AdjustmentsForReconcileProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-5468065</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-1600198</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1202066</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1669</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">6943</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">11171</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:CashAdvancesAndLoansMadeToRelatedParties
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">132668</ifrs-full:CashAdvancesAndLoansMadeToRelatedParties>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1669</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-18114</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-132668</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">230019</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">990639</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7593380</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <OKYO:ProcessedFromOptionsExercised
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">15870</OKYO:ProcessedFromOptionsExercised>
    <OKYO:ProcessedFromWarrantsExercised
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2153270</OKYO:ProcessedFromWarrantsExercised>
    <OKYO:CashAdvancesAndLoansToRelatedParties
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-518000</OKYO:CashAdvancesAndLoansToRelatedParties>
    <ifrs-full:CashAdvancesAndLoansFromRelatedParties
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">496810</ifrs-full:CashAdvancesAndLoansFromRelatedParties>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">12331</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">6139</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2153270</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">7826938</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">963310</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-3316464</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">6208627</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-371423</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6889329</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">235485</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">627616</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-872141</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">445217</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-20708</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2700724</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6889329</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">235485</ifrs-full:CashAndCashEquivalents>
    <OKYO:DisclosureOfReportingEntityExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_807_ecustom--DisclosureOfReportingEntityExplanatory_zN3ed7cfS9gb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="a_001"/&gt;1.
&lt;span id="xdx_822_zIrU2AH0WvJd"&gt;Reporting Entity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OKYO
Pharma Limited (the &#x201c;Company&#x201d; or &#x201c;OKYO&#x201d;) is a company domiciled in Guernsey and listed with a standard listing
on the main market of the London Stock Exchange (LSE) and on the Nasdaq Capital Market (LSE: OKYO, NASDAQ: OKYO).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is developing next-generation therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain.
Our goal is to develop first in class drug candidates that prevent the disease instead of controlling it, and we achieve this through
our collaboration with pioneer scientists in the field.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
ultimate parent of the group is Panetta Partners Limited, incorporated in the British Virgin Islands.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OKYO:DisclosureOfReportingEntityExplanatory>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_806_eifrs-full--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zKGRXvat9wY8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span id="xdx_82C_zrPyXyik5nr8"&gt;ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies
have been applied consistently to all the years presented unless otherwise stated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_zfHxssMul8de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zuiCtMYBwdSe"&gt;Basis
of preparation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eifrs-full--ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_ze6rEvZvCdVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zSHeKIf3gOw6"&gt;Basis
of measurement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DisclosureOfGoingConcernExplanatory_zyjwyoe4H8Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zIJXF9vULX97"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &#xa3;&lt;span id="xdx_908_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20220331_znuD9gZzK7s8" title="Accumulated deficit"&gt;76.8&lt;/span&gt;m (&#xa3;&lt;span id="xdx_90E_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20181231_zaW6Bco1JJu6"&gt;64&lt;/span&gt;m of this accumulated loss relates to a discontinued business prior
to the reorganisation in 2018), a net loss for the year ended March 31, 2022, of &#xa3;&lt;span id="xdx_905_eifrs-full--ProfitLoss_iN_pn5n6_di_uGBP_c20210401__20220331_zm0Cywblto74" title="Net loss"&gt;4.0&lt;/span&gt;m and net cash used in operating activities
of &#xa3;&lt;span id="xdx_908_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pn5n6_di_uGBP_c20210401__20220331_zSQLLI5hFUw2" title="Net cash used in operating activities"&gt;4.0&lt;/span&gt;m.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &#xa3;&lt;span id="xdx_90A_eifrs-full--CashAndCashEquivalents_iI_pn5n6_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zp1LWwYLOLx9" title="Cash"&gt;1.5&lt;/span&gt;m, with current liabilities of &#xa3;&lt;span id="xdx_90F_eifrs-full--CurrentLiabilities_iI_pn3n3_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_ze72JlAwVGUb" title="Current liabilities"&gt;978&lt;/span&gt;k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &#xa3;&lt;span id="xdx_909_ecustom--CashBurnRate_pn5n6_uGBP_c20220801__20221231__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zYmIKoYjsO1" title="Rate of cash burn/spend"&gt;2.4&lt;/span&gt;m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took
strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential
liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are
more specialist investors focused on early-stage opportunities. The Directors are also confident that the nature of the OK101
clinical program is such that various inflection points arise over a relatively short period of time which should provide financing
opportunities, for example the FDA approval of the IND in December 2022 for OK101 in dry-eye and the return of headline data from
the Phase II registration trial to be held between July and December 2023; these pivotal events in the primary clinical program
for OK101 have the benefit of being near term events (which is unusual in the context of the normal timeframes for Phase II clinical
programs to deliver meaningful data points. The Directors have also consulted the Company&#x2019;s investment bankers with a view to
planning a number of alternative financing strategies to ensure the Company has access to sufficient capital to finance its planned
R&amp;amp;D activity in the coming 18 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;To meet the Company&#x2019;s short-term
liquidity needs, the Company has secured a $2m short-term credit facility with a related party in order to bridge any delays in the
occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for a period of 6 months upon first
draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the
6-month period. The loan will extend the Company&#x2019;s fixed cost cash burn to April 2023 without the need to raise additional
funds. The Directors believe that this facility together with additional working capital management measures will be sufficient to
complete the IND application. The Directors also considered any risks to the short-term cash position of the company such as delay
in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash resources and
the additional financing strategies already disclosed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt; text-align: justify"&gt;On completion of the IND application the company will be in a position to raise funds on the market, via the financing
strategies being discussed with the Company&#x2019;s investment bankers. The necessary steps are being taken to affect such a fundraise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Until and unless the Group and Company secures sufficient investment to
fund their clinical pipeline, there is a significant doubt on the Group and Company&#x2019;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this significant
doubt, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident,
based on the previous fund-raising history as well as additional measures already put in place and being planned, that sufficient funds
will be forthcoming and accordingly they have prepared these financial statements on a going concern basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;New
and Revised Standards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Standards
in effect in 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_z8XuKH8VZHrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zAEqUJeIcxTa"&gt;Basis
of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&#x2019;s return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inter-company
transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zL1Tjuw6eBY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_z9pHKU5FVQ77"&gt;Segment
reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_z8j7TbRaDvDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zZmLakyiYkc9"&gt;Taxation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zqPFx9fhSOq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zy5WsOrjQrJ1"&gt;Foreign
currency translation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in US dollars, which is the Group&#x2019;s presentation currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements are translated into US dollars on the following basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
    and liabilities at the rate of exchange ruling at the year-end date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Profit
    and loss account items at the average rate of exchange for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForLicenseFeesExplanatory_z4OBpo4q3jX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zm7114eoO8Gi"&gt;License
fees&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. Licence fees expenses are recognised as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_zV4NMjY7ImUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zdB5ejYOmZq6"&gt;Research
and development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&#x2019;s products, the criteria for development costs to be recognised as an asset, as set out
in IAS 38 &#x2018;Intangible Assets&#x2019;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zmF6nZC13B7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zVywf64qjVV6"&gt;Financial
instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets, initial recognition and measurement and subsequent measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities, initial recognition and measurement and subsequent measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s financial liabilities include trade and other payables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_z9PMWq0U69aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zbwcn0sWvmfd"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents comprise cash on hand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zu5Vz53LAPZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zSSUUkEJ16pj"&gt;Impairment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of financial assets measured at amortised cost&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General
approach&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognised at an amount equal to the lifetime expected credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Simplified
approach&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
simplified approach is applied to the impairment assessment of trade receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of non-financial assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-financial
    assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of
    fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--DescriptionOfAccountingPolicyForShareCapitalExplanatory_zhKIP9EcIGAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zutNHNqPZix7"&gt;Share
capital&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ordinary
shares of the Company are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z3Tp1iH8qZEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_ziZ4K9iwOnRj"&gt;Property,
plant and equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recognition
    and measurement&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalised as part of that equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current period and the comparative period are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zohpzScp5GKj" style="display: none"&gt;DISCLOSURE OF ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixtures
    and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives"&gt;5&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IT
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives"&gt;3&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_ztfRBhkQeQtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForLeaseExplanatory_z2MC8R5u546h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zKMh4tMa5WMa"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&#x2019;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short
term leases&#160;exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit
and loss on a straight-line basis over the term of the lease.&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_zWrtAKrce05d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOrTi2vaPpRa"&gt;Share
based payments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#x2019;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&#x2019;, Directors&#x2019; or
advisers&#x2019; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &#x2013; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &#x2013; warrants, in the case of warrants issued in return for services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForWarrantsExplanatory_zQwDNsR5fr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zbEsSZejhIv1"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
are issued by the Group in return for services and as part of a financing transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
issued in return for services.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
issued as part of a financing transaction.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
of these instruments is governed by the so-called &#x2018;fixed&#x2019; test for non-derivatives, and the &#x2018;fixed for fixed&#x2019;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForBorrowingsExplanatory_zhziKifCc0wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
loan notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Where
the fixed for fixed condition is met&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve. The accrued interest on the principal amount is also recorded in the Convertible
loan note reserve as it is convertible into equity. Upon redemption of the instrument and the issue of share capital, the amount is reclassified
from the convertible loan note reserve to share capital and share premium.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z6QSFNFpPNkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zGUsrfQMiDpk"&gt;Fair Value Measurement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Management have assessed the categorization
of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the
basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 1 - valued using quoted prices in active
markets for identical assets;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 2 - valued by reference to valuation
techniques using observable inputs other than quoted prices included within Level 1;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 3 - valued by reference to valuation
techniques using inputs that are not based on observable market data.&lt;/p&gt;
&lt;p id="xdx_859_zWofBggxCs6b" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_843_ecustom--DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory_zfHxssMul8de" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zuiCtMYBwdSe"&gt;Basis
of preparation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements of the Group and Company have been prepared in accordance with International Financial Reporting Standards
(IFRS) as issued by the International Accounting Standards Board (IASB), IFRIC interpretations and the Companies (Guernsey) Law 2008
as applicable to companies reporting under IFRS.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory>
    <ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84C_eifrs-full--ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements_ze6rEvZvCdVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zSHeKIf3gOw6"&gt;Basis
of measurement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements>
    <ifrs-full:DisclosureOfGoingConcernExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eifrs-full--DisclosureOfGoingConcernExplanatory_zyjwyoe4H8Og" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zIJXF9vULX97"&gt;Going
Concern&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and as of
March 31, 2022, had an accumulated deficit of &#xa3;&lt;span id="xdx_908_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20220331_znuD9gZzK7s8" title="Accumulated deficit"&gt;76.8&lt;/span&gt;m (&#xa3;&lt;span id="xdx_90E_eifrs-full--RetainedEarnings_iNI_pn5n6_di_uGBP_c20181231_zaW6Bco1JJu6"&gt;64&lt;/span&gt;m of this accumulated loss relates to a discontinued business prior
to the reorganisation in 2018), a net loss for the year ended March 31, 2022, of &#xa3;&lt;span id="xdx_905_eifrs-full--ProfitLoss_iN_pn5n6_di_uGBP_c20210401__20220331_zm0Cywblto74" title="Net loss"&gt;4.0&lt;/span&gt;m and net cash used in operating activities
of &#xa3;&lt;span id="xdx_908_eifrs-full--CashFlowsFromUsedInOperatingActivities_iN_pn5n6_di_uGBP_c20210401__20220331_zSQLLI5hFUw2" title="Net cash used in operating activities"&gt;4.0&lt;/span&gt;m.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment
to fund that operation. On the basis of those projections, the directors conclude that the company will not be able to meet its liabilities
as they fall due within the next 12 months from the date when these financial statements are issued. The cash balance as at 1 August
2022 is approximately &#xa3;&lt;span id="xdx_90A_eifrs-full--CashAndCashEquivalents_iI_pn5n6_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zp1LWwYLOLx9" title="Cash"&gt;1.5&lt;/span&gt;m, with current liabilities of &#xa3;&lt;span id="xdx_90F_eifrs-full--CurrentLiabilities_iI_pn3n3_uGBP_c20220801__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_ze72JlAwVGUb" title="Current liabilities"&gt;978&lt;/span&gt;k. The cash burn rate until from the beginning of August to
the end of December 2022 is projected at &#xa3;&lt;span id="xdx_909_ecustom--CashBurnRate_pn5n6_uGBP_c20220801__20221231__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zYmIKoYjsO1" title="Rate of cash burn/spend"&gt;2.4&lt;/span&gt;m, and the company projects that without additional financing facilities it will run
out of cash in October 2022. Consequently, in the opinion of the directors there is a material uncertainty that may cause significant
doubt about the Group&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors are however aware, through their own extensive experience in the sector, that this position is not uncommon in the context
of a pre-revenue life sciences company principally involved in cash consuming research and development activity. The Directors took
strategic advantage of the opportunity to dual list the Company on NASDAQ in May 2022 in order to be able to access potential
liquidity in the US, which is generally a more favorable environment for life sciences companies to raise money and where there are
more specialist investors focused on early-stage opportunities. The Directors are also confident that the nature of the OK101
clinical program is such that various inflection points arise over a relatively short period of time which should provide financing
opportunities, for example the FDA approval of the IND in December 2022 for OK101 in dry-eye and the return of headline data from
the Phase II registration trial to be held between July and December 2023; these pivotal events in the primary clinical program
for OK101 have the benefit of being near term events (which is unusual in the context of the normal timeframes for Phase II clinical
programs to deliver meaningful data points. The Directors have also consulted the Company&#x2019;s investment bankers with a view to
planning a number of alternative financing strategies to ensure the Company has access to sufficient capital to finance its planned
R&amp;amp;D activity in the coming 18 months.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;To meet the Company&#x2019;s short-term
liquidity needs, the Company has secured a $2m short-term credit facility with a related party in order to bridge any delays in the
occurrence of the anticipated clinical milestones for the OK-101 program. The loan is available for a period of 6 months upon first
draw-down and carries an interest rate of 16% per annum, with additional default interest of 4% if the loan is not repaid after the
6-month period. The loan will extend the Company&#x2019;s fixed cost cash burn to April 2023 without the need to raise additional
funds. The Directors believe that this facility together with additional working capital management measures will be sufficient to
complete the IND application. The Directors also considered any risks to the short-term cash position of the company such as delay
in IND filing, and they identified that the risk would be highly unlikely and could be managed within the current cash resources and
the additional financing strategies already disclosed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt; text-align: justify"&gt;On completion of the IND application the company will be in a position to raise funds on the market, via the financing
strategies being discussed with the Company&#x2019;s investment bankers. The necessary steps are being taken to affect such a fundraise.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Until and unless the Group and Company secures sufficient investment to
fund their clinical pipeline, there is a significant doubt on the Group and Company&#x2019;s ability to continue as a going concern, and
therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. Despite this significant
doubt, the Directors conclude that it is appropriate to continue to adopt the going concern basis of accounting as the Directors are confident,
based on the previous fund-raising history as well as additional measures already put in place and being planned, that sufficient funds
will be forthcoming and accordingly they have prepared these financial statements on a going concern basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;New
and Revised Standards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Standards
in effect in 2022&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no new IFRS standards, amendments to standards or interpretations that are mandatory for the financial year beginning on April 1,
2021, that are relevant to the Group or that have had any material impact in the year to March 31, 2022. New standards, amendments to
standards and interpretations that are not yet effective, have been deemed by the Group as currently not relevant, and not likely to
have a material impact on the Group, and hence are not listed here.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfGoingConcernExplanatory>
    <ifrs-full:RetainedEarnings contextRef="AsOf2022-03-31" decimals="-5" unitRef="GBP">-76800000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="AsOf2018-12-31" decimals="-5" unitRef="GBP">-64000000</ifrs-full:RetainedEarnings>
    <ifrs-full:ProfitLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="-5"
      unitRef="GBP">-4000000.0</ifrs-full:ProfitLoss>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="From2021-04-01to2022-03-31"
      decimals="-5"
      unitRef="GBP">-4000000.0</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="AsOf2022-08-01_custom_NonadjustingEventMember"
      decimals="-5"
      unitRef="GBP">1500000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentLiabilities
      contextRef="AsOf2022-08-01_custom_NonadjustingEventMember"
      decimals="-3"
      unitRef="GBP">978000</ifrs-full:CurrentLiabilities>
    <OKYO:CashBurnRate
      contextRef="From2022-08-012022-12-31_custom_NonadjustingEventMember"
      decimals="-5"
      unitRef="GBP">2400000</OKYO:CashBurnRate>
    <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_z8XuKH8VZHrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zAEqUJeIcxTa"&gt;Basis
of consolidation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsidiary
undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following:
(a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability
to use its power over the investee to affect the amount of the investor&#x2019;s return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered
when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control
and are de-consolidated from the date at which control ceases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inter-company
transactions, balances and unrealised gains on transactions between group companies are eliminated upon consolidation. Unrealised losses
are also eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted
by the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForSegmentReportingExplanatory_zL1Tjuw6eBY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_866_z9pHKU5FVQ77"&gt;Segment
reporting&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and
assess the performance of the segments. The Board considers there to be only one operating segment being the research and development
of biotechnological and pharmaceutical products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_840_eifrs-full--DescriptionOfAccountingPolicyForIncomeTaxExplanatory_z8j7TbRaDvDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zZmLakyiYkc9"&gt;Taxation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
tax credit for the year represents the total of current taxation and deferred taxation. The credit in respect of current taxation is
based on the estimated taxable loss for the year. Taxable profit or loss for the year is based on the profit or loss as shown in the
statement of comprehensive income, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes.
The current tax asset for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance
sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities
and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have
been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realised, or the
deferred liability is settled. Deferred tax assets are recognised to the extent that it is probable that the future taxable profit will
be available against which the temporary differences can be utilised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research
and development expenditure. Any difference rebated are recognized when the cash is received from the UK tax authorities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_847_eifrs-full--DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_zqPFx9fhSOq6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86B_zy5WsOrjQrJ1"&gt;Foreign
currency translation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
included in the financial statements of each of the Group&#x2019;s entities are measured using the currency of the primary economic environment
in which the entity operates (the functional currency), which is Pounds sterling.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
consolidated financial statements are presented in US dollars, which is the Group&#x2019;s presentation currency.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign
exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange
rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements are translated into US dollars on the following basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assets
    and liabilities at the rate of exchange ruling at the year-end date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Profit
    and loss account items at the average rate of exchange for the year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Exchange
differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated
as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <OKYO:DescriptionOfAccountingPolicyForLicenseFeesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_841_ecustom--DescriptionOfAccountingPolicyForLicenseFeesExplanatory_z4OBpo4q3jX1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_860_zm7114eoO8Gi"&gt;License
fees&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic
benefits from the asset will flow to the Group and the cost of the asset can be reliably measured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payments
made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire
an asset. Licence fees expenses are recognised as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</OKYO:DescriptionOfAccountingPolicyForLicenseFeesExplanatory>
    <OKYO:DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84B_ecustom--DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory_zV4NMjY7ImUd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86C_zdB5ejYOmZq6"&gt;Research
and development&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment
inherent in the development of the Group&#x2019;s products, the criteria for development costs to be recognised as an asset, as set out
in IAS 38 &#x2018;Intangible Assets&#x2019;, are not met until a product has been granted regulatory approval and it is probable that future
economic benefit will flow to the Group. The Group currently has no such qualifying expenditure.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</OKYO:DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_zmF6nZC13B7c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zVywf64qjVV6"&gt;Financial
instruments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument
in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and
an equity instrument.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component.
Such components shall be classified separately as financial assets, financial liabilities or equity instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity
instrument of another entity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            assets, initial recognition and measurement and subsequent measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition financial assets are measured at their fair value. Subsequent measurement depends on their classification. Financial
assets such as receivables, cash and cash equivalents and deposits are subsequently measured at amortized cost using the effective interest
method, less loss allowance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive
income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"/&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
                                            liabilities, initial recognition and measurement and subsequent measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
initial recognition, financial liabilities are measured at their fair value minus, if appropriate, any transaction costs that are directly
attributable to the issue of the financial liability. All financial liabilities are subsequently measured at amortized cost using the
effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss
on derecognition is also recognized in profit or loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s financial liabilities include trade and other payables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory_z9PMWq0U69aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zbwcn0sWvmfd"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents comprise cash on hand.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84D_eifrs-full--DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_zu5Vz53LAPZ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_864_zSSUUkEJ16pj"&gt;Impairment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of financial assets measured at amortised cost&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified
approach, depending on the nature of the underlying group of financial assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;General
approach&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted
cash and cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses,
unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is
recognised at an amount equal to the lifetime expected credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Simplified
approach&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
simplified approach is applied to the impairment assessment of trade receivables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected
credit losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Impairment
of non-financial assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-financial
    assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-financial
    assets are impaired when their carrying amount exceeds the recoverable amount. The recoverable amount is measured as the higher of
    fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial
    forecasts discounted back to present value.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <OKYO:DescriptionOfAccountingPolicyForShareCapitalExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84F_ecustom--DescriptionOfAccountingPolicyForShareCapitalExplanatory_zhKIP9EcIGAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_868_zutNHNqPZix7"&gt;Share
capital&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ordinary
shares of the Company are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</OKYO:DescriptionOfAccountingPolicyForShareCapitalExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_845_eifrs-full--DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_z3Tp1iH8qZEk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_ziZ4K9iwOnRj"&gt;Property,
plant and equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;(i)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recognition
    and measurement&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Items
of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include
expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality
of the related equipment is capitalised as part of that equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components)
of property, plant and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gains
and losses on disposal of an item of property, IT and equipment are determined by comparing the proceeds from disposal with the carrying
amount of property, IT and equipment, and are recognized in profit or loss. When revalued assets are sold, the amounts included in the
revaluation reserve are transferred to retained earnings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated on the depreciable amount, which is the cost of an asset, less its residual value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and
equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current period and the comparative period are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zohpzScp5GKj" style="display: none"&gt;DISCLOSURE OF ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixtures
    and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives"&gt;5&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IT
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives"&gt;3&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_ztfRBhkQeQtf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line
of the statement of comprehensive income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <OKYO:DisclosureOfEstimatedUsefulLivesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_ecustom--DisclosureOfEstimatedUsefulLivesExplanatory_zv1RRU7J1CDi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives for the current period and the comparative period are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B2_zohpzScp5GKj" style="display: none"&gt;DISCLOSURE OF ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fixtures
    and fittings&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 50%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90D_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--FurnitureAndFixtureMember_zKhnizy7K3y3" title="Estimated useful lives"&gt;5&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IT
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_90E_eifrs-full--UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment_dtY_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__ifrs-full--ComputerEquipmentMember_zniy5FPt1bbl" title="Estimated useful lives"&gt;3&lt;/span&gt;
    years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</OKYO:DisclosureOfEstimatedUsefulLivesExplanatory>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="From2021-04-012022-03-31_custom_FurnitureAndFixtureMember">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="From2021-04-012022-03-31_ifrs-full_ComputerEquipmentMember">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <OKYO:DescriptionOfAccountingPolicyForLeaseExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_84C_ecustom--DescriptionOfAccountingPolicyForLeaseExplanatory_z2MC8R5u546h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_86F_zKMh4tMa5WMa"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
    with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have any leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments
based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies
its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
lease commencement date, the Group recognises a right-of-use asset and a lease liability in its consolidated statement of financial position.
The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs
incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of the lease, and any lease payments made
in advance of the lease commencement date (net of any incentives received).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group depreciates the right-of-use asset on a straight-line basis from the lease commencement date to the earlier of the end of the useful
life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such
indicators exist.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted
using the Group&#x2019;s incremental borrowing rate because as the lease contracts are negotiated with third parties it is not possible
to determine the interest rate that is implicit in the lease. The incremental borrowing rate is the estimated rate that the Group would
have to pay to borrow the same amount over a similar term, and with similar security to obtain an asset of equivalent value. This rate
is adjusted should the lessee entity have a different risk profile to that of the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments
based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably
certain to be exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to initial measurement, the liability will be reduced by lease payments that are allocated between repayments of principal and finance
costs. The finance cost is the amount that produces a constant periodic rate of interest on the remaining balance of the lease liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short
term leases&#160;exempt from IFRS 16 are classified as operating leases. Payments made under operating leases are recognised in profit
and loss on a straight-line basis over the term of the lease.&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

</OKYO:DescriptionOfAccountingPolicyForLeaseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_846_eifrs-full--DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_zWrtAKrce05d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_862_zOrTi2vaPpRa"&gt;Share
based payments&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income
requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the
Company&#x2019;s share price. These assumptions are then applied to a recognized valuation model in order to calculate the fair value
of the awards.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Where
employees, Directors or advisers are rewarded using share based payments, the fair value of the employees&#x2019;, Directors&#x2019; or
advisers&#x2019; services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised
at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options
based upon the fair value of the instrument used and warrants issued in return for services. A corresponding credit is made to a share
based payment reserve &#x2013; options, in the case of options awarded to employees, Directors, advisers and other consultants. A corresponding
credit is made to a share based payment reserve &#x2013; warrants, in the case of warrants issued in return for services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_848_eifrs-full--DescriptionOfAccountingPolicyForWarrantsExplanatory_zQwDNsR5fr6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_867_zbEsSZejhIv1"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
are issued by the Group in return for services and as part of a financing transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
issued in return for services.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued in return for services fall within scope of IFRS 2 and are classified as a share-based payment. The share-based payment is measured
at fair value and charged to the Statement of comprehensive income. There is no remeasurement of fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants
issued as part of a financing transaction.&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued as part of a financing transaction fall outside the scope of IFRS 2. These are classified as equity instruments because a fixed
amount of cash is exchanged for a fixed amount of equity. The relative fair value is recognised within equity and is not remeasured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Classification
of these instruments is governed by the so-called &#x2018;fixed&#x2019; test for non-derivatives, and the &#x2018;fixed for fixed&#x2019;
test for derivatives. Under the fixed test, a non-derivative contract will qualify for equity classification only where there is no contractual
obligation for the issuer to deliver a variable number of its own equity instruments. Under the fixed for fixed test, a derivative will
qualify for equity classification only where it will be settled by the issuer exchanging a fixed amount of cash or another financial
asset for a fixed number of its own equity instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Warrants
issued by the Company as part of a financing transaction, are classified as equity instruments because a fixed amount of cash is exchanged
for a fixed amount of equity of the Company. No other features exist that would result in financial liability classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForWarrantsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_841_eifrs-full--DescriptionOfAccountingPolicyForBorrowingsExplanatory_zhziKifCc0wg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
loan notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group issues Convertible loan notes which can be classified as equity or a liability depending on whether the fixed for fixed condition
is met or not.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Where
the fixed for fixed condition is met&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group classifies convertible loan notes that meet the fixed for fixed condition as equity instruments and records the principal of the
loan note as equity in a Convertible loan note reserve. The accrued interest on the principal amount is also recorded in the Convertible
loan note reserve as it is convertible into equity. Upon redemption of the instrument and the issue of share capital, the amount is reclassified
from the convertible loan note reserve to share capital and share premium.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DescriptionOfAccountingPolicyForBorrowingsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_842_eifrs-full--DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_z6QSFNFpPNkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_86A_zGUsrfQMiDpk"&gt;Fair Value Measurement&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Management have assessed the categorization
of the fair value measurements using the IFRS 13 fair value hierarchy. Categorization within the hierarchy has been determined on the
basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 1 - valued using quoted prices in active
markets for identical assets;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 2 - valued by reference to valuation
techniques using observable inputs other than quoted prices included within Level 1;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Level 3 - valued by reference to valuation
techniques using inputs that are not based on observable market data.&lt;/p&gt;
</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_801_eifrs-full--DisclosureOfAccountingJudgementsAndEstimatesExplanatory_zyknLoeTuQ29" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zDLKxXdOri22"&gt;CRITICAL
  ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being IFRS as
issued by the IASB, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income
and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based
on historical experience and other factors, including expectations of future events.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are considered to be the key sources of estimation uncertainty&lt;b&gt;:&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Share-based
payments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group accounts for share-based payment transactions for employees in accordance with IFRS 2 Share-based Payment, which requires the measurement
of the cost of employee services received in exchange for the options on our ordinary shares, based on the fair value of the award on
the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors selected the Black-Scholes-Merton option pricing model as the most appropriate method for determining the estimated fair value
of our share-based awards without market conditions. For performance-based options that include vesting conditions relating to the market
performance of our ordinary shares, a Monte Carlo pricing model was used in order to reflect the valuation impact of price hurdles that
have to be met as conditions to vesting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group makes estimates as to the useful life of an option award, the expected price volatility of the underlying share, risk free interest
rate for the term of the award and correlations and volatilities of the shares of peer group companies. The Group also makes estimates
as to the vesting period for awards that have performance-based criteria.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
resulting cost of an equity incentive award is recognised as expense over the requisite service period of the award, which is usually
the vesting period. Compensation expense is recognised over the vesting period using the straight-line method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
assumptions used for estimating fair value for share-based payment transactions are disclosed in note 27 to our consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80F_eifrs-full--DisclosureOfOtherOperatingExpenseExplanatory_zKqq8zJDfqt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82C_zXnleg6bN7Tl"&gt;OPERATING
                                            EXPENSES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_zcJQPfshHF66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
expenses are stated after charging:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BA_zv5H4Zdb09P3" style="display: none"&gt;DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_492_20210401_20220331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_490_20200401_20210331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_499_20190401_20200331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--KeyManagementPersonnelCompensationDirectorFees_zePbaRlnR1q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    fees including bonus (excluding Chairman&#x2019;s bonus)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;707,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278,224&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;122,101&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChairmansBonus_zWNaBdmQhEBi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman&#x2019;s
    bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0801"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,160,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--AuditorsRemuneration_zOFBOtlnRyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Auditor&#x2019;s
    Remuneration (refer to Note 20) &lt;span id="xdx_F4F_z1VPTCZ1HRX4"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;349,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;131,511&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;53,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--ProfessionalFeesExpense_maOEz5cJ_zSKJSxSK2Ykd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal
    and Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,143,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;343,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--GainlossOnDisposalOfLeases_zDCjm8fYgV8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Gain)/Loss
    on disposal of leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(179&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ForeignExchangeLossesGains_zjHTgj2143v1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FX
    Gains and losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,577&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200,061&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200,061&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--DepreciationAndAmortisationExpense_maOEz5cJ_zkqnZJ3zsXG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,423&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,512&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0D_zas2XeaQKt8b" style="vertical-align: top; width: 15pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_z2RKUHb9dNke" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#x2019;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#x2019;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AA_zu24TZXfaBfk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89A_ecustom--DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory_zcJQPfshHF66" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
expenses are stated after charging:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BA_zv5H4Zdb09P3" style="display: none"&gt;DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_492_20210401_20220331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_490_20200401_20210331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_499_20190401_20200331" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"/&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: italic 10pt Times New Roman, Times, Serif; width: 52%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;br/&gt;
                                            $&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: left"/&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--KeyManagementPersonnelCompensationDirectorFees_zePbaRlnR1q1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director
    fees including bonus (excluding Chairman&#x2019;s bonus)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;707,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;278,224&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;122,101&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ChairmansBonus_zWNaBdmQhEBi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Chairman&#x2019;s
    bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0801"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,160,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0803"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--AuditorsRemuneration_zOFBOtlnRyMf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Auditor&#x2019;s
    Remuneration (refer to Note 20) &lt;span id="xdx_F4F_z1VPTCZ1HRX4"&gt;*&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;349,665&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;131,511&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;53,402&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--ProfessionalFeesExpense_maOEz5cJ_zSKJSxSK2Ykd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal
    and Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,143,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;343,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;195,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--GainlossOnDisposalOfLeases_zDCjm8fYgV8g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(Gain)/Loss
    on disposal of leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(179&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0815"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ForeignExchangeLossesGains_zjHTgj2143v1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FX
    Gains and losses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(13,577&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200,061&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;200,061&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--DepreciationAndAmortisationExpense_maOEz5cJ_zkqnZJ3zsXG6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,423&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,512&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;212&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0D_zas2XeaQKt8b" style="vertical-align: top; width: 15pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F1D_z2RKUHb9dNke" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#x2019;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#x2019;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory>
    <OKYO:KeyManagementPersonnelCompensationDirectorFees
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">707385</OKYO:KeyManagementPersonnelCompensationDirectorFees>
    <OKYO:KeyManagementPersonnelCompensationDirectorFees
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">278224</OKYO:KeyManagementPersonnelCompensationDirectorFees>
    <OKYO:KeyManagementPersonnelCompensationDirectorFees
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">122101</OKYO:KeyManagementPersonnelCompensationDirectorFees>
    <OKYO:ChairmansBonus
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1160347</OKYO:ChairmansBonus>
    <ifrs-full:AuditorsRemuneration
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      id="Fact000805"
      unitRef="USD">349665</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      id="Fact000806"
      unitRef="USD">131511</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      id="Fact000807"
      unitRef="USD">53402</ifrs-full:AuditorsRemuneration>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1143300</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">343422</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">195433</ifrs-full:ProfessionalFeesExpense>
    <OKYO:GainlossOnDisposalOfLeases
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-179</OKYO:GainlossOnDisposalOfLeases>
    <OKYO:ForeignExchangeLossesGains
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-13577</OKYO:ForeignExchangeLossesGains>
    <OKYO:ForeignExchangeLossesGains
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">200061</OKYO:ForeignExchangeLossesGains>
    <OKYO:ForeignExchangeLossesGains
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">200061</OKYO:ForeignExchangeLossesGains>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2423</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1512</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">212</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_800_eifrs-full--DisclosureOfOperatingSegmentsExplanatory_zK7fl0qf2Pmi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_za9DJG2Orqyf"&gt;SEGMENTAL
                                            REPORTING&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year under review management identified the Group&#x2019;s only operating segment as the research and development of biotechnological
and pharmaceutical products. This one segment is monitored, and strategic decisions are made based upon it and other non-financial data
collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the
annual financial statements.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <OKYO:DisclosureOfEmployeeDetailsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80B_ecustom--DisclosureOfEmployeeDetailsExplanatory_zNzKw4PJSRuk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zUwHzfcQaSGc"&gt;EMPLOYEES
                                            INCLUDING OFFICERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutEmployeesExplanatory_zZzhVfMhnC1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zCg3Dxgsfoia" style="display: none"&gt;DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210401__20220331_zJK1dSHpyP3d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200401__20210331_zS7V6fUe7wfg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190401__20200331_zhysJddbD2dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Group&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Staff
    costs comprised:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DirectorsSalaries_zzJlwL2IxEI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;
    salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;707,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,438,571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;122,101&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--WagesAndSalaries_zCbkmO9Xt7z4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;323,186&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;121,702&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;229,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--SocialSecurityContributions_zMexCkPv3lt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Social
    security costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84,449&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,543&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68,740&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherShorttermEmployeeBenefits_zzA113lNobYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recruitment
    Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,259&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,922&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--EmployeeBenefitsExpense_zAc6HfaUaDle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    employee benefits expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,129,279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,582,739&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;420,188&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March
    31, 2020 were:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zdWNXY20Uey9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_z76vWoTxq5Hd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zMCPgwZdQKmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate
    and administration&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zcb2NreUYGm4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zyXHP3ZnUfcg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zgRPVeAAnHEd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331_zKFobcgy3Io4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331_zn1tzEcmsRe2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331_zAprse49DnKg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_z8nRwVEJndq9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group and Company made $&lt;span id="xdx_907_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20210401__20220331_zYQWoNgRX8Bb" title="Pension contribution"&gt;2,622&lt;/span&gt; of payments to a defined contribution pension schemes on behalf of Directors or employees during the year
ending March 31, 2022 (March 31, 2021: $&lt;span id="xdx_909_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20200401__20210331_zk5BlBACdOd3" title="Pension contribution"&gt;2,904&lt;/span&gt;, March 31 2020: $&lt;span id="xdx_901_eifrs-full--PostemploymentBenefitExpenseDefinedContributionPlans_c20190401__20200331_z0H3IhZ39aQ1" title="Pension contribution"&gt;2,774&lt;/span&gt;)&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




</OKYO:DisclosureOfEmployeeDetailsExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89E_ecustom--DisclosureOfDetailedInformationAboutEmployeesExplanatory_zZzhVfMhnC1g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zCg3Dxgsfoia" style="display: none"&gt;DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210401__20220331_zJK1dSHpyP3d" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20200401__20210331_zS7V6fUe7wfg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20190401__20200331_zhysJddbD2dh" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year
    ended March 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Group&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Staff
    costs comprised:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DirectorsSalaries_zzJlwL2IxEI8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;
    salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;707,385&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,438,571&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;122,101&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--WagesAndSalaries_zCbkmO9Xt7z4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Wages
    and salaries&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;323,186&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;121,702&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;229,347&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--SocialSecurityContributions_zMexCkPv3lt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Social
    security costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;84,449&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9,543&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;68,740&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherShorttermEmployeeBenefits_zzA113lNobYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recruitment
    Costs&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,259&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12,922&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eifrs-full--EmployeeBenefitsExpense_zAc6HfaUaDle" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Total
    employee benefits expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,129,279&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,582,739&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;420,188&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    average monthly number of employees, including directors, employed by the group during the years ending March 31, 2021, and March
    31, 2020 were:&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research
    and Development&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zdWNXY20Uey9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_z76vWoTxq5Hd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--ResearchAndDevelopmentMember_zMCPgwZdQKmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate
    and administration&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zcb2NreUYGm4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zyXHP3ZnUfcg" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331__ifrs-full--ClassesOfIntangibleAssetsOtherThanGoodwillAxis__custom--CorporateAndAdministrationMember_zgRPVeAAnHEd" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Corporate and administration"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20220331_zKFobcgy3Io4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20210331_zn1tzEcmsRe2" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfEmployees_iI_pip0_uInteger_c20200331_zAprse49DnKg" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total number of employees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory>
    <OKYO:DirectorsSalaries
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">707385</OKYO:DirectorsSalaries>
    <OKYO:DirectorsSalaries
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1438571</OKYO:DirectorsSalaries>
    <OKYO:DirectorsSalaries
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">122101</OKYO:DirectorsSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">323186</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">121702</ifrs-full:WagesAndSalaries>
    <ifrs-full:WagesAndSalaries
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">229347</ifrs-full:WagesAndSalaries>
    <ifrs-full:SocialSecurityContributions
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">84449</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">9543</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">68740</ifrs-full:SocialSecurityContributions>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">14259</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:OtherShorttermEmployeeBenefits
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">12922</ifrs-full:OtherShorttermEmployeeBenefits>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1129279</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1582739</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">420188</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2022-03-31_custom_ResearchAndDevelopmentMember"
      decimals="INF"
      unitRef="Integer">2</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2021-03-31_custom_ResearchAndDevelopmentMember"
      decimals="INF"
      unitRef="Integer">1</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2020-03-31_custom_ResearchAndDevelopmentMember"
      decimals="INF"
      unitRef="Integer">1</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2022-03-31_custom_CorporateAndAdministrationMember"
      decimals="INF"
      unitRef="Integer">5</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2021-03-31_custom_CorporateAndAdministrationMember"
      decimals="INF"
      unitRef="Integer">5</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2020-03-31_custom_CorporateAndAdministrationMember"
      decimals="INF"
      unitRef="Integer">3</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="Integer">7</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="Integer">6</ifrs-full:NumberOfEmployees>
    <ifrs-full:NumberOfEmployees
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="Integer">4</ifrs-full:NumberOfEmployees>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2622</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">2904</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">2774</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80B_eifrs-full--DisclosureOfInformationAboutKeyManagementPersonnelExplanatory_z1vAekVUCnMk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zugKqiGQufXe"&gt;REMUNERATION
  OF KEY MANAGEMENT PERSONNEL&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_z82Jw7rgipH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B4_z6eoRVcapVgd" style="display: none"&gt;SCHEDULE OF
REMUNERATION OF DIRECTORS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;&lt;br/&gt;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salary&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;&lt;br/&gt;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salary&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"&gt;&lt;span id="xdx_F42_zoORemjkg0rk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G.
    Cerrone (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zJwRoQbTyQmc" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Directors' fees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zA7MD3BExeDg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zuSVp0qrqYE4" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z1H6cleFajP5" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zaR8Ml2OXp1k" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zkoaGsrBKQN" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,160&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zFKhZNRw7PY9" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z6ZcLf6nkjJ8" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F4A_zcmcM70NVUja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G
    Jacob (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ziZY4SFDKuHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zchuBtXycHxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zMfKmv9pg8zh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zvYjB2pqWyd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,579&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zjK7D1AO1h44" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zTkkst7XIcp9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ztB7f8Ln9vi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zuYxRB6PDBal" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F4E_zzaXpCDtM9a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;W
    Simon&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zLvSegVwVCv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_z5G4arfld85e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zsY4YPBp8slk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zu5FvKgicT3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_zXh5gqSLKmMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_ziR4g5giYx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z2bJ593xY0sj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z9m3kUtwlUle" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F49_zFm9R05AmXLh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;K.
    Shailubhai (6)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zMwQRQ6AgnP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zjYrUyzh4yo2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zDbKs9k3JB73" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zJ3ixkf2DDmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zejh3HSzYFlb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z1GavsmgNkYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zwiEnKf05zP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z6SICVjSSkq3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F41_zmGavRadwrci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;J
    Brancaccio (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zJzQMAz59bGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_znRNaQPTpSZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Bonus"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0911"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zHpFX7ehxCDl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zcWLYBo4WMna" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zkQwVkBcsUhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zs6xJcti6qb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0915"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zz5AMRnJ2gzi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zqFIbPAExZGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F41_zJLgUzqgODTb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G
    Macrae (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zBGIHcmYZX6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z9Q2ETy3Eapl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zuJuf7xlGW37" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_ziIHzwa8a4Jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zx7BK1WLWAXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zNbrCVF1lWa1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z8Jqss0FDSnh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zcPMn6vhFdFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0925"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F46_zSCSXCjYZsBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;B
    Denoyer (5)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zyZh9yANafg5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zLwXKQg5EkV6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zdFhmkfHb2f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0928"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zRZ2rBN2k19k" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zAy5OlAa9cU3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zs7tjKo5mn6a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zkwRWpjCdBa9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_z7It9OMM0Je2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331_zOVK6I3VUsw1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20210401__20220331_zKEURchPa9m6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331_zO6pqSAbZNeh" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331_zivYpMRn1ZBa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,589&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331_z72j0IbuBhV6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DirectorsBonus_pn3n3_c20200401__20210331_zT47m87MiwQj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,201&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20200401__20210331_zrWCboYkOuC7" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331_zPwnrT4BIodj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&#x2019;000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&lt;br/&gt; fees&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share based&lt;br/&gt; payment&lt;br/&gt; expenses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;W Simon&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zUk5yIMoiBg9" style="width: 10%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zmVN5YAfYlQg" style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zyXHfCIzrGE2" style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zi39PWSrFrJj" style="width: 10%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F42_zdgU0nltkua9" style="text-align: justify"&gt;K. Shailubhai (6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zpx0UL5mnXqd" style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zrR0gXsz7Ehd" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z64f6ExpMdM" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zOaOil4dS3J" style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F43_zlZ4vg1RPHdf" style="text-align: justify"&gt;G Macrae (4)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zI66tZZDBpRg" style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zCkK2ZoKldPl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0951"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z14gZjqiWApe" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zbca9H2gAQY5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F45_zhIBMzPADFN7" style="text-align: justify; padding-bottom: 1.5pt"&gt;L Zambeletti (7)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z9zhoSTwAuV" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z6ZUQ1aqQt2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zHVKHhwti3E6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zrZJ4kZhznbk" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331_zeBYIC885IU9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20190401__20200331_ztO78z315hFl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20190401__20200331_zATpAnwJFwse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331_zNGjx3BII9G5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Share based payment expenses"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F0F_zdsAkDzx71u6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zFso84703sok" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gabriele
    Cerrone&#x2019;s bonus awarded for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded"&gt;1,160&lt;/span&gt;k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F07_zhlu0tFfEE9h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zFtqJgI8lMA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gary
    Jacob became an employee and Director of the Company on 7 January 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F00_zVGCkBTOFDal" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_z5cPpMHsrvf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;John
    Brancaccio was appointed as Director on 10 June 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0A_zPbxjDVQGxrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zb9U2ivUxQP4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0E_zkAhLD19uhje" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zju9flrcZlI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bernard
Denoyer was appointed as Director on 24 November 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0F_zeRBkloR8v6h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zC93YuD6Dxp3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;K
    Shailubhai resigned as Director on 17 June 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_zdKOOi2lXYZg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zpYeXyc5fTn2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leopoldo
    Zambeletti resigned as Director on 18 December 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A0_z9ONIEZCOAg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfShareOptionsGrantedToDirectorsExplanatory_zycsLkTejWhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following share options were granted to Directors in the year:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zHNq8SfTnDx9" style="display: none"&gt;SCHEDULE
OF SHARE OPTIONS GRANTED&#160;TO DIRECTORS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;J Brancaccio&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zVeQ2fW9nZo2" style="width: 11%; text-align: right" title="Number of options"&gt;325,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_z2gi1spW5x2" style="width: 11%; text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zHtMVMbte2k3" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;G Jacob&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_z2Qq0qXPnbf3" style="text-align: right"&gt;3,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zJThVA8w4bMh" style="text-align: right"&gt;40,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zSvKRuLfR4j1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;B Denoyer&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zJcYFhtLFxXl" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zZIlA4YDQtgh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zW796tZZY3Fh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zkJGfGiPauX9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;4,575,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zyFwmstGJsfg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;40,450,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzytfXWb2Vv6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zhfh3ZePpKo1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
director has yet benefitted from any increase in the value of share capital since issuance of the options and no director exercised share
options in the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Key Management Personnel of the Group are members of the leadership team who have the authority and responsibility for planning, directing
and controlling the activities of the Group either directly or indirectly. They include all Directors of the Board (executive and non-executive).
Key Management Personnel compensation is set out below.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_z2oWKmgIrQjj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_z4iUaM102BYh" style="display: none"&gt;SCHEDULE OF KEY
MANAGEMENT PERSONNEL COMPENSATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_ziOkPUmYBc6d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_z17rap7c5xG8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_zvQIOP6tZaY4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_pn3n3_z4sLaAo65vX3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,026&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_z6RayWBXrOr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share based payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--KeyManagementPersonnelCompensation_pn3n3_zoREdEZ3Q3Pk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zw8oBPohzHif" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89E_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_z82Jw7rgipH8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors
of the Group and Company received the following remuneration during the years ending March 31 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B4_z6eoRVcapVgd" style="display: none"&gt;SCHEDULE OF
REMUNERATION OF DIRECTORS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="30" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Year
    ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;&lt;br/&gt;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salary&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Directors&#x2019;&lt;br/&gt;
    fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bonus&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Salary&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
    based payment expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"&gt;&lt;span id="xdx_F42_zoORemjkg0rk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G.
    Cerrone (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zJwRoQbTyQmc" style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right" title="Directors' fees"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;164&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zA7MD3BExeDg" style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zuSVp0qrqYE4" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0879"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z1H6cleFajP5" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0880"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zaR8Ml2OXp1k" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;35&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zkoaGsrBKQN" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,160&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_zFKhZNRw7PY9" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0883"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GCerroneMember_fKDEp_z6ZcLf6nkjJ8" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F4A_zcmcM70NVUja" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G
    Jacob (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ziZY4SFDKuHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zchuBtXycHxh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zMfKmv9pg8zh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zvYjB2pqWyd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,579&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zjK7D1AO1h44" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zTkkst7XIcp9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_ztB7f8Ln9vi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GJacobMember_fKDIp_zuYxRB6PDBal" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F4E_zzaXpCDtM9a" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;W
    Simon&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zLvSegVwVCv3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;44&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_z5G4arfld85e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0894"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zsY4YPBp8slk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0895"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--WSimonMember_zu5FvKgicT3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_zXh5gqSLKmMg" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_ziR4g5giYx1d" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0898"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z2bJ593xY0sj" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0899"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--WSimonMember_z9m3kUtwlUle" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F49_zFm9R05AmXLh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;K.
    Shailubhai (6)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zMwQRQ6AgnP1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zjYrUyzh4yo2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0902"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zDbKs9k3JB73" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zJ3ixkf2DDmb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zejh3HSzYFlb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z1GavsmgNkYd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zwiEnKf05zP2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0907"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z6SICVjSSkq3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F41_zmGavRadwrci" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;J
    Brancaccio (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zJzQMAz59bGk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_znRNaQPTpSZ4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Bonus"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0911"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zHpFX7ehxCDl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0912"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zcWLYBo4WMna" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zkQwVkBcsUhi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zs6xJcti6qb7" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0915"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zz5AMRnJ2gzi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_fKDMp_zqFIbPAExZGl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F41_zJLgUzqgODTb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;G
    Macrae (4)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zBGIHcmYZX6e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z9Q2ETy3Eapl" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0919"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zuJuf7xlGW37" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0920"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_ziIHzwa8a4Jb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zx7BK1WLWAXa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zNbrCVF1lWa1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0923"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z8Jqss0FDSnh" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zcPMn6vhFdFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0925"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F46_zSCSXCjYZsBk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;B
    Denoyer (5)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zyZh9yANafg5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zLwXKQg5EkV6" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0927"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DirectorsSalary_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zdFhmkfHb2f" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0928"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zRZ2rBN2k19k" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zAy5OlAa9cU3" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DirectorsBonus_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zs7tjKo5mn6a" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0931"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--DirectorsSalary_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_zkwRWpjCdBa9" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331__srt--TitleOfIndividualAxis__custom--BDenoyerMember_fKDUp_z7It9OMM0Je2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0933"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20210401__20220331_zOVK6I3VUsw1" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;283&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20210401__20220331_zKEURchPa9m6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;75&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20210401__20220331_zO6pqSAbZNeh" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;350&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_986_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20210401__20220331_zivYpMRn1ZBa" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,589&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20200401__20210331_z72j0IbuBhV6" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;158&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_ecustom--DirectorsBonus_pn3n3_c20200401__20210331_zT47m87MiwQj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,201&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20200401__20210331_zrWCboYkOuC7" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;85&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20200401__20210331_zPwnrT4BIodj" style="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&#x2019;000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Directors&lt;br/&gt; fees&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Bonus&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Salary&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Share based&lt;br/&gt; payment&lt;br/&gt; expenses&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;W Simon&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zUk5yIMoiBg9" style="width: 10%; text-align: right"&gt;41&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zmVN5YAfYlQg" style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0943"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zyXHfCIzrGE2" style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0944"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--WSimonMember_zi39PWSrFrJj" style="width: 10%; text-align: right"&gt;4&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F42_zdgU0nltkua9" style="text-align: justify"&gt;K. Shailubhai (6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zpx0UL5mnXqd" style="text-align: right"&gt;38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zrR0gXsz7Ehd" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0947"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_z64f6ExpMdM" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--KShailubhaiMember_fKDYp_zOaOil4dS3J" style="text-align: right"&gt;31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_F43_zlZ4vg1RPHdf" style="text-align: justify"&gt;G Macrae (4)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zI66tZZDBpRg" style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zCkK2ZoKldPl" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0951"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_z14gZjqiWApe" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0952"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--GMacraeMember_fKDQp_zbca9H2gAQY5" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0953"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td id="xdx_F45_zhIBMzPADFN7" style="text-align: justify; padding-bottom: 1.5pt"&gt;L Zambeletti (7)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z9zhoSTwAuV" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DirectorsBonus_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_z6ZUQ1aqQt2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0955"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsSalary_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zHVKHhwti3E6" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331__srt--TitleOfIndividualAxis__custom--LZambelettiMember_fKDcp_zrZJ4kZhznbk" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--DirectorsRemunerationExpense_pn3n3_c20190401__20200331_zeBYIC885IU9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;122&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--DirectorsBonus_pn3n3_c20190401__20200331_ztO78z315hFl" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0959"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--DirectorsSalary_pn3n3_c20190401__20200331_zATpAnwJFwse" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--KeyManagementPersonnelCompensationSharebasedPayments_pn3n3_c20190401__20200331_zNGjx3BII9G5" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Share based payment expenses"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span id="xdx_F0F_zdsAkDzx71u6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_zFso84703sok" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gabriele
    Cerrone&#x2019;s bonus awarded for $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded"&gt;1,160&lt;/span&gt;k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F07_zhlu0tFfEE9h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F18_zFtqJgI8lMA7" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gary
    Jacob became an employee and Director of the Company on 7 January 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F00_zVGCkBTOFDal" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F16_z5cPpMHsrvf8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;John
    Brancaccio was appointed as Director on 10 June 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0A_zPbxjDVQGxrd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F11_zb9U2ivUxQP4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0E_zkAhLD19uhje" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zju9flrcZlI5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Bernard
Denoyer was appointed as Director on 24 November 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F0F_zeRBkloR8v6h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1C_zC93YuD6Dxp3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;K
    Shailubhai resigned as Director on 17 June 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F05_zdKOOi2lXYZg" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F12_zpYeXyc5fTn2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leopoldo
    Zambeletti resigned as Director on 18 December 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_GCerroneMember"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">164000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_GCerroneMember"
      decimals="-3"
      id="Fact000881"
      unitRef="USD">35000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_GCerroneMember"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">1160000</OKYO:DirectorsBonus>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-012022-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">75000</OKYO:DirectorsBonus>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-012022-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000887"
      unitRef="USD">350000</OKYO:DirectorsSalary>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">1579000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">41000</OKYO:DirectorsBonus>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000891"
      unitRef="USD">85000</OKYO:DirectorsSalary>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_GJacobMember"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">468000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">44000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">1000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">42000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">2000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000901"
      unitRef="USD">18000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000904"
      unitRef="USD">-15000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000905"
      unitRef="USD">37000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">17000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">42000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_JBrancaccioMember"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">20000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">31000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31_custom_JBrancaccioMember"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">16000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31_custom_GMacraeMember"
      decimals="-3"
      id="Fact000922"
      unitRef="USD">13000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-012022-03-31_custom_BDenoyerMember"
      decimals="-3"
      id="Fact000926"
      unitRef="USD">15000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-012022-03-31_custom_BDenoyerMember"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">4000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">283000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:DirectorsBonus
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">75000</OKYO:DirectorsBonus>
    <OKYO:DirectorsSalary
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">350000</OKYO:DirectorsSalary>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2021-04-01to2022-03-31"
      decimals="-3"
      unitRef="USD">1589000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">158000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:DirectorsBonus
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">1201000</OKYO:DirectorsBonus>
    <OKYO:DirectorsSalary
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">85000</OKYO:DirectorsSalary>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2020-04-012021-03-31"
      decimals="-3"
      unitRef="USD">503000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2019-04-012020-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">41000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2019-04-012020-03-31_custom_WSimonMember"
      decimals="-3"
      unitRef="USD">4000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000946"
      unitRef="USD">38000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2019-04-012020-03-31_custom_KShailubhaiMember"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">31000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2019-04-012020-03-31_custom_GMacraeMember"
      decimals="-3"
      id="Fact000950"
      unitRef="USD">8000</ifrs-full:DirectorsRemunerationExpense>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2019-04-012020-03-31_custom_LZambelettiMember"
      decimals="-3"
      id="Fact000954"
      unitRef="USD">36000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2019-04-012020-03-31_custom_LZambelettiMember"
      decimals="-3"
      id="Fact000957"
      unitRef="USD">6000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <ifrs-full:DirectorsRemunerationExpense
      contextRef="From2019-04-012020-03-31"
      decimals="-3"
      unitRef="USD">122000</ifrs-full:DirectorsRemunerationExpense>
    <OKYO:KeyManagementPersonnelCompensationSharebasedPayments
      contextRef="From2019-04-012020-03-31"
      decimals="-3"
      unitRef="USD">41000</OKYO:KeyManagementPersonnelCompensationSharebasedPayments>
    <OKYO:BonusAwarded
      contextRef="From2021-04-012022-03-31_custom_GCerroneMember"
      decimals="-3"
      unitRef="USD">1160000</OKYO:BonusAwarded>
    <OKYO:ScheduleOfShareOptionsGrantedToDirectorsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89F_ecustom--ScheduleOfShareOptionsGrantedToDirectorsExplanatory_zycsLkTejWhb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following share options were granted to Directors in the year:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B7_zHNq8SfTnDx9" style="display: none"&gt;SCHEDULE
OF SHARE OPTIONS GRANTED&#160;TO DIRECTORS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of &lt;br/&gt; options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 55%; text-align: justify"&gt;J Brancaccio&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zVeQ2fW9nZo2" style="width: 11%; text-align: right" title="Number of options"&gt;325,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_z2gi1spW5x2" style="width: 11%; text-align: right"&gt;450,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--JBrancaccioMember_zHtMVMbte2k3" style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0977"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;G Jacob&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_z2Qq0qXPnbf3" style="text-align: right"&gt;3,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zJThVA8w4bMh" style="text-align: right"&gt;40,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--GJacobMember_zSvKRuLfR4j1" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;B Denoyer&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zJcYFhtLFxXl" style="text-align: right"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zZIlA4YDQtgh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0982"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember__srt--TitleOfIndividualAxis__custom--BDenoyerMember_zW796tZZY3Fh" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0983"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zkJGfGiPauX9" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;4,575,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zyFwmstGJsfg" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;40,450,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--DirectorsMember_zzytfXWb2Vv6" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Number of options"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0989"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:ScheduleOfShareOptionsGrantedToDirectorsExplanatory>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_JBrancaccioMember"
      decimals="INF"
      unitRef="Shares">325000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_JBrancaccioMember"
      decimals="INF"
      unitRef="Shares">450000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_GJacobMember"
      decimals="INF"
      unitRef="Shares">3250000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31_custom_DirectorsMember_custom_GJacobMember"
      decimals="INF"
      unitRef="Shares">40000000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2021-04-012022-03-31_custom_DirectorsMember_custom_BDenoyerMember"
      decimals="INF"
      unitRef="Shares">1000000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2021-04-012022-03-31_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">4575000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31_custom_DirectorsMember"
      decimals="INF"
      unitRef="Shares">40450000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_898_eifrs-full--DisclosureOfEmployeeBenefitsExplanatory_z2oWKmgIrQjj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_z4iUaM102BYh" style="display: none"&gt;SCHEDULE OF KEY
MANAGEMENT PERSONNEL COMPENSATION&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20210401__20220331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_ziOkPUmYBc6d" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20200401__20210331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_z17rap7c5xG8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20190401__20200331__ifrs-full--CategoriesOfRelatedPartiesAxis__ifrs-full--KeyManagementPersonnelOfEntityOrParentMember_zvQIOP6tZaY4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"/&gt;&lt;td style="text-align: right"&gt;$&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x2019;000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--KeyManagementPersonnelCompensationShorttermEmployeeBenefits_pn3n3_z4sLaAo65vX3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: justify"&gt;Short-term employee benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,026&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,455&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_z6RayWBXrOr9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Share based payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,815&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;515&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--KeyManagementPersonnelCompensation_pn3n3_zoREdEZ3Q3Pk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;392&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">1026000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">1455000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">351000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">1815000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">515000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">41000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">2841000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="From2020-04-012021-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">1970000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="From2019-04-012020-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember"
      decimals="-3"
      unitRef="USD">392000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_801_eifrs-full--DisclosureOfIncomeTaxExplanatory_zuvlOuF4IYze" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82C_zATQaOhRAqnk"&gt;TAXATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_898_eifrs-full--DisclosureOfTaxReceivablesAndPayablesExplanatory_zTpr5AjWRcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zxO6z3GPQzgj" style="display: none"&gt;SCHEDULE
OF TAX CREDIT PERIOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210401__20220331_zpZY4HvA90J9" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200401__20210331_zS2WhvN8YA5h" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20190401__20200331_zMtuGAxFmh4j" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="text-decoration: underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_z3dkca1Qe6ja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;Current year tax (credit)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(509,282&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(24,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--AdjustmentsForCurrentTaxOfPriorPeriod_zHN85F7b3G3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustments in respect of prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(277,239&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_zWGOxkJy6ZA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Origination and reversal of timing differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zR5GhEgBM1yk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(786,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LossBeforeTaxation_zqgQa1G8Jf1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss before taxation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,045,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,378,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,620,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LossChargedAtStandardRateOfCorporationTax_zE24A79JgYul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss charged at standard rate of corporation tax &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210401__20220331_z51STLB7nbFd" title="Corporation tax rate"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200401__20210331_z2R9xAUXttXc"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20190401__20200331_z7R3mreO1z53" title="Corporation tax rate"&gt;19%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,181,337&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(641,915&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(307,866&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_z8SiS2olBDH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax losses arising in the year not recognized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;524,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;660,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TaxLossesSurrenderedForResearchAndDevelopment_zsGR3bFmOfF" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax losses surrendered for Research and Development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;667,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1043"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_z1zbXRnS5075" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses not deductible for taxation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_zeCGmHghSJY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax increase from effect of capital allowances and depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentTaxClaim_zDLPsa4a8cM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and Development tax claim&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(509,282&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ResearchAndDevelopmentEnhancedExpenditure_zDbTg4TDxT5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and Development enhanced expenditure&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(377,187&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_zo30sWgWiie8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and Development tax credits claimed in respect of previous periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(277,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--IncreaseDecreaseThroughForeignExchangeFinancialAssets_zgfKklf11Lb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Consolidation adjustment in relation to foreign exchange movements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,983&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32,504&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_zGPztcPidbjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loans written off&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1071"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_znKrZf957KGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(786,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zkKGziTLr6ii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No
deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will
be recoverable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has tax losses of $&lt;span id="xdx_906_eifrs-full--TaxEffectOfTaxLosses_c20210401__20220331_zlUu7w5u5KKa"&gt;15,870,525&lt;/span&gt; (2021: $&lt;span id="xdx_909_eifrs-full--TaxEffectOfTaxLosses_c20200401__20210331_z5wzR174TGMe"&gt;9,411,521&lt;/span&gt;, 2020: $&lt;span id="xdx_904_eifrs-full--TaxEffectOfTaxLosses_c20190401__20200331_zWe1gHUD8Vba"&gt;4,421,886&lt;/span&gt;) to carry forward for use against future profits&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_898_eifrs-full--DisclosureOfTaxReceivablesAndPayablesExplanatory_zTpr5AjWRcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zxO6z3GPQzgj" style="display: none"&gt;SCHEDULE
OF TAX CREDIT PERIOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210401__20220331_zpZY4HvA90J9" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20200401__20210331_zS2WhvN8YA5h" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20190401__20200331_zMtuGAxFmh4j" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="text-decoration: underline"&gt;Group&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--CurrentTaxExpenseIncome_z3dkca1Qe6ja" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 58%; text-align: left"&gt;Current year tax (credit)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(509,282&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(24,952&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1011"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--AdjustmentsForCurrentTaxOfPriorPeriod_zHN85F7b3G3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Adjustments in respect of prior periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(277,239&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences_zWGOxkJy6ZA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Origination and reversal of timing differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1017"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1018"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1019"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_zR5GhEgBM1yk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(786,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 19%. The difference can be reconciled as follows:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--LossBeforeTaxation_zqgQa1G8Jf1j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loss before taxation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(6,045,372&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,378,501&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,620,347&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LossChargedAtStandardRateOfCorporationTax_zE24A79JgYul" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Loss charged at standard rate of corporation tax &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20210401__20220331_z51STLB7nbFd" title="Corporation tax rate"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20200401__20210331_z2R9xAUXttXc"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFRBWCBDUkVESVQgUEVSSU9EIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eifrs-full--ApplicableTaxRate_pid_dp_uPure_c20190401__20200331_z7R3mreO1z53" title="Corporation tax rate"&gt;19%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,181,337&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(641,915&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(307,866&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense_z8SiS2olBDH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Tax losses arising in the year not recognized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;524,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;660,594&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;340,114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--TaxLossesSurrenderedForResearchAndDevelopment_zsGR3bFmOfF" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax losses surrendered for Research and Development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;667,335&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1043"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss_z1zbXRnS5075" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expenses not deductible for taxation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;370,306&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;145&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation_zeCGmHghSJY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tax increase from effect of capital allowances and depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(334&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ResearchAndDevelopmentTaxClaim_zDLPsa4a8cM4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and Development tax claim&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(509,282&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(43,432&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ResearchAndDevelopmentEnhancedExpenditure_zDbTg4TDxT5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and Development enhanced expenditure&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(377,187&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods_zo30sWgWiie8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and Development tax credits claimed in respect of previous periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(277,240&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--IncreaseDecreaseThroughForeignExchangeFinancialAssets_zgfKklf11Lb5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Consolidation adjustment in relation to foreign exchange movements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,983&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;135&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(32,504&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff_zGPztcPidbjc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Loans written off&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1071"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_di_znKrZf957KGi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Total tax (credit) for the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(786,521&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(24,994&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(76,289&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-509282</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-24952</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-277239</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-42</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-76289</ifrs-full:AdjustmentsForCurrentTaxOfPriorPeriod>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">786521</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">24994</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">76289</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <OKYO:LossBeforeTaxation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6045372</OKYO:LossBeforeTaxation>
    <OKYO:LossBeforeTaxation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3378501</OKYO:LossBeforeTaxation>
    <OKYO:LossBeforeTaxation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1620347</OKYO:LossBeforeTaxation>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Pure">0.19</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Pure">0.19</ifrs-full:ApplicableTaxRate>
    <OKYO:LossChargedAtStandardRateOfCorporationTax
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1181337</OKYO:LossChargedAtStandardRateOfCorporationTax>
    <OKYO:LossChargedAtStandardRateOfCorporationTax
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-641915</OKYO:LossChargedAtStandardRateOfCorporationTax>
    <OKYO:LossChargedAtStandardRateOfCorporationTax
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-307866</OKYO:LossChargedAtStandardRateOfCorporationTax>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">524870</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">660594</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">340114</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense>
    <OKYO:TaxLossesSurrenderedForResearchAndDevelopment
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">667335</OKYO:TaxLossesSurrenderedForResearchAndDevelopment>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">370306</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">145</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-3</OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation>
    <OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-334</OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation>
    <OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">81</OKYO:TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation>
    <OKYO:ResearchAndDevelopmentTaxClaim
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-509282</OKYO:ResearchAndDevelopmentTaxClaim>
    <OKYO:ResearchAndDevelopmentTaxClaim
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-43432</OKYO:ResearchAndDevelopmentTaxClaim>
    <OKYO:ResearchAndDevelopmentEnhancedExpenditure
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-377187</OKYO:ResearchAndDevelopmentEnhancedExpenditure>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-277240</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-42</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-76289</ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-3983</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">135</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-32504</ifrs-full:IncreaseDecreaseThroughForeignExchangeFinancialAssets>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">786521</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">24994</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">76289</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">15870525</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">9411521</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:TaxEffectOfTaxLosses
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">4421886</ifrs-full:TaxEffectOfTaxLosses>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80D_eifrs-full--DisclosureOfFinanceIncomeExpenseExplanatory_z6Bmt2CqwIfl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82E_z7U17UOkOUr7"&gt;FINANCE INCOME AND COSTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_897_eifrs-full--DisclosureOfFinanceCostExplanatory_zVIwQP9Y7xAk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zFA0aooYeKH8" style="display: none"&gt;SCHEDULE
OF FINANCE COST&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; text-align: left"&gt;Finance Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--RevenueFromInterest_c20210401__20220331_z5BQSJecRC5k" style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--RevenueFromInterest_c20200401__20210331_z9iOz0ATOuM8" style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--RevenueFromInterest_c20190401__20200331_zYoGULSQcRp9" style="width: 14%; font-size: 10pt; text-align: right"&gt;48,125&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total finance income&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--FinanceIncome_c20210401__20220331_zfwiJKbvUMJg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--FinanceIncome_c20200401__20210331_z28upqv01yge" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--FinanceIncome_c20190401__20200331_z74SwCEBy9Ab" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;48,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; text-align: left"&gt;Finance Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20210401__20220331_zCXJBdK1vm5i" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20200401__20210331_zT89OdbrWguc" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(1,122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20190401__20200331_zZYfP1t8ckU8" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total finance expenses&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--FinanceCosts_iN_di_c20210401__20220331_zlvnOnYSuWp" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--FinanceCosts_iN_di_c20200401__20210331_zw3FQjmHFMWk" style="font-size: 10pt; text-align: right"&gt;(1,123&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--FinanceCosts_iN_di_c20190401__20200331_zpax2t3ux8lj" style="font-size: 10pt; text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zwhSVyHJp8Xc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <ifrs-full:DisclosureOfFinanceCostExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_897_eifrs-full--DisclosureOfFinanceCostExplanatory_zVIwQP9Y7xAk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zFA0aooYeKH8" style="display: none"&gt;SCHEDULE
OF FINANCE COST&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; text-align: left"&gt;Finance Income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 46%; font-size: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--RevenueFromInterest_c20210401__20220331_z5BQSJecRC5k" style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--RevenueFromInterest_c20200401__20210331_z9iOz0ATOuM8" style="width: 14%; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1085"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--RevenueFromInterest_c20190401__20200331_zYoGULSQcRp9" style="width: 14%; font-size: 10pt; text-align: right"&gt;48,125&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total finance income&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--FinanceIncome_c20210401__20220331_zfwiJKbvUMJg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--FinanceIncome_c20200401__20210331_z28upqv01yge" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--FinanceIncome_c20190401__20200331_z74SwCEBy9Ab" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;48,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-size: 10pt; text-align: left"&gt;Finance Expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Interest expense on lease liabilities&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20210401__20220331_zCXJBdK1vm5i" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1090"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20200401__20210331_zT89OdbrWguc" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(1,122&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--InterestExpenseOnLeaseLiabilities_iN_di_c20190401__20200331_zZYfP1t8ckU8" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;Total finance expenses&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--FinanceCosts_iN_di_c20210401__20220331_zlvnOnYSuWp" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1093"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--FinanceCosts_iN_di_c20200401__20210331_zw3FQjmHFMWk" style="font-size: 10pt; text-align: right"&gt;(1,123&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--FinanceCosts_iN_di_c20190401__20200331_zpax2t3ux8lj" style="font-size: 10pt; text-align: right"&gt;(1,158&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ifrs-full:DisclosureOfFinanceCostExplanatory>
    <ifrs-full:RevenueFromInterest
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">48125</ifrs-full:RevenueFromInterest>
    <ifrs-full:FinanceIncome
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">48125</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1122</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1158</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:FinanceCosts
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1123</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">1158</ifrs-full:FinanceCosts>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_803_eifrs-full--DisclosureOfPropertyPlantAndEquipmentExplanatory_zYzidRpTvYKf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_z5KRlV0SOcm5"&gt;PROPERTY, PLANT AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zeehfFSYz9o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details
of the Group&#x2019;s property, plant and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B7_zk5p61NgWeBc" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;IT equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;At 1 April 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbm3svaqAEf" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331_zYl7p3r5oW7" style="width: 12%; text-align: right"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbyO3Phi8H9f" style="text-align: right" title="Additions"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zljr3IGPH9Bb" style="text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zNphzel2GQFf" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331_z3dls8PGuoFc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zWiB7NCRXNQf" style="text-align: right" title="Foreign exchange"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zDuZKWpxjs0a" style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zTw55nHaBPq1" style="text-align: right" title="Property and equipment, cost, ending  balance"&gt;9,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331_zQvZiKya0EWb" style="text-align: right"&gt;9,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At 1 April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH3QgMQhPXgc" style="text-align: right" title="Depreciation, beginning balance"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331_zz1FiovGWAug" style="text-align: right"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Charge in year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z30av2cacJD8" style="text-align: right" title="Charge in year"&gt;2,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331_zPZFrWjdvkai" style="text-align: right"&gt;2,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOD30thWAeMg" style="text-align: right" title="Foreign exchange"&gt;(63&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331_zbuWdloWm8Mf" style="text-align: right"&gt;(63&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zybgCEbakJy3" style="text-align: right" title="Depreciation, ending balance"&gt;4,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331_z8VmpTu2dWFl" style="text-align: right"&gt;4,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Net Book Value as at 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zdrMW5a86kQ4" style="text-align: right" title="Depreciation, net book value"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331_zu4nnXM8hH2c" style="text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;IT equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;At 1 April 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zadJS1DdOrp9" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331_zfZoEFLWnQUe" style="width: 12%; text-align: right"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zb76uxQ6aUGj" style="text-align: right" title="Additions"&gt;6,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zz70dKhw6yj2" style="text-align: right"&gt;6,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zPShkp99A2Pb" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331_zDIV8GM7OVW4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH9PfEb03lu9" style="text-align: right" title="Foreign exchange"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zchRCv1Ino7f" style="text-align: right"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z0Jhp0XXJQse" style="text-align: right" title="Property and equipment, cost, ending  balance"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331_zqh33mSfm1P6" style="text-align: right"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At 1 April 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z36KRN7x29i3" style="text-align: right" title="Depreciation, beginning balance"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331_zJrJ9WOy6cnl" style="text-align: right"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Charge in year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zDlS8NcyPw0f" style="text-align: right" title="Charge in year"&gt;1,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331_zQa0JJkJaGI7" style="text-align: right"&gt;1,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOEYqzsBcGsf" style="text-align: right" title="Foreign exchange"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331_zccQWkVKq5Fi" style="text-align: right"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zoUwEAla2oTd" style="text-align: right" title="Depreciation, ending balance"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331_zW8ydcV96hcc" style="text-align: right"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Net Book Value as at 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zcQ3Q7oQZbtf" style="text-align: right" title="Depreciation, net book value"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331_zavxPSoOYXCf" style="text-align: right"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zTBboH1RkJzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_zsV6hvqTV6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s property, plant and equipment is located in the following operating segments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"&gt;&lt;span id="xdx_8B2_ztfOLp0m8fl1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;Group&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220331_zyPuhkpTFt8l" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="text-align: right; margin-top: 0; margin-bottom: 0"&gt;Net
Book Value &lt;br/&gt;
March 31 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UKMember_zWOGzuTdEE3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; width: 78%; text-align: justify"&gt;UK&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;2,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UnitedStateMember_zpNO2hZ0Hnga" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--PropertyPlantAndEquipment_iI_znRT2UPILrn9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--PropertyPlantAndEquipment_iI_zey57vwsNt1h" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Property, plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
&lt;p id="xdx_8A1_zeiPPVcibwk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89F_eifrs-full--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_zeehfFSYz9o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Details
of the Group&#x2019;s property, plant and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B7_zk5p61NgWeBc" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;IT equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;At 1 April 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbm3svaqAEf" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20210401__20220331_zYl7p3r5oW7" style="width: 12%; text-align: right"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zbyO3Phi8H9f" style="text-align: right" title="Additions"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zljr3IGPH9Bb" style="text-align: right"&gt;1,669&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zNphzel2GQFf" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1107"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20210401__20220331_z3dls8PGuoFc" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zWiB7NCRXNQf" style="text-align: right" title="Foreign exchange"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20210401__20220331_zDuZKWpxjs0a" style="text-align: right"&gt;(233&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zTw55nHaBPq1" style="text-align: right" title="Property and equipment, cost, ending  balance"&gt;9,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20210401__20220331_zQvZiKya0EWb" style="text-align: right"&gt;9,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At 1 April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH3QgMQhPXgc" style="text-align: right" title="Depreciation, beginning balance"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20210401__20220331_zz1FiovGWAug" style="text-align: right"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Charge in year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z30av2cacJD8" style="text-align: right" title="Charge in year"&gt;2,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20210401__20220331_zPZFrWjdvkai" style="text-align: right"&gt;2,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOD30thWAeMg" style="text-align: right" title="Foreign exchange"&gt;(63&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20210401__20220331_zbuWdloWm8Mf" style="text-align: right"&gt;(63&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zybgCEbakJy3" style="text-align: right" title="Depreciation, ending balance"&gt;4,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20210401__20220331_z8VmpTu2dWFl" style="text-align: right"&gt;4,554&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Net Book Value as at 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zdrMW5a86kQ4" style="text-align: right" title="Depreciation, net book value"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--DepreciationNetValue_pp0p0_c20210401__20220331_zu4nnXM8hH2c" style="text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;IT equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;At 1 April 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zadJS1DdOrp9" style="width: 12%; text-align: right" title="Property and equipment, cost, beginning balance"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PropertyPlantAndEquipmentCost_iS_pp0p0_c20200401__20210331_zfZoEFLWnQUe" style="width: 12%; text-align: right"&gt;1,257&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zb76uxQ6aUGj" style="text-align: right" title="Additions"&gt;6,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zz70dKhw6yj2" style="text-align: right"&gt;6,944&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Disposals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zPShkp99A2Pb" style="text-align: right" title="Disposals"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DisposalsPropertyPlantAndEquipment_iN_pp0p0_di_c20200401__20210331_zDIV8GM7OVW4" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zH9PfEb03lu9" style="text-align: right" title="Foreign exchange"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_pp0p0_c20200401__20210331_zchRCv1Ino7f" style="text-align: right"&gt;142&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z0Jhp0XXJQse" style="text-align: right" title="Property and equipment, cost, ending  balance"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PropertyPlantAndEquipmentCost_iE_pp0p0_c20200401__20210331_zqh33mSfm1P6" style="text-align: right"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Depreciation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;At 1 April 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_z36KRN7x29i3" style="text-align: right" title="Depreciation, beginning balance"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PropertyPlantAndEquipmentDepreciation_iS_pp0p0_c20200401__20210331_zJrJ9WOy6cnl" style="text-align: right"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Charge in year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zDlS8NcyPw0f" style="text-align: right" title="Charge in year"&gt;1,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--EffectOfChargeInYearDepreciation_pp0p0_c20200401__20210331_zQa0JJkJaGI7" style="text-align: right"&gt;1,593&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zOEYqzsBcGsf" style="text-align: right" title="Foreign exchange"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--EffectOfForeignExchangeDepreciation_pp0p0_c20200401__20210331_zccQWkVKq5Fi" style="text-align: right"&gt;71&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zoUwEAla2oTd" style="text-align: right" title="Depreciation, ending balance"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PropertyPlantAndEquipmentDepreciation_iE_pp0p0_c20200401__20210331_zW8ydcV96hcc" style="text-align: right"&gt;2,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Net Book Value as at 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331__ifrs-full--ClassesOfPropertyPlantAndEquipmentAxis__custom--ITEquipmentMember_zcQ3Q7oQZbtf" style="text-align: right" title="Depreciation, net book value"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--DepreciationNetValue_pp0p0_c20200401__20210331_zavxPSoOYXCf" style="text-align: right"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <OKYO:PropertyPlantAndEquipmentCost
      contextRef="AsOf2021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">8343</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentCost contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">8343</OKYO:PropertyPlantAndEquipmentCost>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">1669</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1669</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">-233</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-233</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <OKYO:PropertyPlantAndEquipmentCost
      contextRef="AsOf2022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">9779</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentCost contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">9779</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentDepreciation
      contextRef="AsOf2021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">2286</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2286</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:EffectOfChargeInYearDepreciation
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">2331</OKYO:EffectOfChargeInYearDepreciation>
    <OKYO:EffectOfChargeInYearDepreciation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">2331</OKYO:EffectOfChargeInYearDepreciation>
    <OKYO:EffectOfForeignExchangeDepreciation
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">-63</OKYO:EffectOfForeignExchangeDepreciation>
    <OKYO:EffectOfForeignExchangeDepreciation
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-63</OKYO:EffectOfForeignExchangeDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation
      contextRef="AsOf2022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">4554</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">4554</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:DepreciationNetValue
      contextRef="From2021-04-012022-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">5225</OKYO:DepreciationNetValue>
    <OKYO:DepreciationNetValue
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">5225</OKYO:DepreciationNetValue>
    <OKYO:PropertyPlantAndEquipmentCost
      contextRef="AsOf2020-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">1257</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentCost contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">1257</OKYO:PropertyPlantAndEquipmentCost>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">6944</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">6944</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">142</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">142</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <OKYO:PropertyPlantAndEquipmentCost
      contextRef="AsOf2021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">8343</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentCost contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">8343</OKYO:PropertyPlantAndEquipmentCost>
    <OKYO:PropertyPlantAndEquipmentDepreciation
      contextRef="AsOf2020-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">622</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">622</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:EffectOfChargeInYearDepreciation
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">1593</OKYO:EffectOfChargeInYearDepreciation>
    <OKYO:EffectOfChargeInYearDepreciation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1593</OKYO:EffectOfChargeInYearDepreciation>
    <OKYO:EffectOfForeignExchangeDepreciation
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">71</OKYO:EffectOfForeignExchangeDepreciation>
    <OKYO:EffectOfForeignExchangeDepreciation
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">71</OKYO:EffectOfForeignExchangeDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation
      contextRef="AsOf2021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">2286</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:PropertyPlantAndEquipmentDepreciation contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2286</OKYO:PropertyPlantAndEquipmentDepreciation>
    <OKYO:DepreciationNetValue
      contextRef="From2020-04-012021-03-31_custom_ITEquipmentMember"
      decimals="0"
      unitRef="USD">6057</OKYO:DepreciationNetValue>
    <OKYO:DepreciationNetValue
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">6057</OKYO:DepreciationNetValue>
    <OKYO:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory_zsV6hvqTV6d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s property, plant and equipment is located in the following operating segments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.95pt; text-align: justify"&gt;&lt;span id="xdx_8B2_ztfOLp0m8fl1" style="display: none"&gt;SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;Group&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220331_zyPuhkpTFt8l" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="text-align: right; margin-top: 0; margin-bottom: 0"&gt;Net
Book Value &lt;br/&gt;
March 31 2022&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"/&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UKMember_zWOGzuTdEE3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; width: 78%; text-align: justify"&gt;UK&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;2,937&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eifrs-full--PropertyPlantAndEquipment_iI_hsrt--RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis__custom--UnitedStateMember_zpNO2hZ0Hnga" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;US&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,289&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--PropertyPlantAndEquipment_iI_znRT2UPILrn9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eifrs-full--PropertyPlantAndEquipment_iI_zey57vwsNt1h" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Property, plant and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;5,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;
</OKYO:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2022-03-31_custom_UKMember"
      decimals="0"
      unitRef="USD">2937</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="AsOf2022-03-31_custom_UnitedStateMember"
      decimals="0"
      unitRef="USD">2289</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5225</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5225</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_805_eifrs-full--DisclosureOfTradeAndOtherReceivablesExplanatory_zYmWNBzf8YH6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_824_zbe9wKy7Mzfa"&gt;OTHER RECEIVABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_zN4blPd07Ix8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zyB7ubYrYrAc" style="display: none"&gt;DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220331_z0Zkq71YyAOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210331_z3bCDh3xrjI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Group&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherCurrentReceivables_iI_zjcT4x8f4481" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;19,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CurrentValueAddedTaxReceivables_iI_zxMSIvnZ27L1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;VAT receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--Prepayments_iI_z3DDGg0OFeSb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;711,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentReceivables_iI_zFxjurqPKIth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;812,956&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,370&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zNdzfBV0xgj9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are no differences between the carrying amount and fair value of any of the trade and other receivables above.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepayments
include $&lt;span id="xdx_906_ecustom--PrepaymentsReceivables_iI_c20220331_znQ5zL13I7rg" title="Prepayments receivables"&gt;639,635&lt;/span&gt; of prepaid invoices relating to the OK-101 project.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedTradeAndOtherReceivablesExplanatory_zN4blPd07Ix8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_zyB7ubYrYrAc" style="display: none"&gt;DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20220331_z0Zkq71YyAOk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210331_z3bCDh3xrjI4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Group&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--OtherCurrentReceivables_iI_zjcT4x8f4481" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;Other receivables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;19,130&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--CurrentValueAddedTaxReceivables_iI_zxMSIvnZ27L1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;VAT receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;82,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--Prepayments_iI_z3DDGg0OFeSb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepayments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;711,209&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,072&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--TradeAndOtherCurrentReceivables_iI_zFxjurqPKIth" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;812,956&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;43,370&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">19130</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">4499</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">82617</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:CurrentValueAddedTaxReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">17799</ifrs-full:CurrentValueAddedTaxReceivables>
    <ifrs-full:Prepayments contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">711209</ifrs-full:Prepayments>
    <ifrs-full:Prepayments contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">21072</ifrs-full:Prepayments>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">812956</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">43370</ifrs-full:TradeAndOtherCurrentReceivables>
    <OKYO:PrepaymentsReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">639635</OKYO:PrepaymentsReceivables>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80E_eifrs-full--DisclosureOfTradeAndOtherPayablesExplanatory_zr8WRGgCFXn3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_zaHSkyisDEe7"&gt;TRADE AND OTHER PAYABLES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_895_ecustom--DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_z1TpnBoBBfO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B8_zti1IuYBWd81" style="display: none"&gt;DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220331_zQuvyKgXtT07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210331_zzrruNLNF9jc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Year ended March 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pn3n3_maTAOCPzjQt_zyDD0Inv5u74" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Trade payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;741,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--Accruals_iI_pn3n3_zXnGmfDLkrta" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--BonusAccrual_iI_pn3n3_zLDhyIfvkj7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Bonus accrual&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,391,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_iI_pn3n3_zz0fbhgv4Mxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,306,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,673,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_895_ecustom--DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory_z1TpnBoBBfO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span id="xdx_8B8_zti1IuYBWd81" style="display: none"&gt;DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20220331_zQuvyKgXtT07" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210331_zzrruNLNF9jc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"&gt;&lt;b&gt;Year ended March 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$000&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold"&gt;Group&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherCurrentPayablesToTradeSuppliers_iI_pn3n3_maTAOCPzjQt_zyDD0Inv5u74" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Trade payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;741,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--Accruals_iI_pn3n3_zXnGmfDLkrta" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;457,773&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,093&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--BonusAccrual_iI_pn3n3_zLDhyIfvkj7f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Bonus accrual&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;106,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,391,069&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent_iI_pn3n3_zz0fbhgv4Mxh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt; padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
    and other payables&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,306,150&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,673,154&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">741807000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">210992000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:Accruals contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">457773000</ifrs-full:Accruals>
    <ifrs-full:Accruals contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">71093000</ifrs-full:Accruals>
    <OKYO:BonusAccrual contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">106570000</OKYO:BonusAccrual>
    <OKYO:BonusAccrual contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1391069000</OKYO:BonusAccrual>
    <OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent contextRef="AsOf2022-03-31" decimals="-3" unitRef="USD">1306150000</OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent>
    <OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent contextRef="AsOf2021-03-31" decimals="-3" unitRef="USD">1673154000</OKYO:TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eifrs-full--DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_zpxjWuAEU5F" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zUATpX2dICt5"&gt;CAPITAL AND RESERVES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Capital
Management&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the purpose of the Company&#x2019;s capital management, capital includes called up share capital, share premium, share based payments
for options, share based payments for warrants and all other equity reserves attributable to the equity holders of the parent as reflected
in the statement of financial position.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s objectives when managing capital are to safeguard the Company&#x2019;s ability to continue as a going concern and to maximise
shareholder value through the optimisation of the debt and equity balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its capital to maximise the return to the shareholders through the optimisation of equity. The capital structure of the
Company as at 31 March 2022 consists of equity attributable to equity holders of the Company, comprising issued capital, reserves and
retained deficit as disclosed.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its capital structure and makes adjustments to it, in light of economic conditions and the strategy approved by shareholders.
To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders
or issue new shares and release the Company&#x2019;s share premium account. No changes were made in the objectives, policies or processes
during the year ended 31 March 2022 and 31 March 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share
capital and premium&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue an unlimited number of nil par value shares of a single class. The Company may issue fractional shares
and a fractional share shall have the corresponding fractional rights, obligations and liabilities of a whole share of the same class
or series of shares. Shares may be issued in one or more series of shares as the Directors may by resolution determine from time to time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
share in the Company confers upon the shareholder:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    right to one vote at a meeting of the shareholders or on any resolution of shareholders;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    right to an equal share in any dividend paid by the Company; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;the
    right to an equal share in the distribution of the surplus assets of the Company on its liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may by resolution of the Directors redeem, purchase or otherwise acquire all or any of the shares in the Company subject to regulations
set out in the Company&#x2019;s Articles of Incorporation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Authorized&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zQF1wsIWSUaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue an unlimited number of nil par value shares of a single class.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B1_z99m5UbcSvk1" style="display: none"&gt;SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Share capital&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Issued ordinary shares of US$0.00 each&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2020 &lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zI2GyAWKAQ9" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance, shares"&gt;636,297,049&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--Equity_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7HFLauLesEh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance"&gt;112,079,984&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Shares issued - private placement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfSharesIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2QGkJBMHGKh" style="text-align: right" title="Shares issued - private placement, shares"&gt;36,269,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfSharesIssuedPrivatePlacementValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2yvFVeXfPlh" style="text-align: right" title="Shares issued - private placement"&gt;230,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Relative Fair value charge for warrants issued in conjunction with private placement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueWarrantsIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zPjL31xagFkk" style="text-align: right" title="Relative Fair value charge for warrants issued in conjunction with private placement"&gt;(138,305&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;CLNs issued in lieu of fundraising commission&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IssuedInLieuValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxLU4yt50RG9" style="text-align: right" title="CLNs issued in lieu of fundraising commission"&gt;(558,395&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncreaseDecreaseThroughExerciseOfOptionsShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbe89ng9kIXh" style="text-align: right" title="Options exercised, shares"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgDwdCkblDO7" style="text-align: right" title="Options exercised"&gt;15,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zqz9DVicEiXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance, shares"&gt;672,816,302&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--Equity_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zWroLbqOyWH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance"&gt;111,629,173&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zTVXBueNSpCg" style="text-align: right" title="Exercise of warrants, shares"&gt;386,512,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsyCrb47nzv6" style="text-align: right" title="Exercise of warrants"&gt;3,470,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Conversion of CLN&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z6RoRHfYZqo8" style="text-align: right" title="Conversion of CLN, shares"&gt;315,086,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zU0cjhOvfMUd" style="text-align: right" title="Conversion of CLN"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,876,397&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2VDia2mobG" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"&gt;1,374,415,468&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Equity_iE_pp0p0_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zP07DWSELImc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;123,976,510&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zVsfw1SBhIjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Issuance
of ordinary shares&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2019, &lt;span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zvQkPbvZIRx9" title="Ordinary shares were issued"&gt;36,363,636&lt;/span&gt; ordinary shares were issued at an issue price of &lt;span id="xdx_904_eifrs-full--ParValuePerShare_iI_c20190531__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zAvLHx7KDi21" title="Ordinary shares were issued, per share"&gt;1.1&lt;/span&gt;p per ordinary share by way of a placing of ordinary shares
to raise finance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, &lt;span id="xdx_90B_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zXFtDu3Cgm4b" title="Ordinary shares were issued"&gt;75,825,130&lt;/span&gt; ordinary shares were issued at an issue price of &lt;span id="xdx_90E_eifrs-full--ParValuePerShare_iI_c20200331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z5ewCJ2923Pk" title="Ordinary shares were issued, per share"&gt;1.1&lt;/span&gt;p per ordinary share by way of a further placing of ordinary
shares to raise finance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2020, &lt;span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zZmcPvTNzp9c" title="Ordinary shares were issued"&gt;36,269,253&lt;/span&gt; ordinary shares were issued at an issue price of &lt;span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20200630__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zmEgPBG9T614" title="Ordinary shares were issued, per share"&gt;0.005&lt;/span&gt;p per ordinary share by way of a placing of ordinary shares
to raise finance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2021, &lt;span id="xdx_90C_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_z4k7uTxdG2Bj" title="Ordinary shares were issued"&gt;250,000&lt;/span&gt; ordinary shares were issued in relation to an exercise of options at an issue price of &lt;span id="xdx_901_eifrs-full--ParValuePerShare_iI_c20210331__ifrs-full--ClassesOfShareCapitalAxis__ifrs-full--OrdinarySharesMember_zFMoZgOkJ3ue" title="Ordinary shares were issued, per share"&gt;0.045&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, &lt;span id="xdx_900_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTxpGskBJA4a" title="Ordinary shares were issued"&gt;36,363,636&lt;/span&gt; ordinary shares were issued in relation to an exercise of warrants at an issue price of &lt;span id="xdx_90A_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmYgCHrVA2Zb" title="Ordinary shares were issued, per share"&gt;0.0135&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, &lt;span id="xdx_90F_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zob6Ry0UPcM4" title="Ordinary shares were issued"&gt;72,000,000&lt;/span&gt; ordinary shares were issued in relation to an exercise of warrants at an issue price of &lt;span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveOneMember_zSWAUoKaoX6k" title="Ordinary shares were issued, per share"&gt;0.0055&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, &lt;span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zFSNUmsCUKS" title="Ordinary shares were issued"&gt;76,605,760&lt;/span&gt; ordinary shares were issued in relation to a conversion of loan notes at an issue price of &lt;span id="xdx_90B_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zZBYg7wCXC9a" title="Ordinary shares were issued, per share"&gt;0.004&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, &lt;span id="xdx_909_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zBUMPbDplosh" title="Ordinary shares were issued"&gt;73,304,650&lt;/span&gt; ordinary shares were issued in relation to a conversion of loan notes at an issue price of &lt;span id="xdx_903_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesOneMember_zFVdryIG5KEk" title="Ordinary shares were issued, per share"&gt;0.085&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, &lt;span id="xdx_90A_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zFUKUWP7cXAa" title="Ordinary shares were issued"&gt;39,605,760&lt;/span&gt; ordinary shares were issued in relation to an exercise of warrants at an issue price of &lt;span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20210531__ifrs-full--ComponentsOfEquityAxis__custom--WarrantReserveTwoMember_zWZE0DwgONXj" title="Ordinary shares were issued, per share"&gt;0.004&lt;/span&gt;p per ordinary share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, &lt;span id="xdx_905_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zujPVugIqpU3" title="Ordinary shares were issued"&gt;165,176,000&lt;/span&gt; ordinary shares were issued in relation to a conversion of loan notes at an issue price of &lt;span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220228__ifrs-full--ClassesOfFinancialInstrumentsAxis__custom--LoanNotesMember_zwzazQpbMKx7" title="Ordinary shares were issued, per share"&gt;0.004&lt;/span&gt;p per ordinary
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, &lt;span id="xdx_907_eifrs-full--NumberOfOutstandingShareOptions_iI_pid_uShares_c20220228__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zj13tyNNzYE9" title="Ordinary shares were issued"&gt;238,543,360&lt;/span&gt; ordinary shares were issued in relation to a cashless exercise of warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share
options reserve&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
share-based payment reserve for options represents the cost to issue share-based compensation, primarily share options, based on their
grant date fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share
warrants reserve&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
share-based payment reserve for warrants represent the cost to issue warrants based on their grant date fair value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
Loan Note reserve&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
convertible loan note reserve represents the proceeds received on issuance of convertible loan notes classified as equity instruments,
accrued interest and any relative fair value adjustments. .&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Retained
Deficit reserve&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Retained
deficit represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Translation
reserve&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Dividends&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors paid &lt;span id="xdx_908_eifrs-full--DividendPayables_iI_do_c20220331_zfUL2ZAntQDi" title="Payment of dividend"&gt;&lt;span id="xdx_906_eifrs-full--DividendPayables_iI_do_c20210331_z8taAzLLzEqb" title="Payment of dividend"&gt;no&lt;/span&gt;&lt;/span&gt; dividend during the year to 31 March 2022 and 31 March 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Transfer
between equity reserves&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
company affected a transfer between reserves in equity in order to align the values of the equity reserves on a relative fair value basis.
The total amount recorded in equity remains unaltered.&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_892_eifrs-full--DisclosureOfClassesOfShareCapitalExplanatory_zQF1wsIWSUaa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is authorized to issue an unlimited number of nil par value shares of a single class.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B1_z99m5UbcSvk1" style="display: none"&gt;SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Share capital&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Issued ordinary shares of US$0.00 each&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2020 &lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfSharesOutstanding_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zI2GyAWKAQ9" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance, shares"&gt;636,297,049&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--Equity_iS_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z7HFLauLesEh" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Beginning balance"&gt;112,079,984&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Shares issued - private placement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--NumberOfSharesIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2QGkJBMHGKh" style="text-align: right" title="Shares issued - private placement, shares"&gt;36,269,253&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--NumberOfSharesIssuedPrivatePlacementValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2yvFVeXfPlh" style="text-align: right" title="Shares issued - private placement"&gt;230,019&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Relative Fair value charge for warrants issued in conjunction with private placement&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--FairValueWarrantsIssuedPrivatePlacement_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zPjL31xagFkk" style="text-align: right" title="Relative Fair value charge for warrants issued in conjunction with private placement"&gt;(138,305&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;CLNs issued in lieu of fundraising commission&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IssuedInLieuValue_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zxLU4yt50RG9" style="text-align: right" title="CLNs issued in lieu of fundraising commission"&gt;(558,395&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IncreaseDecreaseThroughExerciseOfOptionsShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zbe89ng9kIXh" style="text-align: right" title="Options exercised, shares"&gt;250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--IncreaseDecreaseThroughExerciseOfOptions_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zgDwdCkblDO7" style="text-align: right" title="Options exercised"&gt;15,870&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--NumberOfSharesOutstanding_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zqz9DVicEiXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance, shares"&gt;672,816,302&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--Equity_iS_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zWroLbqOyWH6" style="border-bottom: Black 2.5pt double; text-align: right" title="Beginning balance"&gt;111,629,173&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exercise of warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--IncreaseDecreaseThroughExerciseOfWarrantsEquityShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zTVXBueNSpCg" style="text-align: right" title="Exercise of warrants, shares"&gt;386,512,756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--IncreaseDecreaseThroughExerciseOfWarrantsEquity_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zsyCrb47nzv6" style="text-align: right" title="Exercise of warrants"&gt;3,470,940&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Conversion of CLN&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z6RoRHfYZqo8" style="text-align: right" title="Conversion of CLN, shares"&gt;315,086,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--IncreaseDecreaseThroughConversionOfConvertibleInstruments_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zU0cjhOvfMUd" style="text-align: right" title="Conversion of CLN"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8,876,397&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;At 31 March 2022&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfSharesOutstanding_iE_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_z2VDia2mobG" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance, shares"&gt;1,374,415,468&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--Equity_iE_pp0p0_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--IssuedCapitalMember_zP07DWSELImc" style="border-bottom: Black 2.5pt double; text-align: right" title="Ending balance"&gt;123,976,510&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">636297049</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2020-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">112079984</ifrs-full:Equity>
    <OKYO:NumberOfSharesIssuedPrivatePlacement
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">36269253</OKYO:NumberOfSharesIssuedPrivatePlacement>
    <OKYO:NumberOfSharesIssuedPrivatePlacementValue
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">230019</OKYO:NumberOfSharesIssuedPrivatePlacementValue>
    <OKYO:FairValueWarrantsIssuedPrivatePlacement
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-138305</OKYO:FairValueWarrantsIssuedPrivatePlacement>
    <OKYO:IssuedInLieuValue
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">-558395</OKYO:IssuedInLieuValue>
    <OKYO:IncreaseDecreaseThroughExerciseOfOptionsShares
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">250000</OKYO:IncreaseDecreaseThroughExerciseOfOptionsShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">15870</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">672816302</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2021-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">111629173</ifrs-full:Equity>
    <OKYO:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">386512756</OKYO:IncreaseDecreaseThroughExerciseOfWarrantsEquityShares>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">3470940</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <OKYO:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">315086410</OKYO:IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares>
    <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">8876397</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="INF"
      unitRef="Shares">1374415468</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:Equity
      contextRef="AsOf2022-03-31_ifrs-full_IssuedCapitalMember"
      decimals="0"
      unitRef="USD">123976510</ifrs-full:Equity>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2019-05-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="Shares">36363636</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2019-05-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="USDPShares">1.1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2020-03-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="Shares">75825130</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2020-03-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="USDPShares">1.1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2020-06-30_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="Shares">36269253</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2020-06-30_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="USDPShares">0.005</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-03-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="Shares">250000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-03-31_ifrs-full_OrdinarySharesMember"
      decimals="INF"
      unitRef="USDPShares">0.045</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">36363636</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">0.0135</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-05-31_custom_WarrantReserveOneMember"
      decimals="INF"
      unitRef="Shares">72000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-05-31_custom_WarrantReserveOneMember"
      decimals="INF"
      unitRef="USDPShares">0.0055</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-05-31_custom_LoanNotesMember"
      decimals="INF"
      unitRef="Shares">76605760</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-05-31_custom_LoanNotesMember"
      decimals="INF"
      unitRef="USDPShares">0.004</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-05-31_custom_LoanNotesOneMember"
      decimals="INF"
      unitRef="Shares">73304650</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-05-31_custom_LoanNotesOneMember"
      decimals="INF"
      unitRef="USDPShares">0.085</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2021-05-31_custom_WarrantReserveTwoMember"
      decimals="INF"
      unitRef="Shares">39605760</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2021-05-31_custom_WarrantReserveTwoMember"
      decimals="INF"
      unitRef="USDPShares">0.004</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-02-28_custom_LoanNotesMember"
      decimals="INF"
      unitRef="Shares">165176000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2022-02-28_custom_LoanNotesMember"
      decimals="INF"
      unitRef="USDPShares">0.004</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-02-28_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">238543360</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:DividendPayables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</ifrs-full:DividendPayables>
    <ifrs-full:DividendPayables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">0</ifrs-full:DividendPayables>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_805_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_zYYBEu6vihkh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"&gt;
&lt;tr style="vertical-align: top"&gt;
  &lt;td style="text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
  &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82F_zTJfekQNeT35"&gt;SHARE OPTIONS AND WARRANTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Options&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_zDs6kwvTCsJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_zKJ43HynaNn2" style="display: none"&gt;SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20210401__20220331_zBnXx2Z27wW" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding"&gt;60,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331_z9OF1qsv9bIc" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding"&gt;6.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20200401__20210331_zB2lpLNRsLP1" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding"&gt;19,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331_zbVxm1ZqgWn3" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zgtZUPpn810d" style="text-align: right" title="Options, granted"&gt;28,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zWqMuyLjpJqf" style="text-align: right" title="Weighted Average Exercise price, Granted"&gt;8.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zwbxypGNTnqj" style="text-align: right" title="Options, granted"&gt;42,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zUEKoj2yvXIf" style="text-align: right" title="Weighted Average Exercise price, Granted"&gt;7.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zVqtXqqkOXCj" style="text-align: right" title="Options, forfeited"&gt;(16,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zDgk82hgVKI6" style="text-align: right" title="Weighted Average Exercise price, Forfeited"&gt;5.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_z2pUMhy3BoYd" style="text-align: right" title="Options, forfeited"&gt;(750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zAmdrblhBC06" style="text-align: right" title="Weighted Average Exercise price, Forfeited"&gt;6.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zzGlESPEcPCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_z2O4EzirWGUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_zguc3dEIz887" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zX2p4vyKAlpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"&gt;6.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding at 31 March&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20210401__20220331_zIVtBWlbq5Lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding"&gt;72,400,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEiE7je0Vt8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding"&gt;7.49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20200401__20210331_zpaele3kquh1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding"&gt;60,750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zarLvtiYX6Hk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331_zaRay0yWGRqc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable"&gt;14,437,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEaNhtLb5dYi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable"&gt;7.36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331_zhPyMEFPupUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable"&gt;9,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zoTKjZIqPjn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable"&gt;6.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; font-size: 10pt"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20190401__20200331_z9Nw9D1OGcEl" style="width: 18%; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20190401__20200331_zwHisMhbOz6l" style="width: 18%; font-size: 10pt; text-align: right"&gt;23,000,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zqco43H2poE3" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zsoFPIjxFTzj" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_iN_di_uUSDPShares_c20190401__20200331_zdLpMC1qYEul" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20190401__20200331_zx1dEbBXrQhi" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zOFfw5ZCGXaj" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zNJeFfoReAR" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Outstanding at 31 March&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zRj9AxlQi7Xd" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20190401__20200331_z9jNGPiKdZqk" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;19,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zWFnhmT6OLY2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20190401__20200331_zbTd2cBcpCsg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;4,875,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A3_zPGI9W9vkCy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year ending 31 March 2022, &lt;span id="xdx_90C_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_doxL_uShares_c20210401__20220331_zbK9xRcJ7hl9" title="Number of option were exercised::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;no&lt;/span&gt;&lt;/span&gt; options were exercised. During the year ending 31 March 2021, &lt;span id="xdx_905_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zBubgi1X0D2l" title="Number of option were exercised"&gt;250,000&lt;/span&gt; options were exercised.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total outstanding fair value charge of the share option instruments is deemed to be approximately $&lt;span id="xdx_90A_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20220331_zch50rZS3538" title="Fair value charge of share option instruments deemed"&gt;2,072,515&lt;/span&gt; (2021: $&lt;span id="xdx_904_eifrs-full--DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue_iI_c20210331_zPvOT2e8E1Aj" title="Fair value charge of share option instruments deemed"&gt;2,682,050&lt;/span&gt;). A
share-based payment charge for the year of $&lt;span id="xdx_907_ecustom--ShareBasedPaymentCharge_c20210401__20220331_zSROmK3WHol4" title="Share based payment charge"&gt;1,718,727&lt;/span&gt; (2021: $&lt;span id="xdx_90A_ecustom--ShareBasedPaymentCharge_c20200401__20210331_zFRLxmK5XLeg" title="Share based payment charge"&gt;545,582&lt;/span&gt;) has been expensed in the statement of comprehensive income.
The share based payment charge in the year to March 31, 2022 includes a forfeiture of $&lt;span id="xdx_909_ecustom--ShareBasedPaymentChargeForfeiture_c20210401__20220331_z9oewG7J2JWk" title="Share based payment charge forfeiture"&gt;19,149&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
weighted average contractual life of options outstanding at March 31, 2022 is &lt;span id="xdx_90C_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20210401__20220331_z60myUIhSgn9" title="Weighted average contractual life of options outstanding"&gt;7.77&lt;/span&gt; years. (2021: &lt;span id="xdx_907_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20200401__20210331_zA5Ql33Zv8Z6" title="Weighted average contractual life of options outstanding"&gt;8.07&lt;/span&gt; years).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eifrs-full--DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_zRmrjLvVy22l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
options outstanding at the end of the year have the following expiry dates and exercise prices:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BE_zCYvDr4CdPn3" style="display: none"&gt;SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;Share Options as at 31 March 2022&lt;br/&gt; (&#x2018;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;6 July 2018&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span id="xdx_905_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_za11cw4SeNB1" title="Expiration date of outstanding"&gt;6 July 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zcUiaNFlUpji" title="Exercise Price"&gt;4.5p&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zBIvgID3y0X9" style="width: 18%; text-align: right" title="Share Options, Outstanding"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;20 August 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zMApVVo1CtZh" title="Expiration date of outstanding"&gt;19 August 2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zjvqLyWDj0v1" title="Exercise Price"&gt;15.5p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zuVt2gcyCy1i" style="text-align: right" title="Share Options, Outstanding"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;6 January 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_zitoPfFeUB66" title="Expiration date of outstanding"&gt;5 January 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_ztF25WaesvWh" title="Exercise Price"&gt;5p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_z6jsGPECbxr3" style="text-align: right" title="Share Options, Outstanding"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;12 January 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_z1kF1A6642vi" title="Expiration date of outstanding"&gt;11 January 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_ziw5ZqV5aZka" title="Exercise Price"&gt;7.9p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_zMNA5wJYgMbc" style="text-align: right" title="Share Options, Outstanding"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;15 April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zbem14aMRwtl" title="Expiration date of outstanding"&gt;15 April 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zVqV0CatIzwd" title="Exercise Price"&gt;7.88p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zzHQBf3ff3C6" style="text-align: right" title="Share Options, Outstanding"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;31 August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zllwEzpr4cok" title="Expiration date of outstanding"&gt;31 August 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_z2kZzFfu4gk5" title="Exercise Price"&gt;4.9p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zDSOG95UtpO3" style="text-align: right" title="Share Options, Outstanding"&gt;14,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;31 January 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zPyxLg3Cazqb" title="Expiration date of outstanding"&gt;30 January 2032&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zm1SfpQal5if" title="Exercise Price"&gt;8.0p&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zHI2Chh2B1Mh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share Options, Outstanding"&gt;8,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331_zvIv48WGKnmc" style="text-align: right" title="Share Options, Outstanding"&gt;72,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zYZ39ohDi5B2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Fair
value of options granted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Historical
volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable
to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has not paid any dividends on share capital since its inception and does not anticipate paying dividends on its share capital
in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has estimated a forfeiture rate of zero.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_zoVLXy2sWdXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zcceEqQFlaP5" style="display: none"&gt;SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;15 April 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 August 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 January 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zsLcnQuMbr3a" style="width: 14%; text-align: right" title="Grant date share price"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zaLPnKmd1Uyl" style="width: 14%; text-align: right" title="Grant date share price"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zb8gctmMfPt5" style="width: 14%; text-align: right" title="Grant date share price"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zdjSH7JJC00d" style="text-align: right" title="Exercise share price"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zsbofvgW7Us7" style="text-align: right" title="Exercise share price"&gt;4.9&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zpLZauYinPC4" style="text-align: right" title="Exercise share price"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--VestingPeriodsDescription_c20210412__20210415_z2z9YUvsxFl" title="Vesting periods"&gt;25% each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--VestingPeriodsDescription_c20210829__20210831_zs9Yfz0ZvKfj" title="Vesting periods"&gt;25% each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--VestingPeriodsDescription_c20220129__20220131_zWJ3KSD4V5ib" title="Vesting periods"&gt;1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210412__20210415_z998cjLwqlXd" style="text-align: right" title="Risk free rate"&gt;0.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210829__20210831_zVLgQdNLfxI7" style="text-align: right" title="Risk free rate"&gt;0.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20220129__20220131_zmBAxFFACaFb" style="text-align: right" title="Risk free rate"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210412__20210415_zQdmFb5a1mB9" style="text-align: right" title="Expected volatility"&gt;80.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210829__20210831_zpI3ijoVB1j1" style="text-align: right" title="Expected volatility"&gt;77.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20220129__20220131_zF2ahJF1mIZ2" style="text-align: right" title="Expected volatility"&gt;83.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--OptionLifePeriod_dtY_c20210412__20210415_z6eKbMSRO7al" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210829__20210831_zqlQyvD4L5Cl" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--OptionLifePeriod_dtY_c20220129__20220131_zRz3C4PGVnZd" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;20 August&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6 January&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12 January &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 42%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20200815__20200820_zzxSqmk2EUa2" style="width: 14%; text-align: right" title="Grant date share price"&gt;15.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210104__20210106_zDt7RmgVTqMb" style="width: 14%; text-align: right" title="Grant date share price"&gt;0.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210110__20210112_z5N1pvF4QuSg" style="width: 18%; text-align: right" title="Grant date share price"&gt;0.79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200815__20200820_z8UYAWz5qj6g" style="text-align: right" title="Exercise share price"&gt;15.5&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210104__20210106_z63tdn6KGE0h" style="text-align: right" title="Exercise share price"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210110__20210112_zjqb5DMz09m2" style="text-align: right" title="Exercise share price"&gt;0.79&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--VestingPeriodsDescription_c20200815__20200820_zeiP75ECJm84" title="Vesting periods"&gt;25%
each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--VestingPeriodsDescription_c20210104__20210106_z1VFiJ4SXayc" title="Vesting periods"&gt;25% each year&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--VestingPeriodsDescription_c20210110__20210112_zGrWABE0LFZ3" title="Vesting periods"&gt;33% in 6 months and 67% in 1 year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20200815__20200820_z1DYsNgaii7j" style="text-align: right" title="Risk free rate"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210104__20210106_zYitdBolAlh7" style="text-align: right" title="Risk free rate"&gt;-0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhcYUU7Y3edg" title="Risk free rate"&gt;0.4&lt;/span&gt;%,
&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_znJdygR1QQI1" title="Risk free rate"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20200815__20200820_zo4CinQ71S92" style="text-align: right" title="Expected volatility"&gt;77.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210104__20210106_zgVo52FLcWec" style="text-align: right" title="Expected volatility"&gt;77.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zv1xdkcnz4f5" title="Expected volatility"&gt;66.7&lt;/span&gt;%,
&lt;span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zIz42KB2JfR8" title="Expected volatility"&gt;83.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--OptionLifePeriod_dtY_c20200815__20200820_zWWcqGk15Hz4" title="Option life"&gt;5&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210104__20210106_z8zjROfjGeSj" title="Option life"&gt;5&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--OptionLifePeriod_dtM_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zKNeCysJyrxj" title="Option life"&gt;6&lt;/span&gt; months to &lt;span id="xdx_90B_ecustom--OptionLifePeriod_dtY_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zp3z6D4jbUE2" title="Option life"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zfDmXVbCLzKc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the acquisition of the OK-101 project, the underlying scientific founders of the OK-101 Project (inukshuk Holdings), who
will continue to be involved in the development of the Project, received &lt;span id="xdx_905_eifrs-full--ConsiderationPaidReceived_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zBPFWTl4tTE6" title="Consideration received"&gt;35,000,000&lt;/span&gt; warrants as consideration. The warrants are exercisable
at a price of &lt;span id="xdx_901_ecustom--WarrantsExercisablePricePerShare_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJ7ZHZDRRrzl" title="Warrants exercisable price per share"&gt;4.5&lt;/span&gt; pence each and are split into four distinct tranches and each tranche becomes exercisable upon satisfaction of a specific
developmental milestone. The warrants are exercisable until &lt;span id="xdx_906_ecustom--WarrantsExercisableDate_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember" title="Warrants exercisable date"&gt;17 July 2023&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2019, warrants were granted over &lt;span id="xdx_90A_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z0SvPoL0lsxa" title="Warrants granted"&gt;36,363,636&lt;/span&gt; shares at an exercise price of &lt;span id="xdx_902_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20190501__20190531__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"&gt;1.35&lt;/span&gt;p per share in connection with a private placement.
These warrants were exercised in May 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, warrants were granted over &lt;span id="xdx_902_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_z6nFfXTp1IO9" title="Warrants granted"&gt;40,000,000&lt;/span&gt; shares at an exercise price of &lt;span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"&gt;0.55&lt;/span&gt;p per share in connection with a private placement.
These warrants were exercised on a cashless basis in February 2022 (post a price reduction offer to &lt;span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"&gt;0.012&lt;/span&gt;p), resulting in the issuance
of &lt;span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zbDn8LswJH3g" title="Warrants granted"&gt;39,400,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
March 2020, warrants were granted over &lt;span id="xdx_90F_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_zMF7RuyLVWni" title="Warrants granted"&gt;35,825,130 &lt;/span&gt;shares at an exercise price of &lt;span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200301__20200331__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsOneMember_pdd" title="Weighted average exercise price, granted"&gt;0.55&lt;/span&gt;p per share in connection with a private placement.
These warrants were exercised in May 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2020, warrants were granted over &lt;span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_zLJ09Q3MNLOd" title="Warrants granted"&gt;36,174,870 &lt;/span&gt;shares at an exercise price of &lt;span id="xdx_90D_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__custom--PrivatePlacementsMember_pdd" title="Weighted average exercise price, granted"&gt;0.55&lt;/span&gt;p per share in connection with a private placement.
These warrants were exercised in May 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2020, warrants were granted over &lt;span id="xdx_909_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_z5kAoOD3wSi4" title="Warrants granted"&gt;909,090 &lt;/span&gt;shares at an exercise price of &lt;span id="xdx_905_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200501__20200531__ifrs-full--TypesOfContractsAxis__custom--LieuOfProfessionalFeesMember_pdd" title="Weighted average exercise price, granted"&gt;2.75&lt;/span&gt;p per share in in lieu of professional fees. The warrants
are exercisable until 21 May 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2020, warrants were granted over &lt;span id="xdx_90C_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zJ6QpUsUUMil" title="Warrants granted"&gt;750,000&lt;/span&gt; shares at an exercise price of &lt;span id="xdx_904_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20200701__20200731__ifrs-full--TypesOfContractsAxis__custom--LieuOfBrokerFeesMember_zDihcs8nbAS1" title="Weighted average exercise price, granted"&gt;14&lt;/span&gt;p per share in in lieu of broker fees. The warrants are
exercisable until 20 July 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, warrants were granted over &lt;span id="xdx_908_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zOLIsy6W2rfi" title="Warrants granted"&gt;76,605,760&lt;/span&gt; shares at an exercise price of &lt;span id="xdx_903_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20210501__20210531__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Weighted average exercise price, granted"&gt;0.4&lt;/span&gt;p per share in connection with the conversion of convertible
loan notes. &lt;span id="xdx_903_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zlJ9X3uUPN56" title="Warrants exercised"&gt;39,605,760&lt;/span&gt; were exercised immediately and the remaining &lt;span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_zbA8ZWrtiIw5" title="Warrants exercised on cashless basic"&gt;37,000,000&lt;/span&gt; were exercised on a cashless basis in February 2022 (post
a price reduction offer to &lt;span id="xdx_90B_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on price reduction offer"&gt;0.012&lt;/span&gt;p), resulting in the issuance of &lt;span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesMember_pdd" title="Warrants exercised on issuances"&gt;36,445,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
February 2022, warrants were granted over &lt;span id="xdx_90D_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zfetb7hcwlYg" title="Warrants granted"&gt;165,176,000&lt;/span&gt; shares at an exercise price of &lt;span id="xdx_90C_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Weighted average exercise price, granted"&gt;0.4&lt;/span&gt;p per share in connection with the conversion
of convertible loan notes. &lt;span id="xdx_90C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_z6oNkzBJdwt8" title="Warrants exercised"&gt;165,176,000&lt;/span&gt; were exercised on a cashless basis in February 2022(post a price reduction offer to &lt;span id="xdx_906_ecustom--WarrantsExercisedOnPriceReductionOffer_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_pdd" title="Warrants exercised on price reduction offer"&gt;0.012&lt;/span&gt;p), resulting
in the issuance of &lt;span id="xdx_902_ecustom--WarrantsExercisedOnIssuances_uShares_c20220201__20220228__ifrs-full--BorrowingsByNameAxis__custom--ConvertibleLoanNotesOneMember_zJXrJtrSstLc" title="Warrants exercised on issuances"&gt;162,698,360&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
summary, during the year, &lt;span id="xdx_900_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zdOf3TMbLfNe" title="Warrants exercised"&gt;147,969,396&lt;/span&gt; warrants were exercised for proceeds of &#xa3;&lt;span id="xdx_906_eifrs-full--ProceedsFromExerciseOfWarrants_pp0p0_uGBP_c20210401__20220331_zujDEkWG8lVf" title="Proceeds from warrants exercised"&gt;1,045,332&lt;/span&gt;, resulting in the issuance of &lt;span id="xdx_904_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331_zEUw6hBb6cl9" title="Warrants granted"&gt;147,969,396&lt;/span&gt;
shares. &lt;span id="xdx_904_ecustom--WarrantsExercisedOnCashlessBasic_uShares_c20210401__20220331_zdYLGe8kXR1l" title="Warrants exercised on cashless basic"&gt;242,716,000&lt;/span&gt; warrants were also exercised on a cashless basis resulting in the issuance of &lt;span id="xdx_909_ecustom--WarrantsExercisedOnIssuances_uShares_c20210401__20220331_zCaWfxjAaRQ9" title="Warrants exercised on issuances"&gt;238,543,360&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_89C_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_z1LLvaPTGXg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B6_z90HQYpTPNWg" style="display: none"&gt;&lt;span&gt;SCHEDULE OF WARRANTS
OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average exercise price (cents)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average exercise price (cents)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcd7KVh6AHU" style="width: 10%; text-align: right" title="Warrants outstanding, beginning balance"&gt;185,022,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z73YajK94nLj" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding beginning balance"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zQm9Dv1h3CFb" style="width: 10%; text-align: right"&gt;147,188,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zF1t7WDV96Lh" style="width: 10%; text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zNm8htQqtqq8" style="text-align: right" title="Warrants granted"&gt;241,781,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zuP7UXhDHn9b" style="text-align: right" title="Weighted average exercise price, granted"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1b5WkEd1382" style="text-align: right"&gt;37,833,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJBsp9LjITQk" style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1En4jVLMUil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercised"&gt;(390,145,396&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTyz7CgI7q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;0.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbfxILNOzhl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1ZvTvKfiZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1579"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at 31 March&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEhXslULHNR7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;36,659,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziAiKkBwPyCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance"&gt;6.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zofZ5ZpVf4rc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,022,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zawgODp3KTmf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zXxAO9XzX8b4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable"&gt;1,659,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z0BdExgerH6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;10.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zUes8Z2X6lyb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,568,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzEs9LlpqhB6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zLqsxtpHPZNg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model based on the assumptions
below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model inputs for warrants granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model included:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_zTfcGa6qE8Ek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zfr88tv0EsF9" style="display: none"&gt;SCHEDULE OF INPUTS FOR
WARRANTS GRANTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;29 May 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEsfwntYcTod" style="width: 16%; text-align: right" title="Grant date share price"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbbL5oIcUDy7" style="text-align: right" title="Exercise share price"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTxlwpqoxfj" style="text-align: right" title="Risk free rate"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zsFN4GAfFsq3" style="text-align: right" title="Expected volatility"&gt;79.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ExpectedLifeOfWarrants_dtY_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zq5wRgYwpVP5" title="Expected life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zzFu9tfNCPWh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_zurTi4FfrK1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zvhWhCbxZyNa" style="display: none"&gt;SCHEDULE OF FAIR VALUE
OF WARRANTS IN SERVICES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;July 2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;May 2020&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 41%"&gt;Grant date share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTpJqRf9hMEe" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;8.3p&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zvkI8JK1i6ej" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;2.8p&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zHxclxQs4x52" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.8p&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zPtfrlpk9lX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14p&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmRiSa4pNCAk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.8p&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zrlDZCTpjmJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5p&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantsVestingPeriod_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zoCvgeiTKvyk" title="Vesting periods"&gt;Fully vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--WarrantsVestingPeriod_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zdPnB7Qb9Id"&gt;50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsVestingPeriod_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zelhksSHOXI9"&gt;Fully
    vested &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk free rate &lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zqUxxQCSCECi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.68%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zOYKlyvnL8X1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.95%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zLShQVeV3NTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.22%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility &lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1F1LpH6qFG" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;88.1%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zV4GtEvwhMr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;79.6%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcatnTJgkge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;82.4%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ExpectedLifeOfWarrants_dtY_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziHcC6IoaUa7"&gt;2&lt;/span&gt; years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ExpectedLifeOfWarrants_dtY_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zyBlZXykt1Ch"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedLifeOfWarrants_dtY_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzKYE5UDPTee"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zp3OWSjNidCd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
remaining fair value of the warrant instruments is deemed to be approximately $&lt;span id="xdx_906_ecustom--FairValueOfWarrants_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjP4zzdj6DZ9" title="Fair value of warrants"&gt;43,348&lt;/span&gt; (2021: $&lt;span id="xdx_904_ecustom--FairValueOfWarrants_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zjoIo1i8tWsh" title="Fair value of warrants"&gt;108,873&lt;/span&gt;). For the consideration warrants,
the charge has been expensed over the vesting period. For all other warrants, the charge has been expensed over the service period. A
share-based payment charge for the year of $&lt;span id="xdx_909_ecustom--ShareBasedPaymentCharge_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzNi3rYUTn05"&gt;61,721&lt;/span&gt; (2021: $&lt;span id="xdx_905_ecustom--ShareBasedPaymentCharge_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmjZFi3iYiEk"&gt;81,914&lt;/span&gt;) has been expensed in the statement of comprehensive income.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_891_ecustom--DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory_zDs6kwvTCsJe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company operates share-based payment arrangements to remunerate Directors and key employees in the form of a share option scheme. It
also issues options in lieu of fees to key suppliers and collaborators. The exercise price of the option is normally equal to the market
price of an ordinary share in the Company at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B7_zKJ43HynaNn2" style="display: none"&gt;SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20210401__20220331_zBnXx2Z27wW" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding"&gt;60,750,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331_z9OF1qsv9bIc" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding"&gt;6.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20200401__20210331_zB2lpLNRsLP1" style="width: 10%; text-align: right" title="Beginning balance, Options outstanding"&gt;19,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331_zbVxm1ZqgWn3" style="width: 10%; text-align: right" title="Beginning balance, Weighted Average Exercise price, outstanding"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20210401__20220331_zgtZUPpn810d" style="text-align: right" title="Options, granted"&gt;28,150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zWqMuyLjpJqf" style="text-align: right" title="Weighted Average Exercise price, Granted"&gt;8.41&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20200401__20210331_zwbxypGNTnqj" style="text-align: right" title="Options, granted"&gt;42,250,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zUEKoj2yvXIf" style="text-align: right" title="Weighted Average Exercise price, Granted"&gt;7.31&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zVqtXqqkOXCj" style="text-align: right" title="Options, forfeited"&gt;(16,500,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_zDgk82hgVKI6" style="text-align: right" title="Weighted Average Exercise price, Forfeited"&gt;5.91&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_z2pUMhy3BoYd" style="text-align: right" title="Options, forfeited"&gt;(750,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zAmdrblhBC06" style="text-align: right" title="Weighted Average Exercise price, Forfeited"&gt;6.21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20210401__20220331_zzGlESPEcPCe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1315"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331_z2O4EzirWGUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_iN_di_uShares_c20200401__20210331_zguc3dEIz887" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, exercised"&gt;(250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331_zX2p4vyKAlpl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise price, Exercised"&gt;6.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Outstanding at 31 March&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20210401__20220331_zIVtBWlbq5Lg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding"&gt;72,400,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEiE7je0Vt8e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding"&gt;7.49&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20200401__20210331_zpaele3kquh1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Options outstanding"&gt;60,750,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zarLvtiYX6Hk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, outstanding"&gt;6.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331_zaRay0yWGRqc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable"&gt;14,437,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331_zEaNhtLb5dYi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable"&gt;7.36&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331_zhPyMEFPupUg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options, Exercisable"&gt;9,250,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331_zoTKjZIqPjn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Ending balance, Weighted Average Exercise price, Exercisable"&gt;6.21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt; Average &lt;br/&gt; exercise price &lt;br/&gt; (cents)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; font-size: 10pt"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20190401__20200331_z9Nw9D1OGcEl" style="width: 18%; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iS_uShares_c20190401__20200331_zwHisMhbOz6l" style="width: 18%; font-size: 10pt; text-align: right"&gt;23,000,000&lt;/td&gt;&lt;td style="width: 1%; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zqco43H2poE3" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1340"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zsoFPIjxFTzj" style="font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1341"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_iN_di_uUSDPShares_c20190401__20200331_zdLpMC1qYEul" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_iN_di_uShares_c20190401__20200331_zx1dEbBXrQhi" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;(3,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_uUSDPShares_c20190401__20200331_zOFfw5ZCGXaj" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1344"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_uShares_c20190401__20200331_zNJeFfoReAR" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Outstanding at 31 March&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zRj9AxlQi7Xd" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOutstandingShareOptions_iE_uShares_c20190401__20200331_z9jNGPiKdZqk" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;19,500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20190401__20200331_zWFnhmT6OLY2" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;5.58&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_iE_uShares_c20190401__20200331_zbTd2cBcpCsg" style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"&gt;4,875,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">60750000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">6.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">19500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">5.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">28150000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">8.41</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">42250000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">7.31</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">16500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">5.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">750000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">250000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">72400000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">7.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">60750000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">6.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">14437500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">7.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AsOf2021-03-31" decimals="INF" unitRef="Shares">9250000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31"
      decimals="INF"
      unitRef="USDPShares">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2019-03-31"
      decimals="INF"
      unitRef="USDPShares">5.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2019-03-31" decimals="INF" unitRef="Shares">23000000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">5.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">3500000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">5.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">19500000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="AsOf2020-03-31"
      decimals="INF"
      unitRef="USDPShares">5.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="AsOf2020-03-31" decimals="INF" unitRef="Shares">4875000</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">250000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2072515</ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue>
    <ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">2682050</ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue>
    <OKYO:ShareBasedPaymentCharge
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1718727</OKYO:ShareBasedPaymentCharge>
    <OKYO:ShareBasedPaymentCharge
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">545582</OKYO:ShareBasedPaymentCharge>
    <OKYO:ShareBasedPaymentChargeForfeiture
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">19149</OKYO:ShareBasedPaymentChargeForfeiture>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2021-04-01to2022-03-31">P7Y9M7D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="From2020-04-012021-03-31">P8Y25D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89F_eifrs-full--DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_zRmrjLvVy22l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share
options outstanding at the end of the year have the following expiry dates and exercise prices:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BE_zCYvDr4CdPn3" style="display: none"&gt;SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Expiry Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;Share Options as at 31 March 2022&lt;br/&gt; (&#x2018;000)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: justify"&gt;6 July 2018&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24%; text-align: center"&gt;&lt;span id="xdx_905_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_za11cw4SeNB1" title="Expiration date of outstanding"&gt;6 July 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_900_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zcUiaNFlUpji" title="Exercise Price"&gt;4.5p&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJulyTwoThousandEighteenMember_zBIvgID3y0X9" style="width: 18%; text-align: right" title="Share Options, Outstanding"&gt;2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;20 August 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zMApVVo1CtZh" title="Expiration date of outstanding"&gt;19 August 2028&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zjvqLyWDj0v1" title="Exercise Price"&gt;15.5p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwentyAugustTwoThousandTwentyMember_zuVt2gcyCy1i" style="text-align: right" title="Share Options, Outstanding"&gt;750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;6 January 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_901_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_zitoPfFeUB66" title="Expiration date of outstanding"&gt;5 January 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90B_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_ztF25WaesvWh" title="Exercise Price"&gt;5p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--SixJanuaryTwoThousandTwentyOneMember_z6jsGPECbxr3" style="text-align: right" title="Share Options, Outstanding"&gt;40,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;12 January 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_z1kF1A6642vi" title="Expiration date of outstanding"&gt;11 January 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_ziw5ZqV5aZka" title="Exercise Price"&gt;7.9p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--TwelveJanuaryTwoThousandTwentyOneMember_zMNA5wJYgMbc" style="text-align: right" title="Share Options, Outstanding"&gt;1,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;15 April 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zbem14aMRwtl" title="Expiration date of outstanding"&gt;15 April 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_904_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zVqV0CatIzwd" title="Exercise Price"&gt;7.88p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--FifteenAprilTwoThousandTwentyOneMember_zzHQBf3ff3C6" style="text-align: right" title="Share Options, Outstanding"&gt;5,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;31 August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_903_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zllwEzpr4cok" title="Expiration date of outstanding"&gt;31 August 2031&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_z2kZzFfu4gk5" title="Exercise Price"&gt;4.9p&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyOneMember_zDSOG95UtpO3" style="text-align: right" title="Share Options, Outstanding"&gt;14,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;31 January 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_90E_ecustom--ExpirationDateOfOutstanding_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zPyxLg3Cazqb" title="Expiration date of outstanding"&gt;30 January 2032&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&lt;span id="xdx_90D_eifrs-full--ExercisePriceShareOptionsGranted2019_c20210401__20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zm1SfpQal5if" title="Exercise Price"&gt;8.0p&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331__custom--GrantDateAxis__custom--ThirtyFirstAugustTwoThousandTwentyTwoMember_zHI2Chh2B1Mh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Share Options, Outstanding"&gt;8,750&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOutstandingShareOptions_iI_pn3n3_uShares_c20220331_zvIv48WGKnmc" style="text-align: right" title="Share Options, Outstanding"&gt;72,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember">2025-07-06</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember"
      decimals="INF"
      unitRef="USDPShares">4.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_SixJulyTwoThousandEighteenMember"
      decimals="-3"
      unitRef="Shares">2000000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember">2028-08-19</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_TwentyAugustTwoThousandTwentyMember"
      decimals="INF"
      unitRef="USDPShares">15.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_TwentyAugustTwoThousandTwentyMember"
      decimals="-3"
      unitRef="Shares">750000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember">2031-01-05</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_SixJanuaryTwoThousandTwentyOneMember"
      decimals="-3"
      unitRef="Shares">40000000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember">2031-01-11</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">7.9</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_TwelveJanuaryTwoThousandTwentyOneMember"
      decimals="-3"
      unitRef="Shares">1500000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember">2031-04-15</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">7.88</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_FifteenAprilTwoThousandTwentyOneMember"
      decimals="-3"
      unitRef="Shares">5000000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember">2031-08-31</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">4.9</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyOneMember"
      decimals="-3"
      unitRef="Shares">14400000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:ExpirationDateOfOutstanding contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember">2032-01-30</OKYO:ExpirationDateOfOutstanding>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-012022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="USDPShares">8.0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="AsOf2022-03-31_custom_ThirtyFirstAugustTwoThousandTwentyTwoMember"
      decimals="-3"
      unitRef="Shares">8750000</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="AsOf2022-03-31" decimals="-3" unitRef="Shares">72400000</ifrs-full:NumberOfOutstandingShareOptions>
    <OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory_zoVLXy2sWdXi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model inputs for options granted during the year ended 31 March 2022 valued under the Black Scholes Valuation model are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zcceEqQFlaP5" style="display: none"&gt;SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Grant Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;15 April 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 August 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 January 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zsLcnQuMbr3a" style="width: 14%; text-align: right" title="Grant date share price"&gt;7.7&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zaLPnKmd1Uyl" style="width: 14%; text-align: right" title="Grant date share price"&gt;4.9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zb8gctmMfPt5" style="width: 14%; text-align: right" title="Grant date share price"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210412__20210415_zdjSH7JJC00d" style="text-align: right" title="Exercise share price"&gt;7.9&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210829__20210831_zsbofvgW7Us7" style="text-align: right" title="Exercise share price"&gt;4.9&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20220129__20220131_zpLZauYinPC4" style="text-align: right" title="Exercise share price"&gt;8.0&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--VestingPeriodsDescription_c20210412__20210415_z2z9YUvsxFl" title="Vesting periods"&gt;25% each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--VestingPeriodsDescription_c20210829__20210831_zs9Yfz0ZvKfj" title="Vesting periods"&gt;25% each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_ecustom--VestingPeriodsDescription_c20220129__20220131_zWJ3KSD4V5ib" title="Vesting periods"&gt;1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210412__20210415_z998cjLwqlXd" style="text-align: right" title="Risk free rate"&gt;0.35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210829__20210831_zVLgQdNLfxI7" style="text-align: right" title="Risk free rate"&gt;0.30&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20220129__20220131_zmBAxFFACaFb" style="text-align: right" title="Risk free rate"&gt;0.97&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210412__20210415_zQdmFb5a1mB9" style="text-align: right" title="Expected volatility"&gt;80.20&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210829__20210831_zpI3ijoVB1j1" style="text-align: right" title="Expected volatility"&gt;77.7&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20220129__20220131_zF2ahJF1mIZ2" style="text-align: right" title="Expected volatility"&gt;83.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_902_ecustom--OptionLifePeriod_dtY_c20210412__20210415_z6eKbMSRO7al" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210829__20210831_zqlQyvD4L5Cl" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_ecustom--OptionLifePeriod_dtY_c20220129__20220131_zRz3C4PGVnZd" title="Option life"&gt;5&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
model inputs for options granted during the year ended 31 March 2021 valued under the Black Scholes Valuation model included:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;20 August&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6 January&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;12 January &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 42%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20200815__20200820_zzxSqmk2EUa2" style="width: 14%; text-align: right" title="Grant date share price"&gt;15.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210104__20210106_zDt7RmgVTqMb" style="width: 14%; text-align: right" title="Grant date share price"&gt;0.8&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--GrantDateShareOptionsGranted2019_uUSDPShares_c20210110__20210112_z5N1pvF4QuSg" style="width: 18%; text-align: right" title="Grant date share price"&gt;0.79&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200815__20200820_z8UYAWz5qj6g" style="text-align: right" title="Exercise share price"&gt;15.5&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210104__20210106_z63tdn6KGE0h" style="text-align: right" title="Exercise share price"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20210110__20210112_zjqb5DMz09m2" style="text-align: right" title="Exercise share price"&gt;0.79&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--VestingPeriodsDescription_c20200815__20200820_zeiP75ECJm84" title="Vesting periods"&gt;25%
each year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_ecustom--VestingPeriodsDescription_c20210104__20210106_z1VFiJ4SXayc" title="Vesting periods"&gt;25% each year&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--VestingPeriodsDescription_c20210110__20210112_zGrWABE0LFZ3" title="Vesting periods"&gt;33% in 6 months and 67% in 1 year&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20200815__20200820_z1DYsNgaii7j" style="text-align: right" title="Risk free rate"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210104__20210106_zYitdBolAlh7" style="text-align: right" title="Risk free rate"&gt;-0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zhcYUU7Y3edg" title="Risk free rate"&gt;0.4&lt;/span&gt;%,
&lt;span id="xdx_908_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_znJdygR1QQI1" title="Risk free rate"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20200815__20200820_zo4CinQ71S92" style="text-align: right" title="Expected volatility"&gt;77.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210104__20210106_zgVo52FLcWec" style="text-align: right" title="Expected volatility"&gt;77.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zv1xdkcnz4f5" title="Expected volatility"&gt;66.7&lt;/span&gt;%,
&lt;span id="xdx_909_eifrs-full--ExpectedDividendAsPercentageShareOptionsGranted_dp_uPure_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zIz42KB2JfR8" title="Expected volatility"&gt;83.7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_ecustom--OptionLifePeriod_dtY_c20200815__20200820_zWWcqGk15Hz4" title="Option life"&gt;5&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--OptionLifePeriod_dtY_c20210104__20210106_z8zjROfjGeSj" title="Option life"&gt;5&lt;/span&gt;
years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--OptionLifePeriod_dtM_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zKNeCysJyrxj" title="Option life"&gt;6&lt;/span&gt; months to &lt;span id="xdx_90B_ecustom--OptionLifePeriod_dtY_c20210110__20210112__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zp3z6D4jbUE2" title="Option life"&gt;1&lt;/span&gt; year&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2021-04-122021-04-15"
      decimals="INF"
      unitRef="USDPShares">7.7</OKYO:GrantDateShareOptionsGranted2019>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2021-08-292021-08-31"
      decimals="INF"
      unitRef="USDPShares">4.9</OKYO:GrantDateShareOptionsGranted2019>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2022-01-292022-01-31"
      decimals="INF"
      unitRef="USDPShares">4.8</OKYO:GrantDateShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-04-122021-04-15"
      decimals="INF"
      unitRef="USDPShares">7.9</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-08-292021-08-31"
      decimals="INF"
      unitRef="USDPShares">4.9</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2022-01-292022-01-31"
      decimals="INF"
      unitRef="USDPShares">8.0</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <OKYO:VestingPeriodsDescription contextRef="From2021-04-122021-04-15">25% each year</OKYO:VestingPeriodsDescription>
    <OKYO:VestingPeriodsDescription contextRef="From2021-08-292021-08-31">25% each year</OKYO:VestingPeriodsDescription>
    <OKYO:VestingPeriodsDescription contextRef="From2022-01-292022-01-31">1.25m options vest 33% each year and 7.5m options have developmental milestone performance conditions</OKYO:VestingPeriodsDescription>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2021-04-122021-04-15"
      decimals="INF"
      unitRef="Pure">0.0035</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2021-08-292021-08-31"
      decimals="INF"
      unitRef="Pure">0.0030</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2022-01-292022-01-31"
      decimals="INF"
      unitRef="Pure">0.0097</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2021-04-122021-04-15"
      decimals="INF"
      unitRef="Pure">0.8020</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2021-08-292021-08-31"
      decimals="INF"
      unitRef="Pure">0.777</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2022-01-292022-01-31"
      decimals="INF"
      unitRef="Pure">0.830</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <OKYO:OptionLifePeriod contextRef="From2021-04-122021-04-15">P5Y</OKYO:OptionLifePeriod>
    <OKYO:OptionLifePeriod contextRef="From2021-08-292021-08-31">P5Y</OKYO:OptionLifePeriod>
    <OKYO:OptionLifePeriod contextRef="From2022-01-292022-01-31">P5Y</OKYO:OptionLifePeriod>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2020-08-152020-08-20"
      decimals="INF"
      unitRef="USDPShares">15.5</OKYO:GrantDateShareOptionsGranted2019>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2021-01-042021-01-06"
      decimals="INF"
      unitRef="USDPShares">0.8</OKYO:GrantDateShareOptionsGranted2019>
    <OKYO:GrantDateShareOptionsGranted2019
      contextRef="From2021-01-102021-01-12"
      decimals="INF"
      unitRef="USDPShares">0.79</OKYO:GrantDateShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2020-08-152020-08-20"
      decimals="INF"
      unitRef="USDPShares">15.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-01-042021-01-06"
      decimals="INF"
      unitRef="USDPShares">0.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2021-01-102021-01-12"
      decimals="INF"
      unitRef="USDPShares">0.79</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <OKYO:VestingPeriodsDescription contextRef="From2020-08-152020-08-20">25%
each year</OKYO:VestingPeriodsDescription>
    <OKYO:VestingPeriodsDescription contextRef="From2021-01-042021-01-06">25% each year</OKYO:VestingPeriodsDescription>
    <OKYO:VestingPeriodsDescription contextRef="From2021-01-102021-01-12">33% in 6 months and 67% in 1 year</OKYO:VestingPeriodsDescription>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2020-08-152020-08-20"
      decimals="INF"
      unitRef="Pure">0.0015</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2021-01-042021-01-06"
      decimals="INF"
      unitRef="Pure">-0.0001</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember"
      decimals="INF"
      unitRef="Pure">0.004</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember"
      decimals="INF"
      unitRef="Pure">0.006</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2020-08-152020-08-20"
      decimals="INF"
      unitRef="Pure">0.774</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2021-01-042021-01-06"
      decimals="INF"
      unitRef="Pure">0.775</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember"
      decimals="INF"
      unitRef="Pure">0.667</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember"
      decimals="INF"
      unitRef="Pure">0.837</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <OKYO:OptionLifePeriod contextRef="From2020-08-152020-08-20">P5Y</OKYO:OptionLifePeriod>
    <OKYO:OptionLifePeriod contextRef="From2021-01-042021-01-06">P5Y</OKYO:OptionLifePeriod>
    <OKYO:OptionLifePeriod contextRef="From2021-01-102021-01-12_ifrs-full_BottomOfRangeMember">P6M</OKYO:OptionLifePeriod>
    <OKYO:OptionLifePeriod contextRef="From2021-01-102021-01-12_ifrs-full_TopOfRangeMember">P1Y</OKYO:OptionLifePeriod>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="0"
      unitRef="USD">35000000</ifrs-full:ConsiderationPaidReceived>
    <OKYO:WarrantsExercisablePricePerShare
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">4.5</OKYO:WarrantsExercisablePricePerShare>
    <OKYO:WarrantsExercisableDate contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember">2023-07-17</OKYO:WarrantsExercisableDate>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2019-05-012019-05-31_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="Shares">36363636</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2019-05-012019-05-31_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="USDPShares">1.35</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="Shares">40000000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="USDPShares">0.55</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2022-02-012022-02-28_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="USDPShares">0.012</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2022-02-012022-02-28_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="Shares">39400000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember"
      decimals="INF"
      unitRef="Shares">35825130</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-03-012020-03-31_custom_PrivatePlacementsOneMember"
      decimals="INF"
      unitRef="USDPShares">0.55</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-04-012020-04-30_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="Shares">36174870</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012020-04-30_custom_PrivatePlacementsMember"
      decimals="INF"
      unitRef="USDPShares">0.55</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember"
      decimals="INF"
      unitRef="Shares">909090</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-05-012020-05-31_custom_LieuOfProfessionalFeesMember"
      decimals="INF"
      unitRef="USDPShares">2.75</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember"
      decimals="INF"
      unitRef="Shares">750000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-07-012020-07-31_custom_LieuOfBrokerFeesMember"
      decimals="INF"
      unitRef="USDPShares">14</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="Shares">76605760</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2021-05-012021-05-31_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="USDPShares">0.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="Shares">39605760</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <OKYO:WarrantsExercisedOnCashlessBasic
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="Shares">37000000</OKYO:WarrantsExercisedOnCashlessBasic>
    <OKYO:WarrantsExercisedOnPriceReductionOffer
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="USDPShares">0.012</OKYO:WarrantsExercisedOnPriceReductionOffer>
    <OKYO:WarrantsExercisedOnIssuances
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesMember"
      decimals="INF"
      unitRef="Shares">36445000</OKYO:WarrantsExercisedOnIssuances>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember"
      decimals="INF"
      unitRef="Shares">165176000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember"
      decimals="INF"
      unitRef="USDPShares">0.4</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember"
      decimals="INF"
      unitRef="Shares">165176000</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <OKYO:WarrantsExercisedOnPriceReductionOffer
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember"
      decimals="INF"
      unitRef="USDPShares">0.012</OKYO:WarrantsExercisedOnPriceReductionOffer>
    <OKYO:WarrantsExercisedOnIssuances
      contextRef="From2022-02-012022-02-28_custom_ConvertibleLoanNotesOneMember"
      decimals="INF"
      unitRef="Shares">162698360</OKYO:WarrantsExercisedOnIssuances>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">147969396</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="GBP">1045332</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">147969396</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <OKYO:WarrantsExercisedOnCashlessBasic
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">242716000</OKYO:WarrantsExercisedOnCashlessBasic>
    <OKYO:WarrantsExercisedOnIssuances
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">238543360</OKYO:WarrantsExercisedOnIssuances>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89C_eifrs-full--DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_z1LLvaPTGXg6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B6_z90HQYpTPNWg" style="display: none"&gt;&lt;span&gt;SCHEDULE OF WARRANTS
OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average exercise price (cents)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Weighted Average exercise price (cents)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Outstanding at 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcd7KVh6AHU" style="width: 10%; text-align: right" title="Warrants outstanding, beginning balance"&gt;185,022,726&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z73YajK94nLj" style="width: 10%; text-align: right" title="Weighted average exercise price, outstanding beginning balance"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iS_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zQm9Dv1h3CFb" style="width: 10%; text-align: right"&gt;147,188,766&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iS_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zF1t7WDV96Lh" style="width: 10%; text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zNm8htQqtqq8" style="text-align: right" title="Warrants granted"&gt;241,781,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zuP7UXhDHn9b" style="text-align: right" title="Weighted average exercise price, granted"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--NumberOfInstrumentsOtherEquityInstrumentsGranted_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1b5WkEd1382" style="text-align: right"&gt;37,833,960&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zJBsp9LjITQk" style="text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1En4jVLMUil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants exercised"&gt;(390,145,396&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTyz7CgI7q1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;0.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbfxILNOzhl8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1578"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1ZvTvKfiZuk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1579"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Outstanding at 31 March&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEhXslULHNR7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding, ending balance"&gt;36,659,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziAiKkBwPyCe" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, outstanding ending balance"&gt;6.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zofZ5ZpVf4rc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;185,022,726&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zawgODp3KTmf" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercisable at 31 March&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zXxAO9XzX8b4" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants exercisable"&gt;1,659,090&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20210401__20220331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z0BdExgerH6c" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, exercisable"&gt;10.30&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement_iE_uShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zUes8Z2X6lyb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;149,568,181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019_iE_uUSDPShares_c20200401__20210331__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzEs9LlpqhB6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">185022726</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">2.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="AsOf2020-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">147188766</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2020-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">2.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">241781760</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">0.5</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">37833960</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">1.2</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">-390145396</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">0.7</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">36659090</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">6.11</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">185022726</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">2.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">1659090</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="AsOf2022-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">10.30</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Shares">149568181</ifrs-full:NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019
      contextRef="AsOf2021-03-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">1.1</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019>
    <OKYO:DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_898_ecustom--DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory_zTfcGa6qE8Ek" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zfr88tv0EsF9" style="display: none"&gt;SCHEDULE OF INPUTS FOR
WARRANTS GRANTED&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;29 May 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Grant date share price&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zEsfwntYcTod" style="width: 16%; text-align: right" title="Grant date share price"&gt;1.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Exercise share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zbbL5oIcUDy7" style="text-align: right" title="Exercise share price"&gt;0.4&lt;/td&gt;&lt;td style="text-align: left"&gt;p&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk free rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zDTxlwpqoxfj" style="text-align: right" title="Risk free rate"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_pid_dp_uPure_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zsFN4GAfFsq3" style="text-align: right" title="Expected volatility"&gt;79.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_ecustom--ExpectedLifeOfWarrants_dtY_c20200528__20200529__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zq5wRgYwpVP5" title="Expected life"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">1.75</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">0.4</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.25</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.796</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <OKYO:ExpectedLifeOfWarrants contextRef="From2020-05-282020-05-29_ifrs-full_WarrantReserveMember">P3Y</OKYO:ExpectedLifeOfWarrants>
    <OKYO:DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_893_ecustom--DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory_zurTi4FfrK1d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors have estimated the fair value of the warrants in services provided during the year ending 31 March 2021 using the Black-Scholes
valuation model based on the assumptions below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zvhWhCbxZyNa" style="display: none"&gt;SCHEDULE OF FAIR VALUE
OF WARRANTS IN SERVICES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;July 2020&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;May 2020&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;April&lt;/span&gt;&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 41%"&gt;Grant date share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zTpJqRf9hMEe" style="font: 10pt Times New Roman, Times, Serif; width: 13%; text-align: right"&gt;8.3p&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zvkI8JK1i6ej" style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"&gt;2.8p&lt;/td&gt;&lt;td style="width: 2%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98D_eifrs-full--WeightedAverageSharePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zHxclxQs4x52" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.8p&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zPtfrlpk9lX1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14p&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zmRiSa4pNCAk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2.8p&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--ExercisePriceShareOptionsGranted2019_uUSDPShares_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zrlDZCTpjmJ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.5p&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vesting periods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_ecustom--WarrantsVestingPeriod_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zoCvgeiTKvyk" title="Vesting periods"&gt;Fully vested&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_ecustom--WarrantsVestingPeriod_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zdPnB7Qb9Id"&gt;50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_ecustom--WarrantsVestingPeriod_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zelhksSHOXI9"&gt;Fully
    vested &lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk free rate &lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zqUxxQCSCECi" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.68%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98F_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zOYKlyvnL8X1" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.95%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_984_eifrs-full--DescriptionOfRiskFreeInterestRateShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zLShQVeV3NTe" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.22%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility &lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_z1F1LpH6qFG" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;88.1%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98C_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zV4GtEvwhMr5" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;79.6%&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_983_eifrs-full--DescriptionOfExpectedVolatilityShareOptionsGranted_uPure_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zcatnTJgkge9" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;82.4%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected life&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ExpectedLifeOfWarrants_dtY_c20200701__20200731__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_ziHcC6IoaUa7"&gt;2&lt;/span&gt; years&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ExpectedLifeOfWarrants_dtY_c20200501__20200531__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zyBlZXykt1Ch"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ExpectedLifeOfWarrants_dtY_c20200401__20200430__ifrs-full--ComponentsOfEquityAxis__ifrs-full--WarrantReserveMember_zzKYE5UDPTee"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">8.3</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">2.8</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">1.8</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">14</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">2.8</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="USDPShares">0.5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <OKYO:WarrantsVestingPeriod contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember">Fully vested</OKYO:WarrantsVestingPeriod>
    <OKYO:WarrantsVestingPeriod contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember">50% of these warrants shall only vest if the 5-day VWAP of the Company exceeds a 100% premium to the Exercise Price, and the remainder shall only vest if the 5-day VWAP of the Company exceeds a 200% premium to the Exercise Price  (conditions have been met)</OKYO:WarrantsVestingPeriod>
    <OKYO:WarrantsVestingPeriod contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember">Fully
    vested</OKYO:WarrantsVestingPeriod>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.0068</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.0095</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.0022</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.881</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.796</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember"
      decimals="INF"
      unitRef="Pure">0.824</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <OKYO:ExpectedLifeOfWarrants contextRef="From2020-07-012020-07-31_ifrs-full_WarrantReserveMember">P2Y</OKYO:ExpectedLifeOfWarrants>
    <OKYO:ExpectedLifeOfWarrants contextRef="From2020-05-012020-05-31_ifrs-full_WarrantReserveMember">P3Y</OKYO:ExpectedLifeOfWarrants>
    <OKYO:ExpectedLifeOfWarrants contextRef="From2020-04-012020-04-30_ifrs-full_WarrantReserveMember">P5Y</OKYO:ExpectedLifeOfWarrants>
    <OKYO:FairValueOfWarrants
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="0"
      unitRef="USD">43348</OKYO:FairValueOfWarrants>
    <OKYO:FairValueOfWarrants
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      decimals="0"
      unitRef="USD">108873</OKYO:FairValueOfWarrants>
    <OKYO:ShareBasedPaymentCharge
      contextRef="From2021-04-012022-03-31_ifrs-full_WarrantReserveMember"
      decimals="0"
      unitRef="USD">61721</OKYO:ShareBasedPaymentCharge>
    <OKYO:ShareBasedPaymentCharge
      contextRef="From2020-04-012021-03-31_ifrs-full_WarrantReserveMember"
      decimals="0"
      unitRef="USD">81914</OKYO:ShareBasedPaymentCharge>
    <ifrs-full:DisclosureOfDebtSecuritiesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_803_eifrs-full--DisclosureOfDebtSecuritiesExplanatory_zcflQnmUxUJc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zKSogIdq5Mxk"&gt;CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has raised convertible equity finance via the issuance of convertible loan notes as per the table below. All notes are not convertible
into cash and are convertible on the fourth anniversary of the date of issue of the Notes, or at the election of the noteholder on completion
of the next non-qualifying equity financing or on the making of a takeover offer for the Company (as defined in the City Code on Takeovers
and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming,
unconditional.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--DisclosureOfIssuanceOfConvertibleNotesExplanatory_z9WXST82QuX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B9_zGA5tD6eUa82" style="display: none"&gt;SCHEDULE OF ISSUANCE OF
CONVERTIBLE LOAN&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Terms&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amount&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"/&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 26%; text-align: left"&gt;29 May 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 54%; text-align: left"&gt;&#x25cf; &lt;span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zlC1BgpyZjid" title="Interest rate"&gt;20&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_905_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zMFSsu4bwI5b" title="Conversion price"&gt;0.4&lt;/span&gt;p &lt;br/&gt;&#x25cf; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of &lt;span id="xdx_907_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjZqVnhHKUll" title="Warrant exercise share"&gt;0.4&lt;/span&gt;p with a maximum life of &lt;span id="xdx_90B_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zPTxfShu5g6c" title="Debt term"&gt;5 years&lt;/span&gt; from the
    date of the conversion of the loan note&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zu9wOhWF6Ow" title="Issue of convertible instruments"&gt;541,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Fees relating to equity fundraise 29 May 2020 issued as CLN&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_90A_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zcGIUh42aq2e" title="Interest rate"&gt;20&lt;/span&gt;%
    coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_z0BRA6hDBFJh" title="Conversion price per share"&gt;0.4&lt;/span&gt;p &lt;br/&gt;&#x25cf;
    Upon conversion the shares will be issued with a warrant attached at an exercise price of &lt;span id="xdx_908_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zpLBCFncD9k9" title="Warrant Exercise per share"&gt;0.4&lt;/span&gt;p
    with a maximum life of &lt;span title="Debt term"/&gt;&lt;span id="xdx_907_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjl3ZONpf4I6" title="Debt term"&gt;5 years&lt;/span&gt; from the date of the conversion of the loan note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zwz1bGTftRQ9" title="Issue of convertible instruments"&gt;32,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;27 July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zDhybC3xgKDe" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;Conversion price of &lt;span id="xdx_908_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zg5p2KPUZNU2" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zX2Ergjjb9ll" title="Issue of convertible instruments"&gt;4,506,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;17 August 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zvbBhLid24w4" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_900_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zUQPz20QAzp9" title="Conversion price per share"&gt;8.5&lt;/span&gt;p &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zNMjjZgsDsi4" title="Issue of convertible instruments"&gt;1,882,641&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3
                                            September 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zpS8ngSKuhwj" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_90D_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_z551mFfXGer5" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zBVNjOa54Sba" title="Issue of convertible instruments"&gt;663,055&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: top; text-align: left"&gt;Fees relating to all other equity fundraise issued as CLN&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#x25cf; &lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zUD9vOcyMPYk" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_znrjvJTeSUV2" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zCyWyWRMn8wl" title="Issue of convertible instruments"&gt;525,922&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331_z11jltf6xKta" title="Issue of convertible instruments"&gt;8,151,777&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zTU2Qis7oQbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
noteholders were offered the option to convert during the year and any conversions took place on May 7, 2021 and February 21, 2022. Loan
note holders were offered conversions including the full interest that would have been accrued had the note reached its full term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfDebtSecuritiesExplanatory>
    <OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_894_ecustom--DisclosureOfIssuanceOfConvertibleNotesExplanatory_z9WXST82QuX4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B9_zGA5tD6eUa82" style="display: none"&gt;SCHEDULE OF ISSUANCE OF
CONVERTIBLE LOAN&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;Terms&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amount&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; vertical-align: bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"/&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; width: 26%; text-align: left"&gt;29 May 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 54%; text-align: left"&gt;&#x25cf; &lt;span id="xdx_90F_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zlC1BgpyZjid" title="Interest rate"&gt;20&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_905_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zMFSsu4bwI5b" title="Conversion price"&gt;0.4&lt;/span&gt;p &lt;br/&gt;&#x25cf; Upon
    conversion the shares will be issued with a warrant attached at an exercise price of &lt;span id="xdx_907_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjZqVnhHKUll" title="Warrant exercise share"&gt;0.4&lt;/span&gt;p with a maximum life of &lt;span id="xdx_90B_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zPTxfShu5g6c" title="Debt term"&gt;5 years&lt;/span&gt; from the
    date of the conversion of the loan note&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_907_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zu9wOhWF6Ow" title="Issue of convertible instruments"&gt;541,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Fees relating to equity fundraise 29 May 2020 issued as CLN&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_90A_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zcGIUh42aq2e" title="Interest rate"&gt;20&lt;/span&gt;%
    coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_z0BRA6hDBFJh" title="Conversion price per share"&gt;0.4&lt;/span&gt;p &lt;br/&gt;&#x25cf;
    Upon conversion the shares will be issued with a warrant attached at an exercise price of &lt;span id="xdx_908_ecustom--WarrantExercisePricePerShare_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zpLBCFncD9k9" title="Warrant Exercise per share"&gt;0.4&lt;/span&gt;p
    with a maximum life of &lt;span title="Debt term"/&gt;&lt;span id="xdx_907_ecustom--DebtTerm_dc_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentyNineMayTwoThousandAndTwentyMember_zjl3ZONpf4I6" title="Debt term"&gt;5 years&lt;/span&gt; from the date of the conversion of the loan note&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember_zwz1bGTftRQ9" title="Issue of convertible instruments"&gt;32,474&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;27 July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zDhybC3xgKDe" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;Conversion price of &lt;span id="xdx_908_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zg5p2KPUZNU2" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--TwentySevenJulyTwoThousandTwentyMember_zX2Ergjjb9ll" title="Issue of convertible instruments"&gt;4,506,446&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;17 August 2020&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zvbBhLid24w4" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_900_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zUQPz20QAzp9" title="Conversion price per share"&gt;8.5&lt;/span&gt;p &lt;br/&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--SeventeenthAugustTwoThousandAndTwentyMember_zNMjjZgsDsi4" title="Issue of convertible instruments"&gt;1,882,641&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3
                                            September 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x25cf; &lt;span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zpS8ngSKuhwj" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_90D_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_z551mFfXGer5" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--ThreeSeptemberTwoThousandAndTwentyMember_zBVNjOa54Sba" title="Issue of convertible instruments"&gt;663,055&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; vertical-align: top; text-align: left"&gt;Fees relating to all other equity fundraise issued as CLN&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#x25cf; &lt;span id="xdx_901_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zUD9vOcyMPYk" title="Interest rate"&gt;2.15&lt;/span&gt;% coupon per annum &lt;br/&gt;&#x25cf; Conversion price of &lt;span id="xdx_901_ecustom--ConversionPricePerShares_iI_c20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_znrjvJTeSUV2" title="Conversion price per share"&gt;8.5&lt;/span&gt;p&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331__ifrs-full--ClassesOfAssetsAxis__custom--FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember_zCyWyWRMn8wl" title="Issue of convertible instruments"&gt;525,922&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eifrs-full--IssueOfConvertibleInstruments_c20210401__20220331_z11jltf6xKta" title="Issue of convertible instruments"&gt;8,151,777&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="Pure">0.20</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="USDPShares">0.4</OKYO:ConversionPricePerShares>
    <OKYO:WarrantExercisePricePerShare
      contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="USDPShares">0.4</OKYO:WarrantExercisePricePerShare>
    <OKYO:DebtTerm contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">P5Y</OKYO:DebtTerm>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember"
      decimals="0"
      unitRef="USD">541239</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember"
      decimals="INF"
      unitRef="Pure">0.20</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember"
      decimals="INF"
      unitRef="USDPShares">0.4</OKYO:ConversionPricePerShares>
    <OKYO:WarrantExercisePricePerShare
      contextRef="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember"
      decimals="INF"
      unitRef="USDPShares">0.4</OKYO:WarrantExercisePricePerShare>
    <OKYO:DebtTerm contextRef="From2021-04-012022-03-31_custom_TwentyNineMayTwoThousandAndTwentyMember">P5Y</OKYO:DebtTerm>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember"
      decimals="0"
      unitRef="USD">32474</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember"
      decimals="INF"
      unitRef="Pure">0.0215</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember"
      decimals="INF"
      unitRef="USDPShares">8.5</OKYO:ConversionPricePerShares>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_TwentySevenJulyTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">4506446</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="Pure">0.0215</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="USDPShares">8.5</OKYO:ConversionPricePerShares>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_SeventeenthAugustTwoThousandAndTwentyMember"
      decimals="0"
      unitRef="USD">1882641</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="Pure">0.0215</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember"
      decimals="INF"
      unitRef="USDPShares">8.5</OKYO:ConversionPricePerShares>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_ThreeSeptemberTwoThousandAndTwentyMember"
      decimals="0"
      unitRef="USD">663055</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember"
      decimals="INF"
      unitRef="Pure">0.0215</ifrs-full:BorrowingsInterestRate>
    <OKYO:ConversionPricePerShares
      contextRef="AsOf2022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember"
      decimals="INF"
      unitRef="USDPShares">8.5</OKYO:ConversionPricePerShares>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-012022-03-31_custom_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember"
      decimals="0"
      unitRef="USD">525922</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:IssueOfConvertibleInstruments
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">8151777</ifrs-full:IssueOfConvertibleInstruments>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80C_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zitXUuwKIzY1" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zy2z7wiDF0Bc"&gt;FINANCIAL INSTRUMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
main risks arising from the Group&#x2019;s financial instruments are liquidity risk, interest rate risk and credit risk. The Directors
regularly review and agree policies for managing each of these risks which are summarized below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Liquidity
risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves
of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated
from by private and public offerings of equity and debt securities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_zoqKyLA0m1F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the maturity profile of the Group&#x2019;s financial liabilities based on contractual undiscounted
payments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BF_zmr1ZUhD4BX9" style="display: none"&gt;SUMMARY OF FINANCIAL
LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_z4B59WqIDKKi" style="font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zDAwKHUJfTwc" style="font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220331_zTfHCzYKtARb" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzENJ_zfcbbF2ZWT3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;649,624&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;92,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;741,810&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzENJ_zyruebiDfWv6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,041&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,041&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzENJ_zEFc68Ej9Lmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;696,665&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;92,186&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;788,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_zNEXJ5qt8gM1" style="font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zAbLSq6XX4W5" style="font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_z2XoYnqigSy7" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzjzM_zQwrY98YGIzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;110,179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;100,813&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzjzM_zmDdJcjuV88g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1702"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1704"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzjzM_zJOtu1pTyPN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;110,179&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;100,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zDrJvqdzcl04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Credit
risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Credit
risk is managed on a Group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial
institutions.as well as outstanding receivables. The Group reviews its banking arrangements carefully to minimize such risks and currently
has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the Group as part of their
internal reporting and assess outstanding receivables for ability to be repaid.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Interest
rate risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has limited exposure to interest-rate risk arising from its bank deposits and convertible loan note instruments. These deposit
accounts are held at variable interest rates based on Barclays bank &amp;amp; Penn base rates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result
for the year or the equity position at the year-end for either the year ended 31 March 2022 or 31 March 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_895_ecustom--DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory_zoqKyLA0m1F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below summarizes the maturity profile of the Group&#x2019;s financial liabilities based on contractual undiscounted
payments:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BF_zmr1ZUhD4BX9" style="display: none"&gt;SUMMARY OF FINANCIAL
LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_z4B59WqIDKKi" style="font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zDAwKHUJfTwc" style="font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20220331_zTfHCzYKtARb" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzENJ_zfcbbF2ZWT3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;649,624&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;92,186&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;741,810&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzENJ_zyruebiDfWv6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,041&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1691"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;47,041&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzENJ_zEFc68Ej9Lmk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;696,665&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;92,186&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;788,851&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210331__ifrs-full--MaturityAxis__custom--LessThanThreeMember_zNEXJ5qt8gM1" style="font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210331__ifrs-full--MaturityAxis__custom--ThreeToTwelveMonthsMember_zAbLSq6XX4W5" style="font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210331_z2XoYnqigSy7" style="font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;Group&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Less than 3&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;3 to 12&lt;br/&gt; months&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--TradeAndOtherPayables_iI_maTAOCPzjzM_zQwrY98YGIzj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Trade and other payables&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;110,179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;100,813&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_maTAOCPzjzM_zmDdJcjuV88g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party payables&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1702"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1703"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1704"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eifrs-full--FinancialLiabilities_iTI_mtTAOCPzjzM_zJOtu1pTyPN6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;110,179&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;100,813&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;210,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2022-03-31_custom_LessThanThreeMember"
      decimals="0"
      unitRef="USD">649624</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember"
      decimals="0"
      unitRef="USD">92186</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">741810</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2022-03-31_custom_LessThanThreeMember"
      decimals="0"
      unitRef="USD">47041</ifrs-full:TradeAndOtherPayablesToRelatedParties>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">47041</ifrs-full:TradeAndOtherPayablesToRelatedParties>
    <ifrs-full:FinancialLiabilities
      contextRef="AsOf2022-03-31_custom_LessThanThreeMember"
      decimals="0"
      unitRef="USD">696665</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AsOf2022-03-31_custom_ThreeToTwelveMonthsMember"
      decimals="0"
      unitRef="USD">92186</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">788851</ifrs-full:FinancialLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2021-03-31_custom_LessThanThreeMember"
      decimals="0"
      unitRef="USD">110179</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember"
      decimals="0"
      unitRef="USD">100813</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">210992</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:FinancialLiabilities
      contextRef="AsOf2021-03-31_custom_LessThanThreeMember"
      decimals="0"
      unitRef="USD">110179</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="AsOf2021-03-31_custom_ThreeToTwelveMonthsMember"
      decimals="0"
      unitRef="USD">100813</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">210992</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_801_eifrs-full--DisclosureOfRelatedPartyExplanatory_zlpdhyDU4FP9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_828_ztD4Awd4yjLl"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
related party transactions occurred in the normal course of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;West
African Minerals Limited (&#x201c;WAML&#x201d;)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
2018, the Group disposed of its Cameroon operations by way of an in-specie distribution of all of its shares in West African Minerals
Limited (formerly Ferrum Resources Limited) to shareholders. As part of this transaction, the Group had agreed to a deed of release with
WAML whereby it agreed to write off $&lt;span id="xdx_905_ecustom--WriteOffExchangeOfLoan_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zNkvIcnw6H6l" title="Write off related party exchange of loan"&gt;17,056,070&lt;/span&gt; of loans in exchange for shares in WAML to be distributed as part of the in-specie distribution.
A remaining amount of $&lt;span id="xdx_904_eifrs-full--RevenueFromSaleOfGoodsRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zSuJzUgCLFD2"&gt;3,400,000&lt;/span&gt; was outstanding from WAML, however, after careful consideration of the operations of WAML and its subsidiaries,
the Group decided to impair this receivable down to $nil in 2018 as it did not expect to recover any of this outstanding debt. In addition
to the $&lt;span id="xdx_903_eifrs-full--NetDebt_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_zgLgRnKOGAm9"&gt;3,400,000&lt;/span&gt; outstanding was a working capital loan advance of $&lt;span id="xdx_90E_eifrs-full--Borrowings_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_z6FP8JHGPwB2"&gt;600,000&lt;/span&gt; which was also impaired as the Group does not expect to
recover any of this outstanding debt. During the year ended March 31, 2022, the Group had funded $&lt;span id="xdx_907_eifrs-full--LoansAndReceivables_iI_do_c20220331_zOlc6rNCXH3d" title="Loans receivable"&gt;0&lt;/span&gt; (2021: $&lt;span id="xdx_905_eifrs-full--LoansAndReceivables_iI_c20210331_zDLLsSV0Da6h" title="Loans receivable"&gt;11,172&lt;/span&gt;) towards this $&lt;span id="xdx_904_eifrs-full--TradeAndOtherPayablesToRelatedParties_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--WestAfricanMineralsLimitedMember_ztWtGN05J9L6"&gt;600,000&lt;/span&gt;
loan facility and as at the year-end no further amounts were payable under this facility. The amounts funded in the year have been immediately
written off as the Group has no reasonable expectation of recovering the contractual cash flows of the loan in its entirety.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Tiziana
Life Sciences Ltd&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Tiziana
Life Sciences Ltd is a related party as the entity is controlled by a person that has significant influence over the Group. The Company
shares premises and other resources with Tiziana Life Sciences Ltd and there is a shared services agreement in place between the Company and
Tiziana Life Sciences PLC. As at 31&lt;sup&gt;st&lt;/sup&gt; March 2022, the Company had incurred $&lt;span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20210401__20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zpnVKbHZo1O3" title="Service received related party transaction"&gt;107,132&lt;/span&gt; (2021: $&lt;span id="xdx_902_eifrs-full--ServicesReceivedRelatedPartyTransactions_c20200401__20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zlYezFQwC8eh" title="Service received related party transaction"&gt;86,567&lt;/span&gt;) worth of costs in relation
to this agreement and at 31 March 2022 $&lt;span id="xdx_90E_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20220331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zJ6LSJcb5ffi" title="Amounts Payable related party transaction"&gt;47,041&lt;/span&gt; was due to Tiziana Life Sciences Ltd. At 31 March 2021, $&lt;span id="xdx_90A_eifrs-full--AmountsPayableRelatedPartyTransactions_iI_c20210331__ifrs-full--CounterpartiesAxis__custom--TizianaLifeSciencesLtdMember__ifrs-full--TypesOfContractsAxis__custom--ServiceAgreementMember_zsnK6ra2YE6b" title="Amounts Payable related party transaction"&gt;27,664&lt;/span&gt; was receivable from Tiziana
Life Sciences Ltd.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <OKYO:WriteOffExchangeOfLoan
      contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember"
      decimals="0"
      unitRef="USD">17056070</OKYO:WriteOffExchangeOfLoan>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions
      contextRef="From2021-04-012022-03-31_custom_WestAfricanMineralsLimitedMember"
      decimals="0"
      unitRef="USD">3400000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:NetDebt
      contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember"
      decimals="0"
      unitRef="USD">3400000</ifrs-full:NetDebt>
    <ifrs-full:Borrowings
      contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember"
      decimals="0"
      unitRef="USD">600000</ifrs-full:Borrowings>
    <ifrs-full:LoansAndReceivables contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">0</ifrs-full:LoansAndReceivables>
    <ifrs-full:LoansAndReceivables contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">11172</ifrs-full:LoansAndReceivables>
    <ifrs-full:TradeAndOtherPayablesToRelatedParties
      contextRef="AsOf2022-03-31_custom_WestAfricanMineralsLimitedMember"
      decimals="0"
      unitRef="USD">600000</ifrs-full:TradeAndOtherPayablesToRelatedParties>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions
      contextRef="From2021-04-012022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">107132</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:ServicesReceivedRelatedPartyTransactions
      contextRef="From2020-04-012021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">86567</ifrs-full:ServicesReceivedRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="AsOf2022-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">47041</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="AsOf2021-03-31_custom_TizianaLifeSciencesLtdMember_custom_ServiceAgreementMember"
      decimals="0"
      unitRef="USD">27664</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_809_eifrs-full--DisclosureOfEarningsPerShareExplanatory_zRUZ2SWf9eri" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.&lt;/b&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82B_zUnyPY1x2PWd"&gt;BASIC AND DILUTED LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eifrs-full--EarningsPerShareExplanatory_zSm0U7stgkp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zwF8RUz40iXi" style="display: none"&gt;SUMMARY
OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20210401__20220331_zNqmuav90nh5" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(6,268,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20200401__20210331_pp0p0" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(3,353,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageShares_c20210401__20220331_z6IzBFm1oPH" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;979,212,888&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--WeightedAverageShares_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;672,767,629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Basic and dilutive loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--BasicAndDilutedEarningsLossPerShare_c20210401__20220331_z1WozRvrawSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--BasicAndDilutedEarningsLossPerShare_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20190401__20200331_z4l19vmKMoP8" style="width: 16%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(1,544,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageShares_c20190401__20200331_zEvPIGB4F4oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;595,474,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Basic and dilutive loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BasicAndDilutedEarningsLossPerShare_c20190401__20200331_z9B8BNlE3wnc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zk7lwaU07q04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered
dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented
on the face of the Statement of comprehensive income are therefore identical.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:EarningsPerShareExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_896_eifrs-full--EarningsPerShareExplanatory_zSm0U7stgkp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
loss per share is calculated by dividing the loss attributable to equity holders of the Group by the weighted average number of ordinary
shares in issue during the year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BD_zwF8RUz40iXi" style="display: none"&gt;SUMMARY
OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20210401__20220331_zNqmuav90nh5" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(6,268,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20200401__20210331_pp0p0" style="width: 12%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(3,353,507&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--WeightedAverageShares_c20210401__20220331_z6IzBFm1oPH" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;979,212,888&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--WeightedAverageShares_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;672,767,629&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Basic and dilutive loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--BasicAndDilutedEarningsLossPerShare_c20210401__20220331_z1WozRvrawSb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--BasicAndDilutedEarningsLossPerShare_c20200401__20210331_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;(Loss) attributable to equity holders of the company ($)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity_c20190401__20200331_z4l19vmKMoP8" style="width: 16%; text-align: right" title="(Loss) attributable to equity holders of the company"&gt;(1,544,059&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Weighted average number of ordinary shares in issue&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--WeightedAverageShares_c20190401__20200331_zEvPIGB4F4oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average number of ordinary shares in issue"&gt;595,474,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Basic and dilutive loss per share (cents per share)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--BasicAndDilutedEarningsLossPerShare_c20190401__20200331_z9B8BNlE3wnc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Basic and dilutive loss per share (cents per share)"&gt;(0.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-6268197</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-3353507</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">979212888</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="Shares">672767629</ifrs-full:WeightedAverageShares>
    <OKYO:BasicAndDilutedEarningsLossPerShare
      contextRef="From2021-04-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</OKYO:BasicAndDilutedEarningsLossPerShare>
    <OKYO:BasicAndDilutedEarningsLossPerShare
      contextRef="From2020-04-012021-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.01</OKYO:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="From2019-04-012020-03-31"
      decimals="0"
      unitRef="USD">-1544059</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:WeightedAverageShares
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="Shares">595474039</ifrs-full:WeightedAverageShares>
    <OKYO:BasicAndDilutedEarningsLossPerShare
      contextRef="From2019-04-012020-03-31"
      decimals="INF"
      unitRef="USDPShares">-0.00</OKYO:BasicAndDilutedEarningsLossPerShare>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80F_eifrs-full--DisclosureOfLeasesExplanatory_zWskv507RpI3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.
&lt;span id="xdx_82E_z3P6cgdVDPji"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group is a lessee and does not have any leases as a lessor.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
leases are accounted for by recognising a right-of-use asset and a lease liability except for:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
    Leases of low value assets; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
with a duration of 12 months or less.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group
does not have leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based
on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its
right-of-use assets in a consistent manner to its property, plant and equipment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties
in their original condition at the end of the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year to March 31, 2022, the Group entered
into new lease agreement on its existing office. The new leases has a term shorter than 12 months, so the Group has applied the exemption
allowed by paragraph 5a in IFRS 16 in respect of short term leases.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the year to March 31, 2021, the group terminated from its lease early resulting in the right of use asset of $&lt;span id="xdx_90C_ecustom--DisposalsRightOfUseAssets_c20200401__20210331_zLfqCQB2D4ck" title="Early Termination write off right of use of assets"&gt;27,069&lt;/span&gt; and lease liability
of $&lt;span id="xdx_90A_ecustom--DisposalsLeaseLiabilities_c20200401__20210331_zjvcN10sMuxg" title="Early Termination write off lease liability"&gt;27,887&lt;/span&gt; being written off to the profit and loss. A new lease was subsequently entered into in January 2021. The initial recognition
resulted in a right of use asset and a lease liability of $&lt;span id="xdx_904_ecustom--InitialRecognitionForRightOfUseAssetAndLeaseLiability_c20200401__20210331_pp0p0" title="initial recognition for right of use asset and lease liability"&gt;104,377&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p id="xdx_89C_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_zZKJgd98QZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zVZpiUE9kMs8" style="display: none"&gt;SCHEDULE
OF RIGHT OF USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Property &lt;br/&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;At 1 April 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--RightofuseAssets_iS_c20210401__20220331_zzxDfJZQtynj" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year"&gt;98,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Derecognition of right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DisposalsRightOfUseAssets_c20210401__20220331_zD1HO3XrvGSh" style="text-align: right" title="Derecognition of right of use asset"&gt;(97,553&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact of Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ImpactOfForeignExchange_iN_di_c20210401__20220331_zzQyo0Jwr6ak" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impact of Foreign exchange"&gt;(1,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--RightofuseAssets_iE_c20210401__20220331_zvgcnVyaIU1" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;At 1 April 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--RightofuseAssets_iS_c20200401__20210331_zUznAy0hxQgc" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year"&gt;30,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of early terminated lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DepreciationOfEarlyTerminatedLease_c20200401__20210331_zMR2gPGEmIF3" style="text-align: right" title="Depreciation of early terminated lease"&gt;(4,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Early Termination write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DisposalsRightOfUseAssets_iN_di_c20200401__20210331_zmJPyy0U421f" style="text-align: right" title="Early Termination write off"&gt;(27,069&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ImpactOfForeignExchange_c20200401__20210331_zA078dNHUbzc" style="text-align: right" title="Impact of Foreign exchange"&gt;1,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AdditionsToRightofuseAssets_c20200401__20210331_zMQcUq9qXCd2" style="text-align: right" title="Additions"&gt;104,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of new lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DepreciationOfNewLease_c20200401__20210331_zjlwxfOcTG7f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation of new lease"&gt;(5,799&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iE_c20200401__20210331_zQH9Uk8SKbP9" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"&gt;98,579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Lease Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210401__20220331_zxT5lM2DB388" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200401__20210331_zAc7Rrn5SjU6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt; &#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--LeaseLiabilities_iS_zZmBklQvjOTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 60%"&gt;At 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LeaseLiabilities_iS_zTo2iwDz0etj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Liabilities, balance as at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--LeaseLiabilitiesInterestExpense_zPIrqOS9pajd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LeasePayments_zNa5PCDQm2n8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1793"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,542&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ImpactOfForeignExchangeLeaseLiabilities_zKImhhjwP1v8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1797"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DerecognitionOfLeaseLiability_zsLlWUqHIva1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Derecognition of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(97,553&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalsLeaseLiabilities_iN_di_zA5gJ4qrPJ5l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Early Termination write off&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,887&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AdditionsToLeaseLiabilities_zTBcNDgE6xAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LeaseLiabilitiesInterestExpenses_zhiVgAqdY6Qc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LeasePayment_zh6mgGmMfmv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--LeaseLiabilities_iE_zupJ8UUubTB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
    30 April&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--LeaseLiabilities_iE_zeKKkfpgmXl" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;span style="font-size: 10pt"&gt;Lease Liabilities, balance as at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A9_zvwFanj0gUL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_zB5CKFgNe3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
liabilities are presented in the statement of financial position as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zbmjPqrG3F3c" style="display: none"&gt;SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220331_zmKwmnIBhzo8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210331_zlyPh0jhynRh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$ &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$
&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zv7XaDQkJUWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;Current &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--NoncurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zl2kQG5N0vVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--LeaseLiabilities_iTI_mtLLzex8_ztlPC1rZi9Rk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 11pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p id="xdx_8A0_zrbiYpZWRDi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Operating
leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_z9RZTlXFUeD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
&lt;span id="xdx_8B4_zcQfZaCgGKG6" style="display: none"&gt;SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;Operating leases which expire:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 68%; text-align: justify"&gt;Within one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zDu9wXXbjjK9" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"&gt;18,713&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_z6tAvFmpciOf" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331_zzpMOaiax946" style="border-bottom: Black 2.5pt double; text-align: right" title="Within one year"&gt;18,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331_ziHlYPfIZQk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z2dKXGvMBz56" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfLeasesExplanatory>
    <OKYO:DisposalsRightOfUseAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">27069</OKYO:DisposalsRightOfUseAssets>
    <OKYO:DisposalsLeaseLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">27887</OKYO:DisposalsLeaseLiabilities>
    <OKYO:InitialRecognitionForRightOfUseAssetAndLeaseLiability
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">104377</OKYO:InitialRecognitionForRightOfUseAssetAndLeaseLiability>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89C_eifrs-full--DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_zZKJgd98QZt8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zVZpiUE9kMs8" style="display: none"&gt;SCHEDULE
OF RIGHT OF USE ASSETS AND LEASE LIABILITY&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Property &lt;br/&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;At 1 April 2021&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eifrs-full--RightofuseAssets_iS_c20210401__20220331_zzxDfJZQtynj" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year"&gt;98,579&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Derecognition of right of use asset&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--DisposalsRightOfUseAssets_c20210401__20220331_zD1HO3XrvGSh" style="text-align: right" title="Derecognition of right of use asset"&gt;(97,553&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Impact of Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ImpactOfForeignExchange_iN_di_c20210401__20220331_zzQyo0Jwr6ak" style="border-bottom: Black 1.5pt solid; text-align: right" title="Impact of Foreign exchange"&gt;(1,026&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;At 31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--RightofuseAssets_iE_c20210401__20220331_zvgcnVyaIU1" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;$&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: left"&gt;At 1 April 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--RightofuseAssets_iS_c20200401__20210331_zUznAy0hxQgc" style="width: 18%; text-align: right" title="Right-of-use assets, balance as at the beginning of the year"&gt;30,099&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of early terminated lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DepreciationOfEarlyTerminatedLease_c20200401__20210331_zMR2gPGEmIF3" style="text-align: right" title="Depreciation of early terminated lease"&gt;(4,060&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Early Termination write off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--DisposalsRightOfUseAssets_iN_di_c20200401__20210331_zmJPyy0U421f" style="text-align: right" title="Early Termination write off"&gt;(27,069&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of Foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ImpactOfForeignExchange_c20200401__20210331_zA078dNHUbzc" style="text-align: right" title="Impact of Foreign exchange"&gt;1,030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--AdditionsToRightofuseAssets_c20200401__20210331_zMQcUq9qXCd2" style="text-align: right" title="Additions"&gt;104,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Depreciation of new lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--DepreciationOfNewLease_c20200401__20210331_zjlwxfOcTG7f" style="border-bottom: Black 1.5pt solid; text-align: right" title="Depreciation of new lease"&gt;(5,799&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;At 31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--RightofuseAssets_iE_c20200401__20210331_zQH9Uk8SKbP9" style="text-align: right" title="Right-of-use assets, balance as at the end of the year"&gt;98,579&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;Lease Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210401__20220331_zxT5lM2DB388" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20200401__20210331_zAc7Rrn5SjU6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt; &#160; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$&lt;/b&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eifrs-full--LeaseLiabilities_iS_zZmBklQvjOTb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; width: 60%"&gt;At 1 April&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;31,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eifrs-full--LeaseLiabilities_iS_zTo2iwDz0etj" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease Liabilities, balance as at the beginning of the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31,689&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--LeaseLiabilitiesInterestExpense_zPIrqOS9pajd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;740&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--LeasePayments_zNa5PCDQm2n8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1793"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,542&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--ImpactOfForeignExchangeLeaseLiabilities_zKImhhjwP1v8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Impact of foreign exchange&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,207&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1797"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DerecognitionOfLeaseLiability_zsLlWUqHIva1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Derecognition of lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(97,553&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DisposalsLeaseLiabilities_iN_di_zA5gJ4qrPJ5l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Early Termination write off&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1802"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"/&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(27,887&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AdditionsToLeaseLiabilities_zTBcNDgE6xAk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--LeaseLiabilitiesInterestExpenses_zhiVgAqdY6Qc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1808"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--LeasePayment_zh6mgGmMfmv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1811"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eifrs-full--LeaseLiabilities_iE_zupJ8UUubTB" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
    30 April&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eifrs-full--LeaseLiabilities_iE_zeKKkfpgmXl" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; font-size: 11pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;span style="font-size: 10pt"&gt;Lease Liabilities, balance as at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1817"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98579</ifrs-full:RightofuseAssets>
    <OKYO:DisposalsRightOfUseAssets
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-97553</OKYO:DisposalsRightOfUseAssets>
    <OKYO:ImpactOfForeignExchange
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">1026</OKYO:ImpactOfForeignExchange>
    <ifrs-full:RightofuseAssets contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">30099</ifrs-full:RightofuseAssets>
    <OKYO:DepreciationOfEarlyTerminatedLease
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-4060</OKYO:DepreciationOfEarlyTerminatedLease>
    <OKYO:DisposalsRightOfUseAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">27069</OKYO:DisposalsRightOfUseAssets>
    <OKYO:ImpactOfForeignExchange
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">1030</OKYO:ImpactOfForeignExchange>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">104377</ifrs-full:AdditionsToRightofuseAssets>
    <OKYO:DepreciationOfNewLease
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-5799</OKYO:DepreciationOfNewLease>
    <ifrs-full:RightofuseAssets contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98579</ifrs-full:RightofuseAssets>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98760</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">31689</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98760</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">31689</ifrs-full:LeaseLiabilities>
    <OKYO:LeaseLiabilitiesInterestExpense
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">740</OKYO:LeaseLiabilitiesInterestExpense>
    <OKYO:LeasePayments
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-4542</OKYO:LeasePayments>
    <OKYO:ImpactOfForeignExchangeLeaseLiabilities
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-1207</OKYO:ImpactOfForeignExchangeLeaseLiabilities>
    <OKYO:DerecognitionOfLeaseLiability
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">-97553</OKYO:DerecognitionOfLeaseLiability>
    <OKYO:DisposalsLeaseLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">27887</OKYO:DisposalsLeaseLiabilities>
    <OKYO:AdditionsToLeaseLiabilities
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">104378</OKYO:AdditionsToLeaseLiabilities>
    <OKYO:LeaseLiabilitiesInterestExpenses
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">382</OKYO:LeaseLiabilitiesInterestExpenses>
    <OKYO:LeasePayment
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">-6000</OKYO:LeasePayment>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98760</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98760</ifrs-full:LeaseLiabilities>
    <OKYO:DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_897_ecustom--DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory_zB5CKFgNe3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lease
liabilities are presented in the statement of financial position as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B5_zbmjPqrG3F3c" style="display: none"&gt;SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220331_zmKwmnIBhzo8" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2022&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20210331_zlyPh0jhynRh" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;31 March 2021&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$ &#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;$
&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eifrs-full--CurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zv7XaDQkJUWf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%"&gt;Current &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34,148&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--NoncurrentLeaseLiabilities_iI_maLLzex8_maLLzC0U_zl2kQG5N0vVc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Non-current &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64,612&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-size: 11pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eifrs-full--LeaseLiabilities_iTI_mtLLzex8_ztlPC1rZi9Rk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-size: 11pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;98,760&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/&gt;&lt;/p&gt;



</OKYO:DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory>
    <ifrs-full:CurrentLeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">34148</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">64612</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">98760</ifrs-full:LeaseLiabilities>
    <OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory_z9RZTlXFUeD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
March 31, 2022 and March 31, 2021, the company had annual commitments under non-cancellable operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
&lt;span id="xdx_8B4_zcQfZaCgGKG6" style="display: none"&gt;SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: justify"&gt;Operating leases which expire:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 68%; text-align: justify"&gt;Within one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_zDu9wXXbjjK9" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"&gt;18,713&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331__ifrs-full--MaturityAxis__ifrs-full--NotLaterThanOneYearMember_z6tAvFmpciOf" style="border-bottom: Black 1.5pt solid; width: 12%; text-align: right" title="Within one year"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1835"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20220331_zzpMOaiax946" style="border-bottom: Black 2.5pt double; text-align: right" title="Within one year"&gt;18,713&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eifrs-full--GrossLeaseLiabilities_iI_pp0p0_c20210331_ziHlYPfIZQk" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="AsOf2022-03-31_ifrs-full_NotLaterThanOneYearMember"
      decimals="0"
      unitRef="USD">18713</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">18713</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfAuditorsRemunerationExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_804_eifrs-full--DisclosureOfAuditorsRemunerationExplanatory_zXZQkSQqwA0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;20.
&lt;span id="xdx_82A_zcZrAJzYJQhg"&gt;Auditor&#x2019;s Remuneration&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_zD2gkHE1hTxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period, the group obtained the following services from the company&#x2019;s auditors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zQMzkE6Qo47b"&gt;SCHEDULE
OF COMPANY AUDITORS FEES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210401__20220331_zbf5K3wx0Av3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200401__20210331_zOUzJkwP8mp" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--AuditorsRemunerationForAuditServices_zNfxNk36Cayc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Fees payable to the company&#x2019;s auditors for the audit of the parent company and consolidated financial statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;200,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fees payable to the company&#x2019;s auditors for other services:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--AuditorsRemunerationForOtherServices_zn1lZdfN4mR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Audit-related assurance services&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;148,892&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;72,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zgB2fVZqwwth" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total auditor&#x2019;s remuneration&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;131,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zecrDmusrV1i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfAuditorsRemunerationExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_89D_ecustom--DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory_zD2gkHE1hTxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the period, the group obtained the following services from the company&#x2019;s auditors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zQMzkE6Qo47b"&gt;SCHEDULE
OF COMPANY AUDITORS FEES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210401__20220331_zbf5K3wx0Av3" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20200401__20210331_zOUzJkwP8mp" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eifrs-full--AuditorsRemunerationForAuditServices_zNfxNk36Cayc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: left"&gt;Fees payable to the company&#x2019;s auditors for the audit of the parent company and consolidated financial statements&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;200,773&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,874&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Fees payable to the company&#x2019;s auditors for other services:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eifrs-full--AuditorsRemunerationForOtherServices_zn1lZdfN4mR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Audit-related assurance services&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;148,892&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;72,637&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eifrs-full--AuditorsRemuneration_zgB2fVZqwwth" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Total auditor&#x2019;s remuneration&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,665&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;131,511&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">200773</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForAuditServices
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">58874</ifrs-full:AuditorsRemunerationForAuditServices>
    <ifrs-full:AuditorsRemunerationForOtherServices
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">148892</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemunerationForOtherServices
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">72637</ifrs-full:AuditorsRemunerationForOtherServices>
    <ifrs-full:AuditorsRemuneration
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">349665</ifrs-full:AuditorsRemuneration>
    <ifrs-full:AuditorsRemuneration
      contextRef="From2020-04-012021-03-31"
      decimals="0"
      unitRef="USD">131511</ifrs-full:AuditorsRemuneration>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80B_eifrs-full--DisclosureOfCashAndCashEquivalentsExplanatory_zkmTECTLSrkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;21.
&lt;span id="xdx_826_zlmiUo2epTI6"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_zNxGs8zLiU9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
&lt;span id="xdx_8B1_zYWdwGwZDKU7" style="display: none"&gt;SCHEDULE OF CASH AND CASH EQUIVALENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash at bank and in hand:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;GBP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand"&gt;2,400,817&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand"&gt;4,344,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;299,907&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;2,544,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--CashOnHand_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;2,700,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CashOnHand_c20210331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;6,889,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z2imog4U0SEl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_892_ecustom--DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory_zNxGs8zLiU9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
&lt;span id="xdx_8B1_zYWdwGwZDKU7" style="display: none"&gt;SCHEDULE OF CASH AND CASH EQUIVALENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.25in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;31 March 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$ &lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Cash at bank and in hand:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 68%; text-align: justify"&gt;GBP&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand"&gt;2,400,817&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--GBPMember_pp0p0" style="width: 12%; text-align: right" title="Cash at bank and in hand"&gt;4,344,740&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eifrs-full--CashOnHand_c20220331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;299,907&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eifrs-full--CashOnHand_c20210331__srt--CurrencyAxis__custom--USDMember_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;2,544,589&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eifrs-full--CashOnHand_c20220331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;2,700,724&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eifrs-full--CashOnHand_c20210331_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash at bank and in hand"&gt;6,889,329&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory>
    <ifrs-full:CashOnHand
      contextRef="AsOf2022-03-31_custom_GBPMember"
      decimals="0"
      unitRef="USD">2400817</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2021-03-31_custom_GBPMember"
      decimals="0"
      unitRef="USD">4344740</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2022-03-31_custom_USDMember"
      decimals="0"
      unitRef="USD">299907</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="AsOf2021-03-31_custom_USDMember"
      decimals="0"
      unitRef="USD">2544589</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2700724</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">6889329</ifrs-full:CashOnHand>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_80E_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zCve7pILUbRa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;22.
&lt;span id="xdx_828_zbqJ9fOVtSX9"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Group&#x2019;s main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain
nature of scientific research and development and the length of time required to reach commercialisation of the products of this research
and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that
the obligation will become payable. Contractual commitments are detailed where amounts are known and certain.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;OK-101
    &#x2013; We are obligated to pay to On Target Therapeutics the following additional amounts in respect of the first licensed product
    or service which achieves the stated development milestones:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.65in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Patient Enrolled in a Phase I Human Clinical trial&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_907_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIHumanClinicalTrialMember_zXzDW5cGvOHa" title="Amount of licensed product or service"&gt;300,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Patient Enrolled in a Phase II Human Clinical trial&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90B_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIHumanClinicalTrialMember_zG3J3HDW16S5"&gt;600,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First Patient Enrolled in a Phase III Human Clinical trial&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;span id="xdx_90D_ecustom--AmountOfLicensedProductOrService_c20210401__20220331__ifrs-full--ProductsAndServicesAxis__custom--PhaseIIIHumanClinicalTrialMember_zcK21OsPDhr"&gt;1,500,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 62pt; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BAM8
    &#x2013; The Group are committed to paying an annual license maintenance fee until the first commercial sale. The annual license maintenance
    fee is $&lt;span id="xdx_900_ecustom--AnnualLicenseMaintenanceFee_c20210401__20220331_pp0p0" title="Annual license maintenance fee"&gt;15,000&lt;/span&gt; until May 2021, and $&lt;span id="xdx_90A_ecustom--AnnualLicenseMaintenanceFeeTherafter_c20210401__20220331_pp0p0" title="Annual license maintenance fee, therafter"&gt;10,000&lt;/span&gt; thereafter.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <OKYO:AmountOfLicensedProductOrService
      contextRef="From2021-04-012022-03-31_custom_PhaseIHumanClinicalTrialMember"
      decimals="0"
      unitRef="USD">300000</OKYO:AmountOfLicensedProductOrService>
    <OKYO:AmountOfLicensedProductOrService
      contextRef="From2021-04-012022-03-31_custom_PhaseIIHumanClinicalTrialMember"
      decimals="0"
      unitRef="USD">600000</OKYO:AmountOfLicensedProductOrService>
    <OKYO:AmountOfLicensedProductOrService
      contextRef="From2021-04-012022-03-31_custom_PhaseIIIHumanClinicalTrialMember"
      decimals="0"
      unitRef="USD">1500000</OKYO:AmountOfLicensedProductOrService>
    <OKYO:AnnualLicenseMaintenanceFee
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">15000</OKYO:AnnualLicenseMaintenanceFee>
    <OKYO:AnnualLicenseMaintenanceFeeTherafter
      contextRef="From2021-04-01to2022-03-31"
      decimals="0"
      unitRef="USD">10000</OKYO:AnnualLicenseMaintenanceFeeTherafter>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="From2021-04-01to2022-03-31">&lt;p id="xdx_809_eifrs-full--DisclosureOfEventsAfterReportingPeriodExplanatory_znWjsdIHUESc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;23.
&lt;span id="xdx_828_zzNJreRL2kGl"&gt;Post Balance Sheet Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 19, 2022, OKYO announced the closing of its underwritten public offering of &lt;span id="xdx_906_eifrs-full--NumberOfSharesIssued_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_z7hh2Ya6rUF3"&gt;625,000&lt;/span&gt; American Depository Shares (the &#x201c;ADSs&#x201d;)
at a public offering price of $&lt;span id="xdx_907_eifrs-full--ParValuePerShare_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_znIYxZab1sAk" title="Price per share"&gt;4.00&lt;/span&gt; per ADS, for gross proceeds of $&lt;span id="xdx_909_eifrs-full--ProceedsFromIssuingShares_pn5n6_c20220502__20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember__ifrs-full--ClassesOfShareCapitalAxis__custom--AmericanDepositorySharesMember_zGm8DDxjg789" title="Gross proceeds from public offering"&gt;2.5&lt;/span&gt; million, before deducting underwriting discounts and offering
expenses. As a result, the Company is now listed on the Nasdaq stock exchange and is therefore a dual listed Company with its existing
listing on the London Stock Exchange.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 19, 2022, the Remuneration committee awarded the Non-Executive Chairman a bonus of $&lt;span id="xdx_902_ecustom--Bonus_iI_c20220519__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z6kbkZgenBSk"&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The committee noted that in order to support the offering the Non-Executive Chairman participated in the offering. It was noted that
the offering may have failed without this subscription, so it was agreed to compensate Mr Cerrone for this transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
August 2022, the Group secured a short-term credit facility from Tiziana Life Sciences, a related party, for $&lt;span id="xdx_908_ecustom--ShorttermCreditFacility_iI_pn6n6_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_zk6EoyVv3Hal"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m
in order to support short term liquidity. The loan is available for a period of 6 months upon first draw-down and carries an interest
rate of &lt;span id="xdx_904_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z5q1Xg9p2Z4c" title="Interest rate"&gt;16&lt;/span&gt;% per annum, with additional default interest of &lt;span id="xdx_907_ecustom--AdditionalBorrowingsInterestRate_iI_pid_dp_c20220815__ifrs-full--NonadjustingEventsAfterReportingPeriodAxis__custom--NonadjustingEventMember_z70UCXqKYT39" title="Additional interest rate"&gt;4&lt;/span&gt;% if the loan is not repaid after the 6-month period.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"/&gt;

</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember"
      decimals="INF"
      unitRef="Shares">625000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="AsOf2022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember"
      decimals="INF"
      unitRef="USDPShares">4.00</ifrs-full:ParValuePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="From2022-05-022022-05-19_custom_NonadjustingEventMember_custom_AmericanDepositorySharesMember"
      decimals="-5"
      unitRef="USD">2500000</ifrs-full:ProceedsFromIssuingShares>
    <OKYO:Bonus
      contextRef="AsOf2022-05-19_custom_NonadjustingEventMember"
      decimals="0"
      unitRef="USD">150000</OKYO:Bonus>
    <OKYO:ShorttermCreditFacility
      contextRef="AsOf2022-08-15_custom_NonadjustingEventMember"
      decimals="-6"
      unitRef="USD">2000000</OKYO:ShorttermCreditFacility>
    <ifrs-full:BorrowingsInterestRate
      contextRef="AsOf2022-08-15_custom_NonadjustingEventMember"
      decimals="INF"
      unitRef="Pure">0.16</ifrs-full:BorrowingsInterestRate>
    <OKYO:AdditionalBorrowingsInterestRate
      contextRef="AsOf2022-08-15_custom_NonadjustingEventMember"
      decimals="INF"
      unitRef="Pure">0.04</OKYO:AdditionalBorrowingsInterestRate>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000805"
          xlink:label="Fact000805"
          xlink:type="locator"/>
        <link:footnote id="Footnote000824" xlink:label="Footnote000824" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">This
                                                                                                                                                                                has been restated for presentational purposes only to include audit-related assurance services in addition to fees payable to the
                                                                                                                                                                                company&#x2019;s auditors for the audit of the parent company (being OKYO Pharma Limited) and consolidated financial statements.
                                                                                                                                                                                Refer to note 20 where details of auditor&#x2019;s remuneration has been disclosed. This has no impact on the primary financial
                                                                                                                                                                                statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000805"
          xlink:to="Footnote000824"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000806"
          xlink:label="Fact000806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000806"
          xlink:to="Footnote000824"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000807"
          xlink:label="Fact000807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000807"
          xlink:to="Footnote000824"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000877"
          xlink:label="Fact000877"
          xlink:type="locator"/>
        <link:footnote id="Footnote000963" xlink:label="Footnote000963" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Gabriele
    Cerrone&#x2019;s bonus awarded for $<xhtml:span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFTVVORVJBVElPTiBPRiBESVJFQ1RPUlMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--BonusAwarded_pn3n3_c20210401__20220331__srt--TitleOfIndividualAxis__custom--GCerroneMember_zWsUp6ggv922" title="Bonus awarded">1,160</xhtml:span>k was awarded on the basis of the co-invention of the use of Chemerin in the COVID-19 indication
    when he was not a director or employee of the Company (now the subject of a patent application); work carried out in procuring, backing
    and completing the refinancing the Company in 2020 and actions taken to make new executive appointments and scientific advisory appointments
    to the Board with the result that the Company now has a clear and accelerated path to the clinic.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000877"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0878"
          xlink:label="xdx2ixbrl0878"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0878"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0879"
          xlink:label="xdx2ixbrl0879"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0879"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0880"
          xlink:label="xdx2ixbrl0880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0880"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000881"
          xlink:label="Fact000881"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000881"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000882"
          xlink:label="Fact000882"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000882"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0883"
          xlink:label="xdx2ixbrl0883"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0883"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0884"
          xlink:label="xdx2ixbrl0884"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0884"
          xlink:to="Footnote000963"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0885"
          xlink:label="xdx2ixbrl0885"
          xlink:type="locator"/>
        <link:footnote id="Footnote000966" xlink:label="Footnote000966" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Gary
    Jacob became an employee and Director of the Company on 7 January 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0885"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000886"
          xlink:label="Fact000886"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000886"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000887"
          xlink:label="Fact000887"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000887"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000888"
          xlink:label="Fact000888"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000888"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0889"
          xlink:label="xdx2ixbrl0889"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0889"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000890"
          xlink:label="Fact000890"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000890"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000891"
          xlink:label="Fact000891"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000891"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000892"
          xlink:label="Fact000892"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000892"
          xlink:to="Footnote000966"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000909"
          xlink:label="Fact000909"
          xlink:type="locator"/>
        <link:footnote id="Footnote000967" xlink:label="Footnote000967" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">John
    Brancaccio was appointed as Director on 10 June 2020</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000909"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0911"
          xlink:label="xdx2ixbrl0911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0911"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0912"
          xlink:label="xdx2ixbrl0912"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0912"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000913"
          xlink:label="Fact000913"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000913"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000914"
          xlink:label="Fact000914"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000914"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0915"
          xlink:label="xdx2ixbrl0915"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0915"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0916"
          xlink:label="xdx2ixbrl0916"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0916"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000917"
          xlink:label="Fact000917"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000917"
          xlink:to="Footnote000967"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0918"
          xlink:label="xdx2ixbrl0918"
          xlink:type="locator"/>
        <link:footnote id="Footnote000968" xlink:label="Footnote000968" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Gregor
    Macrae was appointed as Director on 18 December 2019 and resigned on 10 June 2020</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0918"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0919"
          xlink:label="xdx2ixbrl0919"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0919"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0920"
          xlink:label="xdx2ixbrl0920"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0920"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0921"
          xlink:label="xdx2ixbrl0921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0921"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000922"
          xlink:label="Fact000922"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000922"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0923"
          xlink:label="xdx2ixbrl0923"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0923"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0924"
          xlink:label="xdx2ixbrl0924"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0924"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0925"
          xlink:label="xdx2ixbrl0925"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0925"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000950"
          xlink:label="Fact000950"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000950"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0951"
          xlink:label="xdx2ixbrl0951"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0951"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0952"
          xlink:label="xdx2ixbrl0952"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0952"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0953"
          xlink:label="xdx2ixbrl0953"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0953"
          xlink:to="Footnote000968"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000926"
          xlink:label="Fact000926"
          xlink:type="locator"/>
        <link:footnote id="Footnote000969" xlink:label="Footnote000969" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Bernard
Denoyer was appointed as Director on 24 November 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000926"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0927"
          xlink:label="xdx2ixbrl0927"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0927"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0928"
          xlink:label="xdx2ixbrl0928"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0928"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000929"
          xlink:label="Fact000929"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000929"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0930"
          xlink:label="xdx2ixbrl0930"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0930"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0931"
          xlink:label="xdx2ixbrl0931"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0931"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0932"
          xlink:label="xdx2ixbrl0932"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0932"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0933"
          xlink:label="xdx2ixbrl0933"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0933"
          xlink:to="Footnote000969"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000901"
          xlink:label="Fact000901"
          xlink:type="locator"/>
        <link:footnote id="Footnote000970" xlink:label="Footnote000970" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">K
    Shailubhai resigned as Director on 17 June 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000901"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0902"
          xlink:label="xdx2ixbrl0902"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0902"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0903"
          xlink:label="xdx2ixbrl0903"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0903"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000904"
          xlink:label="Fact000904"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000904"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000905"
          xlink:label="Fact000905"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000905"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0906"
          xlink:label="xdx2ixbrl0906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0906"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0907"
          xlink:label="xdx2ixbrl0907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0907"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000908"
          xlink:label="Fact000908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000908"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000946"
          xlink:label="Fact000946"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000946"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0947"
          xlink:label="xdx2ixbrl0947"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0947"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0948"
          xlink:label="xdx2ixbrl0948"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0948"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000949"
          xlink:label="Fact000949"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000949"
          xlink:to="Footnote000970"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000954"
          xlink:label="Fact000954"
          xlink:type="locator"/>
        <link:footnote id="Footnote000971" xlink:label="Footnote000971" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Leopoldo
    Zambeletti resigned as Director on 18 December 2019</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000954"
          xlink:to="Footnote000971"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0955"
          xlink:label="xdx2ixbrl0955"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0955"
          xlink:to="Footnote000971"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0956"
          xlink:label="xdx2ixbrl0956"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0956"
          xlink:to="Footnote000971"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000957"
          xlink:label="Fact000957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000957"
          xlink:to="Footnote000971"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJU.Y$J5YLY"JX-K<JH=QM5*"S^M&13[&$-)QP;-R-)W4SV[4="+7.L]*<:-
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M&'R[^PA^_>4W#\S5X3#(#S,VRCOYN)./:UPR)'^ME"@UX%5E%)_Y]#4 D1_
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M74#LZ0)-&8.V2J*'J0E'\I]:0PL4I#Y*"I06@M(B4%H,2DM :2D4K2O8-O%
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M<CIE%/UJ:G,"S)X3,*U9COSO_(3Y86!0P^YJC-:@,@M0H)#IT7F7,Y]2]3@
ME5>  B4#>YY.<=BOPS:MP.QIA0LUNL2H,\]T,@P\E^O1"]V44,Z1]@!L@R&G
M3*WE#>VC&+/FZ/ZN,":,N(BJ;V0RVR(LEQU/77<,XPV8Q]3BUG3*0/JGNPW(
M,WM OJ>&E]B/B'I8&%./,<R9ZZL" (H--RJ!I(6@M B4%H/2$E!:"D4[:G=^
M]@&=]6?(2AT^;/:ELQ7W$H]^\*3.BN/'LAZ_J?*GPV=VWN55E>\.+Q]%MA9%
M;2!_?Y_+K;+YIOX8T-.'X][^'U!+ P04    " !E?@]5P!BC"T8(  #C)@
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M8DCTVR\XI+\C7J)S7A00+WDT5C"[QAAG[4R?FIG(P$R8H/.J5$N)3LJ<Y=L
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MF;Z:/SE@)1ZQ[G869<CLX!/2!\1V1:QQ7G>[%J2WQR $F)[E.)K$0!O-(OD
M@FT7B&$(#9)O:(&B&_S<)G;#CJ@^!J7HPL/IP'Z@Z1+VJVC[D-B0##2@ P+0
M-;>L"T0,M&7#!A4"#2)).LI,#3LVW9;44C1ESR3,F/<0)ZG0@^#8E:M S&Y!
M R$*B]:OVZ+F#RTL1<[7 _"F 8M<V).]!JQ^>W'SZL7_($2_FKUF-H"F>K06
ML*X0'E Y--7;#JTZL%HU[H_!U7B D.;3S0R$P@$60+N5;4&L$6T#X@-\6IK;
MSM-FMKUUOFL)/PA+)RF'I@$.]0:= I ?!!1) S+G22'A7V"WHIW#UJ+L(7:L
M8TB@95>1W0$<@;+-_B(P>1)=X(1#HJ(X@>*B!6V7KD;XDEZ!-0=3&<G[[A^7
MCRY54G@0VI4W&\0[#-6:5]T:[[H!7$.[C#'L%HPL:09B19;/ .O!C(%T J7"
M&F#3**-=32=!^"P4A9^&IL:#;@&PJ'!@L4<(S8B>]LYLM@W;K3>O7K!2W0*8
M OSU;Z^09:]L93<+@(&XC@L)*_RI]OL+N[?) 8%+&CP%#6M('#!H01-@R" H
M?. ]N G8^!J>7#D22T27[*"(T=H"^ O;[]#__O?0,#]+&$#3V9ILW6W7PT)4
MK#[DZ,5AVJ$/B:XRY&39R8""\"W9)2PLZE<+,J#!N6[BIF=)4(=V" .9YU*_
M(ZU:3!T:XL02#K.!")70C< H 8:$MK:-0]Z">VWA\.70,+68^X="1T!'J0N0
MC-C2Z>^_^<NSJ\OOGH?"?8 1;3];6$H^R.A;3)[Z3FW!M+;D7G4[$%712#42
MBMP64J.CY6 M _,XL%H5L5*(&@\/A&&)/M:2D]^ZGKG*VUGR*'2VK=6';T#V
MGK]*=BN3E>S<Y3/Q)4 %\4=3N)(B7""_"BO36EN+ RRA!!,^H",W^K^N-L5*
M7<&W( -+4Z&KVT=JD;[!\^#^&;QL[+RK5RCT>V2AV4?14QU$&]Z3WQ"Q &/K
MT*SWI=O?N :-3RM"PG;B @53I(-9WW2&O(NY-:XA@XA/FT+OGT:'.VQ!BY;.
M@X>LO=E=U.C/4&\JXSU%^"T'C7"N1H[BZLNG?\6]X#>0@IF@G<,027GS.ECR
MY*_:,6(1.'1]&"(Y(.RRYQ!-/;T@N 32 AL*-LC/3LONTMU14A D2%R@-0&*
MOP"E;DCW"4S,,#CL0!V(UC_#KC!H.E(@R$F<O;6%#T\L[[N516=Q1 0L-: \
M1FG>F!:\ RF7!,6!D0++50@_*!FZI\;V-EE2B;TY@#OP)U&KP623B()D@>G_
M3#I%X4<AK4B7%'R(F,4H@IP*R#J)I0*IQ(.7@&.[FD4C#;*,'@N"<5MGMX7'
M ;8#&5^]=JLU6%[(NMQG*R:XBC\R#>HR_F.Q%Z8!3;K!5QSXD]4O"#II6DR#
M=2;0)A<JR!DP$(0(5RA8H'E QN,X=D$!F\GT2<)!$J%E#?B'S[:?@4$T]#E[
MR0(H=@@(TA!"&<A_V> R?UN+9A%=$22X6XX:>-/>?+8$FUDN002$;00C03O7
MGX!!#9%=,M_I3)5M6BA%KX &I%"R!PQQLS]T6XNN>2;Q$9J847Y6=\.BC[0Z
M.C3AS:G!GC-)SFTH7->KCE2&4\19E )OP7Q9":'!WFX@C@1^#6T,'$$&&O=O
M=A.00-F>,R/DP-KXE3W,2*++$-<+\ND#&;;%$ "] &QX90/HK65M+U!4A"+[
MB%<GDB0 ,28:8'W09I:((O/J;LO*,T(X9V5%J863IX,0,D6/,X4%QSJ2'+*%
M6XH(D7L7*!&X!:  *_>XU<Z"K".ILUXE:Q1U:3N@+*"_K3@^8]$3_RML*.2&
M%$1%+0)6]6OQQ92>4O$#/C5[MB'CY/B>[ XKLE,$FNO?[$[AWA\ 6\0^USQR
MX00PL*PC\!?%GQ]1DA22K^U Q794J\ #>06(&YQ;\]D8D:1-P7<>UDV(!KC5
M!A\BZD:'G''!4@.09.4X9@)\V!M=SC ;O9SE72!BL)A>1:O-JD,;PA-$,2Y+
M[#4FKA3T.M IQBZ6O7#UN)I!I#J)HLHH(C5/XHB>>@]Q%-,3PKQ94>BJ+; K
ME:5$YT.TZ\!T]O.,'[L2_$;< P#!T>D17J41X65K"H\B0)B,6?S2VZ+>E&MW
M:,-OA@4X1@>&5%%U"JPG,")F81!/@(KE$A''ZQD+>V=]Y0(EC&WONX:-<RY:
MR==<IG#HPY <$,"P+Z CQ/\LNZ;I=G#X]^K,G(.7V6'L' M3;'FM?:[/%N=8
M0^A0(V<H !Y[!AB3=I3MD<7C7$F*)8[R%TK[R70G9Y,W1>*=5><<5K+IQ?H0
M)*\<6$\#4W@96KA!BQ3QB5EP,ND,$U%(V3LJS(KU$"U$Z]H!:-'A0P)&90G"
MCQY,>?_!;TD.LTP):X@:0"1@!$#?._PHYE$"(D6\09\0R!3"1XK6(NO0UK8L
M!WLTVI'G$$<DX:$XPQ_6L4>%*@#P4'JZ16]<FX2$[!7N4MN+K]DH EB!=<8R
M M5[+R1D42!?;3"Q8"<5KR!>G[PAFL45 4!9<GX\9<@K C/70A X\.Y@N DN
M2@Q&ZH2Q1=J;"[0JU3/RRGE9C4Z- B!T* F:#0BXZ):"0@HI<NB3L\94ZJ_V
M6;QS"P*=*7"ZM$# /;NB.FBN3[^+M6$5^+<@IA<?D$(]FO.6Q4.:"Z4^49K;
M%"5OJ974T6Q3Q9VM!!??P0)T$'%2G3R&MJA6$->P3#(JUE/OM,C^(HCE9E&J
M@T1?7/7HV@;+;+:H?<OB&#)2=66Z^(<F<^% [ZIUVS7=BJ(\TD6(FS;@_X<^
M%D+JH2)PS%WNE/3F+N7 XOW(#P&%N/_"^/54:T'K++K?QTT8G*7U% K(MU++
MY7T=-G:Q_-9/;@!6?Q0 @5&BTB[OAO8 !74$'>. /P%65,+QQP^A+3B(K$;/
M&JH@[&+-5J6PA: $G?)V+25AA^5=,.84=?UK(*^%1T%TN2&]X <TE=6VX)X=
ME0'9#$1O!T(&]'?1WE%4FQ)[9,-V\. UP%*HCT56A;]00'R$''"UDN[&$#BS
MN*/\/LC)I*#6D;4D/;4M6! DB"=-[K% 037%^(/D@V*-%$\,H%7#:)IY3!*#
M)?"H.$"^Y= TLP@$IOLNI@<;L-4=!)S( KL!I4.S4#OP)YX+N5CEQ&71I)&P
MP0G(.8ZC<S(P:DCDU,9XOZ=0E=Q;*&IT]_< ,TY:<*HM9MF0/AQ3](P ,+MP
MG@,Z=9*H5-*./XA5BTV-3%3VK7>H&6R ,+W=IY9)*D+5!V!&"S[C\-*J]$ F
M/*8\MN\;-.8C-",]R6Y6'61%(5L_JL[T90H$;%YPCA:+!<N!A+L?:R#F#@H;
M :E>9<AWE5YU6@(PY,)4$')>]MH?Q-(IKOWF-D>V50Q_$D'2Q3*(SGVN$'M,
M+2E4'=O2Y"J3I4EV GS@RG& 5@!1]EH*!0<WV9:XP*(%;5<0]]_L%D4DL4)"
M#*RLNRTCAT__8.8,H"Y>V@YO(&.&K%5)67'/,4##5O,:38^2YF-JWI]J=5L#
M+"A;WBGH2_$S94*<1]:%*J?#974LL -V+62(5=FGP80M<ULB,O9IJ$$L/&TE
M26O<^;SH![WOJ%(#!M9CV6K^E<U\%H8X+@!0?+K1-83KU"9.FQ\C+VN8HA&>
M4X2/P1<>%CE!IXGN3* F=+1W'"")*<$,WU!9+MK;FKX7"I>'95C2'AP1DC7B
M!CO@,#04-"1I8LV/OFS)6^@3Z+2%&)829KC1?F')2/'IRD=(L=O6&ZI(3-EG
M4!D4CU9(= A#%+A"242"Q9,FYK((G.3Z(2,RXZ/73VD;5QZ^5]_\Y6]/O_O;
M<_V" %>'@,>2J-3),^^&DF.),N0<TY[OR1BJR)U8!)) 0=:"Y_!F-7'$.,1Y
M'6D^Y2XG.1:[4794""RH'Y4=\HW.>Z(*<Z[CC"H*"-IM/S"5:XNE,Z0P#@&L
M;;V*J0!J53H&"Q/D%:2X:?\84/O);1YS^8NQUKD^3EW>N@J> 6&P ,%[LZ=C
M5722HH6F@H-S?3SFGQWUX2D")J<9H^4]IX5<X"=/B&,Z8!):=@,BW6XYZ0[%
M%49;J*2C6,Q <.1&A34:'QD5AV+CE%H>L6=$"\0G FY8+M@GPSS/>&],'2/,
MV._E4CX@C,=(1E+D#82HMQBL@?V^-<T0"9?BGI1<$W>W<A9S5J91TG[8CD)B
M8T&.\_->> 2>D'A$KC+8HV"#2!S=\8=3CO8%!!1=>\'5PY.C#V6\[<*HOD"'
MY[DV;IPE%\7\S'"\XKHNQUTKC*NQ(CCV;IBSM:E>5X(QZ5MCRL6EY@K\.I;'
M2,W+M1RD<"HXIE*D*V4>,EU'C9T7-_KQ,TT'/7U^G<65;9H ,$NI!T3A>N"F
M0M("K'XMN(A@R&T66*=9 *HIGA1\E8* V$J?%O2RZ)89A "T'4O:'P-HWW+/
MSK*(K])@G2I-TL<T=U8U0!]L9F'G(3N)_#"%R*B1:&3 90&YL:4;.)<KEJ3(
M>3;ZFM411;V-)BUOKB8& \FZ<1J02P%4"0*'BQ,$D*V@5>>Y'3$ .)S6.O;'
M-#+TE7!1$6("L'E!HJCHDL>#GJ=(8XI@T^8 *Z. @X0>22B+?&-$HD3LN;H9
MJ!(FGS'E-MQD2*RK0;)I>)-ZC>$021Q7.:(&E:/\,>(0,+U0DVAA-Z?=)TZP
M&*_ X01-<S;D(8[XOJ2RC$2R5/Z;8DT&I1!3KDNR8^4-YE0WSB(=T2/64U&*
M=#]55<K!2YJB!+&"8XKV,]M)E,/C'0[). [P.12!['EIX!\4$<OETHD#:HL:
M&0,J:B8RZV(_^Q"EU(GF/ ?-!J!)R0^/)< ?2"\XEMT+V71JV\H@<0*D\'T(
M,Z3XOJ= @GQF3E-27R--+*A8>J .*D=C& FB7I;Z47>6!QG67</MF6/*]069
M=)P=/"@G=7[J(0FLR@A'<80#TK HI:$0[?\GD3BE2%\2#+R1,"!0R[(A.B-:
M%:E$]&.QU,_SI\U>F;[W;C'TL=5+83Z.?![;H:12<W3_]\#['TN(.I80*4Y)
M81Z_D)B!<Z(8,Y],O(X3F+%(<'D E\5O()[1V-/(3'4R_W'_/DE:BUF9*<JD
M662/P6$.["&0(R6<ZY>@>VI2"4__0M*+-I)'MUOPW"U2;;,%$2%YRW]B-?I(
M?X[Y$R)_0%*I-I$+\E08RS%R"HC078^U6,88I7PFQ6;AS90!/ T&BH " 0 B
MN;".-J7L_N?6V0$,AV';K(SOZ9Y#B"58&A;@@5?>VW 432&#V\"SZ U5_&DF
MAE?ZSI39C<9+J1_:4-#$C: )VL_U+WQBVI:$Z0@,E^^!1 W-[.4^1W1JF$&T
M-1?FL;-5F.XD<$?/D-]%(\#M+M0V[Y!O:NP6I@00FU: J9JDW]=+RD3XU%,P
MPZRU&(-&Y"^O9(AM6KQFJAC,D5]HAJH[+,/Q06O.>+RE,F,QBH+CO(XGS2?,
M=<I5*B3A$5(.D]^<+IQ$!B>G:4AX&AGP^\?"1U*2A?)/"0I;H2(&*!DYM7>A
M.<T.)RO_+UEZ1 5U0(6Q$6LA]3Q4)N7.]6_E]ZH(K7J;VT*9(ECZI8L',E',
MG9]VQ0-,E?/5L.%< ;^H,:0JKVF,6QLT-26W-9 T6$<"NLZ5NP\PAJ8H0Q_W
M3-#)X=RL9+]I9_F9\[?C[U$8LE'EU3@\2#/%J@@@2%=BE:-V >R%))?\.Y!B
M"!R5C;XYZ'*9D :U^WC?I;R<4_3[,B70C\,36,ER@:IQ5.^O/E.1A O *0!>
MXW6!..[Y#F>></ DX-<I:XKC=U1/R4D,WH"B'&".5<"M]9"RT; U1VKX&_=K
MSX!9'[*:J\.XCBO[=*E-MM$3VQQ%;41>(O3XVA.@B)>18@19_EC(:52"EQ3#
M21RABEQ\(K#34X'=0?TME;2 *H.OUFP NV6_(YVA/A,5W.S*9UW-I73,J62;
M6.C+)"#I&%7N,+?G8TV?'YSK?X+H*TK\95P$"[+ZBS2F!FHLOV(PB<4SC7/[
M7--A(9 BKR@_56HXGY6R[]G&_*OS11)\_D7N@MO&:%,5T2:&CE%S3N%P_7%"
M2(JFYH)3<^-CB -+6?&I8)GVS]?6Q$ZH'/^</DUNY'TQ*D9F:$]U">):LE0!
M,K!9,:F4!#$6\927:@9?%J>;K[D-$)N<&$UCJ0)EQ7B<VPN0;*&-?%5J0_E!
MC0U-%PM\_$2V> ?=I&C2<DF$%!!C(8#.T7TJ,2V'IQ6>^XA$/#:)$VA8S+V@
MFS0R5QHGO'+K,@GETJ9.7U2#^P5=%>*&[GYBS]OBED(<2)!":BY>;_CJ[6VJ
ML9)2!.F\A._UJ^N;EV_?W7SZ\%J_>Z-?WWR\_O7%Q]>O]*>;UV\^O=5OKW]_
M?:/>N#NR,R3S0(R>FA/?JNN/:BS3C\>TY"0NS,9 <]NA9$',U_ >#%O,B<1C
MS"?.SGC\)X4[>48GE;>10=%*?;&S,==O:1Z,ZML-_WEL14!3HX3P71VJZU]T
MRPMTBZGZAV$1Q=>Y%H6N?$O#(KG5Q2<JREYVXF%9[VBR\/ YN0-3#_D:>+[>
MB3)J1TDIA;>"R5+*K1V.%J-#>8U$9AA)ZNF66U:Q\5 $U62_%M.BJJQR$8<F
M4<$["SP3*,_U[W$*DW=,;0[6[;J3<1WT?:2*.")4VSNJ<7+7[BQ6N,8[Y$$F
MNJA3V73;D@D%MM6&<YX]N!/+EEI%,04H8P$1JD,>\\UG\JI%93W5PA49H",R
M!IZ/*P;C9%0.))N&2._UA6?!6@@R ?G+1^=S3-QC9K?98,N'2X54&#J1DWVU
M"+M62O9%WW^D5SDPCW<]>&9JX@07CJ*DPHA3$XTSY_^,!5S]BL]S1,0%,!5;
M2J-YZAE5Q\7 LFG>Y\8/.-X-9H-6[-:FDRN**:GA@8IZ!(WXVRCL68X1*^I-
MX'W?W(4XP2]]UMH^@H3)* V%Y2&5\U&U-)I'Z2=,4/RD\TJ2?@J0.(1D/.27
M/H)=H,TF7D5?=PH /TDNZGV4"D.%-TY93V,SD<]1>5M)MH;7.6A8FE1"'.)I
MA4@W-2;5NI>@K$A*QB@D%@\MW[J31@8?DQ,<E2OCX[HA52%P"Y#:- / -FT!
M:1+C/6(2]TO81[5VU?6C-QLXSW<DJ?K8QSN!H)4!^Y%JU$QB#2OO(:;X'VL!
ME4N=53J;674/P!*$Y;#%CY)G)CC=:N,+"ICO&1I*YHW87YM-KN[Q7>O@-JZ1
MF\"L8X1L_)JN7<G5)YX03_$?!6"I<!5#OX]X_PAAP[@OS8_*76U&-Z!QE3:3
M7*;(:0=5EBA"C&F6&3><):1023H.Q\*^QJ7019AD#?DN9MKPC'=$TKNVZ&_2
M8^>S?*]APA,6WM-SWT""^W+R<6%CD5I>0F(.PC>]&@PUJME&%J,)Q4!,M^4>
M*A;:.KQ:ME<57AEQK9QQ<#> .P@HI1.6?R9EHTBA>#O*XQPOF_<#I4P9<@X:
MXU@KWI7:IW&\XH4\;1QIPSFW$*?%XZ5I2C!$SD5(Z1!NXI-712^),Z<2?+LJ
MS17EN[MQG!3?W\634,VQ8R@"JQN\<:KHQJG$44"X#4:52&6Z<W7Y=*( DF/C
M1NX\O"]]DK#V\*G#\9"4#^4YJB\G1 1LB4^LYK @)NJC*XN97E&C*(I5HL/]
M_D(&:#75?Z2VA"\0J?-+=_+PG5Q3C'=VOY0&0"I+LS-TVW'8B."RE&ZX;KHR
M=.DN31G=IF8I7V%%UO,5P)"F6HN]RA?3R!:W'6+-+6O"6QW?J>=92B=-TH,]
MN6A3O,*)VN9%NI_3\TU7VV9T<SXEV <4CZD3DY;J SA; CZAVUNLM.2+DQB!
MUWAAT$>IP35I8+5D5.3X;(*_Y#;B_FE:)ATCW\!I*IX6O\*2@ZM$9L>5%6_C
M&'"L8AV=R?")E7JXHU$09"DC001/2^3Z*=X(KE4Q)XI[T<B.3(\3DT.JQ%<I
ME&N[5N0$9_3D"J;(BSXK7@$R$W4KLPO*5+"MM$,WCY+=AW-JDQV]"0NMP14.
M@\2+NJ+L7ZL)7#4#VTK4N3C0U^QX1L03M:8;3M.T+B8QZ!4OY,<CQ>5%7'0S
MA5Y:@C!$WD(D!X!ZO+/2<?LM7F3)F!D&9VQ=4DF*I.7R>01VEJXD&+ZC'/V4
M,)[F)2?$?58(>Q[2Y/=_&!YV&0.J3@*J[P<T$N8(TJ^EV#_C<_$/E5_L-+Y8
M.KU#?)E7JEP5[PHH9@SR0>HK ;K_.7Z?E;S+ (+G+2'-(IVJF6,?9Z;DE+WV
MQ ]E_JG&<R34ZB252;6EFR\7CS[&6_LMECD/ KMRF.>0 '^&N%]>PP3LAC[$
M =0#*I;W+::Z):-9XY2"<&!95)WCS8DXC5&G_A_&J?FYV(+Y&!L&]$8;4UK5
M(M(0Q@LD-.P87VJ2)VY?CJ:=5'HG8@DXOLH*0Y$V2WOH+L#A8?@@8YH$:O0C
MV"TD%+#/"/X14H:>VPHQLBA7T9/E>I76%VNEO2H=:%R&3Z%E'A^2A^ HI)79
M2YZFD/F]$<I\/[%\J1:+7S'5J+I%XU;\=*P7DPSY\E5')N<)^=5#5"W<30PQ
M3N"3R) P*["B&TC_$3)Q8'41;TPDY@GL(FU<@3T4-9Z&\6G([Z#Y.A+0KT/W
M4/T$F-1P_*(VSOZ4FAWB5*J9ND_-#CJB<_U;)TYJ:0TW#:DTPCD+OU^& V:Z
ME# Q2'DX6?@RWPI7] XAH+4M!X")4J%\3A?/Q>F)]F#@-).%L,OGCR9NXO#K
ME/RE4$J1@:>B$YP9@]=[EVA9\G%JC+F:QH0HF-Z$=7KK:8;'2QA>6OPY_Y0T
M()TTV@!(,TG8&#ZPF86 T+.'':>;19*;I@72K)LOJA.33,[MO5A8*BE#=WVB
MK?^TI6Y@;3E+F0@ HTU-4X<<$TGSN&PYBH-(HJ)2T7*2,0E*?-E(N2<'T9),
MV8T;-G/]!MW0[^2&?BW\]J_YK5)<^N&*I'37\(5$G7?_+IW/:#8S[Q2*>5C.
MT1^73ZX=I-V^6N]Q"K#<M7R74WHHWP\HLASFK"K>/(JTV%F:/+BU#5<=MD.\
M03IZ[<Y$6C11ETJO49'2=VHC8G<*C[C4%UI:QXSN'T-';VKSCH=HY!W@BI,?
M:4G12Z^J-,D3-[O*FQUF<"F35719R/V!=H9/[!;(=,.""-C*JXD1Z?8('*G$
M"8T%AWC^XS]UOAPZ>KE+JK<5P$GZAZ\5G.NIEU<_+%XIOK$0B>*+TU'30!/X
M[>+IV_1N]A?\2O+\.+_8_5<(9'$^MK%+6/IH_MVW#[B<'C_TW99>4+[H^K[;
MT)_XFDCK\0'X?=D!W>0#'I#>6/_3_P)02P,$%     @ 97X/5=-BU.GR!0
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MQN-N'W[F^)@BRQNPGAEDU#QP@.WGV? ?4$L#!!0    ( &5^#U6F*EC%'@0
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MQ('/"^*;W1F28/@S6?P%4$L#!!0    ( &5^#U5R@"!*H ,  &@'   9
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MUB@Q3YG07 I0;'W>NO0_CT,K[P3^X&RG&V.PGJRD_,M.OL?G+<\:Q!(6&8M
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M;%B?BUJ8L3LF,YG$DC0R^:[R:Z\>MXR\%"GMN"4S6Z0T[!A.-AAK:[^1+U4
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MSPK@_EI*4TWL ?4/M(M_ %!+ P04    " !E?@]5[5B5@<T$  "'"@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RM5MMNXS80??=7$&I:I( 2ZVXY
MC0TDMK<;='<3Y-++(R.-+78E4DO2<=*O[PRE.,XB<5^* +$N/#-G9LZA>+I1
M^JNI "Q[;&II)EYE;7LR')JB@H:;8]6"Q#=+I1MN\5:OAJ;5P$L':NIA% 39
ML.%">M-3]^Q*3T_5VM9"PI5F9MTT7#^=0ZTV$R_TGA]<BU5EZ<%P>MKR%=R
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M<IG2M$5E 72_E-)L-S9 ,[_#/U!+ P04    " !E?@]588;UY)4#  #."
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R55FUSVC@0_NY?L>-V.M<9
M-W[E+0%F"- T<PFA 7IS'Q5;8$UMRY5$2?[]K22@-"'T,@.K%^\^N\]JUW)W
MP\5WF5.JX+$L*MES<Z7J<]^7:4Y+(L]X32M\LN2B) J78N7+6E"2&:.R\*,@
M:/HE897;[YJ]J>AW^5H5K*)3 7)=ED0\7=*";WINZ.XV[MDJ5WK#[W=KLJ(S
MJA;U5.#*WZ-DK*259+P"09<]=Q">7R9:WRA\8W0C#^:@F3QP_ETOKK.>&^B
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M8<ZO2^SVSY 0ST-*SF@Z"I%=%O=C=];D/&0S.#V<A/$H:D[_40/HW&$GKU1
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MAH\P2L89@F=[!R0B.$<Z;+BR#-O;=$X&#E'EG#X!0R0P>C0R11> ;)+EC&!
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M_X5=8YN, DAK8U5Y<"8&)9?-EWT_Y.'$81R]X9 <'!+/NPGD67YDELTF6NU
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MU!M=!:";5M5,K*I\>]@H2\W&#POJ[JB= >WG2MGCQ 5H_R_,?@!02P,$%
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M-&R ]RNM;?W &S3?RI?_ 5!+ P04    " !E?@]52\!T(\,"  #Y!0  &0
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M7JEI/>M.5!O"$#&&CYI_L^/R@)#I .6BZDM+V!6-!WTTWC>@0;@J*1A_@_J
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M6!W^[,%$+'<<:F1A])0$IUGP\\DY[N=I##GS"J/B^QWSX!&XREW.YSC-6E3
M06R18S]S.8()Y6IHV-")0$@" H&#(IZ+"MDK,86;#3YFJX86HPXN*P%7(S/:
MY+TX'TU5,JK?0D"%<TF0-J/7YFE L:,X\EH[CK=H$/$;\:+ZW AB\XQ$P5Y*
M00G,98PDQP@V;E6QGP%[D- RJDV6^ Y(%(D]5U<]U:_E=ZS]&&Y=1M:5H'LT
M1T\3#'Y_DS@$=T -*B*WAQN'@/B%&MT6]HCK7>0$*]H* @JO:7J/'.T!WY=4
ML91,A8KV8ZQ)J&1BRMT$#IP8P)RZ/4FDP_:(]52O)>L4RWOYE#G-9H-8P3+9
M4 M;<I3#0PC[9!PF<!QJNE8O#?R#(F*YR3&R0&G19H2 F484F'5A2F9_2W&^
MA1-N-&RP3<K">=@)?D!ZP;+LI<GKT# (HYEVFH40B+/98$7[KS!\E-+0V"V-
M<U JU,!H+H.C;8ST42]S_2@;R^-1ZZ;BIN\AY;J,3#I,)._5-9MV["$)G/,(
M5G$$"]*PR*4A$^W_)Y$XIDAW"08>FNH1J64^9C$C6F6I8O"TH4''4^W53IFN
M:]VB[\( ":5Q.$A^:(>B2LTQ0)G ]S^6$'4H(5(EE78:?B!1#>>\(2<ZFE@?
M)JA#D> Z%;X6/H&(2V,G,C'5R539-)PHK=D$WAAEX@F'%F/LE+A!/$Q*..WR
MT]FJ\^G#52^/:?*HV_^.(U:X@!HU%<>_(1U#2\['5FJ(@.H[HO1TI.A\^DS1
MY68+VG T+O^.HT0)HDX_8I?KP/@<"K</P@UJ3H6[U.BC\G;*TV*\B['.T 3*
M9+D4P:5E)((]YCV.HX'ZHT![0,*<7P>#G ]DI6F!/1SVH_)9GF/B "'F8MQ(
MH?DM/H/ L UG<A1ON0T\BZ&$"E_-Q&O)*!"5/083_S0"4E%,S+WO$=K/]>^\
M8@1+FGB AI-C;BF9=XF]W#\-$0%FL77)[35LYF=^+VKKP3,4M* %Y0X_FJK6
M(=_4T*>.Z07VZ6&G:I1^WRXI([%G1Y$@L]9BBA$V?WXA<\7CXC53V:RD?$-C
MK<U^C9H76G/6W5IJ%F33@7C"PO'AGQ%?%U/1 DEXL"F'!9B4#1[=#!YFH7,;
MXYN!H.E0^$A*DE!^EZ"P"<\"J)R18[ SS:EN<-C]_Y*E!U10>U08&K&ZJ<_V
ME4FY4_T^_UQE<6EG4W,W400;.'063 YY</^V7O%,:>':HM]PHH4?E!B/YB?G
MA@U*&F25 W1(&BRR EWGRDTAQMADS:3#SB=&"'B408H;$;)\S>GYX><H#,FH
M\MLXSTW'/%06?9&NA$I;Z3S8"ZD=\/= BMYS2#OX9*]7;7P\.].%(XCY><FL
M:Y\H@4$0/(%E7N>I5$U=N^(K%>JX.Q*RARE/FT["GD\?A;U:9V7-46?['6=A
M":@*9P,^X( L3@%Z_#@FPV%6F]9/N2D>EZ74;GJ#:?#Q?'KR\6.+#2],YW'$
MEZ-X7.!XU>\[)B#C(FID$74" O\IF4JUGUAPZY .N$_@>I VD(B2L Y/\P):
M>,8VI##YEYFN!T/RDI(("6155JX:R2ST6&:Q5T>/I>FY_MBWQ9J=2+/L;LCN
M4,>="N=VU29[EWIUF-0+F%"P3R0@#1M4X+&XQ,N:+CTXU_\"\Z&H\B13AMCQ
MT7?2F$9)0G\'LQDL@FL\CL9E3Q97Z2*) :5B)A=4I*]TLC'_;MJL"G-Z)W<A
M],%T1V7I#N8NP?H<V\/EYQ$AR<8[%EP;,FT($^%5-I[4>(CPTVELL;4JQ9#'
M5Y.#YG>F9<@,W5)AC+@6K;UO*HE!TU#+H(&N6BFG\8TJI&ZISQC&/3"=PUH9
MRHII<1S=0[:/?N95K@WY+VIHK)M0 ^<GDM?8:U<'MY!J<J2 &$\"=HZ."8MY
MWE\MBWX.2,2G 7!P&9LR9W1 5(Y+A,'@-,01A7)IXRA!4(-I05>9N&'(- +S
M.CM\%T:SI->0FE ;OH;C.K8A2"F\M';]S_K5Y=7+MQ^NOGQZK3^\T:^O/E^^
M>_'Y]2O]Y>KUFR]O]=O+/UY?J3?NENP,R3P0HZ/NYX_J\K,:RO3#(2VYBN!G
M0Z2YKYFS(!0,\'@G6\R1Y&W()RX/\&AF#!G3_&1L4R&#@I6ZLW4Z[<C2/.SY
M]$#L6YI%'O58WS$&R]"H*U7QCX>&#8Q'$%H^%4LMP[-F>8;13JR(8[1+:5.J
MSV*$MJ5)OM3>YQ45):4W$CBQ*: 9^?WGY+1IV;>QEYXN4D"UL8-"#64MLI.E
MM" :/,2#/NXU\IUQ)$6D\^1)ZX<3:]2G^-:=9KT@E0J;=.8#0AO!9V3+<_U'
M.$_ $&,'E<U-V<@L);ICL@XXOUG:6ZK[\Z3"2:CZ#B&D*5,Z$EO8>*\!$PK,
MO?6G/!AV*\8V=J%#9I>')R+G^SSF.T;(T6?]L-@?4F03#\CH>9PZFZ.6R6I0
M-CH.,>F>3[RUD#O YL\?G,ZQ'A,2]LT&N\E</J=BZ9%4^YM%V-72QLIFG0:J
MGO*M<*J2!UI'5G#^('#+_ KUY[D@\I^Q@"O"X7D.TK@HK$(C>'!R:48=(['Y
M["UVJ5T+L< &DWPKIG33R&4 ,5?E(;)R@(V$ $'8DQSCKJA?AS=KI,[<$7[I
MD]IV 26L,=#$;IH@/!UT$(+%EA[;",6/^M,HZ<<0"1.BIJT<WP"PMVWV.BJX
MWV,(M*/DHGY@KC!4C.9*Q/'=C*3IU/)1DH3CP4DZ]D,J(3[ZN$+$,Y&C:MU)
MG)CEFL,M1!;W-9]OE^8>+Y/R5I6Z1<-:.A67$ 1(;9Q[8INV@.R7]SU@$O<0
MV4?5=M5T@SN$7,NW$5!%O@NG[T$K/4X1J$&#E34L/_$?4Q(L\10NSD/0VLRJ
M"80E+DR15#NHB3#!Z?PX'P7$--[0\1H&Q"&$V:2B+=]JXMW&57+G!NL8;39\
M3 ><Y9 QGW6*(2G%A+$>&:+1SWC2%W'#4#0.]\NM*+Q=C\956J]R;#%E0E0P
MI* U9'YF."8R9\>MHG3LC\)^BTNA(Z?1&O*M!Q'@"4-$TKLZZ_G38Z>S=$)O
MQ!-FWK/E7IKD&_E8^L*&QHW<D6;V(DJ]Z@V-E["-S*:>LB' 9LMS!5@_;? 0
M]TX5>/C1U;+&WBDW[JJAE(Y8_IE4 P.%PCGD%@]9L'G?4\J8M*<X-IPYP%/)
MNSB"'&]6XNX;WT6BR!VPU(?K22CG$3D7(:5%>/2&O"IZ23P0(/F *^(L9;HE
M(\SZX[V;//U9'3J&++"ZPKL=%-WM('$4$&Z#4252F4XWGS\>J1ZE<+V2TWL?
M<Y\DK-U_:G_R+*9H:7;T[AR-D,WW,QWZIW-1Y],'H[A(Q](<6#B:"'S'*2FN
MU0UA\Y2W9,=972<KDHJ1Z79G<OQ"^PQ)O$NL3)<6IHEHN;$@7-]Q5^H$Z3_-
M#=+%!_U&-(O5:,/U^I6A\_=QPO(Z3CCP;18HFWP;@(]G(C)8^1UU N*ZP5WS
MG GM6QU>K\,#[DXF&_9@<J$+3[ZFWH/)2R2II+%I2EL-+M&)18D]BH=TDTE+
M-14<60.GU>PL5J?2'0J8(I1X=T ;Q!K?B:<(_(@TS4;X2WXMP(]#>'$9^016
M4V&U\!&*EBM$J8;5J-:&0R2A\G>P)N,G9O3^#<UO(4MY$T3P^(K<1(&7@Y0J
M&]Y'6#0)*&>/B,D^=H"*&&O632UR@H/3<AN#R(L^R6X#FXD]R-,?2J6PG7F#
M<0A*=N=/J3U[<),HFJL+G. *=W:(-?I63>!*(QA_HL[9GKXFSS@@GJ@U'28>
MIW4V/D6WO5&@$2@N%YG2N4:ZOPQQ"+R%4!,0;?'$8\-MWW ,,NW,,#I#ZQ++
M>"0MY\\"LK-XH,WP=27!D0KC:8A]1-QGF;"GR7F^"LSPA-H0474443V-:"#,
M :;?2K&IJX732:>+Z9-._Y+%QAS ]*OC#B# T^$'E2Z>'%Y\,;ZM<-EH+$%F
M=QEETTKS!/\.*GW;<WS?IMRU!"G'ECC!>A;+TL/(P(PI#\<Z(U_D6;L:3J11
MWY_T.!8)K^ZN GX.MPK56*_>"X?SL<!] GP/<>]^APG8])T/)P+VJ)@?(1QK
MT U.I<3$C</QK'T0#@.&N:XR-L,QND_/A:[?Y]#YH1OW3&[JL_A,&"^8T&!W
MN'0M'8%X.9B;% _J[0!QO&H3 [@Z2;MOSL +8TPC(^F$:G!NV#JG+6#3'9PV
M)%H=]X="N)._14_F[ZOX?O:NS!K(. :^AD^ANQ@NDL9I*1&0.7,>+9))X,&6
M^1* _-)/%K]L/EHUB\JM^.E0^"<9:O.K&$W*KM+5B%1CO1D9AQ[93R1#W%FV
M*SI4^Q]M)@SG+\+9NL@\P5VDC>O6^Z+&$VMM'!?>FT08".BW;7=?_029V..^
M4QMGWZ5F^WO*U4Q-J=E>$WZNWS?B.9?6</>7"DJ<Z?']=QS%T_&UD9'L_1GE
M*5^7#H==3!\.>YE=+4,7)0+#QGL@TX".3#TFZ"I!SPJ-Q$ROQ[&(TT[UWG1]
MXAPQ()%H,"$7)OW'5"2&H(I\$%438<T0]$^^HN65SV-G-HKQG1"3XV6BQT&/
MRV0X4=C*2$XJ+$CZ%%<:  #2C!(VA%WL"2"0;CD(&-81LNI%G.Z)@[UM5G8:
M97)J)8>*84X9.K@:W-&7+76>2\O9W4C@',Q^'+'V^4Q-WMX6'Q9%1<5J]"AC
M(I9X7UL.DY,/24+MQO6;:7U+I^,NID_'O4%W^P>YVW?3M_E_%R#]+ET3RA5&
M+GQ+7QEOF&Q:]U?NK0=C\0F2SXXB<"GH8?[DVMD6S]<!_UX.H.:7<\:'TN&Q
M+%=E.5/95?+(F1M+,S?7MN+BUK8/MT@,[E$<26Y'RI_Q7CSIL,0&.C9!<8ES
M?:9E:(*W^V??T-6[K>,1//D+,8I36.E\TBVF19P##, N$K#]/#S6(Q0==W5_
MHM7C%9L%BJ!AM8#=>G$3L.GZ !TI^ J-90]A_8??M;XL.KBM+Y9U,^0DB<=[
MHN=CJG _^WLS&PN1._Y5'51[4$O^TS/QT_B7>U[PWZM)C_.?_7D'@3^>3*CL
M$EY],'_RXSUNVH1?NF9+?[UFT71=LZ$?\=IOV^(#\/VR ;+)+[A _'M&S_\7
M4$L#!!0    ( &5^#U6>7Y/_> (  $X%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;(U4;6_:,!#^SJ\X9=*T25,3 GT1@TA 88M$"VJ@^VR2"['J
MV*GME.[?SW8@8Q)%^Y+XSG?//6??X^%>R!=5(&IX+QE7(Z_0NAKXODH++(FZ
M$A5RLY,+61)M3+GS52619"ZI9'X8!#=^22CWHJ'SK60T%+5FE.-*@JK+DLC?
M$V1B/_*ZWM'Q1'>%M@X_&E9DAPGJ3;62QO);E(R6R!45'"3F(V_<'4SZ-MX%
M/%/<JY,UV$ZV0KQ8(\Y&7F )(<-46P1B?F\X1<8LD*'Q>L#TVI(V\71]1)^[
MWDTO6Z)P*M@OFNEBY-UYD&%.:J:?Q/XG'OJYMGBI8,I]8=_$]FX]2&NE17E(
M-@Q*RIL_>3^<PTG"7?!!0GA("!WOII!C>4\TB892[$'::(-F%ZY5EVW(46XO
M)='2[%*3IZ/Q=+K</*[CQQ^P6B[B:3Q+X,N:;!FJKT-?FPHVSD\/:),&+?P
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MCJU_X_"/P)U^,P:K9"7E#SN994,WL(2PP-18!$Z?%QQC45@@HO'S@.F>4MK
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M=F LN-IF,.0A"_\IH('VED8[!Z-[SD6)8RIOP+7KX%B.<T&>6P;!-?+<MX+
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M=PW6+D'B[O+(2,<V5XE423I.]^MW#B6[2>%X+X,!BY3X?><[-Y+CG=*?S0;
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M;L<P^?OA:GHSP=G[.7DLJ/S0]17ZTA9^NL$=6MSH"&X8P0VO5"YA4F4T^Q7
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MQQA\TN=A!L]SZOP);9F$@J=$T4Q77Y/>,IA52]!VV#<<2;K4VG] Z^.)VO
M>^3\[)'SUGGX"[O7B5O.P\RTL>.8?;S9XM.365@R'.JCOW="EA0WF;X'2$CY
MJE+VL-RM[JX: WO"_E2W]Q3</4N&;"GH DV#LQ:V1]BSWTX4K\UY^\@5GMYF
MF.-UB0JM@.\7G*OM1#O87<#Z/P!02P,$%     @ 97X/57&W;UN7 @  P04
M !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULI53;;MI $'WG*T9N5;62
M%5_#)05+!IP&B01D2-H\+O: K=A>=W<)R=]WUP:'*(27OM@[.S-GSO%XIK^C
M[(DGB )>\JS@ RT1HKPR#!XEF!-^04LLI&=-64Z$--G&X"5#$E=)>6;8IMDV
M<I(6FM>O[N;,Z].MR-("YPSX-L\)>QUB1G<#S=(.%V&Z282Z,+Q^23:X0'%?
MSIFTC 8E3G,L>$H+8+@>:+YU-715?!7PD.*.'YU!*5E1^J2,23S03$4(,XR$
M0B#R]8PCS#(%)&G\W6-J34F5>'P^H%]7VJ66%>$XHMGO-!;)0.MJ$..:;#,1
MTMT-[O5<*KR(9KQZPJZ.;3L:1%LN:+Y/E@SRM*C?Y&7_'8X2NN8G"?8^P:YX
MUX4JEF,BB-=G= =,14LT=:BD5MF27%JHIBP$D]Y4Y@EOMKP)0@B#43!Y\(?3
M8 '?EV25(?_1-X3$5U%&M,<:UECV)UB6#;>T$ F'H(@Q?@]@2&(-._O ;FB?
M1;PE[ (<2P?;M.TS>$ZCUJGPG,_4B@09A!AA^ERI/"6RAG!/0Z@AN>(EB7"@
MR2G@R)Y1\[Y]L=KFSS,$W8:@>P[=&T\6H^EL<1\&,+N&<;#T)]-@#,O0'P?@
MWXWA8[^"/_.I?^<O9^'C*35GZYU6\W\D6E^K;JF'U7I$P@#5WP"REU&BFODN
MX!>CV[)5]X6]]06LGFXY)KBZV^NU'OSED1.ZMMZV.F!U](YTSAF6Y%7N"<&A
M8UFZ;?; MG2S8[>6C,38(D4,]$.!KF7KO<LVN([N=$PXU3OC:*QR9)MJ>7"(
MZ+80]80UM\U^\NNQ? NOEYL4OTD+#AFN9:IYT;G4@-4+HS8$+:LA75$A1[XZ
M)G+'(E,!TK^F5!P,5:#9VMX_4$L#!!0    ( &5^#U60MOHGP (   0&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;+546V^;,!1^SZ\X8M.T25&Y
MY$+3)4CDTA4I#1$AV_KH@!-0 3/;-.V_GVT([:8TVLM>\.T[G[^/XW/&1T(?
M68(QA^<\*]A$2S@O;W2=10G.$;LB)2[$R9[0''&QI >=E12C6 7EF6X9QE#/
M45IHSECMK:DS)A7/T@*O*; JSQ%]F>*,'">:J9TV@O20<+FA.^,2'? &\VVY
MIF*EMRQQFN."I:0 BO<3S35OIGV)5X#O*3ZR-W.03G:$/,J%%T\T0PK"&8ZX
M9$!B>,(SG&622,CXU7!J[94R\.W\Q'ZKO LO.\3PC&0_TI@G$^U:@QCO497Q
M@!SO<.-G(/DBDC'UA6.#-32(*L9)W@0+!7E:U"-Z;O[#OP1838"E=-<7*95S
MQ)$SIN0(5*(%FYPHJRI:B$L+F90-I^(T%7'<"0-WO@!W-0<_O%L$L'8?W.ER
ML8'/(=IEF'T9ZUQ<(\%ZU%!.:TKK'4K3@GM2\(3!HHAQ_">!+O2U(JV3R*EU
MD?$>T2OHF5VP#,NZP-=K3?<47^\]TQ3%&-PB!I\GF,(:O2BSY[S63/WS3+)D
M;EB)(CS11$TP3)^PYGSZ8 Z-KQ=T]EN=_4OLSMS;S);^9ALLP+^%^2)TO>5B
M#M[JU@_NW=#S5^!._6WXFC692'<V"[8"MO3<J;?T0D_L+WZNE^[*#?W@X9S)
MBS+.F_POVCH?#<-0698?L_. $04L7Q&(-Q E\A'\C?E&255VZI26=2+![IO=
M:\,&RS2ZHY'5<:.(5BACT!_87=ON@6UVC5&O,R5%Q41G4*=@&L/NP#; [/9&
MXGPXJED[2#P4HAY*P\\D1(#-@00/[9Z8]>%<PO4WE9EC>E#]AT%$JH+71=KN
MMBW.K2O[%5[W1_$##FG!(,-[$6I<V0,-:-USZ@4GI:KS'>&B:ZAI(MHTIA(@
MSO>$\--"7M V?N<W4$L#!!0    ( &5^#U491ZZ HP,  'X'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;*55VV[C-A!]]U<,U$61!=3H+EFI;4!Q
M',1 ;K#C%.@;(]$6NQ*I)2D[VZ_O4+)==^'DI2\B.9PYY\R('(YV0GY3):4:
MWNN*J[%5:MU<.8[*2UH3=2D:RG%G+61--"[EQE&-I*3H@NK*\5TW=FK"N#49
M=;9G.1F)5E>,TV<)JJUK(G]<TTKLQI9G'0P+MBFU,3B344,V=$GUJGF6N'*.
M* 6K*5=,<)!T/;8R[^HZ-/Z=PRNC.W4R!Y/)FQ#?S&)>C"W7"*(5S;5!(#AL
MZ916E0%"&=_WF-:1T@2>S@_HMUWNF,L;470JJC]8H<NQ-;2@H&O25GHA=G=T
MGT]D\')1J>X+N]XWCBW(6Z5%O0]&!37C_4C>]W4X"1BZ'P3X^P"_T]T3=2IO
MB":3D10[D,8;T<RD2[6+1G&,FY^RU!)W&<;IR31[GK]D]Y ]WL!BMIPM7F=+
MN'@A;Q557T>.1@KCZ.1[N.L>SO\ SO/A07!=*ICQ@A;_!7!0VU&@?Q!X[7^*
M^$#D)02>#;[K^Y_@!<>$@PXO^"AATC!-*LAX 0NJJ-Q2=2[/'B4\CV*NRI5J
M2$['%MZ%#L6:_/J+%[N_?Z(Q/&H,/T.?+*=WLYO5_0R>;B%;O=P]+>9_SFY@
MOERN9K!ZO)\_S%]P_;AZN)XMC--SMH#7[!YWEW<9_L9S"7U*>3ZAEY(.IJ)N
M"/\!3 %I=2DD^YL6H 4:5$N!<&@1K&8:K;RMWZ@$L0;.*FB(A"VIT$F5!#&-
MG8!B?%-1R"NBU"7\[TP'RQZ[&R#O?^Y@;K05(&3!.+::$P&KY1?WTG6!DKR$
MQU[OET&F\8@!'C4TXCES(0YBVT\3VPU3\#S?=I/43H?A@8WU^+]!(]F6: I-
MA:7#7H4X&!BGMA\%X >N[7KI8$$K8GH/W!)V*$F.0!L*V%5A1Z0D7!]1&8=<
M\+]:WO>M'=/E&9X++QC:@1O!U\'T_O$TN&*T-:FN6UY(PDS!$;"NT</@7401
M!J8F\*DQ# KH.Y4Y4QCN1R@9R^-%]C!Q?ZZ+!W'BVT,O1F(?Z^+9L9_:7A(,
M9GL$PWO,)QC&=H3%2Z(8 CM,7#L-73Q0?$ME)P6=43M21+:+OJ'GPA!Y$3Y-
M?N9&/CM(0G2*[# >@N<'=IH8 A?.73GGI"?6%&MM.K_"0K1<]^WQ:#T^+EG?
M4_]U[U\FU+!A6*:*KC'4O4PB"V3?[?N%%DW78=^$QG[=34M\(*DT#KB_%D(?
M%H;@^.1._@%02P,$%     @ 97X/5>6.>6L>"   D1<  !D   !X;"]W;W)K
M<VAE971S+W-H965T-# N>&ULK5AM4^+*$OZ>7]'%*6]I%8:\)WC5*A1TN;6K
M%+!ZSL<1!DB99'+R@OKO;_<D!(*$L];9L@0FZ>GW?KIG+M]$\IJN.,_@/0RB
M]*JURK+XHM-)9RL>LE05,8_PS4(D(<MPF2P[:9QP-I>;PJ!C:)K3"9D?M:XO
MY;-1<GTI\BSP(SY*(,W#D"4?-SP0;U<MO;5Y,/:7JXP>=*XO8[;D$Y[]C$<)
MKCH5E[D?\BCU100)7URU>OK%39?H)<&3S]_2G=] EKP(\4J+X?RJI9%"/."S
MC#@P_%KS6QX$Q C5^+ODV:I$TL;=WQON=])VM.6%I?Q6!,_^/%M=M;P6S/F"
MY4$V%F_?>&F/3?QF(DCE)[P5M"Y*G.5I)L)R,ZY#/RJ^V7OIAYT-GM:PP2@W
M&%+O0I#4LL\R=GV9B#=(B!JYT0]IJMR-ROD1!662)?C6QWW9]>1;;SR Q]%T
M^/@P@=Y#'YY[XW'O83J!TRE["7AZ=MG)4!"1=V8ETYN"J=' 5#?@AXBR50J#
M:,[G=08=U+!2T]BH>6,<Y?B#)2J8>AL,S3".\#,KLTW)SVPR>\42#H\Q948*
MO6@.SRQ)6)2EAZPM>%F'>5'97*0QF_&K%M9%RI,U;UW_YP_=T?Y[1%.KTM0Z
MQOUZ<OMMT/_Y'6-T5X7I\>=T,L58#1_NBY -AO??IH,^])X&X][]  9_#L:W
MP\D 1N/A[>"024>%'C9INN+*K0AC%GT @D+",IY"2HX\I[J80\P^L%PSD)Y<
M<OJ=0B:P=L,\DO30]Q,L1Y&DP-#GK_P#>!@'XH,C*S^";,6!@ ;$ EC!&T7)
M\I5PQ%489@H+4@%^FN:X290AQ,V!SW/:N"!F*):XIWD<X_-2'A9+P%X$:H(:
MJ( & 7_GR<Q/.<2)/^.TG70H9?HI1%3Z08!Z_IVS@-C2>\2O5YXIU1X6@4CF
M?H2P5FI=&K/Q%\OD<DX^0/HEI9H*OR&V"A4$586N;++Y62(1QF/_@?*89VF&
MCO"C)6FD0P\M",#1VJZMM35- T?M:J!WV[96K&W5]I1[TA;Y&5Y;+^D\U=+!
M,MI&N7954U<0)A?<)\I3W:E8G"&3K@ZG&Q%G* 2U'92.G\,Y_IT:];=[FIHZ
M( +,5N :;4O;B+2Z^ZION!)PU?;I5MLR7=*)5'6@6VDNQ:'_-&7?;TWN(I^
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MC7;L@JSG7ZUHL:UFSD)H,\$J<6-^&2BM@=E?":$/B@UP_ D-?@-02P,$%
M  @ 97X/593D,J<D P  &P<  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&ULG55MC]HX$/[.KQBE5=63Z.:%;( M( 5VMXVTL"L(=^I'DQAB-8E3VRG=
M^_4W=D*Z)P$ZG2(E'ON9Q\_8,Y/)D8OO,J-4P:\B+^74RI2J[FQ;)ADMB+SA
M%2UQ9<]%012:XF#+2E"2&J<BMSW'">R"L-*:3<S<BYA->*UR5M(7 ;(N"B)>
MYS3GQZGE6J>)-3MD2D_8LTE%#G1#U;9Z$6C9'4O*"EI*QDL0=#^U0O=N[FN\
M ?S)Z%&^&8..9,?Y=VU$Z=1RM"":TT1I!H*?GW1!\UP3H8P?+:?5;:D=WXY/
M[(\F=HQE1R1=\/POEJIL:HTL2.F>U+E:\^-7VL9SJ_D2GDOSAF.#'086)+54
MO&B=44'!RN9+?K7G\,9AY%QP\%H'S^AN-C(J[XDBLXG@1Q :C6QZ8$(UWBB.
ME?I2-DK@*D,_-7N,5N%J$85/$*TV\7J[?%C%&_@8DUU.Y1\36^$>&FDG+=^\
MX?,N\+D>+'FI,@D/94K3?Q/8**Y3Z)T4SKVKC$LB;F#@]L%S/.\*WZ"+>&#X
M!I<B9B4I$T9RB$JI1(T9IN2Y0!L:_SR-+I8[69&$3BVL!DG%3VK-/KQS ^?S
M%9%^)]*_QC[;;)?+</T-GA_A]PT]1>$\>HKBZ&$#\W#S< _/*U@\K^)UN(BW
M"-BN[J/-XGF[BG'M)?QF+O-<:%<W/Q]:G-&>TED!.UW);16SOZD$E5%,254+
MIEZA$GS/$,7W9OZ+X'7UX=W(<X>?)>R[L\\9V;&<*8;^NJI2P!)-,',$UFF-
M@+I,F4QX72J:]BKR:J[I#LX=3.__'4SO/3Q1J>63$@;X* Z8OC%7).\9W2;E
MKL)B05(*I$3Y&*T %&HJ!P)_W \\'\9>WQT%,/3=_LAU>FN:$PP(<4*?U0GM
M#_N.[\*G=M SY!",@WX0W'8<HU%_=.O^-]G781=ENZ[3=X=C<!T']0[ 0WL\
M]B[I_J2?5NT%5SA7#?:;AE50<3!M68*Y[J9W=;-=YP^;AO<;WOPVL#T<6"DA
MIWMT=6Z&MQ:(IA4WAN*5:7\[KK"9FF&&?R\J- #7]YRKDZ$WZ/Z'LW\ 4$L#
M!!0    ( &5^#U7%Z GH/@,  ,8'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;*U5;6_B.!#^SJ\8Y4XG*D7-"^\]0 J%W2*5%A&XU7XTR4"L3>RL
M[93EWY_M ->KNNQJ[[XD&6?FF><9C\?# Q=?9(:HX%N1,SER,J7*.\^3288%
MD;>\1*;_[+@HB-*FV'NR%$A2&U3D7NC[7:\@E#GCH5U;BO&05RJG#)<"9%44
M1!PGF//#R F<\\**[C-E%KSQL"1[C%%MRJ70EG=!26F!3%+.0.!NY$3!W:1M
M_*W#7Q0/\M4W&"5;SK\88YZ.'-\0PAP391"(?KW@/>:Y =(TOIXPG4M*$_CZ
M^XS^P6K76K9$XCW//]%492.G[T"*.U+E:L4/#WC2TS%X"<^E?<+AY.L[D%12
M\>(4K!D4E-5O\NU4AY\)"$\!H>5=)[(LIT21\5#P PCCK=',AY5JHS4YRLRF
MQ$KHOU3'J?$DBN?W$#U-83I_W*QG4WA\CF-8SE80/T2K&3379)NCO!EZ2J<S
M05YR@I[4T.%WH(,0%IRI3,*,I9C^&\#3/"]DPS/927@5<4'$+;0"%T(_#*_@
MM2[B6Q:O]3WQ1-($(I;"E.:5PA0>N92P1 %Q1@2^I[E&;+^/:([0G2Q)@B-'
MGQ&)X@6=\1^_!5W_SRM\VQ>^[6OHXWBS6$2KS_#\ >9/]\^+F=VX>I^FT3J"
M3:PW</X$ZX<9_'!G-<!RLX[6\^>G^#VEU[G8VC5R4Z]2UTN:>@&5D) \J7)B
MBKD]0DI?:$K9'E2&8)V)4H)N*V6Z"A0'_%I1=82,YRD*"7QG73\*7I4&P!@'
M>[0T('E!H2<%L*K8ZIS:EPN-KH=)P^:70)GF("N$M!+GM$<T;7.J7>/_KUWC
MLTX :'J\81K3=&?0:)I6NOE)N0DO2L*.T/S]!II=-^SVW6#0 VVTW%:GY79\
M;30^_;@.\+8.@][ #8/0[??[T.V%;J_;<[OAH%&W/M&MGYK6UY,1WNQE,T&F
M7BUH,OZM'\#E_4:W_Q\D!VZGW7;]SN 7578&';?=TPBM7U?FP\U[1]1[-5L+
M%'M[@^@VYQ53]9B]K%XNJ:B>S?^XUS><'E][RB3DN-.A_FVOXX"H;XW:4+RT
MDWK+E9[[]C/3%RT*XZ#_[SA79\,DN%S=X[\!4$L#!!0    ( &5^#U656WK!
M<@0  )0+   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;*56VV[B2!!]
M]U>4O*-5(IG!-F @"TB&D T2N2B0'<UC8S?8&KN;[6Z&\/=;W3:>D'B8[.X+
M]*U.U:F;:[#GXIM,*%7PDF=,#NU$J>U5LRFCA.9$?N9;RO!FS45.%&[%IBFW
M@I+8".59TW?=H)F3E-FC@3E[%*,!WZDL9?11@-SE.1&',<WX?FA[]O'@*=TD
M2A\T1X,MV= %5<_;1X&[9H42ISEE,N4,!%T/[="[&@?ZO7GP5TKW\M4:-),5
MY]_T9A8/;5<;1#,:*8U \.\[G= LTT!HQM\EIEVIU(*OUT?T&\,=N:R(I!.>
M?4ECE0SMG@TQ79-=II[X_I:6?#H:+^*9-+^P+]YV ANBG50\+X71@CQEQ3]Y
M*?WP2J#G_D3 +P5\8W>AR%AY3109#03?@]"O$4TO#%4CC<:E3 =EH03>IBBG
M1G.*E"1<+,DJH_)RT%0(JJ^:40DP+@#\GP!X/MQQIA()4Q;3^!2@B=94)OE'
MD\;^6<0[(CY#RW/ =WW_#%ZKHM@R>*VS%.N8%7+M>CE=#E=R2R(ZM#'?)17?
MJ3WZ_3<O</\X8U6[LJI]#GVTF-Q.KY_G4WBX@:?9G[=+O7A>3"%<+*;+!83W
MUS"?AG@PGX7CV7RV_%I'X:R2>@I'S=;'-5NF6!M\W=A)"D1*JB0\"FP-0AVL
M4($'X5:DF0Z9!_V>T^GVK6LJ:,0W+#7EQ]<@-(A>5"!PT>\ZG4X++JU9CG::
M6ZPVK"4&]"5*"-M0N/ <UP_P#2IJ>8#Y$24F.:!A?7JCW866Z[A]K1T91RDY
M*J=$9 =05& 1$45CR'1:P$7;<0,7L:?F?EG>:Z&]2!5%T35<^%U\U3]O)1K9
M<JTPC@U?"9[;=EK=[CM#&':J4G?'Z?;[[WE5'C29"_.4K-(,4;%.3^F?"%F?
MX,09B-%%9EA(0:\&RL%FEA$6Z4@ 4: 2"BNZ21E+V4;;J0\.Z+4W0#.&/J12
M(7'\,"!FM^V6Z%MRP':-F='0;NVT_1.'K6O"ZKM=N,0HODN5PD%9:>[A1Y[@
MXW.1:IA8]7I=[=4J%(TR&+WWUC>@U?-K[ \<UW5-:*R66WJT4;KB_SCSB %G
M6DBG:B&=#[>0TX*=31<P_@J3.9;T[&8V"9>SA_NZ]G%607W[,.2M[%52$H&^
MT_=,UU7*#%NIL,JT.TWL,5(,:R"#+9=%D-%1:Y[A3""OX%\2L7Y5!9.=$%HS
M!K?M>.V>=<]9(ZH.@[83>+ZUY(ID'PI(4 4D^'! )@_WRZ=PLGP.YW 7+I^?
M"C)U#.L"<U91?6 P50L_'+^=0%@,)T?XJV,3<:Q*=H"$Q/B&[= ->)2GJDC_
M'7[(!3#M,YW36:9G ]#-'LL-\]D4I[RR_B-=Z^$-$NR3%&W$DDP%O?IEC_N2
MJ@23C+.RI#R,G]?"QE $]+BM#6CSU:244[$Q\Z!$]CNFBJ&I.JU&SK"8M'X\
M+^95M H+7"*'-8JZG[M82Z*8 8N-XELS=ZVXPBG.+!,<FZG0#_!^S;DZ;K2"
M:A ?_0-02P,$%     @ 97X/51<2);W, @  Y@4  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&ULE53;;MLP#'W/5Q!>,6Q 5L=V;LV2 &DN:(%U+9IV
MPQX5FXZ%VI(GR4W[]Z/DQ,V&ML!>;)(B#P\ID>.=5 \Z0S3P5.1"3[S,F'+D
M^SK.L&#Z5)8HZ"25JF"&5+7U=:F0)2ZHR/VPT^G[!>/"FXZ=[49-Q[(R.1=X
MHT!71<'4\SGF<C?Q N]@N.7;S%B#/QV7;(MK-/?EC2+-;U 27J#07 I0F$Z\
M63 ZCZR_<_C!<:>/9+"5;*1\L,IE,O$ZEA#F&!N+P.CWB'/,<PM$-'[O,;TF
MI0T\E@_H*U<[U;)A&N<R_\D3DTV\H0<)IJS*S:W<7>"^GI[%BV6NW1=VM6_4
M]2"NM)'%/I@8%%S4?_:T[\-1P+#S1D"X#P@=[SJ18[E@ADW'2NY 66]"LX(K
MU443.2[LI:R-HE-.<68ZJQ)NI/KX81@&@Z\:;K&H!"KF6O;ICFURU)_'OJ%4
M-L"/][#G-6SX!FP0PI44)M.P% DF?P/XQ+$A&AZ(GH?O(EXQ=0I1T(:P$X;O
MX$5-X9'#Z[Z!MYY?+!?WWY9PO8+Y]=7-[/LOF-TO+N^N;]>P6B[7KQ7]+J2=
MGY$N68P3CP9$HWI$;[JH%!?;ELD02E1<)FVP\E;)J@2Y,30WF#A3*G,:$7(&
M&\ICU) J6;BS6!8E$\_--;'ZVO0(#G6TWJJC%05 S8LSUSDXUH+6"9RT5DB9
M2O9L[QJ,?#<?D53.P1E IDXIF4)A#D' 1$*RT#+G"3-47<H%$S%G.6A#!III
MHRE_IST81- ;MH>#[O^SD.2AFE:-6NXE?U&8NY1,ZTI14GQI9M"E3&<A#,)V
M/QJT[J0A0NR?]Z^.WW_4/6OW^ST(Z-WU@@!>>W;^T>P5J+9NPVBB7@E3CV%C
M;9;8K)[=%_=Z ]*];+G0D&-*H9W30<\#56^56C&R=).\D8;V@A,S6L2HK .=
MIU*:@V(3-*M]^@=02P,$%     @ 97X/57TY'9N/ @  F 4  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#8N>&ULC53;;MLP#'WW5Q!>,6R 4=NRTUR6&,BM
M:X&VRYJF>U9L)C9J2ZFD--W?3Y(3+P/28"\629%'YU@B^SLN7F2.J."]*ID<
MN+E2FY[ORS3'BLI+OD&F=U9<5%1I5ZQ]N1%(,UM4E3X)@BN_H@5SD[Z-S432
MYUM5%@QG N2VJJCX/<*2[P9NZ!X"C\4Z5R;@)_T-7>,<U6(S$]KS&Y2LJ)#)
M@C,0N!JXP[ WBDV^37@N<">/;#!*EIR_&.<V&[B!(80EILH@4+V\X1C+T@!I
M&J][3+<YTA0>VP?T:ZM=:UE2B6->_BHRE0_<C@L9KNBV5(]\=X-[/2V#E_)2
MVB_LZMRH[4*ZE8I7^V+-H"I8O=+W_7\X*N@$'Q20?0&QO.N#+,L)533I"[X#
M8;(UFC&L5%NMR17,7,I<";U;Z#J5C*G,@;(,K#%]W19OM$2F)'QYHLL2Y=>^
MK_0Y)MM/]YBC&I-\@!D2N.=,Y1*F+,/L7P!?$VQ8D@/+$3F+>$_%)42A!R0@
MY Q>U*B.+%YT3O7PA.I38FNH^#24:9J>W- 4!Z[N"HGB#=WD\Z?P*OAVAFC<
M$(W/H2?S\<UTLKB;PH]K& _G-S!\F-3&].?B]GEX-WUX.L7Y+.IISN97..8E
MI.:?X-%+2+GN0:F KT#E""M>ZE8NV+KG_ \])PI!WU^:V\N#8R]T+N#"J9^@
MTLW%7NQ3+!CD>NTYWT<S(%X<!%XG;$/L17'LM>/ 6<PG0+I=KQNT]7Y+1UN=
MKD.\MLYLDQBNO$ZGZT6D"Z>NP#_JE@K%VLX$HW++5-TX3;09.\.ZV_ZFUS-+
M*UD73$*)*UT:7+9;+HAZ#M2.XAO;>TNN="=;,]>C$X5)T/LKSM7!,0<TPSCY
M U!+ P04    " !E?@]5/MSJ 80"  !<!P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6RUE=]OVC 0Q_^54R9-FS0U$'ZJ@T@%@H9$U:HIW<.T!Y-<
MB%4[3FVGM/]];0<R)I4\3.L+.=MW7W_.YLZ3O9"/*D?4\,)9H:9>KG5YZ?LJ
MR9$3=2%*+,Q*)B0GV@SESE>E1)*Z(,[\H-,9^IS0P@LG;NY6AA-1:48+O)6@
M*LZ)?)TA$_NIU_6.$W=TEVL[X8>3DNPP1KTI;Z49^8U*2CD6BHH")&93[ZI[
M.1M;?^?P0'&O3FRPF6R%>+2#53KU.A8(&2;:*A#S><8Y,F:%#,;30=-KMK2!
MI_91?>ER-[ELB<*Y8#]IJO.I-_8@Q8Q43-^)_0\\Y#.P>HE@ROW"OO;MCSQ(
M*J4%/P0; DZ+^DM>#N=P$M =G@D(#@&!XZXW<I0+HDDXD6(/TGH;-6NX5%VT
M@:.%O9182[-*39P.%ZMXOKZ)-W<1W"PABN]7UU?WT0(V<;3<K&&]>HAB^+)
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MP;[Z<? FXPT69ZCG?T6!%P0=!4W>#_<[X/'[X=X;W?3:L^A9OMZQLRA*RI\
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MS;%AJYL,.)7B4-][0($H *BH^$'5O][$N&C$@O WB[3KO!Y2=U4"I5$H6E%
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M2\.HP*D"77).U*\!,EGU@W:PVYC1=6[<1IC$!5GC',VBF"KKA0U+1CD*3:4
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M=8#:GS,FGR;Z ?5?1? 74$L#!!0    ( &5^#U7Z2EXJ0@4  ,@4   9
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;*U8VW+;-A#]%8QZF62FB0C>Y=J:
ML45EXIEX[/&E[2M,0A(:DF !2'+Z]5V0-"51(&(W?A$OVEW@'.PN#G&ZY>*K
M7%&JT%.1E_)LM%*J.AF/9;JB!9$?>45+^&?!14$4/(KE6%:"DJQV*O*QZSCA
MN""L'$U/ZW<W8GK*URIG);T12*Z+@HAO%S3GV[,1'CV_N&7+E=(OQM/3BBSI
M'54/U8V IW$7)6,%+27C)1)T<38ZQR<)CK5#;?$'HUNY=X\TE$?.O^J'R^QL
MY.@9T9RF2H<@<-G0&<US'0GF\4\;=-2-J1WW[Y^C?ZK! YA'(NF,YW^R3*W.
M1O$(971!UKFZY=O/M 44Z'@ISV7]B[:-;12.4+J6BA>M,\R@8&5S)4\M$7L.
M>,C!;1W<OH,_X."U#MY+'?S6P:^9::#4/"1$D>FIX%LDM#5$TS<UF;4WP&>E
M7O<[)>!?!GYJ>C?[/$\>OLS1]2=T?_X7FMW.D\M[=#._O;Q.T+N$*L)R^1Y]
M0 ]W\/SS^].Q@F&U\SAMA[AHAG 'AL NNN*E6DDT+S.:'088PWR[2;O/D[YP
MK1&OB/B(//P;<AW7-4QH]G)W;'!/7N[N6-!XW1)X=3QO(-X]>2*Z!DS,-IZ^
MV5/WA!-9D92>C:#H)14;.IK^^A,.G=]-K+QEL.2-@ATPYG>,^;;HT]E:"%HJ
M](T2@11Y0N]203.FC,G9A KK4+H+;J8? F?BQI XFWUV#':N/PEZ9HEU9F;<
MR (YZ" '5LCGV=_0#*#A*HF8[KBR@LZ)^ )5@G&!*@J73)H(: ('!\"BR/4F
M/0(,=GX?O<$F"MUX%^H 7-B!"ZW@K@5;LI(T&T&9 ;H-%9+D&IYBT/66*&.+
M!85%3ZD1HS7^BU:EX>"-XB0_'N> R*@C,K(2><\5L+9?$0BD 5(KVB:(B;O(
ML*9Q&.C6>) ?!CLHD(G?2Q%3N.$4B3MDL179%RXE>J2 AFI\@PTS/AX]=/S
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MTT_?\B6"*_=$51W;O\(HV2@M\@9L*LA94;_IKM'A ."? @0-('@+Z)T =!M
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MXA1R+"Y9 52]63*>8ZFF?&6+@@-.#"C/;+?3Z=DY)M0*!F;M@0<#MI89H?#
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MPZ7JBI'K +4^9TP^3W3CE?;9]C]02P,$%     @ 97X/54E;G 6: @  [P8
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MC>]1$,[\X2@,T"SR@Q#YCP$:SQ[""$7A(!P^^W>C<(K"WY.1_^C/QM$?=!&
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MVJW#TY*Z$M<=ADM9S#:8\=(HFPF_O! 1 /Y]BS%[ZXCZV%Z'[C]02P,$%
M  @ 97X/5?M)&'GC!   )!4  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N
M>&ULM5AK;^(X%/TK5G:UFI&FC>V\NX $E*I(?0F&66E'^\$%4[*3U]H&NO]^
M[21-@ 0OK9A^:)WDWN-[KJ]]3]W9INP'7U$JP&L<);QKK(3(KDR3SU<T)OPR
MS6@BORQ3%A,A']F+R3-&R2)WBB,30^B:,0D3H]?)WSVQ7B==BRA,Z!,#?!W'
MA/T[H%&Z[1K(>'LQ"5]60KTP>YV,O- I%;/LB<DGLT)9A#%->)@F@-%EU^BC
MJR&VE$-N\2VD6[XS!HK*<YK^4 _C1=> *B(:T;E0$$3^V= AC2*%)./XIP0U
MJCF5X^[X#?TF)R_)/!-.AVGT1[@0JZ[A&V!!EV0=B4FZO:4E(4?AS=.(Y[_!
MMK2%!IBON4CCTEE&$(=)\9>\EHG8<4#N$0=<.N!#!_N(@U4ZY)DSB\AR6M=$
MD%Z'I5O E+5$4X,\-[FW9!,F:AFG@LFOH?03O>GP=G0]NQN!QQO0GWV]?9R,
M_QQ=@_%T.AN!V</=^'[\53X_S.X'HXDR>NI/P+?^G?PZO>U/1E/PZ9H*$D;\
M,[@ L^DU^/3KYXXI9&AJ G->AC$HPL!'PD 8W*>)6'$P2A9TL0]@2DX5,?Q&
M;("UB/>$70(+?0$88MP2T/!T=Z0)QZKR;.5XUA&\\9+QJ2""RBT@[N3'L1QR
M\%T-03[^JRUK!:C=#JJV^!7/R)QV#;F'.64;:O1^^P6Y\/<VQF<"V^-O5_QM
M'7IO0"*2S&D;Q\+1S1W5J;/I.18*;.AWS,UN^$V["V1#A.S*;B\RIXK,T4;V
MF*GSA /Z2MD\Y(?%5\2HA7CO.A1@S@X1Y/@>;*?A5C1<+8U1&3Y(EV!+&".)
MX&U,W.;DM@L#! ^RK9WM@\7B55R\CQ:+UR@"'-B>#?%!^$V[PZ+:B\RO(O.U
MD8TY7],%F),L%"0"WV,:/U/6NG6U0.\MF3.![7$.*L[!SSBZ@G/R/Q/8'G\$
MZQX)3ZG'+X"OB,1O;6^PL:]<#_O(M1JEV69JN3CPH!VT5R?:Z>;HHSNG]-S=
M$@@A.2_RK,,(VTPQ](+ /W+8(EQ'B+413O,4@K#82!<@8^%&UA;((KE^JL*T
M6=9BO[>H2K3=A9#KX ;8L8ZPK+L]TC;3_V?9RNZLW;Y$VSLJ+0C1L1JK.SG2
MM_()C8C2WN"&A QL2+2F8"[YOE @_ZVHFL\;^3 !\S3Y>YT4NGT;BM6)Z="&
M\>YTV(W%OD"6;T'G2#YJ_8#T F)X][!+-@KI6C7AY3I9,!+R,'F1"8AC:2'Y
MMQ(]J[HHT?9TDN/X5G",:*TPD%YB-)22=JN>24"4I)JR!3M0_ASA5"L-I)<:
M)ZD_/<:[N32UB4;_H5J:(+TV:5. VA7RF\>?[SH(>XY[V!!^AOY M0!!VOY^
MLK8M878S:]D>E++OD,_/T!.XUA-8KR>&:;*A++\)D8SD^:%;)MR4"Q9RH._:
M#<VNG_:CM&KQ@?7BHT&KE4Y36_B^YUJ!=TA&.]E'R=0Z!>MUR@F:#S?U [(\
MVT:.[1[^\]IBV]2'^Z'68@/KQ89&].&F"$!8YEIN\T;QM)@V]&$1H;ESWQ13
MV?C5-1R776Z=B.*&IGI;7?7U\PNN@_<#=#4L+NQJF.+^\%[JB5">RQ%=2DAX
MZ<G,L>)*KG@0:9;?:CVG0J1Q/EQ1LJ!,&<CORS05;P]J@NIBM/<?4$L#!!0
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M:N6=--H4U]ZZC=(T6A<W'X2_$'$^('M\&47I\YW\<EZ[B]S-_P502P,$%
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MU1T-YR@=#0?M:*":BVH"U3Q4\U%-HEJ :B&J192F9J[N:#AT1T,/MHX;VM%
M-8%J'JKYJ";?6"3K5U4VUUL:=F/"T(X&JD64IB:L[F@X:$=#K[6.%]K10#6!
M:AZJ^:@FG?UK:+PL:* '#%$MHC3UE7?K@D;O* 4-O=HV2*CFHII -0_5?%23
MO?V"QJCQDJ#H84-4BRAM':=N_I0DA1L7\?ALEF2/R64RG>;&7;J<EWQ5V]C>
M:V3)0W7-IW<7=J=;SJR'C\\6\6/R(<X>)_/<F"8/Y53S9%A^G+/)X]/VC2)=
M5*3Q)2V*=+:Z^93$]TE6#2C?_Y"FQ<\WJ@,\I]G7U>F-_P=02P,$%     @
M97X/5>5QD0=T!0  K24  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN>&UL
MM9I=<YLX%(;O]U=HO-N==F;7(&Q#DG4\XP1,LM,FF3AM9Z>S%XHMVTP L4)Q
MTG^_XB/84"';R>E-#/9Y'PY'+T*<,'QB_"%=42K0<Q3&Z6EG)41R8ACI;$4C
MDG990F/YRX+QB BYRY=&FG!*YKDH"@W+-&TC(D'<&0WS[V[X:,@>11C$](:C
M]#&*"/]^1D/V=-K!G9<O;H/E2F1?&*-A0I9T2L7GY(;+/:.BS(.(QFG 8L3I
MXK0SQB<^/LH$><27@#ZE6]LH.Y5[QAZRG<OY:<?,,J(AG8D,0>3'FI[3,,Q(
M,H__2FBG.F8FW-Y^H4_RDY<G<T]2>L["K\%<K$X[1QTTIPOR&(I;]G1!RQ,:
M9+P9"]/\+WHJ8\T.FCVF@D6E6&80!7'Q29[+0NPCL$J!U1#@?HN@5PIZ^PKZ
MI:#?$/3:!(-2,-CW"'8IL/<5.*7 R0>KJ&X^-"X19#3D[ GQ+%K2LHU\?'.U
M')$@SJPX%5S^&DB=&$W/+SSW\T</74_0]&)\ZZ&S\=1ST<WXGT_>U1T:?QW?
MNNC3M>M]1)=7-Y_OINCZYN[R^FJ*_-OQU9T,?>]208(P_8#^1+\A Z4KPFDZ
M-(1,+SN(,2M3.2M2L5I2^9O$7=3#?R#+M"R%_%PO'S\N*SE6R-T=\H1W$1ZT
MRKT]DL=6JWRRA]RT6^7^'N=NF;G<K,L-:8C*%5;E"BOG]5IXEPN>3@415$XZ
MXJ/\\5)NINA;MHGR[7]5XUM ^VIH-JF>I F9T=..G#53RM>T,_K]5VR;?ZE&
M&Q+F0L(\2-@$$N8#P6J>Z56>Z>GH(Y^36*"Y-$TQ Z"$!S.JLDG!P869LWOE
M>M3O'@V-]?;P*X..ZT&N(LCI.O4@KPARMF+,KM,@310DLYF3KPC"@^Z@BJK5
MK5_5K:^MF_=,^2Q(=U:MH-A;QVZ6K+]/R11!3C/(Z^]3,@7)W"I&43)%4'O)
M!E7)!MJ2?:&I".(E2B@/V%QYJ]$#<-<:1(@EV6HH16N)0[W>.T3);(6^4\(1
MB>?(Z6[%K,B:RB7.6J[=DFQ2)*&\&X=2R.2,*//(%X7QC*(9B^=!KE%-:OJT
MK,%6#JII[&UR3R_/*A#$R$81B\4JS6M@._EWN TY>5M&_D[Y+RWRFF_LRC>V
MEG<;I ]HP2E%7$Y3*ML4>MRK>=HTCQMSRGE+7*]QL;6%-:X23YOVH7<4?0W>
MRP3PNP^JP6C)%K=<K4Y5=6?'!)?(YPXZ1VL6$A&$@?BN*GT!.:Y/P(V"GCNJ
M%!VG,3RN,NS(M!IEU^9]:-E;4FM.B"UA?76-CZH:'VEK?)U/4R@,%DI;Z\6#
M_/I2SE>O%;JO%7I:X:%C\MHL_%<(:^-V7(W;L99TQH1\PD-L(6>D>$G1MXA&
M]Y0K5]=:TJ&K:TB8"PGS(&$32)@/!*L9!9N;!W7S9SR3E50@VX#27%":!TJ;
M@-)\*%K=.UM-'OS&A8\><+!-(&DN*,TK:3\L<_J-QQO0H_I0M+H!-OT<K'WT
MWW<-IJ<<[ +0%@XHS2MI#1?8MM-T 6A_!HI6=\&F0X/U+9H=JT2]^N#1AZ2Y
MH#1O1YU>'H&5]P7(1'PH6MT0F]83UO>>[EBRW]I3SSG8&I T%Y3F@=(FH#0?
MBE9WRZ;KA@<_906J;?(<[!U(F@M*\T!I$U":#T6K>V?3><-O;;WI 0?;!)+F
M@M(\W-)HLYMK#\BC^E"TN@$V34 ,T@744PYV 23-!:5Y6-VD[/VP H4\J@]%
MJ[M@TZ;$;^I3ZM4'CSXDS06E>3OJU/X/%] T?"A:80=CZSV4[$6F3X0O@SA%
M(5U(O-EUY#V(%^\&%3N")?FK*?=Y&S3?7%$RISP+D+\O&!,O.]G;+M4;6J/_
M 5!+ P04    " !E?@]5]7Q/0QL$  ";$   &0   'AL+W=O<FMS:&5E=',O
M<VAE970W,"YX;6RU6&V/XC80_BM66E6MM"5Q DG8 A(ON5VDN[T5[-Y6.O6#
M20:(+B_4-K"5^N-K)]F00 BY/?J%V(GGF7G&GO$,O7U,O[$U $>O81"QOK+F
M?'.KJLQ=0TA8*]Y )+XL8QH2+J9TI;(-!>(E0F&@ZIIFJB'Q(V702]X]TD$O
MWO+ C^"1(K8-0T+_&4$0[_L*5MY>S/S5FLL7ZJ"W(2N8 W_>/%(Q4W,4SP\A
M8GX<(0K+OC+$MV-L28%DQ1<?]JPP1I+*(HZ_R<G4ZRN:M @"<+F$(.*Q@S$$
M@402=OR=@2JY3BE8'+^A?TC("S(+PF <!R^^Q]=]Q5:0!TNR#?@LWM]#1J@C
M\=PX8,DOVJ=KK:Z"W"WC<9@)"PM"/TJ?Y#5S1$' T,\(Z)F WE3 R 2,A&AJ
M64)K0C@9]&B\1U2N%FARD/@FD19L_$ANXYQ3\=47<GPP']\[D^>/#OK\ ;T,
M9[/AP],<?7Y^FC\-'R;3ASLD'NC%F=[=/SD3-/SBS(9W#G+^=&;CZ=Q!C[/I
MV$&_3H 3/V"_]50N;)+(JIOI'Z7Z]3/ZL8X^Q1%?,^1$'GAE %60R1GI;XQ&
M>BWB)T);R, W2-=T';$UH<#0STC-AA4FCIL#XDN )9.-?!.,1(-Q1L-T2=F<
M$PXB/OA'\7$JA@Q]E4.4C/^J\FP*VJX&E?%_RS;$A;XB IP!W8$R^.4G;&I_
M5/G@2F E_NV<?[L.??!"*"419V@E'\>G("6;(G02!)F;=@/<MKIFU^B:/757
M9%*KZYU,.CF33C,F\ K4]5DUETYC+K7:WLG%S+F83;B@#!E]#2%< *T\BK5(
MWWL4KP16(FWEI*W_(Q2M:_*_$EB)OYWSMYL=8''E,TXBSX]6-V@!*S^*Q%!<
MF0&)7*CR@7UZJNV.R,&6?GRJ*U:V+6S;EGE86;*^FUO?K;<^N;7!0V0'5%0A
M>1BB#?5=N"FR.B6%_JV_)T:I<JP7#-=;^(C<A44E7E@[7-/:#Z?(#*+H5[V-
M+1M;IG9D9,52P[(-D8"T,Y86"@K\8WN0,;CH[4Q/R9-:JW/,I&(5;NEG6.@'
M%OH5$GD&4G3C[T97P^W.:2JO5U@=UJ@FHO&ANL"UE_?E'<DY7MX3HVI/K&.J
M[R@F:JD>"@G<L)(HI2_( OY\[L*GY85AFIVNUCV)G(I"Y"3-E:T_% _X0O7P
M/>FK3.KRSJ6JK8+=9@L?)Z]L5</L=:@D<*-2(H\FL@BJM\$\=6[U+E0L;'<[
MIHWM<\8>*@!<>\$V#A=)XK+;K1.W8ZUE'-.QJI+8,1.UT.:%0%=)]\N0&V\C
MGO9'^=N\PQXF?>71^Y'LO)/V\0"3MNVBUQ&7(D,!+ 6DB&SA89IVPNF$QYND
MF5S$7+2FR7 -Q ,J%XCORSCF;Q.I(/\_8O ?4$L#!!0    ( &5^#U4KCA9&
M#@4  /(D   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;+6::W.C-A2&
M_XJ&7F9WIC4W8YO4]DP2KO9F-^,TS8>=?B"V;#/AXA5RG/S[BDN((0+C]C0?
M@H#S/I+@/2 9C0\Q>4JV&%/T$@91,A&VE.XN1#%9;G'H);UXAR-V9AV3T*-L
MEVS$9$>PM\I$82 JDC000\^/A.DX.W9+IN-X3P,_PK<$)?LP],CK%0[BPT20
MA;<#"W^SI>D!<3K>>1M\A^G][I:P/;&DK/P01XD?1XC@]42XE"_FLI(*LHB_
M?'Q(CLHH[<IC'#^E.^YJ(DAIBW" ES1%>&SSC*]Q$*0DUHX?!50HZTR%Q^4W
MNI5UGG7FT4OP=1P\^"NZG0@C :WPVML'=!$?'%QT2$MYRSA(LO_HD,<.5 $M
M]PF-PT+,6A#Z4;[U7HH+<220^PT"I1 H705J(5"["OJ%H-]5H!4"K:M@4 @&
M707#0C"L"YHNZZ@0C.H"K4&@%P*]:PVR]';GI*Z]D,N;G9LN=TEF,<.CWG1,
MX@,B:3SCI87,IYF>.<N/TI2ZHX2=]9F.3N^N'=.X_V*B;Q9RO][>_WF'K&\+
M]'"Y6%Q^93MVNC$-],G U/.#Y#/Z'?V,1)1L/8*3L4A9&U*2N"SJ<_/ZE(;Z
M9'031W2;(#-:X555+[*VEQU0WCIPI;0"9U[40ZK\&U(D1>&TY[I=?KG?E'*9
M(S=.R'>DAV2M46YV:+RL-,JM#G)IT"BW._1=D3*YQ)$[[?(;[Q4I>J/:/='V
M?5!>>)Y\=KKR%O6\PVU3N3VOF% MLTC->&H#SUV3Y(YZ%+.7#?W"3KJLF*#O
M:1%EY;\YC;S*H7T^-'V97B0[;XDG GM;)I@\8V'ZZT_R0/J#YW-(F $),R%A
M%B3,AH0YD# 7$C:#A,V!8)4\ZY=YUF^C3\T73)9^@O/7#]H1?XEYB953!ADE
M'50^3T=C\?DX6_((63D*Z??T:I#!"1K6@\P\:'@4(_6&M2"+0Y)Z6C7(Y@3)
M6CW*:;U"Y]H,$C:#A,V!8!6;::7-M%:;+?SD":T)QHBP9SK/8+E>5BOW4Y+T
M8<UF#7%JS6A-8;5[;[8V^]PG:?LU^,0:(/_RF??4;&BM7'<J9&M=2-@,$C8'
M@E6<.BB=.FB]2P\>(5Y$44%&WT,</F+"'6VTDLX=;4#"#$B8"0FS(&$V),R!
MA+F0L!DD; X$JR37L$RNX?\QJA]"YADDS("$F9 P"Q)F0\(<2)@+"9M!PN9
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M]M7@IIQPJ6E1:0-4FH%*,U%I0U3:")5FG?"8N7'=/6R%TZ2-XOB$7%?>0;
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M#JJYJ.:AFH]J :J%J!916C.P=5=(^Y:ND+2NH!TW._2189C'+Z7RL7LG$ZT
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MU2)*:R:XKBSI'2M+DI,R<J)W7-$>$ZK9^G$;:SHL_S3W^AUT5!?5/%3S42U
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M)FT KK4/J OM, :[3@#7UPKD4/N)Z)K8L8_S]=0,&X:#&\_DZZX9P'5U ]5
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M2Q\RMNXZV-EVC.AL+G6'&W469 9CD!\70ZZ>W HEH3D4@K("<4B[3@_?W.)
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MH8HG+^O5\D&RA2GYIDRJ M(TYZK&!ZXGJ/&4,;E]T ZJ?PVB;U!+ P04
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M]ZSNF?5$T'W51394R)Y4#5/YF8&9,I#[6TK%ZT0Y:#]<_-]02P,$%     @
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MQQ-LA&QF>[/18F7'XT)H'+9V6>!U"-(XX/=<"+W=F #=!9O\!E!+ P04
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M<?BTEQG^ 0%I'/#^2F!E5 NS0?V79O@/4$L#!!0    ( &5^#U7&#$\5PP(
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M027AFZ)U[;_E++]8<=1]+<GFJ;(KV*FQ/C"\=9&=8Q 9'X/(HZC)WC&(3(Y
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 97X/521*OXCO    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 97X/
M59E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !E?@]5G'IWI ,'  #]*0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 97X/
M5:I* 9P\!0  E18  !@              ("!1P\  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( &5^#U7*A[UXN00   (2   8
M      " @;D4  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !E?@]5BJ<C?(<,   H=P  &               @(&H&0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 97X/5< 8HPM&"   XR8  !@
M             ("!928  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( &5^#U4H8E_'=@,  %0'   8              " @>$N  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !E?@]5,L06SY@?  "]
M7@  &               @(&-,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ 97X/5=-BU.GR!0  J@T  !@              ("!6U(
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( &5^#U6F*EC%
M'@0  &X(   8              " @8-8  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " !E?@]5>"_*:_L"  !8!@  &0
M@('77   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( &5^
M#U5R@"!*H ,  &@'   9              " @0E@  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ 97X/5="67XCX!0  K T  !D
M         ("!X&,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " !E?@]5[5B5@<T$  "'"@  &0              @($/:@  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( &5^#U4R1>1RA (  ,L%
M   9              " @1-O  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ 97X/56&&]>25 P  S@@  !D              ("!SG$
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !E?@]588"#
M)=L"   >!@  &0              @(&:=0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( &5^#U7+Y7*$O@(  -L%   9
M  " @:QX  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M97X/54Q]EWD4"0  -18  !D              ("!H7L  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " !E?@]5P9([#( *   #'   &0
M            @('LA   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( &5^#U56A0*>D 0  ! *   9              " @:./  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 97X/50YV%@CI!0
M.@T  !D              ("!:I0  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " !E?@]523W(!,8#   ["   &0              @(&*
MF@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( &5^#U6#
MBMX>[0,  "@)   9              " @8>>  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ 97X/5<-*R9!U!@  -P\  !D
M     ("!JZ(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &5^#U5<W<X4UR   -MH   9              "
M@<ZV  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 97X/
M59Y?D_]X @  3@4  !D              ("!W-<  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " !E?@]5O]!9M!\$  " "   &0
M        @(&+V@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( &5^#U73;$26B0,  $8'   9              " @>'>  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 97X/5<Q>M\<\!0  Z P
M !D              ("!H>(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " !E?@]5#RGT)VH$  "_"0  &0              @($4Z
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( &5^#U7V0#)4
MBP(  +@%   9              " @;7L  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ 97X/55YVK0RN P  C D  !D
M ("!=^\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !E
M?@]5<;=O6Y<"  #!!0  &0              @(%<\P  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( &5^#U60MOHGP (   0&   9
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M970T,BYX;6Q02P$"% ,4    " !E?@]5Q>@)Z#X#  #&!P  &0
M    @('A"P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M &5^#U656WK!<@0  )0+   9              " @58/ 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ 97X/51<2);W, @  Y@4  !D
M             ("!_Q,! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " !E?@]5?3D=FX\"  "8!0  &0              @($"%P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( &5^#U4^W.H!A (
M %P'   9              " @<@9 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ 97X/5>/C\L=!!0  :28  !D              ("!
M@QP! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !E?@]5
M4XTT-N$$  "($0  &0              @('[(0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( &5^#U42+KY_,@0   $2   9
M      " @1,G 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ 97X/5<F&1D][ @  B 8  !D              ("!?"L! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !E?@]5F3.JO1,(  #.1@
M&0              @($N+@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( &5^#U75.]Z:9P(  &H%   9              " @7@V 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 97X/552U7Y'!
M P  %A4  !D              ("!%CD! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " !E?@]5*;>VTQ #  !A"   &0
M@($./0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( &5^
M#U7Z2EXJ0@4  ,@4   9              " @55  0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ 97X/51-!;@!@ @  <08  !D
M         ("!SD4! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " !E?@]5)K^+NF<"  !N!@  &0              @(%E2 $ >&PO=V]R
M:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( &5^#U5^2+GIS0(  )\)
M   9              " @0-+ 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
M4$L! A0#%     @ 97X/55O;EZ.&!   JQ0  !D              ("!!TX!
M 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !E?@]5P)4L
M4_X"  !S"P  &0              @('$4@$ >&PO=V]R:W-H965T<R]S:&5E
M=#8Q+GAM;%!+ 0(4 Q0    ( &5^#U5)6YP%F@(  .\&   9
M  " @?E5 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M97X/5287F!CZ 0  # 0  !D              ("!RE@! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    " !E?@]5.GDU*\("   :!P  &0
M            @('[6@$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( &5^#U7[21AYXP0  "05   9              " @?1= 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ 97X/59D80+_0!@
M\$X  !D              ("!#F,! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    " !E?@]5IC,\GX\$  !!%   &0              @($5
M:@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( &5^#U6Z
MV])M:@D  "F&   9              " @=MN 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ 97X/5>5QD0=T!0  K24  !D
M     ("!?'@! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &5^#U76>3/2J00  $H8   9              "
M@0B< 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 97X/
M5<BUQB5] P  R X  !D              ("!Z* ! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    " !E?@]5<-?(?@($  !!$   &0
M        @(&<I $ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( &5^#U74Q6/Z2P,  ,0(   9              " @=6H 0!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ 97X/55HA&H^%!   UA,
M !D              ("!5ZP! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    " !E?@]5*)DJ=GX"  #Z!P  &0              @($3L0$
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( &5^#U5VTHG"
M@@(  /4'   9              " @<BS 0!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ 97X/52-'RV^C @  ; <  !D
M ("!@;8! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " !E
M?@]53CS8O<<#  #>#   &0              @(%;N0$ >&PO=V]R:W-H965T
M<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( &5^#U7&#$\5PP(  #<*   9
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M 0!X;"]S='EL97,N>&UL4$L! A0#%     @ 97X/59>*NQS     $P(   L
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64$L%!@    != %T @AD  -78 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>189</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/StatementsOfShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - Reporting Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ReportingEntity</Role>
      <ShortName>Reporting Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AccountingPolicies</Role>
      <ShortName>ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty</Role>
      <ShortName>CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - OPERATING EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/OperatingExpenses</Role>
      <ShortName>OPERATING EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - SEGMENTAL REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/SegmentalReporting</Role>
      <ShortName>SEGMENTAL REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/EmployeesIncludingOfficers</Role>
      <ShortName>EMPLOYEES INCLUDING OFFICERS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel</Role>
      <ShortName>REMUNERATION OF KEY MANAGEMENT PERSONNEL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - TAXATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/Taxation</Role>
      <ShortName>TAXATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - FINANCE INCOME AND COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/FinanceIncomeAndCosts</Role>
      <ShortName>FINANCE INCOME AND COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - OTHER RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/OtherReceivables</Role>
      <ShortName>OTHER RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - TRADE AND OTHER PAYABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/TradeAndOtherPayables</Role>
      <ShortName>TRADE AND OTHER PAYABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - CAPITAL AND RESERVES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CapitalAndReserves</Role>
      <ShortName>CAPITAL AND RESERVES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - SHARE OPTIONS AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ShareOptionsAndWarrants</Role>
      <ShortName>SHARE OPTIONS AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity</Role>
      <ShortName>CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/FinancialInstruments</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/BasicAndDilutedLossPerShare</Role>
      <ShortName>BASIC AND DILUTED LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Auditor???s Remuneration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AuditorsRemuneration</Role>
      <ShortName>Auditor???s Remuneration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Post Balance Sheet Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/PostBalanceSheetEvents</Role>
      <ShortName>Post Balance Sheet Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AccountingPoliciesPolicies</Role>
      <ShortName>ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AccountingPoliciesTables</Role>
      <ShortName>ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/AccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - OPERATING EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/OperatingExpensesTables</Role>
      <ShortName>OPERATING EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/OperatingExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/EmployeesIncludingOfficersTables</Role>
      <ShortName>EMPLOYEES INCLUDING OFFICERS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/EmployeesIncludingOfficers</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables</Role>
      <ShortName>REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - TAXATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/TaxationTables</Role>
      <ShortName>TAXATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/Taxation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/FinanceIncomeAndCostsTables</Role>
      <ShortName>FINANCE INCOME AND COSTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/FinanceIncomeAndCosts</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - OTHER RECEIVABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/OtherReceivablesTables</Role>
      <ShortName>OTHER RECEIVABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/OtherReceivables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/TradeAndOtherPayablesTables</Role>
      <ShortName>TRADE AND OTHER PAYABLES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/TradeAndOtherPayables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - CAPITAL AND RESERVES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CapitalAndReservesTables</Role>
      <ShortName>CAPITAL AND RESERVES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/CapitalAndReserves</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ShareOptionsAndWarrantsTables</Role>
      <ShortName>SHARE OPTIONS AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/ShareOptionsAndWarrants</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables</Role>
      <ShortName>CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/FinancialInstrumentsTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/BasicAndDilutedLossPerShareTables</Role>
      <ShortName>BASIC AND DILUTED LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/BasicAndDilutedLossPerShare</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/Leases</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Auditor???s Remuneration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AuditorsRemunerationTables</Role>
      <ShortName>Auditor???s Remuneration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/AuditorsRemuneration</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://okyopharma.com/role/CashAndCashEquivalents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails</Role>
      <ShortName>DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/AccountingPoliciesDetailsNarrative</Role>
      <ShortName>ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/AccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails</Role>
      <ShortName>DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails</Role>
      <ShortName>DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative</Role>
      <ShortName>EMPLOYEES INCLUDING OFFICERS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/EmployeesIncludingOfficersTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails</Role>
      <ShortName>SCHEDULE OF REMUNERATION OF DIRECTORS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails</Role>
      <ShortName>SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails</Role>
      <ShortName>SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails</Role>
      <ShortName>SCHEDULE OF TAX CREDIT PERIOD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical</Role>
      <ShortName>SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - TAXATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/TaxationDetailsNarrative</Role>
      <ShortName>TAXATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/TaxationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfFinanceCostDetails</Role>
      <ShortName>SCHEDULE OF FINANCE COST (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails</Role>
      <ShortName>DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/OtherReceivablesDetailsNarrative</Role>
      <ShortName>OTHER RECEIVABLES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/OtherReceivablesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails</Role>
      <ShortName>DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails</Role>
      <ShortName>SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CapitalAndReservesDetailsNarrative</Role>
      <ShortName>CAPITAL AND RESERVES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/CapitalAndReservesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails</Role>
      <ShortName>SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails</Role>
      <ShortName>SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails</Role>
      <ShortName>SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails</Role>
      <ShortName>SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative</Role>
      <ShortName>SHARE OPTIONS AND WARRANTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/ShareOptionsAndWarrantsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails</Role>
      <ShortName>SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails</Role>
      <ShortName>SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails</Role>
      <ShortName>SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails</Role>
      <ShortName>SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails</Role>
      <ShortName>SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails</Role>
      <ShortName>SCHEDULE OF COMPANY AUDITORS FEES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails</Role>
      <ShortName>SCHEDULE OF CASH AND CASH EQUIVALENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>00000084 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="form20-f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative</Role>
      <ShortName>Post Balance Sheet Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://okyopharma.com/role/PostBalanceSheetEvents</ParentRole>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:DocumentRegistrationStatement -  form20-f.htm 29</Log>
  </Logs>
  <InputFiles>
    <File doctype="20-F" original="form20-f.htm">form20-f.htm</File>
    <File>ex12-1.htm</File>
    <File>ex12-2.htm</File>
    <File>ex13-1.htm</File>
    <File>ex13-2.htm</File>
    <File>ex15-1.htm</File>
    <File>okyo-20220331.xsd</File>
    <File>okyo-20220331_cal.xml</File>
    <File>okyo-20220331_def.xml</File>
    <File>okyo-20220331_lab.xml</File>
    <File>okyo-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form20-f_001.jpg</File>
    <File>form20-f_002.jpg</File>
    <File>form20-f_003.jpg</File>
    <File>form20-f_004.jpg</File>
    <File>form20-f_005.jpg</File>
    <File>form20-f_006.jpg</File>
    <File>form20-f_007.jpg</File>
    <File>form20-f_008.jpg</File>
    <File>form20-f_009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="718">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form20-f.htm": {
   "axisCustom": 1,
   "axisStandard": 18,
   "contextCount": 189,
   "dts": {
    "calculationLink": {
     "local": [
      "okyo-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "okyo-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form20-f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "okyo-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "okyo-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "okyo-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 525,
   "entityCount": 1,
   "hidden": {
    "http://okyopharma.com/20220331": 141,
    "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 122,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 267
   },
   "keyCustom": 122,
   "keyStandard": 218,
   "memberCustom": 53,
   "memberStandard": 11,
   "nsprefix": "OKYO",
   "nsuri": "http://okyopharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://okyopharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - SEGMENTAL REPORTING",
     "role": "http://okyopharma.com/role/SegmentalReporting",
     "shortName": "SEGMENTAL REPORTING",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfEmployeeDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - EMPLOYEES INCLUDING OFFICERS",
     "role": "http://okyopharma.com/role/EmployeesIncludingOfficers",
     "shortName": "EMPLOYEES INCLUDING OFFICERS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfEmployeeDetailsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL",
     "role": "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel",
     "shortName": "REMUNERATION OF KEY MANAGEMENT PERSONNEL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - TAXATION",
     "role": "http://okyopharma.com/role/Taxation",
     "shortName": "TAXATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - FINANCE INCOME AND COSTS",
     "role": "http://okyopharma.com/role/FinanceIncomeAndCosts",
     "shortName": "FINANCE INCOME AND COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "role": "http://okyopharma.com/role/PropertyPlantAndEquipment",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - OTHER RECEIVABLES",
     "role": "http://okyopharma.com/role/OtherReceivables",
     "shortName": "OTHER RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - TRADE AND OTHER PAYABLES",
     "role": "http://okyopharma.com/role/TradeAndOtherPayables",
     "shortName": "TRADE AND OTHER PAYABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - CAPITAL AND RESERVES",
     "role": "http://okyopharma.com/role/CapitalAndReserves",
     "shortName": "CAPITAL AND RESERVES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - SHARE OPTIONS AND WARRANTS",
     "role": "http://okyopharma.com/role/ShareOptionsAndWarrants",
     "shortName": "SHARE OPTIONS AND WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "role": "http://okyopharma.com/role/BalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "lang": null,
      "name": "OKYO:RelatedPartyReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY",
     "role": "http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity",
     "shortName": "CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - FINANCIAL INSTRUMENTS",
     "role": "http://okyopharma.com/role/FinancialInstruments",
     "shortName": "FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://okyopharma.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - BASIC AND DILUTED LOSS PER SHARE",
     "role": "http://okyopharma.com/role/BasicAndDilutedLossPerShare",
     "shortName": "BASIC AND DILUTED LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Leases",
     "role": "http://okyopharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Auditor\u2019s Remuneration",
     "role": "http://okyopharma.com/role/AuditorsRemuneration",
     "shortName": "Auditor\u2019s Remuneration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Cash and Cash Equivalents",
     "role": "http://okyopharma.com/role/CashAndCashEquivalents",
     "shortName": "Cash and Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Commitments and Contingencies",
     "role": "http://okyopharma.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Post Balance Sheet Events",
     "role": "http://okyopharma.com/role/PostBalanceSheetEvents",
     "shortName": "Post Balance Sheet Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - ACCOUNTING POLICIES (Policies)",
     "role": "http://okyopharma.com/role/AccountingPoliciesPolicies",
     "shortName": "ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - ACCOUNTING POLICIES (Tables)",
     "role": "http://okyopharma.com/role/AccountingPoliciesTables",
     "shortName": "ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - OPERATING EXPENSES (Tables)",
     "role": "http://okyopharma.com/role/OperatingExpensesTables",
     "shortName": "OPERATING EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Tables)",
     "role": "http://okyopharma.com/role/EmployeesIncludingOfficersTables",
     "shortName": "EMPLOYEES INCLUDING OFFICERS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)",
     "role": "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables",
     "shortName": "REMUNERATION OF KEY MANAGEMENT PERSONNEL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - TAXATION (Tables)",
     "role": "http://okyopharma.com/role/TaxationTables",
     "shortName": "TAXATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - FINANCE INCOME AND COSTS (Tables)",
     "role": "http://okyopharma.com/role/FinanceIncomeAndCostsTables",
     "shortName": "FINANCE INCOME AND COSTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceCostExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "role": "http://okyopharma.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - OTHER RECEIVABLES (Tables)",
     "role": "http://okyopharma.com/role/OtherReceivablesTables",
     "shortName": "OTHER RECEIVABLES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - TRADE AND OTHER PAYABLES (Tables)",
     "role": "http://okyopharma.com/role/TradeAndOtherPayablesTables",
     "shortName": "TRADE AND OTHER PAYABLES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - CAPITAL AND RESERVES (Tables)",
     "role": "http://okyopharma.com/role/CapitalAndReservesTables",
     "shortName": "CAPITAL AND RESERVES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2019-03-31_ifrs-full_IssuedCapitalMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Consolidated Statements of Shareholders' Equity",
     "role": "http://okyopharma.com/role/StatementsOfShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2019-03-31_ifrs-full_IssuedCapitalMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - SHARE OPTIONS AND WARRANTS (Tables)",
     "role": "http://okyopharma.com/role/ShareOptionsAndWarrantsTables",
     "shortName": "SHARE OPTIONS AND WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)",
     "role": "http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables",
     "shortName": "CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://okyopharma.com/role/FinancialInstrumentsTables",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables)",
     "role": "http://okyopharma.com/role/BasicAndDilutedLossPerShareTables",
     "shortName": "BASIC AND DILUTED LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Leases (Tables)",
     "role": "http://okyopharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Auditor\u2019s Remuneration (Tables)",
     "role": "http://okyopharma.com/role/AuditorsRemunerationTables",
     "shortName": "Auditor\u2019s Remuneration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Cash and Cash Equivalents (Tables)",
     "role": "http://okyopharma.com/role/CashAndCashEquivalentsTables",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_FurnitureAndFixtureMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)",
     "role": "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails",
     "shortName": "DISCLOSURE OF ESTIMATED USEFUL LIVES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfEstimatedUsefulLivesExplanatory",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_FurnitureAndFixtureMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RetainedEarnings",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - ACCOUNTING POLICIES (Details Narrative)",
     "role": "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
     "shortName": "ACCOUNTING POLICIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfGoingConcernExplanatory",
       "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:RetainedEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "GBP",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:KeyManagementPersonnelCompensationDirectorFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)",
     "role": "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails",
     "shortName": "DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory",
       "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:KeyManagementPersonnelCompensationDirectorFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://okyopharma.com/role/StatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:DirectorsSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)",
     "role": "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails",
     "shortName": "DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutEmployeesExplanatory",
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:DirectorsSalaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - EMPLOYEES INCLUDING OFFICERS (Details Narrative)",
     "role": "http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative",
     "shortName": "EMPLOYEES INCLUDING OFFICERS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "OKYO:DisclosureOfEmployeeDetailsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DirectorsRemunerationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
     "shortName": "SCHEDULE OF REMUNERATION OF DIRECTORS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:DirectorsRemunerationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_GCerroneMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "OKYO:BonusAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)",
     "role": "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical",
     "shortName": "SCHEDULE OF REMUNERATION OF DIRECTORS (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_GCerroneMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "OKYO:BonusAwarded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails",
     "shortName": "SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:ScheduleOfShareOptionsGrantedToDirectorsExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_DirectorsMember",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails",
     "shortName": "SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory",
       "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails",
     "shortName": "SCHEDULE OF TAX CREDIT PERIOD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTaxExpenseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000057 - Disclosure - SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)",
     "role": "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical",
     "shortName": "SCHEDULE OF TAX CREDIT PERIOD (Details) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTaxReceivablesAndPayablesExplanatory",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ApplicableTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TaxEffectOfTaxLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000058 - Disclosure - TAXATION (Details Narrative)",
     "role": "http://okyopharma.com/role/TaxationDetailsNarrative",
     "shortName": "TAXATION (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfIncomeTaxExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TaxEffectOfTaxLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2019-04-012020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000059 - Disclosure - SCHEDULE OF FINANCE COST (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfFinanceCostDetails",
     "shortName": "SCHEDULE OF FINANCE COST (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfFinanceCostExplanatory",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2019-04-012020-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfReportingEntityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000006 - Disclosure - Reporting Entity",
     "role": "http://okyopharma.com/role/ReportingEntity",
     "shortName": "Reporting Entity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "OKYO:DisclosureOfReportingEntityExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:PropertyPlantAndEquipmentCost",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000060 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "lang": null,
      "name": "OKYO:PropertyPlantAndEquipmentCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000061 - Disclosure - SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails",
     "shortName": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory",
       "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31_custom_UKMember",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000062 - Disclosure - DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)",
     "role": "http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails",
     "shortName": "DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedTradeAndOtherReceivablesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherCurrentReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:PrepaymentsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000063 - Disclosure - OTHER RECEIVABLES (Details Narrative)",
     "role": "http://okyopharma.com/role/OtherReceivablesDetailsNarrative",
     "shortName": "OTHER RECEIVABLES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:PrepaymentsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000064 - Disclosure - DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)",
     "role": "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails",
     "shortName": "DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000065 - Disclosure - SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
     "shortName": "SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2020-04-012021-03-31_ifrs-full_IssuedCapitalMember",
      "decimals": "INF",
      "lang": null,
      "name": "OKYO:NumberOfSharesIssuedPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000066 - Disclosure - CAPITAL AND RESERVES (Details Narrative)",
     "role": "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
     "shortName": "CAPITAL AND RESERVES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:DividendPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000067 - Disclosure - SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails",
     "shortName": "SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2019-03-31",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2022-01-292022-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000068 - Disclosure - SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails",
     "shortName": "SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-012022-03-31_custom_SixJulyTwoThousandEighteenMember",
      "decimals": null,
      "lang": "en-US",
      "name": "OKYO:ExpirationDateOfOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2022-01-292022-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "OKYO:GrantDateShareOptionsGranted2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000069 - Disclosure - SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails",
     "shortName": "SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2022-01-292022-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "OKYO:GrantDateShareOptionsGranted2019",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ACCOUNTING POLICIES",
     "role": "http://okyopharma.com/role/AccountingPolicies",
     "shortName": "ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000070 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
     "shortName": "SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2020-03-31_ifrs-full_WarrantReserveMember",
      "decimals": "INF",
      "lang": null,
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2022-01-292022-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000071 - Disclosure - SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
     "shortName": "SCHEDULE OF INPUTS FOR WARRANTS GRANTED (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2022-01-292022-01-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExercisePriceShareOptionsGranted2019",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000072 - Disclosure - SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
     "shortName": "SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2020-07-012020-07-31_ifrs-full_WarrantReserveMember",
      "decimals": null,
      "lang": "en-US",
      "name": "OKYO:WarrantsVestingPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000073 - Disclosure - SHARE OPTIONS AND WARRANTS (Details Narrative)",
     "role": "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative",
     "shortName": "SHARE OPTIONS AND WARRANTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory",
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IssueOfConvertibleInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000074 - Disclosure - SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails",
     "shortName": "SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfIssuanceOfConvertibleNotesExplanatory",
       "ifrs-full:DisclosureOfDebtSecuritiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IssueOfConvertibleInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000075 - Disclosure - SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)",
     "role": "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails",
     "shortName": "SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LoansAndReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000076 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:LoansAndReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000077 - Disclosure - SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)",
     "role": "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails",
     "shortName": "SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:EarningsPerShareExplanatory",
       "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000078 - Disclosure - SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails",
     "shortName": "SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2020-03-31",
      "decimals": "0",
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentLeaseLiabilities",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000079 - Disclosure - SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails",
     "shortName": "SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY",
     "role": "http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty",
     "shortName": "CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000080 - Disclosure - SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:GrossLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:DisposalsRightOfUseAssets",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000081 - Disclosure - Leases (Details Narrative)",
     "role": "http://okyopharma.com/role/LeasesDetailsNarrative",
     "shortName": "Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "0",
      "lang": null,
      "name": "OKYO:InitialRecognitionForRightOfUseAssetAndLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000082 - Disclosure - SCHEDULE OF COMPANY AUDITORS FEES (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails",
     "shortName": "SCHEDULE OF COMPANY AUDITORS FEES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory",
       "ifrs-full:DisclosureOfAuditorsRemunerationExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AuditorsRemunerationForAuditServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashOnHand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000083 - Disclosure - SCHEDULE OF CASH AND CASH EQUIVALENT (Details)",
     "role": "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails",
     "shortName": "SCHEDULE OF CASH AND CASH EQUIVALENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "OKYO:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CashOnHand",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:AnnualLicenseMaintenanceFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000084 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "OKYO:AnnualLicenseMaintenanceFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2020-04-012021-03-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000085 - Disclosure - Post Balance Sheet Events (Details Narrative)",
     "role": "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative",
     "shortName": "Post Balance Sheet Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "AsOf2022-05-19_custom_NonadjustingEventMember",
      "decimals": "0",
      "lang": null,
      "name": "OKYO:Bonus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - OPERATING EXPENSES",
     "role": "http://okyopharma.com/role/OperatingExpenses",
     "shortName": "OPERATING EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form20-f.htm",
      "contextRef": "From2021-04-01to2022-03-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherOperatingExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 64,
   "tag": {
    "OKYO_AdditionalBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional interest rate.",
        "label": "Additional interest rate"
       }
      }
     },
     "localname": "AdditionalBorrowingsInterestRate",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "OKYO_AdditionsToLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions.",
        "label": "AdditionsToLeaseLiabilities",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToLeaseLiabilities",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AdjustmentsForChangeInFairValueOfForfeitureOfOptions": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for change in fair value of forfeiture of options.",
        "label": "AdjustmentsForChangeInFairValueOfForfeitureOfOptions",
        "negatedLabel": "Forfeiture of options"
       }
      }
     },
     "localname": "AdjustmentsForChangeInFairValueOfForfeitureOfOptions",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AdjustmentsForChangeInFairValueOfWarrantCharge": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for change in fair value of warrant charge.",
        "label": "AdjustmentsForChangeInFairValueOfWarrantCharge",
        "negatedLabel": "Warrant charge"
       }
      }
     },
     "localname": "AdjustmentsForChangeInFairValueOfWarrantCharge",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AdjustmentsForDecreaseIncreaseRelatedPartyReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease increase related party receivables.",
        "label": "Net decrease/(increase) in related party receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseRelatedPartyReceivables",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AdjustmentsForIncreaseDecreaseInRelatedPartyPayables": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase decrease in related party payables.",
        "label": "Net increase/(decrease) in related party payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInRelatedPartyPayables",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American depository shares [member]",
        "label": "American depository shares [member]"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_AmountOfLicensedProductOrService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Licensed Product or Service.",
        "label": "Amount of licensed product or service"
       }
      }
     },
     "localname": "AmountOfLicensedProductOrService",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee.",
        "label": "Annual license maintenance fee"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFee",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_AnnualLicenseMaintenanceFeeTherafter": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fee, therafter.",
        "label": "Annual license maintenance fee, therafter"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFeeTherafter",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_BDenoyerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "B Denoyer [member]",
        "label": "B Denoyer [member]"
       }
      }
     },
     "localname": "BDenoyerMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_BasicAndDilutedEarningsLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings loss per share.",
        "label": "Basic and dilutive loss per share (cents per share)"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsLossPerShare",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings loss per share attributable to common shareholders.",
        "label": "Basic and diluted loss per share attributable to common shareholders"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsLossPerShareAttributableToCommonShareholders",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_Bonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus.",
        "label": "[custom:Bonus-0]"
       }
      }
     },
     "localname": "Bonus",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_BonusAccrual": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus accrual.",
        "label": "Bonus accrual"
       }
      }
     },
     "localname": "BonusAccrual",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_BonusAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus awarded.",
        "label": "Bonus awarded"
       }
      }
     },
     "localname": "BonusAwarded",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_CashAdvancesAndLoansToRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash advances and loans to related parties.",
        "label": "Loan to related party"
       }
      }
     },
     "localname": "CashAdvancesAndLoansToRelatedParties",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_CashBurnRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of cash burn/spend.",
        "label": "Rate of cash burn/spend"
       }
      }
     },
     "localname": "CashBurnRate",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ChairmansBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chairman bonus.",
        "label": "Chairman\u2019s bonus"
       }
      }
     },
     "localname": "ChairmansBonus",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ConversionPricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion price per shares.",
        "label": "Conversion price per share"
       }
      }
     },
     "localname": "ConversionPricePerShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_ConvertibleLoanNoteReserve": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan note reserve",
        "label": "Convertible Loan Note reserve"
       }
      }
     },
     "localname": "ConvertibleLoanNoteReserve",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ConvertibleLoanNoteReserveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan note reserve [member]",
        "label": "Convertible loan note reserve [member]"
       }
      }
     },
     "localname": "ConvertibleLoanNoteReserveMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ConvertibleLoanNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan notes [member]",
        "label": "Convertible loan notes [member]"
       }
      }
     },
     "localname": "ConvertibleLoanNotesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ConvertibleLoanNotesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible loan notes one [member]",
        "label": "Convertible loan notes one [member]"
       }
      }
     },
     "localname": "ConvertibleLoanNotesOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_CorporateAndAdministrationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate and administration [member]",
        "label": "Corporate and administration [member]"
       }
      }
     },
     "localname": "CorporateAndAdministrationMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_CurrentTaxationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current taxation receivable",
        "label": "Current taxation receivable"
       }
      }
     },
     "localname": "CurrentTaxationReceivable",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DebtTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt term.",
        "label": "Debt term"
       }
      }
     },
     "localname": "DebtTerm",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "OKYO_DepreciationNetValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation net value.",
        "label": "Depreciation, net book value"
       }
      }
     },
     "localname": "DepreciationNetValue",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DepreciationOfEarlyTerminatedLease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation of early terminated lease.",
        "label": "Depreciation of early terminated lease"
       }
      }
     },
     "localname": "DepreciationOfEarlyTerminatedLease",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DepreciationOfNewLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation of new lease.",
        "label": "Depreciation of new lease"
       }
      }
     },
     "localname": "DepreciationOfNewLease",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DerecognitionOfLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derecognition of lease liability.",
        "label": "Derecognition of lease liability"
       }
      }
     },
     "localname": "DerecognitionOfLeaseLiability",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DescriptionOfAccountingPolicyForLeaseExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Accounting Policy For Lease Explanatory [PolicyText Block]",
        "label": "DescriptionOfAccountingPolicyForLeaseExplanatory",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLeaseExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DescriptionOfAccountingPolicyForLicenseFeesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Accounting Policy For License Fees Explanatory [Policy Text Block]",
        "label": "License fees"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForLicenseFeesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for research and development explanatory [Policy Text Block]",
        "label": "Research and development"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DescriptionOfAccountingPolicyForShareCapitalExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for share capital explanatory [Policy Text block]",
        "label": "Share capital"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForShareCapitalExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DirectorsBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors bonus",
        "label": "Bonus"
       }
      }
     },
     "localname": "DirectorsBonus",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors [member]",
        "label": "Directors [member]"
       }
      }
     },
     "localname": "DirectorsMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_DirectorsSalaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors salaries.",
        "label": "Directors\u2019 salaries"
       }
      }
     },
     "localname": "DirectorsSalaries",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DirectorsSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors salary",
        "label": "[custom:DirectorsSalary]"
       }
      }
     },
     "localname": "DirectorsSalary",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DisclosureAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies"
       }
      }
     },
     "localname": "DisclosureAccountingPoliciesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureBasicAndDilutedLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic And Diluted Loss Per Share",
        "verboseLabel": "Summary Of Income And Share Data Used In Basic And Diluted Loss Per Share Computations"
       }
      }
     },
     "localname": "DisclosureBasicAndDilutedLossPerShareAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureCapitalAndReservesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital And Reserves"
       }
      }
     },
     "localname": "DisclosureCapitalAndReservesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents"
       }
      }
     },
     "localname": "DisclosureCashAndCashEquivalentsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureCommitmentsAndContingenciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies"
       }
      }
     },
     "localname": "DisclosureCommitmentsAndContingenciesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Instruments Classified As Equity"
       }
      }
     },
     "localname": "DisclosureConvertibleInstrumentsClassifiedAsEquityAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Critical Accounting Judgements And Key Sources Of Estimation Uncertainty"
       }
      }
     },
     "localname": "DisclosureCriticalAccountingJudgementsAndKeySourcesOfEstimationUncertaintyAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureEmployeesIncludingOfficersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees Including Officers"
       }
      }
     },
     "localname": "DisclosureEmployeesIncludingOfficersAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureFinanceIncomeAndCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Income And Costs",
        "verboseLabel": "Schedule Of Finance Cost"
       }
      }
     },
     "localname": "DisclosureFinanceIncomeAndCostsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureFinancialInstrumentsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "terseLabel": "Schedule Of Lease Liabilities By Classification",
        "verboseLabel": "Schedule Of Right Of Use Assets And Lease Liability"
       }
      }
     },
     "localname": "DisclosureLeasesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policies of basis of preparation.",
        "label": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfAccountingPoliciesBasisOfPresentationExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information abou lease liabilities by classification explanatory.",
        "label": "SCHEDULE OF LEASE LIABILITIES BY CLASSIFICATION"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAbouLeaseLiabilitiesByClassificationExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about cash and cash equivalents.",
        "label": "SCHEDULE OF CASH AND CASH EQUIVALENT"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CashAndCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about company auditors fees explanatory.",
        "label": "SCHEDULE OF COMPANY AUDITORS FEES"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutCompanyAuditorsFeesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AuditorsRemunerationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about contractual maturities of lease liabilities explanatory.",
        "label": "SCHEDULE OF CONTRACTUAL MATURITIES OF LEASE LIABILITIES"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutContractualMaturitiesOfLeaseLiabilitiesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutEmployeesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about employees explanatory.",
        "label": "DISCLOSURE OF EMPLOYEES COST AND NUMBER OF EMPLOYEES EXPLANATORY"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutEmployeesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/EmployeesIncludingOfficersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about fair value of warrants in services explanatory.",
        "label": "SCHEDULE OF FAIR VALUE OF WARRANTS IN SERVICES"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFairValueOfWarrantsInServicesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about inputs for warrants granted explanatory.",
        "label": "SCHEDULE OF INPUTS FOR WARRANTS GRANTED"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutInputsForWarrantsGrantedExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about operating expenses explanatory.",
        "label": "DISCLOSURE OF DETAILED INFORMATION ABOUT OPERATING EXPENSES EXPLANATORY"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOperatingExpensesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/OperatingExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information about options outstanding and weighted average exercise price explanatory.",
        "label": "SCHEDULE OF OPTIONS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutOptionsOutstandingAndWeightedAverageExercisePriceExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed information about payables and accrued liabilities.",
        "label": "DISCLOSURE OF DETAILED INFORMATION ABOUT PAYABLES AND ACCRUED LIABILITIES EXPLANATORY"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/TradeAndOtherPayablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Detailed Information About Property Plant And Equipment Located Operating Segment Explanatory [Table Text Block]",
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT LOCATED OPERATING SEGMENT"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentLocatedOperatingSegmentExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about share-based payment award model inputs options granted explanatory.",
        "label": "SCHEDULE OF SHARE BASED PAYMENT AWARD MODEL INPUTS OPTIONS GRANTED"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutShareBasedPaymentAwardModelInputsOptionsGrantedExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of detailed information of maturities of financial instruments explanatory.",
        "label": "SUMMARY OF FINANCIAL LIABILITIES BASED ON CONTRACTUAL UNDISCOUNTED PAYMENTS"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationOfMaturitiesOfFinancialInstrumentsExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfDetailedTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detailed trade and other receivables.",
        "label": "DISCLOSURE OF DETAILED TRADE AND OTHER RECEIVABLES EXPLANATORY"
       }
      }
     },
     "localname": "DisclosureOfDetailedTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/OtherReceivablesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfEmployeeDetailsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of employee details explanatory.",
        "label": "EMPLOYEES INCLUDING OFFICERS"
       }
      }
     },
     "localname": "DisclosureOfEmployeeDetailsExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/EmployeesIncludingOfficers"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfEstimatedUsefulLivesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for estimated useful lives explanatory.",
        "label": "DISCLOSURE OF ESTIMATED USEFUL LIVES"
       }
      }
     },
     "localname": "DisclosureOfEstimatedUsefulLivesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfIssuanceOfConvertibleNotesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure Of Issuance Of Convertible Notes Explanatory.",
        "label": "SCHEDULE OF ISSUANCE OF CONVERTIBLE LOAN"
       }
      }
     },
     "localname": "DisclosureOfIssuanceOfConvertibleNotesExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOfReportingEntityExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Reporting Entity Explanatory.",
        "label": "DisclosureOfReportingEntityExplanatory",
        "verboseLabel": "Reporting Entity"
       }
      }
     },
     "localname": "DisclosureOfReportingEntityExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ReportingEntity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_DisclosureOperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "verboseLabel": "Disclosure Of Detailed Information About Operating Expenses Explanatory"
       }
      }
     },
     "localname": "DisclosureOperatingExpensesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureOtherReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables",
        "verboseLabel": "Disclosure Of Detailed Trade And Other Receivables Explanatory"
       }
      }
     },
     "localname": "DisclosureOtherReceivablesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosurePostBalanceSheetEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post Balance Sheet Events"
       }
      }
     },
     "localname": "DisclosurePostBalanceSheetEventsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosurePropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment"
       }
      }
     },
     "localname": "DisclosurePropertyPlantAndEquipmentAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureRelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "DisclosureRelatedPartyTransactionsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureRemunerationOfKeyManagementPersonnelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remuneration Of Key Management Personnel"
       }
      }
     },
     "localname": "DisclosureRemunerationOfKeyManagementPersonnelAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureReportingEntityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Entity"
       }
      }
     },
     "localname": "DisclosureReportingEntityAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureSegmentalReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segmental Reporting"
       }
      }
     },
     "localname": "DisclosureSegmentalReportingAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureShareOptionsAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Options And Warrants",
        "verboseLabel": "Schedule Of Options Outstanding And Weighted Average Exercise Price"
       }
      }
     },
     "localname": "DisclosureShareOptionsAndWarrantsAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureTaxationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxation",
        "terseLabel": "Schedule Of Tax Credit Period Details",
        "verboseLabel": "Schedule Of Tax Credit Period"
       }
      }
     },
     "localname": "DisclosureTaxationAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisclosureTradeAndOtherPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade And Other Payables",
        "verboseLabel": "Disclosure Of Detailed Information About Payables And Accrued Liabilities Explanatory"
       }
      }
     },
     "localname": "DisclosureTradeAndOtherPayablesAbstract",
     "nsuri": "http://okyopharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "OKYO_DisposalsLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposals Lease Liabilities.",
        "label": "Early Termination write off lease liability",
        "negatedLabel": "Early Termination write off"
       }
      }
     },
     "localname": "DisposalsLeaseLiabilities",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/LeasesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_DisposalsRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Termination write off.",
        "label": "Derecognition of right of use asset",
        "negatedLabel": "Early Termination write off",
        "verboseLabel": "Early Termination write off right of use of assets"
       }
      }
     },
     "localname": "DisposalsRightOfUseAssets",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/LeasesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_EffectOfChargeInYearDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of charge in year depreciation.",
        "label": "Charge in year"
       }
      }
     },
     "localname": "EffectOfChargeInYearDepreciation",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_EffectOfForeignExchangeDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of foreign exchange depreciation.",
        "label": "EffectOfForeignExchangeDepreciation",
        "verboseLabel": "Foreign exchange"
       }
      }
     },
     "localname": "EffectOfForeignExchangeDepreciation",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ExpectedLifeOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected life.",
        "label": "Expected life",
        "verboseLabel": "[custom:ExpectedLifeOfWarrants]"
       }
      }
     },
     "localname": "ExpectedLifeOfWarrants",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "OKYO_ExpirationDateOfOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding.",
        "label": "Expiration date of outstanding"
       }
      }
     },
     "localname": "ExpirationDateOfOutstanding",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "OKYO_FairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrants",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_FairValueWarrantsIssuedPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value warrants issued private placement",
        "label": "Relative Fair value charge for warrants issued in conjunction with private placement"
       }
      }
     },
     "localname": "FairValueWarrantsIssuedPrivatePlacement",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees relating to all other equity fundraise issued as CLN [member]",
        "label": "Fees relating to all other equity fundraise issued as CLN [member]"
       }
      }
     },
     "localname": "FeesRelatingToAllOtherEquityFundraiseIssuedAsCLNMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees relating to equity fundraise 29 May 2020 issued as CLN [member]",
        "label": "Fees relating to equity fundraise 29 May 2020 issued as CLN [member]"
       }
      }
     },
     "localname": "FeesRelatingToEquityFundraiseTwentyNineTwoThousandAndTwentyIssuedASCLNMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_FifteenAprilTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15 April 2021 [member]",
        "label": "15 April 2021 [member]"
       }
      }
     },
     "localname": "FifteenAprilTwoThousandTwentyOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ForeignCurrencyTranslationReserve": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign currency translation reserve",
        "label": "Foreign currency translation reserve"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationReserve",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ForeignExchangeLossesGains": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange loss gain.",
        "label": "FX Gains and losses"
       }
      }
     },
     "localname": "ForeignExchangeLossesGains",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_FurnitureAndFixtureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Furniture and fixtures [member]",
        "label": "Furniture and fixtures [member]"
       }
      }
     },
     "localname": "FurnitureAndFixtureMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GBPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GBP [Member]",
        "label": "GBP [Member]"
       }
      }
     },
     "localname": "GBPMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GCerroneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G Cerrone [member]",
        "label": "G Cerrone [member]"
       }
      }
     },
     "localname": "GCerroneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GJacobMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G Jacob [member]",
        "label": "G Jacob [member]"
       }
      }
     },
     "localname": "GJacobMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GMacraeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "G Macrae [member]",
        "label": "G Macrae [member]"
       }
      }
     },
     "localname": "GMacraeMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GainlossOnDisposalOfLeases": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on disposal of leases.",
        "label": "(Gain)/Loss on disposal of leases"
       }
      }
     },
     "localname": "GainlossOnDisposalOfLeases",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_GrantDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Date Axis.",
        "label": "Grant Date [Axis]",
        "verboseLabel": "GrantDateAxis [Axis]"
       }
      }
     },
     "localname": "GrantDateAxis",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "OKYO_GrantDateDomain": {
     "auth_ref": [],
     "localname": "GrantDateDomain",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_GrantDateShareOptionsGranted2019": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant date share options granted.",
        "label": "Grant date share price"
       }
      }
     },
     "localname": "GrantDateShareOptionsGranted2019",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_ITEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IT equipment [member]",
        "label": "IT equipment [member]"
       }
      }
     },
     "localname": "ITEquipmentMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_IfrsStatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementLineItems [Line Items]"
       }
      }
     },
     "localname": "IfrsStatementLineItems",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails",
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative",
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails",
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails",
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails",
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails",
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical",
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails",
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity",
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "OKYO_IfrsStatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IfrsStatementTable [Table]"
       }
      }
     },
     "localname": "IfrsStatementTable",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical",
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "OKYO_ImpactOfForeignExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of Foreign exchange.",
        "label": "Impact of Foreign exchange",
        "negatedLabel": "Impact of Foreign exchange"
       }
      }
     },
     "localname": "ImpactOfForeignExchange",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ImpactOfForeignExchangeLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impact of foreign exchange lease liabilities.",
        "label": "Impact of foreign exchange"
       }
      }
     },
     "localname": "ImpactOfForeignExchangeLeaseLiabilities",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ImpairmentOfLoan": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of loan",
        "label": "Impairment of loan"
       }
      }
     },
     "localname": "ImpairmentOfLoan",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_IncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense.",
        "label": "IncomeTaxExpenseBenefitContinuingOperations",
        "negatedLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through conversion of convertible instruments shares",
        "label": "Conversion of CLN, shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstrumentsShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_IncreaseDecreaseThroughExerciseOfForfeiture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through exercise of forfeiture",
        "label": "Options forfeiture"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfForfeiture",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_IncreaseDecreaseThroughExerciseOfOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through exercise of options shares",
        "label": "IncreaseDecreaseThroughExerciseOfOptionsShares",
        "verboseLabel": "Options exercised, shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptionsShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_IncreaseDecreaseThroughExerciseOfWarrantsCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through exercise of warrants charge",
        "label": "Warrants charge"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsCharge",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_IncreaseDecreaseThroughExerciseOfWarrantsEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease through exercise of warrants equity shares",
        "label": "Exercise of warrants, shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquityShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_InitialRecognitionForRightOfUseAssetAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition for right of use asset and lease liability .",
        "label": "initial recognition for right of use asset and lease liability"
       }
      }
     },
     "localname": "InitialRecognitionForRightOfUseAssetAndLeaseLiability",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_IssuedInLieuValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued in lieu value",
        "label": "CLNs issued in lieu of fundraising commission"
       }
      }
     },
     "localname": "IssuedInLieuValue",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_JBrancaccioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "J Brancaccio [member]",
        "label": "J Brancaccio [member]"
       }
      }
     },
     "localname": "JBrancaccioMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_KShailubhaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "K Shailubhai [member]",
        "label": "K Shailubhai [member]"
       }
      }
     },
     "localname": "KShailubhaiMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_KeyManagementPersonnelCompensationDirectorFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Director fees.",
        "label": "Director fees including bonus (excluding Chairman\u2019s bonus)"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationDirectorFees",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_KeyManagementPersonnelCompensationSharebasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]",
        "label": "Share based payment expenses"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayments",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LZambelettiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "L Z ambeletti [member]",
        "label": "L Z ambeletti [member]"
       }
      }
     },
     "localname": "LZambelettiMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LeaseLiabilitiesInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities interest expense.",
        "label": "Interest expense"
       }
      }
     },
     "localname": "LeaseLiabilitiesInterestExpense",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LeaseLiabilitiesInterestExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liabilities interest expense.",
        "label": "LeaseLiabilitiesInterestExpenses",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "LeaseLiabilitiesInterestExpenses",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LeasePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Payment",
        "label": "LeasePayment",
        "verboseLabel": "Lease payments"
       }
      }
     },
     "localname": "LeasePayment",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LeasePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease payments.",
        "label": "Lease payments"
       }
      }
     },
     "localname": "LeasePayments",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LessThanThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less Than Three [member]",
        "label": "Less Than Three [member]"
       }
      }
     },
     "localname": "LessThanThreeMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LieuOfBrokerFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lieu of broker-fees [member]",
        "label": "Lieu of broker-fees [member]"
       }
      }
     },
     "localname": "LieuOfBrokerFeesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LieuOfProfessionalFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lieu of professional fees [member]",
        "label": "Lieu of professional fees [member]"
       }
      }
     },
     "localname": "LieuOfProfessionalFeesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LoanNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan notes [member]",
        "label": "Loan notes [member]"
       }
      }
     },
     "localname": "LoanNotesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LoanNotesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan notes one [member]",
        "label": "Loan notes one [member]"
       }
      }
     },
     "localname": "LoanNotesOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_LossBeforeTaxation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss before taxation.",
        "label": "Loss before taxation"
       }
      }
     },
     "localname": "LossBeforeTaxation",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_LossChargedAtStandardRateOfCorporationTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss charged at standard rate of corporation tax.",
        "label": "Loss charged at standard rate of corporation tax 19%"
       }
      }
     },
     "localname": "LossChargedAtStandardRateOfCorporationTax",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_NonadjustingEventMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-adjusting event [member]",
        "label": "Non-adjusting event [member]"
       }
      }
     },
     "localname": "NonadjustingEventMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_NumberOfSharesIssuedPrivatePlacement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued private placement",
        "label": "Shares issued - private placement, shares"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPrivatePlacement",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_NumberOfSharesIssuedPrivatePlacementValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued private placement value",
        "label": "Shares issued - private placement"
       }
      }
     },
     "localname": "NumberOfSharesIssuedPrivatePlacementValue",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_OptionLifePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options life period.",
        "label": "Option life"
       }
      }
     },
     "localname": "OptionLifePeriod",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "OKYO_PhaseIHumanClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase I Human Clinical Trial [member]",
        "label": "Phase I Human Clinical Trial [member]"
       }
      }
     },
     "localname": "PhaseIHumanClinicalTrialMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_PhaseIIHumanClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase II Human Clinical Trial [member]",
        "label": "Phase II Human Clinical Trial [member]"
       }
      }
     },
     "localname": "PhaseIIHumanClinicalTrialMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_PhaseIIIHumanClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase III Human Clinical Trial [member]",
        "label": "Phase III Human Clinical Trial [member]"
       }
      }
     },
     "localname": "PhaseIIIHumanClinicalTrialMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_PrepaymentsReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments receivables.",
        "label": "Prepayments receivables"
       }
      }
     },
     "localname": "PrepaymentsReceivables",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/OtherReceivablesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_PrivatePlacementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placements [member]",
        "label": "Private placements [member]"
       }
      }
     },
     "localname": "PrivatePlacementsMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_PrivatePlacementsOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placements one [member]",
        "label": "Private placements one [member]"
       }
      }
     },
     "localname": "PrivatePlacementsOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ProcessedFromOptionsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Processed from options exercised.",
        "label": "Processed from options exercised"
       }
      }
     },
     "localname": "ProcessedFromOptionsExercised",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ProcessedFromWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Processed from warrants exercised.",
        "label": "Processed from warrants exercised"
       }
      }
     },
     "localname": "ProcessedFromWarrantsExercised",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_PropertyPlantAndEquipmentCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment, cost.",
        "label": "PropertyPlantAndEquipmentCost",
        "periodEndLabel": "Property and equipment, cost, ending balance",
        "periodStartLabel": "Property and equipment, cost, beginning balance"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentCost",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_PropertyPlantAndEquipmentDepreciation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property plant and equipment depreciation.",
        "label": "PropertyPlantAndEquipmentDepreciation",
        "periodEndLabel": "Depreciation, ending balance",
        "periodStartLabel": "Depreciation, beginning balance"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDepreciation",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_RelatedPartyReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party receivables.",
        "label": "Related party receivables"
       }
      }
     },
     "localname": "RelatedPartyReceivables",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ResearchAndDevelopmentEnhancedExpenditure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development enhanced expenditure.",
        "label": "Research and Development enhanced expenditure"
       }
      }
     },
     "localname": "ResearchAndDevelopmentEnhancedExpenditure",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development [member]",
        "label": "Research and development [member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ResearchAndDevelopmentTaxClaim": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development tax claim.",
        "label": "Research and Development tax claim"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxClaim",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ScheduleOfShareOptionsGrantedToDirectorsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share options granted to directors explanatory [Table Text Block]",
        "label": "SCHEDULE OF SHARE OPTIONS GRANTED TO DIRECTORS"
       }
      }
     },
     "localname": "ScheduleOfShareOptionsGrantedToDirectorsExplanatory",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "OKYO_ServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service agreement [member]",
        "label": "Service agreement [member]"
       }
      }
     },
     "localname": "ServiceAgreementMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_SeventeenthAugustTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "17 August 2020 [member]",
        "label": "17 August 2020 [member]"
       }
      }
     },
     "localname": "SeventeenthAugustTwoThousandAndTwentyMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ShareBasedPaymentCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment charge.",
        "label": "Share based payment charge"
       }
      }
     },
     "localname": "ShareBasedPaymentCharge",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ShareBasedPaymentChargeForfeiture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment charge forfeiture.",
        "label": "Share based payment charge forfeiture"
       }
      }
     },
     "localname": "ShareBasedPaymentChargeForfeiture",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnConvertibleDebtAndWarrantInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on convertible debt and warrant interest.",
        "label": "Convertible loan note and warrant interest"
       }
      }
     },
     "localname": "SharesIssuedOnConvertibleDebtAndWarrantInterest",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnConvertibleDebtConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on convertible debt, conversion.",
        "label": "Convertible loan note conversion"
       }
      }
     },
     "localname": "SharesIssuedOnConvertibleDebtConversion",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnConvertibleDebtConversionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on convertible debt conversion, shares.",
        "label": "Convertible debt conversion, shares"
       }
      }
     },
     "localname": "SharesIssuedOnConvertibleDebtConversionShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_SharesIssuedOnConvertibleDebtInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on convertible debt interest.",
        "label": "Convertible loan note interest"
       }
      }
     },
     "localname": "SharesIssuedOnConvertibleDebtInterest",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on currency translation on convertible loan note conversion.",
        "label": "Currency translation on Convertible Loan note conversion"
       }
      }
     },
     "localname": "SharesIssuedOnCurrencyTranslationOnConvertibleLoanNoteConversion",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnOptionsCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on options charge",
        "label": "Options charge"
       }
      }
     },
     "localname": "SharesIssuedOnOptionsCharge",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnTotalTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on total transactions",
        "label": "Total transactions"
       }
      }
     },
     "localname": "SharesIssuedOnTotalTransactions",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SharesIssuedOnTotalTransactionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on total transactions shares,",
        "label": "Total transactions, shares"
       }
      }
     },
     "localname": "SharesIssuedOnTotalTransactionsShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_SharesIssuedOnWarrantsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued on warrants exercised shares.",
        "label": "Warrants exercised, shares"
       }
      }
     },
     "localname": "SharesIssuedOnWarrantsExercisedShares",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_ShorttermCreditFacility": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term credit facility.",
        "label": "[custom:ShorttermCreditFacility-0]"
       }
      }
     },
     "localname": "ShorttermCreditFacility",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_SixJanuaryTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6 January 2021 [member]",
        "label": "6 January 2021 [member]"
       }
      }
     },
     "localname": "SixJanuaryTwoThousandTwentyOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_SixJulyTwoThousandEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6 July 2018 [member]",
        "label": "6 July 2018 [member]"
       }
      }
     },
     "localname": "SixJulyTwoThousandEighteenMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_StockIssuedDuringPeriodSharesShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares share capital",
        "label": "Issuance of share capital, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareCapital",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_StockIssuedDuringPeriodShareslExerciseOfOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares exercise of options",
        "label": "Options exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareslExerciseOfOptions",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_StockIssuedDuringPeriodValueNewIssue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value new issue",
        "label": "Issue of share capital"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssue",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_StockIssuedDuringPeriodValueTransferBetweenEquityReserves": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value transfer between equisty reserves.",
        "label": "Transfer between equity reserves"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTransferBetweenEquityReserves",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax increase from effect of capital allowances and depreciation.",
        "label": "Tax increase from effect of capital allowances and depreciation"
       }
      }
     },
     "localname": "TaxIncreaseFromEffectOfCapitalAllowancesAndDepreciation",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_TaxLossesSurrenderedForResearchAndDevelopment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax losses surrendered for Research and Development.",
        "label": "Tax losses surrendered for Research and Development"
       }
      }
     },
     "localname": "TaxLossesSurrenderedForResearchAndDevelopment",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_ThirtyFirstAugustTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "31 August 2021 [member]",
        "label": "31 August 2021 [member]"
       }
      }
     },
     "localname": "ThirtyFirstAugustTwoThousandTwentyOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ThirtyFirstAugustTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "31 January 2022 [member]",
        "label": "31 January 2022 [member]"
       }
      }
     },
     "localname": "ThirtyFirstAugustTwoThousandTwentyTwoMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ThreeSeptemberTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "03 September 2022 [member]",
        "label": "03 September 2022 [member]"
       }
      }
     },
     "localname": "ThreeSeptemberTwoThousandAndTwentyMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_ThreeToTwelveMonthsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three to Twelve Months [member]",
        "label": "Three to Twelve Months [member]"
       }
      }
     },
     "localname": "ThreeToTwelveMonthsMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TizianaLifeSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiziana Life Sciences Ltd [member]",
        "label": "Tiziana Life Sciences Ltd [member]"
       }
      }
     },
     "localname": "TizianaLifeSciencesLtdMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade and current payables.",
        "label": "TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesExcludingDeferredIncomeClassifiedAsCurrent",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "OKYO_TranslationReserveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Translation reserve [member]",
        "label": "Translation reserve [member]"
       }
      }
     },
     "localname": "TranslationReserveMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TwelveJanuaryTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "12 January 2021 [member]",
        "label": "12 January 2021 [member]"
       }
      }
     },
     "localname": "TwelveJanuaryTwoThousandTwentyOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TwentyAugustTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "20 August 2020 [member]",
        "label": "20 August 2020 [member]"
       }
      }
     },
     "localname": "TwentyAugustTwoThousandTwentyMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TwentyNineMayTwoThousandAndTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "29 May 2020 [member]",
        "label": "29 May 2020 [member]"
       }
      }
     },
     "localname": "TwentyNineMayTwoThousandAndTwentyMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_TwentySevenJulyTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "27 July 2020 [member]",
        "label": "27 July 2020 [member]"
       }
      }
     },
     "localname": "TwentySevenJulyTwoThousandTwentyMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_UKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UK [member]",
        "label": "UK [member]"
       }
      }
     },
     "localname": "UKMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_USDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "USD [member]",
        "label": "USD [member]"
       }
      }
     },
     "localname": "USDMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_UnitedStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US [member]",
        "label": "US [member]"
       }
      }
     },
     "localname": "UnitedStateMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_VestingPeriodsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period description.",
        "label": "Vesting periods"
       }
      }
     },
     "localname": "VestingPeriodsDescription",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "OKYO_WSimonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "W Simon [member]",
        "label": "W Simon [member]"
       }
      }
     },
     "localname": "WSimonMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_WarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercise price per share.",
        "label": "Warrant Exercise per share"
       }
      }
     },
     "localname": "WarrantExercisePricePerShare",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_WarrantReserveOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant reserve one [member]",
        "label": "Warrant reserve one [member]"
       }
      }
     },
     "localname": "WarrantReserveOneMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_WarrantReserveTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant reserve two [member]",
        "label": "Warrant reserve two [member]"
       }
      }
     },
     "localname": "WarrantReserveTwoMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_WarrantReservesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Reserves [member]",
        "label": "Warrant Reserves [member]"
       }
      }
     },
     "localname": "WarrantReservesMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_WarrantsExercisableDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercisable date.",
        "label": "Warrants exercisable date"
       }
      }
     },
     "localname": "WarrantsExercisableDate",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "OKYO_WarrantsExercisablePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercisable price per share.",
        "label": "Warrants exercisable price per share"
       }
      }
     },
     "localname": "WarrantsExercisablePricePerShare",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_WarrantsExercisedOnCashlessBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised on cashless basic.",
        "label": "Warrants exercised on cashless basic"
       }
      }
     },
     "localname": "WarrantsExercisedOnCashlessBasic",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_WarrantsExercisedOnIssuances": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised on issuances.",
        "label": "Warrants exercised on issuances"
       }
      }
     },
     "localname": "WarrantsExercisedOnIssuances",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "OKYO_WarrantsExercisedOnPriceReductionOffer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised on price reduction offer .",
        "label": "Warrants exercised on price reduction offer"
       }
      }
     },
     "localname": "WarrantsExercisedOnPriceReductionOffer",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "OKYO_WarrantsVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting periods.",
        "label": "WarrantsVestingPeriod",
        "verboseLabel": "Vesting periods"
       }
      }
     },
     "localname": "WarrantsVestingPeriod",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "OKYO_WestAfricanMineralsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "West African Minerals Limited [member]",
        "label": "West African Minerals Limited [member]"
       }
      }
     },
     "localname": "WestAfricanMineralsLimitedMember",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "OKYO_WriteOffExchangeOfLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off exchange of loan.",
        "label": "Write off related party exchange of loan"
       }
      }
     },
     "localname": "WriteOffExchangeOfLoan",
     "nsuri": "http://okyopharma.com/20220331",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r191",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://okyopharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "ifrs-full_Accruals": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees."
       }
      },
      "en-us": {
       "role": {
        "label": "Accruals"
       }
      }
     },
     "localname": "Accruals",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "verboseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortization of right of use asset"
       }
      }
     },
     "localname": "AdjustmentsForAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForCurrentTaxOfPriorPeriod": {
     "auth_ref": [
      "r45"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments of tax expense (income) recognised in the period for current tax of prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments in respect of prior periods"
       }
      }
     },
     "localname": "AdjustmentsForCurrentTaxOfPriorPeriod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net (increase)/decrease in operating assets/other receivables"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation of fixed assets"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for gain (loss) on disposals, property, plant and equipment",
        "negatedLabel": "Gain on disposal of right of use asset"
       }
      }
     },
     "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on loans and advances recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment of loan to West African Minerals Ltd"
       }
      }
     },
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossLoansAndAdvances",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net (decrease)/increase in trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLoss": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash inflow from taxation"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share option charge"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "auth_ref": [
      "r92",
      "r99"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "(Gain)/Loss on foreign exchange"
       }
      }
     },
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r19",
      "r60",
      "r122",
      "r131",
      "r132",
      "r148",
      "r156",
      "r158",
      "r172",
      "r173",
      "r175",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails",
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmountsPayableRelatedPartyTransactions": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amounts Payable related party transaction"
       }
      }
     },
     "localname": "AmountsPayableRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ApplicableTaxRate": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      },
      "en-us": {
       "role": {
        "label": "Corporation tax rate"
       }
      }
     },
     "localname": "ApplicableTaxRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetailsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r17",
      "r114",
      "r115",
      "r116",
      "r166",
      "r168"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AuditorsRemuneration": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor\u2019s Remuneration (refer to Note 20)",
        "verboseLabel": "Total auditor\u2019s remuneration"
       }
      }
     },
     "localname": "AuditorsRemuneration",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails",
      "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AuditorsRemunerationForAuditServices": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for auditing services."
       }
      },
      "en-us": {
       "role": {
        "label": "Fees payable to the company\u2019s auditors for the audit of the parent company and consolidated financial statements"
       }
      }
     },
     "localname": "AuditorsRemunerationForAuditServices",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AuditorsRemunerationForOtherServices": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable to the entity's auditors for services that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Audit-related assurance services"
       }
      }
     },
     "localname": "AuditorsRemunerationForOtherServices",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCompanyAuditorsFeesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Borrowings": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings"
       }
      }
     },
     "localname": "Borrowings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BorrowingsByNameAxis": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Borrowings by name [axis]"
       }
      }
     },
     "localname": "BorrowingsByNameAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BorrowingsByNameMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]"
       }
      }
     },
     "localname": "BorrowingsByNameMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BorrowingsInterestRate": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest rate"
       }
      }
     },
     "localname": "BorrowingsInterestRate",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r142",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Bottom of range [member]"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAdvancesAndLoansFromRelatedParties": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Loan repayment from related party"
       }
      }
     },
     "localname": "CashAdvancesAndLoansFromRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAdvancesAndLoansMadeToRelatedParties": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for loans and advances made to related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash advances and loans made to related parties",
        "negatedLabel": "Loan to West African Minerals Ltd"
       }
      }
     },
     "localname": "CashAdvancesAndLoansMadeToRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r15",
      "r97",
      "r110"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalent, end of period",
        "periodStartLabel": "Cash and cash equivalent, beginning of period",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r85",
      "r98"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashOnHand": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash held by the entity. This does not include demand deposits."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash at bank and in hand"
       }
      }
     },
     "localname": "CashOnHand",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r80",
      "r82",
      "r117",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r80",
      "r117",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets other than goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails",
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r33",
      "r101",
      "r104",
      "r105",
      "r109"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Total comprehensive income",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComputerEquipmentMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Computer equipment [member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ConsiderationPaidReceived": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consideration received"
       }
      }
     },
     "localname": "ConsiderationPaidReceived",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r20",
      "r105",
      "r106"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      },
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities - current",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r21",
      "r105",
      "r108"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current year tax (credit)"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax expense (income) and adjustments for the current tax of prior periods. [Refer: Current tax expense (income); Adjustments for current tax of prior periods]"
       }
      },
      "en-us": {
       "role": {
        "label": "Research and Development tax credits claimed in respect of previous periods"
       }
      }
     },
     "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentValueAddedTaxReceivables": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "VAT receivable"
       }
      }
     },
     "localname": "CurrentValueAddedTaxReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of aggregate deemed cost of investments in subsidiaries, joint ventures or associates for which deemed cost is fair value in the entity's first IFRS financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries, joint ventures and associates reported in separate financial statements; IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fair value charge of share option instruments deemed"
       }
      }
     },
     "localname": "DeemedCostOfInvestmentsForWhichDeemedCostIsFairValue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Origination and reversal of timing differences"
       }
      }
     },
     "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r39",
      "r111",
      "r164",
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for borrowings. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Convertible loan notes"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Fair Value Measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for foreign currency translation."
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign currency translation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for the impairment of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for income tax."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for income tax [text block]",
        "verboseLabel": "Taxation"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for restricted cash and cash equivalents [text block]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRestrictedCashAndCashEquivalentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Segment reporting"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share based payments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Warrants"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "verboseLabel": "Risk free interest rate, share options granted"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DirectorsRemunerationExpense": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of remuneration paid or payable to the entity's directors."
       }
      },
      "en-us": {
       "role": {
        "label": "Directors' fees"
       }
      }
     },
     "localname": "DirectorsRemunerationExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY"
       }
      }
     },
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CriticalAccountingJudgementsAndKeySourcesOfEstimationUncertainty"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more, and more than, twelve months after reporting date."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [table]"
       }
      }
     },
     "localname": "DisclosureOfAmountsToBeRecoveredOrSettledAfterTwelveMonthsForClassesOfAssetsAndLiabilitiesThatContainAmountsToBeRecoveredOrSettledBothNoMoreAndMoreThanTwelveMonthsAfterReportingDateTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails",
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfAuditorsRemunerationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of compensation to the entity's auditors."
       }
      },
      "en-us": {
       "role": {
        "label": "Auditor\u2019s Remuneration"
       }
      }
     },
     "localname": "DisclosureOfAuditorsRemunerationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AuditorsRemuneration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for consolidation."
       }
      },
      "en-us": {
       "role": {
        "label": "Basis of consolidation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfConsolidationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CashAndCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF AUTHORIZED ISSUE UNLIMITED NUMBER OF PAR VALUE SHARES"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDebtSecuritiesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of debt instruments. [Refer: Debt instruments issued; Debt instruments held]"
       }
      },
      "en-us": {
       "role": {
        "label": "CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY"
       }
      }
     },
     "localname": "DisclosureOfDebtSecuritiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ConvertibleInstrumentsClassifiedAsEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of borrowings."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about borrowings [table]"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF PROPERTY PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "BASIC AND DILUTED LOSS PER SHARE"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BasicAndDilutedLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for employee benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF KEY MANAGEMENT PERSONNEL COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfEmployeeBenefitsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "verboseLabel": "Post Balance Sheet Events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinanceCostExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance cost. [Refer: Finance costs]"
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF FINANCE COST"
       }
      }
     },
     "localname": "DisclosureOfFinanceCostExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/FinanceIncomeAndCostsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "FINANCE INCOME AND COSTS"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/FinanceIncomeAndCosts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfGoingConcernExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's ability to continue as a going concern."
       }
      },
      "en-us": {
       "role": {
        "label": "Going Concern"
       }
      }
     },
     "localname": "DisclosureOfGoingConcernExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "TAXATION"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/Taxation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "REMUNERATION OF KEY MANAGEMENT PERSONNEL"
       }
      }
     },
     "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnel"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF WARRANTS OUTSTANDING AND WEIGHTED AVERAGE EXERCISE PRICE"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the offsetting of financial assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets [table]"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "SEGMENTAL REPORTING"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/SegmentalReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/OperatingExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails",
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF RIGHT OF USE ASSETS AND LEASE LIABILITY"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF SHARE OPTIONS OUTSTANDING EXPIRY DATES AND EXERCISE PRICES"
       }
      }
     },
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "CAPITAL AND RESERVES"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "SHARE OPTIONS AND WARRANTS"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTaxReceivablesAndPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of tax receivables and payables."
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF TAX CREDIT PERIOD"
       }
      }
     },
     "localname": "DisclosureOfTaxReceivablesAndPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/TaxationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "TRADE AND OTHER PAYABLES"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/TradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "OTHER RECEIVABLES"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/OtherReceivables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "SCHEDULE OF REMUNERATION OF DIRECTORS"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RemunerationOfKeyManagementPersonnelTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DividendPayables": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of dividends that the company has declared but not yet paid."
       }
      },
      "en-us": {
       "role": {
        "label": "Payment of dividend"
       }
      }
     },
     "localname": "DividendPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "SUMMARY OF INCOME AND SHARE DATA USED IN THE BASIC AND DILUTED LOSS PER SHARE COMPUTATIONS"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BasicAndDilutedLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Exchange difference"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Total employee benefits expense"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r17",
      "r25",
      "r100",
      "r103",
      "r114",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders\u2019 Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExercisePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The exercise price of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Exercise Price",
        "terseLabel": "Exercise price, share options granted",
        "verboseLabel": "Exercise share price"
       }
      }
     },
     "localname": "ExercisePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the measurement basis (or bases) used in preparing the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Basis of measurement"
       }
      }
     },
     "localname": "ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance (expense)",
        "negatedTerseLabel": "Finance costs"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFinanceCostDetails",
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance Income",
        "verboseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFinanceCostDetails",
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialLiabilities": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinancialLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gain on the recovery of loans and advances previously written off."
       }
      },
      "en-us": {
       "role": {
        "label": "Loans written off"
       }
      }
     },
     "localname": "GainOnRecoveryOfLoansAndAdvancesPreviouslyWrittenOff",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "auth_ref": [
      "r130",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Within one year"
       }
      }
     },
     "localname": "GrossLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r35",
      "r43",
      "r49",
      "r50",
      "r75",
      "r113",
      "r165"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Total tax (credit) for the period"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Net (decrease)/increase in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Conversion of CLN"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Options exercised"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Warrants Exercised",
        "verboseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughForeignExchangeFinancialAssets": {
     "auth_ref": [
      "r150",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in financial assets resulting from foreign exchange. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Consolidation adjustment in relation to foreign exchange movements"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": {
     "auth_ref": [
      "r81",
      "r83",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwillMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedLabel": "Interest expense on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFinanceCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfConvertibleInstruments": {
     "auth_ref": [
      "r6"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The change in equity resulting from the issuing of convertible instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of convertible instruments"
       }
      }
     },
     "localname": "IssueOfConvertibleInstruments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfIssuanceOfConvertibleLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel compensation, share-based payment",
        "verboseLabel": "Share based payments"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits"
       }
      }
     },
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Key management personnel of entity or parent [member]"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfKeyManagementPersonnelCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "periodEndLabel": "Lease Liabilities, balance as at the beginning of the year",
        "periodStartLabel": "Lease Liabilities, balance as at the beginning of the year",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails",
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r17",
      "r114",
      "r115",
      "r116",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_LoansAndReceivables": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than: (a) those that the entity intends to sell immediately or in the near term, which shall be classified as held for trading, and those that the entity, upon initial recognition, designates as at fair value through profit or loss; (b) those that the entity, upon initial recognition, designates as available for sale; or (c) those for which the holder may not recover substantially all of its initial investment, other than because of credit deterioration, which shall be classified as available for sale. An interest acquired in a pool of assets that are not loans or receivables (for example, an interest in a mutual fund or a similar fund) is not a loan or receivable. [Refer: Derivative financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Loans receivable"
       }
      }
     },
     "localname": "LoansAndReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MaterialIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "MaterialIncomeAndExpenseAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r19",
      "r60",
      "r122",
      "r131",
      "r132",
      "r148",
      "r154",
      "r156",
      "r172",
      "r173",
      "r175",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails",
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetDebt": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of net debt of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Net debt"
       }
      }
     },
     "localname": "NetDebt",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r20",
      "r105",
      "r107"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      },
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities - non current",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/ScheduleOfLeaseLiabilitiesByClassificationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r18",
      "r131",
      "r132",
      "r156",
      "r161",
      "r176"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Not later than one year [member]"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfContractualMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfEmployees": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of personnel employed by the entity at a date."
       }
      },
      "en-us": {
       "role": {
        "label": "Total number of employees"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r143",
      "r145"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Warrants granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercisable in share-based payment arrangement",
        "periodEndLabel": "Warrants exercisable"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Warrants exercised"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "auth_ref": [
      "r136",
      "r140",
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares were issued",
        "periodEndLabel": "Ending balance, Options outstanding",
        "periodStartLabel": "Beginning balance, Options outstanding",
        "verboseLabel": "Share Options, Outstanding"
       }
      }
     },
     "localname": "NumberOfOutstandingShareOptions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsOutstandingExpiryDatesAndExercisePricesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercisable in share-based payment arrangement",
        "periodEndLabel": "Options, Exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "negatedLabel": "Options, exercised",
        "verboseLabel": "Number of option were exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "negatedLabel": "Options, forfeited"
       }
      }
     },
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of options",
        "verboseLabel": "Options, granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpenseExcludingCostOfSales",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OperatingExpenseExcludingCostOfSales": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating expense excluding the cost of sales. [Refer: Cost of sales]"
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense excluding cost of sales",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenseExcludingCostOfSales",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r29",
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r22",
      "r38"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Exchange differences on translating foreign operations"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r22",
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReceivables": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r7",
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherShorttermEmployeeBenefits": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Recruitment Costs"
       }
      }
     },
     "localname": "OtherShorttermEmployeeBenefits",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares were issued, per share",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Repayment of leasing liabilities"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods."
       }
      },
      "en-us": {
       "role": {
        "label": "Pension contribution"
       }
      }
     },
     "localname": "PostemploymentBenefitExpenseDefinedContributionPlans",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/EmployeesIncludingOfficersDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Prepayments": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered."
       }
      },
      "en-us": {
       "role": {
        "label": "Prepayments"
       }
      }
     },
     "localname": "Prepayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of convertible loan notes"
       }
      }
     },
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of ordinary shares",
        "verboseLabel": "Gross proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/PostBalanceSheetEventsDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r123",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r123",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Legal and Professional fees"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutOperatingExpensesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r32",
      "r91",
      "r101",
      "r104",
      "r105",
      "r166",
      "r167",
      "r174",
      "r178"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Loss for the period",
        "negatedLabel": "Net loss",
        "totalLabel": "Loss for the year"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) attributable to ordinary equity holders of the parent entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "(Loss) attributable to equity holders of the company"
       }
      }
     },
     "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r146",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Loss from operations before income taxes",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows",
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r13",
      "r57"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property and Equipment, net",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r58",
      "r81",
      "r129"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails",
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Acquisition of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r142",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r142",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpenseExcludingCostOfSales",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfSharebasedPayments": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity resulting from share-based payments."
       }
      },
      "en-us": {
       "role": {
        "label": "Share options reserve"
       }
      }
     },
     "localname": "ReserveOfSharebasedPayments",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r25",
      "r40"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained deficit",
        "negatedLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/AccountingPoliciesDetailsNarrative",
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r7",
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RevenueFromInterest": {
     "auth_ref": [
      "r9",
      "r112",
      "r163",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income"
       }
      }
     },
     "localname": "RevenueFromInterest",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFinanceCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromSaleOfGoodsRelatedPartyTransactions": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods in related party transactions. [Refer: Revenue; Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods, related party transactions"
       }
      }
     },
     "localname": "RevenueFromSaleOfGoodsRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right of use asset",
        "periodEndLabel": "Right-of-use assets, balance as at the end of the year",
        "periodStartLabel": "Right-of-use assets, balance as at the beginning of the year"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets",
      "http://okyopharma.com/role/ScheduleOfRightOfUseAssetsAndLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ServicesReceivedRelatedPartyTransactions": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of services received in related party transactions. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Service received related party transaction"
       }
      }
     },
     "localname": "ServicesReceivedRelatedPartyTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SocialSecurityContributions": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Social security costs"
       }
      }
     },
     "localname": "SocialSecurityContributions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfAuthorizedIssueUnlimitedNumberOfParValueSharesDetails",
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative",
      "http://okyopharma.com/role/StatementsOfShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax losses arising in the year not recognized"
       }
      }
     },
     "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses not deductible for taxation"
       }
      }
     },
     "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfTaxCreditPeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TaxEffectOfTaxLosses": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax effect of tax losses"
       }
      }
     },
     "localname": "TaxEffectOfTaxLosses",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/TaxationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r142",
      "r155",
      "r175"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Top of range [member]"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfShareBasedPaymentAwardModelInputsOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]"
       }
      },
      "en-us": {
       "role": {
        "label": "Related party payable"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r23",
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade payable"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedInformationAboutPayablesAndAccruedLiabilitiesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r14",
      "r24"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfDetailedTradeAndOtherReceivablesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayables": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables [Default Label]",
        "verboseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayablesToRelatedParties": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinancialLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payables due to related parties. [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Related party payables",
        "verboseLabel": "Payables to related parties"
       }
      }
     },
     "localname": "TradeAndOtherPayablesToRelatedParties",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://okyopharma.com/role/SummaryOfFinancialLiabilitiesBasedOnContractualUndiscountedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r124",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r124",
      "r177"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Estimated useful lives"
       }
      }
     },
     "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WagesAndSalaries": {
     "auth_ref": [
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Wages and salaries"
       }
      }
     },
     "localname": "WagesAndSalaries",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/DisclosureOfEmployeesCostAndNumberOfEmployeesExplanatoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WarrantReserve": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://okyopharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Warrants reserve"
       }
      }
     },
     "localname": "WarrantReserve",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_WarrantReserveMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Warrant reserve [member]"
       }
      }
     },
     "localname": "WarrantReserveMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/CapitalAndReservesDetailsNarrative",
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails",
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price, exercisable"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Weighted average exercise price, outstanding ending balance",
        "periodStartLabel": "Weighted average exercise price, outstanding beginning balance"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement",
        "periodEndLabel": "Ending balance, Weighted Average Exercise price, Exercisable"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise price, Exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise price, Forfeited",
        "negatedLabel": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise price, Granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r136",
      "r140"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement",
        "periodEndLabel": "Ending balance, Weighted Average Exercise price, outstanding",
        "periodStartLabel": "Beginning balance, Weighted Average Exercise price, outstanding"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfOptionsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average contractual life of options outstanding"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ShareOptionsAndWarrantsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "ifrs-full_WeightedAverageSharePriceShareOptionsGranted2019": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price, share options granted",
        "verboseLabel": "Grant date share price"
       }
      }
     },
     "localname": "WeightedAverageSharePriceShareOptionsGranted2019",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfFairValueOfWarrantsInServicesDetails",
      "http://okyopharma.com/role/ScheduleOfInputsForWarrantsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares in issue"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://okyopharma.com/role/SummaryOfIncomeAndShareDataUsedInBasicAndDilutedLossPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfCashAndCashEquivalentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [],
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateWriteDownOrReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Line Items]"
       }
      }
     },
     "localname": "RealEstateWriteDownOrReserveLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateWriteDownOrReserveTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-28, Real Estate Companies, Investment in Real Estate, Write-down or Reserve [Table]"
       }
      }
     },
     "localname": "RealEstateWriteDownOrReserveTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfPropertyPlantAndEquipmentLocatedOperatingSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetails",
      "http://okyopharma.com/role/ScheduleOfRemunerationOfDirectorsDetailsParenthetical",
      "http://okyopharma.com/role/ScheduleOfShareOptionsGrantedToDirectorsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "31",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_31_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "58",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "Clause": "vi",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "Clause": "vii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "13C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_13C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20B&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r181": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r182": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r183": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r184": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r185": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r186": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r187": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r188": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r189": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r191": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r192": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r193": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r194": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r195": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r196": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r197": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r198": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r199": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "80",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_80&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "9",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Section": "Scope",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "18",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_21_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "40",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_40_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001493152-22-022836-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-022836-xbrl.zip
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M\KP:/2NO]L[S6_3:OT+L8EFYM$DS&@9J3J5/U9 ;%7,JAMR >-0QX.:8:[_
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M1/\%[,\JKKWH53<_>T'\#5!+ P04    " !E?@]5(')K^YG& P!U,BL #
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M1V7960TKG^0\&J[L!(<537(AU5=VQL/*-W).G7A:K4ZL>"_G5I:G*X0Z(J+
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M_+JWN>\3;QM1\\M)*OP 3.)SX++W\73D2/%W$S]CCBE_).8=O]Y,_41^GB)
M?BB6=-YU3OA])K.^?@A]RP&'Z0Q^  PD9..EUC]>4M;'(S?QA?C*!&*^CVS+
ML 2MFFD-$3O==7[>@0F]NR!2P0CR$#31%W\\ .=VOEO^SGM\)G?2G*R)\9.T
MO<TG;B.Y)E;TQ[OM=9-(RX$5A!V*)Q"]0GQ3]B*MH=I*+U*2DRI9I-:Z+U*K
MRD4J=&C7:[E22JWY'*76JOXHS+F,6-]5EI-9;)6;U1\=2%C&&,]K;K.FID:Z
M?XOK<.18?@/!#8U$,L_DM%=M;,1J3&Y+E;H^9^OS6@.]@JW/F?8KV?JIC94V
M=N<I:)@[Y]>U[6>S>B9M-@?,FOXK88:9;?DVE@N2R=EY,W\E##"K:>S&[C\O
M BN8]NO8_#7SJ5:[2%$ELG*.ZN0<9?WB%6V]<HY>WDI>Z=8KY^@U;[MRCFKJ
M'+V0^E?.45V<HY?0!LHY>H72O[;.T4H6:3*-2SE'-7".*KT +]QZY1S5P$I>
MY=8KY^@U;[MRCNKJ'+V,^E?.46V<HQ?0!LHY>A727PC4JCR E_< :IYM. ?O
M*!?BI6S)=>4=Y8,HOEF";Y034RLG9EVY27E!=?&"UI6#E!M5!S=J+;AG*LJ5
M\K[JX'W5MJ)N*N\H[ZL.5O0Z\8[ROA3?+,$WRONJK?>U3MRDO*\Z>E_KQ$'*
M^ZJ;]U5?[IF$9U+>5\V\K_J!-,W!.\K[JH45O4:\H[POQ3=+\(WRONKK?:T1
M-RGOJY;>UQIQD/*^:N=]U8][,JU0E,_U\C[7BG%)E<M4'Y?IA;9>>3RO>=N5
MPU(KA^7%U;_R-VI3<?0"VD"Y"Z](^ELGNZWV.L,QR E4+2$GX+5)";EV'=W\
M"_X&%7'QR**.W&LO(!,3\SN] $WBD>OA9[>TB FA*5B)EY69DX2#74F/ O$.
M^HN83S%&31DC%7O)L,:\L9>4>EEMY.XR!#,D"#WL17II?<>_-H6CSFP=NQ/=
M]&X]%Q8O&-_:(*<P3SR81SAT@IL*UT'%\A:]2T ;* QXJVA:YM?&4&ES,&<I
M%$_-X22@B:Q[Q@#6]YP],MO=3%ZZ<L!ZZ&-D@'=8I@@A=E+\Z+KFDV7;"24U
M;4DVVXG(IOLIYE@7YE@%H$E3,<=Z,L<J@ XG(M$>>!1P>,%2=,RAY5A^X%%,
MYE4SR*QE>5W'BV*2=6.2%SAF%).L&Y-4>MS,BK1\/&.>YSIK'E[QO>#=@Q78
M#)G"M!XM,]23NY^>I7)T%RIB4BRB*I5F:9%?=</M;CB#).:H-,AB&D2QA](>
M4^J-[JWANINGL]@C.4>E/18# U'LH;1'L?;X[7Z@6W;8A?_=;!Z9F*C2(POI
M$<4H2J/,I5%^_>#ICJ$;AN5N-J-,3%1IE(4TBF(4I5'FBX]\U@U/W_0(6G*2
M2I,L%B%1#*(TR#0-\N&<.>Z8>9O-(>E9*AVRD Y1+**TR*RN)BJ4MC+VJ"W<
M>S%[J B)8I2Y&$69JXI!IC+(IW_KL#PV"X(-UR03$U6,LI!?<VYYS A<3R .
M;%QD+9&V"(O:=ST+,Q?OF W_,F]A>^#?"7;*+,=L9MJ\Z-[Z.5Z*AQ4/K[MG
MJ'A8\?"&VA*;D'VX#NQ;FPS(C;$@%.>^,L[=&+M!<>[KXMS-L18VXQ9M'7BW
M1C=Y&V,Q*.Y]A=R[,5:#XM[7Q[WK;SDH/E7G]:+GM>(9=4HN>DHJGE%GTSQ(
MI[^Q\6?=T?L,5^.6>;[K.,R^Z5W0.MQXL.1L@X#G9O!4_.0BZZ).MT4[I2NN
M6W.N6Z/S47'=IG!=#4_8?.S%JX=7"QQ.5MG$_%?--:M"59SE_"M&4+#QB^/[
M*JZIC_I8!7)O4VU_7;=_%7"KA6% Q0AU.CWJY_+DGQY??EMO9L';J#NFVQ>P
MPAR!V3#"84@.S#D;><RP"(KYG/F&9XWPSYB=$MPCUV'##X_L[CL6K-,]+IUB
M V*#[()L-C^@CWR8Z5/NF9:C>^/[ ?CQFW,]($\2FI;H1#_1JSQGZB^W_W)O
M5F),JOVOW?ZOI%<,O.-H=[^I]K^>^X][4^G^3UZVJ/VOR_ZOHL-+:^+\_T/W
M/'C-*VE3'C^1-^^7W?S*#W^Y^1+!)[4"-^O>E6/.'O4%LWY=6__)U9UK-]A
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M0Q]"'\P&U'0TMD V_<_GT_&^__W?G9LGMH :2H!)P^!?<\=.I;?D3&CG_=G
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MX;<3[_"=L@&7 M+,<&!B">7B_:@]C$?P_D_N$_-HKW[4KO4AXXM\[>(B6BD
M3/E+@N;=%%3.VC8!6NM^UFL,.'IU_7!W<_[E[.'JYKI4J-'-!PQ?+8]=.:*-
M08<W,. M@R1VU*7K#;5V<_>2MZY#O45)L[*9R6]_WC1D,Y/$9]KM0/>&NO8I
M,+-?XZBBQT'VJR<F/XFZI82^? 8O'L6';NBE&NHA09FWTN/8(>]I $?'6'.?
ML(^"'W9]R[1T;]Q(_>#*,<KKGU"'3=U /KUW;6:/M[=X_U'GD3D6<F.#V#3P
M=)-A@PT8P.>9/-1O@^?VT+?4Z<"/^M^EVG7 LV.MRS@W>;P=#G8VQ8)*'!Z6
M\_@@8L&#DS8PJ#\>=ET;WM>%A_S0&"0EQ(>?VKRK:A?9W?&QLZ^)3;:PMX=H
M#N)Z/+H)K[ \ZON#AM<C(V[U@'<MVZ8Q=!\F%31DMGHOM&WF![Q+:["]19%6
M31^-;!@5S2Q;?VK(47EF.];CL<#=TQXF)X]-)'3+@8_CLN;Y%]3M:2Z.[C>V
MMW@#(MF(<.2YF#XZ%@U+\J:XI_W!--.E25H.]IR576AA;4S+']FP,32\T!D6
M\\7M;S&)V&(W32-VR\2.M9H.)-@4G_8'UHCVN(&O@A>[GL_Q>N"?U( )/L!G
M@/@0DR :M',96I36J/F4HM,MTYXG=$""?+Z=3Q;P&_7*,F&3;3O_J*,.RR;Z
M(5YT)@&KR&_O_V?RP\1'T8&&-DE\IGE1ER\C]/"54EBT+XX5<""]@ M9A_JO
MZ T2P$(J;S&DX<//Z.JE/TE3YIOMK?@KW/[]'R=_,L*7S$_R;S"ZZ0Z5:-1\
M2D6B@6HNXBW9JI@Z=?NBT!L_L#$;AZM2..V0'T6+6?H6M*YCHC9M:,-$O54#
M!MYECFX$4M/2$8;C(BWP2K<'1X*+N9"@L$7K2N0M'_X(0?0R[Z)CQ@X][+H,
M8D%G #C^OA"3IYR1AKIOA'@MJ?49G9NI$8D,K<>&EH./ (4."P,<GS^MN+I&
M7N;\36'V52RKK%C6*PAFJ18S"U(O1L?D3!_AD-YIX0A,?T/''B@_==_?@N$/
MKZ0S "R.GI8+$*=UKL^UFX=?+NZT\\Y#1T6-:GQRH!N)?E;2CQ1'*%BK(7BC
M6,; 3/)]4952MGAN:WJ=][F'X[KG\L:88P8V-OID\)//N@<NY7ZKH6$_0_R?
M%C_;X:]F0XL\SNVM$9"A>[Q;IFX8H'8Q+Y-\/&V!_MCD#UY=WMTW)EIBS]$'
M>WN+&F'S03KW'_:T:]>A,C=<E-SY@ZZE)K^%Q(/EP< "0??5,-@(%U*/7SWB
M94VVC&U(.WQ[B_L.RF*I^91N0O .8\ZP$@H1C/,15YV<,]).H7!&]S!(RQVR
M."PF?3(X:,'Z:.2'O2;=X.TMV;<66)C4N8B6:#VL6LIXEQBR<;6D8\R9>8B1
M%Q[7TBA-&HCASF5KK]E$E^)_6GOMULF^E-\GG2)4FN/"I+LA)O1O;\E?4AB:
MF2@"(*\8Z6':!]WYAM_A*O_I>M\P7/UK"!+2/N6*8D^[QY!<@C;P25!D?/)@
M,=[D,'"=?=V#39,!.0I,\3>*I^FT2LV0(G8&A?? CPE)+@<Z_)#Z>(]$/8P)
M)R#0Q$2/7D*/R"R>6""3]C):=B6N-9_2'R DM-_$Y91"0KMIXONY1@<&]]UA
MQ$H]JT\ ?>)\-/.%<8_.$\J$M<<-S>']=N%K^7-_X#XY>"8%;J#;/HHJ?PW9
MVC[%L$7 &=M1>W!T#!FX#9K>[WNLKTN8MB1)Q,R@8@R&=,$W)89M:FAR3?$0
M#Y2'6)J'J%S$U00\-DDTUV,/9CFZ9YTOF/#0N?L3S.^'SL/%YXOK!^WNXF/G
M[OSJ^J-V>7/W!_RY^^GFYC?\=_1,N>U87W!_9ZV0W/T29UL'JX#[P^D4BNA>
M%=;A"9S"7=MUOZ&MD'#^Z "VG$=LFT3I"5C!BFZ 9_GBLC4$W>GA0%B-#5:"
MG?(>Q4MBJR)#14-<61(6:^)W8 C PX$K; PP91O"0,E0Z$7U.>C!8@%NP/I@
MH/3" ,MW7-Z&!UR$Z*/(EP&?W/4M'O@7WU$=3X@K.?+<OWCW1</U _X![]8#
M?]JZPR?O=O_B%\9$\3#JJM(@,[YX8?&BF_'X?W3U!@92-N-DB+?C$VDHEFUG
M/R.#?^+!O _YU7_V4T:M)B?26_B==_9AG'[VLV@ALE\@OR"L23#Q39?9%IO\
M 0.!&"8>CX@!.Q"KKB:H<3'+ +9S<DTP A'&5X.)#!VG[\*&1+\0#JI#9FCD
M9/E@NS)O2"$7<+3BJW6/S"?\SG)<V^V/17( S\RPJ,5L;YP*(G5EK@9G--I_
M>:W+'Y%2]LTA.YHDB_]-LM9("QI/(N T\0LDA(M!.7&E$X@&MZ%3L@(&O,@9
MQ!0'#GMIP]+;/+2%^V8%(#,@*^3<DX../QG@!D5.0Q>="@Y3"$ZE:?7H$B[8
MWNI)R)!D< !8"EZ&KJ9+),)FRT"5/ULTIN@DFOC(<LCOC_0+^1LYJ3,HA]W8
MXTU2J#_JELVW$I,Z1*1/.KW\[\GQ0!XP+ "_>D*GFGB8)]@DQJ8\H*%/"1VZ
M[SKT%B##XB J]'@\I<;$[V7&CVT-*:2"2^@@[]D,)(,O :F[:%72*3T85X%9
MQ?$2SA) ,?F&L&IF2,I-QXT:Z'@*/>+^_1U:'K&S2S%"CW<K<WL\\R"2-0SV
M1:OG,6 F9+_$!"CJD]S![:T4K_/[T:R$O*OHT-T_V#LZS)H6^4?O;G.OO1F=
MW\MM[UY.[_%JXS<EM>9N3_3F%JQ2+NFG1\>G50"%5T LZ$1.G(FGACOBZ1$]
MM(E0C\ Q VJ&(H4SK31*AP2MA@9;#QX&^TOD7@CU1IK9H6@/Z+C $)$JPX9G
M#33:D X_@%>@T04'-YY'_%3P1$<Q?EN!"8QCM+&^\21,.-TLU]3,T,.7\\@N
MCT'3D2AUOQB/DAN[C%X?JSJI>#'JC3<_G!K\-+DRL"Q]3Q_Z^=CJ*/PO+I-5
M%#U'C+>:H<6"UF QE8);=P7GXB47B7+7LA%@#"Q"MXN6)0GW$*UN_ ?HL=#F
MBD4?8=(9&(;B\G12%\H+3WE[XW)?6UXJ,?(C\4U"=U" NQ&K%)[IQE4:*!Q0
M3(;P9,DL%"/B@+KG@$Z+7@BZBMG\UEJ0"2.87M@7CHZGC\9*-[T.W51;;:34
M3X[ZX9$E4 G2P&A(Y=# Z%*(#C[&J5 ]&-B^W,- %HQ4H(*4E"LI5U)>$V(C
M+RKV?[@O$=D4B%N*YSA:"4J@E4 K@:XUL9% XX=T)O<]]RD8Q'%2&5084MM+
M)=A*L)5@KP&Q>>$ 3\<ZS$0-LJ&/P FWHYA@XEEY]4@%U1K=->)G!O,<)>=*
MSI6<UX382,Z3OK3.KR/XD4VYLQ0!E,XWR;(^XM*.=Q#XM<P[4=*MI%M)=TV(
MC:2;9S?I/%Z>3AB;$>_'O![;9CQW)@(,@3\"CD&GY%W)NY+WFA";9[7K 9S,
M1B#2 TBF_P99MGJ8C<:&(]L=RQ9KW]@8<P1\UW&8K01;";82[)H0FR?8Z&*3
M9%,-<C"P/'-WI./I[(>(-"9[8R=NS<0G'.LK,91(>P7?GH%N@ -?F?%*^I7T
MUX78V(P7E0%)&SY=M]$@4]_QQ8GN,":Z5B;"=J+\P^E318 2="7H2M#K06Q\
M$3Z1;)P!#Q$0$PWM(D2?7"?H"0S:I3'^)&H+M6TB1!(O!8JY&G1]!6FPY)3^
M=,/M+5'?$@$J$^J>: 006('-HN*N.\O_IEWR2BA9X$5G "*V&J$O80*?43:U
MO879FE3XE"R%$O5/+ORFJ.J)X'6FU#QU>*T0OB6N/A-T-3!7U- = ;4;(IK0
MV TC<-YIQ5+Y15&4W$YYH:*N2S>,$"/8"MZCYE.Z##U,X!V"4FML;UF]&8R5
MVF0P?,0V-T1>,O^W,9;E9I*G][0K1[.Q^%0F,/@P2<+)!'%)%2+"* 1*.;6F
MKZ$AOR9*U+@!)]@\#;:%8C!* +*)!&=LK#M&20HIY3D&.^8A&Q*&[:TGQGE;
ME"[2ZB1J=/$\X"F6%.@%7W'$#!X+ M,29N#I0T:%;R!9(-J$_TSPU8'^#6%Y
M8#!8%DX7>HXA_-, #1".J&00A^P5U[UAX2 CHO6TN#NP_XGBN:@<F;H*TGPC
M""0T<1%E"X?P&);K<05CZT]*>&L^I?1!AA6:DXT-9.F3Z1IAH@9?5F[V+)OC
MM#/1U8B?A1/#R%I1+-1$I%D>)!',C%7\)O$FC9TXYR)WBI=$9=1"LNJ7'WI/
M@C9^PT+BPL.K8ZH7=6?J)UD0O+T%9RYY:%ZR</HUL/04U)]#A?I3%NK/HP+]
MJ<9KVP14F-)/FQHCW/#W6.;/.__^VFRVH@W$?JO;6U>; O3SDF@^)<\BO6/M
M:,>N'BX^;V^UWFE7YQ?7#U</?VHWE]KYU=W%V<,-XL/>7UQ?W=QIGSO7G8\<
MZ0D1C#OGOU_=7]R5B^A4W]-UK:=T[8)/TXD:YVS4W%Y@NRJ5R_V,7+;?@3A>
M7MP1B-K5_</5V3W)W\6_;D% +\ZUAZO/%P^=#Y\NE"36?THDB7$+J]?@EZRO
M*!YD1''_G?;;Q9_:U?7ES=WG3NDM'^NPA1MC['3VMK?NF<VA]V(D_',]T"N<
MVN'>R9SX4"N"AUIK9GS NKB>:]ON$T'^4-S!#X= (3S%&S 4-%Z ?^L9(#8_
MU7R!H_@D$<D)+RY_N$3PE8\\NX4#_6\K:N&0P$XWX<T(I$&!KRE32,9[]01"
M/IP?_+H&VPA*<+D,&":'!DG@M4]K&E'0!*)S_T%T81,]+E*_W=Z*8H&^[ HA
M5_N6PMG:&6]_FFP@<8-=J^@^@/I':&]2][ _J..PYE/B31Q"QY"U:[(WGL4[
M&XP0)S["_M_3?G&?V",V9D"!B5G;B_J1C$)OY/KXRJ+&(8GF)S$;A[X(.R,0
MY@0UC03GR^X.Q+^9-@Y[V@V&K'V?"3A(VTJ4XW@L^6,I<[+3@<<U"GVZO=75
M;1(H?\ 8J0C&)Q2G$4V,!A1Z&*C+C)C63XF^&%0>-(!Q!JZ-L7?9'Q3O;@+<
M %B.^ 4<JM)UDNBWZ3>!OHL;7Z1P_67GB"20O\DX3"GNF<,"CB+)M#>VZ_L_
M4&]8_)7\!8%HRH2)Z+5![ONH9"+"1(7I8:,\V#T<&?0/?>HZ BBN> &4ZJCY
ME"XY.VQO13J#^$'G6%3(8^(+%+[,]5"!G&>EB@2\Z%E2&2D9YKU7Z&1%8+Z)
M9B41D%],)L&1IKE:DFI0/B'>=U$^H20;=$M@,PET2/BLJ7F#6"> ;U,B$@@E
ML(L'?49-($HT2$6 UUP%"@SVT06)%2L3YR_%JZS3%1V>Z/3(]I9HP<1/?1/%
MG0H241R%)I/Y4[$]A'=S$3BV!!3*R+$2SII/J<,[ .69L,DV9!SF,LZJ>)PX
MOJ@Q4J()TL_8 VF_M7]R>M28_/RDV3HZ%H#:\JOM+?JNO7]Z=-QN)'IIVZ]"
MQT^YQ3WZ4;L9D9B]P]?<BZRUUWFUN[__CW2.\.03!\^X^^UXH$"-R7O?UHQK
MWSSZTF^G#O63:<WEW!6OP;Y-[D0&97JNE2G_GGN3KHO7]LY^ONXV&Z'VR85.
M>&4R1VJ^?GWRZ2C%N"N3IF1KE%1K""V.GODR&)H,-R4[,E)@2V252>A_M,I=
MYR]A3O-XT6)M3R,G<E;0BG>BX'/DYCRLA@C:7<%HVF%#9F;?<'M30&HDVYQ2
MEP'\\%9V69&9VUT&Z[#17=_61VMTWY^E>/ ^Z4S<I)V)LY0S\0F<"8KAORLI
MB)]W*LVQPZOLZS#'B3[_?&>?_:>'DQT?LJ<]7XE$'56!)49S?6)H^>"/;# [
MQ6RBQ22;M*"0#&C#1?EYIS5AO$PQ;'->FB>.?U+H_B(=NL].()?:G%?DE:O5
M:@7;Y2\@NHCEK->Z3+?UNJ;;K+\T+* XYISW&S*BW-#7L8NQJ)&@L#.O^F">
M^!>:2S\L1N#\2P&*&C:N3VUW45F['CB0_>Z;=O.@T=X_:;0/#W_(*6.==,!B
M4TE>1;R3-$\MWIT<*7]'9GBX\P^HJ"D:<"FF^6, =GH.IXC#_K#]CSRW_4Z@
MQF<[TA3$.MK_*)##3#9^[KO^IV#05I8TL81O6HW]YH0FGOJ*"3%]&;J/#]:0
MZL/6R7.H7KVF^UAX=U&U4+\Y:)RVCF8+]0^5$[+?:)U.V&0O04BKT6P=STU(
M)1IN\FT/V%!>7E8E3L3*5^.HT5Y@-2KEC_VC6C!JJW&X?[@:_GB6,J$X T_0
MBL(1BDTVF4WF5R,WO%FN2( 12J3RM=BMBPG[IE6+$^9D?@9=O?IXT+]K!K:9
M#JI>A^-YUF$UC-&>0U)70\GQ@FNR(L5QS0+*AB$P4:L;!K)GM(L89%2PGDAO
MJUR"#AL'^Q-^U L=-X?[=2 $CIN#"1^M1FKEIB!-4H5TUHR:%2F<RW3*W[@@
M [?ZLWJ_#F;M_D%MCLJ3.=;C9>/&W%>>5#6K<(*.)B).+W,J-9MU8%LXE0X.
M7RB64F,5JJBID[KXH/N6P6\++#NDY!UI[.*-6=K K5QBFGN3%P0O(;DUHF/B
M+G>V HF 3-<V3VICBIG3Z5(?1+'9/16;J6PHE0VELJ'JD"^CLJ$V>;H;G@VU
MYIE/T_-9SG2?Y[(8^ <6##_J-J:G9V?Q$BD6[<;Q@ODL^>SP$K0?-4Y.3M>4
M]O;DU>+<E*\H@/>'ZWT3?4*Q17#5CD*[<7HPQ^7>:AS?PT;[9 ZO9567GK6^
M&.#1.EX'7O52'.2EW[W835^C>5H;8@Y/)U1A+;0(YXYBZ(RW;TS6LPPKJ#P2
M@0IFP=!WE0IFO[7@AE6J8%2(9J/*^_]@VULH5P[3GM+'.&)M\2NY0&)WV,R/
M/TN >*B"Q9I$X#[L;6^=\>T3G=UY82IP3S=@IL/P:JPR#FXW]]ISXPJN%=H)
MS,MRYL1+7!<H5B5JRP6[0=3NF.YC!;!$0[NA5EDH<5]\JH6_]5P#NS(JH5-"
M]ZKV;@8TQA3XH&.%%%00[RD5*:BMD((V%"EH+DF4M&T0(D[)Y_LYGN^)WIH5
M'N&MH[W6"YT"/UD1*UB5.;9[1>=XR3,AS*(N(FBBGSH _S79Q]&#S?3WM#_C
MUHP("V29F*NL>ZP78L,W O;!!S63^89G=1&D%C%Y&J 1^KR;880H[8H2FZB3
M(8Z(G2(%M&P>Y#4'&D(WNPA)6,L%&-K3KGJ\#61/-$&5B$F<7!=[6W(T7[D"
MC20R.%#&>X(W(G"F24A,T0^O[[E/,,61!"?"9L(<;2G1&H\7L")0-G7= \O7
M$/#DDTW^;-^52^,C5'IA?SS"B[*<1]=^E/N [TFUX.1PR'(2G+2)EGW))K6P
M^99AC?08>\IGTZAH9/M5BI='C7/C/2QD%R*;V3Y[&C"/:;G,P$%5J6<G,=+]
MQ1DV/(1Q88[WC$D<J;.X56 ,0707]82_%!/Y)"82/1.!2NE=]Q%MV#67\/7W
M&?$\\=%MM'EI;^ 2+W\0 KO6^5_KOSMP@F TE$#970=4B<?0@H$_#'<XM +4
M'U@&!3N&'6RC@P9%'3\$?6F&1H"]JTU+M'+P(BABIGLV]?KL<USD!%X%C6!%
M0'F^.\26UY3JA T);&PYRC&/ SP5'ID3,CA)>K)M+Y=LQ3M+Q=7+#B&0,3+)
M$@WMYK?=5I.WW( _VTV$+@8V ;]UH,%Q.A:<(M@FR2;$//QD>63\:QOA#R?>
M(E_2P(8',%W;%O8(]2;8->",(5!'&A"/;,\-^QPRT3<L>!7:3-R+ M]*C[JR
MYXL&==[%HQ7L"]W.O@$.2@1<1IM)@"136_F)58C$B-\JC%'4(J:7,XR8GS=;
M@-DA%F6$+(G2B780!>1\;.D )) @D;CP'@_4,=MD(X:G[X#ICPAAZ0J\\-!
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M*(-'?L P$!YCAHRHS0H%KFR\=N'Q7^E*$(B2K@6P?L(&2-9E=77?BMXUQ?O
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MC.=(QV+7'PR[),3_W#9%EZT5^JM0*_BR8A_C%2(F:T/.,3-H[5)FO]5]D/(
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M8>1KS!P#PY3^F0/S.%\ 89>;#:JBEZSP]HY*DN^B=2ZGD%0#EP+?AROP_<S
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MV>_;T"_;?]G^R_9_W]M?RL!J #+(^A&^*:_@+KMSV9W+[GS/67KZCYCAJP*
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M2<AX><\IB7^A%-N(B)IRM@7T+F'V?P1KJJ<+LMB)P Z9D[^^ZKJJ6+4E=Q-
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M\EZMHAN.)':/=KE]"MPF?JXD73T Z#K65WR@$QGEV Y@%\&0H85.N1L0'B*
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M487K(#D=[G;J;KE;J1ZD(>6:ZPN5'$,88,,:7)*%N!D;-GZ)9#*[@>838I7
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M)2A1$_)5,LY_YP7-]!ZGG)M/TY],VBA:8R[1D[(XJVD21W(T6V158N9F)D?
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M.<^GM5?Y:*8O],YVQV-]ZKFH5GU2"88%$D-N:72*U"<:YG_L/4MU@Z5SGG.
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MH#T= $ROJNZ6A0WXWQQ!8/2F>!&36I+!B@]$@=$(V8GXR1591+08[TI.F'5
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M03N@DBR2IB"Y1M((LFUZ%]F$>R:^J/^'59M'A>+(^K?ZR&#2X-L>01B(0=W
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M?-KE-,2Z>U098R?")!5YC:89Z[:J*I:P%%=2T*C"6J@$R5/?!17@N.1@QZL
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M6,W51(B:G9Q-O2^M\$X_>XW>(\R9REN4X_ZJZ^O_M<MGHE7E^9GN5V[UNJ2
M':T/\T\P::^!9\_^OO4A5C1.87&8S@\ X0!4L]//WU60]T!#H_5R2Q\K )NU
M[KMMC88ZQL4?)CCJEX):7CWYRMZX'Z(N(9DE>1LS?8]U'X6N%<%8*G <(-AH
MP"[.SWXD:RD4R6[EZ3NI5F;(6%2\J\A$R4/*11,QX\#+*%,,DE5?,E[>UK;
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M,26@.7CA+)>J)+*755G,9VV. ?JVCE-O@&<-:0HEZN"TX90LHBD LH54CJQ
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M)JSOD8UB:GC!#"^9+AAR]^+G9PF@X<7<1PL0K1]QM;@,C.68Y*WG1_50W&@
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MA%1H!C>W<+.,8T->3@0=(MM?.+1FI'DR;C:%E]Q>.$2')?:4YPB.3C!AP0T
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M\ZHJJT-)):6 /"!%*:E1R*-2FN_N()U/-[RPHW Z7]L)*\<=J0VNG],[WU^
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MI[)VB-:7%TWB%2?_==*%JHK7CZ/)*LCZW'0@.06D/[A.VH$J@+#B3@]\77J
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M;5VK,:Q*,"'H"$7GI+">@@Q(PKRRB8RX]HV^*X:?^7K-VJ+X*1G0M>HNC(G
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MW:[&.]W\-Y_"VRV1.QS.SWN(I3"'_O!D;7ONO%:;Q:!;BW!RX)_>V6+=R26
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M?28N:MFN9PB W@4'>T16?9B6XUBUQ3?Y+!#>?4S@07I-')_ZP[,N^25.@)T
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M^=E.@A]3@@\/C_S1L-TD;%TTKIP4/ZH>'@W\DT&[7007<-JU,[Y#*^=(UYT
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M;Q)),1M$;Y(6L,S]WC2X@K41D&&9Z_6N@P]O67T1,2-..2@UE9 @JM LQ]A
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M'_-8H240:LE'1^X?J<R^ SE*F"!RP"I@W^O8JLBUM^)S\V"8NQ5")1V,@59
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MW?)XZO'4XVE;X>KQM&-XVFW)?T_&U)\KG;IX!U93<]3J=UYI:VGXWBVCA;/
MUA2@+>6$=\K^GGX_]VL]"#WRM13YOE]';#T$/>YYW/.XUS7(>:'[,';&2H,V
M=VQR+)KU_A@(UIL=G@-^/P?<ZQH'],BW-LBW_](CGT<^;W=XW&L;Y.X8]U[L
M=@WY?'R#05/TBB#EF-L(/ 8J]<:&9WO?'^(]Z!K;\\BW-LBW[Y'/(Y\W-CSN
MM0YR=XQ[!SM=0[["V+!M;=:_B#JM%$TWBZJ_.0MNM97263)=M6%6;'7U_<H;
MM9SM-2BIC0%5.4YP5$&*TS:4[96-0R BR5VPLX3G\X98$&_L%(V/"?6'.P/3
M+,(V<T.9PH_SJ6TWI[X$8QE?*$'#1;&#.-[I2)<]$-ZJ$%NBTXPDX\PPZDY.
M([.NQ+\3\YE:'N#DD&22BFENIHF=9T'#%FJ=#[#Y:JJ*G?/P"(,=V8V*9D7O
MA"")+U7,LTYMEW;#$SNP^T(Z3O+(FMAQD@$PJ)]?9G+NU6?4%*<IQ9E]03:V
MPZ6:X' @E4&6RX@Z]]@G19K#MBL +7Z+1\77V[<B%2B[E_E+L.\E\ +O '*I
M-0I?N>/D#FBP$V+[7O;ZJ*ZJ43[=WHU^<B2;\AYI&K/41ES**"?N@1U88VK2
M APJ ,[%%>3BPN XS%"$Y?!BZME2#+MW7$O@;"+^ =7U;M$@.=CE) E5Q-PO
MF4QS&M!#[]@B1LL;"JHMAW ,:9PJRQQQQ5#R5!K:S1+64*@YZZCD=*F+U =I
ML%D0"L(W.@VB),7A>=0Z5HE:;RFZL4ZW>'ZXIGTK/86N%&H71=JZTP=RUW+/
MI[C[&4)P111&< HM=MN:3A/X-W6KEA=&<=]JFE?@[M75WF-38]>Q^AEQ[ETD
M35)<W9B]Q3V]4"W%^2]N?=J&SI#%8S=HMSXL9GN$T1@:VT$Z +55$0O'>]E_
MM;NW,\"FU%/05E&>;(O3V/7I?V&W=06Z=_.@]<-EJ/977PYZ=9KC=%GX^=58
M@WBJ?DLMKKD-"H_&,$DZQ:;/:"LD<4[BYF_/7CP?[#W?+]3L<DQ=V:RL+OMV
M>'ZQ%*/<T("W<K&#@Z>#IW#.VR^VBP.%A9+P20#RD9[$V]$X)F'JNG 7-T$R
M-P$]&R2H:DZ\< R7&H;#Q<-UA)HY+VK[5=C08B%__E'&*LLD_+_)8NR\61UP
M^#&2\95.W<!"]Y7ZHDR 'TON&D>=O7>?/A^\?/9RL/_R&0#?H/ F=;_X,9P'
MCS6T/=7_MK/MAA+A/W=?O!0;0^7F<ML#%0O1S#TPP6K'B'G(KG0#D$.+IEJE
MF]OUG](@H\JQZ;D@( -IF&<BC['745TUX7[Q\_2#LU">VC^Y]QU YV)<J$G]
MGM.3Z'KQ'&D^(139VV52&.+1J+4>+I",1JE":I8:C#9K[Z59H1$5((2_ YXI
MU020GT?;=EV/1U_T>PM:)-:Z+G9:%J_AO9&[J=86TW8M7CP5+<5Q!J$"43;1
M,;N-\,<\F)H&8URAJ32PGJ<D)NF$PZR)NGD. O!*')Z*[!))G>1,.01IO;#C
MAAD$+_T,@GN90?#4SR#XSHOS,PC6Q:E1]5N0;NL;7G?R2(L;7G/LI"[/R02S
M*O5U+:QO-NE\+VO?R_K^,T-]+^L'.I'O9=V6TV$O:WL>;GO,S:PQ/&T_( \/
MV%/V3VQG+6HMDOTE/O3I7J,S=?$MUB_1WV%K[W!Y/W+AN\>W[K;L&* *Q:U7
MX^M[Z,K\*XV?Q8W^+H-D^'CZ,=X#;.^FWJE#,.Y6S\L7=]WS<G\%N=F=A*S'
MU(YAZO/OKY[J)& ]HG8,40]VGWM,]9C: 4Q]N8+>2RUH>.UKM'R-UIK7:-U?
M#0)GQ)ID:C #D-:7%-5;4(K >ZG4(W2H%*'CH5Y?=M#!LH,'R6]7DVF4S!:E
MM[\QVP)];>)LFSUM TJM.QIK54W1.!V-=* ,)4&_48&:#)41>Y7L;2$G'+A'
M9*FDN%>RY7=?<G[OMOA8R3*O_7Y ^Z%]B#$F]N$@;'@Z$JF,< W,]]T_X'Q?
M>BM'*XI\\7R*:Q[L_(A_4#XR/=[OV>?+!$%>=JH,<#, :Z#$12*C=%N<P)<A
M9WE7MX.Y[XZ/.KX*KYKFP#\QS?PI;8HVEAB0R/BV="R!8U,YJGNFW[O2400B
M,\U$ H)3/"563#F)3X7Z"S>%=:O!^+Z3$AN(N;>'[O6.<\@[)S; CWZ/$021
M#3/B;5%'Z) [!<H0(Q2\F#$3JY'.J&SY"K/WDTL=$H]%HN.<U"+]U5979[ #
M6@O_'W$>7J3@E!HUPK)8!(B>B%PI1KM2&4"<'I68_-__]6)O]_FKM,H47#&(
M38B=X3LXVY;JOO%K'&D?R#Q5 XS^:J NS/A) =J<R7.1)"&63Z= -B! 2KI!
M="? #%4--J[()55 !D2 %OL3++, U<+J'):0D7(=%Y"4<!2[S-YH1A4?HY$*
M,MK+[AYH*G$V!FH;)5&47*%2@XLXW<.=31,G"'F3N#\'5UQ%XOUL&8( ,QC\
MZ8A2R_5D"#R,^2A^,E%8=AW!SO$P%WBU:J+S"<&FWWMF]R-NW,[V@HLJ(53B
MCU%E,0IQM '6CL<7R%8(C;(QO 4P%]]C4<HFWB&JI1F<!;.G4S65-F6KE S,
M62]43%7Y1D5*VD*)2.H)YT_#(B-YF1A?)-$RO>8TS^AV23<__BO7V4P<8JR8
M*H?>@F8'=_IOD#E;QW'HE;A6.@$HR;+D%6S]6VF!Y$<Z"Q&M41<2U0U;X57>
M/7)3O'K)5X],"FFV**D8E((&:Z50NX//D/)K-1AE/1Q^NZ#9QD]K!?AK4<IG
M:'Y/FL6JO8'KD)_9_5274VOK5#.3SLCLL9DO?P"IFF@&U&$_<*E,_NH>^'3'
MM@*V>G4?L9Y8?%0N,[!^O7RS8H-+T#N?:-;-:_L5G1 V<P?L!W\)#T,[4VU+
MBRO4,W<?'<[QVV^.VEVU_'ZT&7[="D#O-BMB5S_\I_"<=C@0[3&V-?"\>XS=
MV=[QB6AMQ=6].\^?WGGV9&?W"8:R/%A7"=8#!NO^;N=UJ-83=&O1K?60N^OA
M)/LK4X9:#TJ/A"U%0M!OGOJAB.W O]7+V?W=)SLO5J&^/%;X[3#\'D9/6>UL
M.D^7:P6Y.Y8+=[#'5H+1(Z!'0(^ ;8@3>=A]!^R\YZ21&:^CR(:<SO3DAOY2
M:X)HK61O=RPE]KP+Q>-@"UPH?M1K._#O;B) SY_L[>R^\/#['OCMO? NE,=+
MEZV$G+=@/0*VZ'(] JXS GH72LMAYUTH=1#]GHQC.YX9*U)E$.CD,2!;*UG<
M7>?E'G@GBL? AW6B[!YX)TH[\&_UXG;/YE'L?2^+>>3PV]_Q*HLGT;9"[J[;
M5_I(C\? !U92?+)L6_#/)\NV#GX/FBSKE936H5@K(7?713U>2?$8^-!*RO>F
M*G0 B)U O[O14:@>^7L[^3]R^.WO/82.XK-1VH%7K82<3P;P"-BBR_4(N,X(
MZ+-16@X[[S6I@^BU,K$TH6V^I^)DIKYWBFDGD*V5+.ZN?2B^J,?CH/>B>/3S
M7I1VPV^9%^7>)C2N\E /-V)BQ:<XML.!^CWNX<U=V,7'"%Y!TW\^)/&6^Y$X
MRX=;]!7.@_CCK/B[TU!8Q_E3-"AD(G4L1DIFN5'%F,4_8AKA>*E",7_C^'>:
M3^ @L%8HABI*KNYWD$_'+W:EU*E_.::Y4SK2V>SG)]J36)M([#"*^KUR5DYE
M'(X;FT-<TDU?*PCPR(Y2HV%:,8TNQ,E=:3Y,=:B!\A2/\:K.<IM*M-'U%.>"
M 4W7Z7@!Z^;1@I_4),=17?0QO':BLPS'P*D(=DJCTF"Q4%_J,)<132V\&B<3
M.R;.S3*4/.MSJ(HIAW/3YSR'>#@.8:<^X/@V-S_%\XE6\8E3-^!S(F=5,I(9
MT'PP9DI*#/U_:D<8+B/=#?P=?/TZD2;$25U!E/.0+YS-2,-=4US[C65& Y''
MF8Z$K"W8[Y4K:AH!-I%1-!/P+*CB.AVK<%.$BJ</WO>XT8ZCTZH5 #N+I]^;
MT@0>$AHAO@L',A+/]G3?3KK_<ZPCN#<D5S<MR4[ (IDJ0Z) '@=K)%%QPJ+]
M/>KM[Z7YK#*G-+Q+XA"^/:/Q[<=?@K&,+]2 OE(6101CR%29QOL *+-^+TXR
MY#Z12I'#2'Z3M%-)[5LF.@PC_#V]^J\\R20K 33V-&ZN.[+<:$3ZCP+XPAE"
M.4N%GN#@4]!6@*O MA)CA][V>_4I[X* ));!"/=\1W"R\Y:'_'(Y28!1BG2J
M CW2:/G,KF'#-#=WZ9[5%<Z=3=/<#KUNW ]* 3C7 /4XX-J@0E[2@.NYNXD3
MG/T:B4L9Y02RN0N@F=3T"ER"?S*#WQO-&[::(NMS@9SJ#)9K:*'5'5:8S!-[
MM7%.$[WAH>99<2*PT2D-$Q=*@B!C1B2LF&,NA7+N6HE6$3/B0U+A;86\G,A0
M@6*JX0UT94:%>: 6@9;,U=O";KUX)1S@_VQMB;=:1>%/XB/0]"M8X*]<Q0$\
M^'Q';&TY#R$H_&X?-P_7XB,6OWA&8NFKYEW>;HKE(NE7!C.;(<HLF2[TEY?.
M3S>L:O_'$F!UKZW[17,H3.$ K<#30?*5.)]-88.'1@YU\$K@J$F&-J N0/C9
M0?6I)^XQ_&K9Z_<7SZ2I[AD]I<Y+^O,3N+Y%-VF4_+PU5,"284=3NG][=P"L
M#EW<_%4TIIW>"C+56\#K8?3O/)5W9_N@NGY"3 :S!U56-$N 17M%M8V*ZB&.
M?V?9[6S3'(>SWNPN!N,15310R^)T!+(=Z) ]3W:Y ,E_! P =#Z2W:Q@S4"<
M*]9-[ _I2V(N T88LHQ)5[3Z$NE'\+<I%:0,X#$&R1Z#^FE2E.S6E=;0,4$-
M5 !=JPT%V@3Y!*=A!P EHV#?AK5+4A]PU+7=E541DS@B/<0J&\1"8<NH$8\R
M"R5Z(^LH&M4= YK-3$ET =9_4^S*4T"+*.!DQ'9:X68%;3I0,E6I=7U:)VYA
M%SCM&?X$P9LB.@#JQ?_)S6P@0D02\MF#DA]%6V.PC !1 6%0=8U#P#PX$OPY
M5(',4U9EAWF*2C#P2_@B*)1SF=EWDQ(](>RRU(98F^2%Y9-'F9X0BEV!FIV.
M];2AZI,5I$U#37<J=$C1/J"15'\1$P#0&%DW(2_1(A!+RKH[6@9V"V[T?,@[
MA>=3$6G0[-WJH]S 2PV\!8@UO,FN<B3*Y@PMR1:24_/M@9QK^BK)(W@UJ$P7
MRI#M8W"XO5%H/XA\:LW$<1(1-TM@5Y_!,!$7"M^-IM"(/R<+B7^66M[W*0<R
M?^G>> X/ @\TZ#D+%]A=1-]*XBV#K5'%([8]P2@'))%HO$Q!%L)3$H,&Z=S/
M"7#%>6L75MX/F$9T00N8"VV">3#!/&.O/C*F@J_-7SW#/6TR1V<A%S9:R @/
M4$.U%F@F(:@7^PW ^M8V; !,G#R;<,H,;79"E92^2]%>SPN.O$!8Y+&UA:^Q
M&P- /  @XM<5&:_X2D! 1-.4C'B'0>)*HHA ^! N5[82)HIE&&P=]IGE&2*(
M45?2A.3?&$D=Y6MG+G:<7Y^";*XPI)'ED43V[*J:,6(X[HQ^<](YZL26*D-$
M:,18IH#I\ /ZB)GA !$#_0I(X$0 Q?L(C<J7;@Y8?LQI,[= 9$<\*:LN.@V,
MHI\@<47.H;&8!?)AD;OH),3=(J\,E"(GV3/+QFV\KL(DYADZ'Y3X&G]9XP-(
M6  ]4]D&T-D408*>.>=>J[$;),=K1,VUC$6LDJ\@IGP78Q$KXBL $<]8VK-]
ML%"/$C--  &4=<)ZT[1UC)XUO0&I&A4N0X&!")A[.*O:90/'64"!KAML"P,2
M4G!\ !D&T&EFDJ9[?%!322G,+D5FE<%K?^N8A$L&L9M*!7RGLPAU=_@,JRMH
M)P'IK7-.=OC-W*(L:H($5&O@27%@^2([Y),)"0F0"L;@T0J1B,\81=S(Y(&3
M8U5;!M\%$DA.9'0!_U/HG!5I:NT2E!/]'LM #EY(M.UK:2-S/)]%%5D'\)<5
M62192FDY?\G%\]O"X4+]5QS8^CI<F+NF*AA0LIEDFJ3.*2 NDR@'A=T !J/)
M 5O.IQR(;9ZZB%G,655S)V>4BU50PAEW<84).2#5\NF ) 3^F]5W^'96@=4U
MLKK?^UIA?9UM\.VR&E#D+A3];Y''_9Y7]%N^?9#''Y6A7!2R+4L\\E*Y95*9
MDHNK%LE"UI_FP_\ >W/LFLE5!C43:EK>>(5Q@"2E4/8 8\=NM2(TS^[A84K!
MM0P'=V'$F[_ L#4Q@9LB^!Z?'HS*3](T9Q*?SRJX=U*_<UI96_IOJJHVXZ7P
MNB[G#U\99.*D#QE_1M>-AO^!%Q4*$Z4RHM[VW__U8F_W^:MB'W.:=%QS@;C=
M#8 O72KD,T9=@"J0LAN90I>@0X/V  K8G+Y#FC3H#;0:F1.%@5+SL;BWK!F[
MN2'99-<GF]Q+LLDSGVSBDTVZ*J16;3J I.CWR,;VYD++U(5: 81-Y?C:1!,K
M4.DQ&_<%J9Y'A6\A2S"YM4Q717U@;^?5&S#JJ3R+U0#Z=/=5-4RR>_!CPQ/6
M5"7J^;/SU4_7OTM,E$23)J%T7](/*OZRE+3@JO^)'3(;<E.,43.AH!1O9% -
MO5>C_QCDHLR#VZI> ^M8K-ID[-PL7'WRBK0A3+X=V%O"+WDY'2.WQ*.FP5@!
M*#;@$UN)<M-=;I9IR8G)2B\J)9%3S@S<3NS2O#?(V>,6WV17#^E8% CBT#KZ
MTU+<DS@,)P K>-4K^GYCN EH0F6P<'V<N3-B:-: .0]).C'&L&9<F,>QIL5Z
M;#TG9,UTO>YL'Z3 891AYQ_$3'(^9A$[P &1'$UXZ= RZ7 2IYF2(;&?4$7H
MP'5L9'GQ0>D-T@V6QY'LP74>911#-A,HD.D8%%C.'$";LA;'YXR@0AR@YYBP
MR;B-SNT+=' 0$=84+(H/%I6*4 "I\.R[-^JT]+P/0)]QOG&C(G6)HJ]>\4!,
M#(_C]D-1H&$E48&*6X;P,I%=)9XU/3!KHFOQ'*AE'(C<6=?P"AEEM]%1%:<9
MDX:R(3'-B'7%B8XQ] DL)BQJ-H<J5B/-@4<L<(M!P7"UN99JYUY @<\@,8:<
MZK-I OK'=(P&+W(!UMI +Z0.!,B!B,,% 16V4=RZ#'9'ZD*G49']@T6DPPRU
M)&(G.L9_]WLC>9E03C>L]86*C7F!(E2.Z547.:R3 %]#W2DKPLV5+"N*8E<4
MI$W@T0Q3Z?*<& S(X&PQ8O5QRHBU/[KV CCS-%1I8/00XP'$]P+XIJ@B PZ/
MJA[IC90%P,MQ6=Q9-0L4@.'21"=*H?;GN6>;B/9# MJYHRDB4S*7I, <:*.I
MGAU0"JX2E(/1"&D&\&2) D^>+%L(ZI:LXDHA?A<J!A2K1,W 8\C#R=?S,D&3
M,X&));!QZ"5NRXCW)HGKLFTIDRG-0=NWQGXR=0_<JIL59X6@DV; ":P4G0+Q
MX^H2B!^XZJ<4_^1DEX(S</(*?NKRB='TL,US*OF>M]D.KV[]$9J2=VW.+270
M4"85IC,M#J<7;4.6%!V5_I/F3VY3QB5#>)T*UXR#W1"HVO.!JGL)5#WW@2H?
MJ.JJ,%QQO\VC[7Z/NC>)CP8=[P$FO=QS\\PY^;YB\;XVS5$K!0*_HL,NID2U
M];VX-NB:J^["A'4WV&[)1>E0%L &T/Z_I':*& TR Q>MDZD(U<BE.9,CYOAH
M6QRFE/6#$4?NW!-@ A"A W?)E6DH_Q*1#115ZE!A;U>V!9/!Z@,R'R>4P!]G
M9B8N2L2J/D7Q*\R41F51?5$3JPUFI,92/ X0<^SJX3$S/YI1MGAE.X'#W\I;
M^CU,%0\QNN?:+UW5<]Q'"96=39(TNVXA8?)(%:<3P3A); H_>9ZJ[AR*[]&J
MN$.;"4\II/98/ZT5SBTFHU+-J*H53;7CJX]=4P-6-@0$5)*53?<HH&ZW>M?P
M7ETS]/F=KSX]].6SYR_O<.^KW.RQHU?>(GFW1URC\E<N,9@?8:8D<(J,$B[?
M)F8"CV[]DUS&P,BHLB66>4B5,,!E@8]H&1&O8_NZ&MBCS'#GHPYR8] MUUB>
M=_)BZQ]EXFD2\&^Y<+=<, 6P4-D)AM&HW&^["O:B(3V2:CLIJ$LTX_?:0"R/
M5&W;:\<Y[YFM'=Q]QIJ851^1Q^HXU13% FULA!K>-!]&.BB9Y\BV%DFI3V;9
M,8:2JFR3331R+G6F;0. 2-NF-NBWY&T4K[D:)^@,Q8@FI\?!$HIB:)+3O%R6
M%K[8>F.+?HZVAPQWOPQE)CFG0[N4?%9P:RU:8)D_ML^V>1=<E(K;Y#I ,U=Z
MY/J BL,@\SR_&QC?[;UZGM_2O7:<YR,WLR9YM=55R?FQ?TR4I+E1KATPUT07
M$:H@">DKUV^,RB[S(.-9%<!V ^[V7(RS8.7<3K3PW+,;N-/MO7KNV=*]K@'W
MK+)-TA>3'/NPH)YI$XA0GU2Q[8T5%'D)]&/-?<^I.0A60+!'%UL_A@J3%'#5
MDG-R]Q1Q97 %NQ'01*GJ08:A ?;K4IV+]Q39QM/<X'N$;9\[34#9)@5<*\^&
M.X*$W=ZK9\,MW>NZL>&$6>\B)DIU$BEF?U!W4_<ISW>@T-%B7EA.%5W'4%*G
MCX0161MB1$SXY]$A&R4+8XQ3%VNGM'6M<D2#:X.2M1AJ:L../L#H XPM%@\^
MP%BR!MQ;F%"=N.42EMRI(_?!L[V=C6#3NH8Y\IB8?-*@^^DT F2SPS-M_49:
ME$-;-_*V.,.:\@4+\"[<!"K[C2M6/XXO<$:>B.05)^\V4D%LV0C6'P18$41I
MQ-;9XMC9@,R.0R0)]-S#Q@[3- GLW*:J6]QNI2QL77C@PO-=>?GM8. MB4Y0
M1K?WZBV)ENYUS63#SL'&<'-C;]/%%RV/M/QQL9.&2Q@Q<P5YI.!L.SO3.54I
MEW=P0U6:!%-9Q6ZH])0;5%AIO,.V.,W-DC?6L^6N>2MWIM6FTA7>6SL=.])A
MA&6$%^-^S^9)NB10E]M92P:]W@;B7$O8MTWWK.9Z%G[##XEMKFNKI#XD,?U:
M<_)GU?#>:&A6!YM%5Y5_)93'RC.\Q#4//=W9W!9ON9RJW!^[4D$WPE2OIA/5
M->X%-6N.?(/-C?V"?*V/%!,0&NLT':+<CCD'4!O,4&"?:97VJ;:SL0A6;>J4
MNWI/%+::X$P&HDA\H"3?IF%9&J&UK>]M;AQN;FB]>;]U5)XLOTF:X+QL;K_.
M&<N@=$O;33U6-![#4+*+R%,>'L2%\:(D)W0P2+$XH[S2VJJBBB_.R&[B%J6=
M2S.48#1LG7Z)U Q35[BI">?ZV'J]2HXZ(7TS#1U_NPW/HH4"'T0S-CQJR31D
M;=#L$*):[M4[H>K&3+GN\J,1UCV%<\.28+/7Y]]0Z:0+/=_DKRG(:KO?>\LC
MA_&7EQKN%2?<YV89A]1QH*>4CIXJ>P:;'F6[[;L>7=0=8.J8(]="'MG67@C!
M)389L=>]5V_TR/8!31%_1%$@(MZ!-6AK"-:*4+ZEKG+?UU7>2UWE"U]7Z>LJ
MNRKA5UZJ5^JXQ32-?^8)"LFC0D(=1E9PEXR[4MB'L_U\35_[CP2WB#U7W*72
M=8.XSXVU!4(>=4*:G4UF!G'_[NR8E)/"G0M?<V=)91MG@J5]I8:ISFC:B=21
MG<^(W;XO8MA N$1_H_A586=P-DDE7%E)ON,>GZ1H\6 3'O\#"B*H9F,;$G,_
M8T73G9#6QS<-*@/9J.$1=DL"?82"JSC")Q@GJ8H7JTJT5>I6-8UD+*N]-'A6
MGDW_2ZC?98*C)'5:*\;1:0V$0WP0-32:P!#GZ'SVYD_+CT0-6$IL3.>0T3;L
M6L(DN9X@'9<&R%)..W#=OS#.R\-3SRM_49O.E/JO2N$*4Q$AL2?:))\ >J59
MX0$AU$PG9*D!"4QTB(?"B$A&M&E?[M&O?;(Y2771W@Y=HZ\=DWSCF.3:2=Z'
M:X-PUR>#"^SW%H@Y3(_D.LUH5B9*PD^H.9'UL;%K?,'3S(>**6,H[P;.[*<%
MBI^B)\0H5?1*K'SQWFR+WY-Q+%X;8#\R"'3"'[Y&!@:O?*/B9$;=K$/Z_$Q/
M$CBQDCAPGF,+-A'4*&Z12)51)'VY\3CZC0RZ 2H=8ZLMMZM>___DX06Y3:D%
MM3%4HE^VE6MX,4G;*)*<V!>+$\!Q;WS45-7!;=T:E5=6&AFP1@+PQ%_:K@;]
M'ONE7!4!>8C6"CG74%SCN,5FFD$U@6!0H A^6B+(B,8>DU9(D^.Q3_Y8&Z>H
M-3M<5GHTD-MRX8]@)UEM)"&-&HS@C3S3,I(IIDQLV8](_J-7_4I27D:BJSW3
MF0MP[W;NJ :J9)*G2]X]*'JH8>JUU7BY-H5:M17]VQ1<C[:I#Z15$"C<KC".
M!K!6*W(*NF^)'<U_/2_I'H^CL-M'LG/NIKK><]"U(D#.6IAV+H!D_YR_].;
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MR+M[H^)D=D.AIB?6SA+K5M>(U>.>Q[TU%Q3MM@0.L>D,[NSF6;CP']M6;^/
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M'/_S/F5/EP\-.5] X!&P19?K$= CH$? +H+1(Z!'P.[IQFO4!^-[S6]/P)Z
MO03I).0\ GH$;-'E>@3T".@1\.'!Z/W+F>^#T5H"N),8D,]9]OCW@/BW^]SC
MG\>_A\._9Q[_//X](/Y]MQ-R777DSN0L^SX8CXA>=U]TKL; X]\:X=_.@<^9
M]_CW</BWM]NY/@0>_]8(_W:>=:[&U/N4,]\'XS'1Z&[W;%J/?VN$?SO//?YY
M_'M _O?4^Y0]_CT@_WO1.?SS/F7?!^/1TNONGO<I>_Q[2'WYF<<_CW\/J"][
M_//X]X#\[V7G8FK>I^SI\J$AYPL(/ *VZ'(] GH$] C813!Z!/0(V#W=>(WZ
M8'RO^]$3L"=@+T$Z"3F/@!X!6W2Y'@$] GH$?'@P>O]RYOM@M)8 ?!VNQ[]U
MP[]=CW\>_QZ2__D<#(]_#\G_? Y&QW.6?1^,QT2O![X.W..?M]<\_K42<O>0
M,[_G\<_CWP/RO\[U;?4^Y<SWP7A4-/JT<S:MQ[]UPC_?6]GCWX/Z"+R.[/'/
M^PC:IR-WQJ?L^V \*GKU^K+'/Q^#]/C72LC= __S]IK'OX?D?]WU*3_)Y#!2
M\.]^[^?IUV][(LV%ABWC3XO_UD_SGSS-]&AF/]1QJ'#QG>T#'=_A(:=T)#C4
M_]G:$F^UBL*?Q$=YH5[! G_E*@[@P><OQ=:60_U07[I]#!,3*K/%9L!/XG4$
M=H#8W3Z LZ5)I$-W[.(7SW #/Q,D1:"B:"K#4,<7?_]AYP?Z&_84N+_K[P"[
M(I+3%#;C_O5*7.DP&^.Q=GY<<,Z*A=.T6[)DNA"12GRT2^_O_U@"K(ZQ[A=/
M?ZPO%<"M*0.+5>#I(/E*G,^FL,%#(X<Z>"4^R(EB:']($,+/GU:?>N(>PZ^6
MO7[_QX546]TSHK!#WY^?P/4MNDFCY.>MH1HE!G8TI?NW=P? ZM#%S5]%[76W
MA$SU%O!Z&/WOFO+OG,J[S;A.XW[O,+^ EXE]JBK>$]E8B4C"!T9-$[#= 0TD
M8.C4:*":9"3 N!> ACJ69B;2L33PPB06[\Z.Q95,!0)I_Q7*I9=BJIH_%1M_
M(Y-QP5?]WE"F\#98"[>@O@1C&0.:&)DID:H,-F^RL9##Y%)M;J_5+:PC8N4&
M,&L"WP:PXAM I51G>-=GA#$#N'QQ^.8,_C&6ETH,E8)K-Q(9H,. #S(-Y5_B
M2$[AR0B+WS\#%N2P8T/?I[/),(D X5[L[>V\.OW'OT_IG[NO1*J1P[^7,['[
M?-#O(5IOBW-X9 3L,KG"=S#;!;1*&:\&^'^T+&"F3L)4 &A@[X#_ _JXH(8Q
M2 ,AXU# 2B*(X%RP7$DBJ:,1/%W]*/U>XRPZ%G]LGVV+$+FX21\#4G^5N+O]
ML6\G&']8M9NVM2[86]@NW]3AHM#$[L4<A$O$C__^P_.F!G2->MRJTWU$EL '
M^JC,ST,CGOR"G$'\[:XC"!XU[P<U][N*FK^!'/.W\-"G>Y=<>4[0!=?D E3[
M-BC>O6'J ;G&P?U6-"9[#Q^,X<&.H-SZ<3W?_Z13/&_](.<1L,O%$M8G\NS%
MCW<+H]_SV%J_Z(/[[NNTV][[L;5TZYQ-=PS7%9&'V^W>XH#7ZO:[M_WL^Z<E
M=1*V'E>[AJN[VR]>=!A7VV:O/+28_CV/9BL30:VEY0X0\!T+F/W.I4%Y]%L;
M]-O=?MDY].N,L7*7<.'<EU(^B(TL$?6$F$U/M.M)M" S?.JV1[\'E!F=Z][X
M2#*WNWVD^9S.P:V2.@_?G&$"W>[S5^GU*7B8YODW1%_*XH3''D/B6F>RE'\>
M_O)ZN]_[&,%Z<+-O=)H9/<PSG<0_/QG^XJ^JW4?ZD( Z*J?3"-1K8+&>M-I%
M6D= 6LP&4T]-[3\2I:$WJQ6P#B$"MLC%!EBX<)ND<DSY+O*ZZTM41.6O43)<
MGJS>[\TO["F\713^!BC\3$41IO53L<(XB> 6/;EWX$A>>+::M(Z!M-[HR.NB
M'3G2XR.GZVNV7^SXFNU[J=D^\#7;OF:[JUQYQ4+S+0C-XR]3%:>*:DO1FCA)
MTUQY"=K^(ZVU! 7D=%=VSYBXXE/P8CK\^P__\_]V=O=^<(<Y.3]^W^_M[H"D
M>O/FY/SD],/A.W'RX>WII_>'^)>GP-9=Y2%:[]1IP@8M_!VU_TB>2W:!M#"J
M]%Y-$B/C,)^0/_00U=*(]9+#-$T"+;UMWXTC_:GZ/1T'B9DFU&%G.!-&C90A
M0TO'60**ID[%81SG,A*?*&Q,NF>HTL#H*=ZSBQR#^0;;#(6LH(,LT0$LGCB3
M.H9?Z)@>^*0N,"Q)WP*_SF #L$2&OO2WB9F(MUN[(@$33L<RBF9BI"-X]DIG
M8]K!V?$1_O*]-,%8/'4A;IFZ?:P7_^B^3.:8&9B@&C#I"'Y@9.##9UTXTO&7
M0$U1-@-) ^69*YT" ] IMCUB:E[ )#: K40Y=7+B1EYC/=19*N!YE26; W&E
M*'X6)YD(<@,<)XMF Y(GU L*/Z=^4#HN\U:RJZ3?FREI8+=3X#,S 1Q*QC,
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MF@Q>#&;D4&57U-%\WEQU#]F/R??MC$G CW-: -:.(@03F$:*34M[ZA -)MX
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M3"12!6HOE/C+P6&]*57\;[Z1!>H8[ TD?.:*0%V& _5%GNC(6N&<;D%PJ29
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M2S3$Z[DK'$')5Q#"DP2 (8;O0XH3_5V<EN72"'J)!\$0(@:1GI"%G!1$YXJ
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M5SX0E+UXO&:!]8R)AY4"HGS M*%(P8Y.%O#TIZ@_%&)A";A+$W2QIM^'*W\
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M&I[IB>./@B^5_7A5GQ74^W%%-,C&88 +MEAH>32<#4Q >.YR-X$'V5/?,>F
MOX58&DY,&83+?)FWB&$ %$X<7PE1/*9NO%WM&T,Z#6U,Y;]&&&L.3&[NW+!
M./"Q1*5PC;SV2'BZN=&\1D@B;ELHZ[IU89M!+8*WK6UA*3'-0</#FPQQ7SAS
M9J0T&5\GD@/2'Q<>I8UDNGU,*\5=OP&#(\_BYC><R&89-YXF$P/"!8%3T,7A
M;/ 'ODH!4^X%XW+"[\,G@JEN?-4C[M_!J2 ?B6N:<GGQN!.+PS,)PA:=_YJ[
M.>!8WO#CUK[B>XY+Y^<>9 \@9*"=D>ZQ28D BF)<Q]+040JWUY79!/3>P.W
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MUS5L7W!XZLR^;MX<?SK[].6TG:%&Z54R67#+(_+4R?VFK5)<=58RTJZHE];
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M8PS3+.Y4*RC2=*B54GTE@$H L\A&)8!* %\8HFJ>\Q-4K-9O>T/#OF)'YF#
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M4JF4DY5"-?7Z'3)1=IAH6<F//GX$;>I BSY^!&WJ0(L^?@1MZD"+/GX$;6)
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M41Z95);P Y5<VS1T_M2$TW93F]B9FJE@:3D"_U4"'\O3$?BO$OA%!#X"/TO
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MSUK?KZ73J]:YU+H\N:K?-"\^2O7&3?-;\Z9Y<OT>N\YFL^OL!M:82#(B !&
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MSV&<-?9$*A?D0L;<RNCB1<F2;<F2SJZZ"$ $8,K(B !$ &X\^*U,N0.;EN:
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M9(:5ZGK<LN%N0!44COV]<]71^E)!D25@/YFNA_Z**1>CP8@/N=0)78#!G$I
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MO* ]*=P,%>-3]>^ODS]I%D2G[8GQJ_BE9MRWK*O?K*LXV[R\OP>;Y=54Q*?
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MW13_%28*RMV8878@JL ,NW?U.#=B&>H1I-Z9 .K&3>1;AS$ZJ@F-^23^9!7
M\=I?H:E+_?-0]FT'//>EO]?#PJZR9\C8AL?Z[X^KK1HQ,ANC,X?S9WM!\T7A
MO96H/AG:="*637X98+L;TT&1%(5YCO2N]I<<A\2<4=];EI05JNO]AL)+2@/J
M/HE#FZ@RR7*Z%Z_$6?^K@<R;V$Z&QD"@00" U5 +OHQ.1LC&T7RO2C[('JX@
M&)APHM-I".:LA^3^7Q<,2?QB)^&E/N*"0;A=G'(R"-,IJ"9/H$3?:W?#WKX8
MG>:,A=WF*XN@#R /<<A4#B,8HM.<5@^]P.^F<6L,B8">>UNJPQ/PHN$<YT2N
M"2"5J8Q0[[?!6(9.LS(O\GWX#+2K6.WJSY7ZY^AVGGK+)8.RDVP'M"8FF4<T
MAA7Q8S0,B5L=T6]$N39P]RQ*.5N#C=NS9R[X['OF_X5"XH97GD2G.5;6KL\K
MMU>;(DE;@$8H+TZ@@*I#7\X08&J7KW4YOJLWDY5A:9!_H.8^=9^X&&JY<[NG
MT5RR%CPSYM*AR7"F4WI*DL!38@![_]%!1\,-,O$[O1L.1B852]*'6TI<Y^^W
MXD01XK#XV-L1O6PBPEH06#O%K??DS1^+M<BJB$[CC\GIR9EJ0QV.%#L[9)0!
M6*IU(UO&JTM'2C/G(:,_J1ITNM X6,B%QIQC5E)D*YMJ/,H:8=R!W 0XX@XR
M!P>_"C](9?\PALW:W#."A49\#T ?#K(RRPOP"XP*3R$(TDS]&4841:>)/*;H
M--@\IE07+'80W$NJF@=0 B&U;[;FZQ^#1X:J9&[[U'LPX:6=/A Z'914Z'A(
MRAGG^[)V6/WNM?YS&Q^!)?52,3*1C,73AW-2D=%\%++PYPWC$$V96)*,O%*\
MJ/(A/TG%4C09BR?2OCHU*]E.KLOV@F%B<CFM95F036A UON%E?D(X='52W0B
ME\[>#EXG L8BL>VC&P+=-'NAT:D=MFO7VT"S9':]KD26!7C$GH"PBF[6E7FN
MR\G=26.B ,>M;GJ2:K7O\VFQ5^:62W8*&V]%IX'T(3"J:KY8'HI:MUD1]%?Z
M<\K&G^9OK9Q6+=>*K=)3Z:GS6:Z6LI5JN9E_+N2+G=%3J?7T..B4GEJM3K94
M+0Q+;R_-(?/\J=^U<E*G4IZ_/2=)IO)$,L^U8:\PRFUN$LB2I6-ONM491S>S
MG[G.BZ:]L.>^3/+(RVRW6Z6;\;$"ZI2>C(<+;8=J)3;OBEF?&VO!K $<5[1-
M^B!0XCJ>5PT6Q.$\R^P#AZ.<PE"'?O''9HNY^]E0^ MVEHK/E1((S,ZD8E2&
MBL7CAS5B>&J?,( 2OQ682E"QK*=1DI<+1A\LM#B9CF52AV=H'V^(V50>O(XU
MMSBG\"HT\]!U&@J8\M)$%>8=$07C!B+:3@8_BD $_U,P\GYUQ:$*9*W4KH.^
M)34!-V'!5AUU5\^T^!8M"?GB33JH<A'X>D* EP JP9CWM2]9(T1)(ZP+ZX#S
MFQ@/J9GSX<;OW&623L0R?@]2^WTP@RTYF4J1L:2+[&2$%S=XP9=^C"?(&$6=
MBA=G?5!8.>863(#:,J['02!P94EI A6@]OB<R!7!% B2;(QHU]5*,]XKC^O]
MLJ^^N4UFJZMS&=FIQ<F,TC_;V<Y#AX85<10,_9:SJ50:&K0A'NKMLFXO$;_<
MFL-$ D?-X1J_KMMO)2BM6*W>MR113=**2$9I//1/JV(1H!T5/%H9BB*,\'<-
M18("TJ+3KD[IO9>FV$J2Z<"*=JV3JH:]Q2T/:R:<-](I9U0E)P'6;]:.I\E8
MG/3B'82,/<)8"GT&VL!G+%")4P7^P>PLO$?5VH2-3K\ 1L%<?YU#!1MH\;5J
M:#L9&EV\E<(%A<KX9C!LW=HV1OIE,RQW=1O5*L XHQ'*MY9T,\MC&N8#9SOH
M.<,0'F$;6)@L?FEQ'9P ]2%E&O=BUOL.T&#@B4_H97#N2EG)O/A*YCE;\,A_
M%!A^W-6+]PV523 9]L&+:/-D1^UR?\PB/G2L<_+=?H"%;F!%R*26!^CYT <>
MCR7BH02=6_,RF<+K?64/"822.$32CS,,0X[74.)8+_;:@T2[^-E.]GTU>W8*
M!&"=B@"K8X6/NAU@%YQ9DT['J$PH<W^N:=US=^/YSYXB\?(IY68(%:0^5R,C
MU*XNQ4GU>?#,\R 3#NUN!*U54\M#OMZ<$6.&O$,S)N94! 0[02;A)3-U_O$G
MO@ Y&B[C(W1#/G=FU]BLA?M7!.9_VT,H[09#>'D 'UCZ9*$:'X R+T)MSD.7
M4%6!!F7HH'\W$OH4==_S$FEV;P45)-$HQK6F0BRQ8PI)P:K+DQ"DT7FA360>
MF!A+4Q#(LE\W'8_'0S@X6RF6S80R#!0<6+&EW*D0I^>"(U,_RJ?H6)(\(;;F
MQJZL,+Q8%YN A8)#F=?[]Q(CJH9&F!HAL%7IP;/":QH0Z_U^5Z\T=(UM\%SO
M/:!Q@GOZF.!YB9EY-F@X]C>A<WG-%FX=CO0>A\./E0=? VA[!G-&0-L%-!HS
MT)PE4\[SN!GQ3GGK9Y/INPJ/T2Z+9LQ$,V9V6X 1XJ(9,U\":Y<S8\;MJN)B
M5Q_=572^?:^D^)5&N)#UG!L[-#TOUPCZ^#7I^S?.-F^58)"S1 P9-&@ B+:V
MA(U8KZ8PB!X6);(LHRB\61X[0PVL/< R$]7H89U ET31H,NBS=%@%4TB9D-@
M=#_ OUM?G_&"\/V;-80%&@&(9*XO%J@73A/M(?C^S=A#8M"!MBJ$AMC\SV8O
M:VI78>BR)-FY\5CH3-*SY"1Y=\<<5?JV?*S?5@B51,TBT!!QBI08J"7^1&_\
MN0V3K#N8;+4H)V=ZDTHGVI4'%^V@KF&"3<%G8PF*VF&9&0")$>AU#@!)N +(
M=IOS,Z &-YUBYJF'D4CPZ<Y$+$%3L4S&J1[6 ,A?2-PAV3A?2D;D42#)R R@
M2%0UHC]!"6="-BHUU7][OZXW]AM=DNAPE'SF*G'PR0H3#OSZ]W^NKH@R#P3N
M)]%@!N ?^+"/"6I[@0^AXL35U<**X_BI>^-K8Q55RE@6==0J:W<+JIUV4NW=
M3^]D(]GLJK5'VS^YV)U5OK)#; &K?XCV7(8GR$%5R;/_$#7("R8\:Q("(96V
M?^OOQ=?0GU;VV<(V^_=O"&HGJ"N &5V9 X=^0J<9(<N^ \P$\I(X;22WH@1Y
M_>GV0Z'3F@>RD8>CG>CW)GHS5&REUBQ+?.<2>K*X<PG]@>=T]51^K-&%CUFU
M+WBV<,^Z?\W9M'''9R:#>=L>O\8F+N" (D/[^7*Q:=XQ?&V)QN5[R6LZR8N8
M%]EEUR6]Y;[N/Q'F(ZSKZ0Q=ZNKI#I7NU$?UCI*&PJ=:R]4*):):*]0?2D2N
M5B0*]5:[M3ST^ODMK\_N\YG"/PCN+4BJMI-IL^E#3+OQ]:[^5)T]-K*OZ<_<
MZ*)Y=1W%^417+^=(1I)>P=W-JJJ(XU5X=_@6B"IH?+8*-Z5BY[[T_5N]3"RH
M *%^8Y1'* 3+.G+HP\AQI^I_+,/=>Z/3MB#TCM#1QF4=%T5[VFEZ_';J Z=P
M(DC/ZZK=O-+C\$X/,/=]:>S6&QVY^Q13?L<C[6NG3]KLNN\5_UD\WQOJ=T55
M?S<T41&:+@%-Y"6A*9")W8[KB@^@R71V+?N*,+TBOXN'+G](<;A.X\L\;<O(
M2J2VPRE.%%1%? -45$EI)Z&-I]%.L9E]D+3M='5QB W@+6.;F?4*"+2L3)P8
M+8J+8^\8O)E_;-T"MEE(KMR+Q8D2AXYT9"U(9L\PB).@$ X,E%QA8"O:GN7K
M.IEKUR</&?\QD/S2&"BZP<!V>/]5JG3N6X]L4\YZQ\"!K(##87Q."F1BE&/.
M"!?6_=;W!X]SH("J;RE\9VE]DBF)QWP\0,SKHPK78KK.HKP_XV_O>M/.P^T
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M;!.U&$4M1E%&+- 6(W+SR+ZV?Z0]M7]L#GW!;+XQW&V+*G)U!0T(OZ >(S*
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M7P*T;#"0B_XQC,?'K?Z8:J2"1E4X,!*U&(7X-%&+T>^!*CPM1B1N&7M\W52
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MA_%:_GR?*!^-NZHV#$Q7[A0*:Y'#C8C::66^"!+FT5">6]HVG1VG6'X]BC]
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M=&[6*0.%-QC'"$2/47GU^OLW>"#X/(T1"&8L38QX)HO>PME>K("Q8;=-1$9
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MRVOG9[BY*NZ4R_8_)H*&P ?-KQJW@,=0A*+*;T"#3:#O\'&CMIE:7P!S$P:
M10UD]+VV\LLF_B7QER!-WK71Y)VXED68-J_]G2!F(_G\;":((F)PX D>,N4>
M3P@2L&.F0&$V^FXZ@!/-\9OFE%2^SPOPV<VF=Q$8,L#*P33;9 7NP?B=":)
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M=.[*$#VD6,NW6M5*M5PB\BVB?-^IME\L2EIJL(TYZI>[)J=EYYIIJ5#<JZP
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MXH$J.LA>; A4Y7NUU@?S_)QZ2I]PH"IG[\:"?I9?I ]AV)IGO@-5T0>JJ.]
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M(EV15?1URY#"W45]\%E_3S)%=KY+S42@>B,WBQ0J0A"("\D 7=ZH$$ /%GH
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MC7@>*/33KU)&[@YY<#+3;TBP#>N<H'*X"6N"@+P2"E(91O=QF!X2,Y321EX
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MD;_<! @L=Z$!N5*4(TKD)VVNZ4(WPE([X9>68+]L^>M=P^N?XB!S EU&6/9
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M"'D:BVF-^7!F;UN='>740XB(XOT0--#M+'H8X2/O"S*9@<]J'^>=Q8./*=#
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M^;0A:LE"H+L2V4B_#B3OJYJ:E-W9S6LV]@_\G3Q7703!\KQY/]635V@@9-.
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MFIDSY]<YNZ]57:OWJEU[=>VU]WU7K7J8>U@#GBG**L@"2$A(@,GC!WA8!*0
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M\:-Q7"*0)4&L*\K2%C#(VP10NHLR#6B8C<,2284LY:2&=BEN8ZI-*VZ8\'#
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MI%C(PT6';ZH]W=;S(D=C-+V,4BK-H T\.!I7=-NHL79QQ@8!GB_(FS>M6A\
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MU]"(#.V"&IL>;[A*Y&NM,LRZIU]Z\61*&(#.@A*>O[+=_CTPB\+50W6,TO@
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MIKVS/OJ(EQB':&3BRZQS^=+!#7ECIM<&Q:F;3P0;+>=/7D)<!KHWJ>S>4C\
MB_UO9;2F?J\A?IFU-JQN*7*VC)?TCT^7CNRJ_/A73H#VWQBT_R#C&D8SW*R_
MB,4'(6O8@'HV0IE"H"@$B8V1GD+!A&,EGBF%%=TT30#C!@?O.%O_6:T[H=R!
M]DA<^OT1_]IM]RS56$3TJR S:0W930),'0S83.EF8\(">$\M1;7@[8C%FB"!
M@B$ZA9S:6?&%M(0ILP52O!0.TOXUF2=USUC\,\TR^I=_)$A1-96)WZ;^B")D
MKLHF06T)C#K=?^,U P?+-K"_T#S!#D>7S%H7/KTH3,5])?6B[G&(E[6L6:S4
M2&N0-V"@FL]RSW!@O9;5[4E9_OIU.=90RS!3'1:Y\$AIRVA\M"VTF@+3)"61
M&#,VW5$R791M#YZ#&9H#9$D8H(P'J*>D8_JL3,11QHA,+2-3LAUH=A\T"61B
M<9](IO".+7%K[(E7'L=!',7&M-?.GR(7U\37I+OTQVUE:B9/SHI?\T/,$OL'
MU([;2AZCJ65+/:RXT37A,3[.(FGA86VE,A&)0VJ,*8U[XI$+%6$ETH:G!2['
MB=):-+T'VG]M%;?H$S\:3S,^JMJ,B68%KI-,^5J6X/.2Y^P,:TB*6Q >#:)K
M^OPW_\GG)DBIZWA72$O^G?ZGU/KNJ>O/G^08UCP#L!7H@ _?RA\ 6UW_L8.&
MN[NW1]FX?O[(NDHNH'T79E>,Z/32DM5:SA-8%W559A[R%[Q T_ W_K:&]236
M].G%QW_:A+R4QHSK)OQMY_ZM@;P;E>Y[?\>.WS\?@&@=+O!\=]7H\GN(<@G\
MF_$ 3?R/K0QYTKF>^MZ-PFTG[S5$=Q=O[CI#R$&GS0 8R8=(-.MTQ,^][:[(
M] $0JU^]./LK T,([^KNK]31LGMN*/NYRR^9/%O;O+T2B\_".7I?H(#H"6$G
M"&E,0N=GY7G&I]O[1?_5Z0> 3*SVE]C.^>+]?>4E(B$Q$6874?;O-HM3)Z-U
M/_7U <A:?'=SW;$A]_>& !ZV*[3E!V 6XY%#*Y.]NPTZ$-N/\-^E*;,33 R?
M8NULJQ\,>0"V2A\ MYOI#+Y[B4?^U_O(_\2?%S_.3$R91R5L/YJ8$TE7KG4/
M)%\.4J<X]?G//UW2D9( SHBF:AKS*\J]C#[6+.][NV^ A?F@>KVN%5S5TB%?
M51&_-2ZU.S[AU$_:'EC;5 _?I<Q%.D>!OG-"8U7\L7\C%^_F'6?34P#$*IZ<
MT4SNPA4_6#7T8FQ0N-_:VQ1)W,T@L/ N.6,[TV;^G,+FZD-XIKH(OOA,8I*[
M"@\<I9\Y,;4O="Q3)?+D1G<^)8L3(*6@AS8R:GLV;6I?>/)ZU,]22I?QU.?=
M%:H%6+DEH4/6*#\F7=S:Y>H92A4MZS$II)K8D^(^,2=48J#[([>STE9F]O@/
M>+OE_?7EIWF7(]H]<CR\YS?EOAX9C$+R#I[2]SNH<I,S>X$+%M#/0UF8M.]>
MVE-&ML(R?>7>_YWFAGT1-FN]W.^4^'-%W^1I9."!\C'-B?Y;!N$^HX+S*-A>
MEJ) W^YJR7;2]>MD'5[:M[0"5M/6#>T1_.>%O31O2D7$W(JR?J=5KF.2J8)6
M6PYT@6!HR-7%7:9C*9ZE</!^KW>)S'Y@5@%W3]&ESG%>NDIHDC#<^/O,L$1C
MX@%=PKQXK"/1^Q4^ $YN?6?'@9;<*#Q-[LOB4#N*\J8]'J]Z:5X^I@59NL!Q
M2=9 Q##>Z[RSTI@79JGZF6K(DV%.5/W]P"EWK$,\:W\T!2?NS!LY4 S#C:1O
MX$;2^>?#^9*VH05EE*OOD4T_8(XT2RZK+X/D;FB;V7"K%=;I495,296\U*6H
M&+C"F]X+=#Y-7W/;U,GUDA)!5_V@\7R&?IJ8)EJ+7[P8?;6H -<39#.?V-IA
M9]Y]8DWL,WR>SV%=)S/JI2BJQ9:H(USZEFDA\A.#ZE!16.E<Y$(Z.'=CBS&L
M9$5+#S_"8V)/<6.+*:QDG3$M0H<B]"-R1I2:#,I_]?55LMWX/$A$112[5J@$
ML<X-G?(#D.U;](\7"1/>H(G]>HR P/.LBRW_;[%_VZ]0$R=Z *K=5J\Q%OXE
M5UKL[TJ3#*!Q/SCEOTME^Z^)UG]3&+>(D%3_?J*\__Y9&P$4E,#_L1?0_G_Y
M+PK2P_S_!5!+ P04    " !E?@]55S)K0DU8   @9@  $    &9O<FTR,"UF
M7S P,RYJ<&?,O'5<'-&R+MI(&)R@@:#!);@[A.!!@[O;X.X0" 0(3H! </?@
MKL'=(1E\\,'=X;'W.6??<]_;^[YS]]OWW;OZ5W_,KWNZ5W6MJOJ^6FOUT^^G
M5>"EG)2L%  '!P<8/1_ TP(@ 2 C(8&07B"#0" 4%&14=#P,=#0T="(<7"P\
MTM?D9*2O24@HJ%GH*"C?4I&0T/,RO&5CY^+B(J?C%^;C$&+AY.+XRTW@4%!0
MT-'0"3$P"#G>D+SA^)]N3YT -C*\!#P\ APE (\-AX -]]0#D , W NXOS;@
MWQL</ +B"R00,@HJVO,%=2\!>#@$!'A$A!<O$!&?S_H]GP<0L5_@O&$71\)5
M,091.N%Q?(K+1J9Z5]6%KSIY3,UIXAR$@DKPBI#H-0TM'3T#(Q<W#R\?OX#$
M>TDI:1E9N8]JZAJ:6MHZIF;F%I96UC8NKF[N'IY>WL&?0T*_A(5'Q"=\2TQ*
M_IZ2FI.;EU]06%1<4EU36U??T-C4_*N[I[>O?V!P:&IZ9G9N_O<?R!IT?6-S
M:WMG%W9R>G9^<7EU?7/[%[W@  2X_VA_5R_L9[W@$1$1$$%_T0L.WN,O%V C
MOGC#CH0CK@(R=L*EY/B$C/<N+KNJ"X6*4_48W\1Y$I6 FFN-YN0OJOU5L_^:
M8D'_E&9_4^R_Z04!T!'@GHV'@ V( E>W]#F!J/]'RT_1ZT1HE*%XQ_%2=**?
MM0FW8&$H^$=1<)D-_.IJK.#M!"A+1>_==3LYJE52@PCM?-:L_Q]WHZ ]I;H;
MS@9!N5(>1?%=&!)C=,?ZGH)AIPC##\G4R^&/T\SC*20G7+B_9&YT07$9CE8(
MDU85N%V9+\_;#)B)I5-UNTKTM*B_,H^V2"5_*!+Z%2F&,>;M RU_ GX-3B2K
M!PUIN?%1-3;>O>5-T!I(.I5/>Z&-W+6A##*6=!)([E7"M/9HCLH;+AID26=-
M=C>N\2+ [A\;X4,;XPA@G)@3\LJQ&BX,FN>ML<&^F:N_)#@0BI>./$(5-&T#
M7&<TZ0).L-Y71W?;>H<L]>Z36T?,38UN?)><:*$@4L8BN57Q."'OKH?PI!3W
M"_<N>O_ JPF=0XJWUO8_1N8?V'$1(S7'W^[ $))T@C)K]DZW+8U<QL'>V*DZ
M#IDH='A8;_HGYI;>RT]PZ>LJ3VTKO ,OO-"FC8!,YK\A\G 86+="-$LSY8+[
M/:E7=]3#BJ6] [$O:,#5ERY^ OJ_\536)BA**Q<A>1YE)'[Y>:]567NL?MF0
M"]%;7-(98=ZHSUB:6&@2/?WM)AZY>DX''RA,$+%!#B5+=LBUGF_0\$[5@[U(
M6N[4YF_Z]G.9B5R_[6PWPG8%MY7;(5MW#T?)N;[&P"\D>?]@2X(-\9LK#+D?
M1H]0E=,41=4/(?B)6025_TH[-3_2&G&+% +]@$-8O(V(H#U\HBDF(#E79%?G
M6M,097Y&7>F&(S6")X#;S2)SOX/0F%/5L48_C156=LX5M]':4L<;MZ]7%.;4
MF/'G0)<+4)'$^U\FFNF^RL=]Q3]7/&V.E";79K.G*S)T?\A:R/2$O3LY.W8)
M-O@J"7CY/0&A%U$ZT[^> //C\O;05(O&9 Z(I LNXR^D#\$62,Y*I)X%X$>T
M>8<ZPS!>@LNBR3T"@F-M7,9@JASC3X,W7A>]WNEX<-M8:\SFK>+'6WO[NQL[
M2<Z2OLLVCP>1C(%P]WK!4XTWC^2>D,O;P3HTZ=;F^MGUYA\JR9IOXWO(*:A!
MGSLOMJ,%YELFQ<B,?$G+;T1QYO>+TQVQC>]F'[8/_WAM;VY$-Q9E'?\,OQ<M
MNC8UF*[]S4W\0QB;JV68H!D;GPKDW#24X<D-^Z8,BO?\T65 ,>.K8@GUXLKV
MHV[VK&^IK)DUF,R)9:?(2[,W<!0_&A6Z9M*:$EW#G>-BAE_FKTUA\3UX<X&Q
M4;9(@,NVV9(YH%FF(D8BVGT TIMR(\<UV$NZ/)8O7D'[/H?B48%Z"K?7M1[+
M&;%AF6P8 UV)QA6?9JY#H:VN#U]/=<)^-[FF96;T:4R:Z,!@5#UG>C^K/>.6
M20;G<)5Q5* /8>!5(%%SFC(H2=M7] 044N9+[%<@:5>\8N6D)^UB,>WU3IR=
M^L9>"@XQ;HQ3WNGXKN=U1^B]G8M[TEQS1U@J7?2H^6)LV7M\#5^CJAT9:)M]
M!'"JA.,IT6/P1H1DOF RL'5Z+7YY3RY&C5V0@1 ]H0 0L@3M*@3 P11RK :-
MUTX*1LG#UF8J5A-4[^0)9QW-+.W+'P=&O0_PX+:\YS]Q*[CT^'-;_'&P+MVM
MU(6,Z9$,!--1.".)C==96S4'A'$[H VO=>#NN"=I,!4^1(Z2_OXVTOD"O00T
MU$BTL<V]I,KQ1;4,3I5-_$B,3/B85ZFU65_)8&;K%<ZOXCS(!P%"8Y*#"\2#
M;4A;1.GOW]J[2>'6QF",\EJO/WCTV)IT=(#37)DRG"3>_V+!W]9XI)I=T N=
MG-K>[]9N"EM,TH^G+(TC$#CYM% '>#/C=S=$5T @O:O3)EX5!^4%:M9A</G?
M^B/7L_92;?T%.QJ8:?/S)4B06>(B.9-,J1&8 \5N%/F.Q$AG\7M$(]U^. @0
MES-.']C4E^/T.\LUI+\10^DG+-44H6TG0YVI8Z5D\KGCIVYP)/:U@=VA1:>H
MI)WMBI':X7>#"9HSOYRC+10)27KY,$EC:VV9C9TQ8@QU^I:(4Y%$6R<;"'74
M]>;NQ@58E9U)P2J.R'[_2@LJT:7S)&7C'P4\OFEBN:S[R8BFV.52Z>;HU'[E
MZN/'+Z1^T2=(8@G);3HYN&AU6@BP>.^&'^^6@I^^WO,!#J(N>U/-'@L\=WX3
MOVO1L_KTG'H/3%->RSLA!7PKB_Y@8*RIYYA+@;U<U\H.U3VP6.WV,\6O$4[3
MC+U131X2D2*F,-KPKX6;5C'0S/;L4*M5L+\]U/TQP"PUB;?IE5C 0)[\*?W[
MZK90-%-6_4E2KA<>3^RN%;=LQ6O"^ZF3SJ'BUL:WV571[)%;@8)R3.&S0@Y^
M!2O2%JYQ-#W*TMR+3C4#_B92OX<J4%;3ZD$V/M<MJG=FG=9ST '#]G22=J\S
MH:4F#:;H5T)D+LN!@@),XUP=A+ )3_\Y63O*9K NX>$%2H8ON[0%@E$_<PCU
M-D*=FP')'(M;B^[7IG)H*+9@+](\38IZQ*$]WYB ,M(HGHK8BW^9:'*7*4#)
M16!:K+5+K H-_4=;D2-'G8-4%/2#??RT@0(Z3%3=\P+IHS]$<N9<T(-?S&8+
MTKX3.!!UO>Q3 $_ 2:KZ*>)%2/]A,$L>_(V[9;$7*)(VA:%!<,HC+5C;&5M*
MSA <W#(-B@#:_F-@:^_E6!?M[-EDQZ]5?-LX88(G:KX:+$>E1R"8_^5-FO0$
MU.R>%-RHFIZQ=U/9Z[ET@N@0(JH>/N6_0K?-I1:J=HGGE6-_T]\.EHL NFN/
M0X--"'5W82VI/-0M[#3$SF[",7*3,1^J(Y:A2W;3@TT>7K&17RSO_HR7Z^8$
MLMGY$JW=\6W)N%Z@L:G;37&2EG0%!2D!+S%!^4I>:U%D]Z*0M]VO$@LL-,WM
M]N$38L4W .3=7O"D&-%HUF[,EGVMQ):7;I/0C33[U8&R_K6N5)LJ736(H[6G
MM#I]_*H)D80$/3JQ2A*PJ/^4WUQ=E_IR&F5@<//7/NCGE12CK@)M7]_[>,B2
MJ>LGYF]!GE$N=0'HJ2V2@%G +_:<L&71_>M+(06TR,P4HJM8K\<3NH4Z[E:&
MG/;OS3[:20W:OILC%7JB"EUG+7SKY;:38H13GA_??X,D52G;J5'KZG\9PA3C
M$V4#9;BHUSX!(.NYU+JY0B&P\$:#JA[U%ZKA1?9(2R($*KYQ[DD5,<+J:_EW
M/_;]+=*)T211D!=_HV*^R_ WPN+C+V<29/)!UB'6^NQ44QLB??4]7@DJ6_HO
MCFUZ!+D.PO-?W02)K1:)?LD,;\56VTI2Q,7$;A.;D?8A4[9 S@P)A_$+P^GL
M]%GLC5*Y[E 78/(.FT;&U?G)\8N'V^=9F$>2T7RN7SUS&E*7U%Z:IFUVFVW3
M-='1"9^E=FAGD$9<DF/^EBX:H6UY&<,A=E<=L'S4QW^DXPJ7S+&L*^Y]>?EH
M.Z74_":NDS'7@ZX>"U]1GDB;>8Z8*-X-8;C)"VE#L'KAV.=BG7_<9H<^"]W/
M9&Q[H+GUBUI+8-Z'81(?GJ!72[(/X'>_-'\HUB5))'O&?;^-1[)._7G_Z:AC
M;UGI 7$R_PD8H!U^;*1[#**'7_J7>NQ_41Q3#[[7G^ ?S A\^>*QU!>DY6:$
MUEOGR'-V);,-:O-PB_'(W8%_!"_LZ=(V-J$U';Y+"R$D7)HNVCT0P_&T[V/F
M[4XB<-1GGE%YCV_QCJ>CL=]!;J9  EWC.(]-*NY],&I8U@NRSH\[0$YIVT.)
M!/6H /*Z7?2?G>5,'>L9V^Y?F=8QKNOL42N>RO V':>@]B?@IY?H.:Y4\A-
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M\!LU>AD)W3(3R8/DEN)QYPD0FC S,?0TO?NHK+N70J6YSHY(_5(0-P.< P
M(4(67JTRW(<DZE2Z"/%O3J%$,(8+C-D9 HUQ)S<."53GL6W 3P%!ML%,TK1
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MO_J[^7_V][]7_OS'_LXC2T"?(2VH F<A$JBNP$Z^WP=5?M_ O%4I+";JZ@_
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M!HCA'S)'SO-4AP+O-L,NAN(>;.*U8? ^*>GE.MI\4A1I]$*T@IA-(H7<I9*
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M!7^R5 OWZ0R4G8.9$9 K75]!E!"(2^EL_:_402QE;/L:N!$BE[=AX= *8%%
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M6OBM.*;#M:^(#\G[7SS1^?_2\>_G_PU02P,$%     @ 97X/50>-^55A*0
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M]"+H:JH5O&,1\JU<^9(U2R0227,X3_[^Y6Z569:.EJNV5? -X%B_]9>X_/?
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ML!HJ>_A0M/2X90%9N'D2*:9W4C.Z$'9U ^@);]5W1?,SA2 -/ZD9'=KO]=0
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MED8ILJ$[O^*'"9U(V[5W\>/&M0/8.2QYE*S'ONZ6)NNR/ *.)-DYB5MS%EC
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M,C M9E\P,#8N:G!GM7H'4!1-N^ZL"RPY@V20X"))<H8E2!81D!P%E)QS3HJ
MQ)4@<1&)D@26# *2!)3LDB5GR<$E[N'[[G_NN>>O_U3=<^N>GGJKIJM[IN>9
M>?KMY^UW,%.818!475E-&0"!0(#E[0%@9@%% !<'!X*#C0N!0/#P</$)*8D(
M"0@(:<DI2"@9Z9B9&.D8&%C8^: LK#QL# R<8@]X^ 6$A869H1(RXH+2?$+"
M@G_=!(2'AT=(0$A#1$0C>(_AGN!_NV Z #)<$ >(& QB!>Z0@<!D($PWP P
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M/2ORIH>+6:0:AM9-7-N!)S?S8P'._X9QIT4N#;^JJ$/LV@D;6K?\LL$VBH#
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MY2A%NAKD)A(+RXLQ (.(Q5?$$703<?H7IXRSS%>ZFC,P0+%:Z E8&VUI_36
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M_*7HEM*.IA76%6"+1#=4$T$BASC)^7[KZQA NTTC4/^S )Z18<3LQ$KX)I$
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M0?KUL]0O&X$,A*Y:S9UEYPE$E(#\!^SG\@RH)!YX"6['=&+O6"CAL,CC1U
M4^^%>1V(W"+,9F,9JPSX5B!@>W$PP3;_7=C&+&&)_%B03QNR5^D[['@'#TP8
M91-(V@L/D/%$(5<S+9%S,,(731M8=TM?>:8]LEA'"=6-S#VZS9_"^4E]6UM'
MA[!#&421_V74/&:8PODTL/'7H9UG=>=:M42*;+76Y, 1UDD2^WS7@XAB]JT/
MYZ2X;T1T%QX(2UK0L9(0O&#@N\*3V;U2#/3;PI@0M*@D$T+<<YD7(6D1(O*W
MU$LY8.?BE<W/&U<[7WRHYZA;BSEJ07/?-1]$:<-/=2'EL5&6D#YAC_2S?7$A
MS.C<-BS 'P\$%5OR-K$BLB-)A7*>EC[0Y5K5H4;<WR4$C=?=X<IN%ZJ6-INI
M.R0@7079](*2DGKHO# >>/.>LQ_;:H4'E$Q/>DC_QI<1/WJCL!@APQ2^?SR1
M4Q?"=4S?VQ:<2A1W)GPD#@U2(A-WZRT1/K?' V_'9'>.U(<Y6M<P Z1)KSSS
MQNK?6)6'"7<EM >\GW99G\-F',2#F-CKQQ@^SDV]-BDZ$K??S*B*'Y+BW[XD
MF[ER<)<HAW[^48#'9-TG7G#PKN5[YRS,1KNA1+1PN.1FUT&N@]F[)X&VW"F#
MF#39Q%FJJN[,]PMQG"06C(4<(B>LPV+0TUOR@GC G0!?Y:J["\V=+=,(/##\
ME4" 8T&R,;.MX_I39AH(U:)8"?$G),T=:I#QF1P";ASGRCAVXS<4X$-S>"#:
M\1?KVMA3M_ZW:;!I>B$9;8]^NH_@2SH4O7 61<%75:^O>]U>/5BD757<N!]X
MM39&* [ST51M&&1@QPE(4]KE>C+=2(J!:TEU=RB>#;H)C[?6V&#VY&L[+V0Y
M]@I*#ITVG"@^C+>E_&#,L@.5F$& 5*^2U^34G7*0)0-Q0SSP^L8)8JJ;0'PI
M I!<A#C*/SV"F6Y<I/M._W.*^AB3Y,4CGF(O@VX$P<]XNPSD> '.]MND];^Q
M@I[BF@*'*&86MELAJ^+;^?&JZYDM'UWZS['QZ"G89:R:W,W8_ L/^G!W?<Z5
M5%U*_V=;X/1<3AY)66:'KDXYT;$0'8_0#36EH#OUJ.4@B?<YAK;F2&FWWT1G
M*RB'X GL#5L8';=^%-)6"GUQ5!I8FHZC7<$QO*Q=1-HTPG;%2S-X&0F$_Q?I
M]R"4HOKG<X(?-Z:8N'*J97])5KH6@.:HE^4\V=+%RI4W?"D??=I8W1"B[U]K
M>(:QZ%)-3-UAJT#)&)2R.YSXI4<83O:U[Z1.W^MWK&'7Z ENMO'>_+JABX%H
MI*N7CV2GWXM5$9GQ#9GA2Y#^LC_@0AT /].%F"F[6XJ.,%.DL=/'&[]UE.B_
MIOQ<4N2IBT+SMMJ9X<U@Y&=5=[NRJ-E9\PG9$X8#<SHK,?/R&&WOMW5)^?>)
M@B0\"5!B%_I/*"GO.>'4K5[!-GXC5YT,L%?E+OJCL18W\^W8TF;NM+:RSC@&
M+U7+/Z?<VS(,O(,'NOG'\<!&T!_4!:-<\T/$-H0@1'2$KK*9Y7<I^H=-5VP<
MUA9Y=$Z43?MU98:>L,/C)L/TOX;X'^5M+;*GCZ7F5# KP-+:/0R\G%OOC\C)
M]W.B+X8-#<JQ!LZZ"=E6J%D[Y 7Q -EA>CAL7TL,>G9HM>Q45*(S'PNC$@/C
M >TWV%ZO]ZYNBLKT,3C^W45W,==2A\AUM=LNPYPQV<6<$KPE5]MPDHDC9C7A
MI5@I/^IYR6\CM)<..V:3[1J0EU9@\T]]6G$!V&MX()20'Q=6P>/VI5>'&_@P
M%?K5Y_<EY)GNSW3=/XMOF]"/_=:;ZL=^]#D/J[@G.YE;:?HRD"ZD.Y?(5]]0
MY9GV(A4V70,XDN9C]2EM;3QD'X;M\L,Z*I_O.(M3P.$V'E0_N=]RA[46<I5>
M#^+)X2%*C&M8RX!^J'<.W1-LF]@20Y[Q.U&I\W[W$:]%NR'G;7W>K<1*PPB,
M27,E1LZ>5.J;N_JV ]'B2NK 4ME;-S]F!^][[A[M1)0V_D>%\OL%4H#?B$Q,
MD_\5'<CM6C#3F@);:0LK'FCI_8AKCL8#F<4!("L8@I,3JY6Z#SU^NH<'P!IG
MI!__(#?H3Y'4W2C]O6JBMA(UY&0+!"3.^=J]4*Q61.6703;TUZ13',>L'-0L
M[\AP\8G4_*2FOA1/UN_F%+LW^^KY;-] ?;&+3,&QYO%'?OX2/7=J:3<='O:7
MX,D2[%T)V*_Q[ORIWV;-;/-1JG*9U39$8A3[5]+KHFI88K2E,JBKG>Q=[I%G
MJ1-)QKV@W+)V)SNA9VM(MW,0.S";;*6KJ%ZSH"%:&4%=X 'I"F7 G9V#P 1O
MT!P/3)"KV7H(4T+/I!0/C(/^>*@YOW/*VR""!VH$+^@<!=^H<E!X$>K*!T9_
M6)[Q#.7Q!/[44:US6Q\/*-);1UV^S2(QE3=%#=K7YWA;V/WCRG"*#OQ2/G>L
MJ7N(.FPL@34F/-?<61:L1C:2MI)K./(+#SR9M>.2V(;M#1N.(&9[/JU_3H/J
M$B-_U)W@@6<#8GY6K8JQX9,0;CR0)<BS5U)2ZQK><V6^(2@[HT)CW7%F0>D9
M'C"<5;+BLT\Q"-M.6C$WY>I>Z:J+\2-=:"A,N#"[H$)TSX=#E!\4@ON3I'8.
M4A2T/:GXN -"[@3H8(9U(@Y#HXR58SNQ3EJ8Y^BHH:<KC*S^0U^C9C&JAU$'
M^>W#M3#T/1^D^LS7+Z]6?A/(W8%A4T[F(9]U*2P:? O9(I<3HOKK.K!2BSXJ
M5<+<NMR<AXFDLRB[6?"#^9BBS"G&*D5!2GP2RX('8G4N$V+A[6?D*H46:*TR
M(C,WQR4\2-YFKS4=8Q+(;>[&$QN'!\S'RHP7*0'(]^>8:3,<@]%K**-H9^SY
MO!-=B+$+.H6XHSPNZ@!UQ,1?C]Z.&1705H'7H0X_:A]TZJF19L[D<WW7 #4!
M7H<%$7F!^D-% MZ@$>IW35OR-,ANC50_A^CT\RVGV<]-#327 [E_/WN*NV&7
M?[YA>?Z 4'WD"&5%\H)?[E7Z5:?:C@ZW2[]__T&XG2HZ.O5AA52?KUM@?BI
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M.Z2CCLMI+$6=R?JH5:\IKO."HZI_F+5.+>J=74JV@Q^6O YDF+Z]9<4P&P2
M+YC981I(+!]+O<?"U+Y'ZD=[9$L".*T30?GD/:D.Z]/(N@4=L",S1_@1OR$'
MG:76C=RZGC+Q(N,GI/"F7HLRC =2[GW]UD+=J .7$=^Q\5=N.S9>,(>+MI!/
MT44 <B%M) A]P72*Y2OEH-R)L&*8X2C.L9K7Z]\M7UZ>,?-%&'@/:N2R!?ZX
MRGFTI1RT7D\G/.=,@:LG0&Z Q&6<R69NRU^G/*1OJB/IM2OQ$\GA3=VT3Z3
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MAM \[^COZW[[]NW;?>^?NVO,,?8XYXQ39ZVS]YQSK:KGQ>=- )XR2 D$0$!
M )B]? #/*P Y !H*"BH*,AHJ*BHZ.AH&%A$V%B8F%CD!(2X1-04M#34%%14=
M(S<+'0,GD(J*58B-\PT//S\_+8N(A#"O.#<?/^\_-T% 1T?'PL0BP\8FXZ6G
MHN?]/Q[/70!\- 2*5QJ(" R 5_@(B/@(SS\!M    C+"OP;@OPZ$5XA(R"BH
M:.@8F"\7-.,!7B$@(KY"0D1&1D)Z.1OX<AZ A(],0,\C@T*H^1&5P8V(-S2I
M  TH6]]-K#5UQLAG[AZ&CD%"2D9.P<3,PLK&SB\@*"0L(BKW5AZDH*BD_%Y;
M1U=/W\#0PM+*VL;6SM[CDZ>7MX^O7_CGB,@O45^CP<DIJ6GIWS(R"XN*2TK+
MRBN^-S0V-4.@L);6GMZ???T#@T/#TS.S<_,+BTO+6]OPG=V]_8/#H_.+RZOK
MF]N[^X=_XD( ("+\Q_B?QH7_$M<K)"1$)-1_XD)XY?W/!?A(R/0\* 0RFJ@?
MW0@9>$/1B&23"NJ[T8%\6F?$YNY3&"2,_%M,Y_^$]J_(_O<""_M_%=E_!O;?
MXEH&8"$BO+P\1'R %.#V@;4P!(.U_#5W47U#[M'[J*VX8I=\\GST@QJ''L,J
M:(R'D\=-IX2@1E:6K[F4\ C[5R("XG"$>)Y0^;_-Y8:_-JR3A\)&&PK1G9@9
MWNG]QHP0PSO=!&)E>]Y'Z'%T1 1R?VK2H\@\K7K XEL,C*-848Z_^>C>H+1'
MHB5;Z3+X^(73FT:A0_WA[_?7-NE/:/HK&S+64_>J5L%O%"Y1UB*ZDTMG$L4T
MAWOV]>1](27E]EI)[E CKI/J9O*XUB'1=-O=1=Y?K!)H\/Q]@!NT.O)1NWV.
M&[G2@"NG> 2K?CC6,IFU2E_8D1LQ'B,;7CZ!&!>VMTO\LS/F]^9CT(?I@X&/
M7#O,' 9%440K$03U*[PYO7MJ':(>W97VAF<&G&J[V7H\JTN*S)%K/<=I)FUH
ME[RN>LF)9 1O1&=V/GI "NNO5QX?Y<IDRF*")2_V!U^+-K)CQ_?5H;%0^MGD
M9E#;1]1 OZ\>D>C:'+M!5B);W2AAP<SR<G7.E-XH$TR0J_OZT47N3U=Z- %J
MWV5*.ZZ&;!A6[69,EQE P^9H1)\#ZC<2X8FD9.(>6CD.QO&GU+P693&_.KGR
M,^@]J)2'CX='.CFE8T.\N8^OR'8OZEKFIHPS?_GU74%NO"8LD/HYBL1K,15+
M"I(LAEG=0MPU&.%E GKJ\Z?'GP*9MZ__SL/?IITJ(,^VF'*&R)BC][H/L(@
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M0#]?0R'RJ5G484S,)34TG9G7U3BT<8^<T8DQMYFF)!"[XZ8":P$7'7S50"[
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MQRG#@%&3KOM2):?7RY77"+'$</I3S.S?GPY90/+&Z9+F9'\@<3)/:"QA-\:
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M:\L.Y]/B>$;C7%[UF_X*X9N]OJYL>O>O^[X $8D'?=F- MU MBD4M(VBB/2
ME3<Z<_#//Q;^&Q@$)P6FU\B 0A@1)%KA/EHR=#0P1AR)[X;_V,?_%4",;/0J
M>*(XI8WF\UM@4\Z5\5@J8-JR[,X)4N( T)O*)OOA'4H.D:8T\O\7$"?8+F^=
M8R^V*()2FWRQ\IU71??W)D1^;=AM^6^:&M]E_92DGSWFY_I S;"@PD:I.%\I
M-L'!?1RPRAZB ,PLH?S:""V$[<Q?9ZG)]0I2]'!ZWXZXW40T)P54%5H2D&/2
M;'BFH\ZZ&?P@/[<N\L?]//_@6YJGY=#-4986O6[@U)9NK0&PL#,-F-GQCYB0
M*X2MO*9:'=J^N\)6D!/D<F44O AL9<N Q/XY^'P\B-KR/5/AI\J:\E[?_MEJ
M6JO)VHPAYEZK[BL9&(#069')+1=%(T!SB-X#V%'8$"!5+=A1B*UH1/DI:0>?
M+; O2;_<.;R&+R&HM'U"Y2ZF>FPS1^]DYMMU5.*J@?&](M+D?0$Z(J5[&=WY
M9$(U!G;<$'"QO ;UIQ1A_N3UUZ8[1V#K(T-%F^_K;:C5(';4U+BE\+%$A*1I
ME-""8>S-,F[DSAQ#]#Q'K=B)"M[%FC=66/$^!$5I?SI>R9G;TON3'KU4PK$Y
MA<<  I@C"W76F3((NYV]99SGDF"#6_BW=KO .2^VO]$7M=P>L?>?JN83J/_H
M(9_QRGVGZG=;?(PV!J]WC\9?O+@&5M;":,#_*3B$;<_*0W7MPOJ)W@P^[<VO
M"KG]2NX7S9PJQS[)Y\2>I:N,FOB-BN/W>F$YA#&3*9.<P7W+1!D<KQDB[MH5
MA@L3J5)C7]6_2]=JBO:'AABL*%>X>3*N&.2Z*G+_C(WXD)O:H7^S<2%B'WR#
MV_0,F$KG1ZC_KSOD?P\6J^M'^'>=&G7Q*A\M)+(O!ZLQR;U!4S6(OP&(>Q6/
M9:=YO]WJ_WW9NAL.A/\^%?"/TY ]QUH6Z%MF-PEU3BYN R$@U#?7]\M[-@_(
M/P.8PN!_NRJ> 45JVBZ36BR0,U4OCSO?[5F;I$^>&<%!X@-9H\:6$!#/8?BA
M3M,&($Z"'TDT(]%.RFY'KFEDW^:I-IW\=J)9YQP'*ID -Y'U*8C4:+CS4TE%
M(5XWL-QTZ3_I/-ZGC;.6WWZ-9Z<GRID)_>I8TM39"&M/FA^3_HS6RTJO;J*=
MR].4*S-F9R?0>5TAI"+W7N[.TZW8GD+G9RY=VJD$S^ZC.+9]5*&0%AJ3NHIE
M."QYID2^QL?NJC:RX8#DQ#/0G['JIL%H!<;PGON:L486(:]=D2J(.-VAZJ[0
M:,Q4(<O4-V",<6-Y7>"S:[L%\+2P?C/\CSZPVD:FZBB(=E*<-M!-W"\V<OCT
M,&#%<OT['58Y+7(DKBX2R6_U:1==CJ*YJS@!_FJ<";4$2J=-_0:QQ#<:^V-N
M"QN8U;7ME!\+?A3J[O7K@3GFPK/YTJPXV@I0J?T13S0/'@:^<EY+O%+3,&J<
M/6F>,^?:ANJ/U5^,A,7BF"C(:C3;'(K>QD3;BO:M-R+=""TGZW?D+>&KKYTB
MIE/M[QX J'#:IY65UJ1^::X)U-?7!@@DZ"R4S#D)8/KKP99N4F S]&WKVA;L
MEJ@VB.O03RY8"D4.0@M3QBCQ>VAT^F_9PW@(DO+2$;.O,  U*MOC:0]]_5_L
MT#]*<I?$V)@<DEP_:>L1;[L0C52N'OQX'>5;?UB+I$0J9NA!J<)ZO?F9"$ZN
MQ/5V.<9YH-S.%.?J253-?PP&WJ8V4)7EY;GQ4=^V>)_<KY^[!BL7?WWV^R_^
MF@[WSBR7<U&$<M?7XI5>AO/8IN]MBW 84.(H/KWZ+EECEI^M6<)^0KMY?NJ;
MD9QS?98[D!?[)1$^W2S+=:;O%YJ--+ <EN.K'21*3JLI!\H&G/&KA],!'.%I
MAX/ :-UTUW9_FB%YG_5P>"WI469)SO[BM5@,9DM["U=_$F2=;*C_.IO'7"$@
MUK-F9BOX3_*:V--AYY7#['!6=!N;DD1\3S1KU?!_+SG_CXBWVX)$C8A7$#G,
MK86%WF6"RW^1YIG-,,%HK+7+GQ:18NNHQ>)]J=UF,@&YF"M&&33"W S@MX!6
MCK"1W QJ>3.%_(VW9"BAEY@REZ,#ORU)']N][A6H<@,=#T@6'*?73<5/;1AL
MS7/%R;PM$WF5WH<A?."!=G*N-"W7,8B0F#:V]APT'--3SS9$#B"%@!0@"O-U
M32D="7U^^9TP:*YIW3+>I/04J\DME5F;QT+V7^+)>0GHGWC#O*?P$ZDKJS$Z
MP?\9R;%S9$55<UFWY$#D,/CC%UDP4)2Z;BH<^'X&7W </0.N=X7^AMB5>)M;
MWYLO'[A+<ISG131+X#MA'VE0KB]E,("7AIO,]W@WPV! 6W'OFK"5 4FJMM;(
M96R%@!G1_I@=1=Z?FUBIU[5(:61E[QKZP:PBO>5 @>JMB7L*_H2'IR_/ #GB
M^;-S/9LO5/-5F;I&SX#TC"L!(DUCFW8B37G /R#>"R:5VL-]!C@] VYR_*Q\
M\_HF[L.? 2O!3V6&DW=3?=^> 6TJN_>YQI.@!4R1M3U6=AQX+$V[#>W?@L,/
M16<)?RUH;WJ? ?9Z&3K8*G\-@J2F6RM?N^5:JRDM#+PO78/^R;C*Z2_S)/UZ
MW%3<%%%]RE4"<P@7P<DU8D@D_(C*_';?]>]KF1S#>Z*!C#2UL8LPGGZ19P!#
M!W!SXD\\:?#UYC/@@5=T4W(>HGOX/E6!J[US,W?WA:!]9?YA:>/3MDU3[+O,
M^]<"@4(G0FAA L&2;WO"U-]4H7J8$%O:DZ;WG"I6E=:'.DU9I=;,)FY]I93!
M$@S<:)?S/+#K:[HBA&K!SB)3G1Q'RJ2Y:DBZJ^A3DEGC@8/(QHFKEX,B-4(]
M&YBG5T\@YCGX5%P*CVH$Y[3L+4B:*$/E"MYPQM=5TVJ*9_)SO)\5RWXLM'D(
MR&L6D)^=4W^E%>3\I82K]NMNYA3W;KVBTYS>A =?0*QQ#8 5'9%\AZV;2J="
MB5Z 1$SI3"'R2FBC]%"SJY\E(LJ+:2J*45!I;=)S7$QKT8>EM]5^N;HTLQP2
MQR%;JF=6*M-\9RTR"$<5,(?KP<*V^Z7JV0QN[OM*>^5:PLH1[5;=U7W)NK][
MY3*W=%H;.;&K9GCUVUPRZ*H2&'&136ALK4I:W;=L?= H-V!0H^V6I)QTV?TQ
MP__-Z=1JD/?56!--@;NBYM]3]M$@\FF&AL9&%549&[>;;X2CP6#5Y#:1H=T$
M5&!FJ;B6Y2P75\%,61(+1ZN.$AE#+E^J;!%VHC?Q8UGR=,E<<V4;-8C#P98N
M?=3J'9-[]DE2%M?X&R(OB6#&^]8$.>5]U<:V'TT=N=2W)%:QN+"XB,CY32JJ
M!,/AF&X:JK!Y2MLKV$^\-<J?"?Z)3$#D!/'S?ER:N0^_^X18)^4=/E*.2-0E
M!0PQ(C!QM&A&Q=:(?G*\D#2FFHMY>1$2"^D2Q:_P3N/81]W)4,Q>P9.:+"$*
M+&4%O^FF8HKN6'K]4 JX;C**>UT\F&4221P19UD9(VAZB;&D</]PN'Q_!MCU
M%O52;WY39U1P:QZ017&5##&[K3:A?9>GV>3+[01>M@R,HU"V1 SQ.Z'.RA7=
MK[9]M\MQ2J(@@AK2SN54G6-.38/T8]5T=,2,YY103.;V5?-5!_>(_ R\;F;K
MPJF(4U.(I%^)!:QTI&9<F)SL'P%^X;W$88K=XU;G\')3V?+I%:,A=E2D"O;B
M6#B4&/NT"4(RK^IDT]K21F\.A6"VQ$\/4"YI Q".@@T[O1VPK[/GT]E^H$\.
M,.S$#8/0!O=+K&DQ[9QL(:.O3?#__+299;$#.CK=4_W8)6,TP\.QJ_0D[)1-
M/._/_DV;ZN#/J$KWFKTP(F;,2WX5$V4K)3S$33<AF@M4U^K3U.:X%IA\@J W
M0G#,K9>VUA/?YC;QH9GWSD%!<=3.\GO$1]GOQR@,YE-7$M^2?V\(9 ?0YQ$'
M.P:VX3WE&S]E@[KN<PT2:IZ^=8][.4NM=[VJ7",IR:I6T&V=KSGFKZT'.1;&
M*P@IGNR3KD4@*RZ^Z?3'7C@]'R7TB?\T!QY#L@SL/&[8XQ5,:,P(>M^VMT^5
M* RG_J7R;I)_3<M%\!3%AJ-^6/7\_NO3 H:TY\Z?ZJ0A>*;W#4G635Y3X#?T
M@-]-EF*X>2,7E['P4[?XO#B.@B,+J7C.JJI/&;_-4VH*J*R8--A0]@_$&]F"
M!]_0-#VZ4"YIV#FY/P05O%K["5ZNJJ2QT;74A#ID4[6>N<V7I7=G8D9=6C #
M%0O1TGG+.<B1>1$!?8'J:B+M(G:,#ZRA8#%JX#>G&X(5B-,[?8@T8!_)AE[=
MI^PT9IW^W"6JIEV4O\7I1'>;[33:.)9@! WD;=5]]&J?:I^LSUKAG$4%,L-5
MXTD.Y'*_;""C)@[XMFN)>PE;2T3%3!/?U#-ULW#REFB:Z?NA8O,:?XA2OT++
M;2,2F&<X%M/C)] N6+=BI.0,*6E/=O'@E)<3W#.N?*6=ZY6=8$\8URP]<R K
M;F0_O7[<T.[@P$8@4A.2,((<1G7Q6$?<S4(%"*8@W2#@IY;TCM=-^3YXN.<<
MIQ-F)L9F0QEB <5,8Z1"C#Z84:J/-44.,;^/60W[^17]7<X$+2MB= EI!+^#
MOP.'O[^=T_20LO0+?7Q-51K2&NZJ8P&3)=H:=\B]_R!"H ]^ZS2XR9NT2N%)
MI$WT'WKSG[I#=5R!%+M)C*&$%(+VQ^?/D7+%]Q03AK,A]_E!NL"9\J%8LS^]
MA_,A?$T.&[CK@X0:)#'BXK[LI)]LJ"+Z%<AW*H#KY9!F]P;5:G^R91IY2RNK
M019'TT]X ZC Y &4*ENA<P?2=#[R-!<6Z\%,=**?<#^^<(8P(;-8K-"F"W>'
MPM(K\[?NRO10WVQ)?,PW;SE7L<[R"33JR*NXF!^HY?K\BNM*>LKKF[18H&"2
M\<?P6Q,98"ZL[Y- PHM. M/*G@%FCQI/Y!Z*UGW_.'_-0#5"DQ@E6V9<@<;5
MXHW7:;*\E:]-5KY\^U+ZQN],_F. ]+S+E1H*9HYH,+-UJ_Z(H^YPJD7L&XFN
M6JY@"I\T-5UJF6:9/3FDQ+('<5^$)?(VB[\&M<YK#OJ:*:E3?::TRK'W3/ZY
MC_*^G2]22_1+=+U# E+DNR\+J:8S92/%(@>YYWLQ=S 4NKIZ6=_YG=?B^!R_
M)%FI[I_6K:Y-U#-@1V_N&?!KV.4),)]C[9/P5S[0]&][Z3-@$EOX-*KR3&7J
MK^K]7M.?%^D%@I*> :9USX #\T9V(X<E_I5REP)M.Z<<:VDXNW+V/\QTJ&(=
M$$>TIE^R%F3[0*DS=WQEI-W2P8>6J_.9S&GGVV^+"#)YEN00X2/I(_D/M8 Y
M28Z[+UI-BA03J@C<]'F?$SV(8NAH?<Z4 8%?JSM(M\<[*AR6/6/G,^W[/#RI
MN+6$L!#?H)('M2]\"PJY6)5ML[/;\V<BTI3I^C_R*U;: J_OK>Z> <J=_SG[
M57W&%_-%:L=*8_\94-P0X?>Z.^^>BOLE,]W/@"M+SWV=@TZ4X!W7MF= +>I+
MT9BT@/ @*?:T')2WXY]*I*EX3_=/&Z8J4!;^]N]BF-B*[6XG-&J"*,YVFDPO
MUSN"GB]\E="(.#DX?R#89^&UOS?Y4C.Q(#YE<* WF\B XXF$\GZFK:K5R?CG
M1%\]UU[&]YQ1%H]LB6_>-X<B:)!W[=<BYK*3L4S^CNC(R>"1;U<TCU[LCWU?
M**F'(6-\,NB2/B,@<!I'/T/#P::_6B5C;F?\>I0VZ&1%'1U8,RU,RW;@H.^C
M/K]\^'HO\'9OM8_QA[8\-*]]:]@%-;F+/GBIM-IL=A(Z^VE,!@YFH%ZMZ?<Q
M4 G<+G8&P"/IKGYI7W4HR/C?AO5/&JV.<,9N'*B1[(^3I2VC&#G[BICQC;//
MDG#@--@D]K>9Z3LE2BKI['Z+Q:+]AL,W$.2F9%,@;_,I.::M0O8"F%BZ=@<,
MQL#QRNEPVR#?BT/4XHC)P5@_4854[AW"\8<AG#T$BR;E6XJK[BAS(OLE6O/%
MDYXYDC+N,U%@RPU&+]7]Q9RI.K9^(3@BM0R5_4!1?[J+U'*- 86I@!GG#T-!
M=U? T- ^6/$DM,\R#\&.$H-;4W7/ [*^2@(_3=[=@6?SW-]+"3%'F'ES\J]3
MY^FFH3?=+9\HK_"#]9-A #3*8;B+,%*V37P3M#4^HLP^CNI&&':ARYS!&1-T
M'.G4%G8AJ:5(/O!^/4\HLFEO;G/.F7&#G[>Q+(>($\&B"VNHQ=7/B>XAN:MB
M?\;QU-DJTZCTH]NW@(X1J' W8NP^ACNO_]0GBC2GWXZY%P[".$P:&5VQ$2P_
M*,G,A<?1@4 )^UVKQ0,2PZ!J_PK9F/VU[)8+"R1O*>%W.X1+W^"(9-4L20PF
MTZ*%.UCU74/"M-4L.SRSFO)T_Y=:R8&A?@)$3>9)=,2*$-*:2.9,NTYE<20U
M,9VGU#:35T+U^.[55*9J$/]0:3S:*!BF<WBJ88;J<<SZ2ID]>76UE50[>IE[
MVI@JSR41O_O6+/ [4)A3YQI=9]9C5_;57_+W?PZHX]@Y1$Z=Z=T@MM:H$:"O
M*<FG<. S@+J2Y*7B%5,(IZK,+K(0]\-/]/\D;FE#A!S#KRG_ZC\?;WRA9KMA
MLI8YS6>3QD >K#A2;GVOQXXPP>@6;B@0MUU>72,N(=&\D;5C+.[*\Q52MWZ4
M?]G=+=*]><4_ORF?C^2P<E@$C4=.!!*)*U+N<:4>X24G)>*H@%'L[00FF3(8
M(-SU88\QF[RLR-]< WVNKU_EG\VFY6IUVUKQ-%<)8= (J'*<#J!'3 Q[A$A1
M_%AFSC18-&2T^GL?E;+6_\8+#ES^ZHSV T<:V&%I%#RX6_$,6)2<>0: C.>K
MZOK$<9&FBI,42VB$WNFDQ.+)'/'HBZKG697>U6I']HROSS/7-[DGOBTO@:YB
M;>*TXPXG4F._* "54)_I/?%)YZ_KX"O46MI:L[O*?ZH8Z%-0[=^0:_CUVI<[
MW,PQJ77:0K&\"-,+?N-GP$)R\('=A^X/4F>5?T$Q>0\7+D_8'-/<+IYH?TS+
M%A68ZNISQWUW="-BVXIL%Q!N0Q NM9]F;C5N8?L_ VPJ4E]HKE;745.>^.M!
MQ#\2].^L;C?_[ZP_$W\0W8G40;LSD6O_0O+P=8U;W(L*]O^<UBH;\>V<=0Y\
MN2NZ+R)I_L/Q(@217U^$X"SXH*\J>N&L]D\\!<M3\ M/%I&TS]R(=O:F%_W)
MN$9^8<6[NG]8L9;OKN49\";XT>49T/1KAF/T+W?P*.W?E6? B>C\E_YXSH&G
M9=/7HY?L!17!(Z\''G0>_NM$S\0E--OX'^5A#Y9Z8DKAF K">@8,;GD_ SZ\
M\'P1L%:T5OZ.[^5\Q,:3C]3?V'@8[M3YQNG,U<NAU?+":(6A?W7?/%IKOG@$
MEVL(0V;V4.@8TMS7S1.VH_#*S*$B9DK[E!J&!Y6TNK-6D,MA5<A93_U]\ALD
M.J]NB]QA!,GLRR[^A<0,59^/5O5ARP[^,E2:O(Q*.4DN :WE ]*=K,*T,CJ.
M 5S^5I4QY;L1YM%KTTBRH18LPFH_=$^R][\@AEZ<9^K,<W-E+IU<NYRHD$VK
M?-VW37Z-MHR %<+6;;ZD&484KR&@HC#;_.O6H67O1_P245IBS$?'HA&D\P0A
M5W,%*WB>_ZPAA1_JEUK^2I&W>=8&T4KUYD#[QI.)M3A4'51ZA?=]NJUG :7C
MR^-CVY'+8K4"A;&% )@FS/EKMYDV5-I]:55L?:XY$+3,&C0Z7R\<HB*41RB)
MKBL,X+U:'#@;(!_C7#Z9]>M<&EB*'D#]=M.F].U/!#0\&VEP:7+GEAJCK:-G
M>![H@KMN<@C5A09;OQ=#%F.TID3D>^5>!!X#BWH-_5;U<?=LA,S,:-1%D*];
M1PM:8+<LEY.K3[6T6.]PJ_O"!; 38@3(K[.,Y/TY8,[,R\E=FEKR ))%BG<_
M:]25OSQVD K,VTV/2)1E<9R^!J9N8G'#H5=]. ?\-F(LD=PU 0H23[,DA"\5
M4$ UE#-:1DLZBGHD7HC/N]MX4XDEDD4G35%RG"G1)4D%CREY;WQO)1OON&4?
MD8RZLJ*P+"-^<,^%W\"Z8>9J\=.3).ND6 .HY&/(%3+@@[XSHVL+4.JU;96X
M2+ET9LRH$]*"'J;0Z2"&,EB.NKZ6\>07;-.]O[65[?)-?5:A'<_!/-A(-FD
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M.N_ 1$TM9O:L$3:!FUX^.YKJLG\6X'!7_C=?7*:(JR759K@S/\B<ORI)/9/
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M5X4;>5TF>Y$'N=\UK>K7@0C96  .Y24'Y*>:BJ_^N,2SM\1;FNV;V7=>+X
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MQ/#\2>1B2.0!I@J3> $(YK_^SR4!$GP19D!S#'YC"DL6\[M/9DJRO-O ^]E
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M0H*W)@%* "%,;?[K%-J,^3X+GA(R2&O6I^P6U&ZD;<;NAR+,SNUO2B.8<HQ
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M*G_6_%TK=+7GZ.;BF>*7ZP$$,W2"@I"$.BGZH$\?>V]4#B;*EW937=F3'IM
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MFMJ2>%\OC@3_UF_I2"M=)4U63SKP\R<\MD]]I^EV;LEW4)"IR;?1SPL>'"\
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MCD2IS*JI!%RQ#[-=.-UD6'SC@LJ5'D&'XT;UM8W@R;@.1IV!,Z4^NL^I/(1
MQM] "B4/@H!V[-"<[QK5O[6BT"5]J\-$A]E]?O%M/![?9>OE6VR2!L^SN@H\
M*;*N2='2L T^Y#9( E>9 ([O'@*1#?DJG57/R/Y:FI6W6ER'*0PAY5SH]L';
M?#E#9O?T!*KA1/=DV,&#[ Z:C[()UR2=*\2$BANQ6)*W6.9R&"'3TCO(D>VT
M4F27Y '\BL)K6VOC?VXP<7$#R<S9_#8 ;YQ7-K)MMC-,8?V;RU"+.ITK%.%^
M I7RZOH2#@'I#$+?6Q7OH*(C3=<*,UL?97M+ZRU$^?%W!?SR@RBZ4O-+&@07
MQ,-P'3:?9:GG2;9[V+KS1]_?7B9RO >O<R5;5?!IK:)_3/K%N*ES!K4H&2#0
M9[9;]3"\J]@.'5=OC#2KPSE)7I(RGL23*)&-JY3 C7HVH=H_]&)."Y"6WPW:
MY<5P'*/&T+QAP(Y!_GMYFJ"#9S4U6K(F21FFD!#\8["(6B+2(PE5-G06#R.N
MB"8B\XG?I#9D)$[J#YNN&/5T! !V*HB[N[ZL;.L/Z\:(T$.ZZ#"%8VMO2843
MH=/&XG><_VC;RN=,OI_F?>1)'?X]CKJ>?A/^M+O:&;H'19\Y,R D@!L\]".:
MX\9\;\#N.NS!$O7=?%A7\[$VBQSBRKPHY*$^IK$7S< %AI97:"NW19 .FSM!
M1NU,H[_AQPV0RQ[U 9V0IQJ*<[ DGG&:=F>J[*I<@44Q)V^E(X>SO[JA 8,M
ME]B*[!53.XE-!C]RBV H^DW?:1^A*=52QS+4?D>-XFA.ZHQRXJ.*X\G G9P4
M);N.W!SD\LA/*HHXO.8U$Z-&]?ORA_14'E2)/-1T%ZOPH'7Y7A7ABU,TZV1K
MSCMY]PZ^CO\HPOWGP$CCY,(&ND4U)ZU!A_:@ ]07A$E/L1Q&B[+D@^S+NHJV
MN\*"(]6QU@Z [<^7QWI$C0P69MP]"=)OI K39)$TI:$#H\[:AAQ!?3=2]=#?
MTV^M?X6:6LX:=#?TGJ<XCH_.)W<@5P!,!S?EEUE(//(FN0HM0?71%16%SN2;
MNF*6%L):8M1\F[=CLF4J'CSG3*0#SX.%87LR;@>!RW\Z0#5\P=D?GG2Q^!;G
M15AY*_@$#6J>.J<KY[H$O,/;)C2QLW>2D(?18#<B'JP>O<J66[%UZY&R+@9*
MDZW3Z(.\P7G"HQOD-7A.K4$< GC8!'!#*[?H:DVS-,U!_5+3\7_6$.75@>@_
M,#YSL"2+Y\2/IT;!G6,E56_[HQO>1MMH33'A&6.G6N!^C\HPSO6@$6H/SMWP
M64MQR2:2+B']VINTJ:NI684A$^\9^HYVM>WSYR3A8*ST6@WU_O1<R<;)4WL[
MP71/'6F:5LG@0M'W'],]B.VV[<1(8_5,&+'AE85+:5M^3?E4L;?>S2X6MJDS
MBIQ*=?"B:2/^(-L.[ 6_ ())T*U)!^J.P*2Z10TMC6N1C3OQM7@0Y%75/OX/
MG]6-'L4G78Z_V+(ZO0"^AG),,8[".71^3#Q_'&?+_-UU_ *P*FP]&TLMLFK@
MM[VTM_5TP_EA!FW4CO2VU:]*;ZJ1?JS%CKDM8%HH*;UE7B>7VZ7_TY?K=$+=
MY'.JD[8^O-A"#.].(TU^/ZMHTJE-DE7O[[$D_%W0J=S,;TY+*C4^;C,VO@D.
M3>P.!H1'X[#VF^Y1,[(^TY7\+*@52S;2R!&\S"ZE.63K)#I,V9HO:!)19K$-
ML*/^IC)=63$'+F'9;.[RY"!,S.D?T_='V9&2W8Y ,K=^1DY0#SK8^C5EVI1U
M !H9)F; "=>VJHN30P+B1V=BJ\B6B&QB0L&9PI^M?\HZ$M9GJ!LV]71T,]8B
MOA>6@(LINY$&'DRL6#NRAB,586UB3/44*WA',@V48GW$0N%#%K3@%6(2>,:G
MIDVS.[XD5Y*B18H@8LM7)*NH-W"F19Z,R,J &V6;&4KHN%@Q:DH>EI=)VQ[)
MV@&9<-\3:PZ-\& !$.": @_.8YAL+T.GZPCJZAK#)!$/%<EP/PS%HW8?:\)'
ML3H@%Q%BGD;;EG.E<@M$\Q\*F$)Y'GY"ZX,YWW3$F:9*P:GQ\0D%DLTT&++5
MM:51T@Y=_($D&37$4R:63X:_R<YV'/H%8R#>Y@KFL?VH2S1.QKX@%+&2/@"#
MN.OJGF4S5W8!5A^-LWB7US*6E$KO(\72/TT+3]GU=@WU.?18F'>U^)V-':^^
M/BX]6,>IB]9:.@03)&]TG%'%H.8D%5Z06N'6B!/1U2910PG-YWO.AYVM\2U3
M6 C6+3E6L!G>KDC2=I'[="G/.F=!80$Z9BBMV%QJ! G:OULBV5'6=/'HPEB/
M>SS9?YX[\7X1.Q2C1O(F?_L\Q'ML;DY_'R1+F>((&@I+M>UWH-"QS;$Q2G2C
MHRV@X!3_'/N K?6@.(99T83S/1.MUIZR=2D?S<.IP+&?:[F*\NN<^[UK8OFG
M^4'2TM:)OLGOO/KY ^3A?)14-B9I""3MWZM.6N7?YEMPON?HJ=Q6S:)D,L&/
M1\-,,&4'^IBL%[+6;Z:TSUR1MGBS"(S^GB:9/G;RJ95Z ;#!!_.I0RWBH_._
M+9$JDX.M&N8QBWK>>EN7?:61I0LR1J@)IF,;V""SVXASXO]29^<CQ<+*^@XL
M4+:8_$>O%['N:SEX$"_+H&L;X5SNWJ3)SX3#["]B\"8LK5L9LB53^0G";]H:
MLYGW16;/@I<NZ9G$XO&]WH^S^>ME04Z)V*21ZH((P=]M1H_>J6@G>T\.9'OV
MP(^N(F262Y*M[NX*GSB[T;OQZU38/[1NM-8P6J!X@%PV&AP^@#V26<0JQC(_
MNWMCS!T)**-+UK -R07I=H*V;R6PI&3(IG"_?]X46#9"-["L*/IZM&N &@*!
MGILK!*EIZ^!3;1.S5V^8UEL<9KV9^<#EC<[+XA(6A3=.A;ZSM3SB.T1MR0+C
M)1=6)=XPCF'_;;:-!*W[B'^@'3<T(09RHY*::I$;*R7L25=RNUD.'!3<4/X8
MN15*'WNM5/"*@]U !/#Q' =\BK#Y='3'8V$X.:>"N<FMN\ITQ97 #/NP"TK6
M[!=FG8%&?!F"LXEP\0ROQKGF"HZ1@WNSWV4RIAX3R'%7;L^TPC#8,[?I\_F'
MI(@3,K9#H;M*V2I7[9H@X)6T;,6Q>9/G&N^P/I=]O6;?"J)(;QT#S+B""'.L
M+6*WX@I3W%?5KFU&:V'U*6K1QB#'T[MQC[3QY&:Y\=9Y5%8D\DO,/5C&)5-K
M<SNSHA&$5CH5O$9 9#8FY;#N'B,S,(0[,:D_EK)MS0+6,^!8&SK67XX,35HC
M+P[1>!P"L0K_!1QW\G52F:>_ % )>RMK'6T9ZR]KP+V.MI]MJ'63.<:(8VY(
M [I@9S,8IN=P,ZHZ?B1G@A1TC="LI;$ME(V$(1;F.*AYGPP2 YEC?)R#V'8Q
M=]-_\!7W=ZNRH'/-\S6;>(-C@%>L8\=CB*PD 1S97VEGU%"S55(3)@CGMS3(
MOURC85;-;RFPJGJ'N(#QELK88CZ&X?+_[+NFD$R_JPCIJZ$56^JFIH+YY7/=
M_VOSPS=\&S&[R*&FV*31Y46Y%$DT_\,^;IH6T\=V[YMC= ;!A8L\9$'=P XJ
MF.-!K&$]1:TO;6J^H6$O;OQ&&%0??[H)'H*LALQ+IDU'&<G-D#Q%ZJO=/?]F
M=V<S5DVTB^C-^Q< R._SFF8HZ4UV%0 ^+[;K7D%]G*.3DVMHO_.DT%4%1H12
M&"8J@W ,G];F\J#.D-A[D?JIYT3$WV[DZOF4L->R30 Z8VO:''$JDSHW,?B4
MB;X+^X7FTTLK2L*9,$-/OE[)==E.\'LOL))[N*6,R1EM,+T0E8O:_BPIP@)X
MI?I.T)4 KM$R]V .1QJSOFU@V]65=&$S"*43]@)P@7L!S)>*_ W=;T$#GJ)Y
MRN.]FV%%Z\D'GO<]2OFI7K!BM]/^>N3;:LETVY-*NC)@9FZWCO#(0_/9DS+(
MY1G9!-N/1H_W^>5C+7B(;C\@6'[O^:;EC'QM/BYBG^5NOSB>M+,GT*;OO168
M>?D,G#IA-<V2;!DI5I.9NW>-$=6V9 'ZECL^?K(('"<4FOMNYEXLZ?.*:/FP
MZXU.3V;&#;* PRC"CL'-P$/KN-JSY/Q2J[3ZK)1B2R+;+P>,><O9[)M8PXP(
M^,EK4,!;%-1G,C;NB;;\DN'<^N/Z@OEVRSA2C^,O.F8RI/FX7 %V_8))A\*&
M*#F2P\K8!W/\D>MB!'GNZS<G(%?%GK<H4;TJ>'#O1 \T3GRH?PXCGG?O]=,L
M\;_U#C?5N<FH_F2^%)SEE.,<$=N94IV-8<E3D[^T0NK3;^_(P54>(?JAFT>:
M.F,O/DN1G^6#^#3W\NAGYKH'NB#\Z_1)$JD1_5 3ZFTZ. U8]E8.IN?ED7PD
M_1]8,*G'$$&TK H/CC;PDE&$L8KU6Y'B%YLE9)P[!L B9S[CNZ'-0 P401C9
MP^P'? -+K7PYZ(Q%34COI;\Y9'-6QJ1S =RDYN4V:CKH^'/9(\_SI)+JFV;0
M?BM$YK R69RU(.L3WPL@X/0F!RO4']MR>J'77&N7-R^^4"KT_&L!1D^RP.0W
MLA,^A*U2RV?<Z7)N5'NX+'%]8)YWN()J($F?B)M^K@W#7=@X=_;6"X#HPW=N
M3$::&9=;R9'(W6Z7 **PYC+^@:D<??@)9,%O46^LH@QY?N.,"L[K47\//<B-
M6)-R"B46?VN^>E$Y#0THE9J>%P2X7&>13MML?]TBLB5VB9/F_C-52B"0\J4E
M+H#, 4H&-Z'1OJ#GGXX01*05)&NF6,L?9 IJV\ "XCG7U_ [=I3[(QJ #;X2
M!:_KK?=]8,5H5$$Z!ZWTAJO]N=/_:&[,1_Z+[ZA"$?0W),J+)KCQ7D.]DF9J
MKQ&WC*5CF7@D0K2/%Q CY< I2IX9&^I2(;Q)%T0<5=VPOV1=8G9^RU3O7KT$
M-;^3 HS+Z0I^_"DKB(_0')ZC*8ECJ(A74R5Z6 D?F' 3>.AK.=?37SE.\'60
MK.%(,$R''/*6.F=?AFP[JM)7T4H%2;(HE*N%-XMWN\G5/+K=WY.K![CL!# 8
M!% X\%Z7F<C7$)GO2SQL?\QN<7QX-DK)L*!T,2$7(6F2!!@/;EJ#PV$/$M!
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M>6')-VR=1VWASB#$3>S "S$NJ<]I<W%6[J))-5.0B\R'82NB[(])]JYR6AA
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M&]^AG_OE>NVHBX+82E+WHHML6W^].OH*^-*G7$>!=O- 8?%LI\=@@7)X0@,
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MIRF  [K+M:SWT:76*!>" 4!.T!$=M'G6$'11$(H!3 6@JPII6 R*K )OY&$
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M4C8:IH+=* X,T#M=NL:>R7"[5K-&4G@W,T^_@'7<Y2N,20I784:P:Z86/K7
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M3V]8A%>(BVMFTS62O13+.VWQ,7T[VC:J45\0P8>F:@B&KB U,4 #MKYN[L,
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M@SX1/C =W\0 *V6FB3"$!Q0YSM>EO9?2=MAV! 8=$W2F&*4BOZF?+?8M=6
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MZJF.9.W7)Z6)1 OL,$#41Z>Q]R'NW\.ALI0V#V,T$I2ZZ'6+2N.A[QT->2H
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M]%(_?BF69PU!/\>:P1[^HW$L V/^\<NC]!<\)TAL+H%A<XP]6LCKU\_"YB$
M?*4'FW\B,8 O_'@0M 9V/%,<,W2,*V48$?_F:W=.A6/:DXKV!:'/3'=AOWSZ
M^6^W7Z89^<.$[_SA/ $]Y HVEV$KXD\C*)L?/MNU_,?0_\N&Q*?G#;W8KA:0
MY#Y4@3L?Y >\P#)0,&;L_P!02P,$%     @ 97X/596&L<>/'0  ATD! !$
M  !O:WEO+3(P,C(P,S,Q+GAS9.T]:W/;.)*?[ZKN/_!\57=[5>?XD<=,LLEN
MT9+L<"*).I%*)OME"B8ABQN*U/!A6_/KKQM\B"1(D%*<$7Q2/LS(0 /L!]
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M)67&AC S!]57B=G[JLK>:VVLPD8$58H^&K M2T\WS$-5*)/ A]U'M)ZXQ(N
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M'*M?U&E?&>G] 8;,3V! <*ZQH^ SD66W>[Y;^>_>D5#\/PGM8_E=HJ/ZWW4
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MPQI5 G_N%(L&='NC?0]L(;Y;;3R>Q7:C1(#I1VB8VR1CK:>S#NRY4B@:K,W
MD@U2WI!2&HR9":E5*>W2C[2"5]F-8!:Q#/L$6$^\.ZIY?&;^\@*U=:OG2_]F
M]\1M+W=L^TQXD6T^LLU(B\U\U\:R6L'*]%1W9)I7I"A[][&>%YW;RLJ*2>!;
M-(1]]77@+]-QG.^U-Q<@Q$#/@CCN)%%+71V4K.2QO([V/7Z*I9.&Q2DT_<(
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M)WEBBN9OU/3\,!),SQ9PB0F=) E.UQ.88.@$S=-M-!/;H8G$!+-H_\(17+"
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MZ>>SW[#K_N'YS]X4H]#WMMGHF6%70!7%>>%C!TF1?F+[U7=C+T)!$B0<,#,
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M@;,+1?JHT/A$R0-/K<YY_$_HT,>:%!7J0^J]FWC"R.+KHL493NSC.O0[.4J
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MOR*J:,=M/459\78597DA&++EKLM$W9[[,B_4WH7IZ_K!-7/ ?<)]^[$U[_*
M<=+0&R-UCQ@G#M$QT#T7QJE">0CC6H/GIS,X]Y@3^/+#CI:$Y<?I^M!Z[]'5
M/SLGCQ@3D_@:?O?^LM1%6A3I9K:F:!676KBRMD_"A'#[!V&,H$?<$:-CC\%
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M"_?1,,-V_;N#%OTIBPKR]7&ZV>R2ZF2(%X,HD+/5TE*8=:MSA;Q@@ P9\UY
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MM*HL?/@ZJFS\'LYGLM(0VH(E.-2I35DA</^^\#1I%^PN>-/DKZX=1_0U*Z:
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MT<BD& V9=)3\H)0!4M%^3B?NS-^9&:^DT(\.V(SDJ;O?BA072KT1R>HZI^E
MP%RV9GA;YL,H?>&9,+?.X3%;7T.8SG44/$0Q7<RWCQ<X:WWQG':X1<LKCD.+
MWEN ##7GWV;\H47I]X]YTS7@YA,Q"1N;\=ZJO]U#;]_KP&TS/W<R#]G!/(/-
M>7WV-IOSVRQ]CE;$IS^\H76M?A8;]&Q()QWODA7\%QPH/P>Q-.>6O@&WCYNJ
M"B9_U52D[1N=#7$;A.A2GD,, /T#[TVY2]EOT)Z"6G"1T7E1D'F?QI&W&"TW
M2I73-._0 WZ,D@1\$01T>/X@R62]QF$Q6]?I#^9D.E)F4<IGIEYID"V[#NJ
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M/5NC>FL3M?8V$=W<1(UI5-M&K:W-$_79+_CMAGSAD3Z&1)8+>9HD.(8S!H*
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M ^Z?^;Z7A[==#RJ'^.I75%F@=\!\\^D.Y^H^C><'P->8J/O1Z$>8,7O3:75
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MSI4G 0,-V3MN.J2@^\.G(5;\8.<AT/N\C4I;J'W> (GDV0L292;YXU+YA,&
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MSS+^N_#$)<4+#7=;R/F\HB1LYQ3J>.QJX;12_Q /9PN;1V=G#1 N<[%PJ+A
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M.5.EG0ZTM[FC<[U?W^OKQ[L6%-48M7.H?=G@;_QB^.PD0O#]BB3A/JN"6VC
MGX>TC+<+LT$O*!TD*LU8&=2G4F/ *))TUIG)RZ?B$2;B(MF7Q)H[V8R 2B<N
M?)K2M)<\'A^PSHODG.'Y3F;MYBVHN-OY=X)Q8$Y)QXS![Z]E/3;9#\%B6<-=
M6#0.!A7'2_GO'@\]9U-5+4,(6'3CS*=VH%@0O6E)$WV@?$0E_3Y/6DD_&/W^
MVS_=LK_8S_5/[#]P'F&__!]02P,$%     @ 97X/52$SUV)-4   C"T% !4
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M'BP?[NM.K=7!>OSK='([HV\[J^G-[9P&O"WF-##.7DW'F\5*>;VI8TB:HZ7
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MK3QDLA_6B%2I7ORP0_6EZBY:!O:E#K151K,OJ_",SLE_IO[CBW5^Y(#]KN:
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MI1Z\BK^0_[ES$H1_\_\!4$L! A0#%     @ 97X/5?#?E$JQ!P  )"T   H
M             ( !     &5X,3(M,2YH=&U02P$"% ,4    " !E?@]58DOV
M9L\'   H.P  "@              @ '9!P  97@Q,BTR+FAT;5!+ 0(4 Q0
M   ( &5^#U6DLZ) : 0  (P:   *              "  = /  !E>#$S+3$N
M:'1M4$L! A0#%     @ 97X/5>%>JGU?!   !QH   H              ( !
M8!0  &5X,3,M,BYH=&U02P$"% ,4    " !E?@]5C..].?0"   G"@  "@
M            @ 'G&   97@Q-2TQ+FAT;5!+ 0(4 Q0    ( &5^#U4@<FO[
MF<8# '4R*P ,              "  0,<  !F;W)M,C M9BYH=&U02P$"% ,4
M    " !E?@]5#6XSGHTL  #K.P  $               @ '&X@, 9F]R;3(P
M+69?,# Q+FIP9U!+ 0(4 Q0    ( &5^#U6A.0QQDCD  ")!   0
M      "  8$/! !F;W)M,C M9E\P,#(N:G!G4$L! A0#%     @ 97X/55<R
M:T)-6   (&8  !               ( !04D$ &9O<FTR,"UF7S P,RYJ<&=0
M2P$"% ,4    " !E?@]5!XWY56$I  "X+   $               @ &\H00
M9F]R;3(P+69?,# T+FIP9U!+ 0(4 Q0    ( &5^#U4WKMZMQ1H  )XE   0
M              "  4O+! !F;W)M,C M9E\P,#4N:G!G4$L! A0#%     @
M97X/5527QZA\*   "BL  !               ( !/N8$ &9O<FTR,"UF7S P
M-BYJ<&=02P$"% ,4    " !E?@]5L/'H3YXG  "[*0  $
M@ 'H#@4 9F]R;3(P+69?,# W+FIP9U!+ 0(4 Q0    ( &5^#U5+E[F3;'4
M /UZ   0              "  ;0V!0!F;W)M,C M9E\P,#@N:G!G4$L! A0#
M%     @ 97X/52+C- &E+@  5D(  !               ( !3JP% &9O<FTR
M,"UF7S P.2YJ<&=02P$"% ,4    " !E?@]5E8:QQX\=  "'20$ $0
M        @ $AVP4 ;VMY;RTR,#(R,#,S,2YX<V102P$"% ,4    " !E?@]5
M[]ED3Q$7  #W^   %0              @ '?^ 4 ;VMY;RTR,#(R,#,S,5]C
M86PN>&UL4$L! A0#%     @ 97X/5:EEI64/-P  (T,# !4
M ( !(Q & &]K>6\M,C R,C S,S%?9&5F+GAM;%!+ 0(4 Q0    ( &5^#U7*
MV7N$G'\  %S_!@ 5              "  65'!@!O:WEO+3(P,C(P,S,Q7VQA
M8BYX;6Q02P$"% ,4    " !E?@]5(3/78DU0  ",+04 %0
M@ $TQP8 ;VMY;RTR,#(R,#,S,5]P<F4N>&UL4$L%!@     4 !0 RP0  +07
$!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
